[
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "Retatrutide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "maridebart cafraglutide (MariTide)",
  "event_type": "readout",
  "indication": "Obesity/overweight (adults without type 2 diabetes)",
  "notes": "Phase 3 MARITIME-1 (NCT06858839); registry primary completion 2027-01-21, status active/not recruiting; trade press reports both Phase 3 MariTide trials expected to read out in 2027; topline inferred Q1 2027; no company topline guidance located.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06858839",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06858839",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0001",
  "guidance_detail": "Phase 3 MARITIME-1 (NCT06858839); registry primary completion 2027-01-21, status active/not recruiting; trade press reports both Phase 3 MariTide trials expected to read out in 2027; topline inferred Q1 2027; no company topline guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0002",
   "v16-0139",
   "v16-0140"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "Retatrutide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "maridebart cafraglutide (MariTide)",
  "event_type": "readout",
  "indication": "Obesity/overweight (adults with type 2 diabetes)",
  "notes": "Phase 3 MARITIME-2 (NCT06858878); registry primary completion 2027-01-21, status active/not recruiting; trade press reports both Phase 3 MariTide trials expected to read out in 2027; topline inferred Q1 2027; no company topline guidance located.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06858878",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06858878",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0002",
  "guidance_detail": "Phase 3 MARITIME-2 (NCT06858878); registry primary completion 2027-01-21, status active/not recruiting; trade press reports both Phase 3 MariTide trials expected to read out in 2027; topline inferred Q1 2027; no company topline guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0001",
   "v16-0137",
   "v16-0141"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "AbbVie Inc.",
  "competitors": [
   "Benlysta (GSK)",
   "Saphnelo (AstraZeneca)",
   "Lupkynis (Aurinia)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "upadacitinib",
  "event_type": "readout",
  "indication": "Systemic lupus erythematosus (moderate to severe)",
  "notes": "Phase 3 SELECT-SLE (NCT05843643); registry primary completion March 2027; topline expected 2027; no company readout guidance located.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05843643",
  "ticker": "ABBV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05843643",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0003",
  "guidance_detail": "Phase 3 SELECT-SLE (NCT05843643); registry primary completion March 2027; topline expected 2027; no company readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0228"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "AbbVie Inc.",
  "competitors": [
   "Avastin (Roche)",
   "Lynparza (AstraZeneca/MSD)",
   "Zejula (GSK)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "mirvetuximab soravtansine + bevacizumab",
  "event_type": "readout",
  "indication": "FR\u03b1-high platinum-sensitive ovarian cancer (maintenance)",
  "notes": "Phase 3 GLORIOSA (NCT05445778), mirvetuximab soravtansine + bevacizumab vs bevacizumab alone as maintenance; registry primary completion April 2027; topline expected 2027; no company readout guidance located. [Source verified 2026-09-20: NCT05445778 (GLORIOSA): 'Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy' \u2014 lead sponsor AbbVie, 'primaryCom]",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05445778",
  "ticker": "ABBV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05445778",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0004",
  "guidance_detail": "Phase 3 GLORIOSA (NCT05445778), mirvetuximab soravtansine + bevacizumab vs bevacizumab alone as maintenance; registry primary completion April 2027; topline expected 2027; no company readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "AbbVie Inc.",
  "competitors": [
   "Vectibix (Amgen)",
   "Erbitux (Eli Lilly)",
   "Fruzaqla (Takeda)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "telisotuzumab adizutecan",
  "event_type": "readout",
  "indication": "c-Met-high refractory metastatic colorectal cancer",
  "notes": "Phase 3 AndroMETa-CRC-064 (NCT06614192): two-dose optimization of telisotuzumab adizutecan monotherapy in c-Met-high refractory mCRC; registry primary completion August 2027; topline expected 2027; no company readout guidance located.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06614192",
  "ticker": "ABBV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06614192",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0005",
  "guidance_detail": "Phase 3 AndroMETa-CRC-064 (NCT06614192): two-dose optimization of telisotuzumab adizutecan monotherapy in c-Met-high refractory mCRC; registry primary completion August 2027; topline expected 2027; no company readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "AbbVie Inc.",
  "competitors": [
   "Entyvio (Takeda)",
   "Stelara (J&J)",
   "Tremfya (J&J)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "risankizumab",
  "event_type": "readout",
  "indication": "Ulcerative colitis (head-to-head vs vedolizumab)",
  "notes": "Phase 3b head-to-head study (NCT06880744) risankizumab vs vedolizumab; registry primary completion August 2027; a regional registry showed 'recruitment stopped' so status signals conflict; topline timing inferred; no company readout guidance located. [Source verified 2026-09-20: NCT06880744 (REVAMP): 'Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab' in moderate-to-severe UC \u2014 lead sponsor AbbVie, 'primaryCompletionDateStruct': {'date': '2027-08', 'type]",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06880744",
  "ticker": "ABBV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06880744",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0006",
  "guidance_detail": "Phase 3b head-to-head study (NCT06880744) risankizumab vs vedolizumab; registry primary completion August 2027; a regional registry showed 'recruitment stopped' so status signals conflict; topline timing inferred; no company readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "AbbVie Inc.",
  "competitors": [
   "Orilissa (AbbVie)",
   "Myfembree (Pfizer)",
   "Visanne (Bayer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "elagolix + combined oral contraceptive",
  "event_type": "readout",
  "indication": "Endometriosis-associated dysmenorrhea",
  "notes": "Phase 3 study (NCT04333576) of elagolix + combined oral contraceptive vs placebo for dysmenorrhea in endometriosis; registry primary completion July 2027; topline expected 2027; no company readout guidance located. [Source verified 2026-09-20: NCT04333576 (ELARIS EM-COC): Phase 3b study of elagolix in combination with combined oral contraceptives in endometriosis \u2014 lead sponsor AbbVie, 'primaryCompletionDateStruct': {'date': '2027-07', 'type': 'ESTIMATED'}.]",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04333576",
  "ticker": "ABBV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04333576",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0007",
  "guidance_detail": "Phase 3 study (NCT04333576) of elagolix + combined oral contraceptive vs placebo for dysmenorrhea in endometriosis; registry primary completion July 2027; topline expected 2027; no company readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Women's Health",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Alkermes plc",
  "competitors": [
   "Oveporexton (Takeda)",
   "Xywav (Jazz Pharmaceuticals)",
   "Wakix (Harmony Biosciences)"
  ],
  "country": "Ireland",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "alixorexton",
  "event_type": "readout",
  "indication": "Narcolepsy type 1 (Brilliance Study 302)",
  "notes": "Phase 3 Brilliance NT1 Study 302 (NCT07455383), 12-week pivotal trial initiated April 2026; registry primary completion May 2027; topline expected H2 2027; no company readout-year guidance located.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260401025174/en/Alkermes-Announces-Initiation-of-Phase-3-Brilliance-Studies-Evaluating-Alixorexton-for-the-Treatment-of-Narcolepsy-Type-1-and-Type-2",
  "ticker": "ALKS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07455383",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0008",
  "guidance_detail": "Phase 3 Brilliance NT1 Study 302 (NCT07455383), 12-week pivotal trial initiated April 2026; registry primary completion May 2027; topline expected H2 2027; no company readout-year guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0010",
   "v16-0009"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for alixorexton in Narcolepsy type 1 (Brilliance Study 302) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Alkermes can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "Alkermes plc",
  "competitors": [
   "Oveporexton (Takeda)",
   "Xywav (Jazz Pharmaceuticals)",
   "Wakix (Harmony Biosciences)"
  ],
  "country": "Ireland",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "alixorexton",
  "event_type": "readout",
  "indication": "Narcolepsy type 2 (Brilliance Study 303)",
  "notes": "Phase 3 Brilliance NT2 Study 303 (NCT07502443), 12-week pivotal trial initiated April 2026; registry primary completion May 2027; topline expected H2 2027; no company readout-year guidance located.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260401025174/en/Alkermes-Announces-Initiation-of-Phase-3-Brilliance-Studies-Evaluating-Alixorexton-for-the-Treatment-of-Narcolepsy-Type-1-and-Type-2",
  "ticker": "ALKS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07502443",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0009",
  "guidance_detail": "Phase 3 Brilliance NT2 Study 303 (NCT07502443), 12-week pivotal trial initiated April 2026; registry primary completion May 2027; topline expected H2 2027; no company readout-year guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0010",
   "v16-0008"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for alixorexton in Narcolepsy type 2 (Brilliance Study 303) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Alkermes can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Alkermes plc",
  "competitors": [
   "Oveporexton (Takeda)",
   "Xywav (Jazz Pharmaceuticals)",
   "Wakix (Harmony Biosciences)"
  ],
  "country": "Ireland",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "alixorexton",
  "event_type": "readout",
  "indication": "Narcolepsy type 1 (Brilliance Study 304)",
  "notes": "Phase 3 Brilliance NT1 Study 304 (NCT07540897), 12-week pivotal trial; registry primary completion June 2027; topline expected H2 2027; no company readout-year guidance located.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260401025174/en/Alkermes-Announces-Initiation-of-Phase-3-Brilliance-Studies-Evaluating-Alixorexton-for-the-Treatment-of-Narcolepsy-Type-1-and-Type-2",
  "ticker": "ALKS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07540897",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0010",
  "guidance_detail": "Phase 3 Brilliance NT1 Study 304 (NCT07540897), 12-week pivotal trial; registry primary completion June 2027; topline expected H2 2027; no company readout-year guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0009",
   "v16-0008"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for alixorexton in Narcolepsy type 1 (Brilliance Study 304) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Alkermes can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "Ascendis Pharma A/S",
  "competitors": [
   "Conventional calcium/vitamin D therapy",
   "Encaleret (BridgeBio)",
   "AZP-3601 (Amolyt Pharma)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "palopegteriparatide",
  "event_type": "readout",
  "indication": "Hypoparathyroidism (higher-dose regimen)",
  "notes": "Phase 3 higher-dose palopegteriparatide study (NCT07081997); registry primary completion June 2027; topline expected H2 2027; company Q2 2026 update says label-expansion studies ongoing with no readout-year guidance; study design details not yet verified. [Source verified 2026-09-20: NCT07081997 (PaTHway60): 'A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 ug/Day']",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07081997",
  "ticker": "ASND",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07081997",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0011",
  "guidance_detail": "Phase 3 higher-dose palopegteriparatide study (NCT07081997); registry primary completion June 2027; topline expected H2 2027; company Q2 2026 update says label-expansion studies ongoing with no readout-year guidance; study design details not yet verified.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0012"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ascendis Pharma A/S",
  "competitors": [
   "Conventional calcium/vitamin D therapy",
   "Encaleret (BridgeBio)",
   "AZP-3601 (Amolyt Pharma)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "palopegteriparatide",
  "event_type": "readout",
  "indication": "Hypoparathyroidism (adolescents)",
  "notes": "Phase 3 adolescent palopegteriparatide study (NCT07706764); registry primary completion August 2027; topline expected H2 2027; company Q2 2026 update says label-expansion studies ongoing with no readout-year guidance; study design details not yet verified. [Source verified 2026-09-20: NCT07706764: 'A Phase 3, Multicenter, Open-Label Single-Arm Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of Palopegteriparatide Administered Subcutaneously Daily in the Adolescent Pop]",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07706764",
  "ticker": "ASND",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07706764",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0012",
  "guidance_detail": "Phase 3 adolescent palopegteriparatide study (NCT07706764); registry primary completion August 2027; topline expected H2 2027; company Q2 2026 update says label-expansion studies ongoing with no readout-year guidance; study design details not yet verified.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0011"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "Annovis Bio",
  "competitors": [
   "Leqembi (Eisai/Biogen)",
   "Kisunla (Eli Lilly)",
   "Blarcamesine (Anavex)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "buntanetap",
  "event_type": "readout",
  "indication": "Early Alzheimer's disease",
  "notes": "Pivotal Phase 3 in early Alzheimer's fully enrolled; company guides topline Q1 2027 (March 2027 per secondary reporting).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/07/3323032/0/en/annovis-reaches-full-enrollment-in-pivotal-phase-3-trial-of-buntanetap-for-early-alzheimer-s-disease.html",
  "ticker": "ANVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06709014",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0013",
  "guidance_detail": "Pivotal Phase 3 in early Alzheimer's fully enrolled; company guides topline Q1 2027 (March 2027 per secondary reporting).",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0020"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for buntanetap in early Alzheimer's disease is expected in Q1 2027 \u2014 the pivotal readout that determines whether Annovis Bio can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Ardelyx",
  "competitors": [
   "Linzess (AbbVie/Ironwood)",
   "Motegrity (Takeda)",
   "Trulance (Bausch Health)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "tenapanor (Ibsrela)",
  "event_type": "readout",
  "indication": "Chronic idiopathic constipation",
  "notes": "Company guides ACCEL Phase 3 (NCT07382167) topline H2 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/01/28/3227602/0/en/First-Patient-Dosed-in-ACCEL-Phase-3-Chronic-Idiopathic-Constipation-Study-of-IBSRELA.html",
  "ticker": "ARDX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07382167",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0014",
  "guidance_detail": "Company guides ACCEL Phase 3 (NCT07382167) topline H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for tenapanor (Ibsrela) in chronic idiopathic constipation is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Ardelyx can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "argenx SE",
  "competitors": [
   "Nipocalimab (J&J)",
   "Ianalumab (Novartis)",
   "Dazodalibep (Amgen)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "efgartigimod",
  "event_type": "readout",
  "indication": "Sj\u00f6gren's disease",
  "notes": "UNITY Phase 3 (NCT06684847) topline guided H2 2027. Confirms UNITY is an ongoing Phase 3 trial in moderate-to-severe Sjogren's disease with topline results expected in H2 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/03/3305765/0/en/argenx-Presents-New-Efgartigimod-Data-Showing-Long-Term-Sustained-Patient-Benefit-in-Myositis-and-Sjogren-s-Disease-at-EULAR-2026.html",
  "ticker": "ARGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06684847",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0015",
  "guidance_detail": "UNITY Phase 3 (NCT06684847) topline guided H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0042",
   "v16-0446"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "argenx SE",
  "competitors": [
   "IVIg (Grifols/CSL Behring)",
   "Hizentra (CSL Behring)",
   "Nipocalimab (J&J)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "empasiprubart",
  "event_type": "readout",
  "indication": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
  "notes": "Registrational CIDP study EMVIGORATE (NCT06920004) readout guided 2H 2027 per Q1 2026 company materials. Intentional: two separate registrational CIDP trials (EMVIGORATE and EMNERGIZE).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://argenx.com/content/dam/argenx-corp/media-documents/ARGX_Q1_2026_Slides_Final.pdf",
  "ticker": "ARGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06920004",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0016",
  "guidance_detail": "Registrational CIDP study EMVIGORATE (NCT06920004) readout guided 2H 2027 per Q1 2026 company materials.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0017",
   "v16-0097"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "argenx SE",
  "competitors": [
   "IVIg (Grifols/CSL Behring)",
   "Hizentra (CSL Behring)",
   "Nipocalimab (J&J)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "empasiprubart",
  "event_type": "readout",
  "indication": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
  "notes": "Registrational CIDP study EMNERGIZE (NCT07091630) readout guided 2H 2027 per Q1 2026 company materials. Intentional: two separate registrational CIDP trials (EMVIGORATE and EMNERGIZE).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://argenx.com/content/dam/argenx-corp/media-documents/ARGX_Q1_2026_Slides_Final.pdf",
  "ticker": "ARGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07091630",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0017",
  "guidance_detail": "Registrational CIDP study EMNERGIZE (NCT07091630) readout guided 2H 2027 per Q1 2026 company materials.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0016",
   "v16-0097"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "Arrowhead Pharmaceuticals, Inc.",
  "competitors": [
   "Evkeeza (Regeneron)",
   "Juxtapid (Amryt/Chiesi)",
   "Leqvio (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zodasiran",
  "event_type": "readout",
  "indication": "Homozygous familial hypercholesterolemia (HoFH)",
  "notes": "Enrollment complete; company said YOSEMITE (NCT07037771) should complete mid-2027 with regulatory submissions to follow if successful; Q2/Q3 boundary timing preserved.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260727697851/en/Arrowhead-Pharmaceuticals-Completes-Enrollment-in-Global-Phase-3-YOSEMITE-Study-of-Zodasiran-for-the-Treatment-of-Homozygous-Familial-Hypercholesterolemia",
  "ticker": "ARWR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07037771",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0018",
  "guidance_detail": "Enrollment complete; company said YOSEMITE (NCT07037771) should complete mid-2027 with regulatory submissions to follow if successful; Q2/Q3 boundary timing preserved.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for zodasiran in Homozygous familial hypercholesterolemia (HoFH) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Arrowhead Pharmaceuticals can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Akari Therapeutics",
  "competitors": [
   "Trodelvy (Gilead)",
   "Datroway (AstraZeneca/Daiichi)",
   "Enhertu (AstraZeneca/Daiichi)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AKTX-101 (TROP2 ADC)",
  "event_type": "ind",
  "indication": "Solid tumors (first-in-human)",
  "notes": "Company says IND-enabling work supports planned Phase 1 initiation mid-2027; IND clearance inferred around the Q2/Q3 2027 boundary; no explicit IND-clearance guidance.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/13/3344959/0/en/akari-therapeutics-reports-second-quarter-2026-financial-results-and-highlights-progress-of-aktx-101-towards-phase-1-and-strategic-collaboration-for-its-adc-payload-platform.html",
  "ticker": "AKTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0019",
  "guidance_detail": "Company says IND-enabling work supports planned Phase 1 initiation mid-2027; IND clearance inferred around the Q2/Q3 2027 boundary; no explicit IND-clearance guidance.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Annovis Bio",
  "competitors": [
   "Leqembi (Eisai/Biogen)",
   "Kisunla (Eli Lilly)",
   "Blarcamesine (Anavex)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "buntanetap",
  "event_type": "nda_filing",
  "indication": "Early Alzheimer's disease",
  "notes": "Conditional on successful Q1 2027 readout; company says NDA submission follows the six-month readout, with rolling filing potentially beginning May 2027 per September 2026 corporate update.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/04/10/3271713/0/en/Annovis-Closes-10-Million-Offering-Extending-Cash-Runway-Through-Phase-3-Alzheimer-s-Disease-6-Month-NDA-Submission.html",
  "ticker": "ANVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0020",
  "guidance_detail": "Conditional on successful Q1 2027 readout; company says NDA submission follows the six-month readout, with rolling filing potentially beginning May 2027 per September 2026 corporate update.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Annovis Bio is expected to file its new drug application for buntanetap in early Alzheimer's disease in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-24",
  "company": "Apnimed, Inc.",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Inspire therapy (Inspire Medical Systems)",
   "Sunosi (Axsome Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-28",
  "date_quality": "hard",
  "drug": "AD109 (aroxybutynin + atomoxetine)",
  "event_type": "pdufa",
  "indication": "Obstructive sleep apnea",
  "notes": "FDA accepted NDA for AD109 (aroxybutynin + atomoxetine) in obstructive sleep apnea (Phase 3 SynAIRgy and LunAIRo); PDUFA date February 28, 2027. Apnimed completed an upsized IPO and began trading on the Nasdaq Global Select Market as APMD on 2026-07-31.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/apnimed-announces-fda-acceptance-of-new-drug-application-for-ad109-an-investigational-oral-pill-to-treat-adults-with-obstructive-sleep-apnea-osa-302825008.html",
  "ticker": "APMD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0021",
  "guidance_detail": "FDA accepted NDA for AD109 (aroxybutynin + atomoxetine) in obstructive sleep apnea (Phase 3 SynAIRgy and LunAIRo); PDUFA date February 28, 2027.",
  "audit_status": "v16_verified",
  "audit_action": "source-repair",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on AD109 (aroxybutynin + atomoxetine) for Obstructive sleep apnea falls on 2027-02-28 \u2014 the agency's yes-or-no moment for Apnimed, Inc.'s application."
 },
 {
  "ticker": "AURA",
  "company": "Aura Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "bel-sar (belzupacap sarotalocan)",
  "indication": "early-stage choroidal melanoma (CoMpass)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "darovasertib (Ideaya Biosciences)",
   "Kimmtrak (Immunocore)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/01/3304295/0/en/Aura-Biosciences-Announces-Enrollment-Completion-in-Phase-3-CoMpass-Trial-of-Bel-sar-in-Early-Choroidal-Melanoma.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Phase 3 CoMpass topline guided H2 2027; enrollment completed Jun 2026.",
  "us_tradable": true,
  "nct_id": "NCT06007690",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0022",
  "guidance_detail": "Phase 3 CoMpass topline guided H2 2027; enrollment completed Jun 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for bel-sar (belzupacap sarotalocan) in early-stage choroidal melanoma (CoMpass) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Aura Biosciences, Inc. can file for approval."
 },
 {
  "ticker": "AXSM",
  "company": "Axsome Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "AXS-12 (reboxetine)",
  "indication": "cataplexy in narcolepsy",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-05-01",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [
   "Wakix (Harmony Biosciences)",
   "Xywav (Jazz Pharmaceuticals)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/07/15/3327580/33090/en/axsome-therapeutics-announces-fda-acceptance-of-new-drug-application-for-axs-12-for-the-treatment-of-cataplexy-in-narcolepsy.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "FDA accepted NDA; PDUFA May 1, 2027; no AdCom planned. [Source verified 2026-09-20: 'The FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of May 1, 2027. The FDA also indicated that it does not currently plan to hold an advisory committee meeting to discuss the application.' (July]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0023",
  "guidance_detail": "FDA accepted NDA; PDUFA May 1, 2027; no AdCom planned.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "AXSM",
  "company": "Axsome Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "solriamfetol (SUSTAIN)",
  "indication": "excessive daytime sleepiness in shift work disorder",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.globenewswire.com/news-release/2026/02/23/3242481/33090/en/Axsome-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-Business-Update.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Phase 3 SUSTAIN topline expected 2027 per FY2025 business update.",
  "us_tradable": true,
  "nct_id": "NCT06568367",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0024",
  "guidance_detail": "Phase 3 SUSTAIN topline expected 2027 per FY2025 business update.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "tozorakimab",
  "indication": "COPD",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Dupixent (Regeneron/Sanofi)",
   "Trelegy Ellipta (GSK)"
  ],
  "source_url": "https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/Tozorakimab-demonstrated-statistically-significant-and-highly-clinically-meaningful-reduction-in-COPD-exacerbations-in-OBERON-and-TITANIA-Phase-III-trials.html",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "BLA accepted under Priority Review; PDUFA anticipated Q1 2027, exact date undisclosed.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0025",
  "guidance_detail": "BLA accepted under Priority Review; PDUFA anticipated Q1 2027, exact date undisclosed.",
  "audit_status": "v17_reverified",
  "audit_action": "pdufa_acceptance_confirmed",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0039"
  ],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "efzimfotase alfa",
  "indication": "hypophosphatasia (patients aged 2+)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "Strensiq (AstraZeneca)"
  ],
  "source_url": "https://www.astrazeneca-us.com/content/az-us/media/press-releases/2026/Efzimfotase-alfa-granted-Priority-Review-in-the-US-as-treatment-for-patients-with-hypophosphatasia-aged-2-years-and-older.html",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "BLA accepted under Priority Review; PDUFA anticipated H1 2027, exact date undisclosed; only competitor is AZN's own Strensiq.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0026",
  "guidance_detail": "BLA accepted under Priority Review; PDUFA anticipated H1 2027, exact date undisclosed; only competitor is AZN's own Strensiq.",
  "audit_status": "v17_reverified",
  "audit_action": "pdufa_acceptance_confirmed",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "camizestrant (CAMBRIA-1)",
  "indication": "ER+/HER2- early breast cancer (adjuvant, post endocrine therapy)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "Verzenio (Eli Lilly)",
   "Kisqali (Novartis)"
  ],
  "source_url": "https://www.biospace.com/drug-development/astrazenecas-newly-approved-cancer-pill-fails-late-stage-study-blocking-path-to-bigger-market",
  "source_type": "trade press",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-04-20; 2027 topline reported by secondary sources. Reviewed 2026-09-20: upgraded inferred->guidance; CAMBRIA-1 readout expected H1 2027 per Leerink via BioSpace and Morningstar (analyst-derived, not company guidance); bucket 2027-H1. QUALITY DOWNGRADE (2026-09-23): date_quality guidance->inferred. The 2026-09-20 upgrade rested on Leerink via BioSpace/Morningstar (analyst-derived, not company guidance). Per brief \u00a71, guidance requires a company-guided window.",
  "us_tradable": true,
  "nct_id": "NCT05774951",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0027",
  "guidance_detail": "Phase 3; registry primary completion 2027-04-20; 2027 topline reported by secondary sources.",
  "audit_status": "v18_reverified",
  "audit_action": "improved",
  "date_history": [
   {
    "from": "2027-H2",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "Mechanical correction: audit trail already stated H1 (Leerink guidance, PCD 2027-04-20); H2 was a bucketing error"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "balcinrenone/dapagliflozin",
  "indication": "heart failure with impaired kidney function",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Entresto (Novartis)",
   "Kerendia (Bayer)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06307652",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-04-16; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT06307652",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0028",
  "guidance_detail": "Phase 3; registry primary completion 2027-04-16; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "AZD0780",
  "indication": "hypercholesterolaemia / LDL-C in ASCVD",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "Praluent (Regeneron/Sanofi)",
   "Repatha (Amgen)"
  ],
  "source_url": "https://www.tradingview.com/news/gurufocus:9db2a0668094b:0-astrazeneca-shares-rise-as-j-p-morgan-stays-overweight/",
  "source_type": "trade press",
  "as_of": "2026-09-23",
  "notes": "Phase 3 study NCT07000123; registry primary completion Jan 2027. Phase 3 (two studies NCT07000123/NCT07000136); registry primary completions Jan 2027. Reviewed 2026-09-20: upgraded inferred->guidance; J.P. Morgan note (Sep 2026) places laroprovstat (AZD0780 INN) Phase 3 readout in Q1 2027 (analyst-derived); bucket 2027-H1. QUALITY DOWNGRADE (2026-09-23): date_quality guidance->inferred. The 2026-09-20 upgrade to guidance rested on a J.P. Morgan analyst note (via press) placing laroprovstat Phase 3 readout in Q1 2027 - analyst-derived, not company guidance. Per brief \u00a71 date-quality table, guidance requires a company-guided window; insufficient basis corrected.",
  "us_tradable": true,
  "nct_id": "NCT07000123",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0030",
  "guidance_detail": "Phase 3 study NCT07000123; registry primary completion Jan 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "improved",
  "date_history": [
   {
    "from": "2027-Q1",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "Quality downgrade guidance->inferred (prior upgrade rested on JPM analyst note, not company guidance); bucket corrected"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0001"
  ],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "laroprovstat/rosuvastatin FDC",
  "indication": "hypercholesterolaemia",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Praluent (Regeneron/Sanofi)",
   "Repatha (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07619118",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3 study NCT07619118; registry primary completion 2027-05-28. Phase 3 (two studies: NCT07619118 and NCT07619131); registry primary completions 2027-05-28 and 2027-07-30.",
  "us_tradable": true,
  "nct_id": "NCT07619118",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0031",
  "guidance_detail": "Phase 3 study NCT07619118; registry primary completion 2027-05-28.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0002"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "anifrolumab",
  "indication": "active proliferative lupus nephritis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "Benlysta (GSK)",
   "Lupkynis (Aurinia)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05138133",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-02-23; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT05138133",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0032",
  "guidance_detail": "Phase 3; registry primary completion 2027-02-23; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0033"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "zibotentan/dapagliflozin (ZENITH High Proteinuria)",
  "indication": "chronic kidney disease with high proteinuria",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "Vanrafia (Novartis)",
   "Kerendia (Bayer)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06087835",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-02-18; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT06087835",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0033",
  "guidance_detail": "Phase 3; registry primary completion 2027-02-18; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "datopotamab deruxtecan (TROPION-Breast05)",
  "indication": "PD-L1+ locally recurrent/metastatic triple-negative breast cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Trodelvy (Gilead)",
   "Keytruda (Merck)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06103864",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3 TROPION-Breast05 (Dato-DXd with or without durvalumab vs investigator-choice chemo + pembrolizumab, PD-L1+ locally recurrent/metastatic TNBC, n=625, sponsor AstraZeneca); registry primary completion 2027-07-28 (RECRUITING per 2026-09-27 CT.gov API check); topline typically at/after PCD -> 2027-H2 bucket. [2026-09-27 link audit] Replaced migrated/paywalled OncologyPipeline->ApexOnco aggregator URL with the official CT.gov registry record (NCT06103864); reclassified guidance->inferred (registry-anchored, no located company readout-date guidance).",
  "us_tradable": true,
  "nct_id": "NCT06103864",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0034",
  "guidance_detail": "Phase 3; registry primary completion 2027-07-28; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0027",
   "v16-0036"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "datopotamab deruxtecan (TROPION-Breast03)",
  "indication": "stage I-III triple-negative breast cancer without pCR post-neoadjuvant",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Trodelvy (Gilead)",
   "Keytruda (Merck)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05629585",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Phase 3; registry primary completion 2027-09-01; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT05629585",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0036",
  "guidance_detail": "Phase 3; registry primary completion 2027-09-01; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0027",
   "v16-0034"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "durvalumab + definitive chemoradiation",
  "indication": "esophageal squamous cell carcinoma (ESCC)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Keytruda (Merck)",
   "Opdivo (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04550260",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-06-30; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT04550260",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0037",
  "guidance_detail": "Phase 3; registry primary completion 2027-06-30; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "acalabrutinib + venetoclax",
  "indication": "previously untreated CLL/SLL",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Venclexta (AbbVie)",
   "Imbruvica (Johnson & Johnson/AbbVie)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05057494",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-07-15; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT05057494",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0038",
  "guidance_detail": "Phase 3; registry primary completion 2027-07-15; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "tozorakimab (TILIA)",
  "indication": "viral lung infection requiring supplemental oxygen",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "otilimab (GSK)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05624450",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-11-04; topline could slip to 2028.",
  "us_tradable": true,
  "nct_id": "NCT05624450",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0039",
  "guidance_detail": "Phase 3; registry primary completion 2027-11-04; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0025"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "volrustomig (eVOLVE-Cervical)",
  "indication": "high-risk locally advanced cervical cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Keytruda (Merck)",
   "Avastin (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06079671",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-11-26; topline could slip to 2028. Reviewed 2026-09-20: upgraded inferred->guidance; AZ 2025 Development Pipeline lists eVOLVE-Cervical readout as 2027 (year-level company guidance); bucket 2027-H2 retained. [2026-09-23 source check] Adobe CQ author-preview URL returns 403 to crawlers (access-blocked, not confirmed dead); document substance verified via search-index crawl 2026-09-23. Needs browser re-source to the public astrazeneca.com pipeline page.",
  "us_tradable": true,
  "nct_id": "NCT06079671",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0040",
  "guidance_detail": "Phase 3; registry primary completion 2027-11-26; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record eVOLVECervical, AstraZeneca Phase 3 volrustomig in high-risk locally advanced cervical cancer; primary completion est. 2027-11-26 (supports 2027-H2)."
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "capivasertib + CDK4/6i + fulvestrant (CAPItello-292)",
  "indication": "HR+/HER2- advanced/metastatic breast cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Verzenio (Eli Lilly)",
   "Kisqali (Novartis)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04862663",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-11-01; topline could slip to 2028.",
  "us_tradable": true,
  "nct_id": "NCT04862663",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0041",
  "guidance_detail": "Phase 3; registry primary completion 2027-11-01; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "baxdrostat",
  "indication": "primary aldosteronism",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "lorundrostat (Mineralys)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07007793",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Phase 3; registry primary completion 2027-07-27; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT07007793",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0042",
  "guidance_detail": "Phase 3; registry primary completion 2027-07-27; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0002"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "BAYRY",
  "company": "Bayer AG",
  "country": "Germany",
  "us_listed": false,
  "drug": "finerenone (FIONA)",
  "indication": "pediatric chronic kidney disease with proteinuria",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [],
  "source_url": "https://clinicaltrials.gov/study/NCT05196035",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-04-10; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT05196035",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0043",
  "guidance_detail": "Phase 3; registry primary completion 2027-04-10; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BAYRY",
  "company": "Bayer AG",
  "country": "Germany",
  "us_listed": false,
  "drug": "darolutamide (ARASTEP)",
  "indication": "hormone-sensitive prostate cancer with PSA rise after local therapies",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Erleada (Johnson & Johnson)",
   "Xtandi (Pfizer/Astellas)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05794906",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-07-30; Bayer guided two additional Phase 3 darolutamide readouts in 2027/2028.",
  "us_tradable": true,
  "nct_id": "NCT05794906",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0044",
  "guidance_detail": "Phase 3; registry primary completion 2027-07-30; Bayer guided two additional Phase 3 darolutamide readouts in 2027/2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BAYRY",
  "company": "Bayer AG",
  "country": "Germany",
  "us_listed": false,
  "drug": "sevabertinib (SOHO-02)",
  "indication": "HER2-mutant advanced non-small cell lung cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Kadcyla (Roche)",
   "Enhertu (Daiichi Sankyo/AstraZeneca)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06452277",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3 confirmatory; registry primary completion 2027-10-28; drug received accelerated US approval Sep 2026; topline could slip to 2028.",
  "us_tradable": true,
  "nct_id": "NCT06452277",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0045",
  "guidance_detail": "Phase 3 confirmatory; registry primary completion 2027-10-28; drug received accelerated US approval Sep 2026; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BBIO",
  "company": "BridgeBio Pharma, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "encaleret",
  "indication": "autosomal dominant hypocalcemia type 1 (ADH1)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-05-08",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [],
  "source_url": "https://investor.bridgebio.com/news/news-details/2026/BridgeBio-Announces-FDA-Acceptance-of-NDA-for-Encaleret-for-ADH1/default.aspx",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "FDA accepted NDA; PDUFA May 8, 2027; no AdCom planned; no approved or advanced competitor in ADH1.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0046",
  "guidance_detail": "FDA accepted NDA; PDUFA May 8, 2027; no AdCom planned; no approved or advanced competitor in ADH1.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BCRX",
  "company": "BioCryst Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "navenibart (ALPHA-ORBIT)",
  "indication": "hereditary angioedema",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "guidance",
  "competitors": [
   "Takhzyro (Takeda)",
   "Haegarda (CSL Behring)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/29/3318829/29446/en/BioCryst-Sharpens-Scientific-Focus-on-External-Innovation-with-Wind-Down-of-Internal-Discovery-Programs-and-Closure-of-Birmingham-Research-Facility.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Six- and 12-month Phase 3 ALPHA-ORBIT endpoints guided Q3 2027.",
  "us_tradable": true,
  "nct_id": "NCT06842823",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0047",
  "guidance_detail": "Six- and 12-month Phase 3 ALPHA-ORBIT endpoints guided Q3 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0048"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for navenibart (ALPHA-ORBIT) in hereditary angioedema is expected in Q3 2027 \u2014 the pivotal readout that determines whether BioCryst Pharmaceuticals, Inc. can file for approval."
 },
 {
  "ticker": "BCRX",
  "company": "BioCryst Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "navenibart",
  "indication": "hereditary angioedema",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Takhzyro (Takeda)",
   "Haegarda (CSL Behring)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/05/04/3286545/29446/en/BioCryst-Announces-European-Licensing-Agreement-with-Irish-Affiliate-of-Neopharmed-Gentili-for-Navenibart-in-Hereditary-Angioedema.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "US regulatory filing guided by end-2027; navenibart is a monoclonal antibody (BLA pathway).",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0048",
  "guidance_detail": "US regulatory filing guided by end-2027; navenibart is a monoclonal antibody (BLA pathway).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "BioCryst Pharmaceuticals, Inc. is expected to file its biologics license application for navenibart in hereditary angioedema in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "ONC",
  "company": "BeOne Medicines Ltd.",
  "country": "United States",
  "us_listed": true,
  "drug": "tislelizumab + chemotherapy",
  "indication": "urothelial carcinoma",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Keytruda (Merck)",
   "Tecentriq (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03967977",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-06-30; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT03967977",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0049",
  "guidance_detail": "Phase 3; registry primary completion 2027-06-30; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ONC",
  "company": "BeOne Medicines Ltd.",
  "country": "United States",
  "us_listed": true,
  "drug": "zanubrutinib",
  "indication": "primary membranous nephropathy",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Fabhalta (Novartis)",
   "Gazyva (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05707377",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 2/3; registry primary completion 2027-10; topline could slip to 2028.",
  "us_tradable": true,
  "nct_id": "NCT05707377",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0050",
  "guidance_detail": "Phase 2/3; registry primary completion 2027-10; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ONC",
  "company": "BeOne Medicines Ltd.",
  "country": "United States",
  "us_listed": true,
  "drug": "tislelizumab SC vs IV + chemotherapy",
  "indication": "unresectable/metastatic gastric or GEJ adenocarcinoma",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Keytruda (Merck)",
   "Opdivo (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07043400",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-10-30; topline could slip to 2028.",
  "us_tradable": true,
  "nct_id": "NCT07043400",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0051",
  "guidance_detail": "Phase 3; registry primary completion 2027-10-30; topline could slip to 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BHVN",
  "company": "Biohaven Ltd.",
  "country": "United States",
  "us_listed": true,
  "drug": "BHV-8000",
  "indication": "early Parkinson's disease",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "tavapadon (AbbVie)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06976268",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 2/3; registry primary completion 2027-08; record verified Sep 2026.",
  "us_tradable": true,
  "nct_id": "NCT06976268",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0052",
  "guidance_detail": "Phase 2/3; registry primary completion 2027-08; record verified Sep 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for BHV-8000 in early Parkinson's disease is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Biohaven Ltd. can file for approval."
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "felzartamab (TRANSCEND)",
  "indication": "antibody-mediated rejection in kidney transplant",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "ALXN2030 (AstraZeneca)"
  ],
  "source_url": "https://www.fool.com/earnings/call-transcripts/2026/08/07/biogen-biib-q2-2026-earnings-call-transcript/",
  "source_type": "earnings transcript",
  "as_of": "2026-09-23",
  "notes": "Phase 3 TRANSCEND readout guided H1 2027 per Biogen Q2 2026 earnings call: Head of Development Priya Singhal: 'we have also accelerated the expected phase III readouts for felzartamab in AMR, with data now expected in the first half of 2027' (verbatim call transcript via MarketBeat). Biogen 8-K Ex. 99.1 (Q2 2026) independently confirms the Phase 3 readout is 'anticipated next year' (2027). Re-verified 2026-09-20. Full verbatim transcript of Biogen's Q2 2026 earnings call (July 29, 2026): Head of Development Priya Singhal states felzartamab in AMR and litifilimab in CLE Phase 3 readouts were 'accelerated... with data now expected in the first half of 2027.' H1 timing is management oral guidance; Biogen's official Q2 2026 press release says only 'next year' (2027).",
  "us_tradable": true,
  "nct_id": "NCT06685757",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0053",
  "guidance_detail": "Phase 3 TRANSCEND readout guided H1 2027 per Biogen Q2 2026 earnings call: Head of Development Priya Singhal: 'we have also accelerated the expected phase III readouts for felzartamab in AMR, with data now expected in the first half of 2027' (verbatim call transcript via MarketBeat).",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0058"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "litifilimab (AMETHYST)",
  "indication": "cutaneous lupus erythematosus",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "Saphnelo (AstraZeneca)"
  ],
  "source_url": "https://www.fool.com/earnings/call-transcripts/2026/08/07/biogen-biib-q2-2026-earnings-call-transcript/",
  "source_type": "earnings transcript",
  "as_of": "2026-09-23",
  "notes": "Phase 3 AMETHYST readout guided H1 2027 per Biogen Q2 2026 earnings call: Head of Development Priya Singhal: 'we have also accelerated the expected phase III readouts for litifilimab in CLE, with data now expected in the first half of 2027' (verbatim call transcript via MarketBeat). Biogen 8-K Ex. 99.1 (Q2 2026) independently confirms the Phase 3 readout is 'anticipated next year' (2027). Re-verified 2026-09-20. Same transcript as row 54: Priya Singhal confirms litifilimab (AMETHYST) CLE Phase 3 readout accelerated to H1 2027. Oral management guidance; not stated in Biogen's written Q2 2026 materials, which only reference 'next year.'",
  "us_tradable": true,
  "nct_id": "NCT05531565",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0054",
  "guidance_detail": "Phase 3 AMETHYST readout guided H1 2027 per Biogen Q2 2026 earnings call: Head of Development Priya Singhal: 'we have also accelerated the expected phase III readouts for litifilimab in CLE, with data now expected in the first half of 2027' (verbatim call transcript via MarketBeat).",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "zorevunersen (EMPEROR)",
  "indication": "Dravet syndrome",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "guidance",
  "competitors": [
   "Fintepla (UCB)",
   "Epidiolex (Jazz Pharmaceuticals)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260903210314/en/Stoke-Therapeutics-and-Biogen-Present-Long-Term-Clinical-Data-that-Support-the-Disease-Modifying-Potential-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome-at-the-16th-European-Epilepsy-Congress-EEC",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Phase 3 EMPEROR readout guided Q3 2027; rolling NDA completion planned H2 2027. Intentional multi-ticker entry: same EMPEROR readout as the STOK row (partnered program).",
  "us_tradable": true,
  "nct_id": "NCT06872125",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0055",
  "guidance_detail": "Phase 3 EMPEROR readout guided Q3 2027; rolling NDA completion planned H2 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0205",
   "v16-0056",
   "v16-0204",
   "v16-0105"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "zorevunersen",
  "indication": "Dravet syndrome",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Fintepla (UCB)",
   "Epidiolex (Jazz Pharmaceuticals)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260903210314/en/Stoke-Therapeutics-and-Biogen-Present-Long-Term-Clinical-Data-that-Support-the-Disease-Modifying-Potential-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome-at-the-16th-European-Epilepsy-Congress-EEC",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Rolling NDA completion planned H2 2027 per Biogen/Stoke Sep 2026 update.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0056",
  "guidance_detail": "Rolling NDA completion planned H2 2027 per Biogen/Stoke Sep 2026 update.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "tofersen (ATLAS)",
  "indication": "presymptomatic SOD1-ALS",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "tofersen (Biogen/Ionis)"
  ],
  "source_url": "https://www.biospace.com/fda-adcomm-backs-accelerated-approval-for-biogen-s-tofersen",
  "source_type": "trade press",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-08-07; ATLAS is the confirmatory study for Qalsody with 2027 data expected. Reviewed 2026-09-20: upgraded inferred->guidance; BioSpace reports Biogen FDA briefing docs state ATLAS data expected in 2027 (company-derived, year-level); bucket 2027-H2 retained.",
  "us_tradable": true,
  "nct_id": "NCT04856982",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0057",
  "guidance_detail": "Phase 3; registry primary completion 2027-08-07; ATLAS is the confirmatory study for Qalsody with 2027 data expected.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0004"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "felzartamab (PREVAIL)",
  "indication": "IgA nephropathy",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Fabhalta (Novartis)",
   "Trutakna (Vera Therapeutics)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06935357",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-05-31; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT06935357",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0058",
  "guidance_detail": "Phase 3; registry primary completion 2027-05-31; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0053",
   "v16-0148"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "higher-dose nusinersen (ASCEND)",
  "indication": "spinal muscular atrophy (post-risdiplam)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Evrysdi (Roche)",
   "Zolgensma (Novartis)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05067790",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-09-24; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT05067790",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0059",
  "guidance_detail": "Phase 3; registry primary completion 2027-09-24; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BIIB",
  "company": "Biogen Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "peginterferon beta-1a (pediatric)",
  "indication": "pediatric relapsing-remitting multiple sclerosis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "Gilenya (Novartis)",
   "Copaxone (Teva)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03958877",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3; registry primary completion 2027-05-20; no company 2027 guidance found.",
  "us_tradable": true,
  "nct_id": "NCT03958877",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0060",
  "guidance_detail": "Phase 3; registry primary completion 2027-05-20; no company 2027 guidance found.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "BMRN",
  "company": "BioMarin Pharmaceutical Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "BMN 333",
  "indication": "achondroplasia",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "infigratinib (BridgeBio)",
   "TransCon CNP (Ascendis Pharma)"
  ],
  "source_url": "https://www.biomarin.com/news/press-releases/biomarin-announces-new-three-year-voxzogo-vosoritide-data-in-hypochondroplasia-and-bmn-333-early-results-at-endo-2026/",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Registration-enabling Phase 2/3 dose-finding update expected 2027; not full pivotal topline.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0061",
  "guidance_detail": "Registration-enabling Phase 2/3 dose-finding update expected 2027; not full pivotal topline.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "mezigdomide",
  "indication": "relapsed/refractory multiple myeloma",
  "event_type": "pdufa",
  "phase": "3",
  "date_exact": "2027-05-13",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [
   "Carvykti (Johnson & Johnson/Legend Biotech)",
   "linvoseltamab (Regeneron)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260713597234/en/U.S.-Food-and-Drug-Administration-Accepts-Bristol-Myers-Squibbs-New-Drug-Application-for-Mezigdomide-in-Patients-with-Relapsed-or-Refractory-Multiple-Myeloma",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "FDA accepted NDA for mezigdomide (MeziKd: oral mezigdomide + carfilzomib + dexamethasone) in relapsed/refractory multiple myeloma, based on Phase 3 SUCCESSOR-2 (NCT05552976; PFS 18.0 vs 8.3 months, HR 0.48, p<0.0001). BMS PR 2026-07-13: 'The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of May 13, 2027 for this indication.' GAP: acceptance letter text not viewed; acceptance confirmed via company PR only. Distinct from v17-0037 (CA057-1040 Ph1/2 readout) and v16-0067 (SUCCESSOR-1 readout). iberdomide NDA acceptance (Feb 2026, PDUFA Aug 17 2026) is a separate 2026 event, not in the 2027 book. Re-checked 2026-09-23: BMS July 13, 2026 acceptance release prints exact PDUFA date of May 13, 2027 - upgraded guidance to hard. Quarter unchanged (Q2). Source: businesswire.com/news/home/20260713597234/en/. Quote: \"May 13, 2027\".",
  "us_tradable": true,
  "nct_id": "NCT05552976",
  "application_type": "NDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0062",
  "guidance_detail": "FDA accepted NDA for mezigdomide (MeziKd: oral mezigdomide + carfilzomib + dexamethasone) in relapsed/refractory multiple myeloma, based on Phase 3 SUCCESSOR-2 (NCT05552976; PFS 18.0 vs 8.3 months, HR 0.48, p<0.0001). BMS PR 2026-07-13: 'The FDA has granted a Prescription Drug User Fee Act (PDUFA) date of May 13, 2027 for this indication.' GAP: acceptance letter text not viewed; acceptance confirmed via company PR only. Distinct from v17-0037 (CA057-1040 Ph1/2 readout) and v16-0067 (SUCCESSOR-1 readout). iberdomide NDA acceptance (Feb 2026, PDUFA Aug 17 2026) is a separate 2026 event, not in the 2027 book.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_to_hard",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0067"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "milvexian (LIBREXIA-AF)",
  "indication": "atrial fibrillation (stroke prevention)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Xarelto (Bayer)",
   "Xarelto (Johnson & Johnson)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Phase 3 LIBREXIA-AF topline guided Q1 2027 per BMS Q2 2026 Results presentation (July 30, 2026): milvexian pipeline appendix (Phase III LIBREXIA-AF, NCT05757869, non-valvular atrial fibrillation) lists \"Projected data readout Q1 2027 (event driven)\". [V17 audit 2026-09-23: removed older stale snippet citing a 2026 readout which contradicted the row bucket; fresh deck read confirms Q1 2027.]",
  "us_tradable": true,
  "nct_id": "NCT05757869",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0063",
  "guidance_detail": "Phase 3 LIBREXIA-AF topline guided Q1 2027 per Q2 2026 earnings materials.",
  "audit_status": "v17_reverified",
  "audit_action": "corrected",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0145"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "admilparant (ALOFT-PPF)",
  "indication": "progressive pulmonary fibrosis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Registrational readout guided 2027 per Q2 2026 investor deck.",
  "us_tradable": true,
  "nct_id": "NCT06025578",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0064",
  "guidance_detail": "Registrational readout guided 2027 per Q2 2026 investor deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "Cobenfy (KarXT) \u2014 ADEPT-1",
  "indication": "Alzheimer's disease psychosis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Nuplazid (Acadia)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "ADEPT-1 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT05511363). BMS guides ADEPT-1/-2/-4 readouts to begin early 2027 and continue through 2027; per-trial windows not separately guided. Row split from combined ADEPT-1/-2/-4 row on 2026-09-23.",
  "us_tradable": true,
  "nct_id": "NCT05511363",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0065",
  "guidance_detail": "ADEPT-1 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT05511363).",
  "audit_status": "v17_reverified",
  "audit_action": "corrected",
  "date_history": [
   {
    "from": "2027-H1",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "BMS Q2 2026 deck guides ADEPT program at year-level 2027; per-trial H1 was invented precision"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0023",
   "v17-0022",
   "v17-0021",
   "v16-0066"
  ],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "Cobenfy (KarXT) \u2014 BALSAM-1",
  "indication": "bipolar I disorder",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Vraylar (AbbVie)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "BALSAM-1 Phase 3 readout in manic episodes in bipolar-I disorder (NCT06951698). BMS guides BALSAM-1/-2 readouts in 2027; individual study windows unresolved. Row split from combined BALSAM-1/-2 row on 2026-09-23.",
  "us_tradable": true,
  "nct_id": "NCT06951698",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0066",
  "guidance_detail": "BALSAM-1 Phase 3 readout in manic episodes in bipolar-I disorder (NCT06951698).",
  "audit_status": "v17_reverified",
  "audit_action": "split",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0023",
   "v17-0022",
   "v17-0021",
   "v16-0065"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "mezigdomide (SUCCESSOR-1)",
  "indication": "relapsed/refractory multiple myeloma",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Carvykti (Johnson & Johnson/Legend Biotech)",
   "linvoseltamab (Regeneron)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Registrational SUCCESSOR-1 readout guided 2027 per Q2 2026 investor deck.",
  "us_tradable": true,
  "nct_id": "NCT05519085",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0067",
  "guidance_detail": "Registrational SUCCESSOR-1 readout guided 2027 per Q2 2026 investor deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0062"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "sotyktu (POETYK SjS-1)",
  "indication": "Sjogren's syndrome",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "dazodalibep (Amgen)",
   "ianalumab (Novartis)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Registrational POETYK SjS-1 readout guided 2027 per Q2 2026 investor deck.",
  "us_tradable": true,
  "nct_id": "NCT05946941",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0068",
  "guidance_detail": "Registrational POETYK SjS-1 readout guided 2027 per Q2 2026 investor deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "golcadomide (GOLSEEK-1)",
  "indication": "non-Hodgkin lymphoma",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Ordspono (Regeneron)",
   "Epkinly (AbbVie)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Registrational GOLSEEK-1 readout guided 2027 per Q2 2026 investor deck.",
  "us_tradable": true,
  "nct_id": "NCT06356129",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0069",
  "guidance_detail": "Registrational GOLSEEK-1 readout guided 2027 per Q2 2026 investor deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0644"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "zolacel (Breakfree-SLE)",
  "indication": "systemic lupus erythematosus",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Benlysta (GSK)",
   "Saphnelo (AstraZeneca)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Pivotal Breakfree-SLE readout guided 2027 per Q2 2026 investor deck. PHASE CORRECTION (2026-09-23): CT.gov NCT07015983 phases=['PHASE2'] - protocol outranks marketing language; BMS Q2 2026 deck describes Breakfree-SLE as pivotal/registrational (noted here, does not change phase tag). Re-checked 2026-09-23: Q2 2026 BMS deck guides Breakfree-SLE readout in 2027, but BMS voluntarily paused enrollment across its zola-cel (zolacabtagene autoleucel, BMS-986353) autoimmune program in late Aug 2026 after detecting transient and reversible inflammatory events during routine safety surveillance (reported Aug 31-Sep 1, 2026). BMS says it aims to resume as quickly as possible and the pause is precautionary, not a regulatory hold - but the 2027 readout timing is now at risk and under review. Bucket kept at 2027. Source: https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf. Quote: \"Bristol Myers Squibb voluntarily pauses enrollment in its Zola-cel autoimmune studies over transient inflammatory events.\". [Registry check 2026-09-23] CT.gov now lists primary completion 2028-05-17 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT07015983",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0070",
  "guidance_detail": "Pivotal Breakfree-SLE readout guided 2027 per Q2 2026 investor deck.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "BMS-986365 (rechARge)",
  "indication": "metastatic castration-resistant prostate cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Zytiga (Johnson & Johnson)",
   "Xtandi (Pfizer/Astellas)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 rechARge (NCT06764485) readout projected 2027 per Q2 2026 investor deck.",
  "us_tradable": true,
  "nct_id": "NCT06764485",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0071",
  "guidance_detail": "Phase 3 rechARge (NCT06764485) readout projected 2027 per Q2 2026 investor deck.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "CABA",
  "company": "Cabaletta Bio, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "rese-cel (resecabtagene autoleucel)",
  "indication": "myositis",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "KYV-101 (Kyverna Therapeutics)",
   "Orencia (Bristol Myers Squibb)"
  ],
  "source_url": "https://www.cabalettabio.com/news-media/press-releases/detail/128/cabaletta-bio-announces-2027-rese-cel-bla-submission",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "BLA submission guided for 2027, reconfirmed in Jan 2026 strategic priorities.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0072",
  "guidance_detail": "BLA submission guided for 2027, reconfirmed in Jan 2026 strategic priorities.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Cabaletta Bio, Inc. is expected to file its biologics license application for rese-cel (resecabtagene autoleucel) in myositis sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Dyne Therapeutics, Inc.",
  "competitors": [
   "Exondys 51 (Sarepta)",
   "deramiocel (Capricor)",
   "WVE-N531 (Wave Life Sciences)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-21",
  "date_quality": "hard",
  "drug": "zeleciment rostudirsen (z-rostudirsen, DYNE-251)",
  "event_type": "pdufa",
  "indication": "Duchenne muscular dystrophy amenable to exon 51 skipping",
  "notes": "FDA accepted BLA and granted Priority Review; exact PDUFA date disclosed in company PR.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/20/3329635/0/en/Dyne-Therapeutics-Announces-U-S-FDA-Acceptance-of-Biologics-License-Application-BLA-for-Z-Rostudirsen-in-Exon-51-Duchenne-Muscular-Dystrophy-DMD.html",
  "ticker": "DYN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0073",
  "guidance_detail": "FDA accepted BLA and granted Priority Review; exact PDUFA date disclosed in company PR.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for z-rostudirsen (DYNE-251) in Duchenne muscular dystrophy amenable to exon 51 skipping is expected on 2027-01-21 \u2014 the pivotal readout that determines whether Dyne Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Cellectar Biosciences, Inc.",
  "competitors": [
   "Brukinsa (BeOne Medicines)",
   "Venclexta (AbbVie)",
   "Jaypirca (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "iopofosine I-131",
  "event_type": "nda_filing",
  "indication": "relapsed/refractory Waldenstrom macroglobulinemia",
  "notes": "Company guides NDA submission mid-2027 under Accelerated Approval (Q2/Q3 boundary); pivotal CLOVER-2 data support filing.",
  "phase": null,
  "source_type": "SEC 10-Q",
  "source_url": "https://www.cellectar.com/investors/sec-filings/all-sec-filings/content/0001104659-26-060693/0001104659-26-060693.pdf",
  "ticker": "CLRB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0074",
  "guidance_detail": "Company guides NDA submission mid-2027 under Accelerated Approval (Q2/Q3 boundary); pivotal CLOVER-2 data support filing.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Cellectar Biosciences, Inc. is expected to file its new drug application for iopofosine I-131 in relapsed/refractory Waldenstrom macroglobulinemia in Q2 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-23",
  "company": "COMPASS Pathways plc",
  "competitors": [
   "Spravato (Johnson & Johnson)",
   "Auvelity (Axsome Therapeutics)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "COMP360 (psilocybin)",
  "event_type": "regulatory_other",
  "indication": "treatment-resistant depression",
  "notes": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Rolling NDA final submission guided Q4 2026; Breakthrough Therapy designation suggests priority review (~6-month clock) and company anticipates launch H1 2027 subject to approval and DEA rescheduling; timing implied by submission guidance only \u2014 re-verify at monthly refresh. Reviewed 2026-09-20: upgraded inferred->guidance; company guides COMP360 launch H1 2027 conditional on FDA approval and DEA rescheduling (rolling NDA, final submission on track Q4 2026); event is conditional, noted honestly.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://ir.compasspathways.com/News--Events-/news/news-details/2026/Compass-Pathways-Announces-Six-Month-Data-from-Second-Phase-3-Trial-Confirming-Rapid-and-Durable-Profile/default.aspx",
  "ticker": "CMPS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0075",
  "guidance_detail": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Rolling NDA final submission guided Q4 2026; Breakthrough Therapy designation suggests priority review (~6-month clock) and company anticipates launch H1 2027 subject to approval and DEA rescheduling; timing implied by submission guidance only \u2014 re-verify at monthly refresh.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24",
  "why_it_matters": "Compass Pathways' rolling NDA for COMP360 (psilocybin) in treatment-resistant depression is guided to complete in Q4 2026, with a possible FDA decision in the first half of 2027."
 },
 {
  "ticker": "COGT",
  "company": "Cogent Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "bezuclastinib",
  "indication": "advanced systemic mastocytosis (AdvSM)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-06-29",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [
   "Ayvakit (Sanofi)",
   "Rydapt (Novartis)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/09/15/3361988/0/en/cogent-biosciences-announces-fda-acceptance-of-new-drug-application-nda-for-bezuclastinib-in-patients-with-advanced-systemic-mastocytosis-advsm.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "FDA accepted NDA and set PDUFA target action date 2027-06-29; no AdCom planned at this time. NonAdvSM (2026-12-30) and GIST (2026-11-30) PDUFAs fall in 2026. [Source verified 2026-09-20: FDA has accepted its New Drug Application (NDA) for bezuclastinib in patients with Advanced Systemic Mastocytosis (AdvSM) and assigned a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2027. In addi]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0076",
  "guidance_detail": "FDA accepted NDA and set PDUFA target action date 2027-06-29; no AdCom planned at this time.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on bezuclastinib for advanced systemic mastocytosis (AdvSM) falls on 2027-06-29 \u2014 the agency's yes-or-no moment for Cogent Biosciences, Inc.'s application."
 },
 {
  "ticker": "DFTX",
  "company": "Definium Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "DT120 ODT (lysergide tartrate)",
  "indication": "generalized anxiety disorder (GAD)",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "CYB004 (Cybin)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260914329364/en/Definium-Therapeutics-Announces-Positive-Topline-Results-from-Phase-3-Panorama-Study-of-DT120-ODT-in-Generalized-Anxiety-Disorder",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Company guides pre-NDA meeting in 4Q 2026 and NDA filing anticipated in 1H 2027 following three positive Phase 3 readouts (Voyage/Panorama in GAD, Emerge in MDD).",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0077",
  "guidance_detail": "Company guides pre-NDA meeting in 4Q 2026 and NDA filing anticipated in 1H 2027 following three positive Phase 3 readouts (Voyage/Panorama in GAD, Emerge in MDD).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Definium Therapeutics, Inc. is expected to file its new drug application for DT120 ODT (lysergide tartrate) in generalized anxiety disorder (GAD) in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "DFTX",
  "company": "Definium Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "DT120 ODT (lysergide tartrate)",
  "indication": "major depressive disorder (MDD)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "COMP360 (COMPASS Pathways)",
   "CYB003 (Cybin)",
   "Spravato (Johnson & Johnson)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260512064160/en/Definium-Therapeutics-Announces-First-Patient-Dosed-in-Ascend-the-Second-Phase-3-Pivotal-Study-of-DT120-ODT-in-Major-Depressive-Disorder",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Ascend is the second pivotal Phase 3 in MDD (12-week double-blind vs placebo, n~175); topline anticipated in 2027.",
  "us_tradable": true,
  "nct_id": "NCT07592689",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0078",
  "guidance_detail": "Ascend is the second pivotal Phase 3 in MDD (12-week double-blind vs placebo, n~175); topline anticipated in 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0077",
   "v16-0230",
   "v16-0133"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for DT120 ODT (lysergide tartrate) in major depressive disorder (MDD) is expected sometime in 2027 \u2014 the pivotal readout that determines whether Definium Therapeutics, Inc. can file for approval."
 },
 {
  "ticker": "CLDX",
  "company": "Celldex Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "barzolvolimab",
  "indication": "chronic spontaneous urticaria (CSU)",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Rhapsido (Novartis)",
   "Dupixent (Regeneron/Sanofi)",
   "Dupixent (Regeneron/Sanofi)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/02/25/3244485/24180/en/Celldex-Completes-Enrollment-in-Global-Phase-3-Studies-EMBARQ-CSU1-and-EMBARQ-CSU2-of-Barzolvolimab-in-Chronic-Spontaneous-Urticaria.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "BLA submission planned for 2027 following Q4 2026 Phase 3 topline (EMBARQ-CSU1/2 enrollment completed 6 months ahead of guidance).",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0079",
  "guidance_detail": "BLA submission planned for 2027 following Q4 2026 Phase 3 topline (EMBARQ-CSU1/2 enrollment completed 6 months ahead of guidance).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Celldex Therapeutics, Inc. is expected to file its biologics license application for barzolvolimab in chronic spontaneous urticaria (CSU) sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "CGEM",
  "company": "Cullinan Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "zipalertinib",
  "indication": "locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-27",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "Rybrevant (Johnson & Johnson)"
  ],
  "source_url": "https://www.taihooncology.com/us/news/us-food-and-drug-administration-accepts-new-drug-application-for-zipalertinib-for-the-treatment-of-locally-advanced-or-metastatic-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations/",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "FDA accepted NDA (post-platinum, with or without prior amivantamab) with PDUFA 2027-02-27 per Cullinan/Taiho; REZILIENT3 first-line Ph3 read out 2026, not a 2027 event.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0080",
  "guidance_detail": "FDA accepted NDA (post-platinum, with or without prior amivantamab) with PDUFA 2027-02-27 per Cullinan/Taiho; REZILIENT3 first-line Ph3 read out 2026, not a 2027 event.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on zipalertinib for locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations after platinum-based chemotherapy falls on 2027-02-27 \u2014 the agency's yes-or-no moment for Cullinan Therapeutics, Inc.'s application."
 },
 {
  "ticker": "CRMD",
  "company": "CorMedix Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "REZZAYO (rezafungin for injection)",
  "indication": "prophylaxis of invasive fungal disease in adults undergoing allogeneic hematopoietic stem cell transplant",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "PFE (fluconazole/voriconazole)",
   "MRK (posaconazole)",
   "ALPMY (micafungin/isavuconazole)"
  ],
  "source_url": "https://cormedix.com/wp-content/uploads/2026/06/CorMedix_Corporate-Presentation_5-22-26-vF.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-18",
  "notes": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA. CorMedix (Aug 13, 2026 PR) anticipates sNDA submission for expanded REZZAYO prophylaxis indication in Q3 2026; FDA action guided H1 2027 only 'provided the application is accepted for FDA review'. Reclassified per the PDUFA acceptance gate (v1.4). Deck lists 'REZZAYO prophylaxis sNDA submission and potential approval' under 2026 / 1H 2027; keep the H1-2027-if-accepted-for-review caveat from the Q2 2026 PR.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0081",
  "guidance_detail": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "CorMedix expects to submit its supplemental application expanding REZZAYO to fungal-disease prophylaxis in Q3 2026, with an FDA decision possible in the first half of 2027."
 },
 {
  "ticker": "VRTX",
  "company": "Vertex Pharmaceuticals Incorporated",
  "country": "United States",
  "us_listed": true,
  "drug": "atumelnant",
  "indication": "classic congenital adrenal hyperplasia (21-hydroxylase deficiency) in adults",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "NBIX (crinecerfont/Crenessity)",
   "Spruce Biosciences (tildacerfont)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07144163",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "CT.gov: Phase 3 CALM-CAH est. primary completion May 2027 (N=150, 32-wk treatment); topline typically follows within months; no company 2027 readout guidance found. Crinetics acquired by Vertex; deal closed before market open 2026-09-01; program now under VRTX.",
  "us_tradable": true,
  "nct_id": "NCT07144163",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0082",
  "guidance_detail": "CT.gov: Phase 3 CALM-CAH est.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "VRTX",
  "company": "Vertex Pharmaceuticals Incorporated",
  "country": "United States",
  "us_listed": true,
  "drug": "paltusotine",
  "indication": "carcinoid syndrome due to well-differentiated neuroendocrine tumors",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "inferred",
  "competitors": [
   "NVS (octreotide)",
   "IPSEY (lanreotide)",
   "LXRX (telotristat)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07087054",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "CT.gov: Phase 3 CAREFNDR est. primary completion Aug 2027 (16-wk blinded period, 104-wk extension); topline may fall Q4 2027 or early 2028. Crinetics acquired by Vertex; deal closed before market open 2026-09-01; program now under VRTX.",
  "us_tradable": true,
  "nct_id": "NCT07087054",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0083",
  "guidance_detail": "CT.gov: Phase 3 CAREFNDR est.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "CYTK",
  "company": "Cytokinetics, Incorporated",
  "country": "United States",
  "us_listed": true,
  "drug": "aficamten (MYQORZO)",
  "indication": "non-obstructive hypertrophic cardiomyopathy (nHCM)",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "inferred",
  "competitors": [
   "BMY (mavacamten/Camzyos)"
  ],
  "source_url": "https://ir.cytokinetics.com/press-releases/press-release-details/2026/Cytokinetics-Announces-Positive-Results-from-ACACIA-HCM-Presented-in-Hot-Line-Session-at-the-European-Society-of-Cardiology-ESC-Congress-2026-and-Published-in-The-New-England-Journal-of-Medicine/default.aspx",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Company plans sNDA in Q4 2026 following positive Phase 3 ACACIA-HCM topline (May 2026) and guides potential nHCM launch in 2027; no acceptance or PDUFA date disclosed yet; re-verify at monthly refresh. [Source verified 2026-09-20: Official Cytokinetics IR release (Aug 28, 2026, GlobeNewswire): 'Based on the positive results from ACACIA-HCM, Cytokinetics plans to submit a supplemental New Drug Application to the U.S. Food and Drug Administration (F]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0084",
  "guidance_detail": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Company plans sNDA in Q4 2026 following positive Phase 3 ACACIA-HCM topline (May 2026) and guides potential nHCM launch in 2027; no acceptance or PDUFA date disclosed yet; re-verify at monthly refresh.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "HELP",
  "company": "Helus Pharma Inc.",
  "country": "Canada",
  "us_listed": true,
  "drug": "CYB003 (deuterated psilocin analog)",
  "indication": "major depressive disorder (MDD)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "CMPS (COMP360)",
   "JNJ (Spravato)",
   "AXSM (Auvelity)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06793397",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3 EMBRACE (CYB003 deuterated psilocin analog, MDD, N=330); registry primary completion 2027-06-07 (RECRUITING per 2026-09-27 CT.gov API check); topline typically at/after PCD -> 2027-H1 bucket. No company EMBRACE readout guidance found in any primary source (Sep 2025 milestone release and Nov 2025 deck cover only APPROACH topline Q4 2026 and EMBRACE initiation Q4 2025); the prior Q1 2027 claim traced to an aggregator extrapolation and has been removed. Company renamed Cybin Inc. -> Helus Pharma Inc., ticker CYBN -> HELP, effective 2026-10-01 (shareholder-approved 2026-09-22; company GlobeNewswire release). [2026-09-27 link audit] Replaced bot-walled AInvest aggregator URL with the official CT.gov registry record (NCT06793397).",
  "us_tradable": true,
  "nct_id": "NCT06793397",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0085",
  "guidance_detail": "CT.gov: Phase 3 EMBRACE est.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0230",
   "v16-0133"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for CYB003 (deuterated psilocin analog) in major depressive disorder (MDD) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Cybin Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Exelixis, Inc.",
  "competitors": [
   "regorafenib (Stivarga)",
   "fruquintinib (Fruzaqla)",
   "trifluridine/tipiracil (Lonsurf)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-03",
  "date_quality": "hard",
  "drug": "zanzalintinib (XL092) + atezolizumab (Tecentriq)",
  "event_type": "pdufa",
  "indication": "previously treated metastatic colorectal cancer",
  "notes": "FDA extended the original 2026-12-03 target action date to 2027-03-03 after updated safety and efficacy data submitted in response to an FDA information request were classified as a major amendment. Disclosed by the company via Form 8-K (Item 8.01) filed 2026-09-11; no standalone company PR exists \u2014 sourced via Reuters' direct quote of the filing.",
  "phase": null,
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/cgi-bin/browse-edgar?CIK=EXEL&owner=exclude&action=getcompany&Find=Search",
  "ticker": "EXEL",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0086",
  "guidance_detail": "FDA extended the original 2026-12-03 target action date to 2027-03-03 after updated safety and efficacy data submitted in response to an FDA information request were classified as a major amendment.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "EyePoint Pharmaceuticals, Inc.",
  "competitors": [
   "faricimab (Vabysmo)",
   "aflibercept 8 mg (Eylea HD)",
   "brolucizumab (Beovu)",
   "ranibizumab port delivery system (Susvimo)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DURAVYU (vorolanib intravitreal insert) \u2014 COMO",
  "event_type": "readout",
  "indication": "diabetic macular edema",
  "notes": "COMO is one of two pivotal Phase 3 DME trials; company guided topline in Q4 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/30/3335900/0/en/EyePoint-Completes-Enrollment-of-Both-Pivotal-Phase-3-Trials-of-DURAVYU-for-Treatment-of-Diabetic-Macular-Edema-DME.html",
  "ticker": "EYPT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07449936",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0087",
  "guidance_detail": "COMO is one of two pivotal Phase 3 DME trials; company guided topline in Q4 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0089",
   "v16-0088"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for DURAVYU (vorolanib intravitreal insert) \u2014 COMO in diabetic macular edema is expected in Q4 2027 \u2014 the pivotal readout that determines whether EyePoint Pharmaceuticals, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "EyePoint Pharmaceuticals, Inc.",
  "competitors": [
   "faricimab (Vabysmo)",
   "aflibercept 8 mg (Eylea HD)",
   "brolucizumab (Beovu)",
   "ranibizumab port delivery system (Susvimo)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DURAVYU (vorolanib intravitreal insert) \u2014 CAPRI",
  "event_type": "readout",
  "indication": "diabetic macular edema",
  "notes": "CAPRI is the second pivotal Phase 3 DME trial; company guided topline in Q4 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/30/3335900/0/en/EyePoint-Completes-Enrollment-of-Both-Pivotal-Phase-3-Trials-of-DURAVYU-for-Treatment-of-Diabetic-Macular-Edema-DME.html",
  "ticker": "EYPT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07449923",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0088",
  "guidance_detail": "CAPRI is the second pivotal Phase 3 DME trial; company guided topline in Q4 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0089",
   "v16-0087"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for DURAVYU (vorolanib intravitreal insert) \u2014 CAPRI in diabetic macular edema is expected in Q4 2027 \u2014 the pivotal readout that determines whether EyePoint Pharmaceuticals, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Fortress Biotech, Inc.",
  "competitors": [
   "febuxostat (Uloric)",
   "allopurinol (generic)",
   "pegloticase (Krystexxa)",
   "verinurad (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "dotinurad \u2014 RUBY",
  "event_type": "readout",
  "indication": "gout (hyperuricemia)",
  "notes": "RUBY Phase 3 (NCT07089875) run by Urica/Crystalys; registry primary completion 2027-11-29 and management expects topline late 2027; Fortress holds indirect economic interest via minority Crystalys equity and 3% future net-sales royalty. PR confirms RUBY (NCT07089875) Phase 3 vs allopurinol in hyperuricemia associated with gout; registry API verifies estimated primary completion 2027-11-29. No management topline guidance in the PR, so date_quality guidance->inferred.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html",
  "ticker": "FBIO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07089875",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0090",
  "guidance_detail": "RUBY Phase 3 (NCT07089875) run by Urica/Crystalys; registry primary completion 2027-11-29 and management expects topline late 2027; Fortress holds indirect economic interest via minority Crystalys equity and 3% future net-sales royalty.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0878",
   "v16-0091"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for dotinurad \u2014 RUBY in gout (hyperuricemia) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Fortress Biotech, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Fortress Biotech, Inc.",
  "competitors": [
   "febuxostat (Uloric)",
   "allopurinol (generic)",
   "pegloticase (Krystexxa)",
   "verinurad (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "dotinurad \u2014 TOPAZ",
  "event_type": "readout",
  "indication": "tophaceous gout",
  "notes": "TOPAZ Phase 3 in tophaceous gout (NCT07089888); registry primary completion 2027-12-31 and topline expected late 2027. PR confirms TOPAZ (NCT07089888) Phase 3 in tophaceous gout; registry API verifies estimated primary completion 2027-12-31. No management topline guidance in the PR, so date_quality guidance->inferred.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/10/21/3170212/28889/en/Fortress-Biotech-and-Subsidiary-Urica-Therapeutics-Announce-First-Patients-Dosed-in-Crystalys-Therapeutics-Global-Phase-3-Trials-of-Dotinurad-for-the-Treatment-of-Gout.html",
  "ticker": "FBIO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07089888",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0091",
  "guidance_detail": "TOPAZ Phase 3 in tophaceous gout (NCT07089888); registry primary completion 2027-12-31 and topline expected late 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0878",
   "v16-0090"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for dotinurad \u2014 TOPAZ in tophaceous gout is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Fortress Biotech, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "4D Molecular Therapeutics, Inc.",
  "competitors": [
   "faricimab (Vabysmo)",
   "aflibercept 8 mg (Eylea HD)",
   "brolucizumab (Beovu)",
   "RGX-314 (REGENXBIO)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "4D-150 \u2014 4FRONT-1",
  "event_type": "readout",
  "indication": "wet age-related macular degeneration",
  "notes": "4FRONT-1 is one of two Phase 3 wet AMD trials of the intravitreal R100 vector-based gene therapy; topline guided H1 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3290540/0/en/4DMT-Reports-First-Quarter-2026-Financial-Results-Operational-Highlights-and-Expected-Upcoming-Milestones.html",
  "ticker": "FDMT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06864988",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0092",
  "guidance_detail": "4FRONT-1 is one of two Phase 3 wet AMD trials of the intravitreal R100 vector-based gene therapy; topline guided H1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0093",
   "v16-1046",
   "v16-1045"
  ],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for 4D-150 \u2014 4FRONT-1 in wet age-related macular degeneration is expected in the first half of 2027 \u2014 the pivotal readout that determines whether 4D Molecular Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "4D Molecular Therapeutics, Inc.",
  "competitors": [
   "faricimab (Vabysmo)",
   "aflibercept 8 mg (Eylea HD)",
   "brolucizumab (Beovu)",
   "RGX-314 (REGENXBIO)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "4D-150 \u2014 4FRONT-2",
  "event_type": "readout",
  "indication": "wet age-related macular degeneration",
  "notes": "4FRONT-2 is the second Phase 3 wet AMD trial of 4D-150; topline guided H2 2027. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-11 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3290540/0/en/4DMT-Reports-First-Quarter-2026-Financial-Results-Operational-Highlights-and-Expected-Upcoming-Milestones.html",
  "ticker": "FDMT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07064759",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0093",
  "guidance_detail": "4FRONT-2 is the second Phase 3 wet AMD trial of 4D-150; topline guided H2 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0092",
   "v16-1046"
  ],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for 4D-150 \u2014 4FRONT-2 in wet age-related macular degeneration is expected in the second half of 2027 \u2014 the pivotal readout that determines whether 4D Molecular Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Gilead Sciences, Inc.",
  "competitors": [
   "cabotegravir long-acting (Apretude)",
   "lenacapavir subcutaneous twice-yearly (Sunlenca)",
   "emtricitabine/tenofovir disoproxil fumarate (Truvada)",
   "emtricitabine/tenofovir alafenamide (Descovy)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-02",
  "date_quality": "hard",
  "drug": "Yeztugo (lenacapavir, oral once-weekly)",
  "event_type": "pdufa",
  "indication": "HIV pre-exposure prophylaxis",
  "notes": "FDA accepted the NDA for the once-weekly oral formulation, potentially the first long-acting pill for HIV prevention; standard-review action date 2027-02-02.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.gilead.com/news/news-details/2026/u-s--fda-accepts-gileads-application-for-investigational-once-weekly-oral-yeztugo-potentially-the-first-long-acting-pill-for-hiv-prevention",
  "ticker": "GILD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0094",
  "guidance_detail": "FDA accepted the NDA for the once-weekly oral formulation, potentially the first long-acting pill for HIV prevention; standard-review action date 2027-02-02.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Genmab A/S",
  "competitors": [
   "pembrolizumab (Keytruda)",
   "nivolumab (Opdivo)",
   "cetuximab (Erbitux)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "petosemtamab (with BioNTech)",
  "event_type": "readout",
  "indication": "head and neck squamous cell carcinoma, 2L/3L recurrent/metastatic",
  "notes": "Phase 3 topline in previously treated HNSCC guided for Q1 2027; EGFR x LGR5 bispecific antibody. Q1 2027 petosemtamab Phase 3 HNSCC readout timing is currently supported only by third-party call-transcript mirrors (MarketBeat, SeekingAlpha); no Quartr-hosted transcript or company/SEC evidence located. Keep Q1 2027 bucket with flagged confidence. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-02 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://attachment.news.eu.nasdaq.com/aa165d0f7ffb1bebe9428c153431d14dd",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06496178",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0095",
  "guidance_detail": "Phase 3 topline in previously treated HNSCC guided for Q1 2027; EGFR x LGR5 bispecific antibody.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Genmab A/S",
  "competitors": [
   "polatuzumab vedotin + R-CHP (Polivy)",
   "glofitamab (Roche)",
   "tafasitamab + lenalidomide (Monjuvi)",
   "zilovertamab vedotin (Merck)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "epcoritamab (Epkinly) + R-CHOP",
  "event_type": "readout",
  "indication": "newly diagnosed diffuse large B-cell lymphoma",
  "notes": "Timing inferred from ClinicalTrials.gov NCT05578976 (active Phase 3, primary completion 2027-06); no company readout guidance confirmed for 2027 and History of Changes could not be verified in this pass.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05578976",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05578976",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0096",
  "guidance_detail": "Timing inferred from ClinicalTrials.gov NCT05578976 (active Phase 3, primary completion 2027-06); no company readout guidance confirmed for 2027 and History of Changes could not be verified in this pass.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Grifols, S.A.",
  "competitors": [
   "efgartigimod subcutaneous (Vyvgart Hytrulo)",
   "immune globulin subcutaneous (Hizentra)",
   "immune globulin intravenous (Privigen)"
  ],
  "country": "Spain",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "XEMBIFY (20% subcutaneous immunoglobulin) vs Gamunex-C (IVIg) \u2014 XPERT",
  "event_type": "readout",
  "indication": "chronic inflammatory demyelinating polyneuropathy (CIDP)",
  "notes": "Phase 3 XPERT PK/safety study of XEMBIFY versus Gamunex-C in CIDP (NCT07540221); registry primary completion 2027-12-31, timing inferred from registry; History of Changes could not be verified in this pass.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.grifols.com/documents/6155538/8685461/np-20260716-en.pdf/dc90afd8-9311-0077-327d-412815460dce?t=1784181778511",
  "ticker": "GRFS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07540221",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0097",
  "guidance_detail": "Phase 3 XPERT PK/safety study of XEMBIFY versus Gamunex-C in CIDP (NCT07540221); registry primary completion 2027-12-31, timing inferred from registry; History of Changes could not be verified in this pass.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0017",
   "v16-0016"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for XEMBIFY (20% subcutaneous immunoglobulin) vs Gamunex-C (IVIg) \u2014 XPERT in chronic inflammatory demyelinating polyneuropathy (CIDP) is expected in Q4 2027 \u2014 the pivotal readout that determines whether Grifols, S.A. can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "Grifols, S.A.",
  "competitors": [
   "alpha1-proteinase inhibitor IV (Prolastin-C)",
   "alpha1-proteinase inhibitor IV (Aralast NP)",
   "alpha1-proteinase inhibitor IV (Glassia)",
   "fazirsiran (ARO-AAT)"
  ],
  "country": "Spain",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "subcutaneous alpha1-proteinase inhibitor \u2014 SWIFT-SC",
  "event_type": "readout",
  "indication": "alpha-1 antitrypsin deficiency",
  "notes": "Phase 3 SWIFT-SC noninferiority/PK study of subcutaneous alpha1-PI (NCT07555483); registry primary completion 2027-09-30, timing inferred from registry; History of Changes could not be verified in this pass.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.grifols.com/documents/6155538/8659835/np-20260629-1-en.pdf/70e08a2c-8c6f-eea5-32f6-de64b41988e6?t=1782729405010",
  "ticker": "GRFS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07555483",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0098",
  "guidance_detail": "Phase 3 SWIFT-SC noninferiority/PK study of subcutaneous alpha1-PI (NCT07555483); registry primary completion 2027-09-30, timing inferred from registry; History of Changes could not be verified in this pass.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for subcutaneous alpha1-proteinase inhibitor \u2014 SWIFT-SC in alpha-1 antitrypsin deficiency is expected in Q3 2027 \u2014 the pivotal readout that determines whether Grifols, S.A. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "GSK plc",
  "competitors": [
   "topotecan (generic)",
   "lurbinectedin (Zepzelca)",
   "tarlatamab (Imdelltra)",
   "ifinatamab deruxtecan (Daiichi Sankyo/Merck)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "risvutatug rezetecan \u2014 EMBOLD SCLC-301",
  "event_type": "readout",
  "indication": "relapsed extensive-stage small cell lung cancer",
  "notes": "GSK's Q2 2026 roadmap shows pivotal data expected in 2027; company reported a 54% reduction in risk of death versus topotecan in relapsed SCLC in China; registry NCT07099898 primary completion 2027-11-05.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.gsk.com/en-gb/media/press-releases/ris-rez-reduced-risk-of-death-by-54-versus-topotecan-in-patients-with-relapsed-small-cell-lung-cancer-in-china/",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07099898",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0099",
  "guidance_detail": "GSK's Q2 2026 roadmap shows pivotal data expected in 2027; company reported a 54% reduction in risk of death versus topotecan in relapsed SCLC in China; registry NCT07099898 primary completion 2027-11-05.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0899"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Harrow, Inc.",
  "competitors": [
   "midazolam (generic)",
   "propofol (generic)",
   "dexmedetomidine (generic)",
   "remimazolam (Byfavo)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MELT-300 (G-MELT)",
  "event_type": "nda_filing",
  "indication": "procedural sedation",
  "notes": "Harrow disclosed plans for an NDA submission in H1 2027 for MELT-300 (sublingual midazolam/ketamine) in procedural sedation following its acquisition of Melt Pharmaceuticals.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://pnr-files.pro1.gus.wdc.dianum.io/globenewswire/articles/3156941/en/harrow-to-acquire-melt.pdf",
  "ticker": "HROW",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0100",
  "guidance_detail": "Harrow disclosed plans for an NDA submission in H1 2027 for MELT-300 (sublingual midazolam/ketamine) in procedural sedation following its acquisition of Melt Pharmaceuticals.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24",
  "why_it_matters": "Harrow, Inc. is expected to file its new drug application for MELT-300 (G-MELT) in procedural sedation in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-24",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "sodium oxybate (Xyrem)",
   "calcium/magnesium/potassium/sodium oxybates (Xywav)",
   "solriamfetol (Sunosi)",
   "pitolisant (Wakix)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-01",
  "date_quality": "hard",
  "drug": "pitolisant GR (gastro-resistant tablets)",
  "event_type": "pdufa",
  "indication": "narcolepsy",
  "notes": "Pitolisant GR = gastro-resistant tablets (not granules), pediatric narcolepsy formulation; NDA accepted by FDA July 2026; target PDUFA date 2027-04-01 per Q2 2026 company update.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0101",
  "guidance_detail": "Pitolisant GR = gastro-resistant tablets (not granules), pediatric narcolepsy formulation; NDA accepted by FDA July 2026; target PDUFA date 2027-04-01 per Q2 2026 company update.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "sodium oxybate (Xyrem)",
   "calcium/magnesium/potassium/sodium oxybates (Xywav)",
   "solriamfetol (Sunosi)",
   "pitolisant (Wakix)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pitolisant HD \u2014 ONSTRIDE-1",
  "event_type": "readout",
  "indication": "narcolepsy",
  "notes": "Phase 3 ONSTRIDE-1 of high-dose pitolisant in narcolepsy guided for 2027 topline.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07675135",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0102",
  "guidance_detail": "Phase 3 ONSTRIDE-1 of high-dose pitolisant in narcolepsy guided for 2027 topline.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0103"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for pitolisant HD \u2014 ONSTRIDE-1 in narcolepsy is expected sometime in 2027 \u2014 the pivotal readout that determines whether Harmony Biosciences Holdings, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "calcium/magnesium/potassium/sodium oxybates (Xywav)",
   "solriamfetol (Sunosi)",
   "pitolisant (Wakix)",
   "modafinil/armodafinil (generic)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pitolisant HD \u2014 ONSTRIDE-2",
  "event_type": "readout",
  "indication": "idiopathic hypersomnia",
  "notes": "Phase 3 ONSTRIDE-2 of high-dose pitolisant in idiopathic hypersomnia guided for 2027 topline.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07500090",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0103",
  "guidance_detail": "Phase 3 ONSTRIDE-2 of high-dose pitolisant in idiopathic hypersomnia guided for 2027 topline.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0102"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for pitolisant HD \u2014 ONSTRIDE-2 in idiopathic hypersomnia is expected sometime in 2027 \u2014 the pivotal readout that determines whether Harmony Biosciences Holdings, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "diazoxide choline (Vykat XR)",
   "setmelanotide (Imcivree)",
   "tesofensine/metoprolol (in development)",
   "livoletide (in development)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pitolisant \u2014 TEMPO",
  "event_type": "readout",
  "indication": "Prader-Willi syndrome",
  "notes": "Phase 3 TEMPO guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3; timing was pushed from H2 2026 due to enrollment challenges.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06366464",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0104",
  "guidance_detail": "Phase 3 TEMPO guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3; timing was pushed from H2 2026 due to enrollment challenges.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for pitolisant \u2014 TEMPO in Prader-Willi syndrome is expected in Q3 2027 \u2014 the pivotal readout that determines whether Harmony Biosciences Holdings, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "stiripentol (Diacomit)",
   "cannabidiol (Epidiolex)",
   "fenfluramine (Fintepla)",
   "soticlestat (in development)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "EPX-100 (clemizole) \u2014 ARGUS",
  "event_type": "readout",
  "indication": "Dravet syndrome",
  "notes": "Phase 3 ARGUS guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3. Re-checked 2026-09-23: HRMY EPX-100 ARGUS (Dravet). Company Q2 2026 PR (via NeurologyLive): topline from both studies expected in H1 2027. Calendar had Q3 based on \"mid-2027\" mapping; revised to H1 2027 per company guidance. Source: https://www.neurologylive.com/view/favorable-phase-1-data-orexin-2-agonist-bp-205-broader-pipeline-progress-headline-harmony-q2-update. Quote: \"Topline data from both studies are expected during the first half of 2027\".",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04462770",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0105",
  "guidance_detail": "Phase 3 ARGUS guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "Calendar had Q3 from mid-2027 mapping; company Q2 2026 PR guides topline (ARGUS, Dravet) in H1 2027"
   }
  ],
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0106",
   "v16-0204",
   "v16-0055"
  ],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for EPX-100 (clemizole) \u2014 ARGUS in Dravet syndrome is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Harmony Biosciences Holdings, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "cannabidiol (Epidiolex)",
   "fenfluramine (Fintepla)",
   "stiripentol (Diacomit)",
   "soticlestat (in development)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "EPX-100 (clemizole) \u2014 LIGHTHOUSE",
  "event_type": "readout",
  "indication": "Lennox-Gastaut syndrome",
  "notes": "Phase 3 LIGHTHOUSE guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3. Re-checked 2026-09-23: HRMY EPX-100 LIGHTHOUSE (Lennox-Gastaut). Company Q2 2026 PR (via NeurologyLive): topline from both studies expected in H1 2027. Calendar had Q3 based on \"mid-2027\" mapping; revised to H1 2027 per company guidance. Source: https://www.neurologylive.com/view/favorable-phase-1-data-orexin-2-agonist-bp-205-broader-pipeline-progress-headline-harmony-q2-update. Quote: \"Topline data from both studies are expected during the first half of 2027\".",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05066217",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0106",
  "guidance_detail": "Phase 3 LIGHTHOUSE guided for mid-2027 topline, mapped to the Q2/Q3 boundary as Q3.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "Calendar had Q3 from mid-2027 mapping; company Q2 2026 PR guides topline (LIGHTHOUSE, LGS) in H1 2027"
   }
  ],
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0105"
  ],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for EPX-100 (clemizole) \u2014 LIGHTHOUSE in Lennox-Gastaut syndrome is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Harmony Biosciences Holdings, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Immunocore Holdings plc",
  "competitors": [
   "nivolumab + ipilimumab (Bristol Myers Squibb)",
   "relatlimab + nivolumab (Opdualag)",
   "lifileucel (Amtagvi)",
   "BRAF/MEK inhibitor combinations"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "brenetafusp + nivolumab \u2014 PRISM-MEL-301",
  "event_type": "readout",
  "indication": "first-line advanced cutaneous melanoma",
  "notes": "Timing inferred from ClinicalTrials.gov NCT06112314 (recruiting Phase 3, primary completion 2027-10-16); no company readout guidance confirmed for 2027 and History of Changes could not be verified in this pass.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06112314",
  "ticker": "IMCR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06112314",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0107",
  "guidance_detail": "Timing inferred from ClinicalTrials.gov NCT06112314 (recruiting Phase 3, primary completion 2027-10-16); no company readout guidance confirmed for 2027 and History of Changes could not be verified in this pass.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for brenetafusp + nivolumab \u2014 PRISM-MEL-301 in first-line advanced cutaneous melanoma is expected in Q4 2027 \u2014 the pivotal readout that determines whether Immunocore Holdings plc can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Immunome, Inc.",
  "competitors": [
   "nirogacestat (Ogsiveo)",
   "sorafenib (Bayer)",
   "pazopanib (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-28",
  "date_quality": "hard",
  "drug": "varegacestat (AL102)",
  "event_type": "pdufa",
  "indication": "desmoid tumors",
  "notes": "FDA accepted the NDA for the gamma-secretase inhibitor in adults with desmoid tumors; action date 2027-04-28.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://investors.immunome.com/immunome-announces-u-s-fda-acceptance-of-new-drug-application-for-varegacestat-for-the-treatment-of-adults-with-desmoid-tumors/",
  "ticker": "IMNM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0108",
  "guidance_detail": "FDA accepted the NDA for the gamma-secretase inhibitor in adults with desmoid tumors; action date 2027-04-28.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on varegacestat (AL102) for desmoid tumors falls on 2027-04-28 \u2014 the agency's yes-or-no moment for Immunome, Inc.'s application."
 },
 {
  "ticker": "IONS",
  "company": "Ionis Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "obudanersen (ION582)",
  "indication": "Angelman syndrome \u2014 Phase 3 REVEAL study",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "RARE (Ultragenyx \u2014 GTX-102 intrathecal ASO, Phase 3 Angelman syndrome)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260706516467/en/Ionis-completes-enrollment-in-pivotal-cohort-of-the-Phase-3-REVEAL-study-evaluating-obudanersen-in-Angelman-syndrome",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Phase 3 REVEAL pivotal cohort (n=136, ages 2-<18) enrollment complete; topline data guided 2H 2027.",
  "us_tradable": true,
  "nct_id": "NCT06914609",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0109",
  "guidance_detail": "Phase 3 REVEAL pivotal cohort (n=136, ages 2-<18) enrollment complete; topline data guided 2H 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for obudanersen (ION582) in Angelman syndrome \u2014 Phase 3 REVEAL study is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Ionis Pharmaceuticals, Inc. can file for approval."
 },
 {
  "ticker": "IMUX",
  "company": "Immunic, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "vidofludimus calcium (IMU-838)",
  "indication": "relapsing multiple sclerosis",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "NVS (Kesimpta/ofatumumab \u2014 anti-CD20 RMS)",
   "ROG (Ocrevus/ocrelizumab \u2014 anti-CD20 RMS)",
   "BIIB (Tecfidera/Vumerity \u2014 oral fumarates RMS)",
   "SNY (Aubagio/teriflunomide \u2014 oral DHODH inhibitor RMS)"
  ],
  "source_url": "https://imux.com/wp-content/uploads/2026/02/20260226-Immunic-Q4-2025-Earnings-Release.pdf",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Planned US NDA submission 'mid-2027' (Q2/Q3 boundary; filed in 2027-Q2 per spec), contingent on positive ENSURE-1/ENSURE-2 Phase 3 topline expected by end-2026. Re-checked 2026-09-23: Immunic's Feb 26, 2026 Q4 2025 earnings release guides only 'mid-2027' for the US NDA submission of vidofludimus calcium in RMS (contingent on positive ENSURE-1/2 topline by end-2026). The row's 2027-Q2 bucket was over-precise; rebucketed conservatively to 2027-H2 since mid-2027 sits on the Q2/Q3 boundary. Source: https://imux.com/wp-content/uploads/2026/02/20260226-Immunic-Q4-2025-Earnings-Release.pdf. Quote: \"mid-2027\".",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0110",
  "guidance_detail": "Planned US NDA submission 'mid-2027' (Q2/Q3 boundary; filed in 2027-Q2 per spec), contingent on positive ENSURE-1/ENSURE-2 Phase 3 topline expected by end-2026.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q2",
    "to": "2027-H2",
    "changed": "2026-09-23",
    "why": "Immunic Feb 2026 earnings guides only mid-2027 US NDA submission (contingent on ENSURE-1 readout)"
   }
  ],
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Immunic, Inc. is expected to file its new drug application for vidofludimus calcium (IMU-838) in relapsing multiple sclerosis in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "INCY",
  "company": "Incyte Corporation",
  "country": "United States",
  "us_listed": true,
  "drug": "povorcitinib (INCB54707)",
  "indication": "nonsegmental vitiligo",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "INCY (Opzelura/ruxolitinib cream \u2014 approved topical JAK for vitiligo)",
   "ABBV (upadacitinib \u2014 oral JAK1 in Phase 3 for vitiligo)",
   "PFE (ritlecitinib \u2014 JAK3/TEC inhibitor studied in vitiligo)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260428703817/en/Incyte-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Phase 3 STOP-V1/STOP-V2 positive in 2026; regulatory applications planned H1 2027; first systemic/oral vitiligo therapy candidate. [Source verified 2026-09-20: Official Incyte Q1 2026 Business Wire release (Apr 28, 2026): 'Today the Company announced positive results from the Phase 3 program evaluating povorcitinib (30mg) in adult patients with nonsegmental vitiligo... The posi]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0111",
  "guidance_detail": "Phase 3 STOP-V1/STOP-V2 positive in 2026; regulatory applications planned H1 2027; first systemic/oral vitiligo therapy candidate.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "LLY",
  "company": "Eli Lilly and Company",
  "country": "United States",
  "us_listed": true,
  "drug": "retatrutide",
  "indication": "obesity (weight management); also knee OA pain, OSA",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "NVO (semaglutide/Wegovy; amycretin oral \u2014 obesity)",
   "VKTX (VK2735 \u2014 dual GLP-1/GIP obesity candidate)",
   "AMGN (maridebart cafraglutide \u2014 monthly obesity candidate)"
  ],
  "source_url": "https://lilly.mediaroom.com/2026-07-23-Lillys-triple-agonist,-retatrutide,-successful-in-two-additional-Phase-3-obesity-trials,-delivering-significant-improvements-in-weight-and-A1C?asPDF=1",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Lilly plans BLA (not NDA) for retatrutide in Q1 2027 after 5 positive Phase 3 TRIUMPH/TRANSCEND readouts; GIP/GLP-1/glucagon triple agonist.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0112",
  "guidance_detail": "Lilly plans BLA (not NDA) for retatrutide in Q1 2027 after 5 positive Phase 3 TRIUMPH/TRANSCEND readouts; GIP/GLP-1/glucagon triple agonist.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "LLY",
  "company": "Eli Lilly and Company",
  "country": "United States",
  "us_listed": true,
  "drug": "tirzepatide",
  "indication": "obesity \u2014 cardiovascular morbidity/mortality outcomes (SURMOUNT-MMO)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "NVO (semaglutide/Wegovy \u2014 SELECT CVOT established MACE benefit in obesity)",
   "AMGN (maridebart cafraglutide \u2014 monthly obesity candidate)",
   "VKTX (VK2735 \u2014 dual GLP-1/GIP obesity candidate)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05556512",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred: NCT05556512 estimated primary completion October 2027; Phase 3 CV outcomes trial of tirzepatide in obesity without T2D.",
  "us_tradable": true,
  "nct_id": "NCT05556512",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0113",
  "guidance_detail": "Inferred: NCT05556512 estimated primary completion October 2027; Phase 3 CV outcomes trial of tirzepatide in obesity without T2D.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0138",
   "v16-0139"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "INCY",
  "company": "Incyte Corporation",
  "country": "United States",
  "us_listed": true,
  "drug": "povorcitinib (INCB54707)",
  "indication": "hidradenitis suppurativa",
  "event_type": "regulatory_other",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "ABBV (Humira/adalimumab \u2014 approved in HS)",
   "NVS (Cosentyx/secukinumab \u2014 approved in HS)",
   "UCB (Bimzelx/bimekizumab \u2014 approved in HS)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260428703817/en/Incyte-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "NDA (HS) and MAA under FDA/EMA review since Q1 2026; company guides US approval/launch in Q1 2027. Exact PDUFA date not disclosed as of 2026-09-18. [Source verified 2026-09-20: Same official Incyte Q1 2026 release: 'The New Drug Application (NDA) submission for povorcitinib as a treatment for patients with moderate to severe HS was accepted by the FDA in the first quarter of 2026. The Company a]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0114",
  "guidance_detail": "NDA (HS) and MAA under FDA/EMA review since Q1 2026; company guides US approval/launch in Q1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "KOD",
  "company": "Kodiak Sciences Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "KSI-101",
  "indication": "macular edema secondary to inflammation (MESI) \u2014 PEAK/PINNACLE",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "guidance",
  "competitors": [
   "ABBV (Ozurdex/dexamethasone intravitreal implant \u2014 macular edema)",
   "EYPT (Yutiq/fluocinolone implant \u2014 chronic non-infectious uveitis)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/kodiak-sciences-completes-enrollment-in-first-pivotal-cohort-in-the-phase-3-peak-trial-of-ksi-101-for-macular-edema-secondary-to-inflammation-and-reaffirms-topline-clinical-data-release-remains-on-track-for-december-2026-302844806.html",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Pivotal Analysis 2 (PEAK patients 301-600 + PINNACLE patients 1-300) topline guided 2Q 2027; IL-6/VEGF bispecific protein. PEAK Analysis 1 due Dec 2026. Pivotal Analysis 2 pools PEAK (NCT06990399) and PINNACLE (NCT06996080); one event across two registrational studies, so no single nct_id is assigned.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0115",
  "guidance_detail": "Pivotal Analysis 2 (PEAK patients 301-600 + PINNACLE patients 1-300) topline guided 2Q 2027; IL-6/VEGF bispecific protein.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_documented_pooled",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for KSI-101 in macular edema secondary to inflammation (MESI) \u2014 PEAK/PINNACLE is expected in Q2 2027 \u2014 the pivotal readout that determines whether Kodiak Sciences Inc. can file for approval."
 },
 {
  "ticker": "INBX",
  "company": "Inhibrx Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "ozekibart (INBRX-109)",
  "indication": "unresectable or metastatic conventional chondrosarcoma",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-04-14",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [
   "Servier (Tibsovo/ivosidenib \u2014 IDH1 inhibitor, Phase 3 in IDH1-mut chondrosarcoma)",
   "LLY (LY3410738 \u2014 mutant IDH inhibitor in chondrosarcoma)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/inhibrx-announces-us-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conventional-chondrosarcoma-302800101.html",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "FDA accepted BLA (no filing review issues); PDUFA goal April 14, 2027. Would be first FDA-approved therapy for chondrosarcoma.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0116",
  "guidance_detail": "FDA accepted BLA (no filing review issues); PDUFA goal April 14, 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on ozekibart (INBRX-109) for unresectable or metastatic conventional chondrosarcoma falls on 2027-04-14 \u2014 the agency's yes-or-no moment for Inhibrx Biosciences, Inc.'s application."
 },
 {
  "ticker": "IMTX",
  "company": "Immatics N.V.",
  "country": "Germany",
  "us_listed": true,
  "drug": "anzu-cel (IMA203/anzutresgene autoleucel)",
  "indication": "advanced melanoma (2L+ cutaneous melanoma) \u2014 SUPRAME",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "MRK (Keytruda/pembrolizumab \u2014 advanced melanoma)",
   "BMY (Opdivo/nivolumab \u2014 advanced melanoma)",
   "IOVA (Amtagvi/lifileucel \u2014 TIL therapy, post-PD-1 melanoma)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1809196/000119312526354715/imtx-ex99_1.htm",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Company guides topline SUPRAME Phase 3 results in H1 2027 after FDA-agreed streamlined final analysis; PRAME-directed TCR T-cell therapy. Full release text (verbatim on Intrado-distributed mirrors and stocktitan) states: expects to disclose SUPRAME topline final PFS data in H1 2027 after replacing planned interim+final analyses with a single streamlined final analysis per FDA feedback.\n[2026-09-23 primary-source upgrade] 6-K Exhibit 99.1 (Q2 2026 PR): 'The Company expects to disclose topline data from the final PFS analysis in the first half of 2027' after replacing interim+final with a single streamlined final analysis per FDA feedback.",
  "us_tradable": true,
  "nct_id": "NCT06743126",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0117",
  "guidance_detail": "Company guides topline SUPRAME Phase 3 results in H1 2027 after FDA-agreed streamlined final analysis; PRAME-directed TCR T-cell therapy.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0118"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for anzu-cel (IMA203/anzutresgene autoleucel) in advanced melanoma (2L+ cutaneous melanoma) \u2014 SUPRAME is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Immatics N.V. can file for approval."
 },
 {
  "ticker": "IMTX",
  "company": "Immatics N.V.",
  "country": "Germany",
  "us_listed": true,
  "drug": "anzu-cel (IMA203/anzutresgene autoleucel)",
  "indication": "advanced melanoma (2L+ cutaneous melanoma) \u2014 SUPRAME",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "MRK (Keytruda/pembrolizumab \u2014 advanced melanoma)",
   "BMY (Opdivo/nivolumab \u2014 advanced melanoma)",
   "IOVA (Amtagvi/lifileucel \u2014 TIL therapy, post-PD-1 melanoma)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1809196/000119312526354715/imtx-ex99_1.htm",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Company guides BLA submission in H1 2027 and commercial launch in 2H 2027, following SUPRAME topline. Latest official guidance (Q2 2026 PR) states \"a BLA submission in 2027\" with no half specified; the earlier Q1 2026 6-K guided BLA in H1 2027 + commercial launch 2H 2027, but that half-level precision was not repeated in the latest release, so the bucket reflects the current company wording. Release text states 'followed by a BLA submission in 2027' \u2014 no H1 half specified \u2014 and mentions building commercial infrastructure for launch after BLA approval, with no explicit 2H 2027 launch date in the PR.\n[2026-09-23 primary-source upgrade] Same 6-K Exhibit 99.1: '...followed by a BLA submission in 2027' after the H1 2027 SUPRAME final PFS topline.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0118",
  "guidance_detail": "Company guides BLA submission in H1 2027 and commercial launch in 2H 2027, following SUPRAME topline.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Immatics N.V. is expected to file its biologics license application for anzu-cel (IMA203/anzutresgene autoleucel) in advanced melanoma (2L+ cutaneous melanoma) \u2014 SUPRAME sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "JAZZ",
  "company": "Jazz Pharmaceuticals plc",
  "country": "Ireland",
  "us_listed": true,
  "drug": "dordaviprone (Modeyso)",
  "indication": "newly diagnosed H3 K27M-mutant diffuse glioma (frontline confirmatory) \u2014 ACTION",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "No approved frontline therapy for H3 K27M-mutant diffuse glioma (radiotherapy is standard of care)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-announces-second-quarter-2026-financial-results-302841421.html",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27 based on current pace of event accrual. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-06 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT05580562",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0119",
  "guidance_detail": "Company anticipates the OS interim analysis for the event-driven Phase 3 ACTION trial in 1H27 based on current pace of event accrual.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "JAZZ",
  "company": "Jazz Pharmaceuticals plc",
  "country": "Ireland",
  "us_listed": true,
  "drug": "zanidatamab (Ziihera)",
  "indication": "HER2+ metastatic breast cancer post trastuzumab deruxtecan \u2014 EmpowHER-BC-303",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "AZN/Daiichi Sankyo (Enhertu/trastuzumab deruxtecan \u2014 prior-line ADC)",
   "ROG (Kadcyla/trastuzumab emtansine \u2014 HER2+ mBC)",
   "GILD (Trodelvy/sacituzumab govitecan \u2014 mBC)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1232524/000123252426000012/a4q25financialpr.htm",
  "source_type": "SEC filing",
  "as_of": "2026-10-01",
  "notes": "EDGE CASE: enrollment on track to complete 1H27; company guides top-line results 'late 2027 or early 2028' \u2014 2027 inclusion is precautionary. [Source verified 2026-09-20: Official SEC EDGAR exhibit (Jazz 8-K EX-99.1, Feb 24, 2026): 'EmpowHER-BC-303 trial in mBC patients previously treated with, or intolerant to, trastuzumab deruxtecan on track to complete enrollment in 1H27, with top-line] [Registry check 2026-09-23] CT.gov now lists primary completion 2028-04-28 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT06435429",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0120",
  "guidance_detail": "EDGE CASE: enrollment on track to complete 1H27; company guides top-line results 'late 2027 or early 2028' \u2014 2027 inclusion is precautionary.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0232"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "LYEL",
  "company": "Lyell Immunopharma, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "rondecabtagene autoleucel (ronde-cel)",
  "indication": "relapsed/refractory large B-cell lymphoma (3L+) \u2014 PiNACLE",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "GILD/Kite (Yescarta/axicabtagene ciloleucel)",
   "BMY (Breyanzi/lisocabtagene maraleucel)",
   "NVS (Kymriah/tisagenlecleucel)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/12/3311241/0/en/Lyell-Immunopharma-Presents-Updated-Safety-Data-and-Translational-Insights-for-Rondecabtagene-Autoleucel-Ronde-Cel-in-Patients-with-Large-B-Cell-Lymphoma-at-European-Hematology-Ass.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "BLA submission guided for 2H 2027 following mid-2027 pivotal PiNACLE data; contingent on positive pivotal data. PiNACLE is the single-arm pivotal 3L+ trial, not the randomized Phase 3 PiNACLE-H2H.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0121",
  "guidance_detail": "BLA submission guided for 2H 2027 following mid-2027 pivotal PiNACLE data; contingent on positive pivotal data.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Lyell Immunopharma, Inc. is expected to file its biologics license application for rondecabtagene autoleucel (ronde-cel) in relapsed/refractory large B-cell lymphoma (3L+) \u2014 PiNACLE in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "LXRX",
  "company": "Lexicon Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "sotagliflozin",
  "indication": "hypertrophic cardiomyopathy (obstructive and non-obstructive) \u2014 SONATA-HCM",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "BMY (Camzyos/mavacamten \u2014 cardiac myosin inhibitor, HCM)",
   "Cytokinetics (aficamten \u2014 cardiac myosin inhibitor, HCM)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/07/27/3333536/0/en/Lexicon-Pharmaceuticals-Completes-Enrollment-of-Pivotal-Phase-3-SONATA-HCM-Study-of-Sotagliflozin-in-Symptomatic-Non-Obstructive-and-Obstructive-Hypertrophic-Cardiomyopathy-HCM.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Topline results anticipated Q1 2027 after enrollment completion July 2026; primary endpoint KCCQ CSS at week 26; SGLT1/SGLT2 inhibitor.",
  "us_tradable": true,
  "nct_id": "NCT06481891",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0122",
  "guidance_detail": "Topline results anticipated Q1 2027 after enrollment completion July 2026; primary endpoint KCCQ CSS at week 26; SGLT1/SGLT2 inhibitor.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for sotagliflozin in hypertrophic cardiomyopathy (obstructive and non-obstructive) \u2014 SONATA-HCM is expected in Q1 2027 \u2014 the pivotal readout that determines whether Lexicon Pharmaceuticals, Inc. can file for approval."
 },
 {
  "ticker": "LTGO",
  "company": "Latigo Biotherapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "onzotrigine (LTG-001)",
  "indication": "moderate-to-severe acute pain (bunionectomy)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "VRTX (Journavx/suzetrigine \u2014 oral NaV1.8 inhibitor, acute pain)",
   "Generic opioids/NSAIDs (standard of care for acute pain)"
  ],
  "source_url": "https://www.genengnews.com/topics/translational-medicine/latigo-reports-positive-phase-iib-data-for-non-opioid-acute-pain-candidate/",
  "source_type": "trade press",
  "as_of": "2026-09-18",
  "notes": "Topline expected 2H 2027 from Phase 3 bunionectomy trial plus open-label Phase 3 safety trial (both to start 2H 2026); oral NaV1.8 inhibitor; abdominoplasty results published in NEJM. GEN explicitly links and quotes Latigo's SEC-filed S-1: Phase 3 bunionectomy and open-label safety trials planned for H2 2026 with topline results expected H2 2027.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0123",
  "guidance_detail": "Topline expected 2H 2027 from Phase 3 bunionectomy trial plus open-label Phase 3 safety trial (both to start 2H 2026); oral NaV1.8 inhibitor; abdominoplasty results published in NEJM.",
  "audit_status": "v16_verified",
  "audit_action": "nct_backfill_not_found",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for onzotrigine (LTG-001) in moderate-to-severe acute pain (bunionectomy) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Latigo Biotherapeutics, Inc. can file for approval."
 },
 {
  "ticker": "MANE",
  "company": "Veradermics Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "VDPHL01",
  "indication": "female pattern hair loss \u2014 Study 306",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "Pelage Pharmaceuticals (PP405 \u2014 Phase 2 topical, androgenetic alopecia)",
   "Cosmo (clascoterone/Breezula \u2014 topical antiandrogen, androgenetic alopecia)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260811850534/en/Veradermics-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Recent-Corporate-and-Clinical-Progress",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "CLASSIFICATION: company calls Study 306 (n=556, enrollment complete) a registration-directed Phase 2/3 trial of an oral treatment for female pattern hair loss; treated as Phase 3 readout. Topline anticipated 1H27.",
  "us_tradable": true,
  "nct_id": "NCT07146022",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0124",
  "guidance_detail": "CLASSIFICATION: company calls Study 306 (n=556, enrollment complete) a registration-directed Phase 2/3 trial of an oral treatment for female pattern hair loss; treated as Phase 3 readout.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for VDPHL01 in female pattern hair loss \u2014 Study 306 is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Veradermics Inc. can file for approval."
 },
 {
  "ticker": "PVLA",
  "company": "Palvella Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "QTORIN rapamycin (partner: Palvella Therapeutics)",
  "indication": "microcystic lymphatic malformations",
  "event_type": "regulatory_other",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "PFE (Rapamune/sirolimus \u2014 used off-label; no FDA-approved therapy for microcystic LMs)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/08/31/3353213/0/en/palvella-therapeutics-completes-rolling-submission-of-new-drug-application-to-fda-for-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations.html",
  "source_type": "company PR",
  "as_of": "2026-11-01",
  "notes": "ATTRIBUTION: this is Palvella's rolling NDA (completed Aug 31, 2026; Breakthrough/Fast Track/Orphan); Palvella targets potential US launch 1H 2027 if approved; Ligand holds tiered 8-9.8% royalty. Sponsor corrected LGND -> PVLA: this is Palvella's rolling NDA; Ligand holds only a tiered royalty. [Source verified 2026-09-20: Genuine GlobeNewswire release (Aug 31, 2026, source Palvella Therapeutics): Palvella completed the rolling NDA submission to FDA for QTORIN 3.9% rapamycin gel in microcystic LMs (Breakthrough/Fast Track/Orphan); 'Acceler] Update 2026-10-28: FDA accepted the QTORIN NDA for filing and granted Priority Review, PDUFA target action date February 28, 2027 (see PDUFA row v41-0017); the H1 2027 US launch target stands, subject to approval.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0125",
  "guidance_detail": "ATTRIBUTION: this is Palvella's rolling NDA (completed Aug 31, 2026; Breakthrough/Fast Track/Orphan); Palvella targets potential US launch 1H 2027 if approved; Ligand holds tiered 8-9.8% royalty.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v41-0017"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-11-01",
  "why_it_matters": "Palvella's rolling NDA for QTORIN rapamycin in microcystic lymphatic malformations is complete, with a potential US launch in the first half of 2027 if approved."
 },
 {
  "ticker": "KPTI",
  "company": "Karyopharm Therapeutics Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "selinexor (Xpovio) + ruxolitinib",
  "indication": "myelofibrosis (JAKi-naive) \u2014 SENTRY (XPORT-MF-034)",
  "event_type": "regulatory_other",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "INCY (Jakafi/ruxolitinib)",
   "NVS (Jakavi/ruxolitinib ex-US)",
   "GSK (Ojjaara/momelotinib)",
   "SOBI (Vonjo/pacritinib)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/karyopharm-submits-supplemental-new-drug-application-to-the-fda-for-xpovio-selinexor-plus-ruxolitinib-for-patients-with-myelofibrosis-302864537.html",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "sNDA submitted 2026-08-31 under Accelerated Approval with Priority Review requested; company stated PDUFA target ~6 months after FDA receipt (~Feb 2027) if granted. Inferred 2027-H1 FDA decision; standard 10-month review would also land H1 2027. No acceptance/action date confirmed as of 2026-09-18.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0126",
  "guidance_detail": "sNDA submitted 2026-08-31 under Accelerated Approval with Priority Review requested; company stated PDUFA target ~6 months after FDA receipt (~Feb 2027) if granted.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Karyopharm's supplemental application for selinexor plus ruxolitinib in myelofibrosis was submitted in August 2026, with an FDA decision possible in the first half of 2027."
 },
 {
  "ticker": "INSM",
  "company": "Insmed Incorporated",
  "country": "United States",
  "us_listed": true,
  "drug": "ARIKAYCE (amikacin liposome inhalation suspension)",
  "indication": "MAC lung disease (newly diagnosed) \u2014 ENCORE (Phase 3b)",
  "event_type": "pdufa",
  "phase": "3",
  "date_exact": "2027-01-28",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "AN2 Therapeutics (epetraborole \u2014 Phase 3 NTM)",
   "No approved therapy for newly diagnosed MAC (ARIKAYCE approved for refractory MAC only)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/fda-grants-priority-review-to-insmeds-snda-for-arikayce-amikacin-liposome-inhalation-suspension-for-treatment-of-mac-lung-disease-with-pdufa-target-action-date-set-for-january-28-2027-302884017.html",
  "source_type": "company IR",
  "as_of": "2026-09-24",
  "notes": "FDA accepted the sNDA for ARIKAYCE (amikacin liposome inhalation suspension) in MAC lung disease and granted Priority Review; PDUFA target action date January 28, 2027 (company PR 2026-09-21). Expands to newly diagnosed MAC and converts the 2018 accelerated approval.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "priority",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-09-21",
  "record_id": "v16-0127",
  "guidance_detail": "FDA accepted the sNDA for ARIKAYCE (amikacin liposome inhalation suspension) in MAC lung disease and granted Priority Review; PDUFA target action date January 28, 2027 (company PR 2026-09-21).",
  "audit_status": "v17_reverified",
  "audit_action": "upgrade",
  "date_history": [
   {
    "from": "2027-H1",
    "to": "2027-Q1",
    "changed": "2026-09-23",
    "why": "Upgrade regulatory_other/inferred -> pdufa/hard: FDA accepted sNDA under Priority Review; PDUFA 2027-01-28"
   }
  ],
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "KYTX",
  "company": "Kyverna Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "mivocabtagene autoleucel (miv-cel, formerly KYV-101)",
  "indication": "stiff person syndrome \u2014 KYSA-8",
  "event_type": "regulatory_other",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Cabaletta Bio (rese-cel \u2014 autoimmune anti-CD19 CAR-T)",
   "No approved therapies for SPS (off-label IVIg/benzodiazepines standard of care)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/05/12/3293353/0/en/Kyverna-Therapeutics-Announces-Initiation-of-Rolling-SPS-BLA-Submission-and-Reports-First-Quarter-2026-Financial-Results.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Rolling BLA initiated May 12, 2026 after positive pre-BLA meeting (FDA aligned that single-arm pivotal Phase 2 KYSA-8 supports BLA); RMAT and Orphan designations; company preparing for launch in 2027 (bare year). No BLA acceptance or PDUFA date confirmed as of 2026-09-18. [Source verified 2026-09-20: Genuine GlobeNewswire release (May 12, 2026, Kyverna): FDA alignment on KYSA-8 single-arm trial supporting the BLA; 'The Company has initiated its rolling BLA submission, seeking priority review under the program's Regen]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0128",
  "guidance_detail": "Rolling BLA initiated May 12, 2026 after positive pre-BLA meeting (FDA aligned that single-arm pivotal Phase 2 KYSA-8 supports BLA); RMAT and Orphan designations; company preparing for launch in 2027 (bare year).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Kyverna began its rolling BLA for mivocabtagene autoleucel (miv-cel) in stiff person syndrome in May 2026 and is preparing for a potential launch in 2027."
 },
 {
  "ticker": "INMB",
  "company": "INmune Bio, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "ebstrocel (CORDStrom)",
  "indication": "recessive dystrophic epidermolysis bullosa (RDEB)",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "KRYS (Vyjuvek/beremagene geperpavec \u2014 approved topical gene therapy, DEB)",
   "ABEO (Zevaskyn/prademagene zamikeracel \u2014 approved autologous cell therapy, RDEB)",
   "Chiesi/Amryt (Filsuvez/birch triterpenes \u2014 approved topical, DEB)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/08/26/3351194/0/en/inmune-bio-advances-ebstrocel-toward-european-marketing-authorization-with-ema-regulatory-filings.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Company guides US BLA filing for Accelerated Approval in early 2027 based on completed clinical readouts; Phase 3 open-label registration trial planned to run in 2027 as post-marketing commitment. [Source verified 2026-09-20: Genuine GlobeNewswire release (Aug 26, 2026, INmune Bio): 'The EMA filings are intended to support the Company's planned EU MAA in Q1 2027 and form part of a coordinated global registration strategy that includes a plann]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0129",
  "guidance_detail": "Company guides US BLA filing for Accelerated Approval in early 2027 based on completed clinical readouts; Phase 3 open-label registration trial planned to run in 2027 as post-marketing commitment.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "INmune Bio, Inc. is expected to file its biologics license application for ebstrocel (CORDStrom) in recessive dystrophic epidermolysis bullosa (RDEB) in Q1 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "IPHA",
  "company": "Innate Pharma S.A.",
  "country": "France",
  "us_listed": true,
  "drug": "lacutamab",
  "indication": "S\u00e9zary syndrome",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Kyowa Kirin (Poteligeo/mogamulizumab \u2014 approved, CTCL/SS)",
   "PFE/Seagen (Adcetris/brentuximab vedotin \u2014 CTCL)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260810719841/en/Innate-Pharma-to-Advance-Lacutamab-Towards-Phase-3-Following-Partnership-With-Sobi-and-Appoints-New-Chief-Medical-Officer",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Filing for accelerated approval in S\u00e9zary syndrome based on TELLOMAK Phase 2 data, once TELLOMAK-3 confirmatory Phase 3 is underway (FPI expected Q1 2027). H2 2027 filing timing stated by CMO on the Q2 2026 earnings call; Breakthrough Therapy designation granted. [Source verified 2026-09-20: Genuine Business Wire regulatory news (Aug 10, 2026, Innate Pharma): Innate will conduct the TELLOMAK-3 Phase 3 confirmatory trial in CTCL 'supporting a planned accelerated approval filing in Sezary syndrome (SS), based ]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0130",
  "guidance_detail": "Filing for accelerated approval in S\u00e9zary syndrome based on TELLOMAK Phase 2 data, once TELLOMAK-3 confirmatory Phase 3 is underway (FPI expected Q1 2027).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Innate Pharma S.A. is expected to file its biologics license application for lacutamab in S\u00e9zary syndrome in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "LEGN",
  "company": "Legend Biotech Corporation",
  "country": "United States",
  "us_listed": true,
  "drug": "ciltacabtagene autoleucel (CARVYKTI)",
  "indication": "newly diagnosed multiple myeloma, transplant-ineligible or transplant-deferred \u2014 CARTITUDE-5",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "BMY (Abecma/ide-cel \u2014 BCMA CAR-T, multiple myeloma)",
   "JNJ (Tecvayli/teclistamab \u2014 BCMA bispecific, multiple myeloma)",
   "REGN (linvoseltamab \u2014 BCMA bispecific, multiple myeloma)"
  ],
  "source_url": "https://www.fool.com/earnings/call-transcripts/2026/05/12/legend-biotech-legn-q1-2026-earnings-transcript/",
  "source_type": "earnings transcript",
  "as_of": "2026-09-23",
  "notes": "AMBIGUOUS WINDOW: CEO guided CARTITUDE-5 data 'at some point in either 2026 or 2027' (Q1 2026 earnings call); trial is event-driven. 2027 inclusion is precautionary \u2014 the readout could land in 2026. Preserve the ambiguous 2026/2027 warning. The quote is currently supported only by third-party transcript mirrors (the candidate Quartr document is a presentation, not a call transcript). Keep with flagged confidence. [Registry check 2026-09-23] CT.gov now lists primary completion 2029-02-14 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT04923893",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0131",
  "guidance_detail": "AMBIGUOUS WINDOW: CEO guided CARTITUDE-5 data 'at some point in either 2026 or 2027' (Q1 2026 earnings call); trial is event-driven.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for ciltacabtagene autoleucel (CARVYKTI) in newly diagnosed multiple myeloma, transplant-ineligible or transplant-deferred (CARTITUDE-5) is expected sometime in 2027 \u2014 the pivotal readout that determines whether Legend Biotech Corporation can file for approval."
 },
 {
  "ticker": "LRMR",
  "company": "Larimar Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "nomlabofusp",
  "indication": "Friedreich's ataxia",
  "event_type": "regulatory_other",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "BIIB (Skyclarys/omaveloxolone \u2014 approved for FA)",
   "PTC (vatiquinone \u2014 Phase 3 MOVE-FA, FA)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/02/24/3243356/0/en/Larimar-Therapeutics-Announces-FDA-Breakthrough-Therapy-Designation-for-Nomlabofusp-in-FA-and-Reiterates-Planned-BLA-Submission-in-June-2026.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Rolling BLA for accelerated approval: first module submitted June 29, 2026, remaining modules expected 2H 2026; Breakthrough Therapy designation Feb 2026; company targets US launch in 1H 2027 if approved. [Source verified 2026-09-20: Larimar's Feb 24, 2026 GlobeNewswire release (opened): 'Planned BLA submission seeking accelerated approval on track for June 2026; U.S. launch targeted for first-half 2027, if approved.' Milestone list: 'BLA seeking acc] Re-checked 2026-09-23: LRMR nomlabofusp: H1 2027 was a commercial launch target (\"company targets US launch in 1H 2027 if approved\"), not a defined regulatory milestone. Rolling BLA: first module submitted June 29, 2026, remaining modules expected 2H 2026. FDA approval decision timing depends on BLA completion; H1 2027 launch is contingent, not a regulatory catalyst. Event definition revised to reflect regulatory uncertainty; bucket kept 2027-H1. Source: https://www.globenewswire.com/news-release/2026/02/24/3243356/0/en/Larimar-Therapeutics-Announces-FDA-Breakthrough-Thera. Quote: \"the remaining modules are expected to be submitted in the second half of 2026\".",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0132",
  "guidance_detail": "Rolling BLA for accelerated approval: first module submitted June 29, 2026, remaining modules expected 2H 2026; Breakthrough Therapy designation Feb 2026; company targets US launch in 1H 2027 if approved.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Larimar's rolling BLA for nomlabofusp in Friedreich's ataxia began in June 2026, targeting a US launch in the first half of 2027 if approved."
 },
 {
  "ticker": "NBIX",
  "company": "Neurocrine Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "osavampator (NBI-1065845)",
  "indication": "major depressive disorder (adjunctive)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "AXSM (Auvelity)",
   "COMP (COMP360)",
   "JNJ (Spravato)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-second-quarter-2026-financial-results-302839431.html",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Phase 3 topline on track for H2 2027 per Q2 2026 PR; three Ph3 studies (MDD3025/3026 + 1) show registry PCD Jul 2027. Phase 3 efficacy studies: MDD3025 (NCT06911112) and MDD3026 (NCT06963021); company guides program-level topline, so no single nct_id is assigned.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0133",
  "guidance_detail": "Phase 3 topline on track for H2 2027 per Q2 2026 PR; three Ph3 studies (MDD3025/3026 + 1) show registry PCD Jul 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_documented_program",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0085",
   "v16-0078"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "NBIX",
  "company": "Neurocrine Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "direclidine (NBI-1117568 / NBI-568)",
  "indication": "schizophrenia (SCZ3029)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "BMY (Cobenfy)",
   "ABBV (emraclidine, discontinued)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/neurocrine-biosciences-reports-second-quarter-2026-financial-results-302839431.html",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Inferred from registry PCD Oct 2027 (NCT06963034); company guides first Ph3 readout H2 2027; oral M4 agonist. Re-checked 2026-09-23: sponsor Q2 2026 PR: \"With multiple important clinical milestones in 2027, including Phase 3 readouts for osavampator in major depressive disorder and direclidine in schizophrenia...\" No half/quarter printed by sponsor, so conservative window 2027. Registry PCD Oct 2027 (NCT06963034) stays in notes only.",
  "us_tradable": true,
  "nct_id": "NCT06963034",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-07",
  "record_id": "v16-0134",
  "guidance_detail": "Inferred from registry PCD Oct 2027 (NCT06963034); company guides first Ph3 readout H2 2027; oral M4 agonist.",
  "audit_status": "v20_reverified",
  "audit_action": "inferred_to_guidance",
  "date_history": [
   {
    "from": "2027-Q4",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Upgrade inferred->guidance: sponsor guides Phase 3 readout in 2027 with no half/quarter printed; window broadened"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0135"
  ],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "NBIX",
  "company": "Neurocrine Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "direclidine (NBI-1117568 / NBI-568)",
  "indication": "schizophrenia (SCZ3030)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "BMY (Cobenfy)",
   "ABBV (emraclidine, discontinued)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07105098",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD Nov 2027 (NCT07105098); second pivotal Ph3; company guides first readout H2 2027.",
  "us_tradable": true,
  "nct_id": "NCT07105098",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0135",
  "guidance_detail": "Inferred from registry PCD Nov 2027 (NCT07105098); second pivotal Ph3; company guides first readout H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0134"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "ziltivekimab",
  "indication": "post-acute myocardial infarction (ARTEMIS)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "NVS (canakinumab, CANTOS)",
   "colchicine (generic, COLCOT/LoDoCo2)"
  ],
  "source_url": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 ARTEMIS readout expected H1 2027 per Q2 2026 results deck.",
  "us_tradable": true,
  "nct_id": "NCT06118281",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0136",
  "guidance_detail": "Phase 3 ARTEMIS readout expected H1 2027 per Q2 2026 results deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "CagriSema",
  "indication": "type 2 diabetes, switch from semaglutide (REIMAGINE SWITCH)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (tirzepatide)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07817251",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-06-09 (NCT07817251; not yet recruiting Sep 2026); switch tolerability study.",
  "us_tradable": true,
  "nct_id": "NCT07817251",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0137",
  "guidance_detail": "Inferred from registry PCD 2027-06-09 (NCT07817251; not yet recruiting Sep 2026); switch tolerability study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0045",
   "v16-0139",
   "v16-0138",
   "v16-0002",
   "v16-0141"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "CagriSema",
  "indication": "obesity / type 2 diabetes CV outcomes (REDEFINE 3)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "LLY (tirzepatide/retatrutide)",
   "AMGN (MariTide)"
  ],
  "source_url": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "REDEFINE 3 CVOT (7000 pts, event-driven) readout guided H2 2027; gates CagriSema EU regulatory pathway.",
  "us_tradable": true,
  "nct_id": "NCT05669755",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0138",
  "guidance_detail": "REDEFINE 3 CVOT (7000 pts, event-driven) readout guided H2 2027; gates CagriSema EU regulatory pathway.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0045",
   "v16-0139",
   "v16-0137",
   "v16-0113"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "CagriSema",
  "indication": "obesity, full weight-loss potential (REDEFINE 11)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "LLY (tirzepatide)",
   "AMGN (MariTide)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/02/23/3242381/0/en/Novo-Nordisk-A-S-CagriSema-demonstrated-23-weight-loss-in-an-open-label-head-to-head-REDEFINE-4-trial-in-people-with-obesity-the-primary-endpoint-was-not-achieved.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "REDEFINE 11 (600 pts, 80-wk vs placebo) readout guided H1 2027; registry PCD Mar 2027 (NCT07011667).",
  "us_tradable": true,
  "nct_id": "NCT07011667",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0139",
  "guidance_detail": "REDEFINE 11 (600 pts, 80-wk vs placebo) readout guided H1 2027; registry PCD Mar 2027 (NCT07011667).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0045",
   "v16-0138",
   "v16-0137",
   "v16-0001",
   "v16-0219"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "cagrilintide",
  "indication": "obesity (RENEW programme)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "Zealand/Roche (petrelintide)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07220642",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-11 (NCT07220642); dedicated cagrilintide monotherapy Ph3 (RENEW, started Q4 2025).",
  "us_tradable": true,
  "nct_id": "NCT07220642",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0140",
  "guidance_detail": "Inferred from registry PCD 2027-05-11 (NCT07220642); dedicated cagrilintide monotherapy Ph3 (RENEW, started Q4 2025).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0142",
   "v16-0141",
   "v16-0001",
   "v16-0219",
   "v16-0139"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "cagrilintide",
  "indication": "overweight/obesity with type 2 diabetes (RENEW programme)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "Zealand/Roche (petrelintide)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07220759",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-12 (NCT07220759); cagrilintide monotherapy Ph3 in T2D population.",
  "us_tradable": true,
  "nct_id": "NCT07220759",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0141",
  "guidance_detail": "Inferred from registry PCD 2027-05-12 (NCT07220759); cagrilintide monotherapy Ph3 in T2D population.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0142",
   "v16-0140",
   "v16-0002",
   "v16-0137"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "cagrilintide",
  "indication": "obesity (presentation comparability)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "Zealand/Roche (petrelintide)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07745504",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-18 (NCT07745504); placebo-controlled comparability of two cagrilintide presentations.",
  "us_tradable": true,
  "nct_id": "NCT07745504",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0142",
  "guidance_detail": "Inferred from registry PCD 2027-05-18 (NCT07745504); placebo-controlled comparability of two cagrilintide presentations.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0141",
   "v16-0140"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "insulin icodec",
  "indication": "type 1 diabetes",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "LLY (efsitora alfa, weekly insulin)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07076199",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-01-25 (NCT07076199); 26-wk Ph3 weekly icodec vs daily glargine in T1D.",
  "us_tradable": true,
  "nct_id": "NCT07076199",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0143",
  "guidance_detail": "Inferred from registry PCD 2027-01-25 (NCT07076199); 26-wk Ph3 weekly icodec vs daily glargine in T1D.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "drug": "semaglutide",
  "indication": "diabetic retinopathy (FOCUS)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "REGN (Eylea)",
   "Roche (Vabysmo)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03811561",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-11-07 (NCT03811561); long-term Ph3 of semaglutide effects on diabetic eye disease.",
  "us_tradable": true,
  "nct_id": "NCT03811561",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0144",
  "guidance_detail": "Inferred from registry PCD 2027-11-07 (NCT03811561); long-term Ph3 of semaglutide effects on diabetic eye disease.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "abelacimab",
  "indication": "atrial fibrillation (LILAC-TIMI 76)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "BMY/PFE (Eliquis)",
   "JNJ (Xarelto)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 LILAC readout guided 2027 per Q1 2026 deck; anti-FXI mAb in AF unsuitable for oral anticoagulation.",
  "us_tradable": true,
  "nct_id": "NCT05712200",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0145",
  "guidance_detail": "Phase 3 LILAC readout guided 2027 per Q1 2026 deck; anti-FXI mAb in AF unsuitable for oral anticoagulation.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0063"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "inclisiran (Leqvio)",
  "indication": "CV outcomes, elevated LDL-C (ORION-4)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "AMGN (Repatha)",
   "REGN/SNY (Praluent)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 CV outcomes readout guided 2027 (event-driven) per Q1 2026 deck; registry PCD had shown Oct 2026 estimate.",
  "us_tradable": true,
  "nct_id": "NCT03705234",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0146",
  "guidance_detail": "Phase 3 CV outcomes readout guided 2027 (event-driven) per Q1 2026 deck; registry PCD had shown Oct 2026 estimate.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0026",
   "v16-0147"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "inclisiran (Leqvio)",
  "indication": "secondary prevention of CV events (VICTORION-2P)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "AMGN (Repatha)",
   "REGN/SNY (Praluent)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 CV outcomes readout guided 2027 (event-driven) per Q1 2026 deck.",
  "us_tradable": true,
  "nct_id": "NCT05030428",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0147",
  "guidance_detail": "Phase 3 CV outcomes readout guided 2027 (event-driven) per Q1 2026 deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0026",
   "v16-0146"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "zigakibart",
  "indication": "IgA nephropathy (BEYOND)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "VRTX (povetacicept)",
   "Otsuka (sibeprenlimab)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 BEYOND readout guided H1 2027 per Q1 2026 deck; anti-APRIL mAb.",
  "us_tradable": true,
  "nct_id": "NCT05852938",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0148",
  "guidance_detail": "Phase 3 BEYOND readout guided H1 2027 per Q1 2026 deck; anti-APRIL mAb.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0011",
   "v16-0058"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "ianalumab",
  "indication": "lupus nephritis (SIRIUS-LN)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "GSK (Benlysta)",
   "AZN (Saphnelo)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 SIRIUS-LN readout guided 2027 per Q1 2026 deck; anti-BAFF-R mAb. Intentional multi-trial entry: distinct registrational trials (SIRIUS-LN, SIRIUS-SLE 1, SIRIUS-SLE 2).",
  "us_tradable": true,
  "nct_id": "NCT05126277",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0149",
  "guidance_detail": "Phase 3 SIRIUS-LN readout guided 2027 per Q1 2026 deck; anti-BAFF-R mAb.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0019",
   "v17-0018",
   "v17-0017",
   "v17-0016",
   "v16-0151"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "ianalumab",
  "indication": "systemic lupus erythematosus (SIRIUS-SLE 1)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "GSK (Benlysta)",
   "AZN (Saphnelo)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 SIRIUS-SLE 1 readout guided 2027 per Q1 2026 deck. Intentional multi-trial entry: distinct registrational trials (SIRIUS-LN, SIRIUS-SLE 1, SIRIUS-SLE 2).",
  "us_tradable": true,
  "nct_id": "NCT05639114",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0150",
  "guidance_detail": "Phase 3 SIRIUS-SLE 1 readout guided 2027 per Q1 2026 deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0019",
   "v17-0018",
   "v17-0017",
   "v17-0016",
   "v16-0151"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "ianalumab",
  "indication": "systemic lupus erythematosus (SIRIUS-SLE 2)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "GSK (Benlysta)",
   "AZN (Saphnelo)"
  ],
  "source_url": "https://www.novartis.com/sites/novartiscom/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Phase 3 SIRIUS-SLE 2 readout guided 2027 per Q1 2026 deck. Intentional multi-trial entry: distinct registrational trials (SIRIUS-LN, SIRIUS-SLE 1, SIRIUS-SLE 2).",
  "us_tradable": true,
  "nct_id": "NCT05624749",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0151",
  "guidance_detail": "Phase 3 SIRIUS-SLE 2 readout guided 2027 per Q1 2026 deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0019",
   "v17-0018",
   "v17-0017",
   "v17-0016",
   "v16-0150"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "iptacopan (Fabhalta)",
  "indication": "generalized myasthenia gravis (APPRAISE)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "AZN (Ultomiris/Soliris)",
   "UCB (Rystiggo/Zilbrysq)",
   "JNJ (IMAAVY/nipocalimab)"
  ],
  "source_url": "https://www.novartis.com/sites/novartis_com/files/q1-2026-investor-presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-18",
  "notes": "Phase 3 APPRAISE readout guided 2027 per Q1 2026 deck; factor B inhibitor (NCT06517758).",
  "us_tradable": true,
  "nct_id": "NCT06517758",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0154",
  "guidance_detail": "Phase 3 APPRAISE readout guided 2027 per Q1 2026 deck; factor B inhibitor (NCT06517758).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-1014",
   "v16-0221",
   "v16-0209"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "nemtabrutinib (MK-1026)",
  "indication": "untreated CLL/SLL without TP53 aberrations",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (venetoclax)",
   "BEIG (Brukinsa)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05624554",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-19 (NCT05624554). Non-covalent BTK inhibitor vs chemoimmunotherapy.",
  "us_tradable": true,
  "nct_id": "NCT05624554",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0156",
  "guidance_detail": "Inferred from registry PCD 2027-05-19 (NCT05624554).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "MK-1406 (CD388)",
  "indication": "influenza prevention (ANCHOR)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "GSK (flu vaccines)",
   "SNY (flu vaccines)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07159763",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-06-30 (NCT07159763). Drug-Fc conjugate; sponsor Cidara Therapeutics (Merck subsidiary).",
  "us_tradable": true,
  "nct_id": "NCT07159763",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0157",
  "guidance_detail": "Inferred from registry PCD 2027-06-30 (NCT07159763).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "alimatravir (MK-8527)",
  "indication": "HIV PrEP (EXPrESSIVE-11)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "GILD (Yeztugo/lenacapavir)",
   "GSK/ViiV (Apretude)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07044297",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-07-22 (NCT07044297). Oral monthly PrEP.",
  "us_tradable": true,
  "nct_id": "NCT07044297",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0158",
  "guidance_detail": "Inferred from registry PCD 2027-07-22 (NCT07044297).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0160"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "bomedemstat (MK-3543)",
  "indication": "essential thrombocythemia",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "INCY (Jakafi)",
   "PharmaEssentia (Besremi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06079879",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Inferred from registry PCD 2027-07-14 (NCT06079879). LSD1 inhibitor vs best available therapy.",
  "us_tradable": true,
  "nct_id": "NCT06079879",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0159",
  "guidance_detail": "Inferred from registry PCD 2027-07-14 (NCT06079879).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0168"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "alimatravir (MK-8527)",
  "indication": "HIV PrEP (EXPrESSIVE-10)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "GILD (Yeztugo/lenacapavir)",
   "GSK/ViiV (Apretude)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07071623",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-10-18 (NCT07071623). Oral monthly PrEP.",
  "us_tradable": true,
  "nct_id": "NCT07071623",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0160",
  "guidance_detail": "Inferred from registry PCD 2027-10-18 (NCT07071623).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0158"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "pembrolizumab (Keytruda)",
  "indication": "NSCLC, monotherapy vs sacituzumab govitecan",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "GILD (Trodelvy)",
   "AZN/Daiichi (Dato-DXd)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05609968",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-01-12 (NCT05609968). Merck-sponsored active-comparator Ph3.",
  "us_tradable": true,
  "nct_id": "NCT05609968",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0161",
  "guidance_detail": "Inferred from registry PCD 2027-01-12 (NCT05609968).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0171",
   "v16-0167",
   "v16-0166",
   "v16-0163"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "suvorexant (Belsomra)",
  "indication": "insomnia",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Eisai (Dayvigo)",
   "Idorsia (Quviviq)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06655883",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-06-24 (NCT06655883). Lifecycle Ph3 of approved orexin antagonist.",
  "us_tradable": true,
  "nct_id": "NCT06655883",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0162",
  "guidance_detail": "Inferred from registry PCD 2027-06-24 (NCT06655883).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "pembrolizumab (Keytruda)",
  "indication": "endometrial cancer, vs chemotherapy",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "GSK (Jemperli)",
   "AZN (Imfinzi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05173987",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-27 (NCT05173987).",
  "us_tradable": true,
  "nct_id": "NCT05173987",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0163",
  "guidance_detail": "Inferred from registry PCD 2027-05-27 (NCT05173987).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0171",
   "v16-0167",
   "v16-0166",
   "v16-0161"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "9vHPV vaccine (Gardasil 9)",
  "indication": "oral persistent HPV infection",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "GSK (Cervarix)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04199689",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-01",
  "notes": "Inferred from registry PCD 2027-01-15 (estimated; NCT04199689, moved in from 2027-08-27 per registry update 2026-09-29). Efficacy against oral persistent infection; vaccine lifecycle Ph3.",
  "us_tradable": true,
  "nct_id": "NCT04199689",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0164",
  "guidance_detail": "Inferred from registry PCD 2027-01-15 (estimated; NCT04199689, moved in from 2027-08-27 per registry update 2026-09-29).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027-Q1",
    "changed": "2026-10-01",
    "why": "Registry PCD moved 2027-08-27 -> 2027-01-15 (estimated) per CT.gov update 2026-09-29; re-bucketed per stale-guidance detector"
   }
  ],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "enlicitide decanoate (MK-0616)",
  "indication": "hyperlipidemia / hypercholesterolemia",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "AMGN (Repatha)",
   "REGN (Praluent)",
   "NVS (Leqvio)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07821944",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-11-26 (NCT07821944). Oral PCSK9 inhibitor; trial NOT_YET_RECRUITING Sep 2026 \u2014 2027 readout uncertain.",
  "us_tradable": true,
  "nct_id": "NCT07821944",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0165",
  "guidance_detail": "Inferred from registry PCD 2027-11-26 (NCT07821944).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "pembrolizumab (Keytruda)",
  "indication": "small cell lung cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Imfinzi)",
   "Roche (Tecentriq)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04624204",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-10-28 (NCT04624204). Placebo-controlled Ph3 with chemoradiation.",
  "us_tradable": true,
  "nct_id": "NCT04624204",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0166",
  "guidance_detail": "Inferred from registry PCD 2027-10-28 (NCT04624204).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0171",
   "v16-0167",
   "v16-0163",
   "v16-0161"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "pembrolizumab (Keytruda)",
  "indication": "bladder cancer, with radiotherapy",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "PFE (Padcev)",
   "AZN (Imfinzi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04241185",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-01-31 (NCT04241185). Pembro + bladder radiotherapy vs radiotherapy arms.",
  "us_tradable": true,
  "nct_id": "NCT04241185",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0167",
  "guidance_detail": "Inferred from registry PCD 2027-01-31 (NCT04241185).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0171",
   "v16-0166",
   "v16-0163",
   "v16-0161"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "bomedemstat (MK-3543)",
  "indication": "essential thrombocythemia (MK-3543-007)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "INCY (Jakafi)",
   "PharmaEssentia (Besremi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06456346",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-09-28 (NCT06456346). LSD1 inhibitor vs hydroxyurea; second Ph3 ET study in 2027.",
  "us_tradable": true,
  "nct_id": "NCT06456346",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0168",
  "guidance_detail": "Inferred from registry PCD 2027-09-28 (NCT06456346).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0159"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "sacituzumab tirumotecan (MK-2870)",
  "indication": "previously treated NSCLC, vs docetaxel/pemetrexed",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "GILD (Trodelvy)",
   "AZN (Dato-DXd)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06074588",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-10 (NCT06074588). TROP2 ADC Ph3.",
  "us_tradable": true,
  "nct_id": "NCT06074588",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0169",
  "guidance_detail": "Inferred from registry PCD 2027-05-10 (NCT06074588).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0172",
   "v16-0170"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "sacituzumab tirumotecan (MK-2870)",
  "indication": "breast cancer, single agent and + pembrolizumab",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "GILD (Trodelvy)",
   "AZN (Dato-DXd)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06312176",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-07-11 (NCT06312176). TROP2 ADC Ph3 vs chemo.",
  "us_tradable": true,
  "nct_id": "NCT06312176",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0170",
  "guidance_detail": "Inferred from registry PCD 2027-07-11 (NCT06312176).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0172",
   "v16-0169"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "pembrolizumab (Keytruda)",
  "indication": "NSCLC, + olaparib maintenance",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Lynparza)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04380636",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-05-05 (NCT04380636). Pembro + olaparib/placebo with chemoradiation.",
  "us_tradable": true,
  "nct_id": "NCT04380636",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0171",
  "guidance_detail": "Inferred from registry PCD 2027-05-05 (NCT04380636).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0167",
   "v16-0166",
   "v16-0163",
   "v16-0161"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRK",
  "company": "Merck & Co., Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "sacituzumab tirumotecan (MK-2870)",
  "indication": "gastroesophageal cancer",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "AZN/Daiichi (Enhertu)",
   "Astellas (Vyloy)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06356311",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-01-04 (NCT06356311). TROP2 ADC Ph3 vs trifluridine-tipiracil/irinotecan/taxane.",
  "us_tradable": true,
  "nct_id": "NCT06356311",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0172",
  "guidance_detail": "Inferred from registry PCD 2027-01-04 (NCT06356311).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0170",
   "v16-0169"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MRNA",
  "company": "Moderna, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "mRNA-1403",
  "indication": "norovirus (NOVA 301)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "HilleVax (HIL-214, private)",
   "VXRT (oral norovirus)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06592794",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Interim missed early-success bar (Q2 2026); additional cohort enrolling; registry PCD 2027-02-15 \u2014 final readout case-accrual dependent. [Source verified 2026-09-20: NCT06592794 (Nova 301, Phase 3 mRNA-1403): status ACTIVE_NOT_RECRUITING; \"primaryCompletionDateStruct\":{\"date\":\"2027-02-15\",\"type\":\"ESTIMATED\"} \u2014 primary completion estimated 2027-02-15.]",
  "us_tradable": true,
  "nct_id": "NCT06592794",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0173",
  "guidance_detail": "Interim missed early-success bar (Q2 2026); additional cohort enrolling; registry PCD 2027-02-15 \u2014 final readout case-accrual dependent.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "MIRM",
  "company": "Mirum Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "volixibat",
  "indication": "primary sclerosing cholangitis",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "GILD (cilofexor)",
   "no approved PSC therapy"
  ],
  "source_url": "https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update/default.aspx",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Potential NDA filing H1 2027; conditional \u2014 FDA requested a Ph3 study in PSC.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0174",
  "guidance_detail": "Potential NDA filing H1 2027; conditional \u2014 FDA requested a Ph3 study in PSC.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "MIRM",
  "company": "Mirum Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "brelovitug (BJT-778)",
  "indication": "chronic hepatitis D, vs bulevirtide",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "GILD (Hepcludex/bulevirtide)",
   "VIR (tobevibart/elebsiran)"
  ],
  "source_url": "https://s21.q4cdn.com/142896768/files/doc_presentations/2026/Oct/Mirum-Corporate-Presentation-October-Final.pdf",
  "source_type": "company deck",
  "as_of": "2026-10-20",
  "notes": "AZURE-2 and AZURE-3 Phase 3 topline data expected H2 2027 (EU registrational program; Mirum corporate presentation, Oct 2026). Registrational study BJT-778-302 (NCT07200908, vs bulevirtide), registry PCD 2027-06-30. AZURE-1 met its primary endpoint in Sep 2026.",
  "us_tradable": true,
  "nct_id": "NCT07200908",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10",
  "record_id": "v16-0175",
  "guidance_detail": "AZURE-2 and AZURE-3 Phase 3 topline data expected H2 2027 (EU registrational program; Mirum corporate presentation, Oct 2026). Registrational study BJT-778-302 (NCT07200908, vs bulevirtide), registry PCD 2027-06-30. AZURE-1 met its primary endpoint in Sep 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0695",
   "v16-0533"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-20",
  "why_it_matters": "Phase 3 data for brelovitug (BJT-778) in chronic hepatitis D, vs bulevirtide is expected in H2 2027 \u2014 the pivotal readout that determines whether Mirum Pharmaceuticals, Inc. can file for approval.",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record. Upgraded 2026-10-20 from registry-inferred Q2 2027 to company-guided H2 2027 per Mirum October 2026 corporate presentation (AZURE 2 & 3 topline H2 2027)."
 },
 {
  "ticker": "MLTX",
  "company": "MoonLake Immunotherapeutics",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "sonelokimab",
  "indication": "psoriatic arthritis (IZAR-1, full Week 52)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "NVS (Cosentyx)",
   "UCB (Bimzelx)",
   "LLY (Taltz)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1821586/000121390026086939/0001213900-26-086939-index.htm",
  "source_type": "SEC 8-K",
  "as_of": "2026-10-01",
  "notes": "MoonLake 8-K (2026-08-10, CIK 1821586), Ex. 99.1: 'The IZAR-1 trial remains blinded and will continue until Week 52 with MoonLake expecting the full readout in H1 2027' (psoriatic arthritis, IL-17A/F nanobody). Re-verified 2026-09-20. [Merged 2026-09-23] Absorbed duplicate row v16-0178 (same IZAR-1 Week-52 readout, NCT06641076, H1 2027): v16-0178 carried the MoonLake Q2 2026 PR detail that IZAR-1 'met all endpoints at Week 16 (ACR50 42.1%)' with the trial continuing blinded to Week 52; the Week-16-style readout already occurred Aug 2026. Stronger source retained (SEC 8-K, 2026-08-10, Ex. 99.1).",
  "us_tradable": true,
  "nct_id": "NCT06641076",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0176",
  "guidance_detail": "MoonLake 8-K (2026-08-10, CIK 1821586), Ex.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "date_history": [
   {
    "from": "2027-Q1",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "[via merge of v16-0178] Retargeted to IZAR-1 full Week-52 readout per MoonLake Q2 2026 PR; inferred->guidance"
   }
  ],
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0177"
  ],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for sonelokimab in psoriatic arthritis (IZAR-1, full Week 52) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether MoonLake Immunotherapeutics can file for approval."
 },
 {
  "ticker": "MLTX",
  "company": "MoonLake Immunotherapeutics",
  "country": "Switzerland",
  "us_listed": true,
  "drug": "sonelokimab",
  "indication": "psoriatic arthritis (IZAR-2, 4-arm with risankizumab reference)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "NVS (Cosentyx)",
   "UCB (Bimzelx)",
   "LLY (Taltz)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06641089",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Inferred from registry PCD 2027-01-04 (NCT06641089). Trial identified as IZAR-2: CT.gov NCT06641089 official title = 4-arm Phase 3 with risankizumab reference arm in anti-TNFa inadequate response (per MoonLake PR). MoonLake Aug 10 2026 guidance: IZAR-2 completes enrollment Q3 2026. Prior 'relationship to IZAR-1 unclear' note resolved.",
  "us_tradable": true,
  "nct_id": "NCT06641089",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0177",
  "guidance_detail": "Inferred from registry PCD 2027-01-04 (NCT06641089). Trial identified as IZAR-2: CT.gov NCT06641089 official title = 4-arm Phase 3 with risankizumab reference arm in anti-TNFa inadequate response (per MoonLake PR). MoonLake Aug 10 2026 guidance: IZAR-2 completes enrollment Q3 2026. Prior 'relationship to IZAR-1 unclear' note resolved.",
  "audit_status": "v18_reverified",
  "audit_action": "improved",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0176"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-20",
  "why_it_matters": "Phase 3 data for sonelokimab in psoriatic arthritis (IZAR-2, 4-arm with risankizumab reference) is expected in Q1 2027 \u2014 the pivotal readout that determines whether MoonLake Immunotherapeutics can file for approval.",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "MGTX",
  "company": "MeiraGTx Holdings plc",
  "country": "United States",
  "us_listed": true,
  "drug": "AAV2-hAQP1",
  "indication": "radiation-induced xerostomia",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "guidance",
  "competitors": [
   "none \u2014 no approved disease-modifying therapy"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1735438/000110465926095491/0001104659-26-095491-index.htm",
  "source_type": "SEC filing",
  "as_of": "2026-10-01",
  "notes": "Potential BLA filing guided 'around mid-2027' (Q2/Q3 boundary). [Source verified 2026-09-20: Exhibit 99.1 (company Q2 2026 results press release furnished with 8-K filed 2026-08-13): \"Anticipate submission of global regulatory filings for approval of bota-vec in 2026 and potential BLA filing for AAV2-hAQP1 in mi]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0179",
  "guidance_detail": "Potential BLA filing guided 'around mid-2027' (Q2/Q3 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "MeiraGTx Holdings plc is expected to file its biologics license application for AAV2-hAQP1 in radiation-induced xerostomia in Q2 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "OLMA",
  "company": "Olema Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "palazestrant",
  "indication": "ER+/HER2- metastatic breast cancer, 2L/3L (OPERA-01)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Menarini/Stemline (Orserdu)",
   "AZN (camizestrant)",
   "LLY (imlunestrant)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1750284/000119312526342334/olma-ex99_1.htm",
  "source_type": "SEC filing",
  "as_of": "2026-09-23",
  "notes": "Phase 3 OPERA-01 readout guided Q1 2027 per Q2 2026 results; oral SERD. Olema 8-K filed 2026-08-10, Exhibit 99.1 (GlobeNewswire-issued release): 'Completed enrollment in the pivotal Phase 3 OPERA-01 trial; top-line data are now expected in the first quarter of 2027.'",
  "us_tradable": true,
  "nct_id": "NCT06016738",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0180",
  "guidance_detail": "Phase 3 OPERA-01 readout guided Q1 2027 per Q2 2026 results; oral SERD.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0725"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for palazestrant in ER+/HER2- metastatic breast cancer, 2L/3L (OPERA-01) is expected in Q1 2027 \u2014 the pivotal readout that determines whether Olema Pharmaceuticals, Inc. can file for approval."
 },
 {
  "ticker": "NBTX",
  "company": "Nanobiotix S.A.",
  "country": "France",
  "us_listed": true,
  "drug": "JNJ-1900 (NBTXR3)",
  "indication": "head and neck cancer (NANORAY-312)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "MRK (Keytruda)",
   "BMY (Opdivo)"
  ],
  "source_url": "https://ml.globenewswire.com/Resource/Download/6d787ffd-3810-4c91-8ede-940d13cd7249",
  "source_type": "company PR",
  "as_of": "2026-09-23",
  "notes": "Ph3 readout guided H1 2027; May 2026 amendment removed interim -> modified final analysis (event-dependent). [Source verified 2026-09-20: Nanobiotix Oct 24, 2025 company release on GlobeNewswire (opened via ml.globenewswire.com): 'Nanobiotix estimates that NANORAY-312 interim data will be analyzed and reported, after both the requisite number of events hav] [Registry check 2026-09-23] CT.gov now lists primary completion 2028-06-30 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT04892173",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0181",
  "guidance_detail": "Ph3 readout guided H1 2027; May 2026 amendment removed interim -> modified final analysis (event-dependent).",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for JNJ-1900 (NBTXR3) in head and neck cancer (NANORAY-312) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Nanobiotix S.A. can file for approval."
 },
 {
  "ticker": "OCGN",
  "company": "Ocugen, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "OCU400",
  "indication": "retinitis pigmentosa, broad (liMeliGhT)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Roche/Spark (Luxturna, RPE65 only)",
   "Nanoscope (MCO-010)"
  ],
  "source_url": "https://www.sec.gov/Archives/edgar/data/1372299/000110465926023288/tm267731d1_ex99-1.htm",
  "source_type": "SEC filing",
  "as_of": "2026-10-01",
  "notes": "Phase 3 liMeliGhT topline guided Q1 2027; gene-agnostic modifier gene therapy. [Source verified 2026-09-20: Exhibit 99.1 (company 8-K filed 2026-03-04, opened and confirmed on sec.gov): \"Enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial for retinitis pigmentosa (RP). As a one-year clinical trial, topli]",
  "us_tradable": true,
  "nct_id": "NCT06388200",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0182",
  "guidance_detail": "Phase 3 liMeliGhT topline guided Q1 2027; gene-agnostic modifier gene therapy.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for OCU400 in retinitis pigmentosa, broad (liMeliGhT) is expected in Q1 2027 \u2014 the pivotal readout that determines whether Ocugen, Inc. can file for approval."
 },
 {
  "ticker": "OGN",
  "company": "Organon & Co.",
  "country": "United States",
  "us_listed": true,
  "drug": "MIUDELLA",
  "indication": "contraception (extended use), sNDA",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "guidance",
  "competitors": [
   "Bayer (Mirena/Kyleena)",
   "ABBV (Liletta)"
  ],
  "source_url": "https://www.organon.com/news/organon-announces-us-fda-has-accepted-for-review-a-supplemental-new-drug-application-for-miudella-a-hormone-free-intrauterine-device/",
  "source_type": "company IR",
  "as_of": "2026-10-20",
  "notes": "sNDA accepted for review; FDA action expected Q2 2027 (no exact date disclosed). [Source verified 2026-09-20: Official Organon Business Wire release (opened and confirmed 2026-09-20): \"today announced the US Food and Drug Administration (FDA) has accepted for review Sebela Women's Health's supplemental New Drug Application (sNDA]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0183",
  "guidance_detail": "sNDA accepted for review; FDA action expected Q2 2027 (no exact date disclosed).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Women's Health",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "OGN",
  "company": "Organon & Co.",
  "country": "United States",
  "us_listed": true,
  "drug": "tapinarof cream 1% (VTAMA)",
  "indication": "atopic dermatitis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "PFE (Eucrisa)",
   "INCY (Opzelura)",
   "LEO (Anzupgo)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07265479",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Inferred from registry PCD 2027-08 (NCT07265479); Ph3 vs vehicle in AD (approved for plaque psoriasis). Registry update (Oct 5, 2026): trial status SUSPENDED \u2014 dosing paused as a precaution due to a PK finding in a related study (OG505-3104); the sponsor states no safety signal or change to the benefit-risk profile has been identified. Registry PCD remains Aug 2027 (estimated); readout timing may slip if the pause extends.",
  "us_tradable": true,
  "nct_id": "NCT07265479",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0184",
  "guidance_detail": "Inferred from registry PCD 2027-08 (NCT07265479); Ph3 vs vehicle in AD (approved for plaque psoriasis).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-20",
  "why_it_matters": "Phase 3 data for tapinarof cream 1% (VTAMA) in atopic dermatitis is expected in Q3 2027 \u2014 the pivotal readout that determines whether Organon & Co. can file for approval.",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NTLA",
  "company": "Intellia Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "lonvoguran ziclumeran (lonvo-z)",
  "indication": "hereditary angioedema",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-03-10",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "TAK (Takhzyro)",
   "CSL (Haegarda)",
   "KALV (Ektyro/sebetralstat)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357599/0/en/intellia-therapeutics-announces-fda-acceptance-of-biologics-license-application-with-priority-review-for-lonvoguran-ziclumeran-lonvo-z-for-hereditary-angioedema-hae.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "BLA accepted with priority review; PDUFA 2027-03-10; FDA currently does not plan an AdCom. [Source verified 2026-09-20: Official Intellia GlobeNewswire release (opened and confirmed 2026-09-20): \"today announced the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for lonvo-z and granted the BLA]",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0185",
  "guidance_detail": "BLA accepted with priority review; PDUFA 2027-03-10; FDA currently does not plan an AdCom.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on lonvoguran ziclumeran (lonvo-z) for hereditary angioedema falls on 2027-03-10 \u2014 the agency's yes-or-no moment for Intellia Therapeutics, Inc.'s application."
 },
 {
  "ticker": "NTLA",
  "company": "Intellia Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "nexiguran ziclumeran (NTLA-2001)",
  "indication": "ATTRv polyneuropathy (MAGNITUDE-2)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "ALNY (Amvuttra/Onpattro)",
   "IONS/AZN (Wainua)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06672237",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-07 (NCT06672237); CRISPR-based TTR silencer Ph3.",
  "us_tradable": true,
  "nct_id": "NCT06672237",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0186",
  "guidance_detail": "Inferred from registry PCD 2027-07 (NCT06672237); CRISPR-based TTR silencer Ph3.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0187"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for nexiguran ziclumeran (NTLA-2001) in ATTRv polyneuropathy (MAGNITUDE-2) is expected in Q3 2027 \u2014 the pivotal readout that determines whether Intellia Therapeutics, Inc. can file for approval.",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "ticker": "NTLA",
  "company": "Intellia Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "nexiguran ziclumeran (NTLA-2001)",
  "indication": "ATTR cardiomyopathy (MAGNITUDE)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "PFE (Vyndaqel)",
   "ALNY (Amvuttra)",
   "BBIO (Attruby)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06128629",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Inferred from registry PCD 2027-12 (NCT06128629); event-driven CV outcomes Ph3.",
  "us_tradable": true,
  "nct_id": "NCT06128629",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0187",
  "guidance_detail": "Inferred from registry PCD 2027-12 (NCT06128629); event-driven CV outcomes Ph3.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0186"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for nexiguran ziclumeran (NTLA-2001) in ATTR cardiomyopathy (MAGNITUDE) is expected in Q4 2027 \u2014 the pivotal readout that determines whether Intellia Therapeutics, Inc. can file for approval.",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "as_of": "2026-09-24",
  "company": "Pharvaris N.V.",
  "competitors": [
   "sebetralstat (KalVista Pharmaceuticals)",
   "icatibant (generic)",
   "plasma-derived C1-inhibitor (CSL Behring)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-23",
  "date_quality": "hard",
  "drug": "Deucrictibant immediate-release",
  "event_type": "pdufa",
  "indication": "On-demand treatment of hereditary angioedema attacks (age 12+)",
  "notes": "FDA accepted the NDA for deucrictibant IR for on-demand HAE attacks; PDUFA target action date is April 23, 2027 per company announcement.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-for-on-demand-treatment-of-hereditary-angioedema-attacks",
  "ticker": "PHVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0188",
  "guidance_detail": "FDA accepted the NDA for deucrictibant IR for on-demand HAE attacks; PDUFA target action date is April 23, 2027 per company announcement.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v20-0003"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on deucrictibant immediate-release for on-demand treatment of hereditary angioedema attacks (age 12+) falls on 2027-04-23 \u2014 the agency's yes-or-no moment for Pharvaris N.V.'s application."
 },
 {
  "as_of": "2026-09-18",
  "company": "Pharvaris N.V.",
  "competitors": [
   "berotralstat (Biocryst)",
   "lanadelumab (Takeda)",
   "C1-esterase inhibitor (CSL Behring)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Deucrictibant extended-release",
  "event_type": "nda_filing",
  "indication": "Prophylactic treatment of hereditary angioedema attacks",
  "notes": "Company guided to an NDA filing in H1 2027 following positive CHAPTER-3 pivotal Phase 3 topline for deucrictibant XR in HAE prophylaxis. [Source verified 2026-09-20: Official Pharvaris GlobeNewswire release (opened and confirmed 2026-09-20): \"Data from the CHAPTER-3 study will serve as the basis for marketing authorization applications, which are planned to be submitted starting in t]",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357455/0/en/pharvaris-announces-positive-topline-data-from-chapter-3-pivotal-study-of-deucrictibant-xr-for-prophylaxis-of-hae-attacks.html",
  "ticker": "PHVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0189",
  "guidance_detail": "Company guided to an NDA filing in H1 2027 following positive CHAPTER-3 pivotal Phase 3 topline for deucrictibant XR in HAE prophylaxis.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Pharvaris N.V.",
  "competitors": [
   "sebetralstat (KalVista Pharmaceuticals)",
   "icatibant (generic)",
   "C1-esterase inhibitor (CSL Behring)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Deucrictibant extended-release",
  "event_type": "readout",
  "indication": "Acquired angioedema due to C1-inhibitor deficiency",
  "notes": "CREAATE pivotal Phase 3 (NCT07266805) Part 1 data expected in Q1 2027 per company September 2026 corporate presentation filed with 6-K. [Source verified 2026-09-20: Official Pharvaris GlobeNewswire release (opened and confirmed 2026-09-20), same September 2026 company communication: \"Topline data from Part 1 of CREAATE (NCT07266805), a global, pivotal Phase 3 study evaluating orally]",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357455/0/en/pharvaris-announces-positive-topline-data-from-chapter-3-pivotal-study-of-deucrictibant-xr-for-prophylaxis-of-hae-attacks.html",
  "ticker": "PHVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07266805",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0190",
  "guidance_detail": "CREAATE pivotal Phase 3 (NCT07266805) Part 1 data expected in Q1 2027 per company September 2026 corporate presentation filed with 6-K.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0189"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for deucrictibant extended-release in acquired angioedema due to C1-inhibitor deficiency is expected in Q1 2027 \u2014 the pivotal readout that determines whether Pharvaris N.V. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Organogenesis Holdings Inc.",
  "competitors": [
   "Zilretta (Pacira BioSciences)",
   "Synvisc-One (Sanofi)",
   "Monovisc (Anika Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-24",
  "date_quality": "hard",
  "drug": "ReNu",
  "event_type": "pdufa",
  "indication": "Management of symptomatic knee osteoarthritis pain",
  "notes": "FDA accepted the BLA for ReNu for symptomatic knee OA; PDUFA target action date is April 24, 2027 per company announcement.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/organogenesis-announces-fda-acceptance-of-biologics-license-application-for-renu-for-the-management-of-symptomatic-knee-osteoarthritis",
  "ticker": "ORGO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0191",
  "guidance_detail": "FDA accepted the BLA for ReNu for symptomatic knee OA; PDUFA target action date is April 24, 2027 per company announcement.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on ReNu for Management of symptomatic knee osteoarthritis pain falls on 2027-04-24 \u2014 the agency's yes-or-no moment for Organogenesis Holdings Inc.'s application."
 },
 {
  "as_of": "2026-10-01",
  "company": "Praxis Precision Medicines, Inc.",
  "competitors": [
   "propranolol (generic)",
   "primidone (generic)",
   "topiramate (generic)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-29",
  "date_quality": "hard",
  "drug": "Ulixacaltamide HCl",
  "event_type": "pdufa",
  "indication": "Essential tremor in adults",
  "notes": "FDA accepted the NDA for ulixacaltamide in essential tremor with PDUFA date January 29, 2027; FDA indicated it does not currently plan an Advisory Committee meeting.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/04/14/3273225/0/en/Praxis-Precision-Medicines-Announces-FDA-Acceptance-of-New-Drug-Application-for-Ulixacaltamide-HCl-in-Patients-with-Essential-Tremor.html",
  "ticker": "PRAX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0192",
  "guidance_detail": "FDA accepted the NDA for ulixacaltamide in essential tremor with PDUFA date January 29, 2027; FDA indicated it does not currently plan an Advisory Committee meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on Ulixacaltamide HCl for Essential tremor in adults falls on 2027-01-29 \u2014 the agency's yes-or-no moment for Praxis Precision Medicines, Inc.'s application."
 },
 {
  "as_of": "2026-09-23",
  "company": "Vaxcyte, Inc.",
  "competitors": [
   "Prevnar 20 (Pfizer)",
   "Capvaxive (Merck)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VAX-31",
  "event_type": "readout",
  "indication": "Pneumococcal disease prevention (concomitant seasonal influenza vaccination study in adults)",
  "notes": "OPUS-2 Phase 3 study of VAX-31 co-administered with seasonal influenza vaccine; topline data expected in H1 2027 per Q2 2026 company business update.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339693/0/en/Vaxcyte-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html",
  "ticker": "PCVX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07365826",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0193",
  "guidance_detail": "OPUS-2 Phase 3 study of VAX-31 co-administered with seasonal influenza vaccine; topline data expected in H1 2027 per Q2 2026 company business update.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v17-0020",
   "v16-0551",
   "v16-0194"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for VAX-31 in pneumococcal disease prevention (concomitant seasonal influenza vaccination study in adults) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Vaxcyte, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Vaxcyte, Inc.",
  "competitors": [
   "Prevnar 20 (Pfizer)",
   "Capvaxive (Merck)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VAX-31",
  "event_type": "readout",
  "indication": "Pneumococcal disease prevention (previously pneumococcal-vaccinated adults)",
  "notes": "OPUS-3 Phase 3 study of VAX-31 in previously pneumococcal-vaccinated adults; topline data expected in H1 2027 per Q2 2026 company business update.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339693/0/en/Vaxcyte-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html",
  "ticker": "PCVX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07425392",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0194",
  "guidance_detail": "OPUS-3 Phase 3 study of VAX-31 in previously pneumococcal-vaccinated adults; topline data expected in H1 2027 per Q2 2026 company business update.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v17-0020",
   "v16-0551",
   "v16-0193"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for VAX-31 in Pneumococcal disease prevention (previously pneumococcal-vaccinated adults) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Vaxcyte, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Ultragenyx Pharmaceutical Inc.",
  "competitors": [
   "Ravicti (Horizon Therapeutics/Amgen)",
   "sodium phenylbutyrate (generic)",
   "liver transplantation"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DTX301 (avalotcagene ontaparvovec)",
  "event_type": "readout",
  "indication": "Ornithine transcarbamylase (OTC) deficiency",
  "notes": "Phase 3 Enh3ance study second primary endpoint (treatment burden through 64 weeks) data expected in H1 2027 per company following positive 36-week topline. Ultragenyx Q2 2026 release (Aug 4, 2026): Phase 3 Enh3ance study following treatment and crossover patients through 64 weeks; expects data from the second primary endpoint (reduction in treatment burden) in H1 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338827/20739/en/Ultragenyx-Reports-Second-Quarter-2026-Financial-Results-and-Corporate-Update.html",
  "ticker": "RARE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05345171",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0195",
  "guidance_detail": "Phase 3 Enh3ance study second primary endpoint (treatment burden through 64 weeks) data expected in H1 2027 per company following positive 36-week topline.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for DTX301 (avalotcagene ontaparvovec) in Ornithine transcarbamylase (OTC) deficiency is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Ultragenyx Pharmaceutical Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "ProKidney Corp.",
  "competitors": [
   "Farxiga/dapagliflozin (AstraZeneca)",
   "Kerendia/finerenone (Bayer)",
   "Invokana/canagliflozin (Janssen/J&J)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Rilparencel",
  "event_type": "readout",
  "indication": "Chronic kidney disease (autologous renal cell therapy)",
  "notes": "PROACT 1 Phase 3 topline readout for rilparencel in chronic kidney disease expected in Q2 2027 per company update. Per Caleb's 2026-09-20 directive, call transcripts hosted on Quartr are legitimate sources; no URL change. [Registry check 2026-09-23] CT.gov now lists primary completion 2029-12 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://files.quartr.com/reports/e7619-2026-03-18-08-06-05.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=",
  "ticker": "PROK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05099770",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0196",
  "guidance_detail": "PROACT 1 Phase 3 topline readout for rilparencel in chronic kidney disease expected in Q2 2027 per company update.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0197"
  ],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for Rilparencel in chronic kidney disease (autologous renal cell therapy) is expected in Q2 2027 \u2014 the pivotal readout that determines whether ProKidney Corp. can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "ProKidney Corp.",
  "competitors": [
   "Farxiga/dapagliflozin (AstraZeneca)",
   "Kerendia/finerenone (Bayer)",
   "Invokana/canagliflozin (Janssen/J&J)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Rilparencel",
  "event_type": "bla_filing",
  "indication": "Chronic kidney disease (autologous renal cell therapy)",
  "notes": "Company guided to a BLA filing for rilparencel in Q4 2027, contingent on PROACT 1 Phase 3 results. Per Caleb's 2026-09-20 directive, call transcripts hosted on Quartr are legitimate sources; no URL change.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://files.quartr.com/reports/e7619-2026-03-18-08-06-05.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=",
  "ticker": "PROK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0197",
  "guidance_detail": "Company guided to a BLA filing for rilparencel in Q4 2027, contingent on PROACT 1 Phase 3 results.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24",
  "why_it_matters": "ProKidney Corp. is expected to file its biologics license application for Rilparencel in chronic kidney disease (autologous renal cell therapy) in Q4 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-18",
  "company": "Prime Medicine, Inc.",
  "competitors": [
   "allogeneic hematopoietic stem cell transplant (standard of care)",
   "lentiviral HSC gene therapy candidates"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PM359",
  "event_type": "bla_filing",
  "indication": "p47phox chronic granulomatous disease",
  "notes": "Company guided to a BLA filing for PM359 (Prime Editing autologous HSC product) in H1 2027 per Q2 2026 financial results and business update. Verbatim release text across all wire-network mirrors: 'FDA grants Regenerative Medicine Advanced Therapy designation to PM359; continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027.' [2026-09-23 re-source] Old source was a stockhouse.com aggregator mirror (403, not citable per evidence ladder). Timing re-verified 2026-09-23 via Prime Medicine Q2 2026 GlobeNewswire release (Aug 6, 2026): 'continued regulatory engagement with the FDA toward a BLA submission for PM359 in 1H 2027'. Flagged for primary IR re-source via browser.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-8-6-prime-medicine-reports-second-quarter-2026-financial-results-and-provides-business-updates",
  "ticker": "PRME",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0198",
  "guidance_detail": "Company guided to a BLA filing for PM359 (Prime Editing autologous HSC product) in H1 2027 per Q2 2026 financial results and business update.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23",
  "why_it_matters": "Prime Medicine, Inc. is expected to file its biologics license application for PM359 in p47phox chronic granulomatous disease in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Quoin Pharmaceuticals Ltd.",
  "competitors": [
   "off-label topical/systemic therapies (no approved treatment for Netherton syndrome)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "QRX003 (QYLEKI lotion 4%)",
  "event_type": "nda_filing",
  "indication": "Netherton syndrome",
  "notes": "Company anticipates a potential NDA filing in 2027 following pivotal Phase 3 initiation in H2 2026; if approved QRX003 would be the first approved therapy for Netherton syndrome. [Source verified 2026-09-20: Genuine GlobeNewswire company release (opened and confirmed 2026-09-20): \"Quoin's pivotal Phase 3 study is expected to initiate in the second half of 2026, with a potential NDA filing in 2027.\"]",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/30/3319682/0/en/Quoin-Pharmaceuticals-Receives-U-S-Notice-of-Allowance-for-Patent-Covering-Combination-Treatment-for-Netherton-Syndrome.html",
  "ticker": "QNRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0199",
  "guidance_detail": "Company anticipates a potential NDA filing in 2027 following pivotal Phase 3 initiation in H2 2026; if approved QRX003 would be the first approved therapy for Netherton syndrome.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Quoin Pharmaceuticals Ltd. is expected to file its new drug application for QRX003 (QYLEKI lotion 4%) in Netherton syndrome sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-20",
  "company": "Roche Holding AG",
  "competitors": [
   "eculizumab (AstraZeneca/Alexion)",
   "ravulizumab (AstraZeneca)",
   "inebilizumab (Amgen)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-10",
  "date_quality": "hard",
  "drug": "satralizumab (Enspryng)",
  "event_type": "pdufa",
  "indication": "Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)",
  "notes": "FDA granted Priority Review of the sBLA for Enspryng in MOGAD with a target action date of January 10, 2027. Source disagreement documented: CheckRare lists January 20, 2027; Roche's own disclosure (primary source) states January 10, 2027 and is kept.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260909654496/en/U.S.-FDA-Grants-Priority-Review-for-Genentechs-Enspryng-for-MOGAD-an-Autoimmune-Disease-With-No-Approved-Treatments",
  "ticker": "RHHBY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0200",
  "guidance_detail": "FDA granted Priority Review of the sBLA for Enspryng in MOGAD with a target action date of January 10, 2027. Source disagreement documented: CheckRare lists January 20, 2027; Roche's own disclosure (primary source) states January 10, 2027 and is kept.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-20"
 },
 {
  "as_of": "2026-09-23",
  "company": "Roche Holding AG",
  "competitors": [
   "elacestrant (Stemline Therapeutics/Menarini)",
   "fulvestrant (AstraZeneca)",
   "capivasertib + fulvestrant (AstraZeneca)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "giredestrant",
  "event_type": "readout",
  "indication": "First-line endocrine-resistant ER+/HER2- metastatic breast cancer",
  "notes": "Roche stated the Phase 3 PionERA trial of giredestrant is expected to read out in 2027; company guidance, no finer timing given. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-04-20 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.roche.com/investors/updates/inv-update-2026-03-09",
  "ticker": "RHHBY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06065748",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0201",
  "guidance_detail": "Roche stated the Phase 3 PionERA trial of giredestrant is expected to read out in 2027; company guidance, no finer timing given.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-24",
  "company": "Sarepta Therapeutics, Inc.",
  "competitors": [
   "givinostat (Italfarmaco)",
   "zeleciment rostudirsen (Dyne Therapeutics)",
   "RGX-202 (REGENXBIO)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-28",
  "date_quality": "hard",
  "drug": "casimersen (AMONDYS 45)",
  "event_type": "pdufa",
  "indication": "Duchenne muscular dystrophy amenable to exon 45 skipping",
  "notes": "FDA accepted the sNDA seeking traditional approval of AMONDYS 45 and assigned a PDUFA date of February 28, 2027.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260630779541/en/Sarepta-Announces-FDA-Acceptance-of-sNDAs-for-AMONDYS-45-and-VYONDYS-53",
  "ticker": "SRPT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0202",
  "guidance_detail": "FDA accepted the sNDA seeking traditional approval of AMONDYS 45 and assigned a PDUFA date of February 28, 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Sarepta Therapeutics, Inc.",
  "competitors": [
   "givinostat (Italfarmaco)",
   "zeleciment rostudirsen (Dyne Therapeutics)",
   "RGX-202 (REGENXBIO)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-28",
  "date_quality": "hard",
  "drug": "golodirsen (VYONDYS 53)",
  "event_type": "pdufa",
  "indication": "Duchenne muscular dystrophy amenable to exon 53 skipping",
  "notes": "FDA accepted the sNDA seeking traditional approval of VYONDYS 53 and assigned a PDUFA date of February 28, 2027.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260630779541/en/Sarepta-Announces-FDA-Acceptance-of-sNDAs-for-AMONDYS-45-and-VYONDYS-53",
  "ticker": "SRPT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0203",
  "guidance_detail": "FDA accepted the sNDA seeking traditional approval of VYONDYS 53 and assigned a PDUFA date of February 28, 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Stoke Therapeutics, Inc.",
  "competitors": [
   "fenfluramine (UCB)",
   "cannabidiol (Jazz Pharmaceuticals)",
   "stiripentol (Biocodex)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zorevunersen",
  "event_type": "readout",
  "indication": "Dravet syndrome",
  "notes": "Phase 3 EMPEROR study completed enrollment of 162 patients in June 2026; company guides topline data in Q3 2027. Intentional multi-ticker entry: same EMPEROR readout as the BIIB row (partnered program).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260630626667/en/Stoke-Therapeutics-Announces-Completion-of-Enrollment-of-162-Patients-Into-the-Phase-3-EMPEROR-Study-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome",
  "ticker": "STOK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06872125",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0204",
  "guidance_detail": "Phase 3 EMPEROR study completed enrollment of 162 patients in June 2026; company guides topline data in Q3 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0205",
   "v16-0056",
   "v16-0055",
   "v16-0105"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for zorevunersen in Dravet syndrome is expected in Q3 2027 \u2014 the pivotal readout that determines whether Stoke Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Stoke Therapeutics, Inc.",
  "competitors": [
   "fenfluramine (UCB)",
   "cannabidiol (Jazz Pharmaceuticals)",
   "stiripentol (Biocodex)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zorevunersen",
  "event_type": "nda_filing",
  "indication": "Dravet syndrome",
  "notes": "Company guides initiation of rolling NDA in Q1 2027 with completion in H2 2027; this entry represents the completion/filing event only.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260630626667/en/Stoke-Therapeutics-Announces-Completion-of-Enrollment-of-162-Patients-Into-the-Phase-3-EMPEROR-Study-of-Zorevunersen-an-Investigational-Medicine-for-the-Treatment-of-Dravet-Syndrome",
  "ticker": "STOK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0205",
  "guidance_detail": "Company guides initiation of rolling NDA in Q1 2027 with completion in H2 2027; this entry represents the completion/filing event only.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Stoke Therapeutics, Inc. is expected to file its new drug application for zorevunersen in Dravet syndrome in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Summit Therapeutics Inc.",
  "competitors": [
   "pembrolizumab + chemotherapy (Merck)",
   "atezolizumab (Roche)",
   "datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ivonescimab",
  "event_type": "readout",
  "indication": "First-line metastatic non-squamous non-small cell lung cancer (HARMONi-3)",
  "notes": "Enrollment in HARMONi-3 is complete and the required PFS events for the non-squamous cohort analysis are expected in H1 2027 per Q2 2026 results. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-12-31 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260723317187/en/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Second-Quarter-and-Six-Months-Ended-June-30-2026",
  "ticker": "SMMT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05899608",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0206",
  "guidance_detail": "Enrollment in HARMONi-3 is complete and the required PFS events for the non-squamous cohort analysis are expected in H1 2027 per Q2 2026 results.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "deucravacitinib (Bristol Myers Squibb)",
   "icotrokinra (Johnson & Johnson)",
   "apremilast (Amgen)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zasocitinib",
  "event_type": "pdufa",
  "indication": "Moderate-to-severe plaque psoriasis",
  "notes": "FDA accepted the NDA under Priority Review with potential to redefine oral treatment expectations; company guides an FDA action in Q1 2027, no exact date disclosed.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260914748441/en/U.S.-FDA-Accepts-New-Drug-Application-Under-Priority-Review-for-Takedas-Zasocitinib-in-Moderate-to-Severe-Plaque-Psoriasis-with-Potential-to-Redefine-Oral-Treatment-Expectations",
  "ticker": "TAK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0207",
  "guidance_detail": "FDA accepted the NDA under Priority Review with potential to redefine oral treatment expectations; company guides an FDA action in Q1 2027, no exact date disclosed.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0563",
   "v16-0562"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "REGENXBIO Inc.",
  "competitors": [
   "aflibercept (Regeneron/Bayer)",
   "faricimab (Roche)",
   "4D-150 (4D Molecular Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "sura-vec (ABBV-RGX-314)",
  "event_type": "regulatory_other",
  "indication": "Wet age-related macular degeneration",
  "notes": "Company guides first global regulatory submissions for sura-vec in 2027; whether the lead submission includes a US FDA BLA is not specified in the observed release. Company guidance states only 'global regulatory submissions' in 2027; a US BLA filing is not specifically guided.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/regenxbio-reports-second-quarter-2026-financial-results-and-operational-highlights-302844662.html",
  "ticker": "RGNX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0208",
  "guidance_detail": "Company guides first global regulatory submissions for sura-vec in 2027; whether the lead submission includes a US FDA BLA is not specified in the observed release.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "REGENXBONE's sura-vec gene therapy for wet age-related macular degeneration is expected to reach its first global regulatory submissions sometime in 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Immunovant, Inc.",
  "competitors": [
   "efgartigimod (argenx)",
   "ravulizumab (AstraZeneca)",
   "rozanolixizumab (UCB)"
  ],
  "country": "Bermuda",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "IMVT-1402",
  "event_type": "readout",
  "indication": "Generalized myasthenia gravis",
  "notes": "Immunovant guides topline data in calendar 2027 from the Phase 3 gMG study (NCT07039916) of IMVT-1402;",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340114/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2026.html",
  "ticker": "IMVT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07039916",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0209",
  "guidance_detail": "Immunovant guides topline data in calendar 2027 from the Phase 3 gMG study (NCT07039916) of IMVT-1402;.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0474",
   "v16-0473",
   "v16-1014",
   "v16-0221",
   "v16-0154"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for IMVT-1402 in generalized myasthenia gravis is expected sometime in 2027 \u2014 the pivotal readout that determines whether Immunovant, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "Sagimet Biosciences Inc.",
  "competitors": [
   "isotretinoin (generic)",
   "clascoterone (Sun Pharma)",
   "adapalene/benzoyl peroxide (Galderma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "denifanstat",
  "event_type": "readout",
  "indication": "Acne (AURORA Phase 3)",
  "notes": "Inferred: screening begins Oct 2026 with ~800 patients enrolled over ~6 months and a 12-week randomized phase, implying topline around Q3 2027; no explicit 2027 company guidance given.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patient-enrollment-in-q4-2026",
  "ticker": "SGMT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0210",
  "guidance_detail": "Inferred: screening begins Oct 2026 with ~800 patients enrolled over ~6 months and a 12-week randomized phase, implying topline around Q3 2027; no explicit 2027 company guidance given.",
  "audit_status": "v16_verified",
  "audit_action": "nct_backfill_not_found",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0211"
  ],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for denifanstat in Acne (AURORA Phase 3) is expected in Q3 2027 \u2014 the pivotal readout that determines whether Sagimet Biosciences Inc. can file for approval."
 },
 {
  "as_of": "2026-09-18",
  "company": "Sagimet Biosciences Inc.",
  "competitors": [
   "isotretinoin (generic)",
   "clascoterone (Sun Pharma)",
   "adapalene/benzoyl peroxide (Galderma)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "denifanstat",
  "event_type": "nda_filing",
  "indication": "Acne (AURORA Phase 3)",
  "notes": "Inferred: company says an NDA is anticipated upon completion of the 12-week randomized phase; combined with the Q4 2026 start, ~6-month enrollment and 12-week phase, filing lands in H2 2027.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/sagimet-biosciences-advances-aurora-u-s-phase-3-trial-of-denifanstat-in-acne-toward-patient-enrollment-in-q4-2026",
  "ticker": "SGMT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0211",
  "guidance_detail": "Inferred: company says an NDA is anticipated upon completion of the 12-week randomized phase; combined with the Q4 2026 start, ~6-month enrollment and 12-week phase, filing lands in H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Sagimet Biosciences Inc. is expected to file its new drug application for denifanstat in Acne (AURORA Phase 3) in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-24",
  "company": "Teva Pharmaceutical Industries Limited",
  "competitors": [],
  "country": "Israel",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ecopipam (EBS-101)",
  "event_type": "pdufa",
  "indication": "pediatric Tourette syndrome",
  "notes": "FDA accepted the ecopipam NDA and granted Priority Review (announced Aug 19, 2026); targeted PDUFA date late Q1 2027. Company expects FDA decision late Q1 2027; no exact PDUFA date disclosed as of 9/18/2026.",
  "phase": null,
  "source_type": "company IR",
  "source_url": "https://ir.tevapharm.com/news-and-events/press-releases/press-release-details/2026/U-S--FDA-Accepts-Tevas-New-Drug-Application-NDA-and-Grants-Priority-Review-for-Ecopipam-a-First-in-Class-Investigational-Therapy-for-Pediatric-Patients-with-Tourette-Syndrome/default.aspx",
  "ticker": "TEVA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0212",
  "guidance_detail": "FDA accepted the ecopipam NDA and granted Priority Review (announced Aug 19, 2026); targeted PDUFA date late Q1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "TG Therapeutics, Inc.",
  "competitors": [
   "Ocrevus (Roche)",
   "Kesimpta (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "subcutaneous BRIUMVI (ublituximab-xiiy)",
  "event_type": "readout",
  "indication": "relapsing forms of multiple sclerosis",
  "notes": "Company guided Phase 3 topline to year-end 2026/Q1 2027; boundary case, could land Dec 2026. Confirms fully enrolled Phase 3 subcutaneous BRIUMVI trial with topline timing of year-end 2026 / first quarter 2027; preserve the Dec-2026/Q1-2027 boundary note.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/03/3337372/8790/en/tg-therapeutics-reports-second-quarter-2026-financial-results-and-raises-briumvi-revenue-guidance.html",
  "ticker": "TGTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07211633",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0213",
  "guidance_detail": "Company guided Phase 3 topline to year-end 2026/Q1 2027; boundary case, could land Dec 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for subcutaneous BRIUMVI (ublituximab-xiiy) in relapsing forms of multiple sclerosis is expected in Q1 2027 \u2014 the pivotal readout that determines whether TG Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Trevi Therapeutics, Inc.",
  "competitors": [
   "camlipixant (Merck)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "nalbuphine ER (Haduvio)",
  "event_type": "readout",
  "indication": "chronic cough in idiopathic pulmonary fibrosis (OCEAN-2)",
  "notes": "Phase 3 OCEAN-2 topline readout guided to H2 2027 per Q1 2026 business update. TIMING TENSION (2026-09-23): CT.gov NCT07671911 (Trevi Phase 3 nalbuphine ER in IPF-related chronic cough, RECRUITING, updated 2026-09-14) carries registry PCD 2028-06 vs company-guided H2 2027 topline; guidance outranks, disagreement noted.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/05/3288254/0/en/Trevi-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html",
  "ticker": "TRVI",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07671911",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0214",
  "guidance_detail": "Phase 3 OCEAN-2 topline readout guided to H2 2027 per Q1 2026 business update.",
  "audit_status": "v18_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for nalbuphine ER (Haduvio) in chronic cough in idiopathic pulmonary fibrosis (OCEAN-2) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Trevi Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Travere Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pegtibatinase",
  "event_type": "readout",
  "indication": "classical homocystinuria (HARMONY)",
  "notes": "Phase 3 HARMONY topline guided to H2 2027; no approved prescription therapy or known late-stage competitor in HCU.",
  "phase": "3",
  "source_type": "company IR",
  "source_url": "https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-Second-Quarter-2026-Financial-Results/default.aspx",
  "ticker": "TVTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06247085",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0215",
  "guidance_detail": "Phase 3 HARMONY topline guided to H2 2027; no approved prescription therapy or known late-stage competitor in HCU.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for pegtibatinase in classical homocystinuria (HARMONY) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Travere Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "United Therapeutics Corporation",
  "competitors": [
   "Uptravi (Johnson & Johnson)",
   "Winrevair (Merck)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-24",
  "date_quality": "hard",
  "drug": "oral ralinepag",
  "event_type": "pdufa",
  "indication": "pulmonary arterial hypertension (PAH)",
  "notes": "FDA accepted the ralinepag NDA (announced Aug 24, 2026) and set PDUFA target action date 2027-06-24 (company PR).",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://ir.unither.com/press-releases/2026/08-24-2026-120021913",
  "ticker": "UTHR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0216",
  "guidance_detail": "FDA accepted the ralinepag NDA (announced Aug 24, 2026) and set PDUFA target action date 2027-06-24 (company PR).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "United Therapeutics Corporation",
  "competitors": [
   "deupirfenidone (PureTech Health)",
   "Esbriet (Roche)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "nebulized Tyvaso (treprostinil)",
  "event_type": "pdufa",
  "indication": "idiopathic pulmonary fibrosis (IPF)",
  "notes": "FDA accepted the sNDA for nebulized Tyvaso (treprostinil) Inhalation Solution in IPF (company PR 2026-09-02); agency review expected complete late April 2027; filing based on positive Phase 3 TETON-1/TETON-2 (FVC +111.8 mL vs placebo, p<0.0001).",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260902138059/en/United-Therapeutics-Corporation-Announces-FDA-Acceptance-of-Supplemental-New-Drug-Application-for-Nebulized-Tyvaso-to-Treat-Idiopathic-Pulmonary-Fibrosis",
  "ticker": "UTHR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0217",
  "guidance_detail": "FDA accepted the sNDA for nebulized Tyvaso (treprostinil) Inhalation Solution in IPF (company PR 2026-09-02); agency review expected complete late April 2027; filing based on positive Phase 3 TETON-1/TETON-2 (FVC +111.8 mL vs placebo, p<0.0001).",
  "audit_status": "v17_reverified",
  "audit_action": "pdufa_acceptance_confirmed",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Vir Biotechnology, Inc.",
  "competitors": [
   "Hepcludex (Gilead)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "tobevibart + elebsiran",
  "event_type": "readout",
  "indication": "chronic hepatitis delta (ECLIPSE 2)",
  "notes": "Phase 3 ECLIPSE 2 readout expected Q1 2027 per Q2 2026 corporate update.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260805596908/en/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Second-Quarter-2026-Financial-Results",
  "ticker": "VIR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07128550",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0218",
  "guidance_detail": "Phase 3 ECLIPSE 2 readout expected Q1 2027 per Q2 2026 corporate update.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0575"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for tobevibart + elebsiran in chronic hepatitis delta (ECLIPSE 2) is expected in Q1 2027 \u2014 the pivotal readout that determines whether Vir Biotechnology, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Viking Therapeutics, Inc.",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "subcutaneous VK2735",
  "event_type": "readout",
  "indication": "obesity without type 2 diabetes (VANQUISH-1)",
  "notes": "CEO guided H2 2027 readout at Sept 2026 Morgan Stanley conference; Timing per CEO remarks at Sept 2026 Morgan Stanley conference; first-party replay/SEC corroboration not yet located. Viking's official Q1 2026 (Apr 29) and Q2 2026 (Jul 29) releases confirm VANQUISH-1 and VANQUISH-2 are fully enrolled 78-week Phase 3 trials proceeding on track, but state no readout timing. The H2 2027 window comes from CEO Brian Lian's remarks at the Sept 2026 Morgan Stanley conference as quoted in trade/aggregator coverage; no company release, SEC filing, or deck corroborates the timing.",
  "phase": "3",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07104500",
  "ticker": "VKTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07104500",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0219",
  "guidance_detail": "CEO guided H2 2027 readout at Sept 2026 Morgan Stanley conference; Timing per CEO remarks at Sept 2026 Morgan Stanley conference; first-party replay/SEC corroboration not yet located.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0220",
   "v16-0139",
   "v16-0140"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for subcutaneous VK2735 in obesity without type 2 diabetes (VANQUISH-1) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Viking Therapeutics, Inc. can file for approval.",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record VANQUISH 1, Viking Phase 3 subcutaneous VK2735 in obesity; primary completion est. 2027-07-01 (supports 2027-H2)."
 },
 {
  "as_of": "2026-09-23",
  "company": "Viking Therapeutics, Inc.",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "subcutaneous VK2735",
  "event_type": "readout",
  "indication": "obesity with type 2 diabetes (VANQUISH-2)",
  "notes": "CEO guided H2 2027 readout at Sept 2026 Morgan Stanley conference; Timing per CEO remarks at Sept 2026 Morgan Stanley conference; first-party replay/SEC corroboration not yet located. Same as row 223: Viking's official releases confirm VANQUISH-2 is fully enrolled and on track with no readout timing; H2 2027 timing is from CEO remarks at the Sept 2026 Morgan Stanley conference via trade/aggregator coverage only.",
  "phase": "3",
  "source_type": "trade press",
  "source_url": "https://www.marketbeat.com/instant-alerts/event-viking-therapeutics-advances-vk2735-obesity-drug-into-phase-3-after-15-weight-loss-2026-09-14/",
  "ticker": "VKTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07104383",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0220",
  "guidance_detail": "CEO guided H2 2027 readout at Sept 2026 Morgan Stanley conference; Timing per CEO remarks at Sept 2026 Morgan Stanley conference; first-party replay/SEC corroboration not yet located.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0219"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for subcutaneous VK2735 in obesity with type 2 diabetes (VANQUISH-2) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Viking Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Vor Biopharma Inc.",
  "competitors": [
   "Vyvgart (argenx)",
   "Ultomiris (AstraZeneca)",
   "Rystiggo (UCB)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "telitacicept",
  "event_type": "readout",
  "indication": "generalized myasthenia gravis (UPSTREAM MG)",
  "notes": "Global Phase 3 24-week topline expected H1 2027 after enrollment completion. [Source verified 2026-09-20: Genuine GlobeNewswire company release (opened 2026-09-20): \"today announced the completion of enrollment in UPSTREAM MG, its global Phase 3 registrational trial evaluating telitacicept for the treatment of generalized my]",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357492/0/en/vor-completes-enrollment-of-global-phase-3-upstream-mg-trial-and-expands-telitacicept-global-franchise-into-ocular-myasthenia-gravis.html?print=1",
  "ticker": "VOR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06456580",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0221",
  "guidance_detail": "Global Phase 3 24-week topline expected H1 2027 after enrollment completion.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1014",
   "v16-0209",
   "v16-0154"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for telitacicept in generalized myasthenia gravis (UPSTREAM MG) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Vor Biopharma Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Verrica Pharmaceuticals Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "YCANTH (VP-102)",
  "event_type": "readout",
  "indication": "common warts (COVE-2)",
  "notes": "Pivotal Phase 3 COVE-2 topline expected Q1 2027; no approved prescription therapy or known late-stage competitor in common warts.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://verrica.com/press_release/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phase-3-trial-cove-2-evaluating-ycanth-for-the-treatment-of-common-warts-with-topline-data-expected-q1-2027/",
  "ticker": "VRCA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07246590",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0222",
  "guidance_detail": "Pivotal Phase 3 COVE-2 topline expected Q1 2027; no approved prescription therapy or known late-stage competitor in common warts.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0223"
  ],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for YCANTH (VP-102) in common warts (COVE-2) is expected in Q1 2027 \u2014 the pivotal readout that determines whether Verrica Pharmaceuticals Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Verrica Pharmaceuticals Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "YCANTH (VP-102)",
  "event_type": "readout",
  "indication": "common warts (COVE-3)",
  "notes": "Pivotal Phase 3 COVE-3 topline expected mid-2027; mid-year window maps to Q2/Q3 boundary. Re-checked 2026-09-23: VRCA YCANTH COVE-3 Phase 3 common warts. Company guides 'remaining Phase 3 readouts, including COVE-3, anticipated by mid-2027.' Record's Q3 2027 was too late; revised to H1 2027 per \"by mid-2027\" guidance. Source: https://www.stocktitan.net/news/VRCA/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-ma37aynjat2u.html. Quote: \"remaining Phase 3 readouts, including COVE-3, anticipated by mid-2027\".",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://verrica.com/press_release/verrica-pharmaceuticals-announces-completion-of-enrollment-in-first-pivotal-phase-3-trial-cove-2-evaluating-ycanth-for-the-treatment-of-common-warts-with-topline-data-expected-q1-2027/",
  "ticker": "VRCA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07637734",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0223",
  "guidance_detail": "Pivotal Phase 3 COVE-3 topline expected mid-2027; mid-year window maps to Q2/Q3 boundary.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027-H1",
    "changed": "2026-09-23",
    "why": "Company guides remaining Phase 3 readouts incl. COVE-3 by mid-2027; Q3 was too late"
   }
  ],
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0222"
  ],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 3 data for YCANTH (VP-102) in common warts (COVE-3) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Verrica Pharmaceuticals Inc. can file for approval."
 },
 {
  "as_of": "2026-10-01",
  "company": "Viridian Therapeutics, Inc.",
  "competitors": [
   "Tepezza (Amgen)",
   "veligrotug (Viridian)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "elegrobart (VRDN-003)",
  "event_type": "bla_filing",
  "indication": "thyroid eye disease",
  "notes": "BLA submission expected Q1 2027 after two positive pivotal Phase 3 trials (REVEAL-1/2); VRDN's own Lumvoa (veligrotug) approved June 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260505926208/en/Viridian-Therapeutics-Announces-Positive-Topline-Results-from-Elegrobart-Phase-3-REVEAL2-Clinical-Trial-in-Chronic-Thyroid-Eye-Disease",
  "ticker": "VRDN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0224",
  "guidance_detail": "BLA submission expected Q1 2027 after two positive pivotal Phase 3 trials (REVEAL-1/2); VRDN's own Lumvoa (veligrotug) approved June 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Vertex Pharmaceuticals Incorporated",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "inaxaplin",
  "event_type": "readout",
  "indication": "APOL1-mediated kidney disease (AMPLITUDE)",
  "notes": "Vertex IR officer at Cantor (2026-09-12) guided the Phase 3 AMPLITUDE interim analysis for Q1 2027; Sep 2026 company press release (enrollment complete) says interim data due early 2027. Preplanned Phase 3 interim analysis expected early 2027 per Q2 2026 results. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-06-02 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260803535433/en/Vertex-Reports-Second-Quarter-2026-Financial-Results",
  "ticker": "VRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05312879",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0225",
  "guidance_detail": "Preplanned Phase 3 interim analysis expected early 2027 per Q2 2026 results.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [
   {
    "date": "2026-10-01",
    "change": "date_bucket 2027-H1 -> 2027-Q1",
    "reason": "Vertex IR at Cantor (Sep 12, 2026) guided Phase 3 AMPLITUDE interim analysis for Q1 2027; Sep 2026 company PR says interim data due early 2027 (enrollment complete)"
   }
  ],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Verastem, Inc.",
  "competitors": [
   "Mekinist (Novartis)",
   "Zejula (GSK)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "avutometinib + defactinib",
  "event_type": "readout",
  "indication": "recurrent low-grade serous ovarian cancer (RAMP 301)",
  "notes": "Phase 3 RAMP 301 readout expected mid-2027; mid-year window maps to Q2/Q3 boundary. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-10-15 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260304011595/en/Verastem-Oncology-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Highlights-Recent-Business-Updates",
  "ticker": "VSTM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06072781",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0226",
  "guidance_detail": "Phase 3 RAMP 301 readout expected mid-2027; mid-year window maps to Q2/Q3 boundary.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for avutometinib + defactinib in recurrent low-grade serous ovarian cancer (RAMP 301) is expected in Q3 2027 \u2014 the pivotal readout that determines whether Verastem, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Viatris Inc.",
  "competitors": [
   "Benlysta (GSK)",
   "Saphnelo (AstraZeneca)",
   "Lupkynis (Aurinia)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "cenerimod",
  "event_type": "readout",
  "indication": "systemic lupus erythematosus (OPUS-1)",
  "notes": "Phase 3 OPUS-1 readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located. Viatris Q2 2026 earnings presentation (Aug 6, 2026): cenerimod, global SLE \u2014 'enrollment complete; targeting Phase 3 readout in H1 2027.' The deck states the overall SLE Phase 3 program target and does not individually name OPUS-1 in the extracted table; OPUS-1/OPUS-2 naming comes from the prior call transcript.",
  "phase": "3",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/3dd85b1e-88fb-340a-a623-d5ad68653105/presentation.pdf",
  "ticker": "VTRS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05648500",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0227",
  "guidance_detail": "Phase 3 OPUS-1 readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0228",
   "v16-0151",
   "v16-0150"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Viatris Inc.",
  "competitors": [
   "Benlysta (GSK)",
   "Saphnelo (AstraZeneca)",
   "Lupkynis (Aurinia)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "cenerimod",
  "event_type": "readout",
  "indication": "systemic lupus erythematosus (OPUS-2)",
  "notes": "Phase 3 OPUS-2 readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located. Same deck as row 231: cenerimod global SLE targeting Phase 3 readout H1 2027. The deck does not individually name OPUS-2 in the extracted table.",
  "phase": "3",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/3dd85b1e-88fb-340a-a623-d5ad68653105/presentation.pdf",
  "ticker": "VTRS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05672576",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0228",
  "guidance_detail": "Phase 3 OPUS-2 readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0227",
   "v16-0151",
   "v16-0150",
   "v16-0003"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Viatris Inc.",
  "competitors": [
   "Brilinta (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "selatogrel",
  "event_type": "readout",
  "indication": "suspected acute myocardial infarction (SOS-AMI)",
  "notes": "Phase 3 SOS-AMI readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located. The official Viatris Q2 2026 deck supports only that selatogrel (global AMI) enrollment is ongoing and targets Phase 3 enrollment completion in 2026 \u2014 it does NOT guide an H1 2027 SOS-AMI readout. The H1 2027 readout timing comes only from an earnings-call transcript source; no official release, filing, or deck confirms it.",
  "phase": "3",
  "source_type": "company IR",
  "source_url": "https://files.quartr.com/conference-calls/e8b3b-2026-03-19.pdf?ref=U3RvY2tBbmFseXNpcw==",
  "ticker": "VTRS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04957719",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0229",
  "guidance_detail": "Phase 3 SOS-AMI readout expected H1 2027 per Q2 2026 earnings call transcript; first-party transcript/SEC corroboration not yet located.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "evidence_note": "Re-sourced 2026-09-24: Viatris Mar 19 2026 Investor Event presentation (Quartr-hosted): selatogrel SOS-AMI Phase 3 slide states full enrollment expected 2026 with data readout anticipated H1 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Xenon Pharmaceuticals Inc.",
  "competitors": [
   "Spravato (Johnson & Johnson)",
   "Zurzuvae (Biogen/Sage)",
   "Auvelity (Axsome Therapeutics)"
  ],
  "country": "Canada",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "azetukalner",
  "event_type": "readout",
  "indication": "major depressive disorder (X-NOVA2)",
  "notes": "Phase 3 X-NOVA2 topline expected Q1 2027; psychiatry enrollment was paused but already-enrolled participants remain active.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/01/12/3216905/33485/en/Xenon-Outlines-Key-Upcoming-Milestones-at-the-2026-J-P-Morgan-Healthcare-Conference.html",
  "ticker": "XENE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06775379",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0230",
  "guidance_detail": "Phase 3 X-NOVA2 topline expected Q1 2027; psychiatry enrollment was paused but already-enrolled participants remain active.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0085",
   "v16-0078"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for azetukalner in major depressive disorder (X-NOVA2) is expected in Q1 2027 \u2014 the pivotal readout that determines whether Xenon Pharmaceuticals Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "Zai Lab Limited",
  "competitors": [
   "Imdelltra (Amgen)",
   "Zepzelca (Jazz Pharmaceuticals)"
  ],
  "country": "China",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zocilurtatug pelitecan (zoci)",
  "event_type": "bla_filing",
  "indication": "second-line+ small-cell lung cancer",
  "notes": "U.S. accelerated-approval BLA submission expected later 2027 after Phase 3 enrollment completes H1 2027 per Q2 2026 update.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260806560438/en/Zai-Lab-Announces-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Updates",
  "ticker": "ZLAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0231",
  "guidance_detail": "U.S.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Zymeworks Inc.",
  "competitors": [
   "Enhertu (Daiichi Sankyo/AstraZeneca)",
   "Tukysa (Pfizer)",
   "Herceptin (Roche)"
  ],
  "country": "Canada",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zanidatamab",
  "event_type": "readout",
  "indication": "HER2+ metastatic breast cancer (EmpowHER-BC-303)",
  "notes": "Phase 3 topline guided to end 2027 or early 2028 with enrollment now mid-2027; timing straddles the 2027/2028 boundary (topline guided end-2027 or early 2028); re-check on refresh. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-04-28 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340764/0/en/zymeworks-provides-corporate-update-and-reports-second-quarter-2026-financial-results.html",
  "ticker": "ZYME",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06435429",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0232",
  "guidance_detail": "Phase 3 topline guided to end 2027 or early 2028 with enrollment now mid-2027; timing straddles the 2027/2028 boundary (topline guided end-2027 or early 2028); re-check on refresh.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0120"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for zanidatamab in HER2+ metastatic breast cancer (EmpowHER-BC-303) is expected in Q4 2027 \u2014 the pivotal readout that determines whether Zymeworks Inc. can file for approval."
 },
 {
  "as_of": "2026-09-23",
  "company": "ASCO Gastrointestinal Cancers Symposium",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-21",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ASCO Gastrointestinal Cancers Symposium, January 21\u201323, 2027, San Francisco, CA. ASCO multidisciplinary GI oncology symposium.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.asco.org/gi/dates-know",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0233",
  "guidance_detail": "ASCO Gastrointestinal Cancers Symposium, January 21\u201323, 2027, San Francisco, CA.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AHA International Stroke Conference 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-10",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "International Stroke Conference 2027, February 10\u201312, 2027, George R. Brown Convention Center, Houston, Texas. AHA annual stroke science meeting (pre-cons February 9).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://professional.heart.org/en/meetings",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0234",
  "guidance_detail": "International Stroke Conference 2027, February 10\u201312, 2027, George R.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASCO Genitourinary Cancers Symposium",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "February 11-13, 2027 (ASCO save-the-date page, organizer-owned). Venue: San Francisco, CA per 2027 edition listings (third party; ASCO page excerpt does not name the city); prior editions held at Moscone Center, San Francisco.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.asco.org/gu",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0235",
  "guidance_detail": "February 11-13, 2027 (ASCO save-the-date page, organizer-owned).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AACR Immuno-Oncology 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-28",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "AACR Immuno-Oncology 2027, February 28\u2013March 3, 2027, JW Marriott Los Angeles L.A. Live, Los Angeles, California. Immuno-oncology discovery-to-clinical conference.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.aacr.org/meeting/aacr-io-2027/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0236",
  "guidance_detail": "AACR Immuno-Oncology 2027, February 28\u2013March 3, 2027, JW Marriott Los Angeles L.A.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AACR Annual Meeting 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-02",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "AACR Annual Meeting 2027, April 2\u20137, 2027, Orange County Convention Center, Orlando, Florida.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.aacr.org/meeting/aacr-annual-meeting-2027/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0237",
  "guidance_detail": "AACR Annual Meeting 2027, April 2\u20137, 2027, Orange County Convention Center, Orlando, Florida.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ACC Annual Scientific Session 2027 (ACC.27-WCC)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-10",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ACC Annual Scientific Session 2027 (ACC.27-WCC), April 10\u201312, 2027, Houston, Texas. ACC/World Heart Federation flagship cardiology meeting (pre-conference April 9).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://accscientificsession.acc.org/Registration-and-Hotels",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0238",
  "guidance_detail": "ACC Annual Scientific Session 2027 (ACC.27-WCC), April 10\u201312, 2027, Houston, Texas.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "ASCO Annual Meeting 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-04",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ASCO Annual Meeting 2027, June 4\u20138, 2027, McCormick Place, Chicago, IL. (Organizer dates-know page verified 2026-09-23.)",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.asco.org/annual-meeting/dates-know?intcmp=nw_ascoorg_am_ascovoices_site_amlandingpage_all__glob_092925__qklnk__aware_text_",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0239",
  "guidance_detail": "ASCO Annual Meeting 2027, June 4\u20138, 2027, McCormick Place, Chicago, IL.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ENDO 2027",
  "competitors": [],
  "country": "Canada",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-05",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ENDO 2027, June 5\u20137, 2027, Toronto, Ontario, Canada. Endocrine Society signature annual meeting.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://endocrine.org/meetings-and-events/endo-future-meetings",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0240",
  "guidance_detail": "ENDO 2027, June 5\u20137, 2027, Toronto, Ontario, Canada.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "EHA2027 Congress",
  "competitors": [],
  "country": "Spain",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-10",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "EHA2027 Congress, June 10\u201313, 2027, Barcelona, Spain. European Hematology Association annual congress.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://ehaweb.org/connect-network/eha2027-congress",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0241",
  "guidance_detail": "EHA2027 Congress, June 10\u201313, 2027, Barcelona, Spain.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Alzheimer's Association International Conference 2027 (AAIC)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-18",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "Alzheimer\u2019s Association International Conference 2027, July 18\u201321, 2027, Chicago, United States, and online. World\u2019s largest dementia science meeting.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.alz.org/research/for_researchers/scientific-conferences?lang=en-US&form=FUNSETYDEFK&form=FUNYWTPCJBN",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0242",
  "guidance_detail": "Alzheimer\u2019s Association International Conference 2027, July 18\u201321, 2027, Chicago, United States, and online.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AHA BCVS Scientific Sessions 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-19",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "AHA BCVS Scientific Sessions 2027, July 19\u201322, 2027, Westin Boston Seaport District, Boston, Massachusetts. Basic cardiovascular sciences sessions.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://professional.heart.org/en/meetings",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0243",
  "guidance_detail": "AHA BCVS Scientific Sessions 2027, July 19\u201322, 2027, Westin Boston Seaport District, Boston, Massachusetts.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "AHA Vascular Discovery: From Genes to Medicine Scientific Sessions 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-22",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "AHA Vascular Discovery: From Genes to Medicine Scientific Sessions 2027, July 22\u201325, 2027, Westin Boston Seaport District, Boston, Massachusetts. Vascular biology research meeting.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://professional.heart.org/en/meetings",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0244",
  "guidance_detail": "AHA Vascular Discovery: From Genes to Medicine Scientific Sessions 2027, July 22\u201325, 2027, Westin Boston Seaport District, Boston, Massachusetts.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "ESC Congress 2027",
  "competitors": [],
  "country": "Italy",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-08-27",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ESC Congress 2027, August 27\u201330, 2027, Milan, Italy. World\u2019s foremost cardiology meeting. (Dates + city per ESC; specific venue not printed.)",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses/esc-congress/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0245",
  "guidance_detail": "ESC Congress 2027, August 27\u201330, 2027, Milan, Italy.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "IASLC World Conference on Lung Cancer 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "2027 World Conference on Lung Cancer, September 11-14, 2027, Denver, Colorado. IASLC annual lung cancer meeting. (Organizer press release 2025-12-16.) [2026-09-27 link audit] Replaced access-denied IASLC search URL with the official IASLC press release; confirms Sep 11-14, 2027, Denver.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.iaslc.org/iaslc-news/press-release/global-lung-cancer-experts-selected-lead-iaslcs-2027-world-conference",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0246",
  "guidance_detail": "2027 World Conference on Lung Cancer, September 11\u201314, 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "63rd EASD Annual Meeting",
  "competitors": [],
  "country": "Hungary",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-21",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "63rd EASD Annual Meeting, September 21\u201324, 2027, Budapest, Hungary. European diabetes research congress.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.easd.org/annual-meeting/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0248",
  "guidance_detail": "63rd EASD Annual Meeting, September 21\u201324, 2027, Budapest, Hungary.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "32nd World Muscle Society Congress",
  "competitors": [],
  "country": "Finland",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-28",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "32nd World Muscle Society (WMS) Congress, September 28 - October 2, 2027, Helsinki, Finland. Source: WMS official journal (Neuromuscular Disorders) general information page with Future WMS Meeting Dates (organizer-affiliated, verified 2026-09-18; direct curl probes get bot-blocked 403). Source upgraded 2026-09-18: WMS official events page directly exposes Sep 28-Oct 2 2027 Helsinki dates.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.worldmusclesociety.org/m/events",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0249",
  "guidance_detail": "32nd World Muscle Society (WMS) Congress, September 28 - October 2, 2027, Helsinki, Finland.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "ASBMR 2027 Annual Meeting",
  "competitors": [],
  "country": "Canada",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-15",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ASBMR 2027 Annual Meeting, October 15-18, 2027, Metro Toronto Convention Centre, Toronto, Ontario, Canada. World's largest bone and mineral research meeting. [2026-09-23 conference re-source] Re-sourced from bare homepage to deeper dated organizer page; date confirmed hard. [2026-09-27 link audit] Prior /meetings/future-asbmr-meetings URL now returns a genuine 404 (page removed by organizer); replaced with the current ASBMR Future Meetings page, re-verified in-browser: confirms Oct 15-18, 2027, Toronto.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.asbmr.org/Annual-Meeting/Future-Meetings",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0250",
  "guidance_detail": "ASBMR 2027 Annual Meeting, October 15\u201318, 2027, Metro Toronto Convention Centre, Toronto, Ontario, Canada.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "50th San Antonio Breast Cancer Symposium (SABCS)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-12-07",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "San Antonio Breast Cancer Symposium (50th), December 7\u201310, 2027, San Antonio, Texas. Breast cancer research symposium.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://sabcs.org/media/future-symposia/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0251",
  "guidance_detail": "San Antonio Breast Cancer Symposium (50th), December 7\u201310, 2027, San Antonio, Texas.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ESMO Genitourinary Cancers Asia 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-15",
  "date_quality": "hard",
  "notes": "Inaugural ESMO Genitourinary Cancers Asia 2027, January 15-17 2027, Kerry Hotel, Hong Kong SAR, China. GU oncology (prostate, bladder, kidney, testicular). Source: esmo.org meeting calendar (organizer-owned, verified 2026-09-18; dates corroborated by ESMO-produced announcement video).",
  "country": "China",
  "source_url": "https://www.esmo.org/meeting-calendar/esmo-genitourinary-cancers-asia-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0252",
  "guidance_detail": "Inaugural ESMO Genitourinary Cancers Asia 2027, January 15-17 2027, Kerry Hotel, Hong Kong SAR, China.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Complex Coronary Summit 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-20",
  "date_quality": "hard",
  "notes": "Inaugural Complex Coronary Summit, January 20-22 2027, Fontainebleau Miami Beach, Miami Beach, FL; merging CTO Plus and Interventional Complications (CRF).",
  "country": "United States",
  "source_url": "https://cto2025.crfconferences.com/cto-hotel",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0253",
  "guidance_detail": "Inaugural Complex Coronary Summit, January 20-22 2027, Fontainebleau Miami Beach, Miami Beach, FL; merging CTO Plus and Interventional Complications (CRF).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "THT 2027 (Technology and Heart Failure Therapeutics)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-22",
  "date_quality": "hard",
  "notes": "THT 2027, Technology and Heart Failure Therapeutics, February 22-24 2027, Omni Boston Hotel at the Seaport, Boston, MA (CRF).",
  "country": "United States",
  "source_url": "https://fellows2024.crfconferences.com/contact-us",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0254",
  "guidance_detail": "THT 2027, Technology and Heart Failure Therapeutics, February 22-24 2027, Omni Boston Hotel at the Seaport, Boston, MA (CRF).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ASGCT 30th Annual Meeting 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-03",
  "date_quality": "hard",
  "notes": "Philadelphia, PA and online; premier gene and cell therapy meeting",
  "country": "United States",
  "source_url": "https://www.asgct.org/events-meetings/2027-annual-meeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0255",
  "guidance_detail": "Philadelphia, PA and online; premier gene and cell therapy meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "SITC 42nd Annual Meeting & Pre-Conference Programs 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-03",
  "date_quality": "hard",
  "notes": "National Harbor, MD; Nov 3-7, 2027",
  "country": "United States",
  "source_url": "https://www.sitcancer.org/edu/41st-annual-meeting/archive",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0256",
  "guidance_detail": "National Harbor, MD; Nov 3-7, 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "AD/PD 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-16",
  "date_quality": "hard",
  "notes": "21st International Conference on Alzheimer's and Parkinson's Diseases and Related Disorders (AD/PD 2027), March 16-20 2027, Barcelona, Spain and online (hybrid). Source: official AD/PD 2027 site (Kenes), press information page (organizer-verified 2026-09-18).",
  "country": "Spain",
  "source_url": "https://adpd.kenes.com/press-information/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0257",
  "guidance_detail": "21st International Conference on Alzheimer's and Parkinson's Diseases and Related Disorders (AD/PD 2027), March 16-20 2027, Barcelona, Spain and online (hybrid).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "13th Congress of the European Academy of Neurology (EAN 2027)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-12",
  "date_quality": "hard",
  "notes": "Gothenburg, Sweden; overarching theme 'Transforming Neurology: Embracing Every Brain'",
  "country": "Sweden",
  "source_url": "https://www.ean.org/congress2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0258",
  "guidance_detail": "Gothenburg, Sweden; overarching theme 'Transforming Neurology: Embracing Every Brain'.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ESCMID Global 2027 (37th Congress of ESCMID)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-09",
  "date_quality": "hard",
  "notes": "Stockholm, Sweden; infectious diseases and clinical microbiology congress; opening ceremony 10.04.2027",
  "country": "Sweden",
  "source_url": "https://www.escmid.org/congress-events/escmid-global/about/general-information/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0259",
  "guidance_detail": "Stockholm, Sweden; infectious diseases and clinical microbiology congress; opening ceremony 10.04.2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EASL Congress 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-16",
  "date_quality": "hard",
  "notes": "EASL Congress 2027, June 16\u201319 2027, ExCeL London, London, United Kingdom (+ online). Four-day congress; abstract submission and registration open 28 Sep 2026; abstract deadline 19 Jan 2027. (Third-party 18\u201319 Jun adjudicated against organizer.)\n[2026-09-23 correction] The cited EASL welcome-message page (https://www.easlcongress.eu/2027-welcome-message/) now returns dead on probe (page removed/relocated) \u2014 event retained: EASL Congress 2027 dates (Jun 16-19, London) were organizer-confirmed. Needs browser re-source to the current EASL Congress page.",
  "country": "United Kingdom",
  "source_url": "https://www.easlcongress.eu/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-24",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0260",
  "guidance_detail": "EASL Congress 2027, June 16\u201319 2027, ExCeL London, London, United Kingdom (+ online).",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official EASL Congress site lists EASL Congress 2027, 16-19 June, London (old /2027-welcome-message/ URL dead).",
  "organizer_dates_printed": true
 },
 {
  "company": "IAS 2027 (14th IAS Conference on HIV Science)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-12",
  "date_quality": "hard",
  "notes": "Geneva, Switzerland and virtual; dates updated 18 Feb 2026 (was 11-15 July)",
  "country": "Switzerland",
  "source_url": "https://www.iasociety.org/news-release/ias-2027-top-hiv-science-meeting-comes-global-health-hub-geneva",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0261",
  "guidance_detail": "Geneva, Switzerland and virtual; dates updated 18 Feb 2026 (was 11-15 July).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "CHEST 2027 Annual Meeting (American College of Chest Physicians)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-24",
  "date_quality": "hard",
  "notes": "CHEST 2027 Annual Meeting, October 24-27 2027, Vancouver, BC, Canada; pulmonary, critical care and sleep medicine. Source: chestnet.org future annual meeting dates (organizer-owned, verified 2026-09-18; dates subject to change per CHEST).",
  "country": "Canada",
  "source_url": "https://www.chestnet.org/learning-and-events/events/chest-annual-meeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0262",
  "guidance_detail": "CHEST 2027 Annual Meeting, October 24-27 2027, Vancouver, BC, Canada; pulmonary, critical care and sleep medicine.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ARVO 2027 Annual Meeting (Association for Research in Vision and Ophthalmology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-02",
  "date_quality": "hard",
  "notes": "San Diego, CA; premier global eye and vision research meeting",
  "country": "United States",
  "source_url": "https://www.arvo.org/news/terri-young-2026-2027-arvo-president",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0263",
  "guidance_detail": "San Diego, CA; premier global eye and vision research meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAO 2027 (American Academy of Ophthalmology Annual Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-12",
  "date_quality": "hard",
  "notes": "Las Vegas, NV (Venetian Expo & Hotel); Subspecialty Day Nov 12-13",
  "country": "United States",
  "source_url": "https://www.aao.org/annual-meeting/past-and-future-meetings",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0264",
  "guidance_detail": "Las Vegas, NV (Venetian Expo & Hotel); Subspecialty Day Nov 12-13.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAD 2027 Annual Meeting (American Academy of Dermatology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-19",
  "date_quality": "hard",
  "notes": "San Francisco, CA (Moscone Center); 85th edition",
  "country": "United States",
  "source_url": "https://assets.ctfassets.net/1ny4yoiyrqia/6q27HOlexxkUKnBkBzrknt/b7d680e0f4ce0c13c240268d9a02e87b/am27-exhibitor-prospectus.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0265",
  "guidance_detail": "San Francisco, CA (Moscone Center); 85th edition.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Heart Rhythm 2027 (Heart Rhythm Society Annual Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-13",
  "date_quality": "hard",
  "notes": "Heart Rhythm Society annual meeting; organizer homepage states Heart Rhythm 2027 will be held May 13-16, 2027 in San Francisco, CA.\n[2026-09-23 conference re-source] Re-sourced from bare homepage to dated organizer events page; date confirmed hard.",
  "country": "United States",
  "source_url": "http://hrsonline.org/events/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0266",
  "guidance_detail": "Heart Rhythm Society annual meeting; organizer homepage states Heart Rhythm 2027 will be held May 13-16, 2027 in San Francisco, CA.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "company": "HFSA 2027 Annual Scientific Meeting (Heart Failure Society of America)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-24",
  "date_quality": "hard",
  "notes": "Charlotte, NC; heart failure science, research, management and late-breaking clinical research",
  "country": "United States",
  "source_url": "https://hfsa.org/hfsa-annual-scientific-meeting-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0267",
  "guidance_detail": "Charlotte, NC; heart failure science, research, management and late-breaking clinical research.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EuroPCR 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-18",
  "date_quality": "hard",
  "notes": "Paris, France (Palais des Congr\u00e8s); world-leading interventional cardiology course, 50 years of coronary interventions",
  "country": "France",
  "source_url": "https://www.pcronline.com/Courses/EuroPCR/about",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0268",
  "guidance_detail": "Paris, France (Palais des Congr\u00e8s); world-leading interventional cardiology course, 50 years of coronary interventions.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ATC 2027 (American Transplant Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-05",
  "date_quality": "hard",
  "notes": "Seattle, WA; joint annual meeting of AST and ASTS; scientific sessions begin June 5 Distinct conference from ENDO 2027 (separate event, separate organizer); shares only the start date 2027-06-05 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.asts.org/events-meetings/events-landing/2027/06/05/default-calendar/american-transplant-congress-(atc)-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0269",
  "guidance_detail": "Seattle, WA; joint annual meeting of AST and ASTS; scientific sessions begin June 5 Distinct conference from ENDO 2027 (separate event, separate organizer); shares only the start date 2027-06-05 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAAAI 2027 Annual Meeting (American Academy of Allergy, Asthma & Immunology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-19",
  "date_quality": "hard",
  "notes": "New Orleans, LA; leading allergy/immunology annual meeting",
  "country": "United States",
  "source_url": "https://annualmeeting.aaaai.org/attendee/future-dates-locations",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0270",
  "guidance_detail": "New Orleans, LA; leading allergy/immunology annual meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ACMG 2027 Annual Clinical Genetics Meeting (American College of Medical Genetics and Genomics)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-13",
  "date_quality": "hard",
  "notes": "Minneapolis, MN (Minneapolis Convention Center); medical genetics/genomics meeting\n[2026-09-23 conference re-source] Re-sourced to deeper dated organizer-hosted document; date confirmed hard.",
  "country": "United States",
  "source_url": "https://cdn.asp.events/CLIENT_ACMG_A41B0E50_05F7_BDBC_57979A443F6299C5/sites/ACGM-2026/media/libraries/PDF-Documents/2027-ACMG-Industry-Satellite-Symposia-Guidelines-and-Terms.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0271",
  "guidance_detail": "Minneapolis, MN (Minneapolis Convention Center); medical genetics/genomics meeting.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "company": "WORLDSymposium 2027 (23rd Annual, lysosomal disease research)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-31",
  "date_quality": "hard",
  "notes": "San Diego, CA (Manchester Grand Hyatt); largest international lysosomal/rare disease research meeting; 2,000+ attendees from 50+ countries",
  "country": "United States",
  "source_url": "https://worldsymposia.org/worldsymposium-attendees/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0272",
  "guidance_detail": "San Diego, CA (Manchester Grand Hyatt); largest international lysosomal/rare disease research meeting; 2,000+ attendees from 50+ countries.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "Tandem Meetings 2027 (ASTCT + CIBMTR, transplantation & cellular therapy)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-17",
  "date_quality": "hard",
  "notes": "Orlando, FL (Orlando World Center Marriott); pre-conference Feb 16; hematopoietic cell transplantation, cellular and gene therapy",
  "country": "United States",
  "source_url": "https://cibmtr.org/CIBMTR/Meetings/Tandem-Meetings",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0273",
  "guidance_detail": "Orlando, FL (Orlando World Center Marriott); pre-conference Feb 16; hematopoietic cell transplantation, cellular and gene therapy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "SSIEM 2027 Annual Symposium (Society for the Study of Inborn Errors of Metabolism)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-08-31",
  "date_quality": "hard",
  "notes": "Dublin, Ireland (Dublin Convention Centre); inherited metabolic disorders; theme: Complexity - Diversity - Inclusion",
  "country": "Ireland",
  "source_url": "https://www.ssiem.org/index.php?option=com_content&view=article&id=110&catid=24",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0274",
  "guidance_detail": "Dublin, Ireland (Dublin Convention Centre); inherited metabolic disorders; theme: Complexity - Diversity - Inclusion.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ACOG 2027 ACSM (Annual Clinical & Scientific Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-21",
  "date_quality": "hard",
  "notes": "Los Angeles, CA; ob-gyn clinical and scientific meeting",
  "country": "United States",
  "source_url": "https://annualmeeting.acog.org/about-acsm/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0275",
  "guidance_detail": "Los Angeles, CA; ob-gyn clinical and scientific meeting.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20"
 },
 {
  "company": "PAS 2027 (Pediatric Academic Societies Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-30",
  "date_quality": "hard",
  "notes": "Minneapolis, MN (98th meeting); premier pediatric research meeting (AAP/APA/APS/SPR)",
  "country": "United States",
  "source_url": "https://www.pas-meeting.org/2027-key-dates/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0276",
  "guidance_detail": "Minneapolis, MN (98th meeting); premier pediatric research meeting (AAP/APA/APS/SPR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ORS 2027 Annual Meeting (Orthopaedic Research Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-19",
  "date_quality": "hard",
  "notes": "San Francisco, CA (Moscone West Convention Center) Distinct conference from AAAAI 2027 Annual Meeting (American Academy of Allergy, Asthma & Immunology) (separate event, separate organizer); shares only the start date 2027-02-19 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.ors.org/futureannualmeetings/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0277",
  "guidance_detail": "San Francisco, CA (Moscone West Convention Center) Distinct conference from AAAAI 2027 Annual Meeting (American Academy of Allergy, Asthma & Immunology) (separate event, separate organizer); shares only the start date 2027-02-19 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ERA 2027 Congress (64th European Renal Association Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-03",
  "date_quality": "hard",
  "notes": "64th ERA Congress (European Renal Association), June 3-6 2027, Rotterdam, Netherlands (live + virtual). Source: ERA Glasgow 2026 event page (era-online.org), Road to Rotterdam 2027 section, organizer-confirmed 2026-09-18.",
  "country": "Netherlands",
  "source_url": "https://www.era-online.org/events/glasgow-2026/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0278",
  "guidance_detail": "64th ERA Congress (European Renal Association), June 3-6 2027, Rotterdam, Netherlands (live + virtual).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-03",
  "date_quality": "hard",
  "notes": "AAOS 2027 Annual Meeting, March 3-6 2027 (Wednesday-Saturday), The Venetian Convention & Expo Center, Las Vegas, Nevada. Source: AAOS Future Meetings page on aaos.org (organizer-owned, verified 2026-09-18). [2026-09-23 re-source] AAOS CDN bot-blocks direct curl (RemoteDisconnected); organizer content verified via search-index crawl (~14h): 'AAOS 2027 will take place March 3-6, 2027 (Wednesday to Saturday) at the Venetian Convention & Expo Center in Las Vegas, Nevada'. Date confirmed current.",
  "country": "United States",
  "source_url": "https://www.aaos.org/annual/attend/future-meetings/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0279",
  "guidance_detail": "AAOS 2027 Annual Meeting, March 3-6 2027 (Wednesday-Saturday), The Venetian Convention & Expo Center, Las Vegas, Nevada.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ECCO 2027 (22nd Congress of the European Crohn's and Colitis Organisation)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-03",
  "date_quality": "hard",
  "notes": "Copenhagen, Denmark; leading IBD congress Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event, separate organizer); shares only the start date 2027-03-03 \u2014 not a duplicate.",
  "country": "Denmark",
  "source_url": "https://ecco-ibd.eu/congress-events/event-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0280",
  "guidance_detail": "Copenhagen, Denmark; leading IBD congress Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event, separate organizer); shares only the start date 2027-03-03 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "OMA Annual 2027 (Obesity Medicine Association Annual Conference)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-31",
  "date_quality": "hard",
  "notes": "Orlando, FL; obesity medicine clinical conference",
  "country": "United States",
  "source_url": "https://obesitymedicine.org/education/annual-conference/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0281",
  "guidance_detail": "Orlando, FL; obesity medicine clinical conference.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "MDA Clinical & Scientific Conference 2027 (Muscular Dystrophy Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-21",
  "date_quality": "hard",
  "notes": "MDA Clinical & Scientific Conference 2027, March 21-24 2027, Rosen Shingle Creek, Orlando, Florida. Source: MDA press release (organizer-owned, verified 2026-09-18).",
  "country": "United States",
  "source_url": "https://www.mda.org/press-releases/registration-open-for-2027-mda-clinical-scientific-conference-showcasing-rapid-advances-in",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0282",
  "guidance_detail": "MDA Clinical & Scientific Conference 2027, March 21-24 2027, Rosen Shingle Creek, Orlando, Florida.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "39th European Congress of Pathology (ECP 2027, European Society of Pathology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-04",
  "date_quality": "hard",
  "notes": "Maastricht, Netherlands (MECC); pathology/diagnostics relevant to oncology biomarkers",
  "country": "Netherlands",
  "source_url": "https://www.espcongress.org/future-congresses/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0283",
  "guidance_detail": "Maastricht, Netherlands (MECC); pathology/diagnostics relevant to oncology biomarkers.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "CROI 2027 (34th Conference on Retroviruses and Opportunistic Infections)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-21",
  "date_quality": "hard",
  "notes": "San Diego, CA; HIV/hepatitis/SARS-CoV-2 research; organizer notes dates preliminary and subject to change Distinct conference from MDA Clinical & Scientific Conference 2027 (Muscular Dystrophy Association) (separate event, separate organizer); shares only the start date 2027-03-21 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.croiconference.org/about/croi-2027-preliminary-important-dates-and-deadlines/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0284",
  "guidance_detail": "San Diego, CA; HIV/hepatitis/SARS-CoV-2 research; organizer notes dates preliminary and subject to change Distinct conference from MDA Clinical & Scientific Conference 2027 (Muscular Dystrophy Association) (separate event, separate organizer); shares only the start date 2027-03-21 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Crohn's & Colitis Congress 2027 (10th Annual; Crohn's & Colitis Foundation + AGA)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-21",
  "date_quality": "hard",
  "notes": "New Orleans, LA; IBD research and care Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event, separate organizer); shares only the start date 2027-01-21 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://gastro.org/news/registration-is-open-for-the-2027-crohns-colitis-congress/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0285",
  "guidance_detail": "New Orleans, LA; IBD research and care Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event, separate organizer); shares only the start date 2027-01-21 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ERS Lung Science Conference 2027 (European Respiratory Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-18",
  "date_quality": "hard",
  "notes": "Estoril, Portugal (also online); ERS basic-science meeting; flagship ERS International Congress 2027 dates not yet announced",
  "country": "Portugal",
  "source_url": "https://www.ersnet.org/news-and-features/congress-category/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0286",
  "guidance_detail": "Estoril, Portugal (also online); ERS basic-science meeting; flagship ERS International Congress 2027 dates not yet announced.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EAACI Congress 2027 (European Academy of Allergy and Clinical Immunology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-11",
  "date_quality": "hard",
  "notes": "Helsinki, Finland; world's largest allergy/clinical immunology congress; immunotherapy, biologics, food allergy",
  "country": "Finland",
  "source_url": "https://www.eaaci.org/eaaci-events/eaaci-congresses/upcoming-congress.html",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0287",
  "guidance_detail": "Helsinki, Finland; world's largest allergy/clinical immunology congress; immunotherapy, biologics, food allergy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "EAACI SAM 2027 (Skin Allergy Meeting; EAACI Focused Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-11",
  "date_quality": "hard",
  "notes": "EAACI Skin Allergy Meeting (SAM) 2027, March 11-13 2027, Paris, France. Focused meeting on skin allergy (urticaria, angioedema, atopic/contact dermatitis, drug hypersensitivity), organized with ESCD and ISAD. Source: dedicated SAM 2027 page on eaaci.org (organizer-owned, verified 2026-09-18).",
  "country": "France",
  "source_url": "https://eaaci.org/events_meetings/sam-2027-2/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0288",
  "guidance_detail": "EAACI Skin Allergy Meeting (SAM) 2027, March 11-13 2027, Paris, France.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "APASL Annual Meeting 2027 (Asian Pacific Association for the Study of the Liver)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-01",
  "date_quality": "hard",
  "notes": "APASL Annual Meeting 2027 (36th), April 1-4 2027, Sydney, Australia. Source: official APASL 2027 congress site (cited by APASL).\n[2026-09-23 correction] A prior note claimed a re-source to a deeper dated organizer page, but the source URL was never actually changed and the APASL future-meetings page now returns 404 (removed). Event retained: dates browser-verified 2026-09-18 and re-verified 2026-09-23. Needs browser re-source. [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) \u2014 event retained per policy (events are never removed over URL problems alone; dates browser-verified 2026-09-18, v16-0289 re-verified 2026-09-23). Needs browser re-source to the per-event official APASL page.",
  "country": "Australia",
  "source_url": "https://www.apasl2027.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0289",
  "guidance_detail": "APASL Annual Meeting 2027 (36th), April 1-4 2027, Sydney, Australia.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official 36th APASL Annual Meeting 2027 site: Sydney, 1-4 April 2027.",
  "organizer_dates_printed": true
 },
 {
  "company": "Dermatology Summit 2027 (Advancing Innovation in Dermatology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-10",
  "date_quality": "hard",
  "notes": "San Francisco, CA; derm industry/business-development forum for innovators and investors",
  "country": "United States",
  "source_url": "https://advancing-derm.org/platform/conferences/dermatology-summit-2027/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0290",
  "guidance_detail": "San Francisco, CA; derm industry/business-development forum for innovators and investors.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ESGO 2027 (28th European Congress on Gynaecological Oncology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-25",
  "date_quality": "hard",
  "notes": "28th European Congress on Gynaecological Oncology (ESGO 2027), February 25-27 2027, London, United Kingdom, Excel London. Theme: Bridging Science and Care. Source: official ESGO Congress welcome letter (congress.esgo.org), organizer-confirmed 2026-09-18.",
  "country": "United Kingdom",
  "source_url": "https://congress.esgo.org/about/welcome-letter/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0291",
  "guidance_detail": "28th European Congress on Gynaecological Oncology (ESGO 2027), February 25-27 2027, London, United Kingdom, Excel London.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "CRT 2027 (Cardiovascular Research Technologies)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-06",
  "date_quality": "hard",
  "notes": "Washington, DC; interventional cardiology with innovation/medtech sessions",
  "country": "United States",
  "source_url": "https://crtmeeting.org/attend-crt/about-crt/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0292",
  "guidance_detail": "Washington, DC; interventional cardiology with innovation/medtech sessions.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "RSNA 2027 (113th Scientific Assembly and Annual Meeting, Radiological Society of North America)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-14",
  "date_quality": "hard",
  "notes": "McCormick Place, Chicago; world's largest radiology/imaging meeting; imaging diagnostics and AI",
  "country": "United States",
  "source_url": "https://www.rsna.org/-/media/files/rsna/annual-meeting/preparing-to-attend/travel/int901-international-visa-letter-updates-for-2027_interactive.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0293",
  "guidance_detail": "McCormick Place, Chicago; world's largest radiology/imaging meeting; imaging diagnostics and AI.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "Jefferies Biotech on the Beach Conference 2027 (flagship)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-09",
  "date_quality": "hard",
  "notes": "Miami, FL; Jefferies flagship biotech investor conference (presentations & meetings)",
  "country": "United States",
  "source_url": "https://jefferies.com/wp-content/uploads/sites/4/2026/08/8_21_26_Jefferies_2026_Conference_Summit_Calendar.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0294",
  "guidance_detail": "Miami, FL; Jefferies flagship biotech investor conference (presentations & meetings).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAN Annual Meeting 2027 (79th, American Academy of Neurology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-01",
  "date_quality": "hard",
  "notes": "Washington, DC (and online); AAN 79th Annual Meeting",
  "country": "United States",
  "source_url": "https://www.aan.com/events/upcoming-events",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0295",
  "guidance_detail": "Washington, DC (and online); AAN 79th Annual Meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "IFPA Conference 2027 (International Federation of Psoriasis Associations)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-20",
  "date_quality": "hard",
  "notes": "Stockholm, Sweden (Waterfront Congress Centre); psoriasis-focused",
  "country": "Sweden",
  "source_url": "https://www.ifpa-pso.com/ifpa-conference-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0296",
  "guidance_detail": "Stockholm, Sweden (Waterfront Congress Centre); psoriasis-focused.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "International Symposium on ALS/MND 2027 (38th)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-12-06",
  "date_quality": "hard",
  "notes": "Dublin, Ireland; host: Irish MND Association",
  "country": "Ireland",
  "source_url": "https://symposium.mndassociation.org/about-the-event/future-dates/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0297",
  "guidance_detail": "Dublin, Ireland; host: Irish MND Association.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AANS Annual Scientific Meeting 2027 (95th)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-09",
  "date_quality": "hard",
  "notes": "San Diego, CA; American Association of Neurological Surgeons; theme 'Navigating the Impossible' Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event, separate organizer); shares only the start date 2027-04-09 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.aans.org/annual-meeting/meeting-dates/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0298",
  "guidance_detail": "San Diego, CA; American Association of Neurological Surgeons; theme 'Navigating the Impossible' Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event, separate organizer); shares only the start date 2027-04-09 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Global Summit on Immunotherapies for Hematologic Malignancies 2027 (8th annual)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-12",
  "date_quality": "hard",
  "notes": "Eighth Annual Global Summit on Immunotherapies for Hematologic Malignancies, March 12-13 2027 (Fri-Sat), JW Marriott Brickell, Miami, FL; Miami Cancer Institute / Baptist Health South Florida CME event (leukemia, lymphoma, multiple myeloma, CAR-T, transplant). Source: 2027 Summit exhibitor prospectus PDF on cmeonline.baptisthealth.net (organizer-issued, verified 2026-09-18).",
  "country": "United States",
  "source_url": "https://cmeonline.baptisthealth.net/sites/default/files/2027%20Immunotherapy%20Summit%20Prospectus.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0299",
  "guidance_detail": "Eighth Annual Global Summit on Immunotherapies for Hematologic Malignancies, March 12-13 2027 (Fri-Sat), JW Marriott Brickell, Miami, FL; Miami Cancer Institute / Baptist Health South Florida CME event (leukemia, lymphoma, multiple myeloma, CAR-T, transplant).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official Baptist Health CME 2027 prospectus: Global Summit on Immunotherapies for Hematologic Malignancies, 8th annual, March 12-13 2027, JW Marriott Brickell Miami."
 },
 {
  "company": "SIO Annual Scientific Meeting 2027 (Society of Interventional Oncology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-24",
  "date_quality": "hard",
  "notes": "Toronto, ON, Canada (Sheraton Centre Toronto Hotel); interventional oncology",
  "country": "Canada",
  "source_url": "https://www.sio-central.org/Events",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0301",
  "guidance_detail": "Toronto, ON, Canada (Sheraton Centre Toronto Hotel); interventional oncology.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Transplant AI Symposium 2027 (Mayo Clinic)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-15",
  "date_quality": "hard",
  "notes": "Transplant AI Symposium 2027, January 15-16 2027, Arizona Biltmore, Scottsdale, AZ. Mayo Clinic CME course (in-person and livestream). Source: ce.mayo.edu course page (search-engine-verified 2026-09-18; direct curl probes get bot-blocked 403). Distinct conference from ESMO Genitourinary Cancers Asia 2027 (separate event, separate organizer); shares only the start date 2027-01-15 \u2014 not a duplicate. [2026-09-23 source check] ce.mayo.edu course page returns 403 on direct probe (access-blocked, not confirmed dead). Event retained.",
  "country": "United States",
  "source_url": "https://ce.mayo.edu/transplant-medicine/content/transplant-ai-symposium-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0302",
  "guidance_detail": "Transplant AI Symposium 2027, January 15-16 2027, Arizona Biltmore, Scottsdale, AZ.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ESOT Congress 2027 (European Society for Organ Transplantation)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-26",
  "date_quality": "hard",
  "notes": "Prague, Czech Republic; International Transplant Congress, theme 'Mens et Machina'",
  "country": "Czech Republic",
  "source_url": "https://esot.org/esot-events/esot-congress-2027/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0303",
  "guidance_detail": "Prague, Czech Republic; International Transplant Congress, theme 'Mens et Machina'.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "BSG Gut Microbiota for Health Conference 2027 (British Society of Gastroenterology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-01",
  "date_quality": "hard",
  "notes": "Birmingham, UK (Birmingham Conference & Events Centre); microbiome science and therapeutics",
  "country": "United Kingdom",
  "source_url": "https://www.bsg.org.uk/events/bsg-gut-microbiota-for-health-conference-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0304",
  "guidance_detail": "Birmingham, UK (Birmingham Conference & Events Centre); microbiome science and therapeutics.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ESH Scientific Workshop 2027 \u2014 Haematological Tumour Microenvironment (6th, #ESHMICRO2027)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-14",
  "date_quality": "hard",
  "notes": "6th ESH Scientific Workshop on Haematological Tumour Microenvironment (#ESHMICRO2027), starting Feb 14 2027, London, UK. Source: ESH-issued save-the-date campaign archive (Mailchimp, sent from esh.org).",
  "country": "United Kingdom",
  "source_url": "https://mailchi.mp/esh.org/cmlmpn2027_savethedate-5900234",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0305",
  "guidance_detail": "6th ESH Scientific Workshop on Haematological Tumour Microenvironment (#ESHMICRO2027), starting Feb 14 2027, London, UK.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "International Epilepsy Congress 2027, 37th (ILAE)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-08-28",
  "date_quality": "hard",
  "notes": "Amsterdam, Netherlands (RAI Amsterdam); ILAE/IBE Source upgraded 2026-09-18 to ILAE official congress page directly exposing dates and venue (Amsterdam, Aug 28-Sep 1 2027).",
  "country": "Netherlands",
  "source_url": "https://www.ilae.org/congresses/37th-international-epilepsy-congress/section/sectionid/3",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0306",
  "guidance_detail": "Amsterdam, Netherlands (RAI Amsterdam); ILAE/IBE Source upgraded 2026-09-18 to ILAE official congress page directly exposing dates and venue (Amsterdam, Aug 28-Sep 1 2027).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "TCT Plus Africa 2027 (CRF)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-28",
  "date_quality": "hard",
  "notes": "Tunis, Tunisia (Radisson Blu Hotel & Convention Center); CRF regional structural/interventional cardiology meeting",
  "country": "Tunisia",
  "source_url": "https://assets.crfconnect.com/meetings/tctafrica2027/resources/TCT_AFRICA_2027_Industry_Brochure.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0307",
  "guidance_detail": "Tunis, Tunisia (Radisson Blu Hotel & Convention Center); CRF regional structural/interventional cardiology meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "TCT Plus LATAM Valves 2027 \u2014 Structural Heart Summit (CRF)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-17",
  "date_quality": "hard",
  "notes": "TCT Plus LATAM Valves 2027 (Structural Heart Summit), March 17-19 2027, WTC Events Center, Sao Paulo, Brazil (CRF).",
  "country": "Brazil",
  "source_url": "https://fellows2024.crfconferences.com/contact-us",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0308",
  "guidance_detail": "TCT Plus LATAM Valves 2027 (Structural Heart Summit), March 17-19 2027, WTC Events Center, Sao Paulo, Brazil (CRF).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ASCRS Annual Meeting 2027 (American Society of Cataract and Refractive Surgery)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-02",
  "date_quality": "hard",
  "notes": "San Diego, CA; anterior segment/cataract-refractive surgery; ASOA meeting co-located Distinct conference from AACR Annual Meeting 2027 (separate event, separate organizer); shares only the start date 2027-04-02 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://annualmeeting.ascrs.org/for-speakers/important-dates",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0309",
  "guidance_detail": "San Diego, CA; anterior segment/cataract-refractive surgery; ASOA meeting co-located Distinct conference from AACR Annual Meeting 2027 (separate event, separate organizer); shares only the start date 2027-04-02 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "Digestive Disease Week (DDW) 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-15",
  "date_quality": "hard",
  "notes": "Washington, DC (and online); AGA/ASGE/AASLD/SSAT; exhibit hall May 16-18",
  "country": "United States",
  "source_url": "https://news.ddw.org/news/save-the-date-for-ddw-2027/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0310",
  "guidance_detail": "Washington, DC (and online); AGA/ASGE/AASLD/SSAT; exhibit hall May 16-18.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ASCRS Annual Scientific Meeting 2027 (American Society of Colon and Rectal Surgeons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-22",
  "date_quality": "hard",
  "notes": "ASCRS Annual Scientific Meeting, May 22-25 2027, New Orleans, LA (Ernest N. Morial Convention Center; HQ hotel Hilton New Orleans Riverside); tripartite meeting. Source: ASCRS Future Annual Meetings page (organizer-owned, verified 2026-09-18).",
  "country": "United States",
  "source_url": "https://fascrs.org/Web/Web/My-ASCRS/Meetings-Events/Future-Annual-Meetings.aspx",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0311",
  "guidance_detail": "ASCRS Annual Scientific Meeting, May 22-25 2027, New Orleans, LA (Ernest N.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EULAR 2027 Congress (European Alliance of Associations for Rheumatology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-09",
  "date_quality": "hard",
  "notes": "Berlin, Germany (Messe Berlin); 80th anniversary congress of rheumatology",
  "country": "Germany",
  "source_url": "http://congress.eular.org/about",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0312",
  "guidance_detail": "Berlin, Germany (Messe Berlin); 80th anniversary congress of rheumatology.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ISTH 2027 Congress (International Society on Thrombosis and Haemostasis)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-26",
  "date_quality": "hard",
  "notes": "Vancouver, Canada (Vancouver Convention Centre); thrombosis, hemostasis and vascular biology",
  "country": "Canada",
  "source_url": "https://www.isth.org/page/ISTHCongresses",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0313",
  "guidance_detail": "Vancouver, Canada (Vancouver Convention Centre); thrombosis, hemostasis and vascular biology.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ASM Microbe 2027 (American Society for Microbiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-22",
  "date_quality": "hard",
  "notes": "Chicago, IL; 3-meeting structure: Applied & Environmental Microbiology, Health, Mechanism Discovery",
  "country": "United States",
  "source_url": "http://asm.org/events/asm-microbe/home",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0314",
  "guidance_detail": "Chicago, IL; 3-meeting structure: Applied & Environmental Microbiology, Health, Mechanism Discovery.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AACE Annual Meeting 2027 (American Association of Clinical Endocrinology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-14",
  "date_quality": "hard",
  "notes": "San Diego, CA (Marriott Marquis San Diego Marina); abstracts due Dec 1, 2026",
  "country": "United States",
  "source_url": "https://pro.aace.com/education-and-event/product/aace-annual-meeting-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0315",
  "guidance_detail": "San Diego, CA (Marriott Marquis San Diego Marina); abstracts due Dec 1, 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ADA Scientific Sessions 2027 (American Diabetes Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-18",
  "date_quality": "hard",
  "notes": "ADA Scientific Sessions 2027, June 18-21 2027 (Friday June 18 10:30 a.m. ET start, Monday June 21 4:15 p.m. ET close), Walter E. Washington Convention Center, Washington DC. Source: ADA official Scientific Sessions FAQ page (organizer-owned, verified 2026-09-18).",
  "country": "United States",
  "source_url": "https://professional.diabetes.org/scientific-sessions/frequently-asked-questions",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0316",
  "guidance_detail": "ADA Scientific Sessions 2027, June 18-21 2027 (Friday June 18 10:30 a.m.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ATS 2027 International Conference (American Thoracic Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-14",
  "date_quality": "hard",
  "notes": "New Orleans, LA; May 14-15 pre-conference, May 16-19 main conference Distinct conference from AACE Annual Meeting 2027 (American Association of Clinical Endocrinology) (separate event, separate organizer); shares only the start date 2027-05-14 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "http://site.thoracic.org/conference/attendees/future-conferences",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0317",
  "guidance_detail": "New Orleans, LA; May 14-15 pre-conference, May 16-19 main conference Distinct conference from AACE Annual Meeting 2027 (American Association of Clinical Endocrinology) (separate event, separate organizer); shares only the start date 2027-05-14 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ACAAI 2027 Annual Scientific Meeting",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-11",
  "date_quality": "hard",
  "notes": "ACAAI 2027 Annual Scientific Meeting, November 11-15 2027, Nashville, Tennessee. Source: ACAAI annual-meeting future-dates page (browser-verified 2026-09-18; curl probe failed to connect). [2026-09-23 source check] Source unreachable from this network (TLS handshake timeout on both passes \u2014 not confirmed dead); organizer content seen live in search-index crawls within the last 14 days. Flagged for browser re-check.",
  "country": "United States",
  "source_url": "https://annualmeeting.acaai.org/future_meeting_dates.cfm",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0318",
  "guidance_detail": "ACAAI 2027 Annual Scientific Meeting, November 11-15 2027, Nashville, Tennessee.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ESMO TAT 2027 (Targeted Anticancer Therapies Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-22",
  "date_quality": "hard",
  "notes": "Paris, France (Palais des Congres); early-phase drug development congress Distinct conference from THT 2027 (Technology and Heart Failure Therapeutics) (separate event, separate organizer); shares only the start date 2027-02-22 \u2014 not a duplicate.",
  "country": "France",
  "source_url": "https://dam.esmo.org/image/upload/v1785409882/ESMO-TAT-2027-Industry-Guidelines_wbmntv.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0319",
  "guidance_detail": "Paris, France (Palais des Congres); early-phase drug development congress Distinct conference from THT 2027 (Technology and Heart Failure Therapeutics) (separate event, separate organizer); shares only the start date 2027-02-22 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ELCC 2027 (European Lung Cancer Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-17",
  "date_quality": "hard",
  "notes": "European Lung Cancer Congress 2027, March 17-20 2027, Munich, Germany (Messe M\u00fcnchen) and online; ESMO/IASLC joint thoracic oncology congress. Source: ELCC 2027 Industry Guidelines PDF on dam.esmo.org (organizer-issued, verified 2026-09-18). Distinct conference from TCT Plus LATAM Valves 2027 \u2014 Structural Heart Summit (CRF) (separate event, separate organizer); shares only the start date 2027-03-17 \u2014 not a duplicate.",
  "country": "Germany",
  "source_url": "https://dam.esmo.org/image/upload/v1784884466/ELCC-2027-Industry-Guidelines_o6kgid.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0320",
  "guidance_detail": "European Lung Cancer Congress 2027, March 17-20 2027, Munich, Germany (Messe M\u00fcnchen) and online; ESMO/IASLC joint thoracic oncology congress.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "MASCC/ISOO 2027 Annual Meeting",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-24",
  "date_quality": "hard",
  "notes": "Rotterdam, Netherlands; in-person only; supportive care in cancer",
  "country": "Netherlands",
  "source_url": "https://mascc.org/annualmeeting2027/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0321",
  "guidance_detail": "Rotterdam, Netherlands; in-person only; supportive care in cancer.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ISMPP 23rd Annual Meeting 2027",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-03",
  "date_quality": "hard",
  "notes": "Orlando, FL; medical publications professionals Distinct conference from ASGCT 30th Annual Meeting 2027 (separate event, separate organizer); shares only the start date 2027-05-03 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "http://www.ismpp.org/annual-meeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0322",
  "guidance_detail": "Orlando, FL; medical publications professionals Distinct conference from ASGCT 30th Annual Meeting 2027 (separate event, separate organizer); shares only the start date 2027-05-03 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ISPOR 2027 (Annual International Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-23",
  "date_quality": "hard",
  "notes": "Denver, CO (Colorado Convention Center), May 23-26 2027; health economics and outcomes research. Source updated 2026-09-18: ISPOR official calendar on ispor.org directly exposes 23-26 May 2027 Denver dates (registration page lacks dates).",
  "country": "United States",
  "source_url": "https://www.ispor.org/conferences-education/calendar/event",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0323",
  "guidance_detail": "Denver, CO (Colorado Convention Center), May 23-26 2027; health economics and outcomes research.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "IMMUNOLOGY 2027 (AAI 110th Annual Meeting)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-30",
  "date_quality": "hard",
  "notes": "IMMUNOLOGY2027 (AAI 110th Annual Meeting), April 30-May 4 2027, Los Angeles, California. Source: AAI future-meetings page (browser-verified 2026-09-18; curl probe got bot-blocked 403). Distinct conference from PAS 2027 (Pediatric Academic Societies Meeting) (separate event, separate organizer); shares only the start date 2027-04-30 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "http://www.aai.org/Meetings/Future_Meeting.html",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0324",
  "guidance_detail": "IMMUNOLOGY2027 (AAI 110th Annual Meeting), April 30-May 4 2027, Los Angeles, California.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "STS 63rd Annual Meeting 2027 (Society of Thoracic Surgeons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-28",
  "date_quality": "hard",
  "notes": "STS 63rd Annual Meeting, January 28-31 2027, San Diego, CA. Source: STS event page (browser-verified 2026-09-18; curl probe failed to connect). Distinct conference from TCT Plus Africa 2027 (CRF) (separate event, separate organizer); shares only the start date 2027-01-28 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.sts.org/calendar-of-events/63rd-sts-annual-meeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0325",
  "guidance_detail": "STS 63rd Annual Meeting, January 28-31 2027, San Diego, CA.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "VESS 2027 Winter Meeting (Vascular and Endovascular Surgery Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-21",
  "date_quality": "hard",
  "notes": "Steamboat Springs, CO; per 2027 exhibitor prospectus Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event, separate organizer); shares only the start date 2027-01-21 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://vesurgery.org/wp-content/uploads/2026/06/vess-2027-exhibitor-prospectus.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0326",
  "guidance_detail": "Steamboat Springs, CO; per 2027 exhibitor prospectus Distinct conference from ASCO Gastrointestinal Cancers Symposium (separate event, separate organizer); shares only the start date 2027-01-21 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AATS 107th Annual Meeting 2027 (American Association for Thoracic Surgery)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-01",
  "date_quality": "hard",
  "notes": "AATS 107th Annual Meeting, May 1-4 2027, Los Angeles Convention Center, Los Angeles, CA. Source: AATS future-annual-meetings page (previously cited a vendor prospectus). Distinct conference from AAN Annual Meeting 2027 (79th, American Academy of Neurology) (separate event, separate organizer); shares only the start date 2027-05-01 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.aats.org/future-annual-meetings",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0327",
  "guidance_detail": "AATS 107th Annual Meeting, May 1-4 2027, Los Angeles Convention Center, Los Angeles, CA.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "NCVH 28th Annual Conference 2027 (New Cardiovascular Horizons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-01",
  "date_quality": "hard",
  "notes": "New Orleans, LA (The Roosevelt New Orleans); endovascular medicine; organized by Cardiovascular Institute of the South",
  "country": "United States",
  "source_url": "https://www.cardio.com/news/ncvh-continues-to-draw-a-crowd-as-1400-attend-the-27th-annual-conference-at-the-roosevelt/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0328",
  "guidance_detail": "New Orleans, LA (The Roosevelt New Orleans); endovascular medicine; organized by Cardiovascular Institute of the South.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "GEST MSK 2027 (Musculoskeletal Embolization, Global Embolization Symposium)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-22",
  "date_quality": "hard",
  "notes": "GEST MSK 2027 (5th edition), January 22-23 2027; Paris, France (Marriott Rive Gauche, 75014 Paris). MSK embolization specialty meeting (knee OA GAE, adhesive capsulitis, plantar fasciitis, tendinopathies). Dates: organizer 'save the date' announcement (Global Embolization Symposium & Technologies official LinkedIn channel, posted ~Sep 2026). Organizer-owned source: https://www.linkedin.com/company/thegestgroup ; event site: https://gestmsk.com/ (organizer-owned, confirms 2027 5th edition in Paris; verified 2026-09-18).\n[2026-09-23 conference re-source] Re-sourced from gestmsk.com homepage to dated organizer meeting page; date confirmed hard.",
  "country": "France",
  "source_url": "https://thegestgroup.com/annual-msk-meeting/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0329",
  "guidance_detail": "GEST MSK 2027 (5th edition), January 22-23 2027; Paris, France (Marriott Rive Gauche, 75014 Paris).",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "company": "EACR 2027 Congress (European Association for Cancer Research)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-14",
  "date_quality": "hard",
  "notes": "Bilbao, Spain (Bilbao Exhibition Centre); basic, preclinical and translational cancer research",
  "country": "Spain",
  "source_url": "https://eacr.org/congress",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0330",
  "guidance_detail": "Bilbao, Spain (Bilbao Exhibition Centre); basic, preclinical and translational cancer research.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EBMT 2027 (53rd Annual Meeting of the European Society for Blood and Marrow Transplantation)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-11",
  "date_quality": "hard",
  "notes": "Rotterdam Ahoy, Rotterdam, Netherlands; blood/marrow transplantation and cellular therapy",
  "country": "Netherlands",
  "source_url": "https://www.ebmt.org/events/53rd-annual-meeting-ebmt",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0331",
  "guidance_detail": "Rotterdam Ahoy, Rotterdam, Netherlands; blood/marrow transplantation and cellular therapy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "DIA Europe 2027 (Drug Information Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-16",
  "date_quality": "hard",
  "notes": "Basel, Switzerland; regulatory science / life sciences innovation Distinct conference from AD/PD 2027 (separate event, separate organizer); shares only the start date 2027-03-16 \u2014 not a duplicate.",
  "country": "Switzerland",
  "source_url": "https://www.diaglobal.org/en/flagship/dia-europe-2027",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0332",
  "guidance_detail": "Basel, Switzerland; regulatory science / life sciences innovation Distinct conference from AD/PD 2027 (separate event, separate organizer); shares only the start date 2027-03-16 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "DIA 2027 Global Annual Meeting (Drug Information Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-28",
  "date_quality": "hard",
  "notes": "San Diego, CA; per DIA global events calendar",
  "country": "United States",
  "source_url": "https://www.diaglobal.org/en/general/global-events",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0333",
  "guidance_detail": "San Diego, CA; per DIA global events calendar.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "DIA China 2027 Annual Meeting",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-01",
  "date_quality": "hard",
  "notes": "DIA China Annual Meeting 2027, starting May 1, 2027. End date and host city not published on the DIA events calendar as of September 2026; China\u2019s regulatory-industry annual meeting. (Stayed hard: start day is organizer-printed.) Distinct conference from AAN Annual Meeting 2027 (79th, American Academy of Neurology) (separate event, separate organizer); shares only the start date 2027-05-01 \u2014 not a duplicate.",
  "country": "China",
  "source_url": "https://www.diaglobal.org/en/general/global-events",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0334",
  "guidance_detail": "DIA China Annual Meeting 2027, starting May 1, 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ECR 2027 (European Congress of Radiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-03",
  "date_quality": "hard",
  "notes": "Vienna, Austria (Austria Center Vienna); onsite & online Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event, separate organizer); shares only the start date 2027-03-03 \u2014 not a duplicate.",
  "country": "Austria",
  "source_url": "https://www.myesr.org/congress/about-ecr/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0335",
  "guidance_detail": "Vienna, Austria (Austria Center Vienna); onsite & online Distinct conference from AAOS 2027 Annual Meeting (American Academy of Orthopaedic Surgeons) (separate event, separate organizer); shares only the start date 2027-03-03 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "SCOPE 2027 (Summit for Clinical Ops Executives, 18th Annual)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-01",
  "date_quality": "hard",
  "notes": "Rosen Shingle Creek, Orlando, FL; clinical research operations; Cambridge Healthtech Institute Distinct conference from BSG Gut Microbiota for Health Conference 2027 (British Society of Gastroenterology) (separate event, separate organizer); shares only the start date 2027-03-01 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.scopesummit.com/Clinical-Trial-Delivery",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0336",
  "guidance_detail": "Rosen Shingle Creek, Orlando, FL; clinical research operations; Cambridge Healthtech Institute Distinct conference from BSG Gut Microbiota for Health Conference 2027 (British Society of Gastroenterology) (separate event, separate organizer); shares only the start date 2027-03-01 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "St. Gallen International Breast Cancer Conference 2027 (20th, SGBCC)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-17",
  "date_quality": "hard",
  "notes": "Vienna, Austria; primary therapy of early breast cancer; consensus manuscript Distinct conference from TCT Plus LATAM Valves 2027 \u2014 Structural Heart Summit (CRF) (separate event, separate organizer); shares only the start date 2027-03-17 \u2014 not a duplicate.\n[2026-09-23 conference re-source] URL unchanged: homepage is the dedicated 2027 event site and prints the dates; date confirmed hard.\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "country": "Austria",
  "source_url": "https://www.sg-bcc.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0337",
  "guidance_detail": "Vienna, Austria; primary therapy of early breast cancer; consensus manuscript Distinct conference from TCT Plus LATAM Valves 2027 \u2014 Structural Heart Summit (CRF) (separate event, separate organizer); shares only the start date 2027-03-17 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "company": "SAR 2027 Annual Meeting (Society of Abdominal Radiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-28",
  "date_quality": "hard",
  "notes": "Omni La Costa Resort & Spa, Carlsbad, CA Distinct conference from AACR Immuno-Oncology 2027 (separate event, separate organizer); shares only the start date 2027-02-28 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://abdominalradiology.org/sar-subpages/annual-meeting/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0338",
  "guidance_detail": "Omni La Costa Resort & Spa, Carlsbad, CA Distinct conference from AACR Immuno-Oncology 2027 (separate event, separate organizer); shares only the start date 2027-02-28 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "SIR 2027 Annual Scientific Meeting (52nd, Society of Interventional Radiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-20",
  "date_quality": "hard",
  "notes": "SIR 2027 Annual Scientific Meeting, March 20-24, 2027, Los Angeles. [2026-09-23 conference re-source] Re-sourced from bare homepage to deeper dated organizer page; date confirmed hard. [2026-09-27 link audit] Prior aaStatic.asp URL now returns \"link expired\" (retired by organizer); replaced with sirmeeting.org, which now serves as the official SIR 2027 event page, re-verified in-browser: confirms Mar 20-24, 2027, Los Angeles.",
  "country": "United States",
  "source_url": "https://www.sirmeeting.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0339",
  "guidance_detail": "SIR 2027 Annual Scientific Meeting (52nd), March 20\u201324, 2027, Los Angeles, California.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "organizer_dates_printed": true
 },
 {
  "company": "ACAR 2027 (14th Asian Congress of Abdominal Radiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-08-19",
  "date_quality": "hard",
  "notes": "Singapore (joint with SGCR-WIRES 2027); \"Inspiring Excellence in Radiology\"",
  "country": "Singapore",
  "source_url": "http://abdominalradiology-asia.org/annual-meeting/acar2027-in-singapore/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0340",
  "guidance_detail": "Singapore (joint with SGCR-WIRES 2027); \"Inspiring Excellence in Radiology\".",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "AAR 2027 (75th Annual Meeting, Association of Academic Radiology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-13",
  "date_quality": "hard",
  "notes": "Salt Lake City, UT; radiology training and practice in the AI era Distinct conference from ACMG 2027 Annual Clinical Genetics Meeting (American College of Medical Genetics and Genomics) (separate event, separate organizer); shares only the start date 2027-04-13 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://www.apdr.org/annual-meeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0341",
  "guidance_detail": "Salt Lake City, UT; radiology training and practice in the AI era Distinct conference from ACMG 2027 Annual Clinical Genetics Meeting (American College of Medical Genetics and Genomics) (separate event, separate organizer); shares only the start date 2027-04-13 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ACRO 2027: The Radiation Oncology Summit (American College of Radiation Oncology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-18",
  "date_quality": "hard",
  "notes": "ACRO 2027: The Radiation Oncology Summit, February 18-21 2027; Las Vegas, Nevada. American College of Radiation Oncology annual meeting. Source: ACRO official annual-meeting page (organizer-owned, verified 2026-09-18). [2026-09-23 source check] Source unreachable from this network (connection reset on both passes \u2014 not confirmed dead); organizer content seen live in search-index crawls within the last 14 days. Flagged for browser re-check.",
  "country": "United States",
  "source_url": "https://acro.org/page/annualmeeting",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0342",
  "guidance_detail": "ACRO 2027: The Radiation Oncology Summit, February 18-21 2027; Las Vegas, Nevada.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ASN 2027 (50th Annual Meeting, American Society of Neuroimaging)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-15",
  "date_quality": "hard",
  "notes": "50th ASN Annual Meeting, January 15-17 2027; Hilton Head Island, SC. American Society of Neuroimaging annual meeting (neuroimaging education and certification). Source: ASN official homepage (organizer-owned, verified 2026-09-18). Distinct conference from ESMO Genitourinary Cancers Asia 2027 (separate event, separate organizer); shares only the start date 2027-01-15 \u2014 not a duplicate.\n[2026-09-23 conference re-source] URL unchanged: organizer homepage prints the 2027 dates; no deeper organizer page verified; date confirmed hard.\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "country": "United States",
  "source_url": "http://www.asnweb.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0343",
  "guidance_detail": "50th ASN Annual Meeting, January 15-17 2027; Hilton Head Island, SC.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "company": "ACNS 2027 Annual Meeting & Courses (American Clinical Neurophysiology Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-04",
  "date_quality": "hard",
  "notes": "Hyatt Regency Seattle, Seattle, WA; clinical neurophysiology (EEG, epilepsy, neuromuscular) Source upgraded 2026-09-18: ACNS 2027 call-for-proposals PDF (organizer) states March 4-7 2027, Seattle WA.",
  "country": "United States",
  "source_url": "https://www.acns.org/UserFiles/AM27CallForProposal.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0344",
  "guidance_detail": "Hyatt Regency Seattle, Seattle, WA; clinical neurophysiology (EEG, epilepsy, neuromuscular) Source upgraded 2026-09-18: ACNS 2027 call-for-proposals PDF (organizer) states March 4-7 2027, Seattle WA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "IPTA 2027 (14th Congress, International Pediatric Transplant Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-18",
  "date_quality": "hard",
  "notes": "Charleston, SC; TTS official section meeting Distinct conference from ERS Lung Science Conference 2027 (European Respiratory Society) (separate event, separate organizer); shares only the start date 2027-03-18 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0345",
  "guidance_detail": "Charleston, SC; TTS official section meeting Distinct conference from ERS Lung Science Conference 2027 (European Respiratory Society) (separate event, separate organizer); shares only the start date 2027-03-18 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "SPLIT 2027 (31st Annual Meeting, Society of Pediatric Liver Transplantation)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-06",
  "date_quality": "hard",
  "notes": "Chicago, IL; TTS official section meeting",
  "country": "United States",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0346",
  "guidance_detail": "Chicago, IL; TTS official section meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ISVCA 2027 (18th Congress, International Society of Vascularized Composite Allotransplantation)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-08",
  "date_quality": "hard",
  "notes": "Taipei, Taiwan; TTS official section meeting",
  "country": "Taiwan",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0347",
  "guidance_detail": "Taipei, Taiwan; TTS official section meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "CIIRTA 2027 (20th Congress, Intl Intestinal Rehabilitation & Transplantation Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-11",
  "date_quality": "hard",
  "notes": "Tokyo, Japan; TTS official section meeting",
  "country": "Japan",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0348",
  "guidance_detail": "Tokyo, Japan; TTS official section meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "IPITA 2027 (21st International Pancreas & Islet Transplant World Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-07",
  "date_quality": "hard",
  "notes": "Montreal, Canada; TTS official section meeting",
  "country": "Canada",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0349",
  "guidance_detail": "Montreal, Canada; TTS official section meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ISODP 2027 (18th Biennial Congress, International Society for Organ Donation Professionals)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-20",
  "date_quality": "hard",
  "notes": "London, UK; TTS official section meeting",
  "country": "United Kingdom",
  "source_url": "https://tts.org/events/tts-meetings-and-events-calendar",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0350",
  "guidance_detail": "London, UK; TTS official section meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "WCN 2027 (ISN World Congress of Nephrology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-01",
  "date_quality": "hard",
  "notes": "Kuala Lumpur, Malaysia; hosted by Malaysian Society of Nephrology (MSN); flagship ISN meeting Distinct conference from APASL Annual Meeting 2027 (Asian Pacific Association for the Study of the Liver) (separate event, separate organizer); shares only the start date 2027-04-01 \u2014 not a duplicate.",
  "country": "Malaysia",
  "source_url": "https://www.theisn.org/wcn/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0351",
  "guidance_detail": "Kuala Lumpur, Malaysia; hosted by Malaysian Society of Nephrology (MSN); flagship ISN meeting Distinct conference from APASL Annual Meeting 2027 (Asian Pacific Association for the Study of the Liver) (separate event, separate organizer); shares only the start date 2027-04-01 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "APASL STC 2027 Bishkek (Single Topic Conference: MASLD/MAFLD)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-28",
  "date_quality": "hard",
  "notes": "APASL STC 2027 Bishkek, May 28-29 2027. Source: APASL future-meetings page (browser-verified 2026-09-18; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) \u2014 event retained per policy (events are never removed over URL problems alone; dates browser-verified 2026-09-18, v16-0289 re-verified 2026-09-23). Needs browser re-source to the per-event official APASL page.",
  "country": "Kyrgyzstan",
  "source_url": "http://apasl.info/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0352",
  "guidance_detail": "APASL STC 2027 Bishkek, May 28-29 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official APASL homepage Future Meetings table: STC May 28-29 2027, Bishkek Kyrgyzstan.",
  "organizer_dates_printed": true
 },
 {
  "company": "APASL STC 2027 Kaohsiung (Single Topic Conference: MASLD/MAFLD)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-25",
  "date_quality": "hard",
  "notes": "APASL STC 2027 Kaohsiung, June 25-27 2027. Source: APASL future-meetings page (browser-verified 2026-09-18; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) \u2014 event retained per policy (events are never removed over URL problems alone; dates browser-verified 2026-09-18, v16-0289 re-verified 2026-09-23). Needs browser re-source to the per-event official APASL page.",
  "country": "Taiwan",
  "source_url": "http://apasl.info/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0353",
  "guidance_detail": "APASL STC 2027 Kaohsiung, June 25-27 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official APASL homepage Future Meetings table: STC June 25-27 2027, Kaohsiung Taiwan.",
  "organizer_dates_printed": true
 },
 {
  "company": "APASL STC 2027 Danang (Single Topic Conference: From Chronic Liver Disease to HCC)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-07-23",
  "date_quality": "hard",
  "notes": "APASL STC 2027 Danang, July 23-24 2027. Source: APASL future-meetings page (browser-verified 2026-09-18; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) \u2014 event retained per policy (events are never removed over URL problems alone; dates browser-verified 2026-09-18, v16-0289 re-verified 2026-09-23). Needs browser re-source to the per-event official APASL page.",
  "country": "Vietnam",
  "source_url": "http://apasl.info/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0354",
  "guidance_detail": "APASL STC 2027 Danang, July 23-24 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official APASL homepage Future Meetings table: STC July 23-24 2027, Danang Vietnam.",
  "organizer_dates_printed": true
 },
 {
  "company": "APASL STC 2027 Chongqing (Single Topic Conference: Clinical Application of Liver Imaging in A.I. Era)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-08",
  "date_quality": "hard",
  "notes": "APASL STC 2027 Chongqing, October 8-10 2027. Source: APASL future-meetings page (browser-verified 2026-09-18; curl probes are blocked with 404). [2026-09-23 source check] Cited URL http://apasl.info/conf/future-meetings/ returns HTTP 404 on both probe passes (page removed) \u2014 event retained per policy (events are never removed over URL problems alone; dates browser-verified 2026-09-18, v16-0289 re-verified 2026-09-23). Needs browser re-source to the per-event official APASL page.",
  "country": "China",
  "source_url": "http://apasl.info/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0355",
  "guidance_detail": "APASL STC 2027 Chongqing, October 8-10 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official APASL homepage Future Meetings table: STC Oct 8-10 2027, Chongqing China.",
  "organizer_dates_printed": true
 },
 {
  "company": "SIOP 2027 (59th Congress, International Society of Paediatric Oncology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-07",
  "date_quality": "hard",
  "notes": "Sydney, Australia; pediatric and adolescent oncology (note: ISPN calendar lists Sept 8\u201311; SIOP itself says Sept 7\u201310)",
  "country": "Australia",
  "source_url": "https://siop-online.org/news/siop-2027-sydney-proposals/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0356",
  "guidance_detail": "Sydney, Australia; pediatric and adolescent oncology (note: ISPN calendar lists Sept 8\u201311; SIOP itself says Sept 7\u201310).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "EANS 2027 Congress (European Association of Neurosurgical Societies)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-26",
  "date_quality": "hard",
  "notes": "EANS 2027 Congress, September 26-30, 2027, Basel, Switzerland. Source: eans.org EANS_Congress page Future Congresses list (organizer-verified 2026-10-01; direct curl probes get bot-blocked 403). Distinct conference from the ESOT Congress 2027 (Prague, organ transplantation) \u2014 different organizer, city, and field.",
  "country": "Switzerland",
  "source_url": "https://www.eans.org/page/EANS_Congress",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0357",
  "guidance_detail": "EANS 2027 Congress, September 26-30, 2027, Basel, Switzerland.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [
   {
    "date": "2026-10-01",
    "change": "date_exact 2027-09-25 -> 2027-09-26; congress dates corrected to September 26-30 per organizer-printed Future Congresses list (eans.org)"
   }
  ],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "CNS 2027 Annual Meeting (Congress of Neurological Surgeons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-23",
  "date_quality": "hard",
  "notes": "Congress of Neurological Surgeons 2027 Annual Meeting, October 23\u201327, 2027, Phoenix, Arizona. Neurosurgery annual meeting.",
  "country": "United States",
  "source_url": "http://cns.org/meetings/past-and-future-annual-meetings",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0358",
  "guidance_detail": "Congress of Neurological Surgeons 2027 Annual Meeting, October 23\u201327, 2027, Phoenix, Arizona.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "company": "ISPN 2027 (53rd Annual Meeting, International Society for Pediatric Neurosurgery)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-31",
  "date_quality": "hard",
  "notes": "53rd ISPN Annual Meeting, October 31\u2013November 4, 2027, Taipei, Taiwan. International pediatric neurosurgery annual meeting.",
  "country": "Taiwan",
  "source_url": "https://ispnmeeting.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0359",
  "guidance_detail": "53rd ISPN Annual Meeting, October 31\u2013November 4, 2027, Taipei, Taiwan.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20",
  "organizer_dates_printed": true
 },
 {
  "company": "ASPN 2027 (50th Annual Meeting, American Society of Pediatric Neurosurgeons)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-31",
  "date_quality": "hard",
  "notes": "50th ASPN Annual Meeting (American Society of Pediatric Neurosurgeons), January 31 - February 5, 2027, The Ritz-Carlton, Grand Cayman. Source: ASPN official website 'Save the Date' announcement (aspn.memberclicks.net, society-owned); corroborated by ISPN Global Neurosurgical Calendar (updated Jun 3 2026, https://ispnmeeting.org/wp-content/uploads/2026/06/ISPN-Global-Neurosurgical-Calendar-2026-2029-Jun-3-2026.pdf). Verified 2026-09-18. Distinct conference from WORLDSymposium 2027 (23rd Annual, lysosomal disease research) (separate event, separate organizer); shares only the start date 2027-01-31 \u2014 not a duplicate.",
  "country": "Cayman Islands",
  "source_url": "https://aspn.memberclicks.net/login",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0360",
  "guidance_detail": "50th ASPN Annual Meeting (American Society of Pediatric Neurosurgeons), January 31 - February 5, 2027, The Ritz-Carlton, Grand Cayman.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ASPO-HNS 2027 Annual Meeting (American Society of Pediatric Otolaryngology)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-09",
  "date_quality": "hard",
  "notes": "Seattle, WA (Seattle Convention Center), in conjunction with COSM Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event, separate organizer); shares only the start date 2027-04-09 \u2014 not a duplicate.",
  "country": "United States",
  "source_url": "https://WWW.ASPO.US/annual-meeting-members",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-23",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0361",
  "guidance_detail": "Seattle, WA (Seattle Convention Center), in conjunction with COSM Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event, separate organizer); shares only the start date 2027-04-09 \u2014 not a duplicate.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "company": "ASPN 2027 Annual Meeting (American Society of Pediatric Nephrology, inaugural standalone)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-15",
  "date_quality": "hard",
  "notes": "ASPNeph 2027 Annual Meeting (American Society of Pediatric Nephrology), April 15-17, 2027, InterContinental New Orleans, 444 St. Charles Ave, New Orleans, LA. Inaugural standalone meeting. Source: ASPN 2027 prospectus (organizer PDF, search-engine-verified 2026-09-18; direct curl probes get bot-blocked 403).",
  "country": "United States",
  "source_url": "http://aspneph.org/wp-content/uploads/2026/04/2027-Prespectus-V4.27.pdf",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-09-18",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0362",
  "guidance_detail": "ASPNeph 2027 Annual Meeting (American Society of Pediatric Nephrology), April 15-17, 2027, InterContinental New Orleans, 444 St.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "ASPHO 2027 Conference (American Society of Pediatric Hematology/Oncology)",
  "competitors": null,
  "country": "Canada",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "2027 ASPHO annual conference, May 11-14, Palais des congres de Montreal, Montreal, Canada; dates from ASPHO-owned corporate prospectus PDF. Distinct conference from CIIRTA 2027 (20th Congress, Intl Intestinal Rehabilitation & Transplantation Association) (separate event, separate organizer); shares only the start date 2027-05-11 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://aspho.org/uploads/ASPHO25_Corporate_Prospectus_web_2.pdf",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0363",
  "guidance_detail": "2027 ASPHO annual conference, May 11-14, Palais des congres de Montreal, Montreal, Canada; dates from ASPHO-owned corporate prospectus PDF.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "EAU27 Congress (42nd Annual EAU Congress, European Association of Urology)",
  "competitors": null,
  "country": "Netherlands",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-19",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "42nd Annual EAU Congress (EAU27), March 19\u201322, 2027, RAI Amsterdam, Amsterdam, The Netherlands. European urology flagship congress. Distinct conference from AAD 2027 Annual Meeting (American Academy of Dermatology) (separate event, separate organizer); shares only the start date 2027-03-19 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://eaucongress.uroweb.org/the-congress/general-information",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0364",
  "guidance_detail": "42nd Annual EAU Congress (EAU27), March 19\u201322, 2027, RAI Amsterdam, Amsterdam, The Netherlands.",
  "audit_status": "v17_reverified",
  "audit_action": "note-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "CUA 2027 Annual Meeting (Canadian Urological Association)",
  "competitors": null,
  "country": "Canada",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-25",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "Canadian Urological Association annual meeting, June 25-27 2027, Halifax Convention Centre, Halifax, NS, Canada. Distinct conference from APASL STC 2027 Kaohsiung (Single Topic Conference: MASLD/MAFLD) (separate event, separate organizer); shares only the start date 2027-06-25 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.cua.org/upcoming-events",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0365",
  "guidance_detail": "Canadian Urological Association annual meeting, June 25-27 2027, Halifax Convention Centre, Halifax, NS, Canada.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "ACNP 2027 Annual Meeting (65th, American College of Neuropsychopharmacology)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-10",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "65th Annual Meeting of the American College of Neuropsychopharmacology, January 10-13 2027, San Diego, California. Distinct conference from Dermatology Summit 2027 (Advancing Innovation in Dermatology) (separate event, separate organizer); shares only the start date 2027-01-10 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://files.constantcontact.com/61d9ccf2601/cdbd0b72-0001-4aef-9ea3-ad7d8b8bfbd3.pdf",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0366",
  "guidance_detail": "65th Annual Meeting of the American College of Neuropsychopharmacology, January 10-13 2027, San Diego, California.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "New York Valves 2027 (Structural Heart Summit, CRF)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-23",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "New York Valves 2027 structural heart summit, June 23-25 2027 (CRF, in partnership with AATS). Source: CRF organizer site.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://crf.org/crf/news-and-events/events-calendar",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0367",
  "guidance_detail": "New York Valves 2027 structural heart summit, June 23-25 2027 (CRF, in partnership with AATS).",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "IDF Congress 2027 (International Diabetes Federation Congress)",
  "competitors": null,
  "country": "Singapore",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-09",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "IDF Congress 2027, April 9-12 2027, Singapore. Note: one third-party supplier page reports April 10-12; IDF-owned pages report April 9-12. Distinct conference from ESCMID Global 2027 (37th Congress of ESCMID) (separate event, separate organizer); shares only the start date 2027-04-09 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://idf.org/congress-and-events/upcoming-diabetes-events/international-diabetes-federation-world-diabetes-congress-2027/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0368",
  "guidance_detail": "IDF Congress 2027, April 9-12 2027, Singapore.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASHG Annual Meeting 2027 (American Society of Human Genetics)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-26",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ASHG Annual Meeting 2027, October 26-30 2027, Nashville, TN.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.ashg.org/meetings/future-past/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0369",
  "guidance_detail": "ASHG Annual Meeting 2027, October 26-30 2027, Nashville, TN.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "AAP National Conference & Exhibition 2027 (American Academy of Pediatrics)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-15",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "AAP National Conference & Exhibition 2027, October 15-19 2027, McCormick Place, Chicago. Distinct conference from ASBMR 2027 Annual Meeting (separate event, separate organizer); shares only the start date 2027-10-15 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://archive.aapexperience.org/future-dates/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0370",
  "guidance_detail": "AAP National Conference & Exhibition 2027, October 15-19 2027, McCormick Place, Chicago.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "ASTS Winter Symposium 2027 (American Society of Transplant Surgeons)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-28",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ASTS Winter Symposium 2027, January 28-31 2027, JW Marriott Orlando Grande Lakes, Orlando, FL. Distinct conference from TCT Plus Africa 2027 (CRF) (separate event, separate organizer); shares only the start date 2027-01-28 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://asts.org/events-meetings/winter-symposium",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0371",
  "guidance_detail": "ASTS Winter Symposium 2027, January 28-31 2027, JW Marriott Orlando Grande Lakes, Orlando, FL.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "STSA Annual Meeting 2027 (Southern Thoracic Surgical Association, 74th)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "74th STSA Annual Meeting, November 11-14 2027, Hyatt Regency Lost Pines Resort & Spa, Cedar Creek, TX. Distinct conference from ACAAI 2027 Annual Scientific Meeting (separate event, separate organizer); shares only the start date 2027-11-11 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://stsa.org/meeting/archives/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0372",
  "guidance_detail": "74th STSA Annual Meeting, November 11-14 2027, Hyatt Regency Lost Pines Resort & Spa, Cedar Creek, TX.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "ISHLT Annual Meeting & Scientific Sessions 2027 (47th, International Society for Heart and Lung Transplantation)",
  "competitors": null,
  "country": "Australia",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-14",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "ISHLT 47th Annual Meeting & Scientific Sessions, April 14-17 2027, International Convention Centre Sydney, Sydney, Australia (preconference day April 13).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.ishlt.org/annual-meeting/other-annual-meetings/future-dates",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0373",
  "guidance_detail": "ISHLT 47th Annual Meeting & Scientific Sessions, April 14-17 2027, International Convention Centre Sydney, Sydney, Australia (preconference day April 13).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "PVRI Annual Congress 2027 (Pulmonary Vascular Research Institute)",
  "competitors": null,
  "country": "Thailand",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-27",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "PVRI 2027 Annual Congress, January 27-31 2027, Amari Bangkok Hotel & Conference Centre, Bangkok, Thailand. Theme: Bridging Science, Innovation & Care for the Next 20 Years.\n[2026-09-23 conference re-source] Re-sourced from bare homepage to dated organizer event page; date confirmed hard.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://pvrinstitute.org/learning-hub/events/pvri-2027-bangkok",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0374",
  "guidance_detail": "PVRI 2027 Annual Congress, January 27-31 2027, Amari Bangkok Hotel & Conference Centre, Bangkok, Thailand.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "2027 Spine Summit (AANS/CNS Section on Disorders of the Spine and Peripheral Nerves)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-18",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "2027 Spine Summit, annual meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, February 18-21 2027, Disney's Yacht & Beach Club Resort, Orlando/Lake Buena Vista, Florida. Source: 2027 Spine Summit Exhibitor Prospectus on dspnspinesummit.org (organizer-owned, verified 2026-09-18). Distinct conference from ACRO 2027: The Radiation Oncology Summit (American College of Radiation Oncology) (separate event, separate organizer); shares only the start date 2027-02-18 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://dspnspinesummit.org/wp-content/uploads/2026/06/AAN-SpineEP27-Compressed-6-17.pdf",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0375",
  "guidance_detail": "2027 Spine Summit, annual meeting of the AANS/CNS Section on Disorders of the Spine and Peripheral Nerves, February 18-21 2027, Disney's Yacht & Beach Club Resort, Orlando/Lake Buena Vista, Florida.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "AAO-HNSF 2027 Annual Meeting & OTO EXPO (American Academy of Otolaryngology-Head and Neck Surgery Foundation)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-18",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "AAO-HNSF 2027 Annual Meeting & OTO EXPO, September 18-21 2027, New Orleans, Louisiana. Source: AAO-HNSF official site (entnet.org annual meeting webcasts page, organizer-confirmed 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.entnet.org/education/annual-meeting-webcasts/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0376",
  "guidance_detail": "AAO-HNSF 2027 Annual Meeting & OTO EXPO, September 18-21 2027, New Orleans, Louisiana.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASCO Breakthrough 2027",
  "competitors": null,
  "country": "Singapore",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-24",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "oncology",
  "notes": "ASCO Breakthrough (ASCO's global oncology meeting in Asia; 2026 edition in Singapore June 25-27, 2026), June 24-26 2027, Singapore. Source: ASCO Breakthrough 'Dates to Know' page, Future Meetings section (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.asco.org/breakthrough/dates-know?intcmp=nw_ascoorg_brktsum_pre-cfa_site_breakthroughlandingpage_all__glob_091825_110325_qklnk__aware_text_",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0377",
  "guidance_detail": "ASCO Breakthrough (ASCO's global oncology meeting in Asia; 2026 edition in Singapore June 25-27, 2026), June 24-26 2027, Singapore.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "BIO International Convention 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-07",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "biotech industry",
  "notes": "BIO International Convention 2027, June 7-10 2027, Philadelphia, PA (Pennsylvania Convention Center); world's largest biotech industry/partnering convention (~20,000 attendees). Source: BIO official convention site (convention.bio.org) and bio.org events page save-the-date banner (organizer-owned, verified 2026-09-18). Source URL corrected 2026-09-18 to the exact observed organizer listing page.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.bio.org/events/bio-international-convention/?c1=12&page=2",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0378",
  "guidance_detail": "BIO International Convention 2027, June 7-10 2027, Philadelphia, PA (Pennsylvania Convention Center); world's largest biotech industry/partnering convention (~20,000 attendees).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BIO Partnering @ JPM Week 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "biotech industry",
  "notes": "BIO Partnering @ JPM Week, January 11-14 2027, San Francisco, CA; BIO's official partnering event during the J.P. Morgan Healthcare Conference week. Source: BIO official upcoming-events listing (organizer-owned, verified 2026-09-18). Note: this does not itself confirm the JPM conference's own dates.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.bio.org/sites/default/files/2026-07/bio26_brochure_070826-digital-pages.pdf",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0379",
  "guidance_detail": "BIO Partnering @ JPM Week, January 11-14 2027, San Francisco, CA; BIO's official partnering event during the J.P.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BIO Investment & Growth Summit 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-16",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "biotech industry",
  "notes": "BIO Investment & Growth Summit, February 16-17 2027, Miami, FL; BIO investor/partnering summit. Source: BIO official upcoming-events listing (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.bio.org/sites/default/files/2026-07/bio26_brochure_070826-digital-pages.pdf",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0380",
  "guidance_detail": "BIO Investment & Growth Summit, February 16-17 2027, Miami, FL; BIO investor/partnering summit.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "CNS Joint Tumor Section Symposium 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-22",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "brain tumors / neuro-oncology",
  "notes": "Joint Tumor Section Symposium, October 22-23 2027; Congress of Neurological Surgeons (CNS) Tumor Section specialty symposium (in-person CME, brain tumor surgery). Source: CNS official meetings page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.cns.org/meetings-detail/joint-tumor-section-symposium",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0381",
  "guidance_detail": "Joint Tumor Section Symposium, October 22-23 2027; Congress of Neurological Surgeons (CNS) Tumor Section specialty symposium (in-person CME, brain tumor surgery).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "AHA EPI/Lifestyle Scientific Sessions 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-01",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "cardiovascular / cardiometabolic / epidemiology",
  "notes": "AHA Epidemiology & Prevention / Lifestyle and Cardiometabolic Health Scientific Sessions 2027; March 1-4 2027 (sessions begin Mon Mar 1, end Thu Mar 4). Location Boston, MA per third-party reporting (not on organizer page). Source: AHA professional.heart.org organizer page (Key Dates table, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://professional.heart.org/en/meetings/epi-lifestyle?utm_source=meta&utm_medium=paid-social&utm_campaign=epi_2025&utm_content=image&utm_id=120213511874330713_v2_s03&utm_term=120214822762350713",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0382",
  "guidance_detail": "AHA Epidemiology & Prevention / Lifestyle and Cardiometabolic Health Scientific Sessions 2027; March 1-4 2027 (sessions begin Mon Mar 1, end Thu Mar 4).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Vascular Annual Meeting 2027 (VAM27)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-02",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "vascular surgery / peripheral vascular disease",
  "notes": "Society for Vascular Surgery (SVS) Vascular Annual Meeting 2027 (VAM27), June 2-5 2027, San Diego Convention Center, San Diego, CA. Scientific plenaries Jun 2-5; exhibit dates Jun 3-4. Source: SVS official 2027 meeting page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://vascular.org/vascular-specialists/education-and-meetings/meetings/2027-vascular-annual-meeting",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0383",
  "guidance_detail": "Society for Vascular Surgery (SVS) Vascular Annual Meeting 2027 (VAM27), June 2-5 2027, San Diego Convention Center, San Diego, CA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "AANEM Annual Meeting 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-27",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "neuromuscular / electrodiagnostic medicine",
  "notes": "American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting 2027, October 27-30 2027, San Antonio, Texas. Source: AANEM official Future Meetings page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.aanem.org/meetings/future-annual-meetings",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0384",
  "guidance_detail": "American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting 2027, October 27-30 2027, San Antonio, Texas.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASPNR Annual Meeting 2027 (9th, American Society of Pediatric Neuroradiology)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-21",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "pediatric neuroradiology / neuroimaging",
  "notes": "9th ASPNR Annual Meeting, January 21-24 2027, Fontainebleau Miami Beach, Miami Beach FL (pre-meeting workshops Jan 21). Source: ASPNR official meeting page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://aspnr.org/meetings/aspnr-annual-meeting/aspnr2027/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0386",
  "guidance_detail": "9th ASPNR Annual Meeting, January 21-24 2027, Fontainebleau Miami Beach, Miami Beach FL (pre-meeting workshops Jan 21).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "AAHS/ASPN/ASRM 2027 Joint Annual Meetings",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-26",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "hand surgery / peripheral nerve / reconstructive microsurgery",
  "notes": "Joint 2027 annual meetings of AAHS (American Association for Hand Surgery), ASPN (American Society for Peripheral Nerve) and ASRM (American Society for Reconstructive Microsurgery), January 26-30 2027, JW Marriott Miami Turnberry, Aventura FL. Source: AAHS official industry prospectus (organizer-owned PDF, verified 2026-09-18). [2026-09-27 link audit] Prior handsurgery.org file-delivery URL proved unreachable (repeated browser + fetch failures; earlier \"re-verified\" claim was a bad check and has been struck); replaced with the organizer's official 2027 annual meeting site (meeting.handsurgery.org, verified loading 2026-09-27). Joint meeting Jan 26-30, 2027, JW Marriott Miami Turnberry, Aventura, Florida (per the organizer's 2027 industry prospectus).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://meeting.handsurgery.org",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0387",
  "guidance_detail": "Joint 2027 annual meetings of AAHS (American Association for Hand Surgery), ASPN (American Society for Peripheral Nerve) and ASRM (American Society for Reconstructive Microsurgery), January 26-30 2027, JW Marriott Miami Turnberry, Aventura FL.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "organizer_dates_printed": true
 },
 {
  "as_of": "2026-09-18",
  "company": "SCCM 2027 Critical Care Congress (Society of Critical Care Medicine)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-14",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "critical care / intensive care",
  "notes": "2027 Critical Care Congress, March 14-16 2027, San Diego Convention Center, San Diego CA (pre-Congress educational programming March 12-13). Source: SCCM official 2027 Congress page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.sccm.org/annual-congress/critical-care-conference/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0388",
  "guidance_detail": "2027 Critical Care Congress, March 14-16 2027, San Diego Convention Center, San Diego CA (pre-Congress educational programming March 12-13).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "ESH 2027 International Conference on Acute Myeloid Leukemia (8th, 'Molecular and Translational')",
  "competitors": null,
  "country": "Portugal",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-04",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "acute myeloid leukemia (AML)",
  "notes": "ESH 8th International Conference on Acute Myeloid Leukemia 'Molecular and Translational': Advances in Biology and Treatment, October 4-6 2027, Estoril Congress Centre, Estoril, Portugal (registration & abstract submission open). Source: ESH official conference page (organizer-owned, verified 2026-09-18). [2026-09-27 link audit] Canonical https://esh.org/... URL re-verified live; confirms Oct 4-6, 2027, Estoril (registration & abstracts open).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://esh.org/conference/8th-international-conference-acute-myeloid-leukemia-molecular-and-translational-advances-in-biology-and-treatment/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0389",
  "guidance_detail": "ESH 8th International Conference on Acute Myeloid Leukemia 'Molecular and Translational': Advances in Biology and Treatment, October 4-6 2027, Estoril Congress Centre, Estoril, Portugal (registration & abstract submission open).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "ESICM LIVES 2027 (40th Annual Congress)",
  "competitors": null,
  "country": "Denmark",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-25",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "intensive care / critical care",
  "notes": "ESICM 40th Annual Congress (LIVES 2027), Copenhagen, starting September 25 2027 ('Save the dates!'; end date not yet published by organizer). Source: ESICM official events calendar (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.esicm.org/accueil-v2/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0390",
  "guidance_detail": "ESICM 40th Annual Congress (LIVES 2027), Copenhagen, starting September 25 2027 ('Save the dates!'; end date not yet published by organizer).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ESPCI 2027 (18th European Symposium on Pediatric Cochlear Implantation)",
  "competitors": null,
  "country": "Croatia",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-26",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "pediatric cochlear implantation / hearing loss",
  "notes": "18th European Symposium on Pediatric Cochlear Implantation, May 26-29 2027, Valamar Meeting & Events, Dubrovnik, Croatia (hosted by Croatian Society for Cochlear Implantation). Source: official ESPCI 2027 save-the-date flyer PDF (organizer-issued, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.espci2027.org/resources/uploads/sites/196/2026/04/ESPCI-2027-Digital-flyer.pdf",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0391",
  "guidance_detail": "18th European Symposium on Pediatric Cochlear Implantation, May 26-29 2027, Valamar Meeting & Events, Dubrovnik, Croatia (hosted by Croatian Society for Cochlear Implantation).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "SNMMI 2027 Annual Meeting (Society of Nuclear Medicine and Molecular Imaging)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-05",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "nuclear medicine / molecular imaging / theranostics",
  "notes": "SNMMI 2027 Annual Meeting, June 5-8 2027, Walter E. Washington Convention Center, Washington, DC. Source: SNMMI official annual meeting page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://snmmi.org/AM",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0392",
  "guidance_detail": "SNMMI 2027 Annual Meeting, June 5-8 2027, Walter E.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ECTES 2027 (26th European Congress of Trauma and Emergency Surgery)",
  "competitors": null,
  "country": "Switzerland",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-25",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "trauma and emergency surgery",
  "notes": "26th European Congress of Trauma and Emergency Surgery (ECTES 2027), April 25-27 2027, Zurich, Switzerland. PROVENANCE: organizer-issued save-the-date mailing from the official congress PCO (Conventus) plus corroboration from official ESTES society LinkedIn announcement and German Society for Surgery (DGCH) announcement PDF. The direct estes-congress.org registration page confirms the 2027 Zurich event but does not yet expose dates. Recorded as organizer-confirmed per PCO-issued announcement; flagged for the audit.\n[2026-09-23 conference re-source] URL unchanged: dedicated congress site now prints 2027 dates live (previous crawl was stale 2026 content); date confirmed hard.\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://estes-congress.org",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0393",
  "guidance_detail": "26th European Congress of Trauma and Emergency Surgery (ECTES 2027), April 25-27 2027, Zurich, Switzerland.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "FIGO 2027 World Congress (XXVI, International Federation of Gynecology and Obstetrics)",
  "competitors": [],
  "country": "Canada",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-31",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Women's health / OBGYN",
  "notes": "Montreal, Canada (Palais des Congres de Montreal / Montreal Convention Centre), Oct 31-Nov 5 2027; world's largest OBGYN meeting (~8,000 specialists), gynecologic cancer and women's-health research. Official FIGO prospectus on congress.figo.org lists '31 October - 5 November | Congress onsite dates' as key dates.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://congress.figo.org/wp-content/uploads/2026/04/FIGO-2027-Preliminary-Prospectus-V4_TB.pdf",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0394",
  "guidance_detail": "Montreal, Canada (Palais des Congres de Montreal / Montreal Convention Centre), Oct 31-Nov 5 2027; world's largest OBGYN meeting (~8,000 specialists), gynecologic cancer and women's-health research.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Women's Health",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "APA Annual Meeting 2027 (American Psychiatric Association)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-01",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Psychiatry / mental health",
  "notes": "New York City, NY, May 1-5 2027; theme 'Our Future: End Stigma, Advance Science, Secure Parity.' ~9,000 psychiatrists; CNS/psychedelic pipeline abstracts. Organizer psychiatry.org submission guidelines confirm dates and location.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.psychiatry.org/psychiatrists/education/meeting-submission-and-guidelines/annual-meeting-submission-guidelines",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0395",
  "guidance_detail": "New York City, NY, May 1-5 2027; theme 'Our Future: End Stigma, Advance Science, Secure Parity.' ~9,000 psychiatrists; CNS/psychedelic pipeline abstracts.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "EAPCI Congress 2027 (European Association of Percutaneous Cardiovascular Interventions)",
  "competitors": [],
  "country": "Italy",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-18",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Interventional cardiology",
  "notes": "Milan, Italy (Allianz MiCO), Feb 18-20 2027; ESC family interventional cardiology congress, expanded from Summit to Congress format. ESC registration page directly lists 'EAPCI 2027, Milan, 18-20 February.'",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses/eapci-congress/registration/",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0396",
  "guidance_detail": "Milan, Italy (Allianz MiCO), Feb 18-20 2027; ESC family interventional cardiology congress, expanded from Summit to Congress format.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "EAES 2027 (35th International Congress of the European Association for Endoscopic Surgery)",
  "competitors": [],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-15",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Surgery (endoscopic/minimally invasive)",
  "notes": "Dusseldorf, Germany (CCD Congress Center), Jun 15-18 2027; flagship EAES annual congress (1,500-2,000 attendees), minimally invasive surgery. Organizer eaes.eu events calendar directly lists '15 - 18 June 2027, 35th international EAES congress, Dusseldorf, Germany.'",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://eaes.eu/events-calendar/",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0397",
  "guidance_detail": "Dusseldorf, Germany (CCD Congress Center), Jun 15-18 2027; flagship EAES annual congress (1,500-2,000 attendees), minimally invasive surgery.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "SLEEP 2027 (41st Annual Meeting of the Associated Professional Sleep Societies)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-06",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Sleep medicine / sleep and circadian science",
  "notes": "Denver, CO (Colorado Convention Center), Jun 6-9 2027; general session Jun 6-9 (postgraduate courses Jun 5-6). Joint venture of AASM and Sleep Research Society; ~5,000 sleep physicians/scientists; sleep-apnea therapy abstracts. Organizer aasm.org event page directly confirms dates and Denver location.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://aasm.org/event/sleep-2027/",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0398",
  "guidance_detail": "Denver, CO (Colorado Convention Center), Jun 6-9 2027; general session Jun 6-9 (postgraduate courses Jun 5-6).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "PAINWeek 2027 (21st Annual Conference)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-07",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Pain management",
  "notes": "Las Vegas, NV (The Cosmopolitan), Sep 7-10 2027; largest US pain management conference (~2,300 practitioners); analgesic/non-opioid pipeline abstracts. Organizer conference.painweek.org directly lists 'September 7-10, 2027 | The Cosmopolitan of Las Vegas.'\n[2026-09-23 conference re-source] URL unchanged: dedicated conference site prints the 2027 dates; date confirmed hard.\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://conference.painweek.org/",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0399",
  "guidance_detail": "Las Vegas, NV (The Cosmopolitan), Sep 7-10 2027; largest US pain management conference (~2,300 practitioners); analgesic/non-opioid pipeline abstracts.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "AAGP 2027 Annual Meeting (American Association for Geriatric Psychiatry)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-16",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Geriatric psychiatry / CNS",
  "notes": "San Diego, CA (Sheraton San Diego Hotel & Marina), Apr 15-19 2027; theme 'Connecting and Collaborating to Advance Geriatric Mental Health.' Conflict: AAGP organizer location page says April 15-19; organizer prospectus PDF says April 16-20. Start 2027-04-15 used per primary location page.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://aagponline.org/annual-meeting-location/",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0400",
  "guidance_detail": "San Diego, CA (Sheraton San Diego Hotel & Marina), Apr 15-19 2027; theme 'Connecting and Collaborating to Advance Geriatric Mental Health.' Conflict: AAGP organizer location page says April 15-19; organizer prospectus PDF says April 16-20.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "AMSSM 2027 Annual Meeting (American Medical Society for Sports Medicine)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-16",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Sports medicine / musculoskeletal",
  "notes": "Louisville, KY, Apr 16-21 2027; ~2,700 sports medicine physicians, non-surgical musculoskeletal medicine. Organizer amssm.org conferences page directly lists '2027 AMSSM Annual Meeting, Apr 16 - Apr 21, 2027, Louisville, KY.'",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.amssm.org/Conferences.php",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0401",
  "guidance_detail": "Louisville, KY, Apr 16-21 2027; ~2,700 sports medicine physicians, non-surgical musculoskeletal medicine.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "EFIC Congress 2027 (15th Congress of the European Pain Federation)",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-21",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "Pain",
  "notes": "Glasgow, Scotland, Apr 21-23 2027; European Pain Federation biennial congress (European chapter of IASP). IASP's official upcoming-events listing on iasp-pain.org gives '15th Congress of the European Pain Federation EFIC, Glasgow, Scotland, 21-23 April 2027.'",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.iasp-pain.org/upcoming-events/list/?posts_per_page=29",
  "ticker": "",
  "us_listed": null,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0402",
  "guidance_detail": "Glasgow, Scotland, Apr 21-23 2027; European Pain Federation biennial congress (European chapter of IASP).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "PainConnect 2027 (AAPM Annual Meeting)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-18",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "American Academy of Pain Medicine annual meeting; organizer states PainConnect 2027 takes place March 18-21, 2027 at Hyatt Regency Grand Cypress Resort, Orlando, FL. Distinct conference from ERS Lung Science Conference 2027 (European Respiratory Society) (separate event, separate organizer); shares only the start date 2027-03-18 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://painconnect.org/registration/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0403",
  "guidance_detail": "American Academy of Pain Medicine annual meeting; organizer states PainConnect 2027 takes place March 18-21, 2027 at Hyatt Regency Grand Cypress Resort, Orlando, FL.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ANESTHESIOLOGY 2027 (ASA Annual Meeting)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-15",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "American Society of Anesthesiologists annual meeting; ASA Future Dates page lists October 15-19, 2027, Boston, MA. Distinct conference from ASBMR 2027 Annual Meeting (separate event, separate organizer); shares only the start date 2027-10-15 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://asahq.org/annualmeeting/attend/futuredates",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0404",
  "guidance_detail": "American Society of Anesthesiologists annual meeting; ASA Future Dates page lists October 15-19, 2027, Boston, MA.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ASRA 52nd Annual Regional Anesthesiology and Acute Pain Medicine Meeting 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-13",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "ASRA Pain Medicine spring meeting; organizer event page lists May 13-15, 2027, Marriott Marquis Houston, Houston, TX. Distinct conference from Heart Rhythm 2027 (Heart Rhythm Society Annual Meeting) (separate event, separate organizer); shares only the start date 2027-05-13 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://asra.com/events-education/annual-meetings/2027/05/13/events/52nd-annual-regional-anesthesiology-and-acute-pain-medicine-meeting",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0405",
  "guidance_detail": "ASRA Pain Medicine spring meeting; organizer event page lists May 13-15, 2027, Marriott Marquis Houston, Houston, TX.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASRA 26th Annual Pain Medicine Meeting 2027",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-18",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "ASRA Pain Medicine fall meeting; organizer news article states it will be held November 18-20, 2027, in Atlanta, GA.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://asra.com/news-publications/asra-update-item/asra-updates/2026/08/07/dr.-ryan-s.-d-souza-receives-presidential-scholar-award",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0406",
  "guidance_detail": "ASRA Pain Medicine fall meeting; organizer news article states it will be held November 18-20, 2027, in Atlanta, GA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "NCS 25th Annual Meeting 2027 (Neurocritical Care Society)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-27",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "Neurocritical Care Society 25th Annual Meeting; organizer future-meetings page lists September 27-30, 2027, Hyatt Regency New Orleans, New Orleans, LA.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.neurocriticalcare.org/Events/Annual-Meeting/Past-Future-Annual-Meetings",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0407",
  "guidance_detail": "Neurocritical Care Society 25th Annual Meeting; organizer future-meetings page lists September 27-30, 2027, Hyatt Regency New Orleans, New Orleans, LA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "EFORT 2027 (28th Annual Congress, European Federation of Orthopaedics and Traumatology)",
  "competitors": [],
  "country": "Greece",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-19",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "28th EFORT Annual Congress; organizer congress site states it will be held at the Megaron Athens International Conference Centre, Athens, Greece, from Wednesday 19 to Friday 21 May 2027.\n[2026-09-23 conference re-source] Re-sourced from congress.efort.org homepage-path URL form to verified dedicated congress site; date confirmed hard. (Congress is Athens, Greece \u2014 Montpellier reference in earlier evidence was an unrelated events-calendar item.)\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://congress.efort.org/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0408",
  "guidance_detail": "28th EFORT Annual Congress; organizer congress site states it will be held at the Megaron Athens International Conference Centre, Athens, Greece, from Wednesday 19 to Friday 21 May 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "17th EHS Congress 2027 (European Hip Society)",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-07",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "European Hip Society president's welcome confirms 17th EHS Congress in London on 7-8 October 2027; membership page adds venue Olympia, London/Kensington.\n[2026-09-23 conference re-source] Re-sourced to dated organizer calendar page; row clarified as European Hip Society (vs. Hernia Society) in notes; date confirmed hard.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://europeanhipsociety.com/hip-calendar/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0409",
  "guidance_detail": "European Hip Society president's welcome confirms 17th EHS Congress in London on 7-8 October 2027; membership page adds venue Olympia, London/Kensington.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "World Arthroplasty Congress 2027 (5th)",
  "competitors": [],
  "country": "Belgium",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-22",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "World Arthroplasty Congress 2027 (5th), April 22-23 2027; Brussels, Belgium. Corroborated: European Hip Society scientific calendar (co-organizing society) + Union of International Associations directory (lists organizer European Knee Society). UIA: https://uia.org/icco/search?eventcity=S%C3%A9tif&page=40 (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://europeanhipsociety.com/hip-calendar/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0410",
  "guidance_detail": "World Arthroplasty Congress 2027 (5th), April 22-23 2027; Brussels, Belgium.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ISHA 2027 Annual Scientific Meeting (19th, Hip Preservation Society)",
  "competitors": [],
  "country": "Canada",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-16",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "ISHA \u2013 The Hip Preservation Society; organizer announcement states dates changed to 16-18 September 2027, Ottawa, Canada (19th Annual Scientific Meeting).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.ishasoc.net/isha-2027-annual-scientific-meeting-host-destination-announced/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0411",
  "guidance_detail": "ISHA \u2013 The Hip Preservation Society; organizer announcement states dates changed to 16-18 September 2027, Ottawa, Canada (19th Annual Scientific Meeting).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "EURETINA 27th Congress 2027",
  "competitors": [],
  "country": "Denmark",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-16",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "27th EURETINA Congress; organizer future-meetings page lists 16-19 September 2027, Bella Center, Copenhagen, Denmark. Distinct conference from ISHA 2027 Annual Scientific Meeting (19th, Hip Preservation Society) (separate event, separate organizer); shares only the start date 2027-09-16 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://euretina.org/future-meetings/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0412",
  "guidance_detail": "27th EURETINA Congress; organizer future-meetings page lists 16-19 September 2027, Bella Center, Copenhagen, Denmark.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "EURETINA Special Focus Meeting 2027 - Inherited Retinal Diseases",
  "competitors": [],
  "country": "Slovenia",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-26",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "EURETINA Special Focus Meeting 2027 - Inherited Retinal Diseases; organizer future-meetings page lists 26-27 February 2027, Ljubljana, Slovenia.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://euretina.org/future-meetings/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0413",
  "guidance_detail": "EURETINA Special Focus Meeting 2027 - Inherited Retinal Diseases; organizer future-meetings page lists 26-27 February 2027, Ljubljana, Slovenia.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "APSR 31st Congress 2027 (Asian Pacific Society of Respirology)",
  "competitors": [],
  "country": "Indonesia",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-04",
  "date_quality": "hard",
  "drug": "",
  "event_type": "conference",
  "indication": "",
  "notes": "Asian Pacific Society of Respirology 31st Congress; organizer congress page lists 4-7 November 2027, Bali, Indonesia.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://apsr.org/events/congress/",
  "ticker": "",
  "us_listed": false,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0415",
  "guidance_detail": "Asian Pacific Society of Respirology 31st Congress; organizer congress page lists 4-7 November 2027, Bali, Indonesia.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ESICM Intensive Care Innovation 2027",
  "competitors": null,
  "country": "Italy",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-04",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "critical care / intensive care medicine",
  "notes": "Intensive Care Innovation, February 4-5 2027; Humanitas Congress Center, Rozzano (Milan), Italy. ESICM event on the future of intensive care (AI, precision medicine, emerging ICU technologies). Source: ESICM official event page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.esicm.org/events/intensive-care-innovation2027/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0416",
  "guidance_detail": "Intensive Care Innovation, February 4-5 2027; Humanitas Congress Center, Rozzano (Milan), Italy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ESICM LIVES Physiology-Transbiology 2027",
  "competitors": null,
  "country": "Greece",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-03",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "critical care physiology / translational intensive care",
  "notes": "LIVES Physiology-Transbiology, June 3-5 2027; Athens, Greece. ESICM specialty meeting (physiology to translational ICU research). Source: ESICM official events calendar (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.esicm.org/congresses-events/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0417",
  "guidance_detail": "LIVES Physiology-Transbiology, June 3-5 2027; Athens, Greece.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Sleep Medicine Trends 2027 (AASM)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-05",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "sleep disorders / sleep medicine",
  "notes": "Sleep Medicine Trends 2027, February 5-7 2027; M Resort, Spa and Casino, Henderson, Nevada. AASM meeting on emerging technologies and innovations in clinical sleep medicine. Source: AASM official event page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://aasm.org/event/sleep-medicine-trends-2027/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0418",
  "guidance_detail": "Sleep Medicine Trends 2027, February 5-7 2027; M Resort, Spa and Casino, Henderson, Nevada.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "AADOCR/CADR Annual Meeting & Exhibition 2027",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-17",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "dental, oral and craniofacial research",
  "notes": "56th AADOCR / 51st CADR Annual Meeting & Exhibition, March 17-20 2027; Minneapolis, Minnesota. Premier dental, oral and craniofacial research meeting. Source: AADOCR official meeting page (organizer-owned, verified 2026-09-18). [2026-09-23 source check] Source unreachable from this network (TLS handshake timeout on both passes \u2014 not confirmed dead); organizer content seen live in search-index crawls within the last 14 days. Flagged for browser re-check.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "http://www.aadocr.org/2027aaam",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0419",
  "guidance_detail": "56th AADOCR / 51st CADR Annual Meeting & Exhibition, March 17-20 2027; Minneapolis, Minnesota.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Euretina Innovation Spotlight (EIS) 2027",
  "competitors": null,
  "country": "Denmark",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-15",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "retinal diseases / ophthalmology innovation",
  "notes": "Euretina Innovation Spotlight (EIS), 15 September 2027; Bella Center, Copenhagen, Denmark. Pre-congress innovation session adjacent to the 27th Euretina Congress (16-19 Sept 2027). Source: Euretina official future-meetings page (organizer-owned, verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://euretina.org/future-meetings/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0420",
  "guidance_detail": "Euretina Innovation Spotlight (EIS), 15 September 2027; Bella Center, Copenhagen, Denmark.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "2027 CREOG & APGO Annual Meeting (CAAM)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-24",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "obstetrics & gynecology medical education",
  "notes": "2027 CREOG & APGO Annual Meeting (CAAM), February 24-27, 2027, Denver, Colorado. Joint annual meeting of the Council on Resident Education in Obstetrics and Gynecology (CREOG) and the Association of Professors of Gynecology & Obstetrics (APGO); theme: Fostering Inspiration - Equipping and Empowering Medical Educators in OB/GYN. Source: ACOG organizer-owned meeting page (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.acog.org/education-and-events/meetings/creog-apgo-annual-meeting",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0421",
  "guidance_detail": "2027 CREOG & APGO Annual Meeting (CAAM), February 24-27, 2027, Denver, Colorado.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Women's Health",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ASPAN 46th Annual National Conference 2027 (American Society of PeriAnesthesia Nurses)",
  "competitors": null,
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-30",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "perianesthesia nursing",
  "notes": "ASPAN 46th Annual National Conference, April 30 - May 3, 2027, Sheraton New Orleans, New Orleans, Louisiana. Annual national conference of the American Society of PeriAnesthesia Nurses covering perianesthesia clinical care, pediatric advancements, emerging research, medication and safety updates. Source: ASPAN organizer-owned 2027 National Conference page and 2027 Call for Abstracts page (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.aspan.org/Education-Events/2027-ASPAN-National-Conference",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0422",
  "guidance_detail": "ASPAN 46th Annual National Conference, April 30 - May 3, 2027, Sheraton New Orleans, New Orleans, Louisiana.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "EuretinAI 2027 (EuretinaAI: AI in Retina)",
  "competitors": null,
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-09",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "retina / ophthalmology artificial intelligence",
  "notes": "EuretinAI 2027 (EuretinaAI: AI in Retina), April 9-10, 2027, London, UK. Euretina dedicated meeting on artificial intelligence in retina care, research and clinical practice. Source: Euretina organizer-owned About/EuretinaAI page (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://euretina.org/euretinai-2027/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0423",
  "guidance_detail": "EuretinAI 2027 (EuretinaAI: AI in Retina), April 9-10, 2027, London, UK.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "APHRS Summit 2027 (Asia Pacific Heart Rhythm Society)",
  "competitors": null,
  "country": "China",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-20",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "cardiac electrophysiology / heart rhythm disorders",
  "notes": "APHRS Summit 2027, Saturday, February 20, 2027, Shenzhen, China, held in conjunction with CardioRhythm 2027. Single-day summit of the Asia Pacific Heart Rhythm Society. Flagship APHRS 2027 Scientific Session (Taipei) dates not yet announced; not included. Source: APHRS organizer-owned Upcoming Meetings page (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.aphrs.org/22-meetings/meeting/495-aphrs-2027-taipei",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0424",
  "guidance_detail": "APHRS Summit 2027, Saturday, February 20, 2027, Shenzhen, China, held in conjunction with CardioRhythm 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ESC Acute Cardiovascular Care 2027",
  "competitors": null,
  "country": "Spain",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-19",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "acute cardiovascular care",
  "notes": "ESC Acute Cardiovascular Care 2027, March 19-20, 2027, Seville, Spain. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses/acute-cardiovascular-care/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0425",
  "guidance_detail": "ESC Acute Cardiovascular Care 2027, March 19-20, 2027, Seville, Spain.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "EHRA 2027 (European Heart Rhythm Association Congress)",
  "competitors": null,
  "country": "Finland",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "cardiac electrophysiology / arrhythmias",
  "notes": "EHRA 2027 (European Heart Rhythm Association Congress), April 11-13, 2027, Helsinki, Finland. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses/ehra-congress/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0426",
  "guidance_detail": "EHRA 2027 (European Heart Rhythm Association Congress), April 11-13, 2027, Helsinki, Finland.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ESC Preventive Cardiology 2027",
  "competitors": null,
  "country": "Portugal",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-15",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "preventive cardiology",
  "notes": "ESC Preventive Cardiology 2027, April 15-17, 2027, Lisbon, Portugal. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses/esc-preventive-cardiology/",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0427",
  "guidance_detail": "ESC Preventive Cardiology 2027, April 15-17, 2027, Lisbon, Portugal.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Heart Failure 2027 (HFA-ESC Congress)",
  "competitors": null,
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-22",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "heart failure",
  "notes": "Heart Failure 2027 (HFA-ESC Congress), May 22-25, 2027, London, UK. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0428",
  "guidance_detail": "Heart Failure 2027 (HFA-ESC Congress), May 22-25, 2027, London, UK.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ESC Cardio-Oncology 2027",
  "competitors": null,
  "country": "Portugal",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-04",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "cardio-oncology",
  "notes": "ESC Cardio-Oncology 2027, June 4-5, 2027, Porto, Portugal. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0429",
  "guidance_detail": "ESC Cardio-Oncology 2027, June 4-5, 2027, Porto, Portugal.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ACNAP 2027 (Association of Cardiovascular Nursing & Allied Professions Congress)",
  "competitors": null,
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-11",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": "cardiovascular nursing / allied professions",
  "notes": "ACNAP 2027 (Association of Cardiovascular Nursing & Allied Professions Congress), June 11-12, 2027, Sophia Antipolis, France. Source: ESC organizer-owned congresses-events portal (explicit date ranges) corroborated by ESC 'Upcoming congresses' overview, esCardio.org (verified 2026-09-18).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://www.escardio.org/events/congresses",
  "ticker": null,
  "us_listed": null,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0430",
  "guidance_detail": "ACNAP 2027 (Association of Cardiovascular Nursing & Allied Professions Congress), June 11-12, 2027, Sophia Antipolis, France.",
  "audit_status": "v17_reverified",
  "audit_action": "source-repair",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-20",
  "company": "ImmunityBio, Inc.",
  "competitors": [
   "CGON (cretostimogene)",
   "Zusduri (UroGen)",
   "MRK (Keytruda)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-06",
  "date_quality": "hard",
  "drug": "ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG",
  "event_type": "pdufa",
  "indication": "BCG-unresponsive non-muscle invasive bladder cancer with papillary disease (no CIS)",
  "notes": "FDA accepted the sBLA for ANKTIVA + BCG in papillary NMIBC; PDUFA date 2027-01-06. sBLA seeks extrapolation from CIS cohort data (QUILT-3.032 Cohort A) to papillary-only disease.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260519760562/en/ImmunityBio-Announces-FDA-Acceptance-of-Supplemental-BLA-for-ANKTIVA-Plus-BCG-in-BCG-Unresponsive-Non-Muscle-Invasive-Bladder-Cancer-with-Papillary-Disease-PDUFA-Date-Set-for-January-6-2027",
  "ticker": "IBRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0431",
  "guidance_detail": "FDA accepted the sBLA for ANKTIVA + BCG in papillary NMIBC; PDUFA date 2027-01-06.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "why_it_matters": "The FDA's decision date on ANKTIVA (nogapendekin alfa inbakicept-pmln) + BCG for BCG-unresponsive non-muscle invasive bladder cancer with papillary disease (no CIS) falls on 2027-01-06 \u2014 the agency's yes-or-no moment for ImmunityBio, Inc.'s application."
 },
 {
  "as_of": "2026-09-24",
  "company": "PolarityBio, Inc.",
  "competitors": [
   "Apligraf (Organogenesis)",
   "EpiFix (MiMedx)",
   "Santyl (Smith+Nephew)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-16",
  "date_quality": "hard",
  "drug": "SkinTE (autologous cutaneous multicellular units)",
  "event_type": "pdufa",
  "indication": "Wagner Grade 1 diabetic foot ulcers",
  "notes": "Private company; no public ticker. FDA accepted SkinTE BLA for Wagner Grade 1 diabetic foot ulcers with Priority Review (Sep 15, 2026); PDUFA target action date March 16, 2027. RMAT and Breakthrough designations.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.polaritybio.com/news/fda-accepts-skinte-bla-priority-review",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0432",
  "guidance_detail": "Private company; no public ticker.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "unknown",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on SkinTE (autologous cutaneous multicellular units) for Wagner Grade 1 diabetic foot ulcers falls on 2027-03-16 \u2014 the agency's yes-or-no moment for PolarityBio, Inc.'s application."
 },
 {
  "as_of": "2026-09-24",
  "company": "Merck & Co., Inc.",
  "competitors": [
   "SNY (Beyfortus)",
   "PFE (Abrysvo)",
   "Beyfortus (AstraZeneca/Sanofi)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-22",
  "date_quality": "hard",
  "drug": "ENFLONSIA (clesrovimab)",
  "event_type": "pdufa",
  "indication": "RSV lower respiratory tract disease prevention, children <2 yrs at increased risk, second season",
  "notes": "FDA accepted the sBLA for ENFLONSIA (clesrovimab); target action date 2027-03-22. sBLA supported by Phase 3 SMART trial; would add second-season dosing for high-risk infants.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://s2.q4cdn.com/584635680/files/doc_news/U-S--FDA-Accepts-sBLA-for-ENFLONSIA-clesrovimab-cfor-to-Update-its-Respiratory-Syncytial-Virus-RSV-Lower-Respiratory-Tract-Disease-In-S7UWZ.pdf",
  "ticker": "MRK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0433",
  "guidance_detail": "FDA accepted the sBLA for ENFLONSIA (clesrovimab); target action date 2027-03-22.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Sedana Medical AB",
  "competitors": [
   "PFE (Precedex)"
  ],
  "country": "Sweden",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-16",
  "date_quality": "hard",
  "drug": "Isoflurane via Sedana Medical ACD Delivery System",
  "event_type": "pdufa",
  "indication": "Sedation of mechanically ventilated adult ICU patients",
  "notes": "FDA accepted the isoflurane NDA filing (announced Aug 19, 2026); FDA set PDUFA target action date 2027-04-16 (company regulatory release Aug 31, 2026). Sedana Medical announced a PDUFA target action date of 2027-04-16 for its US NDA. Listed on Nasdaq Stockholm, not US-listed; no US ticker. Would be first US inhaled ICU sedation therapy.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.inderes.se/en/releases/sedana-medical-announces-pdufa-target-action-date-for-its-new-drug-application-in-the-us",
  "ticker": "SEDANA",
  "us_listed": true,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0434",
  "guidance_detail": "FDA accepted the isoflurane NDA filing (announced Aug 19, 2026); FDA set PDUFA target action date 2027-04-16 (company regulatory release Aug 31, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "source-repair",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-27",
  "why_it_matters": "The FDA's decision date on Isoflurane via Sedana Medical ACD Delivery System for Sedation of mechanically ventilated adult ICU patients falls on 2027-04-16 \u2014 the agency's yes-or-no moment for Sedana Medical AB's application."
 },
 {
  "as_of": "2026-09-24",
  "company": "Kowa Pharmaceuticals America, Inc.",
  "competitors": [
   "ABBV (Lumigan)",
   "ALC (Rocklatan)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-30",
  "date_quality": "hard",
  "drug": "K-911 (bimatoprost grenod / NCX 470)",
  "event_type": "pdufa",
  "indication": "Open-angle glaucoma / ocular hypertension (IOP lowering)",
  "notes": "FDA accepted the NDA for K-911 (bimatoprost grenod); PDUFA action date 2027-04-30. Parent Kowa Company (Japan) not US-listed; no US ticker. NO-donating bimatoprost; NDA supported by two Phase 3 trials. [Source verified 2026-09-20: The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of April 30, 2027.]",
  "phase": null,
  "source_type": "company IR",
  "source_url": "https://www.kowapharma.com/newsroom/kowa-pharmaceuticals-america-fda-acceptance-k-911",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0435",
  "guidance_detail": "FDA accepted the NDA for K-911 (bimatoprost grenod); PDUFA action date 2027-04-30.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on K-911 (bimatoprost grenod / NCX 470) for Open-angle glaucoma / ocular hypertension (IOP lowering) falls on 2027-04-30 \u2014 the agency's yes-or-no moment for Kowa Pharmaceuticals America, Inc.'s application."
 },
 {
  "as_of": "2026-10-01",
  "company": "Achieve Life Sciences, Inc.",
  "competitors": [
   "PFE (Chantix)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Cytisinicline",
  "event_type": "regulatory_other",
  "indication": "Nicotine dependence (smoking cessation)",
  "notes": "CRL was manufacturing-only; company plans NDA resubmission Q4 2026 with potential approval H1 2027.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/22/3315277/0/en/Achieve-Life-Sciences-Receives-Complete-Response-Letter-from-FDA-for-Cytisinicline-NDA.html",
  "ticker": "ACHV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0436",
  "guidance_detail": "CRL was manufacturing-only; company plans NDA resubmission Q4 2026 with potential approval H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Achieve Life Sciences plans to resubmit its NDA for cytisinicline in smoking cessation in Q4 2026, with potential approval in the first half of 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Abivax SA",
  "competitors": [
   "ABBV (risankizumab)",
   "JNJ (ustekinumab)",
   "Takeda (vedolizumab)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "obefazimod (ABX464)",
  "event_type": "readout",
  "indication": "Crohn's disease (moderately to severely active)",
  "notes": "Phase 2b ENHANCE-CD induction trial; company guides mid-2027 (Q2/Q3 boundary).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/29/3319283/0/en/abivax-reports-positive-abtect-maintenance-part-2-results-for-obefazimod-demonstrating-meaningful-clinical-benefit-in-refractory-ulcerative-colitis-patients-and-strengthening-the-p.html",
  "ticker": "ABVX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0437",
  "guidance_detail": "Phase 2b ENHANCE-CD induction trial; company guides mid-2027 (Q2/Q3 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "ACADIA Pharmaceuticals Inc.",
  "competitors": [
   "AXSM (AXS-05)",
   "JNJ (esketamine)",
   "Sage Therapeutics (zuranolone)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ACP-211 (deuterated R-norketamine)",
  "event_type": "readout",
  "indication": "Major depressive disorder",
  "notes": "Phase 2 study in MDD initiated Q4 2025; company guides topline results sometime between Q2 and Q3 2027 (Q2/Q3 boundary). Per 2025 10-K.",
  "phase": "2",
  "source_type": "SEC 10-K",
  "source_url": "https://stocklight.com/stocks/us/nasdaq-acad/acadia-pharmaceuticals/annual-reports/nasdaq-acad-2026-10K-26681011.pdf",
  "ticker": "ACAD",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0438",
  "guidance_detail": "Phase 2 study in MDD initiated Q4 2025; company guides topline results sometime between Q2 and Q3 2027 (Q2/Q3 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ACP-211 (deuterated R-norketamine) in major depressive disorder are expected in Q2 2027, the first real efficacy signal for ACADIA Pharmaceuticals Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Adagene Inc.",
  "competitors": [
   "AGEN (botensilimab/balstilimab)",
   "BAYRY (regorafenib)",
   "TAK (fruquintinib)"
  ],
  "country": "China",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "muzastotug (ADG126) + pembrolizumab",
  "event_type": "readout",
  "indication": "Late-line microsatellite stable colorectal cancer without liver metastases",
  "notes": "Randomized Phase 2 trial; company guides results in 1H 2027 (FY2025 results corporate update). Partner pembrolizumab (MRK).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/adagene-reports-full-year-2025-financial-results-and-provides-corporate-update",
  "ticker": "ADAG",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0439",
  "guidance_detail": "Randomized Phase 2 trial; company guides results in 1H 2027 (FY2025 results corporate update).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0440"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for muzastotug (ADG126) + pembrolizumab in Late-line microsatellite stable colorectal cancer without liver metastases are expected in the first half of 2027, the first real efficacy signal for Adagene Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Adagene Inc.",
  "competitors": [
   "AGEN (botensilimab/balstilimab)",
   "GSK (dostarlimab)",
   "BMY (nivolumab)"
  ],
  "country": "China",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "muzastotug (ADG126) + pembrolizumab (Keytruda)",
  "event_type": "readout",
  "indication": "Neoadjuvant treatment of stage II/III colorectal cancer",
  "notes": "Investigator-initiated Phase 2 (NCT06846268); registry primary completion 2027-12-31 (NCT06846268); disclosure may slip to 2028. Initial company data was guided H2 2026. Partner pembrolizumab (MRK). [Source verified 2026-09-20: The new study (NCT06846268)... is expected to begin patient enrollment in April 2025. / Trial to begin enrolling in April; expected primary completion in mid-2027]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/02/27/3033784/0/en/Adagene-Announces-Investigator-Initiated-Phase-2-Trial-for-Neoadjuvant-Muzastotug-ADG126-in-Colorectal-Cancer.html",
  "ticker": "ADAG",
  "us_listed": true,
  "nct_id": "NCT06846268",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0440",
  "guidance_detail": "Investigator-initiated Phase 2 (NCT06846268); registry primary completion 2027-12-31 (NCT06846268); disclosure may slip to 2028.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0439"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for muzastotug (ADG126) + pembrolizumab (Keytruda) in Neoadjuvant treatment of stage II/III colorectal cancer are expected in the second half of 2027, the first real efficacy signal for Adagene Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Akebia Therapeutics, Inc.",
  "competitors": [
   "APLS (pegcetacoplan)",
   "NVS (iptacopan)",
   "VERA (atacicept)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ebribafusp (formerly AKB-097)",
  "event_type": "readout",
  "indication": "Rare kidney disease (IgA nephropathy, lupus nephritis, C3 glomerulopathy)",
  "notes": "Open-label Phase 2 basket trial (up to 30 pts, 26 wks SC dosing) initiated Aug 2026; company expects to report initial data in 2027. Asset acquired from Q32 Bio; anti-C3d factor H fusion protein. [Source verified 2026-09-20: The Phase 2 basket trial is open-label, and Akebia expects to report initial data in 2027.]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/03/3337449/37519/en/akebia-therapeutics-announces-initiation-of-a-phase-2-basket-trial-to-study-ebribafusp-a-next-generation-complement-inhibitor-in-rare-kidney-diseases.html",
  "ticker": "AKBA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0441",
  "guidance_detail": "Open-label Phase 2 basket trial (up to 30 pts, 26 wks SC dosing) initiated Aug 2026; company expects to report initial data in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for ebribafusp (formerly AKB-097) in Rare kidney disease (IgA nephropathy, lupus nephritis, C3 glomerulopathy) are expected sometime in 2027, the first real efficacy signal for Akebia Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Aligos Therapeutics, Inc.",
  "competitors": [
   "GSK (bepirovirsen)",
   "VIR (tobevibart/elebsiran)",
   "ABUS (imdusiran)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pevifoscorvir sodium",
  "event_type": "readout",
  "indication": "Chronic hepatitis B virus infection",
  "notes": "Phase 2 B-SUPREME; topline data for HBeAg- and HBeAg+ cohorts expected in 2027 (company guidance unchanged per Apr 2026 update). Re-checked 2026-09-23: Timing refined from \"2027\" to \"late third quarter of 2027\" for B-SUPREME topline data (both HBeAg+ and HBeAg- cohorts). Source: https://www.biospace.com/press-releases/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2025-financial-results. Quote: \"Topline safety and efficacy data are expected to be available in late third quarter of 2027.\".",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/aligos-therapeutics-reports-recent-business-progress-and-fourth-quarter-and-full-year-2025-financial-results",
  "ticker": "ALGS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0442",
  "guidance_detail": "Phase 2 B-SUPREME; topline data for HBeAg- and HBeAg+ cohorts expected in 2027 (company guidance unchanged per Apr 2026 update).",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027",
    "to": "2027-Q3",
    "changed": "2026-09-23",
    "why": "Timing refined from 2027 to late Q3 2027 for B-SUPREME topline (both HBeAg cohorts)"
   }
  ],
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for pevifoscorvir sodium in chronic hepatitis B virus infection are expected in Q3 2027, the first real efficacy signal for Aligos Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-20",
  "company": "Allogene Therapeutics, Inc.",
  "competitors": [
   "GILD (axicabtagene ciloleucel)",
   "BMY (lisocabtagene maraleucel)",
   "NVS (tisagenlecleucel)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "cemacabtagene ansegedleucel (cema-cel)",
  "event_type": "readout",
  "indication": "First-line consolidation in LBCL patients with minimal residual disease",
  "notes": "Pivotal Phase 2 ALPHA3 of cema-cel as 1L MRD+ LBCL consolidation; company anticipates interim EFS (primary endpoint) analysis in mid-2027 (Q2/Q3 boundary), primary EFS analysis mid-2028 (Apr 2026 company PR). Re-checked 2026-09-23: Allogene's September 2026 8-K guides only 'mid-2027' for the ALPHA3 interim EFS analysis (primary EFS analysis mid-2028). The row's 2027-Q2 bucket was over-precise; rebucketed conservatively to 2027-H2. Note the 10-Q caveat: the interim analysis is DSMB-overseen and the company 'may not announce treatment-arm-specific interim EFS results in mid-2027, and any public update may be limited' - the mid-2027 program update may be limited in depth. Source: https://www.globenewswire.com/news-release/2026/04/13/3272397/0/en/Allogene-Therapeutics-Reports-Interim-Futility-Analysis-from-Pivotal-ALPHA3-Trial-Showing-58-3-MRD-Clearance-with-Cemacabtagene-Ansegedleucel-Cema-Cel-vs-16-7-in.html. Quote: \"mid-2027\".",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/04/13/3272397/0/en/Allogene-Therapeutics-Reports-Interim-Futility-Analysis-from-Pivotal-ALPHA3-Trial-Showing-58-3-MRD-Clearance-with-Cemacabtagene-Ansegedleucel-Cema-Cel-vs-16-7-in.html",
  "ticker": "ALLO",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0443",
  "guidance_detail": "Pivotal Phase 2 ALPHA3 of cema-cel as 1L MRD+ LBCL consolidation; company anticipates interim EFS (primary endpoint) analysis in mid-2027 (Q2/Q3 boundary), primary EFS analysis mid-2028 (Apr 2026 company PR).",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q2",
    "to": "2027-H2",
    "changed": "2026-09-23",
    "why": "Allogene Sep 2026 8-K guides only mid-2027 for ALPHA3 interim EFS; Q2 was over-precise"
   }
  ],
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "why_it_matters": "Phase 2 results for cemacabtagene ansegedleucel (cema-cel) in first-line consolidation in LBCL patients with minimal residual disease are expected in the second half of 2027, the first real efficacy signal for Allogene Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "AN2 Therapeutics, Inc.",
  "competitors": [
   "PTGX (rusfertide)",
   "INCB (ruxolitinib)",
   "PharmaEssentia (ropeginterferon alfa-2b)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "epetraborole",
  "event_type": "readout",
  "indication": "Polycythemia vera (phlebotomy-dependent)",
  "notes": "Phase 2 PoC trial planned to start 3Q26; company expects periodic data readouts as early as 4Q26 and throughout 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260511281560/en/AN2-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-and-Scientific-Highlights",
  "ticker": "ANTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0444",
  "guidance_detail": "Phase 2 PoC trial planned to start 3Q26; company expects periodic data readouts as early as 4Q26 and throughout 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0445"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for epetraborole in Polycythemia vera (phlebotomy-dependent) are expected sometime in 2027, the first real efficacy signal for AN2 Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "AN2 Therapeutics, Inc.",
  "competitors": [
   "INSM (Arikayce)",
   "Paratek (omadacycline)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "epetraborole",
  "event_type": "readout",
  "indication": "M. abscessus complex lung disease",
  "notes": "Investigator-initiated Phase 2 (OHSU-led, multicenter RDBPC, screening began Mar 2026); company anticipates topline in late 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260511281560/en/AN2-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-and-Scientific-Highlights",
  "ticker": "ANTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0445",
  "guidance_detail": "Investigator-initiated Phase 2 (OHSU-led, multicenter RDBPC, screening began Mar 2026); company anticipates topline in late 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0444"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for epetraborole in M. abscessus complex lung disease are expected in the second half of 2027, the first real efficacy signal for AN2 Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "argenx SE",
  "competitors": [
   "HNSA (imlifidase)",
   "IMVT (batoclimab)",
   "JNJ (nipocalimab)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "efgartigimod",
  "event_type": "readout",
  "indication": "Antibody-mediated rejection (AMR) after kidney transplantation",
  "notes": "Global Phase 2 proof-of-concept (NCT06503731, ARGX-113-2302); estimated primary completion Nov 2027 (registry last verified May 1, 2026). Readout inferred from completion; company 2025 strategic priorities also guided AMR PoC topline in 2027. [V17 audit 2026-09-23: argenx Jan 2025 outlook guides \"AMR in 2027\" (year-level, no half); quality upgraded inferred->guidance, bucket firmed to 2027.] Re-checked 2026-09-23: ARGX efgartigimod AMR (kidney transplant). Jan 2025 strategic outlook guided \"AMR in 2027\". Phase 2 study (NCT06503731) primary completion Nov 2027. Not mentioned in H1 2026 registrational readout outlook (which focused on registrational studies). Revised to reflect Phase 2 status and late-2027 trial completion timeline; 2027 readout contingent on data availability. Bucket kept at 2027. Source: https://clinicaltrials.gov/study/NCT06503731. Quote: \"Primary Completion (Estimated), 2027-11\".",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06503731",
  "ticker": "ARGX",
  "us_listed": true,
  "nct_id": "NCT06503731",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0446",
  "guidance_detail": "Company-guided 2027 topline (argenx strategic outlook Jan 2025: \"AMR in 2027\").",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v17-0042",
   "v16-0015"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Arcturus Therapeutics Holdings Inc.",
  "competitors": [
   "VRTX (VX-522, Trikafta)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ARCT-032",
  "event_type": "readout",
  "indication": "Cystic fibrosis (Class I / not eligible for CFTR modulators)",
  "notes": "Phase 2 open-label multiple-ascending-dose study (NCT06747858); estimated primary completion Jun 2027 (registry last verified May 1, 2026). Readout inferred from completion; company guided initiation of the 12-week cohort in H1 2026.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06747858",
  "ticker": "ARCT",
  "us_listed": true,
  "nct_id": "NCT06747858",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0447",
  "guidance_detail": "Phase 2 open-label multiple-ascending-dose study (NCT06747858); estimated primary completion Jun 2027 (registry last verified May 1, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ARCT-032 in Cystic fibrosis (Class I / not eligible for CFTR modulators) are expected in the first half of 2027, the first real efficacy signal for Arcturus Therapeutics Holdings Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Arcutis Biotherapeutics, Inc.",
  "competitors": [
   "NVS (Cosentyx)",
   "UCB (Bimzelx)",
   "ABBV (Rinvoq)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "roflumilast (ZORYVE foam 0.3%)",
  "event_type": "readout",
  "indication": "Hidradenitis suppurativa",
  "notes": "Phase 2 proof-of-concept study; company expects to report results plus advancement decision in Q1 2027 (vitiligo PoC data due Q4 2026).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/arcutis-announces-second-quarter-2026-financial-results-and-provides-business-update",
  "ticker": "ARQT",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0448",
  "guidance_detail": "Phase 2 proof-of-concept study; company expects to report results plus advancement decision in Q1 2027 (vitiligo PoC data due Q4 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Autolus Therapeutics plc",
  "competitors": [
   "Kymriah (Novartis)",
   "Blincyto (Amgen)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "obecabtagene autoleucel (obe-cel, AUCATZYL)",
  "event_type": "readout",
  "indication": "pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia",
  "notes": "Company states the Phase 2 portion of the CATULUS trial is underway and Autolus expects to report data at the end of 2027. CATULUS is described as a Phase 1 trial with a Phase 2 portion underway, i.e. a seamless Phase 1/2 study whose Phase 2 portion reads out in 2027, which qualifies per SPEC. End of 2027 -> late 2027 -> H2 bucket. Excluded per SPEC: LUMINA (lupus nephritis) Phase 2 data expected 2028; BOBCAT (progressive MS) is Phase 1.",
  "phase": "2",
  "ticker": "AUTL",
  "us_listed": true,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/03/27/3263674/0/en/Autolus-Therapeutics-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0449",
  "guidance_detail": "Company states the Phase 2 portion of the CATULUS trial is underway and Autolus expects to report data at the end of 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for obecabtagene autoleucel (obe-cel, AUCATZYL) in pediatric relapsed/refractory B-cell precursor acute lymphoblastic leukemia are expected in the second half of 2027, the first real efficacy signal for Autolus Therapeutics plc's program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Avalyn Pharma Inc.",
  "competitors": [
   "Esbriet (Roche)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AP01 (optimized inhaled formulation of pirfenidone)",
  "event_type": "readout",
  "indication": "progressive pulmonary fibrosis",
  "notes": "Company (Nasdaq: AVLN, IPO'd April 2026) completed target enrollment of 375 patients in the global randomized, double-blind, placebo-controlled Phase 2b MIST trial of AP01 (100 mg BID vs 50 mg BID vs placebo) in June 2026; primary endpoint is change from baseline in FVC at 52 weeks. Company expects to report topline 12-month clinical results in the second half of 2027. Late 2027 -> H2 bucket.",
  "phase": "2",
  "ticker": "AVLN",
  "us_listed": true,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/17/3313361/0/en/Avalyn-Completes-Target-Enrollment-in-Phase-2b-MIST-Trial-of-AP01-Inhaled-Pirfenidone-for-Patients-with-Progressive-Pulmonary-Fibrosis.html",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0450",
  "guidance_detail": "Company (Nasdaq: AVLN, IPO'd April 2026) completed target enrollment of 375 patients in the global randomized, double-blind, placebo-controlled Phase 2b MIST trial of AP01 (100 mg BID vs 50 mg BID vs placebo) in June 2026; primary endpoint is change from baseline in FVC at 52 weeks.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for AP01 (optimized inhaled formulation of pirfenidone) in progressive pulmonary fibrosis are expected in the second half of 2027, the first real efficacy signal for Avalyn Pharma Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Bayer AG",
  "competitors": [
   "Entresto (Novartis)",
   "Farxiga (AstraZeneca)"
  ],
  "country": "Germany",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AB-1002 (investigational gene therapy; AskBio)",
  "event_type": "readout",
  "indication": "heart failure with reduced ejection fraction (HFrEF)",
  "notes": "AB-1002 is being developed by AskBio Inc., a wholly owned, independently operated Bayer subsidiary. AskBio completed enrollment/randomization of 173 participants in the Phase 2 GenePHIT trial (one-time intracoronary infusion of AB-1002 vs placebo in NYHA Class III non-ischemic HFrEF) and guides initial results in the first half of 2027. Excluded: BAY 3401016 (SEMA3A mAb, Alport syndrome) Phase 2 initiated Dec 2025 with first dosing expected early 2026 but no company-stated 2027 readout timing.",
  "phase": "2",
  "ticker": "BAYRY",
  "us_listed": false,
  "source_type": "company PR",
  "source_url": "https://www.askbio.com/completion-of-enrollment-in-phase-2-clinical-trial-of-ab-1002-investigational-gene-therapy-for-heart-failure/",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0451",
  "guidance_detail": "AB-1002 is being developed by AskBio Inc., a wholly owned, independently operated Bayer subsidiary.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "JNJ (posdinemab anti-tau mAb)",
   "ACIU (ACI-35.030/JNJ-2056 anti-tau immunotherapy)",
   "BIIB (lecanemab)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BMS-986446 (PRX005)",
  "event_type": "readout",
  "indication": "early Alzheimer's disease",
  "notes": "TargetTau-1 Phase 2 (NCT06268886, ~310 pts, 76-week treatment) fully enrolled; CEO guided Phase 2 data readout in 2027 on Q3'25 earnings call; trial expected to complete 2027; anti-MTBR-tau mAb licensed from Prothena (PRX005). Partner Prothena (PRTA) retains milestone/royalty economics on BMS-986446 (formerly PRX005); folded from duplicate row. [V17 audit 2026-09-23: BMS Q2 2026 deck names this TargetTau-1 program moponetug (anti-MTBRtau, NCT06268886); deck does not print BMS-986446/PRX005 and no primary source found formally equating the names \u2014 kept as one row with naming note, no merge.]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://news.bms.com/news/details/2025/Bristol-Myers-Squibbs-Anti-MTBR-Tau-Targeting-Antibody-BMS-986446-Granted-Fast-Track-Designation-by-U-S--FDA-for-the-Treatment-of-Alzheimers-Disease/",
  "ticker": "BMY",
  "us_listed": true,
  "nct_id": "NCT06268886",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0452",
  "guidance_detail": "TargetTau-1 Phase 2 (NCT06268886, ~310 pts, 76-week treatment) fully enrolled; CEO guided Phase 2 data readout in 2027 on Q3'25 earnings call; trial expected to complete 2027; anti-MTBR-tau mAb licensed from Prothena (PRX005).",
  "audit_status": "v17_reverified",
  "audit_action": "corrected",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-10-01",
  "company": "Cabaletta Bio, Inc.",
  "competitors": [
   "KYTX (KYV-101 CD19 CAR T in autoimmune diseases incl. myositis)",
   "RNAC (Descartes-08 mRNA CAR-T in autoimmune disease)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "rese-cel (resecabtagene autoleucel)",
  "event_type": "readout",
  "indication": "myositis \u2014 dermatomyositis / antisynthetase syndrome",
  "notes": "Registrational single-arm DM/ASyS cohort of the Phase 1/2 RESET-Myositis trial (NCT06154252); company guides topline data 'mid-2027' (Q2/Q3 boundary); primary endpoint: IM-free moderate/major TIS response at 16 weeks; supports planned 2H27 myositis BLA. Exhibit 99.1 confirms registrational 17-patient RESET-Myositis DM/ASyS data in mid-2027 and planned rese-cel myositis BLA submission in 2H27 if successful; preserve the Q2/Q3 mid-2027 boundary note. [Registry check 2026-09-23] CT.gov now lists primary completion 2028-07 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "2",
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1759138/000175913826000038/0001759138-26-000038.txt",
  "ticker": "CABA",
  "us_listed": true,
  "nct_id": "NCT06154252",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0453",
  "guidance_detail": "Registrational single-arm DM/ASyS cohort of the Phase 1/2 RESET-Myositis trial (NCT06154252); company guides topline data 'mid-2027' (Q2/Q3 boundary); primary endpoint: IM-free moderate/major TIS response at 16 weeks; supports planned 2H27 myositis BLA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0072"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for rese-cel (resecabtagene autoleucel) in myositis \u2014 dermatomyositis / antisynthetase syndrome are expected in Q2 2027, the first real efficacy signal for Cabaletta Bio, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Compugen Ltd.",
  "competitors": [
   "MRK (pembrolizumab anti-PD-1 \u2014 checkpoint immunotherapy in ovarian cancer)",
   "BMY (nivolumab anti-PD-1 \u2014 tested with COM701 in platinum-resistant ovarian cancer)",
   "GSK (dostarlimab anti-PD-1 \u2014 ovarian cancer development)",
   "GILD (domvanalimab anti-TIGIT \u2014 same PVRIG/TIGIT checkpoint-axis family)"
  ],
  "country": "Israel",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "COM701 (anti-PVRIG antibody)",
  "event_type": "readout",
  "indication": "relapsed platinum-sensitive ovarian cancer (maintenance)",
  "notes": "MAIA-ovarian adaptive Phase 1/2 platform trial (NCT06888921); sub-trial 1 (randomized placebo-controlled COM701 monotherapy, n=60) interim analysis with median PFS data guided by Q1 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/il/news-releases/compugen-reports-second-quarter-2026-results-302841059.html",
  "ticker": "CGEN",
  "us_listed": true,
  "nct_id": "NCT06888921",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0454",
  "guidance_detail": "MAIA-ovarian adaptive Phase 1/2 platform trial (NCT06888921); sub-trial 1 (randomized placebo-controlled COM701 monotherapy, n=60) interim analysis with median PFS data guided by Q1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for COM701 (anti-PVRIG antibody) in relapsed platinum-sensitive ovarian cancer (maintenance) are expected in Q1 2027, the first real efficacy signal for Compugen Ltd.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Hemab Therapeutics Holdings, Inc.",
  "competitors": [
   "NVO (NovoSeven rFVIIa \u2014 Factor VII deficiency acute-treatment standard)",
   "RHHBY (emicizumab \u2014 bispecific prophylaxis in hemophilia, mechanism paradigm)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "sutacimig (HMB-001)",
  "event_type": "readout",
  "indication": "Factor VII deficiency \u2014 prophylactic treatment (bispecific antibody)",
  "notes": "Phase 2 sutacimig (HMB-001) in congenital Factor VII deficiency (NCT07347249, recruiting, PCD Nov 2027); Hemab July 2026 PR confirms Phase 2b in progress; readout likely late 2027, could slip to early 2028.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/14/3326747/0/en/Hemab-Therapeutics-Presents-Clinical-and-Preclinical-Data-from-Sutacimig-in-Glanzmann-Thrombasthenia-and-Factor-VII-Deficiency-at-the-ISTH-2026-Congress.html",
  "ticker": "COAG",
  "us_listed": true,
  "nct_id": "NCT07347249",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0455",
  "guidance_detail": "Phase 2 sutacimig (HMB-001) in congenital Factor VII deficiency (NCT07347249, recruiting, PCD Nov 2027); Hemab July 2026 PR confirms Phase 2b in progress; readout likely late 2027, could slip to early 2028.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for sutacimig (HMB-001) in Factor VII deficiency \u2014 prophylactic treatment (bispecific antibody) are expected in the first half of 2027, the first real efficacy signal for Hemab Therapeutics Holdings, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Corbus Pharmaceuticals Holdings, Inc.",
  "competitors": [
   "MRK (pembrolizumab \u2014 1L R/M HNSCC standard / PD-1 combo backbone)",
   "BMY (nivolumab \u2014 R/M HNSCC PD-1 therapy)",
   "PFE (enfortumab vedotin/Padcev \u2014 nectin-4 ADC precedent, Astellas/Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CRB-701 + pembrolizumab (nectin-4 ADC + anti-PD-1)",
  "event_type": "readout",
  "indication": "1L oropharyngeal squamous cell carcinoma (OPSCC) \u2014 dose-expansion cohort",
  "notes": "Seamless Phase 1/2 NCT06265727; Part C evaluates the recommended Phase II dose (mono + anti-PD-1). CMO PR (Jul 6 2026) guides 'anticipated data readout of CRB-701 in 1L OPSCC in early 2027'; prior guidance was Q4 2026 (May 26 2026 PR) \u2014 could land late 2026.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://ir.corbuspharma.com/news-events/press-releases/detail/472/corbus-pharmaceuticals-appoints-leonardo-viana-nicacio-m-d-as-chief-medical-officer",
  "ticker": "CRBP",
  "us_listed": true,
  "nct_id": "NCT06265727",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0456",
  "guidance_detail": "Seamless Phase 1/2 NCT06265727; Part C evaluates the recommended Phase II dose (mono + anti-PD-1).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for CRB-701 + pembrolizumab (nectin-4 ADC + anti-PD-1) in 1L oropharyngeal squamous cell carcinoma (OPSCC) \u2014 dose-expansion cohort are expected in the first half of 2027, the first real efficacy signal for Corbus Pharmaceuticals Holdings, Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "chunk": "phase2-chunk03",
  "company": "Cyclerion Therapeutics, Inc.",
  "competitors": [
   "CYBN (CYB003, deuterated psilocin, Phase 3 MDD)",
   "Compass Pathways (COMP360 psilocybin, Phase 3 TRD)",
   "J&J (esketamine/Spravato, marketed TRD)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CYC-126 (anesthetic-based therapy + proprietary delivery system)",
  "event_type": "readout",
  "indication": "Treatment-resistant depression (TRD)",
  "notes": "Phase 2 POC to start 2H26 (Australia), US enrollment H1 2027; company guides initial POC data in 2027",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/cyclerion-therapeutics-announces-strategic-agreement-with-medsteer-and-progress-toward-initiating-phase-2-proof-of-concept-study-for-cyc-126-in-treatment-resistant-depression",
  "ticker": "CYCN",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0457",
  "guidance_detail": "Phase 2 POC to start 2H26 (Australia), US enrollment H1 2027; company guides initial POC data in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for CYC-126 (anesthetic-based therapy + proprietary delivery system) in Treatment-resistant depression (TRD) are expected sometime in 2027, the first real efficacy signal for Cyclerion Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Dar\u00e9 Bioscience, Inc.",
  "competitors": [
   "Inovio (VGX-3100, Phase 3 HPV-driven cervical disease)",
   "PDS Biotech (PDS0101, HPV16+ head & neck cancer)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DARE-HPV (intravaginal antiviral)",
  "event_type": "readout",
  "indication": "Persistent high-risk HPV infection",
  "notes": "Phase 2 (n~100) initiated 2026 with ARPA-H funding; no FDA-approved pharmacologic treatment exists for HPV infection",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/13/3344879/30757/en/dar%C3%A9-bioscience-reports-second-quarter-2026-results-and-highlights-commercial-inflection-as-multi-product-women-s-health-strategy-advances.html",
  "ticker": "DARE",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0458",
  "guidance_detail": "Phase 2 (n~100) initiated 2026 with ARPA-H funding; no FDA-approved pharmacologic treatment exists for HPV infection.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for DARE-HPV (intravaginal antiviral) in Persistent high-risk HPV infection are expected sometime in 2027, the first real efficacy signal for Dar\u00e9 Bioscience, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Delcath Systems, Inc.",
  "competitors": [
   "Sirtex Medical (SIR-Spheres Y-90, liver-directed)",
   "Boston Scientific (TheraSphere Y-90, liver-directed)",
   "Taiho Oncology (trifluridine-tipiracil/Lonsurf, SOC comparator)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "HEPZATO KIT (melphalan/hepatic delivery system) + SOC",
  "event_type": "readout",
  "indication": "Liver-dominant metastatic colorectal cancer (3rd line)",
  "notes": "Phase 2 (n~90, HEPZATO + trifluridine-tipiracil/bevacizumab vs SOC); primary endpoint hPFS anticipated to read out by end-2027 per Dec 2024 PR; Q2 2026 call guided interim readout late 2027 with enrollment below initial expectations",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20241202484109/en/Delcath-Systems-Announces-FDA-Clearance-of-IND-Application-for-Phase-2-Clinical-Trial-of-HEPZATO%E2%84%A2-in-Liver-Dominant-Metastatic-Colorectal-Cancer",
  "ticker": "DCTH",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0459",
  "guidance_detail": "Phase 2 (n~90, HEPZATO + trifluridine-tipiracil/bevacizumab vs SOC); primary endpoint hPFS anticipated to read out by end-2027 per Dec 2024 PR; Q2 2026 call guided interim readout late 2027 with enrollment below initial expectations.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for HEPZATO KIT (melphalan/hepatic delivery system) + SOC in Liver-dominant metastatic colorectal cancer (3rd line) are expected in the second half of 2027, the first real efficacy signal for Delcath Systems, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Disc Medicine, Inc.",
  "competitors": [
   "Vifor Pharma (ferric carboxymaltose, IBD anemia SOC)",
   "Shield Therapeutics (ferric maltol/Accrufer, IBD anemia)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DISC-0974 / selcodebart (anti-hemojuvelin antibody)",
  "event_type": "readout",
  "indication": "Anemia of inflammatory bowel disease (IBD)",
  "notes": "Phase 2 initiated Q1 2026, initial data guided 2027. Ticker re-keyed DFTX -> IRON; Disc Medicine trades as Nasdaq: IRON. [Source verified 2026-09-20: Selcodebart (DISC-0974): Anti-Hemojuvelin Antibody (Hepcidin Suppression) ... Progressing Phase 2 study in patients with inflammatory bowel disease (IBD) with initial data expected in 2027 (WATERTOWN, Mass., July 30, 202]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/30/3336047/0/en/disc-medicine-reports-second-quarter-2026-financial-results-and-provides-business-update.html",
  "ticker": "IRON",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0460",
  "guidance_detail": "Phase 2 initiated Q1 2026, initial data guided 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for DISC-0974 / selcodebart (anti-hemojuvelin antibody) in Anemia of inflammatory bowel disease (IBD) are expected sometime in 2027, the first real efficacy signal for Disc Medicine, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "DiaMedica Therapeutics Inc.",
  "competitors": [
   "Thrombolysis (alteplase/tenecteplase) plus mechanical thrombectomy (standard of care)",
   "No approved neuroprotectant therapy for acute ischemic stroke"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DM199 (recombinant KLK1)",
  "event_type": "readout",
  "indication": "acute ischemic stroke",
  "notes": "Prespecified interim efficacy analysis of the Phase 2/3 ReMEDy2 trial (NCT05065216), triggered after 200 participants complete follow-up; the DSMB will conduct futility/sample-size re-estimation to set final enrollment (300-728). Interim reads out 'early 2027'; company remains blinded to efficacy results. Qualifies as the Phase 2 portion's readout under the seamless-trial rule.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260810989621/en/DiaMedica-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Highlights",
  "ticker": "DMAC",
  "us_listed": true,
  "nct_id": "NCT05065216",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0461",
  "guidance_detail": "Prespecified interim efficacy analysis of the Phase 2/3 ReMEDy2 trial (NCT05065216), triggered after 200 participants complete follow-up; the DSMB will conduct futility/sample-size re-estimation to set final enrollment (300-728).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for DM199 (recombinant KLK1) in acute ischemic stroke are expected in the first half of 2027, the first real efficacy signal for DiaMedica Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "chunk": "phase2-chunk03",
  "company": "Denali Therapeutics Inc.",
  "competitors": [
   "Progranulin gene-therapy/antisense approaches for genetic FTD (early clinical, e.g. Passage Bio)",
   "No approved therapy to slow progression in FTD-GRN (supportive care only)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DNL593 (PTV:PGRN)",
  "event_type": "readout",
  "indication": "frontotemporal dementia (GRN mutation)",
  "notes": "Phase 1/2 study (40 enrolled participants with FTD-GRN) delayed to 2027 to allow longer observation of treatment effects on biomarkers including neurofilament light chain; company exploring a biomarker-driven accelerated-approval path. Earnings call specified H1 2027, but the primary company PR states only '2027', so this is a year-level bucket. Qualifies as the Phase 2 portion's readout. Keep year-level 2027 bucket. The Q2 2026 PR text (DNL593 enrollment complete with 40 participants, results revised from end-2026 to 2027 for longer biomarker observation) is only available via wire mirrors; no canonical GlobeNewswire or direct Denali IR URL was located. The H1 2027 call detail has no accepted official source, so the bucket stays year-level.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "http://finance.minyanville.com/minyanville/article/gnwcq-2026-8-6-denali-therapeutics-reports-second-quarter-2026-financial-results-and-business-highlights",
  "ticker": "DNLI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0462",
  "guidance_detail": "Phase 1/2 study (40 enrolled participants with FTD-GRN) delayed to 2027 to allow longer observation of treatment effects on biomarkers including neurofilament light chain; company exploring a biomarker-driven accelerated-approval path.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Denali Therapeutics Inc.",
  "competitors": [
   "Roche/Prothena prasinezumab (Phase 3 PARAISO in early PD, not LRRK2-directed)",
   "Biogen BIIB122 program discontinued in idiopathic PD after LUMA failure; no other late-stage LRRK2 inhibitor in LRRK2-variant carriers",
   "No approved disease-modifying therapy for Parkinson's disease"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BIIB122/DNL151 (LRRK2 inhibitor)",
  "event_type": "readout",
  "indication": "Parkinson's disease in pathogenic LRRK2 variant carriers",
  "notes": "Phase 2a BEACON study, led and independently funded by Denali after Biogen discontinued the drug in idiopathic PD following the failed Phase 2b LUMA study (May 2026). BEACON assesses safety, PK and biomarkers of lysosomal pathway engagement in carriers of pathogenic LRRK2 variants; data expected H1 2027. [Source verified 2026-09-20: The global Phase 2a BEACON study is designed to assess safety, pharmacokinetics and biomarkers of lysosomal pathway engagement... Data from the BEACON study is anticipated in the first half of 2027. (Official joint Bioge]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/21/3299820/0/en/Biogen-and-Denali-Therapeutics-Provide-Update-on-Phase-2b-LUMA-Study-of-BIIB122-DNL151-in-Early-Stage-Parkinson-s-Disease.html",
  "ticker": "DNLI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0463",
  "guidance_detail": "Phase 2a BEACON study, led and independently funded by Denali after Biogen discontinued the drug in idiopathic PD following the failed Phase 2b LUMA study (May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Dyne Therapeutics, Inc.",
  "competitors": [
   "Avidity Biosciences del-desiran (AOC 1001, Phase 3 in DM1)",
   "PepGen PGN-EDODM1 (Phase 2 FREEDOM2 in DM1; data Nov 2026)",
   "ARTHEx Biotech ATX-01 (anti-miR-23b, Phase 1/2a ArthemiR in DM1)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zeleciment basivarsen (z-basivarsen; DYNE-101)",
  "event_type": "readout",
  "indication": "myotonic dystrophy type 1",
  "notes": "Phase 1/2 ACHIEVE trial: registrational expansion cohort (REC, 71 participants) fully enrolled June 2026; per June 3, 2026 8-K, topline REC data planned Q1 2027 to support a potential BLA for U.S. Accelerated Approval in Q3 2027. The confirmatory Phase 3 HARMONIA trial is separately underway and is not the Phase 2 event. z-rostudirsen (DYNE-251) DMD events belong to Phase 1 scope and are already captured there.",
  "phase": "2",
  "source_type": "SEC 8-K",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1818794/000119312526254597/dyn-20260603.htm",
  "ticker": "DYN",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0464",
  "guidance_detail": "Phase 1/2 ACHIEVE trial: registrational expansion cohort (REC, 71 participants) fully enrolled June 2026; per June 3, 2026 8-K, topline REC data planned Q1 2027 to support a potential BLA for U.S.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "chunk": "phase2-chunk03",
  "company": "Genfit S.A.",
  "competitors": [
   "Yaqrit (private) \u2014 YAQ005 (TLR4 antagonist) +/- G-CSF, Phase 2 A-TANGO in ACLF, initial data Q3 2027",
   "DURE \u2014 larsucosterol, alcohol-associated hepatitis (adjacent acute liver failure indication)"
  ],
  "country": "France",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "G1090N / nitazoxanide (NTZ)",
  "event_type": "readout",
  "indication": "acute-on-chronic liver failure (ACLF)",
  "notes": "Phase 1 data reported early 2026; Orphan Drug Designation granted March 2026; proof-of-concept Phase 2 study initiation targeted for H2 2026 with data expected in 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/21/3299583/0/en/GENFIT-Reports-First-Quarter-2026-Financial-Information-and-Provides-a-Corporate-Update.html",
  "ticker": "GNFT",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0465",
  "guidance_detail": "Phase 1 data reported early 2026; Orphan Drug Designation granted March 2026; proof-of-concept Phase 2 study initiation targeted for H2 2026 with data expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for G1090N / nitazoxanide (NTZ) in acute-on-chronic liver failure (ACLF) are expected sometime in 2027, the first real efficacy signal for Genfit S.A.'s program."
 },
 {
  "as_of": "2026-09-24",
  "chunk": "phase2-chunk03",
  "company": "Genfit S.A.",
  "competitors": [
   "Yaqrit (private) \u2014 YAQ005 (TLR4 antagonist) +/- G-CSF, Phase 2 A-TANGO in ACLF, initial data Q3 2027",
   "DURE \u2014 larsucosterol, alcohol-associated hepatitis (adjacent acute liver failure indication)"
  ],
  "country": "France",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "nangibotide",
  "event_type": "readout",
  "indication": "acute-on-chronic liver failure (ACLF)",
  "notes": "TREM-1 pathway asset acquired summer 2026; Phase 2a proof-of-concept study in ACLF expected to initiate Q4 2026 with data readout targeted in 2027. Source is a wire syndication of GENFIT's Sept 14, 2026 release; direct GENFIT/GlobeNewswire URL not located \u2014 monthly refresh should re-verify against primary. Sept 14, 2026 GENFIT release confirms nangibotide Phase 2a ACLF proof-of-concept study expected to start Q4 2026 with data readout targeted in 2027, but only wire mirrors were found; no direct GENFIT or GlobeNewswire URL located after genuine effort. Re-verify against the primary at monthly refresh.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://lifestyle.thepointnews.com/story/860774/genfit-advances-nangibotide-in-phase-2-clinical-investigation-in-aclf/",
  "ticker": "GNFT",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0466",
  "guidance_detail": "TREM-1 pathway asset acquired summer 2026; Phase 2a proof-of-concept study in ACLF expected to initiate Q4 2026 with data readout targeted in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for nangibotide in acute-on-chronic liver failure (ACLF) are expected sometime in 2027, the first real efficacy signal for Genfit S.A.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "IDEAYA Biosciences, Inc.",
  "competitors": [
   "IMCR (tebentafusp/Kimmtrak)",
   "BMS (Opdivo + Yervoy)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "darovasertib + crizotinib \u2014 OptimUM-02 (Phase 2/3)",
  "event_type": "readout",
  "indication": "first-line HLA*A2-negative metastatic uveal melanoma \u2014 OS interim analysis update",
  "notes": "Company guides OS update as part of prespecified interim analysis expected mid-2027; primary PFS endpoint already met (ASCO 2026). Registry detail: NCT05987332 (OptimUM-02) primary completion 2027-01-15; folded from duplicate row.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html",
  "ticker": "IDYA",
  "us_listed": true,
  "nct_id": "NCT05987332",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0467",
  "guidance_detail": "Company guides OS update as part of prespecified interim analysis expected mid-2027; primary PFS endpoint already met (ASCO 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-1044"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for darovasertib + crizotinib \u2014 OptimUM-02 (Phase 2/3) in first-line HLA*A2-negative metastatic uveal melanoma \u2014 OS interim analysis update are expected in Q2 2027, the first real efficacy signal for IDEAYA Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "IDEAYA Biosciences, Inc.",
  "competitors": [
   "IMCR (tebentafusp)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "darovasertib (IDE196) \u2014 neoadjuvant (OptimUM-09)",
  "event_type": "readout",
  "indication": "localized/primary uveal melanoma (neoadjuvant)",
  "notes": "Inferred from registry primary completion 2027-04-30 (NCT05907954, active not recruiting); no company-guided 2027 readout date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05907954",
  "ticker": "IDYA",
  "us_listed": true,
  "nct_id": "NCT05907954",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0468",
  "guidance_detail": "Inferred from registry primary completion 2027-04-30 (NCT05907954, active not recruiting); no company-guided 2027 readout date.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0902"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for darovasertib (IDE196) \u2014 neoadjuvant (OptimUM-09) in localized/primary uveal melanoma (neoadjuvant) are expected in Q2 2027, the first real efficacy signal for IDEAYA Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "I-Mab",
  "competitors": [
   "Astellas (zolbetuximab/VYLOY)",
   "AZN (AZD0901)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "givastomig (CLDN18.2 x 4-1BB bispecific) + nivolumab + chemo \u2014 global randomized Phase 2",
  "event_type": "readout",
  "indication": "first-line metastatic gastric cancer",
  "notes": "I-Mab guides PFS data in 2027; trial now sponsored/run by NovaBridge Biosciences (NBP), which dosed first patient Feb 2026.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/09/08/3146094/0/en/I-Mab-Announces-Acceleration-of-Givastomig-Investment-and-Leadership-Appointments.html",
  "ticker": "IMAB",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0469",
  "guidance_detail": "I-Mab guides PFS data in 2027; trial now sponsored/run by NovaBridge Biosciences (NBP), which dosed first patient Feb 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for givastomig in first-line metastatic gastric cancer are expected sometime in 2027, the first real efficacy signal for I-Mab's program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Immuneering Corporation",
  "competitors": [
   "AMGN (sotorasib)",
   "BMS (adagrasib)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "atebimetinib + cemiplimab (Libtayo)",
  "event_type": "readout",
  "indication": "non-small cell lung cancer",
  "notes": "Preliminary Phase 2 data guided for late-2027; first patient dosing expected 2H 2026.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339218/0/en/Immuneering-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html",
  "ticker": "IMRX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0470",
  "guidance_detail": "Preliminary Phase 2 data guided for late-2027; first patient dosing expected 2H 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for atebimetinib + cemiplimab (Libtayo) in non-small cell lung cancer are expected in the second half of 2027, the first real efficacy signal for Immuneering Corporation's program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Imunon, Inc.",
  "competitors": [
   "ABBV (mirvetuximab)",
   "GSK (Zejula/niraparib)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IMNN-001 (IL-12 gene therapy) \u2014 MRD translational Phase 2",
  "event_type": "readout",
  "indication": "newly diagnosed advanced ovarian cancer (minimal residual disease)",
  "notes": "Inferred from registry primary completion 2027-06-30 (NCT05739981); preliminary data reported Jul 2026; final readout not company-guided; investigator-led (MD Anderson / Break Through Cancer).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05739981",
  "ticker": "IMNN",
  "us_listed": true,
  "nct_id": "NCT05739981",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0471",
  "guidance_detail": "Inferred from registry primary completion 2027-06-30 (NCT05739981); preliminary data reported Jul 2026; final readout not company-guided; investigator-led (MD Anderson / Break Through Cancer).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for IMNN-001 (IL-12 gene therapy) \u2014 MRD translational Phase 2 in newly diagnosed advanced ovarian cancer (minimal residual disease) are expected in Q2 2027, the first real efficacy signal for Imunon, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Immatics N.V.",
  "competitors": [
   "MSD (Keytruda, solid tumors)",
   "BMS (Opdivo, solid tumors)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IMA402 (PRAME TCER) (Phase 1/2)",
  "event_type": "readout",
  "indication": "recurrent/refractory solid tumors \u2014 Phase 2 expansion readout",
  "notes": "Inferred from registry: NCT05958121 is a recruiting Phase 1/2 trial of IMA402 (PRAME T-cell engager) in recurrent/refractory solid tumors with primary completion 2027-09; Phase 1b RP2D data presented at ESMO Oct 2026 and expansion cohorts underway. Readout could slip into 2028 given the Sep 2027 primary completion date. Separately, first data from the Phase 1b IMA401/IMA402 combination cohort in sqNSCLC is company-guided for 2027 but is Phase 1 (out of scope for Phase 2 output).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05958121",
  "ticker": "IMTX",
  "us_listed": true,
  "nct_id": "NCT05958121",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0472",
  "guidance_detail": "Inferred from registry: NCT05958121 is a recruiting Phase 1/2 trial of IMA402 (PRAME T-cell engager) in recurrent/refractory solid tumors with primary completion 2027-09; Phase 1b RP2D data presented at ESMO Oct 2026 and expansion cohorts underway.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for IMA402 (PRAME TCER) in recurrent/refractory solid tumors \u2014 Phase 2 expansion readout are expected in Q3 2027, the first real efficacy signal for Immatics N.V.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Immunovant, Inc.",
  "competitors": [
   "VRDN (veligrotug, Phase 3 TED)",
   "ARGX (efgartigimod, FcRn class leader)",
   "Amgen (teprotumumab/Tepezza, approved TED)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "IMVT-1402 (Phase 2b)",
  "event_type": "readout",
  "indication": "Graves' disease \u2014 topline Phase 2b results",
  "notes": "Company explicitly guides 2027 topline readout in Graves' disease; registry NCT07018323 (recruiting) lists primary completion 2027-05. MG program is Phase 3 and recorded separately in Phase 1 output.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/08/11/3130764/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2025.html",
  "ticker": "IMVT",
  "us_listed": true,
  "nct_id": "NCT07018323",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0473",
  "guidance_detail": "Company explicitly guides 2027 topline readout in Graves' disease; registry NCT07018323 (recruiting) lists primary completion 2027-05.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0474",
   "v16-0209"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Immunovant, Inc.",
  "competitors": [
   "ARGX (efgartigimod, D2T RA)",
   "JNJ (nipocalimab, D2T RA)",
   "UCB (rozanolixizumab, FcRn class)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IMVT-1402 (Phase 2b)",
  "event_type": "readout",
  "indication": "difficult-to-treat rheumatoid arthritis (D2T RA) \u2014 topline Phase 2b results",
  "notes": "Company explicitly guides 2027 topline readout in D2T RA; registry NCT06754462 (active, not recruiting) lists primary completion 2027-09. Reviewed 2026-09-20: downgraded guidance->inferred; fiscal Q1 2026 company update (quarter ended 2026-06-30) no longer carries the 2027 D2T RA topline guidance stated in the Nov 2025 release.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/08/11/3130764/0/en/Immunovant-Provides-Corporate-Updates-and-Reports-Financial-Results-for-the-Quarter-Ended-June-30-2025.html",
  "ticker": "IMVT",
  "us_listed": true,
  "nct_id": "NCT06754462",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0474",
  "guidance_detail": "Company explicitly guides 2027 topline readout in D2T RA; registry NCT06754462 (active, not recruiting) lists primary completion 2027-09.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0473",
   "v16-0209"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Inhibrx Biosciences, Inc.",
  "competitors": [
   "MSD (Keytruda, perioperative NSCLC)",
   "BMS (Opdivo, neoadjuvant NSCLC)",
   "Roche (Tecentriq, adjuvant NSCLC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "INBRX-106 (Phase 1/2)",
  "event_type": "readout",
  "indication": "perioperative non-small cell lung cancer (NSCLC) \u2014 initial Phase 2 results",
  "notes": "Company targets initial results by mid-2027 from the Phase 1/2 study of INBRX-106 (hexavalent OX40 agonist) in the perioperative NSCLC setting; placed at Q2/Q3 2027 boundary per mid-2027 guidance.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/inhibrxs-inbrx-106-nearly-doubles-response-rate-and-achieves-interim-median-pfs-of-9-6-months-in-phase-2-hnscc-study-302871751.html",
  "ticker": "INBX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0475",
  "guidance_detail": "Company targets initial results by mid-2027 from the Phase 1/2 study of INBRX-106 (hexavalent OX40 agonist) in the perioperative NSCLC setting; placed at Q2/Q3 2027 boundary per mid-2027 guidance.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for INBRX-106 in perioperative non-small cell lung cancer (NSCLC) are expected in Q2 2027, the first real efficacy signal for Inhibrx Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Inhibrx Biosciences, Inc.",
  "competitors": [
   "MSD (Keytruda, KEYNOTE-522 neoadjuvant TNBC)",
   "Gilead (Trodelvy, TNBC)",
   "Roche (Tecentriq, TNBC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "INBRX-106 + pembrolizumab (Phase 2)",
  "event_type": "readout",
  "indication": "neoadjuvant stage II/III triple-negative breast cancer (TNBC) \u2014 Phase 2 readout",
  "notes": "Inferred timing from registry: NCT06353997 is a recruiting Phase 2 trial of neoadjuvant INBRX-106 + pembrolizumab in stage II/III TNBC with primary completion listed as 2027-06; investigator-sponsored (Providence). No company guidance on this readout.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06353997",
  "ticker": "INBX",
  "us_listed": true,
  "nct_id": "NCT06353997",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0476",
  "guidance_detail": "Inferred timing from registry: NCT06353997 is a recruiting Phase 2 trial of neoadjuvant INBRX-106 + pembrolizumab in stage II/III TNBC with primary completion listed as 2027-06; investigator-sponsored (Providence).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for INBRX-106 + pembrolizumab in neoadjuvant stage II/III triple-negative breast cancer (TNBC) are expected in Q2 2027, the first real efficacy signal for Inhibrx Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Incyte Corporation",
  "competitors": [
   "GSK (Zejula/niraparib, ovarian cancer)",
   "AZN (Lynparza/olaparib, ovarian cancer)",
   "MSD (Keytruda, ovarian combos)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "INCB123667 (CDK2 inhibitor, Phase 2)",
  "event_type": "readout",
  "indication": "platinum-resistant ovarian cancer with cyclin E1 overexpression \u2014 Phase 2 readout",
  "notes": "Inferred timing from registry: NCT07023627 is a recruiting Phase 2 trial of INCB123667 (selective CDK2 inhibitor) in platinum-resistant ovarian cancer with primary completion 2027-04-27; no company readout guidance found.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07023627",
  "ticker": "INCY",
  "us_listed": true,
  "nct_id": "NCT07023627",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0477",
  "guidance_detail": "Inferred timing from registry: NCT07023627 is a recruiting Phase 2 trial of INCB123667 (selective CDK2 inhibitor) in platinum-resistant ovarian cancer with primary completion 2027-04-27; no company readout guidance found.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Incyte Corporation",
  "competitors": [
   "IPSEN (Sohonos/palovarotene, approved FOP)",
   "REGN (garetosmab, Phase 3 FOP)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "INCB000928 (ALK2 inhibitor, Phase 2)",
  "event_type": "readout",
  "indication": "fibrodysplasia ossificans progressiva (FOP) \u2014 Phase 2 efficacy/safety/tolerability readout",
  "notes": "Inferred timing from registry: NCT05090891 is a recruiting randomized placebo-controlled Phase 2 trial of INCB000928 in FOP with primary completion 2027-07-30; no company readout guidance found. Registry shows trial still recruiting.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05090891",
  "ticker": "INCY",
  "us_listed": true,
  "nct_id": "NCT05090891",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0479",
  "guidance_detail": "Inferred timing from registry: NCT05090891 is a recruiting randomized placebo-controlled Phase 2 trial of INCB000928 in FOP with primary completion 2027-07-30; no company readout guidance found.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Incyte Corporation",
  "competitors": [
   "AMGN (Nplate/romiplostim, ITP)",
   "RIGL (Tavalisse/fostamatinib, ITP)",
   "SNY (rilzabrutinib, Phase 3 ITP)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "tafasitamab (Phase 2)",
  "event_type": "readout",
  "indication": "primary autoimmune blood cell disorders incl. immune thrombocytopenia (ITP) \u2014 Phase 2 safety/tolerability readout",
  "notes": "Inferred timing from registry: NCT07104565 is a recruiting Phase 2 trial with primary completion 2027-09-23; trial title describes tafasitamab (anti-CD19) in adult participants with primary autoimmune blood cell disorders, though the registry lists the intervention under code INCA000585; no company readout guidance found.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07104565",
  "ticker": "INCY",
  "us_listed": true,
  "nct_id": "NCT07104565",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0480",
  "guidance_detail": "Inferred timing from registry: NCT07104565 is a recruiting Phase 2 trial with primary completion 2027-09-23; trial title describes tafasitamab (anti-CD19) in adult participants with primary autoimmune blood cell disorders, though the registry lists the intervention under code INCA000585; no company readout guidance found.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v17-0043"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Incyte Corporation",
  "competitors": [
   "INCY (Jakafi/ruxolitinib, approved cGVHD)",
   "ABBV (Imbruvica/ibrutinib, approved cGVHD)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "axatilimab (Phase 1b/2)",
  "event_type": "readout",
  "indication": "recurrent/refractory chronic GVHD in Chinese participants \u2014 Phase 2 portion readout",
  "notes": "Inferred timing from registry: NCT06843408 is an active (not recruiting) Phase 1b/2 trial of axatilimab monotherapy in Chinese participants with recurrent/refractory cGVHD with primary completion 2027-01-06; the Phase 2 portion would read out in early 2027. Not duplicated in Phase 1 output (which lists only povorcitinib events for INCY).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06843408",
  "ticker": "INCY",
  "us_listed": true,
  "nct_id": "NCT06843408",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0481",
  "guidance_detail": "Inferred timing from registry: NCT06843408 is an active (not recruiting) Phase 1b/2 trial of axatilimab monotherapy in Chinese participants with recurrent/refractory cGVHD with primary completion 2027-01-06; the Phase 2 portion would read out in early 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "IO Biotech, Inc.",
  "competitors": [
   "BMS (Opdualag/nivolumab+relatlimab, melanoma)",
   "MRK (Keytruda, melanoma)"
  ],
  "country": "Denmark / United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IO102/IO103 (Phase 2)",
  "event_type": "readout",
  "indication": "Advanced melanoma \u2014 IO102/IO103 cancer vaccines + nivolumab + relatlimab (NCT05912244)",
  "notes": "Inferred from registry: Phase 2, active not recruiting, investigator-sponsored by Memorial Sloan Kettering, primary completion 2027-06-09. Caveat: IO Biotech restructured after its Phase 3 failure in 2025 and deprioritized IO102-IO103; this trial is not company-run, but it remains active and reads out in 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05912244",
  "ticker": "IOBT",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0482",
  "guidance_detail": "Inferred from registry: Phase 2, active not recruiting, investigator-sponsored by Memorial Sloan Kettering, primary completion 2027-06-09.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for IO102/IO103 in advanced melanoma \u2014 IO102/IO103 cancer vaccines + nivolumab + relatlimab (NCT05912244) are expected in Q2 2027, the first real efficacy signal for IO Biotech, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Ionis Pharmaceuticals, Inc.",
  "competitors": [
   "ARWR (plozasiran, FCS/severe HTG)",
   "IONS (olezarsen/Tryngolza, sHTG Phase 3)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ION775 (Phase 2b)",
  "event_type": "readout",
  "indication": "Hypertriglyceridemia \u2014 ION775 (NCT07604974)",
  "notes": "Inferred from registry: Phase 2, recruiting, primary completion 2027-09. Ionis Q2 2026 commentary (2026-07-29) confirms ION775 is in Phase 2b with enrollment going well, but management disclosed no external timing; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07604974",
  "ticker": "IONS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0483",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, primary completion 2027-09.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ionis Pharmaceuticals, Inc.",
  "competitors": [
   "No clinical-stage competitors identified (no approved or late-stage disease-modifying therapy for prion disease)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ION717 (Phase 1/2)",
  "event_type": "readout",
  "indication": "Prion disease \u2014 ION717 (NCT06153966)",
  "notes": "Inferred from registry: Phase 1/2, active not recruiting, primary completion 2027-04; the Phase 2 portion readout is expected in 2027. No public company timing located; readout timing inferred from the registry date. Not in the Phase 1 output file (obudanersen ION582 entry there is a different program).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06153966",
  "ticker": "IONS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0484",
  "guidance_detail": "Inferred from registry: Phase 1/2, active not recruiting, primary completion 2027-04; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ionis Pharmaceuticals, Inc.",
  "competitors": [
   "No clinical-stage competitors identified (no approved therapy for MECP2 duplication syndrome)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ION440 (Phase 1/2)",
  "event_type": "readout",
  "indication": "MECP2 duplication syndrome \u2014 ION440 (NCT06430385)",
  "notes": "Inferred from registry: Phase 1/2, recruiting, primary completion 2027-09; the Phase 2 portion readout is expected in 2027. No public company timing located; readout timing inferred from the registry date. Not in the Phase 1 output file.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06430385",
  "ticker": "IONS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0485",
  "guidance_detail": "Inferred from registry: Phase 1/2, recruiting, primary completion 2027-09; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Innate Pharma S.A.",
  "competitors": [
   "BMS (Opdivo, neoadjuvant NSCLC \u2014 CheckMate 816)",
   "MRK (Keytruda, neoadjuvant NSCLC \u2014 KEYNOTE-671)",
   "AZN (Imfinzi/durvalumab, perioperative NSCLC \u2014 AEGEAN)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IPH5201 (Phase 2)",
  "event_type": "readout",
  "indication": "Resectable NSCLC \u2014 neoadjuvant IPH5201 + durvalumab + chemotherapy, MATISSE trial (NCT05742607)",
  "notes": "Inferred from registry: Phase 2, recruiting, primary completion 2027-06. Innate Pharma's H1 2026 business update (2026-09-16) confirmed MATISSE remains ongoing and is enrolling PD-L1>=1% patients after encouraging interim results, but disclosed no external timing; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05742607",
  "ticker": "IPHA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0486",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, primary completion 2027-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for IPH5201 in resectable NSCLC \u2014 neoadjuvant IPH5201 + durvalumab + chemotherapy (MATISSE trial, NCT05742607) are expected in Q2 2027, the first real efficacy signal for Innate Pharma S.A.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Incannex Healthcare Inc.",
  "competitors": [
   "LLY (Zepbound/tirzepatide, obstructive sleep apnea)",
   "APNM (Apnimed, private \u2014 AD109 oral OSA candidate)"
  ],
  "country": "Australia / United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "IHL-42X (dronabinol + acetazolamide) (Phase 2)",
  "event_type": "readout",
  "indication": "Obstructive sleep apnea \u2014 DReAMzz trial (NCT07635563)",
  "notes": "Inferred from registry: Phase 2, recruiting, primary completion 2027-04; drug is dronabinol + acetazolamide per registry interventions. No company timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07635563",
  "ticker": "IXHL",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0487",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, primary completion 2027-04; drug is dronabinol + acetazolamide per registry interventions.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for IHL-42X (dronabinol + acetazolamide) in Obstructive sleep apnea \u2014 DReAMzz trial (NCT07635563) are expected in Q2 2027, the first real efficacy signal for Incannex Healthcare Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Jaguar Health, Inc.",
  "competitors": [
   "Takeda (Gattex/teduglutide, SBS)",
   "Ironwood (apraglutide, SBS-IF confirmatory Phase 3 STARS-2)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Crofelemer (Phase 2)",
  "event_type": "readout",
  "indication": "Short bowel syndrome with intestinal failure (SBS-IF) \u2014 Phase 2 study completion",
  "notes": "Company explicitly guided completion of the Phase 2 SBS-IF crofelemer study by mid-2027 (press release 2026-09-10); study completion reasonably signals a subsequent readout. MVID program (Phase 3/NDA) is separate and out of scope for this output. Official Jaguar Health release (2026-09-10) on ACCESS Newswire confirms 'completion of a Phase 2 study in SBS-IF by mid-2027' in both the body and forward-looking statements. Same release also guides an MVID-program NDA filing in mid-2027 \u2014 do not confuse with the SBS-IF Phase 2 completion milestone.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/all-randomized-pediatric-patients-to-continue-in-the-single-blind-ext-1218995",
  "ticker": "JAGX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0488",
  "guidance_detail": "Company explicitly guided completion of the Phase 2 SBS-IF crofelemer study by mid-2027 (press release 2026-09-10); study completion reasonably signals a subsequent readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Crofelemer in Short bowel syndrome with intestinal failure (SBS-IF) are expected in Q2 2027, the first real efficacy signal for Jaguar Health, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Jazz Pharmaceuticals plc",
  "competitors": [
   "No marketed competitors in diffuse midline glioma beyond Jazz's own dordaviprone/Modeyso (approved Aug 2025 for H3 K27M-mutant DMG)"
  ],
  "country": "Ireland / United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Dordaviprone (ONC201) combinations (Phase 2)",
  "event_type": "readout",
  "indication": "Diffuse midline glioma \u2014 ONC201/dordaviprone combination trial (NCT05009992)",
  "notes": "Inferred from registry: Phase 2, recruiting, investigator-sponsored by UCSF with Jazz Pharmaceuticals as collaborator, primary completion 2027-12-31. PCD at year-end 2027 means the readout could slip into 2028. ACTION frontline confirmatory readout is Phase 3 and recorded in the Phase 1 output.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05009992",
  "ticker": "JAZZ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0489",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, investigator-sponsored by UCSF with Jazz Pharmaceuticals as collaborator, primary completion 2027-12-31.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "JNJ (Talvey/talquetamab, GPRC5D bispecific, approved MM)",
   "JNJ (Carvykti/cilta-cel, BCMA CAR-T, approved MM)",
   "REGN (linvoseltamab, BCMA bispecific, MM)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "JNJ-79635322 (Phase 2)",
  "event_type": "readout",
  "indication": "Relapsed/refractory multiple myeloma \u2014 JNJ-79635322 trispecific antibody (NCT07266441)",
  "notes": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-06-14. JNJ-79635322 (aka JNJ-5322) is an off-the-shelf BCMA x GPRC5D x CD3 trispecific antibody; Phase 1 RP2D (100 mg Q4W SC) and early efficacy signals presented at ASCO 2025. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07266441",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0490",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-06-14.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "NVS (Cosentyx/secukinumab, PsA)",
   "ABBV (Skyrizi/risankizumab, PsA)",
   "JNJ (Tremfya/guselkumab, PsA)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "JNJ-88545223 (Phase 2)",
  "event_type": "readout",
  "indication": "Active psoriatic arthritis \u2014 JNJ-88545223 vs placebo (NCT07321873)",
  "notes": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-06-28. Mechanism of JNJ-88545223 is not publicly disclosed; it is distinct from icotrokinra (JNJ-2113). No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07321873",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0491",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-06-28.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "AMGN (Vectibix/panitumumab, mCRC)",
   "LLY (Cyramza/ramucirumab, mCRC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Amivantamab (Phase 1/2)",
  "event_type": "readout",
  "indication": "Advanced/metastatic colorectal cancer \u2014 amivantamab +/- standard-of-care chemotherapy (NCT05379595)",
  "notes": "Inferred from registry: Phase 1/2, recruiting, Janssen-sponsored, primary completion 2027-04-27; the Phase 2 portion readout is expected in 2027. A new-indication expansion for amivantamab. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05379595",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0492",
  "guidance_detail": "Inferred from registry: Phase 1/2, recruiting, Janssen-sponsored, primary completion 2027-04-27; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0493"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "AZN (Tagrisso/osimertinib, NSCLC)",
   "Roche (Tecentriq/atezolizumab, NSCLC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Amivantamab (Phase 2)",
  "event_type": "readout",
  "indication": "Advanced/metastatic NSCLC \u2014 amivantamab + lazertinib + carboplatin/pemetrexed (NCT05498428)",
  "notes": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-08-17. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05498428",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0493",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Janssen-sponsored, primary completion 2027-08-17.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0492"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "JNJ (Carvykti/cilta-cel, BCMA CAR-T, approved MM)",
   "JNJ (Talvey/talquetamab, GPRC5D bispecific, approved MM)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Ciltacabtagene autoleucel + talquetamab (Phase 2)",
  "event_type": "readout",
  "indication": "High-risk multiple myeloma \u2014 cilta-cel followed by talquetamab (NCT06550895)",
  "notes": "Inferred from registry: Phase 2, active not recruiting, Janssen-sponsored, primary completion 2027-08-26. Combination of the approved BCMA CAR-T and approved GPRC5D bispecific in high-risk MM. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06550895",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0494",
  "guidance_detail": "Inferred from registry: Phase 2, active not recruiting, Janssen-sponsored, primary completion 2027-08-26.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "MRK (Keytruda, mNSCLC)",
   "AZN (Tagrisso/osimertinib, NSCLC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Amivantamab + cetrelimab (Phase 1/2)",
  "event_type": "readout",
  "indication": "Metastatic NSCLC \u2014 amivantamab + cetrelimab (anti-PD-1) combination (NCT05908734)",
  "notes": "Inferred from registry: Phase 1/2, active not recruiting, Janssen-sponsored, primary completion 2027-01-31; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05908734",
  "ticker": "JNJ",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0495",
  "guidance_detail": "Inferred from registry: Phase 1/2, active not recruiting, Janssen-sponsored, primary completion 2027-01-31; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Kairos Pharma, Ltd.",
  "competitors": [
   "PFE (Xtandi/enzalutamide, mCRPC)",
   "JNJ (Erleada/apalutamide, mCRPC)",
   "BAYRY (Nubeqa/darolutamide, mCRPC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ENV-105 (carotuximab) (Phase 2)",
  "event_type": "readout",
  "indication": "Metastatic castration-resistant prostate cancer \u2014 carotuximab + apalutamide (NCT05534646)",
  "notes": "Inferred from registry: Phase 2, recruiting, primary completion 2027-01, lead sponsor Edwin Posadas, MD (Cedars-Sinai; Kairos collaborator). Interim efficacy data were presented at ESMO 2025; final readout timing inferred from the registry date. No company-guided 2027 timing located.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05534646",
  "ticker": "KAPA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0496",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, primary completion 2027-01, lead sponsor Edwin Posadas, MD (Cedars-Sinai; Kairos collaborator).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ENV-105 (carotuximab) in metastatic castration-resistant prostate cancer \u2014 carotuximab + apalutamide (NCT05534646) are expected in Q1 2027, the first real efficacy signal for Kairos Pharma, Ltd.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Kiora Pharmaceuticals, Inc.",
  "competitors": [
   "OCU400 (Ocugen, RP Phase 3)",
   "MCO-010 (Nanoscope Therapeutics, RP)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "KIO-301 (Phase 2)",
  "event_type": "readout",
  "indication": "Late-stage retinitis pigmentosa \u2014 intravitreal KIO-301 (NCT06628947)",
  "notes": "Inferred from registry: Phase 2, recruiting, Kiora-sponsored, primary completion 2027-08. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06628947",
  "ticker": "KPRX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0497",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Kiora-sponsored, primary completion 2027-08.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for KIO-301 in Late-stage retinitis pigmentosa \u2014 intravitreal KIO-301 (NCT06628947) are expected in Q3 2027, the first real efficacy signal for Kiora Pharmaceuticals, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Karyopharm Therapeutics Inc.",
  "competitors": [
   "INCY (Jakafi/ruxolitinib, MF)",
   "GSK (Ojjaara/momelotinib, MF)",
   "BMY (Inrebic/fedratinib, MF)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Selinexor (Phase 2)",
  "event_type": "readout",
  "indication": "Myelofibrosis, JAK inhibitor-naive \u2014 selinexor monotherapy (NCT05980806)",
  "notes": "Inferred from registry: Phase 2, recruiting, Karyopharm-sponsored, primary completion 2027-06. No company-guided 2027 timing located; readout timing inferred from the registry date. SENTRY Phase 3 (selinexor + ruxolitinib) is recorded separately in the Phase 1 output.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05980806",
  "ticker": "KPTI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0498",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Karyopharm-sponsored, primary completion 2027-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0500",
   "v16-0499"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Selinexor in Myelofibrosis, JAK inhibitor-naive \u2014 selinexor monotherapy (NCT05980806) are expected in Q2 2027, the first real efficacy signal for Karyopharm Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Karyopharm Therapeutics Inc.",
  "competitors": [
   "SNY (Sarclisa/isatuximab, MM)",
   "AMGN (Kyprolis/carfilzomib, MM)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Selinexor (Phase 1/2)",
  "event_type": "readout",
  "indication": "Relapsed/refractory multiple myeloma \u2014 selinexor + carfilzomib + isatuximab + dexamethasone (NCT07479979)",
  "notes": "Inferred from registry: Phase 1/2, recruiting, investigator-sponsored (Natalie Callander), primary completion 2027-07; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07479979",
  "ticker": "KPTI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0499",
  "guidance_detail": "Inferred from registry: Phase 1/2, recruiting, investigator-sponsored (Natalie Callander), primary completion 2027-07; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0500",
   "v16-0498"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for selinexor in relapsed/refractory multiple myeloma \u2014 selinexor + carfilzomib + isatuximab + dexamethasone (NCT07479979) are expected in Q3 2027, the first real efficacy signal for Karyopharm Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Karyopharm Therapeutics Inc.",
  "competitors": [
   "INCY (Jakafi/ruxolitinib, MM)",
   "SNY (Sarclisa/isatuximab, MM)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Selinexor (Phase 1/2)",
  "event_type": "readout",
  "indication": "Multiple myeloma \u2014 selinexor + backbone treatments, STOMP platform (NCT02343042)",
  "notes": "Inferred from registry: Phase 1/2 multi-arm platform, recruiting, Karyopharm-sponsored, primary completion 2027-04; prior arms have reported and the Phase 2 portion of continuing arms is expected to read out in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT02343042",
  "ticker": "KPTI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0500",
  "guidance_detail": "Inferred from registry: Phase 1/2 multi-arm platform, recruiting, Karyopharm-sponsored, primary completion 2027-04; prior arms have reported and the Phase 2 portion of continuing arms is expected to read out in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0499",
   "v16-0498"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Selinexor in Multiple myeloma \u2014 selinexor + backbone treatments, STOMP platform (NCT02343042) are expected in Q2 2027, the first real efficacy signal for Karyopharm Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Kura Oncology, Inc.",
  "competitors": [
   "SNX (Revuforj/revumenib, menin inhibitor, approved KMT2Ar AML)",
   "JNJ (bleximenib, menin inhibitor Phase 2/3)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Ziftomenib (Phase 2)",
  "event_type": "readout",
  "indication": "NPM1-mutated or KMT2A-rearranged AML \u2014 ziftomenib (NCT06930352)",
  "notes": "Inferred from registry: Phase 2, recruiting, investigator-sponsored (Uma Borate), primary completion 2027-12-31; PCD at year-end 2027 means the readout could slip into 2028. No company-guided 2027 timing located; readout timing inferred from the registry date. Tipifarnib AIM-HN already reported positive results and is excluded.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06930352",
  "ticker": "KURA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0501",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, investigator-sponsored (Uma Borate), primary completion 2027-12-31; PCD at year-end 2027 means the readout could slip into 2028.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for Ziftomenib in NPM1-mutated or KMT2A-rearranged AML \u2014 ziftomenib (NCT06930352) are expected in Q4 2027, the first real efficacy signal for Kura Oncology, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Kymera Therapeutics, Inc.",
  "competitors": [
   "SNY (Dupixent/dupilumab, asthma)",
   "AZN (Tezspire/tezepelumab, severe asthma)",
   "GSK (Nucala/mepolizumab, eosinophilic asthma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "KT-621 (Phase 2b)",
  "event_type": "readout",
  "indication": "Eosinophilic asthma \u2014 BREADTH Phase 2b trial (NCT07323654)",
  "notes": "Company explicitly guided BREADTH Phase 2b asthma data for late 2027 (press release 2026-06-25); registry lists primary completion 2027-12. The BROADEN2 atopic dermatitis Phase 2b readout was accelerated to year-end 2026 and is excluded from this 2027 calendar. [Source verified 2026-09-20: \"KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027.\" (Kymera Therapeutics GlobeNewswire release, June 25, 2026.)]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/25/3317396/0/en/Kymera-Therapeutics-Completes-Enrollment-in-the-Phase-2b-BROADEN2-Trial-of-KT-621-in-Atopic-Dermatitis-with-Topline-Data-by-Year-end-2026.html",
  "ticker": "KYMR",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0502",
  "guidance_detail": "Company explicitly guided BREADTH Phase 2b asthma data for late 2027 (press release 2026-06-25); registry lists primary completion 2027-12.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Kyverna Therapeutics, Inc.",
  "competitors": [
   "Roche (Ocrevus/ocrelizumab, MS)",
   "NVS (Kesimpta/ofatumumab, MS)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "KYV-101 (Phase 2)",
  "event_type": "readout",
  "indication": "Progressive multiple sclerosis \u2014 KYSA-7 trial (NCT06384976)",
  "notes": "Inferred from registry: Phase 2, active not recruiting, Kyverna-sponsored, primary completion 2027-04. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06384976",
  "ticker": "KYTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0503",
  "guidance_detail": "Inferred from registry: Phase 2, active not recruiting, Kyverna-sponsored, primary completion 2027-04.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0505",
   "v16-0504"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for KYV-101 in Progressive multiple sclerosis \u2014 KYSA-7 trial (NCT06384976) are expected in Q2 2027, the first real efficacy signal for Kyverna Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Kyverna Therapeutics, Inc.",
  "competitors": [
   "ARGX (Vyvgart/efgartigimod, gMG)",
   "UCB (Rystiggo/rozanolixizumab, gMG)",
   "JNJ (Imaavy/nipocalimab, gMG)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "KYV-101 (Phase 2/3)",
  "event_type": "readout",
  "indication": "Generalized myasthenia gravis \u2014 KYSA-6 trial (NCT06193889)",
  "notes": "Inferred from registry: Phase 2/3, recruiting, Kyverna-sponsored, primary completion 2027-09; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06193889",
  "ticker": "KYTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0504",
  "guidance_detail": "Inferred from registry: Phase 2/3, recruiting, Kyverna-sponsored, primary completion 2027-09; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0505",
   "v16-0503"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for KYV-101 (Phase 2/3) in generalized myasthenia gravis \u2014 KYSA-6 trial (NCT06193889) are expected in Q3 2027, the first real efficacy signal for Kyverna Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Kyverna Therapeutics, Inc.",
  "competitors": [
   "ABBV (Rinvoq/upadacitinib, RA)",
   "ABBV (Humira/adalimumab, RA)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "KYV-101 (Phase 1/2)",
  "event_type": "readout",
  "indication": "Rheumatoid arthritis \u2014 rituximab vs KYV-101 head-to-head (NCT06475495)",
  "notes": "Inferred from registry: Phase 1/2, active not recruiting, led by Charite University Berlin with Kyverna Therapeutics as collaborator, primary completion 2027-06; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06475495",
  "ticker": "KYTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0505",
  "guidance_detail": "Inferred from registry: Phase 1/2, active not recruiting, led by Charite University Berlin with Kyverna Therapeutics as collaborator, primary completion 2027-06; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0504",
   "v16-0503"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for KYV-101 in Rheumatoid arthritis \u2014 rituximab vs KYV-101 head-to-head (NCT06475495) are expected in Q2 2027, the first real efficacy signal for Kyverna Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Leap Therapeutics, Inc.",
  "competitors": [
   "MRK (Keytruda/pembrolizumab, endometrial cancer)",
   "GSK (Jemperli/dostarlimab, endometrial cancer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "DKN-01 (Phase 2)",
  "event_type": "readout",
  "indication": "Advanced/recurrent endometrial cancer \u2014 DKN-01 + pembrolizumab (NCT05761951)",
  "notes": "Inferred from registry: Phase 2, active not recruiting, led by M.D. Anderson with Leap Therapeutics as collaborator, primary completion 2027-01-31. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05761951",
  "ticker": "LPTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0506",
  "guidance_detail": "Inferred from registry: Phase 2, active not recruiting, led by M.D.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for DKN-01 in advanced/recurrent endometrial cancer \u2014 DKN-01 + pembrolizumab (NCT05761951) are expected in Q1 2027, the first real efficacy signal for Leap Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "NVO (CagriSema, obesity)",
   "LLY (retatrutide, obesity Phase 3)",
   "AMGN (Maridebart cafraglutide/MariTide, obesity)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Macupatide + eloralintide (Phase 2)",
  "event_type": "readout",
  "indication": "Obesity/overweight and type 2 diabetes \u2014 macupatide (LY3532226) and eloralintide (LY3841136), alone or in combination (NCT07215559)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-03. Eloralintide is a selective amylin receptor agonist (per Lilly EASD 2026 materials). No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07215559",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0507",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-03.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0508"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "NVO (CagriSema, obesity)",
   "LLY (retatrutide, obesity Phase 3)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Macupatide + eloralintide (Phase 2)",
  "event_type": "readout",
  "indication": "Weight management \u2014 macupatide and eloralintide (NCT07589608)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-09. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07589608",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0508",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-09.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0507"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "ARWR (plozasiran, severe hypertriglyceridemia)",
   "IONS (olezarsen/Tryngolza, severe hypertriglyceridemia)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Solbinsiran (LY3561774) (Phase 2)",
  "event_type": "readout",
  "indication": "Severe hypertriglyceridemia \u2014 solbinsiran (NCT07269210)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-03. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07269210",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0509",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-03.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "LLY (Olumiant/baricitinib, alopecia areata)",
   "PFE (Litfulo/ritlecitinib, alopecia areata)",
   "SUN (Leqselvi/deuruxolitinib, alopecia areata)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY4005130 (Phase 2)",
  "event_type": "readout",
  "indication": "Severe alopecia areata \u2014 LY4005130 (NCT07533006)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-06. Mechanism of LY4005130 not publicly disclosed. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07533006",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07533006",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0510",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0511"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "INCY (Opzelura/ruxolitinib cream, vitiligo)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY4005130 (Phase 2)",
  "event_type": "readout",
  "indication": "Non-segmental vitiligo \u2014 LY4005130 (NCT07533019)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05. Mechanism of LY4005130 not publicly disclosed. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07533019",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07533019",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0511",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0510"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "BMY (Cobenfy/xanomeline-trospium, schizophrenia)",
   "ABBV (Vraylar/cariprazine, schizophrenia)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Brenipatide (LY3537031) (Phase 2)",
  "event_type": "readout",
  "indication": "Schizophrenia \u2014 adjunctive brenipatide (NCT07410507)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-11. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07410507",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07410507",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0512",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-11.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0515",
   "v16-0514",
   "v16-0513"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "IRWD (Linzess/linaclotide, IBS)",
   "Ardelyx (Ibsrela/tenapanor, IBS-C)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Brenipatide (LY3537031) (Phase 2)",
  "event_type": "readout",
  "indication": "Irritable bowel syndrome \u2014 brenipatide (NCT07545772)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-07. A second brenipatide IBS trial (NCT07545759, PCD 2027-09) is recorded only once here to avoid duplication. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07545772",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07545772",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0513",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-07.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0515",
   "v16-0514",
   "v16-0512"
  ],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "ABBV (Vraylar/cariprazine, bipolar disorder)",
   "AZN (Seroquel/quetiapine, bipolar disorder)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Brenipatide (LY3537031) (Phase 2)",
  "event_type": "readout",
  "indication": "Bipolar disorder \u2014 brenipatide, RENEW-BP trial (NCT07286175)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-11. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07286175",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07286175",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0514",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-11.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0515",
   "v16-0513",
   "v16-0512"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "LLY (Zepbound/tirzepatide, weight management)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Brenipatide (LY3537031) (Phase 2)",
  "event_type": "readout",
  "indication": "Post-smoking-cessation weight control \u2014 brenipatide (NCT07223840)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-02. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07223840",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0515",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-02.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0514",
   "v16-0513",
   "v16-0512"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "LLY (Mounjaro/tirzepatide, type 2 diabetes)",
   "NVO (Ozempic/semaglutide, type 2 diabetes)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY3457263 (Phase 2)",
  "event_type": "readout",
  "indication": "Type 2 diabetes \u2014 LY3457263 vs placebo (NCT06897475)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05. Mechanism of LY3457263 not publicly disclosed. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06897475",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0516",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "TAK (Entyvio/vedolizumab, UC)",
   "LLY (Omvoh/mirikizumab, UC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY4268989 (MORF-057) + mirikizumab (Phase 2)",
  "event_type": "readout",
  "indication": "Moderately to severely active ulcerative colitis \u2014 MORF-057 co-administered with mirikizumab (NCT07186101)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05. MORF-057 is an oral alpha4beta7 integrin antagonist (Morphic). No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07186101",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0517",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-05.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "TAK (Entyvio/vedolizumab, UC)",
   "LLY (Omvoh/mirikizumab, UC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Eltrekibart + mirikizumab (Phase 2)",
  "event_type": "readout",
  "indication": "Moderately to severely active ulcerative colitis \u2014 eltrekibart and mirikizumab (NCT06598943)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-12; PCD at year-end 2027 means the readout could slip into 2028. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06598943",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0518",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-12; PCD at year-end 2027 means the readout could slip into 2028.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "ABBV (Skyrizi/risankizumab, Crohn's disease)",
   "JNJ (Tremfya/guselkumab, Crohn's disease)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY4395089 + mirikizumab (Phase 2)",
  "event_type": "readout",
  "indication": "Crohn's disease \u2014 LY4395089/mirikizumab co-administration vs mirikizumab (NCT07483099)",
  "notes": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-06. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07483099",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0519",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, Lilly-sponsored, primary completion 2027-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "LLY (Omvoh/mirikizumab, UC)",
   "ABBV (Skyrizi/risankizumab, UC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Multiple agents (Phase 2 master protocol)",
  "event_type": "readout",
  "indication": "Ulcerative colitis \u2014 IIBD master protocol of multiple drugs (NCT07483073)",
  "notes": "Inferred from registry: Phase 2 master protocol, recruiting, Lilly-sponsored, primary completion 2027-06. Individual intervention-specific appendices may report separately. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07483073",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0520",
  "guidance_detail": "Inferred from registry: Phase 2 master protocol, recruiting, Lilly-sponsored, primary completion 2027-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "No disease-modifying therapy for neuronopathic (Type 2) Gaucher disease; SNY (Cerdelga/eliglustat, non-neuronopathic GD)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PR001 (Phase 1/2)",
  "event_type": "readout",
  "indication": "Type 2 Gaucher disease (infants) \u2014 PR001 gene therapy (NCT04411654)",
  "notes": "Inferred from registry: Phase 1/2, active not recruiting, Lilly-sponsored (Prevail Therapeutics program), primary completion 2027-02; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04411654",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0521",
  "guidance_detail": "Inferred from registry: Phase 1/2, active not recruiting, Lilly-sponsored (Prevail Therapeutics program), primary completion 2027-02; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "AMGN (Lumakras/sotorasib, KRAS G12C)",
   "BMY (Krazati/adagrasib, KRAS G12C)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY3537982 (Phase 1/2)",
  "event_type": "readout",
  "indication": "KRAS-mutant cancers \u2014 LY3537982 (NCT04956640)",
  "notes": "Inferred from registry: Phase 1/2, active not recruiting, Lilly-sponsored, primary completion 2027-04; the Phase 2 portion readout is expected in 2027. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04956640",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0522",
  "guidance_detail": "Inferred from registry: Phase 1/2, active not recruiting, Lilly-sponsored, primary completion 2027-04; the Phase 2 portion readout is expected in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Eli Lilly and Company",
  "competitors": [
   "PFE (Lyrica/pregabalin, chronic pain)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "LY4065967 (Phase 2)",
  "event_type": "readout",
  "indication": "Chronic pain \u2014 chronic pain master protocol (CPMP) with LY4065967 (NCT07641517)",
  "notes": "Inferred from registry: Phase 2 master protocol, recruiting, Lilly-sponsored, primary completion 2027-04; related CPMP appendices (NCT07285018, NCT07641504) have later PCDs and are recorded only once here. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07641517",
  "ticker": "LLY",
  "us_listed": true,
  "nct_id": "NCT07641517",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0523",
  "guidance_detail": "Inferred from registry: Phase 2 master protocol, recruiting, Lilly-sponsored, primary completion 2027-04; related CPMP appendices (NCT07285018, NCT07641504) have later PCDs and are recorded only once here.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Lisata Therapeutics, Inc.",
  "competitors": [
   "IONS (Tryngolza/olezarsen, apoC-III, severe hypertriglyceridemia)",
   "ARWR (plozasiran, apoC-III, Phase 3 severe hypertriglyceridemia)",
   "AMRN (Vascepa/icosapent ethyl, hypertriglyceridemia)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MAR001/005 (Phase 2b)",
  "event_type": "readout",
  "indication": "Severe hypertriglyceridemia (sHTG) \u2014 MAR001/005 Phase 2b trial",
  "notes": "Lisata acquired Marea Therapeutics on 2026-09-17; the combined company guides topline data from the ongoing MAR001/005 Phase 2b sHTG trial for Q4 2027. MAR001 is a first-in-class ANGPTL4-targeting monoclonal antibody; MAR005 is the half-life-extended Phase 3 candidate.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/17/3364095/18623/en/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement.html",
  "ticker": "LSTA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0524",
  "guidance_detail": "Lisata acquired Marea Therapeutics on 2026-09-17; the combined company guides topline data from the ongoing MAR001/005 Phase 2b sHTG trial for Q4 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for MAR001/005 in Severe hypertriglyceridemia (sHTG) \u2014 MAR001/005 Phase 2b trial are expected in Q4 2027, the first real efficacy signal for Lisata Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Lisata Therapeutics, Inc.",
  "competitors": [
   "CRNX (paltusotine, oral SST2 agonist, acromegaly)",
   "XERS (Recorlev/levoketoconazole, acromegaly)",
   "NVS (Signifor LAR/pasireotide, acromegaly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MAR002 (Phase 2)",
  "event_type": "readout",
  "indication": "Acromegaly \u2014 MAR002 Phase 2 trial",
  "notes": "Lisata acquired Marea Therapeutics on 2026-09-17; the combined company guides topline Phase 2 proof-of-concept data for MAR002 in acromegaly for Q4 2027. MAR002 is a half-life-extended, allosteric growth hormone receptor antagonist antibody.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/17/3364095/18623/en/lisata-therapeutics-announces-acquisition-of-marea-therapeutics-and-225-million-concurrent-private-placement.html",
  "ticker": "LSTA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0525",
  "guidance_detail": "Lisata acquired Marea Therapeutics on 2026-09-17; the combined company guides topline Phase 2 proof-of-concept data for MAR002 in acromegaly for Q4 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for MAR002 in Acromegaly \u2014 MAR002 Phase 2 trial are expected in Q4 2027, the first real efficacy signal for Lisata Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Maze Therapeutics, Inc.",
  "competitors": [
   "BMRN (Palynziq/pegvaliase and Kuvan/sapropterin, PKU)",
   "PTC (Sephience/sepiapterin, PKU)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MZE782 (Phase 2)",
  "event_type": "readout",
  "indication": "Phenylketonuria (PKU) \u2014 Phase 2 CIPheR proof-of-concept trial (NCT07694440)",
  "notes": "Company explicitly guided initial topline data from the Phase 2 CIPheR trial of MZE782 (oral SLC6A19 inhibitor, plasma phenylalanine reduction) for 2027. Registry lists the Maze-sponsored trial as recruiting with primary completion 2027-12, supporting an H2 2027 read; timing within the year is not company-guided. Event corroborated but canonical source unresolvable: the release is GlobeNewswire-distributed (dateline 'SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE)') and its text is identical across FinancialContent, Intrado, MarketMinute and ADVFN mirrors, confirming 'Phase 2 CIPheR trial of MZE782 in PKU initiated and enrollment ongoing; topline data expected in 2027'.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-8-11-maze-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights",
  "ticker": "MAZE",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0526",
  "guidance_detail": "Company explicitly guided initial topline data from the Phase 2 CIPheR trial of MZE782 (oral SLC6A19 inhibitor, plasma phenylalanine reduction) for 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for MZE782 in Phenylketonuria (PKU) \u2014 Phase 2 CIPheR proof-of-concept trial (NCT07694440) are expected in the second half of 2027, the first real efficacy signal for Maze Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Maze Therapeutics, Inc.",
  "competitors": [
   "VRTX (inaxaplin/VX-147, APOL1 inhibitor, Phase 3 AMKD)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MZE829 (Phase 2)",
  "event_type": "readout",
  "indication": "APOL1-mediated kidney disease (AMKD) \u2014 Phase 2 HORIZON trial updated data",
  "notes": "Company guides updated HORIZON data on three 10-15 patient cohorts (AMKD without diabetes, AMKD with diabetes, AMKD with severe FSGS) for 'late 2026 or early 2027'. Included under the under-coverage mandate with the explicit caveat that the guidance window straddles year-end and the data may land before 2027. Event corroborated but canonical source unresolvable: mirrors of the same GlobeNewswire-distributed release confirm 'Maze continues to enroll the HORIZON trial, and expects to announce updated data in late 2026 or early 2027 on three 10-15 patient cohorts: AMKD without diabetes, AMKD with diabetes and AMKD with severe FSGS.' Guidance window straddles year-end; data may land before 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-8-11-maze-therapeutics-reports-second-quarter-2026-financial-results-and-recent-highlights",
  "ticker": "MAZE",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0527",
  "guidance_detail": "Company guides updated HORIZON data on three 10-15 patient cohorts (AMKD without diabetes, AMKD with diabetes, AMKD with severe FSGS) for 'late 2026 or early 2027'.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for MZE829 in APOL1-mediated kidney disease (AMKD) \u2014 Phase 2 HORIZON trial updated data are expected in the first half of 2027, the first real efficacy signal for Maze Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Moleculin Biotech, Inc.",
  "competitors": [
   "KZIA (paxalisib, AGILE glioblastoma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "WP1066 (Phase 2)",
  "event_type": "readout",
  "indication": "Newly diagnosed IDH-wildtype / MGMT-unmethylated glioblastoma \u2014 WP1066 + radiation therapy (NCT05879250)",
  "notes": "Inferred from registry: Phase 2 multi-arm open-label study, recruiting, primary completion 2027-12-27. Investigator-led (Northwestern University) with Moleculin Biotech and NCI as collaborators; WP1066 is Moleculin's STAT3 inhibitor. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05879250",
  "ticker": "MBRX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0528",
  "guidance_detail": "Inferred from registry: Phase 2 multi-arm open-label study, recruiting, primary completion 2027-12-27.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for WP1066 in newly diagnosed IDH-wildtype / MGMT-unmethylated glioblastoma \u2014 WP1066 + radiation therapy (NCT05879250) are expected in Q4 2027, the first real efficacy signal for Moleculin Biotech, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "MacroGenics, Inc.",
  "competitors": [
   "MRK (Keytruda/pembrolizumab, endometrial cancer)",
   "GSK (Jemperli/dostarlimab, endometrial cancer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Lorigerlimab (Phase 2)",
  "event_type": "readout",
  "indication": "Advanced gynecologic cancers (platinum-resistant ovarian, clear cell gynecologic, endometrial) \u2014 LINNET Phase 2 study (NCT06730347)",
  "notes": "Company explicitly guided updated LINNET Phase 2 results for the first half of 2027 (Q1 2026 results PR): enrollment of 20 additional clear-cell gynecologic cancer patients at 3 mg/kg Q3W to complete by year-end 2026. Lorigerlimab is a PD-1 x CTLA-4 bispecific DART molecule; prostate development was discontinued in 2025.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/13/3294401/0/en/MacroGenics-Reports-First-Quarter-2026-Financial-Results-and-Highlights-Business-Transformation.html",
  "ticker": "MGNX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0529",
  "guidance_detail": "Company explicitly guided updated LINNET Phase 2 results for the first half of 2027 (Q1 2026 results PR): enrollment of 20 additional clear-cell gynecologic cancer patients at 3 mg/kg Q3W to complete by year-end 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for lorigerlimab in advanced gynecologic cancers (platinum-resistant ovarian, clear cell gynecologic, endometrial) \u2014 LINNET Phase 2 study (NCT06730347) are expected in the first half of 2027, the first real efficacy signal for MacroGenics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "MacroGenics, Inc.",
  "competitors": [
   "BMY (Opdivo/nivolumab, colorectal cancer)",
   "AMGN (Vectibix/panitumumab, colorectal cancer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Regorafenib + lorigerlimab (Phase 2)",
  "event_type": "readout",
  "indication": "High-risk colorectal cancer \u2014 RELO regimen, regorafenib + lorigerlimab (NCT07071961)",
  "notes": "Inferred from registry: Phase 2, recruiting, primary completion 2027-05-01. Investigator-led (MD Anderson Cancer Center) with Bayer and MacroGenics as collaborators. No company-guided 2027 timing located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07071961",
  "ticker": "MGNX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0530",
  "guidance_detail": "Inferred from registry: Phase 2, recruiting, primary completion 2027-05-01.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Regorafenib + lorigerlimab in High-risk colorectal cancer \u2014 RELO regimen, regorafenib + lorigerlimab (NCT07071961) are expected in Q2 2027, the first real efficacy signal for MacroGenics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "MeiraGTx Holdings plc",
  "competitors": [
   "NVS (ianalumab, Sj\u00f6gren's dryness \u2014 adjacent dryness indication; no approved disease-modifying therapy for RIX)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AAV2-hAQP1 (Phase 2)",
  "event_type": "readout",
  "indication": "Grade 2/3 radiation-induced xerostomia (RIX) \u2014 pivotal Phase 2 AQUAx2 study (NCT05926765)",
  "notes": "Company guided 12-month data from the pivotal Phase 2 AQUAx2 study for Q2 2027 to support a potential BLA and targeted approval by end of 2027 (Q1 2026 results); Q2 2026 update confirmed enrollment completed in Q2 2026 and AAV2-hAQP1 filings planned for mid-2027. Registry lists primary completion 2027-06, consistent with guidance. FDA Breakthrough Therapy designation granted March 2026. [Source verified 2026-09-20: GlobeNewswire-distributed MeiraGTx Q1 2026 release: 'The Phase 2 AQUAx2 (NCT05926765) randomized, double-blind, placebo-controlled study at 30 sites in the U.S., Canada and the U.K. is closing this month with the 12-mont]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/14/3294852/0/en/MeiraGTx-Reports-First-Quarter-2026-Financial-and-Operational-Results.html",
  "ticker": "MGTX",
  "us_listed": true,
  "nct_id": "NCT05926765",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0531",
  "guidance_detail": "Company guided 12-month data from the pivotal Phase 2 AQUAx2 study for Q2 2027 to support a potential BLA and targeted approval by end of 2027 (Q1 2026 results); Q2 2026 update confirmed enrollment completed in Q2 2026 and AAV2-hAQP1 filings planned for mid-2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0179"
  ],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for AAV2-hAQP1 in Grade 2/3 radiation-induced xerostomia (RIX) \u2014 pivotal AQUAx2 study (NCT05926765) are expected in Q2 2027, the first real efficacy signal for MeiraGTx Holdings plc's program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Mirum Pharmaceuticals, Inc.",
  "competitors": [
   "GSK (linerixibat, PBC pruritus Phase 3)",
   "GILD (Livdelzi/seladelpar, primary biliary cholangitis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Volixibat (Phase 2b)",
  "event_type": "readout",
  "indication": "Cholestatic pruritus due to primary biliary cholangitis (PBC) \u2014 VANTAGE Phase 2b study (NCT05050136)",
  "notes": "Company guided topline VANTAGE results for Q1 2027 following completed enrollment (Q2 2026 results PR). Volixibat is an IBAT inhibitor with Breakthrough Therapy designation for cholestatic pruritus in PBC. Distinct from the volixibat PSC program (VISTAS met its primary endpoint May 2026; NDA targeted H1 2027). Registry lists primary completion 2027-01, consistent with guidance.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260805277342/en/Mirum-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update",
  "ticker": "MIRM",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0532",
  "guidance_detail": "Company guided topline VANTAGE results for Q1 2027 following completed enrollment (Q2 2026 results PR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0174"
  ],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Mirum Pharmaceuticals, Inc.",
  "competitors": [
   "GILD (Hepcludex/bulevirtide, chronic hepatitis delta)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Brelovitug (Phase 2b/3)",
  "event_type": "readout",
  "indication": "Chronic hepatitis delta (HDV) \u2014 Phase 2b/3 switching-to-brelovitug study vs bulevirtide (NCT07454837)",
  "notes": "Inferred from registry: Phase 2b/3 open-label study, recruiting, primary completion 2027-08-31; included because the Phase 2b portion reads out in 2027. Distinct from the AZURE-1/AZURE-4 Phase 3 program (topline expected Q3/Q4 2026). No company-guided 2027 timing for this switch study located; readout timing inferred from the registry date.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07454837",
  "ticker": "MIRM",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0533",
  "guidance_detail": "Inferred from registry: Phase 2b/3 open-label study, recruiting, primary completion 2027-08-31; included because the Phase 2b portion reads out in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0695",
   "v16-0175"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Mirum Pharmaceuticals, Inc.",
  "competitors": [
   "ACAD (Daybue/trofinetide \u2014 approved neurodevelopmental therapy, adjacent indication)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MRM-3379 (Phase 2)",
  "event_type": "readout",
  "indication": "Fragile X syndrome \u2014 BLOOM Phase 2 study in male participants (NCT07209462)",
  "notes": "Inferred from registry: randomized, double-blind, placebo-controlled Phase 2, recruiting, primary completion 2027-10. MRM-3379 is a PDE4D inhibitor. No company-guided 2027 timing located; readout timing inferred from the registry date. No approved therapy for Fragile X syndrome. Reviewed 2026-09-20: upgraded inferred->guidance; Mirum March 2026 corporate deck explicitly lists BLOOM Phase 2 topline expected 2027.",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://s21.q4cdn.com/142896768/files/doc_presentations/2026/Mirum-Updated-Corporate-Presentation_Mar-26-FINAL.pdf",
  "ticker": "MIRM",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0534",
  "guidance_detail": "Inferred from registry: randomized, double-blind, placebo-controlled Phase 2, recruiting, primary completion 2027-10.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Neurocrine Biosciences, Inc.",
  "competitors": [
   "Teva (deutetrabenazine)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "NBI-1065890",
  "event_type": "readout",
  "indication": "tardive dyskinesia (NBI-1065890-TD2033)",
  "notes": "CT.gov NCT07365462: Phase 2, started Feb 2026, primary completion Feb 2027 (est.), study completion Mar 2027; topline inferred H1 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07365462",
  "ticker": "NBIX",
  "us_listed": true,
  "nct_id": "NCT07365462",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0535",
  "guidance_detail": "CT.gov NCT07365462: Phase 2, started Feb 2026, primary completion Feb 2027 (est.), study completion Mar 2027; topline inferred H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "Nektar Therapeutics",
  "competitors": [
   "Provention Bio/Sanofi (teplizumab)",
   "Diamyd (rhGAD65)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "rezpegaldesleukin",
  "event_type": "readout",
  "indication": "type 1 diabetes",
  "notes": "Company stated July 2026: initial Phase 2 T1D data expected in 2027; ZENITH AD and alopecia areata programs are Phase 3",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/nektar-therapeutics-announces-start-of-phase-3-zenith-ad-program-evaluating-novel-regulatory-t-cell-biologic-rezpegaldesleukin-in-moderate-to-severe-atopic-dermatitis-302830206.html",
  "ticker": "NKTR",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0536",
  "guidance_detail": "Company stated July 2026: initial Phase 2 T1D data expected in 2027; ZENITH AD and alopecia areata programs are Phase 3.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for rezpegaldesleukin in type 1 diabetes are expected sometime in 2027, the first real efficacy signal for Nektar Therapeutics's program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Novo Nordisk A/S",
  "competitors": [
   "Retatrutide (Eli Lilly)",
   "Orforglipron (Eli Lilly)",
   "Maridebart cafraglutide (Amgen)"
  ],
  "country": "Denmark",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "UBT251",
  "event_type": "readout",
  "indication": "obesity (global Phase 1b/2a)",
  "notes": "Novo Nordisk Q1 2026 deck guides Phase 1b/2a data in 2027; separate Phase 2 T2D study had no 2027 readout guidance",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/43ca5a64-12bf-3230-a9c2-0b4ea69cc4f0/presentation.pdf",
  "ticker": "NVO",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0537",
  "guidance_detail": "Novo Nordisk Q1 2026 deck guides Phase 1b/2a data in 2027; separate Phase 2 T2D study had no 2027 readout guidance.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Novartis AG",
  "competitors": [
   "Baxdrostat (AstraZeneca)",
   "Lorundrostat (AstraZeneca)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "QCZ484",
  "event_type": "readout",
  "indication": "hypertension (NCT06857955)",
  "notes": "Novartis Q1 2026 deck lists 2027 Phase 2 readout",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/38ad8a85-0a86-3540-b095-af7e1fbf8ed7/presentation.pdf",
  "ticker": "NVS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0538",
  "guidance_detail": "Novartis Q1 2026 deck lists 2027 Phase 2 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Novartis AG",
  "competitors": [
   "Lepodisiran (Eli Lilly)",
   "Olpasiran (Amgen)",
   "Zerlasiran (Silence Therapeutics)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DII235",
  "event_type": "readout",
  "indication": "elevated lipoprotein(a) (NCT07235046)",
  "notes": "Novartis Q1 2026 deck lists 2027 Phase 2b readout",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/38ad8a85-0a86-3540-b095-af7e1fbf8ed7/presentation.pdf",
  "ticker": "NVS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0539",
  "guidance_detail": "Novartis Q1 2026 deck lists 2027 Phase 2b readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Novartis AG",
  "competitors": [
   "Lebrikizumab (Eli Lilly)",
   "Nemolizumab (Galderma)",
   "Amlitelimab (Sanofi)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "GIA632",
  "event_type": "readout",
  "indication": "atopic dermatitis (NCT07220577)",
  "notes": "Novartis Q1 2026 deck lists 2027 Phase 2 readout; separate GIA632 vitiligo readout is guided for 2028 and excluded",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/38ad8a85-0a86-3540-b095-af7e1fbf8ed7/presentation.pdf",
  "ticker": "NVS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0540",
  "guidance_detail": "Novartis Q1 2026 deck lists 2027 Phase 2 readout; separate GIA632 vitiligo readout is guided for 2028 and excluded.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Novartis AG",
  "competitors": [
   "Givinostat (Italfarmaco)",
   "Vamorolone (Catalyst Pharmaceuticals)",
   "Eteplirsen (Sarepta Therapeutics)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Del-zota (AOC 1044)",
  "event_type": "readout",
  "indication": "Duchenne muscular dystrophy, exon 44 skipping (EXPLORE44OLE, NCT06244082)",
  "notes": "Novartis Q1 2026 deck lists 2027 Phase 2 readout",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/38ad8a85-0a86-3540-b095-af7e1fbf8ed7/presentation.pdf",
  "ticker": "NVS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0541",
  "guidance_detail": "Novartis Q1 2026 deck lists 2027 Phase 2 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Novartis AG",
  "competitors": [
   "Nitazoxanide (Romark)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "EDI048",
  "event_type": "readout",
  "indication": "cryptosporidiosis (NCT07249463)",
  "notes": "Novartis Q1 2026 deck lists 2027 Phase 2 readout",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/38ad8a85-0a86-3540-b095-af7e1fbf8ed7/presentation.pdf",
  "ticker": "NVS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0542",
  "guidance_detail": "Novartis Q1 2026 deck lists 2027 Phase 2 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ocugen, Inc.",
  "competitors": [
   "Tinlarebant (Belite Bio)",
   "Gildeuretinol (Alkeus Pharmaceuticals)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OCU410ST",
  "event_type": "readout",
  "indication": "Stargardt disease (GARDian3 Phase 2/3 pivotal confirmatory)",
  "notes": "Company PR 2026-04-01: dosing completed early; topline results expected 2Q27 [Source verified 2026-09-20: GlobeNewswire-distributed Ocugen Q1 2026 business update: 'GARDian3 clinical trial enrollment and dosing were completed ahead of schedule' and 'The interim outcome analysis of 24 subjects at 8 months post-OCU410ST (16 tr]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/05/3287702/0/en/Ocugen-Provides-Business-Update-with-First-Quarter-2026-Financial-Results.html",
  "ticker": "OCGN",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0543",
  "guidance_detail": "Company PR 2026-04-01: dosing completed early; topline results expected 2Q27 [Source verified 2026-09-20: GlobeNewswire-distributed Ocugen Q1 2026 business update: 'GARDian3 clinical trial enrollment and dosing were completed ahead of schedule' and 'The interim outcome analysis of 24 subjects at 8 months post-OCU410ST (16 tr].",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0722"
  ],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for OCU410ST in Stargardt disease (GARDian3 Phase 2/3 pivotal confirmatory) are expected in Q2 2027, the first real efficacy signal for Ocugen, Inc.'s program."
 },
 {
  "ticker": "ODTX",
  "company": "Odyssey Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "OD-001",
  "indication": "moderate-to-severe ulcerative colitis, monotherapy (Phase 2b)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Rinvoq (AbbVie)",
   "Zeposia (Bristol Myers Squibb)",
   "Skyrizi (AbbVie)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/Odyssey-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Company Q1 2026 update: Phase 2b OD-001 monotherapy to start H2 2026, topline induction data expected H2 2027",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0544",
  "guidance_detail": "Company Q1 2026 update: Phase 2b OD-001 monotherapy to start H2 2026, topline induction data expected H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for OD-001 in moderate-to-severe ulcerative colitis, monotherapy (Phase 2b) are expected in the second half of 2027, the first real efficacy signal for Odyssey Therapeutics, Inc.'s program."
 },
 {
  "ticker": "ODTX",
  "company": "Odyssey Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "OD-001 + vedolizumab",
  "indication": "moderate-to-severe ulcerative colitis, combination (Phase 2a)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "Entyvio (Takeda)",
   "Rinvoq (AbbVie)",
   "Omvoh (Eli Lilly)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/Odyssey-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Company Q1 2026 update: Phase 2a OD-001 + vedolizumab to start H2 2026, topline induction data expected H2 2027",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0545",
  "guidance_detail": "Company Q1 2026 update: Phase 2a OD-001 + vedolizumab to start H2 2026, topline induction data expected H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for OD-001 + vedolizumab in moderate-to-severe ulcerative colitis, combination (Phase 2a) are expected in the second half of 2027, the first real efficacy signal for Odyssey Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Molecular Partners AG",
  "competitors": [
   "AstraZeneca (durvalumab)",
   "Merck (pembrolizumab)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MP0317",
  "event_type": "readout",
  "indication": "advanced biliary tract carcinoma / cholangiocarcinoma, 1L + chemoimmunotherapy (TACTIC)",
  "notes": "Company PR 2026-07-16: randomized Phase 2 PoC (NCT07036380) data update expected 2027, trial completion 2028 [Registry check 2026-09-23] CT.gov now lists primary completion 2028-11 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014 primary-source guidance re-check queued. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/16/3328214/0/en/Molecular-Partners-Announces-Clinical-Progress-in-Phase-2-TACTIC-Combination-Trial-of-MP0317-for-Patients-with-Cholangiocarcinoma.html",
  "ticker": "MOLN",
  "us_listed": true,
  "nct_id": "NCT07036380",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0546",
  "guidance_detail": "Company PR 2026-07-16: randomized Phase 2 PoC (NCT07036380) data update expected 2027, trial completion 2028.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for MP0317 in advanced biliary tract carcinoma / cholangiocarcinoma, 1L + chemoimmunotherapy (TACTIC) are expected sometime in 2027, the first real efficacy signal for Molecular Partners AG's program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Oruka Therapeutics, Inc.",
  "competitors": [
   "Eli Lilly (ixekizumab)",
   "Amgen (apremilast)",
   "Janssen (guselkumab)",
   "UCB (bimekizumab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ORKA-002",
  "event_type": "readout",
  "indication": "moderate-to-severe plaque psoriasis (ORCA-SURGE)",
  "notes": "Company PR 2026-08-10: Week 16 Phase 2 ORCA-SURGE data accelerated to Q1 2027; ORKA-001 EVERLAST-B Week 16 moved to Q4 2026 (not a 2027 event)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/10/3341704/0/en/oruka-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html",
  "ticker": "ORKA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0547",
  "guidance_detail": "Company PR 2026-08-10: Week 16 Phase 2 ORCA-SURGE data accelerated to Q1 2027; ORKA-001 EVERLAST-B Week 16 moved to Q4 2026 (not a 2027 event).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for ORKA-002 in moderate-to-severe plaque psoriasis (ORCA-SURGE) are expected in Q1 2027, the first real efficacy signal for Oruka Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Ovid Therapeutics Inc.",
  "competitors": [
   "Xenon Pharmaceuticals (azetukalner)",
   "Marinus Pharmaceuticals (ganaxolone)",
   "UCB (lacosamide)",
   "Praxis Precision Medicines (relutrigine)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OV329",
  "event_type": "readout",
  "indication": "drug-resistant adult focal onset seizures (FOS), Phase 2a",
  "notes": "Company deck Jan 2026: Phase 2a initiation Q2 2026, topline results mid-2027 (Q2/Q3 boundary)",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://s201.q4cdn.com/176459324/files/doc_presentations/2026/Jan/12/January-2026-Corporate-Presentation.pdf",
  "ticker": "OVID",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0548",
  "guidance_detail": "Company deck Jan 2026: Phase 2a initiation Q2 2026, topline results mid-2027 (Q2/Q3 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for OV329 in drug-resistant adult focal onset seizures (FOS), Phase 2a are expected sometime in 2027, the first real efficacy signal for Ovid Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Palisade Bio, Inc.",
  "competitors": [
   "Pfizer (etrasimod)",
   "AbbVie (risankizumab)",
   "Takeda (vedolizumab)",
   "Bristol Myers Squibb (ozanimod)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PALI-2108",
  "event_type": "readout",
  "indication": "moderately to severely active ulcerative colitis (ASCENTRA-UC)",
  "notes": "Company PR 2026-06-29: primary efficacy results expected 2H 2027; ASCENTRA-CD (Crohn's) readout guided early 2028 (not a 2027 event)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/29/3318948/0/en/Palisade-Bio-Receives-FDA-Clearance-of-IND-for-PALI-2108-and-Plans-to-Initiate-Global-Phase-2-ASCENTRA-UC-Study-in-Ulcerative-Colitis.html",
  "ticker": "PALI",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0549",
  "guidance_detail": "Company PR 2026-06-29: primary efficacy results expected 2H 2027; ASCENTRA-CD (Crohn's) readout guided early 2028 (not a 2027 event).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for PALI-2108 in moderately to severely active ulcerative colitis (ASCENTRA-UC) are expected in the second half of 2027, the first real efficacy signal for Palisade Bio, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Processa Pharmaceuticals, Inc.",
  "competitors": [
   "Novartis (remibrutinib)",
   "Genentech/Novartis (omalizumab)",
   "Regeneron/Sanofi (dupilumab)",
   "Sanofi (rilzabrutinib)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VT-7208",
  "event_type": "readout",
  "indication": "food allergy, Phase 2 proof-of-concept",
  "notes": "Company PR 2026-07-29: Phase 2 PoC data in food allergy anticipated 2H 2027; CSU data H1 2028 and RMS H2 2028 (not 2027 events) [Source verified 2026-09-20: GlobeNewswire-distributed Processa July 29, 2026 release: 'Processa expects to use the proceeds to support the advancement of VT-7208 through multiple clinical milestones, including data from a Phase 2 proof-of-concept s]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/29/3335130/0/en/PROCESSA-PHARMACEUTICALS-INC-ANNOUNCES-ACQUISITION-OF-VIDYA-THERAPEUTICS-INC-AND-APPROXIMATELY-200-MILLION-CONCURRENT-PRIVATE-PLACEMENT-TO-ADVANCE-BTK-INHIBITOR-VT-7208-IN-MULTIPLE.html",
  "ticker": "PCSA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0550",
  "guidance_detail": "Company PR 2026-07-29: Phase 2 PoC data in food allergy anticipated 2H 2027; CSU data H1 2028 and RMS H2 2028 (not 2027 events) [Source verified 2026-09-20: GlobeNewswire-distributed Processa July 29, 2026 release: 'Processa expects to use the proceeds to support the advancement of VT-7208 through multiple clinical milestones, including data from a Phase 2 proof-of-concept s].",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for VT-7208 in food allergy, Phase 2 proof-of-concept are expected in the second half of 2027, the first real efficacy signal for Processa Pharmaceuticals, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Vaxcyte, Inc.",
  "competitors": [
   "Pfizer (Prevnar 20)",
   "Merck (Capvaxive)",
   "GSK (Synflorix)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VAX-31",
  "event_type": "readout",
  "indication": "invasive pneumococcal disease in healthy infants, Phase 2 dose-finding",
  "notes": "Company PR 2026-08-05: topline safety/tolerability/immunogenicity (primary series + booster) expected sequentially or together by end H1 2027",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339693/0/en/Vaxcyte-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html",
  "ticker": "PCVX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0551",
  "guidance_detail": "Company PR 2026-08-05: topline safety/tolerability/immunogenicity (primary series + booster) expected sequentially or together by end H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v17-0020",
   "v16-0194",
   "v16-0193"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for VAX-31 in invasive pneumococcal disease in healthy infants, Phase 2 dose-finding are expected in the first half of 2027, the first real efficacy signal for Vaxcyte, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "PepGen Inc.",
  "competitors": [
   "Avidity Biosciences (delpacibart braxlosiran)",
   "Dyne Therapeutics (DYNE-101)",
   "Arthex Biotech (ATX-01)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PGN-EDODM1",
  "event_type": "readout",
  "indication": "myotonic dystrophy type 1 (DM1), FREEDOM2-DM1 12.5 mg/kg MAD cohort",
  "notes": "Company PR 2026-08-06: FREEDOM2 12.5 mg/kg cohort results expected 1H 2027 (10 mg/kg data Nov 2026), then end-of-Phase-2 meeting [2026-09-27 link audit] BusinessWire URL re-verified in-browser: loads the correct PepGen Q2 2026 release with no redirect (earlier \"redirect to Arcus\" observation was transient).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260806833210/en/PepGen-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Highlights",
  "ticker": "PEPG",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0552",
  "guidance_detail": "Company PR 2026-08-06: FREEDOM2 12.5 mg/kg cohort results expected 1H 2027 (10 mg/kg data Nov 2026), then end-of-Phase-2 meeting.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for PGN-EDODM1 in myotonic dystrophy type 1 (DM1), FREEDOM2-DM1 12.5 mg/kg MAD cohort are expected in the first half of 2027, the first real efficacy signal for PepGen Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Pharming Group N.V.",
  "competitors": [
   "vatiquinone (PTC Therapeutics)",
   "elamipretide (Stealth BioTherapeutics)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Napazimone (KL1333)",
  "event_type": "readout",
  "indication": "Primary mitochondrial disease caused by mtDNA mutations",
  "notes": "FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study; pivotal readout guided for 2027 (Pharming Investor Day, Feb 3 2026); KL1333 licensed from Abliva AB [Source verified 2026-09-20: GlobeNewswire-distributed Pharming Q4/FY2025 results: 'Napazimone (KL1333) is being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochondrial disease... Over 20 clinical sites in th]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/03/12/3254281/0/en/Pharming-Group-reports-fourth-quarter-and-full-year-2025-financial-results-delivering-strong-revenue-growth-and-profitability-with-positive-cash-flow.html",
  "ticker": "PHAR",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0554",
  "guidance_detail": "FALCON is a Phase 2, global, randomized, placebo-controlled, potentially registrational study; pivotal readout guided for 2027 (Pharming Investor Day, Feb 3 2026); KL1333 licensed from Abliva AB [Source verified 2026-09-20: GlobeNewswire-distributed Pharming Q4/FY2025 results: 'Napazimone (KL1333) is being evaluated in the pivotal FALCON clinical trial in adult patients with mtDNA-driven mitochond",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for Napazimone (KL1333) in primary mitochondrial disease caused by mtDNA mutations are expected sometime in 2027, the first real efficacy signal for Pharming Group N.V.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Quince Therapeutics, Inc.",
  "competitors": [
   "Sanofi belumosudil (Rezurock; Phase 2 investigator-initiated study in BOS post-hematopoietic cell transplant)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "LAM-001 (inhaled formulation of rapamycin; mTOR inhibitor)",
  "event_type": "readout",
  "guidance_detail": "Phase 2 data in bronchiolitis obliterans syndrome (BOS) post lung transplant anticipated in Q1 2027, per the company's Q2 2026 financial results PR (Aug 14, 2026). The company separately guides Phase 2b PH-ILD data to Q1 2028 (out of scope).",
  "indication": "Bronchiolitis obliterans syndrome (BOS) post lung transplant",
  "notes": "LAM-001 is Quince's lead program acquired via the May 2026 acquisition of Orphai Therapeutics (formerly AI Therapeutics). The Phase 2 BOS study originated as an investigator-initiated trial at UCSF. BOS is the leading cause of death after lung transplantation and has no approved therapies.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/14/3345285/0/en/quince-therapeutics-reports-second-quarter-2026-financial-results-and-corporate-update.html",
  "ticker": "QNCX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0555",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for LAM-001 (inhaled formulation of rapamycin; mTOR inhibitor) in Bronchiolitis obliterans syndrome (BOS) post lung transplant are expected in Q1 2027, the first real efficacy signal for Quince Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Quoin Pharmaceuticals Ltd.",
  "competitors": [
   "BioCryst Pharmaceuticals BCX17725 (KLK5 inhibitor; pivotal study planned 2027)",
   "Azitra ATR-12 (engineered S. epidermidis expressing LEKTI fragment; Phase 1b)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "QRX003 4% lotion (topical broad-spectrum serine protease inhibitor)",
  "event_type": "readout",
  "guidance_detail": "Topline results from the integrated Phase 2/3 CL-QRX003-004 study in Netherton syndrome anticipated in Q2 2027, per the company's Aug 28, 2026 interim-data PR. Company also expects enrollment completion by end of 2026 and plans a pivotal Phase 3 study initiation in H2 2026.",
  "indication": "Netherton syndrome",
  "notes": "CL-QRX003-004 is an integrated Phase 2/3 open-label whole-body study (~20 evaluable patients); interim analysis of the first 6 patients reported Aug 28, 2026 showed no adverse events and no abnormal lab values. A Phase 2 portion readout in 2027 qualifies per the Phase 1/2 or 2/3 rule. QRX003 holds US FDA Fast Track and orphan drug designations for Netherton syndrome.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/28/3352586/0/en/quoin-pharmaceuticals-reports-positive-interim-data-from-ongoing-phase-2-3-study-of-qrx003-in-netherton-syndrome.html",
  "ticker": "QNRX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0556",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for QRX003 4% lotion (topical broad-spectrum serine protease inhibitor) in Netherton syndrome are expected in Q2 2027, the first real efficacy signal for Quoin Pharmaceuticals Ltd.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Cartesian Therapeutics, Inc.",
  "competitors": [
   "CABA/Cabaletta Bio CABA-201 (CAR T in myositis)",
   "FATE/Fate Therapeutics FT819 (CAR T in autoimmune diseases)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Descartes-08",
  "event_type": "readout",
  "indication": "Myositis",
  "notes": "Phase 2 TRITON trial; data from a subset of patients expected 1H27 per Aug 6, 2026 Q2 business update",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/cartesian-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update",
  "ticker": "RNAC",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0557",
  "guidance_detail": "Phase 2 TRITON trial; data from a subset of patients expected 1H27 per Aug 6, 2026 Q2 business update.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-1015",
   "v16-1014"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 2 results for Descartes-08 in Myositis are expected in the first half of 2027, the first real efficacy signal for Cartesian Therapeutics's program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Sanofi",
  "competitors": [
   "NVS/Novartis secukinumab (Cosentyx)",
   "UCB bimekizumab (Bimzelx)"
  ],
  "country": "France",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "brivekimig (dual-target TNF/OX40L Nanobody)",
  "event_type": "readout",
  "indication": "Moderate-to-severe hidradenitis suppurativa (HS)",
  "notes": "Phase 2b BRIGHTEN (NCT07170917) of brivekimig in mod-severe hidradenitis suppurativa; Sanofi Q2 2026 earnings call (CSO) guides Phase 2b results in 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.sanofi.com/assets/dotcom/content-app/events/quaterly-results/2026/2026-q2-2026-results/SAN-EP_Transcript_2026-07-30.pdf",
  "ticker": "SNY",
  "us_listed": true,
  "nct_id": "NCT07170917",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0558",
  "guidance_detail": "Phase 2b BRIGHTEN (NCT07170917) of brivekimig in mod-severe hidradenitis suppurativa; Sanofi Q2 2026 earnings call (CSO) guides Phase 2b results in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "competitors": [
   "BMS/Bristol Myers Squibb milvexian (FXI inhibitor, LIBREXIA program)",
   "BAYN/Bayer asundexian (FXI inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "cenvacibart (REGN7508) + amrecibart (REGN9933), anti-Factor XI antibodies",
  "event_type": "readout",
  "indication": "Stroke prevention in patients with atrial fibrillation (SPA)",
  "notes": "Phase 2 ROXI-ATLAS evaluates cenvacibart (REGN7508) + amrecibart (REGN9933) vs apixaban in AF stroke prevention; Regeneron April 2026 corporate deck lists the trial as enrolling with estimated primary completion supporting a 2Q 2027 readout. Per Caleb's 2026-09-20 directive, Quartr-hosted call transcripts are legitimate sources; no URL change. Re-checked 2026-09-23: ROXI-ATLAS: source guides trial completion (not a readout). With trial completing 2027 and a 12-week readout lag, the company has no public 2027 readout timing - downgraded guidance to inferred. Bucket kept 2027-Q2. Source: https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-investor-conference-participation/.",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://files.quartr.com/conference-calls/91889-2026-04-29-12-51-27.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=",
  "ticker": "REGN",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0559",
  "guidance_detail": "Phase 2 ROXI-ATLAS evaluates cenvacibart (REGN7508) + amrecibart (REGN9933) vs apixaban in AF stroke prevention; Regeneron April 2026 corporate deck lists the trial as enrolling with estimated primary completion supporting a 2Q 2027 readout.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-01",
  "company": "Seaport Therapeutics, Inc.",
  "competitors": [
   "COMP (COMP360 psilocybin, Phase 3 treatment-resistant depression)",
   "JNJ (esketamine/Spravato, approved treatment-resistant depression)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "GlyphAllo (allopregnanolone prodrug)",
  "event_type": "readout",
  "indication": "major depressive disorder (BUOY-1 Phase 2b)",
  "notes": "Company guides BUOY-1 Phase 2b topline data in H1 2027 (Q2 2026 results PR, Aug 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260803578717/en/Seaport-Therapeutics-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Recent-Corporate-and-Clinical-Progress",
  "ticker": "SPTX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0560",
  "guidance_detail": "Company guides BUOY-1 Phase 2b topline data in H1 2027 (Q2 2026 results PR, Aug 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for GlyphAllo (allopregnanolone prodrug) in major depressive disorder (BUOY-1 Phase 2b) are expected in the first half of 2027, the first real efficacy signal for Seaport Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Spyre Therapeutics Inc.",
  "competitors": [
   "TAK (vedolizumab, anti-a4b7, approved UC)",
   "TEVA (duvakitug, anti-TL1A, Phase 2b UC)",
   "ABBV (risankizumab, anti-IL-23, approved UC)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SPY001 / SPY002 / SPY003 (+ SPY120, SPY130, SPY230 combos)",
  "event_type": "readout",
  "indication": "moderate-to-severe ulcerative colitis (SKYLINE Phase 2 platform, Part B)",
  "notes": "Company PR (Apr 2026): SKYLINE Part B randomized induction data for all mono + combo cohorts on track for 2027; Part A already reported [Source verified 2026-09-20: GlobeNewswire-distributed Spyre Sept 8, 2026 release: 'Part B includes two dose levels of each monotherapy as well as three high-dose combination arms (SPY120, SPY130, and SPY230)... Topline induction data from Part B ar]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357613/0/en/spyre-announces-potential-best-in-class-spy003-anti-il-23-part-a-induction-results-from-skyline-trial-completing-proof-of-concept-for-all-three-components-of-its-ibd-combinations.html",
  "ticker": "SYRE",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0561",
  "guidance_detail": "Company PR (Apr 2026): SKYLINE Part B randomized induction data for all mono + combo cohorts on track for 2027; Part A already reported [Source verified 2026-09-20: GlobeNewswire-distributed Spyre Sept 8, 2026 release: 'Part B includes two dose levels of each monotherapy as well as three high-dose combination arms (SPY120, SPY130, and SPY230)..",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for SPY001 / SPY002 / SPY003 (+ SPY120, SPY130, SPY230 combos) in moderate-to-severe ulcerative colitis (SKYLINE Phase 2 platform, Part B) are expected sometime in 2027, the first real efficacy signal for Spyre Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "BMY (deucravacitinib, TYK2 inhibitor, Phase 3 Crohn's)",
   "ABBV (upadacitinib, JAK1 inhibitor, approved Crohn's)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zasocitinib (TAK-279, oral TYK2 inhibitor)",
  "event_type": "readout",
  "indication": "Crohn's disease (Phase 2b)",
  "notes": "Takeda FY2026 = Apr 2026-Mar 2027; Q1 2027 earnings call guided CD/UC Phase 2b data 'at the end of our FY 2026' -> 2027-Q1 (company deck, May 2026)",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://assets-dam.takeda.com/image/upload/v1778639717/Global/Investor/Financial-Results/FY2025/Q4/qr2025_q4_Expected_timelines_en.pdf",
  "ticker": "TAK",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0562",
  "guidance_detail": "Takeda FY2026 = Apr 2026-Mar 2027; Q1 2027 earnings call guided CD/UC Phase 2b data 'at the end of our FY 2026' -> 2027-Q1 (company deck, May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0207",
   "v16-0563"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "BMY (deucravacitinib, TYK2 inhibitor, Phase 2/3 ulcerative colitis)",
   "ABBV (upadacitinib, JAK1 inhibitor, approved ulcerative colitis)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "zasocitinib (TAK-279, oral TYK2 inhibitor)",
  "event_type": "readout",
  "indication": "ulcerative colitis (Phase 2b)",
  "notes": "Separate Phase 2b study (started Jun 2024); same FY2026 guidance as Crohn's cohort (company deck, May 2026)",
  "phase": "2",
  "source_type": "company deck",
  "source_url": "https://assets-dam.takeda.com/image/upload/v1778639717/Global/Investor/Financial-Results/FY2025/Q4/qr2025_q4_Expected_timelines_en.pdf",
  "ticker": "TAK",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0563",
  "guidance_detail": "Separate Phase 2b study (started Jun 2024); same FY2026 guidance as Crohn's cohort (company deck, May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0207",
   "v16-0562"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Tarsus Pharmaceuticals, Inc.",
  "competitors": [
   "TARS (XDEMVY/lotilaner, same molecule, approved Demodex blepharitis)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TP-04 (lotilaner ophthalmic gel)",
  "event_type": "readout",
  "indication": "ocular rosacea (Phase 2)",
  "notes": "Phase 2 initiated 2025 per Jan 2025 PR; Q1 2026 PR guides topline data in H1 2027; no FDA-approved therapy for ocular rosacea (company PR, May 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/06/3289329/0/en/Tarsus-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Achievements.html",
  "ticker": "TARS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0564",
  "guidance_detail": "Phase 2 initiated 2025 per Jan 2025 PR; Q1 2026 PR guides topline data in H1 2027; no FDA-approved therapy for ocular rosacea (company PR, May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Tarsus Pharmaceuticals, Inc.",
  "competitors": [
   "VALN (VLA15 Lyme vaccine, Phase 3, partnered with PFE)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TP-05 (lotilaner, Calliope study)",
  "event_type": "readout",
  "indication": "Lyme disease prevention (Phase 2)",
  "notes": "Phase 2 Calliope study planned to initiate Q2 2026; topline data expected H1 2027 (company PR, May 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/06/3289329/0/en/Tarsus-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Achievements.html",
  "ticker": "TARS",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0565",
  "guidance_detail": "Phase 2 Calliope study planned to initiate Q2 2026; topline data expected H1 2027 (company PR, May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Theriva Biologics, Inc.",
  "competitors": [
   "CORT (relacorilant, Phase 3 PDAC)",
   "AZN (olaparib/Lynparza, approved BRCA-mutated PDAC maintenance)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VCN-01 (zabilugene almadenorepvec, oncolytic adenovirus)",
  "event_type": "readout",
  "indication": "metastatic pancreatic ductal adenocarcinoma (VIRAGE2 Phase 2a)",
  "notes": "First patient dosed Aug 2026; enrollment completes H2 2026; initial PD/safety data anticipated by Q3 2027 (company PR, Aug 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340187/0/en/Theriva-Biologics-Announces-First-Patient-Dosed-in-VIRAGE2-Phase-2a-Clinical-Trial-to-Evaluate-More-Frequent-Dosing-of-VCN-01-zabilugene-almadenorepvec-in-First-Line-Patients-with-.html",
  "ticker": "TOVX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0566",
  "guidance_detail": "First patient dosed Aug 2026; enrollment completes H2 2026; initial PD/safety data anticipated by Q3 2027 (company PR, Aug 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for VCN-01 (zabilugene almadenorepvec, oncolytic adenovirus) in metastatic pancreatic ductal adenocarcinoma (VIRAGE2 Phase 2a) are expected in Q3 2027, the first real efficacy signal for Theriva Biologics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Entrada Therapeutics, Inc.",
  "competitors": [
   "SRPT (exon-skipping PMO franchise: eteplirsen/casimersen/golodirsen, approved)",
   "Nippon Shinyaku/NS Pharma (NS-089, exon 44 skipping PMO)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ENTR-601-44 (exon 44 skipping EEV-PMO)",
  "event_type": "readout",
  "indication": "Duchenne muscular dystrophy, exon 44 amenable (ELEVATE-44-201 Cohort 2, 12 mg/kg)",
  "notes": "Phase 1/2 two-part MAD study; participants transition from MAD dosing into the 6-dose open-label Phase 2 portion (company PR, Feb 2026); Cohort 2 (12 mg/kg) enrollment complete; Phase 2 portion data expected Q1 2027 (company PR, Aug 2026) Full official Entrada Q2 2026 release confirms ELEVATE-44-201 Cohort 2 (12 mg/kg MAD) data expected in Q1 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/entrada-therapeutics-reports-second-quarter-2026-financial-results",
  "ticker": "TRDA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0567",
  "guidance_detail": "Phase 1/2 two-part MAD study; participants transition from MAD dosing into the 6-dose open-label Phase 2 portion (company PR, Feb 2026); Cohort 2 (12 mg/kg) enrollment complete; Phase 2 portion data expected Q1 2027 (company PR, Aug 2026) Full official Entrada Q2 2026 release confirms ELEVATE-44-201 Cohort 2 (12 mg/kg MAD) data expected in Q1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ENTR-601-44 (exon 44 skipping EEV-PMO) in Duchenne muscular dystrophy, exon 44 amenable (ELEVATE-44-201 Cohort 2, 12 mg/kg) are expected in Q1 2027, the first real efficacy signal for Entrada Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Entrada Therapeutics, Inc.",
  "competitors": [
   "SRPT (casimersen/Amondys 45, approved exon 45 skipping)",
   "Nippon Shinyaku/NS Pharma (viltolarsen/Viltepso, approved exon 53 skipping PMO)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ENTR-601-45 (exon 45 skipping EEV-PMO)",
  "event_type": "readout",
  "indication": "Duchenne muscular dystrophy, exon 45 amenable (ELEVATE-45-201 Cohort 2, 10 mg/kg)",
  "notes": "Phase 1/2 two-part MAD study; participants transition from MAD dosing into the 6-dose open-label Phase 2 portion (company PR, Feb 2026); Cohort 2 dosing ongoing at 10 mg/kg; Phase 2 portion data expected H1 2027 (company PR, Aug 2026) Full official Entrada Q2 2026 release confirms ELEVATE-45-201 Cohort 2 MAD (10 mg/kg) data expected in the first half of 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/entrada-therapeutics-reports-second-quarter-2026-financial-results",
  "ticker": "TRDA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0568",
  "guidance_detail": "Phase 1/2 two-part MAD study; participants transition from MAD dosing into the 6-dose open-label Phase 2 portion (company PR, Feb 2026); Cohort 2 dosing ongoing at 10 mg/kg; Phase 2 portion data expected H1 2027 (company PR, Aug 2026) Full official Entrada Q2 2026 release confirms ELEVATE-45-201 Cohort 2 MAD (10 mg/kg) data expected in the first half of 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ENTR-601-45 (exon 45 skipping EEV-PMO) in Duchenne muscular dystrophy, exon 45 amenable (ELEVATE-45-201 Cohort 2, 10 mg/kg) are expected in the first half of 2027, the first real efficacy signal for Entrada Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Tyra Biosciences, Inc.",
  "competitors": [
   "BMRN (vosoritide/Voxzogo, approved pediatric achondroplasia)",
   "ASND (navepegritide/TransCon CNP, achondroplasia program)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "dabogratinib (formerly TYRA-300, oral FGFR3-selective inhibitor)",
  "event_type": "readout",
  "indication": "pediatric achondroplasia (BEACH301 Phase 2)",
  "notes": "Initial safety-sentinel results incl. 6-month annualized height velocity for dose levels 1-5 expected end of Q1 2027 (company PR, Aug 2026) Official Tyra Biosciences release (2026-08-04) on PR Newswire confirms: initial BEACH301 safety-sentinel results, including 6-month annualized height velocity and safety for dose levels 1-5 (~25 children), 'expected to be reported at the end of Q1 2027'.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights-302842952.html",
  "ticker": "TYRA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0569",
  "guidance_detail": "Initial safety-sentinel results incl.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0570"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for dabogratinib (formerly TYRA-300, oral FGFR3-selective inhibitor) in pediatric achondroplasia (BEACH301 Phase 2) are expected in Q1 2027, the first real efficacy signal for Tyra Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Tyra Biosciences, Inc.",
  "competitors": [
   "JNJ (erdafitinib/Balversa, approved FGFR3-altered urothelial carcinoma)",
   "URGN (mitomycin ureteral gel/Jelmyto, approved LG-UTUC)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "dabogratinib (formerly TYRA-300, oral FGFR3-selective inhibitor)",
  "event_type": "readout",
  "indication": "low-grade upper tract urothelial carcinoma (SURF303 Phase 2a/b)",
  "notes": "Initial results from pivotal-intent Phase 2a/b expected in 2027, half not specified (company PR, Aug 2026) Official Tyra Biosciences release (2026-08-04) on PR Newswire confirms: SURF303 (pivotal-intent Phase 2a/b, oral dabogratinib 60/80 mg QD in LG-UTUC) initial results 'expected in 2027'; no half specified.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/tyra-biosciences-reports-second-quarter-2026-financial-results-and-recent-highlights-302842952.html",
  "ticker": "TYRA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0570",
  "guidance_detail": "Initial results from pivotal-intent Phase 2a/b expected in 2027, half not specified (company PR, Aug 2026) Official Tyra Biosciences release (2026-08-04) on PR Newswire confirms: SURF303 (pivotal-intent Phase 2a/b, oral dabogratinib 60/80 mg QD in LG-UTUC) initial results 'expected in 2027'; no half specified.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0569"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for dabogratinib (formerly TYRA-300, oral FGFR3-selective inhibitor) in low-grade upper tract urothelial carcinoma (SURF303 Phase 2a/b) are expected sometime in 2027, the first real efficacy signal for Tyra Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Upstream Bio, Inc.",
  "competitors": [
   "AZN/AMGN (tezepelumab/Tezspire, anti-TSLP approved severe asthma)",
   "GSK (depemokimab, anti-IL-5 in Phase 3 COPD)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "verekitug (anti-TSLP receptor antibody)",
  "event_type": "readout",
  "indication": "chronic obstructive pulmonary disease (VENTURE Phase 2)",
  "notes": "Enrollment completed with 481 participants; data expected H2 2027 (company PR, May 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/13/3293845/0/en/Upstream-Bio-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html",
  "ticker": "UPB",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0571",
  "guidance_detail": "Enrollment completed with 481 participants; data expected H2 2027 (company PR, May 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0572"
  ],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for verekitug (anti-TSLP receptor antibody) in chronic obstructive pulmonary disease (VENTURE Phase 2) are expected in the second half of 2027, the first real efficacy signal for Upstream Bio, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Upstream Bio, Inc.",
  "competitors": [
   "AZN/AMGN (tezepelumab/Tezspire, approved severe asthma)",
   "GSK (mepolizumab/Nucala, approved severe eosinophilic asthma)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "verekitug (anti-TSLP receptor antibody)",
  "event_type": "readout",
  "indication": "severe asthma (VALOUR long-term extension of Phase 2 VALIANT)",
  "notes": "VALOUR (NCT06966479) is the long-term extension study of the Phase 2 VALIANT trial; eligible VALIANT completers enrolled (>90% retention of eligible patients), enrollment completed Mar 2026; long-term safety/efficacy data expected H2 2027 (company PR, Sep 2026). Retained: Phase 2-stage readout per under-coverage policy. [Source verified 2026-09-20: \"VALOUR (NCT06966479), a long-term extension (LTE) study designed to evaluate the long-term safety and efficacy of verekitug. VALOUR completed enrollment in March 2026 with more than 90% retention of eligible patients fr]",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/fr/news-release/2026/09/08/3357341/0/en/upstream-bio-presents-results-from-the-phase-2-valiant-trial-of-verekitug-for-the-treatment-of-severe-asthma-in-oral-presentation-at-ers-congress-2026.html",
  "ticker": "UPB",
  "us_listed": true,
  "nct_id": "NCT06966479",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0572",
  "guidance_detail": "VALOUR (NCT06966479) is the long-term extension study of the Phase 2 VALIANT trial; eligible VALIANT completers enrolled (>90% retention of eligible patients), enrollment completed Mar 2026; long-term safety/efficacy data expected H2 2027 (company PR, Sep 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0571"
  ],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for verekitug (anti-TSLP receptor antibody) in severe asthma (VALOUR long-term extension of Phase 2 VALIANT) are expected in the second half of 2027, the first real efficacy signal for Upstream Bio, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Veru Inc.",
  "competitors": [
   "REGN (trevogrumab, anti-myostatin obesity)",
   "LLY (bimagrumab, anti-activin IIA/B obesity)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "enobosarm + semaglutide (oral SARM + GLP-1 RA)",
  "event_type": "readout",
  "indication": "obesity in older adults (PLATEAU Phase 2b interim body composition)",
  "notes": "Interim DXA body-composition analysis (lean/fat mass) after 32 weeks expected Q1 2027; ~200 pts fully enrolled Jul 2026 (company PR, Aug 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/10/3341649/0/en/veru-reports-fiscal-2026-third-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress.html",
  "ticker": "VERU",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0573",
  "guidance_detail": "Interim DXA body-composition analysis (lean/fat mass) after 32 weeks expected Q1 2027; ~200 pts fully enrolled Jul 2026 (company PR, Aug 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0574"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for enobosarm + semaglutide (oral SARM + GLP-1 RA) in obesity in older adults (PLATEAU Phase 2b interim body composition) are expected in Q1 2027, the first real efficacy signal for Veru Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Veru Inc.",
  "competitors": [
   "REGN (trevogrumab, anti-myostatin obesity)",
   "LLY (bimagrumab, anti-activin IIA/B obesity)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "enobosarm + semaglutide (oral SARM + GLP-1 RA)",
  "event_type": "readout",
  "indication": "obesity in older adults (PLATEAU Phase 2b final topline)",
  "notes": "Final topline clinical data from 68-week Phase 2b PLATEAU expected Q4 2027 (company PR, Aug 2026)",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/10/3341649/0/en/veru-reports-fiscal-2026-third-quarter-financial-results-and-phase-2b-plateau-clinical-trial-progress.html",
  "ticker": "VERU",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0574",
  "guidance_detail": "Final topline clinical data from 68-week Phase 2b PLATEAU expected Q4 2027 (company PR, Aug 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0573"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for enobosarm + semaglutide (oral SARM + GLP-1 RA) in obesity in older adults (PLATEAU Phase 2b final topline) are expected in Q4 2027, the first real efficacy signal for Veru Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Vir Biotechnology, Inc.",
  "competitors": [
   "GILD (bulevirtide/Hepcludex, approved chronic hepatitis delta)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "tobevibart + elebsiran",
  "event_type": "readout",
  "indication": "chronic hepatitis delta (ECLIPSE 3 Phase 2b)",
  "notes": "ECLIPSE 3 is the Phase 2b trial vs bulevirtide monotherapy in bulevirtide treatment-naive CHD; topline expected Q1 2027, registrational program fully enrolled (company PR, Aug 2026); ECLIPSE 1/2 are Phase 3 and excluded",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://investors.vir.bio/news/news-details/2026/Vir-Biotechnology-Provides-Corporate-Update-and-Reports-Second-Quarter-2026-Financial-Results/default.aspx",
  "ticker": "VIR",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0575",
  "guidance_detail": "ECLIPSE 3 is the Phase 2b trial vs bulevirtide monotherapy in bulevirtide treatment-naive CHD; topline expected Q1 2027, registrational program fully enrolled (company PR, Aug 2026); ECLIPSE 1/2 are Phase 3 and excluded.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0218"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for tobevibart + elebsiran in chronic hepatitis delta (ECLIPSE 3 Phase 2b) are expected in Q1 2027, the first real efficacy signal for Vir Biotechnology, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Xilio Therapeutics, Inc.",
  "competitors": [
   "HOWL (WTX-330, IL-12 INDUKINE candidate, advanced solid tumors)",
   "SONN (SON-1010, IL-12-FcHSA candidate, solid tumors)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "efarindodekin alfa (XTX301, masked IL-12)",
  "event_type": "readout",
  "indication": "advanced solid tumors (Phase 1/2 monotherapy \u2014 Phase 2 portion)",
  "notes": "Phase 2 portion of ongoing Phase 1/2 trial of efarindodekin alfa monotherapy; Xilio expects to deliver an option data package to Gilead in H1 2027 (company PR, Aug 2026). This is a partner data delivery, not a confirmed public topline readout \u2014 flagged per under-coverage policy. Official Xilio GlobeNewswire release (Q1 2026) states the identical guidance verbatim: 'Xilio is evaluating efarindodekin alfa as a monotherapy in an ongoing Phase 2 clinical trial in patients with advanced solid tumors and expects to deliver an option data package to Gilead Sciences, Inc. (Gilead) in the first half of 2027.' The Aug 12, 2026 Q2 release (GlobeNewswire-datelined, indexed in mirrors) repeats the same sentence; its standalone globenewswire.com URL was not retrievable via search.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/12/3292720/0/en/Xilio-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Pipeline-and-Business-Updates.html",
  "ticker": "XLO",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0576",
  "guidance_detail": "Phase 2 portion of ongoing Phase 1/2 trial of efarindodekin alfa monotherapy; Xilio expects to deliver an option data package to Gilead in H1 2027 (company PR, Aug 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for efarindodekin alfa (XTX301, masked IL-12) in advanced solid tumors (Phase 1/2 monotherapy \u2014 Phase 2 portion) are expected in the first half of 2027, the first real efficacy signal for Xilio Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Zentalis Pharmaceuticals, Inc.",
  "competitors": [
   "ABBV (mirvetuximab soravtansine/Elahere, approved FR\u03b1-positive PROC)",
   "GSK (niraparib/Zejula, PARP inhibitor approved in ovarian cancer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "azenosertib (WEE1 inhibitor)",
  "event_type": "readout",
  "indication": "Cyclin E1-positive platinum-resistant ovarian cancer (PROC) \u2014 DENALI Part 2",
  "notes": "DENALI is a registration-intended Phase 2 trial; Part 2a and 2b enrollment completed, Part 2c enrolling; topline Part 2 readout guided to H1 2027 to allow data maturation post full enrollment (SEC 8-K exhibit, Aug 6, 2026). ASPENOVA is Phase 3 and excluded.",
  "phase": "2",
  "source_type": "SEC 8-K",
  "source_url": "https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320250375&type=PDF&symbol=ZNTL&cdn=4d8d8089d502200497d6bbce861404ab&companyName=Zentalis+Pharmaceuticals+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-08-06",
  "ticker": "ZNTL",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0577",
  "guidance_detail": "DENALI is a registration-intended Phase 2 trial; Part 2a and 2b enrollment completed, Part 2c enrolling; topline Part 2 readout guided to H1 2027 to allow data maturation post full enrollment (SEC 8-K exhibit, Aug 6, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for azenosertib (WEE1 inhibitor) in Cyclin E1-positive platinum-resistant ovarian cancer (PROC) \u2014 DENALI Part 2 are expected in the first half of 2027, the first real efficacy signal for Zentalis Pharmaceuticals, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Zura Bio Ltd.",
  "competitors": [
   "RHHBY (tocilizumab/Actemra, approved SSc-ILD)",
   "GSK (belimumab/Benlysta, BAFF inhibitor \u2014 same BAFF pathway class)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "tibulizumab (dual BAFF + IL-17 inhibitor)",
  "event_type": "readout",
  "indication": "early diffuse cutaneous systemic sclerosis (SSc) \u2014 TibuSURE Phase 2",
  "notes": "Topline TibuSURE data expected H1 2027; enrollment exceeded 80 participants and was expected to complete early July 2026 (company PR, Jun 29, 2026). TibuSHIELD (HS) reads out Q4 2026 and is excluded.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260629189605/en/Zura-Bio-Exceeds-Enrollment-Target-in-Both-Hidradenitis-Suppurativa-HS-Systemic-Sclerosis-SSc-Phase-2-Studies-and-Expands-Tibulizumab-Program",
  "ticker": "ZURA",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0578",
  "guidance_detail": "Topline TibuSURE data expected H1 2027; enrollment exceeded 80 participants and was expected to complete early July 2026 (company PR, Jun 29, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for tibulizumab (dual BAFF + IL-17 inhibitor) in early diffuse cutaneous systemic sclerosis (SSc) \u2014 TibuSURE Phase 2 are expected in the first half of 2027, the first real efficacy signal for Zura Bio Ltd.'s program."
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-291",
  "indication": "non-Hodgkin lymphoma",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "competitors": [
   "mosunetuzumab (Roche)",
   "epcoritamab (Genmab/AbbVie)",
   "glofitamab (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06667687",
  "notes": "Phase 1 study NCT06667687; registry primary completion 2027-04, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06667687",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0579",
  "guidance_detail": "Phase 1 study NCT06667687; registry primary completion 2027-04, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-295",
  "indication": "obesity",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "MariTide (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07291232",
  "notes": "Phase 1 study NCT07291232; registry primary completion 2027-03, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07291232",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0580",
  "guidance_detail": "Phase 1 study NCT07291232; registry primary completion 2027-03, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-319",
  "indication": "B-cell lymphomas (DLBCL, CLL, follicular lymphoma)",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "epcoritamab (Genmab/AbbVie)",
   "mosunetuzumab (Roche)",
   "odronextamab (Regeneron)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05512390",
  "notes": "Phase 1 study NCT05512390; registry primary completion 2027-02, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05512390",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0581",
  "guidance_detail": "Phase 1 study NCT05512390; registry primary completion 2027-02, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-383 (etentamig)",
  "indication": "multiple myeloma",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Tecvayli (Johnson & Johnson)",
   "Elrexfio (Pfizer)",
   "Carvykti (Johnson & Johnson)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06223516",
  "notes": "Phase 1 study NCT06223516; registry primary completion 2027-02, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06223516",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0582",
  "guidance_detail": "Phase 1 study NCT06223516; registry primary completion 2027-02, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-400 combinations",
  "indication": "hepatocellular carcinoma, pancreatic ductal adenocarcinoma, biliary tract cancers",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "competitors": [
   "Tecentriq + Avastin (Roche)",
   "Imfinzi + Imjudo (AstraZeneca)",
   "Onivyde (Ipsen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06084481",
  "notes": "Phase 1 study NCT06084481; registry primary completion 2027-09, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06084481",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0583",
  "guidance_detail": "Phase 1 study NCT06084481; registry primary completion 2027-09, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0584"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-400 combinations",
  "indication": "NSCLC and other advanced solid tumors",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "competitors": [
   "Keytruda (Merck)",
   "Enhertu (Daiichi/AstraZeneca)",
   "Opdivo (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05029882",
  "notes": "Phase 1 study NCT05029882; registry primary completion 2027-11, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05029882",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0584",
  "guidance_detail": "Phase 1 study NCT05029882; registry primary completion 2027-11, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0583"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-453 + obinutuzumab",
  "indication": "chronic lymphocytic leukemia / small lymphocytic lymphoma",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "competitors": [
   "Calquence (AstraZeneca)",
   "Brukinsa (BeiGene)",
   "Jaypirca (Eli Lilly)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06291220",
  "notes": "Phase 1 study NCT06291220; registry primary completion 2027-07, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06291220",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0585",
  "guidance_detail": "Phase 1 study NCT06291220; registry primary completion 2027-07, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-706",
  "indication": "advanced solid tumors",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "competitors": [
   "Imdelltra (Amgen)",
   "Keytruda (Merck)",
   "Enhertu (Daiichi/AstraZeneca)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05599984",
  "notes": "Phase 1 study NCT05599984; registry primary completion 2027-11, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05599984",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0586",
  "guidance_detail": "Phase 1 study NCT05599984; registry primary completion 2027-11, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-744 + navitoclax/ruxolitinib",
  "indication": "myelofibrosis",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Jakafi (Incyte)",
   "Ojjaara (GSK)",
   "Inrebic (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04454658",
  "notes": "Phase 1 study NCT04454658; registry primary completion 2027-01, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT04454658",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0587",
  "guidance_detail": "Phase 1 study NCT04454658; registry primary completion 2027-01, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ABBV-969",
  "indication": "metastatic castration-resistant prostate cancer",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "competitors": [
   "Pluvicto (Novartis)",
   "Xtandi (Pfizer/Astellas)",
   "Lynparza (AstraZeneca/MSD)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06318273",
  "notes": "Phase 1 study NCT06318273; registry primary completion 2027-05, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06318273",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0588",
  "guidance_detail": "Phase 1 study NCT06318273; registry primary completion 2027-05, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "IMGN151",
  "indication": "recurrent gynecological cancers",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Elahere (AbbVie)",
   "Trodelvy (Gilead)",
   "Enhertu (Daiichi/AstraZeneca)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05527184",
  "notes": "Phase 1 study NCT05527184; registry primary completion 2027-02, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05527184",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0589",
  "guidance_detail": "Phase 1 study NCT05527184; registry primary completion 2027-02, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "IMGN632 combinations",
  "indication": "acute myeloid leukemia",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Mylotarg (Pfizer)",
   "Vyxeos (Jazz Pharmaceuticals)",
   "Vanflyta (Daiichi Sankyo)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04086264",
  "notes": "Phase 1 study NCT04086264; registry primary completion 2027-02, status active; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT04086264",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0590",
  "guidance_detail": "Phase 1 study NCT04086264; registry primary completion 2027-02, status active; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "azirkitug + budigalimab + bevacizumab + telisotuzumab adizutecan",
  "indication": "advanced solid tumors (NSCLC, head and neck, MSS colorectal, gastric/esophageal)",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "competitors": [
   "Keytruda (Merck)",
   "Opdivo (Bristol Myers Squibb)",
   "Tecentriq (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05005403",
  "notes": "Phase 1 study NCT05005403; registry primary completion 2027-07, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05005403",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0591",
  "guidance_detail": "Phase 1 study NCT05005403; registry primary completion 2027-07, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "livmoniplimab",
  "indication": "advanced solid tumors",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "competitors": [
   "Keytruda (Merck)",
   "Opdivo (Bristol Myers Squibb)",
   "Tecentriq (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03821935",
  "notes": "Phase 1 study NCT03821935; registry primary completion 2027-06, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT03821935",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0592",
  "guidance_detail": "Phase 1 study NCT03821935; registry primary completion 2027-06, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "livmoniplimab + budigalimab",
  "indication": "hepatocellular carcinoma",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "competitors": [
   "Tecentriq + Avastin (Roche)",
   "Imfinzi + Imjudo (AstraZeneca)",
   "Opdivo + Yervoy (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06487559",
  "notes": "Phase 1 study NCT06487559; registry primary completion 2027-02, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06487559",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0593",
  "guidance_detail": "Phase 1 study NCT06487559; registry primary completion 2027-02, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-24",
  "drug": "telisotuzumab adizutecan combinations",
  "indication": "non-small cell lung cancer",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "competitors": [
   "Rybrevant (Johnson & Johnson)",
   "Keytruda (Merck)",
   "Enhertu (Daiichi/AstraZeneca)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06772623",
  "notes": "Phase 1 study NCT06772623; registry primary completion 2027-11, status active; topline typically ~3-6 mo later; Phase 1/2 study per registry; separate row \u2014 distinct trial from Temab-A Phase 3 readout",
  "nct_id": "NCT06772623",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0594",
  "guidance_detail": "Phase 1 study NCT06772623; registry primary completion 2027-11, status active; topline typically ~3-6 mo later; Phase 1/2 study per registry; separate row \u2014 distinct trial from Temab-A Phase 3 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABCL",
  "company": "AbCellera Biologics Inc.",
  "country": "Canada",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ABCL386",
  "indication": "undisclosed",
  "event_type": "ind",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/67e6151b-ba69-3a5f-99da-cded0571e2c1/presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Company deck guides ABCL386 entering Phase 1/2 in 2027 as part of three targeted 2027 INDs; target undisclosed so competitors are antibody-platform peers, not indication rivals",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0595",
  "guidance_detail": "Company deck guides ABCL386 entering Phase 1/2 in 2027 as part of three targeted 2027 INDs; target undisclosed so competitors are antibody-platform peers, not indication rivals.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABCL",
  "company": "AbCellera Biologics Inc.",
  "country": "Canada",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ABCL688",
  "indication": "undisclosed",
  "event_type": "ind",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/67e6151b-ba69-3a5f-99da-cded0571e2c1/presentation.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "Company deck guides ABCL688 entering Phase 1/2 in 2027 as part of three targeted 2027 INDs; target undisclosed so competitors are antibody-platform peers, not indication rivals",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0596",
  "guidance_detail": "Company deck guides ABCL688 entering Phase 1/2 in 2027 as part of three targeted 2027 INDs; target undisclosed so competitors are antibody-platform peers, not indication rivals.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALEC",
  "company": "Alector, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "AL137 (ABC-enabled anti-amyloid beta antibody)",
  "indication": "Alzheimer's disease",
  "event_type": "ind",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Leqembi (Eisai/Biogen)",
   "Kisunla (Eli Lilly)",
   "trontinemab (Roche)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340733/0/en/Alector-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Company targets IND submission in Q1 2027 (10-K allows late 2026 or early 2027) Source quote (2026-09-20): \"Following successful completion of IND-enabling studies evaluating both subcutaneous (SC) and intravenous (IV) administration, Alector selected AL137 as the lead molecule for its anti-amyloid beta (A\u03b2) antibody program\u2026\"",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0598",
  "guidance_detail": "Company targets IND submission in Q1 2027 (10-K allows late 2026 or early 2027) Source quote (2026-09-20): \"Following successful completion of IND-enabling studies evaluating both subcutaneous (SC) and intravenous (IV) administration, Alector selected AL137 as the lead molecule for its anti-amyloid beta (A\u03b2) antibody program ].",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "drug": "ALN-2232",
  "indication": "obesity (Phase 1/2)",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "MariTide (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07463846",
  "notes": "Phase 1 study NCT07463846; registry primary completion 2027-04-28, status active; topline typically ~3-6 mo later ; Phase 1/2 study per registry",
  "nct_id": "NCT07463846",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0599",
  "guidance_detail": "Phase 1 study NCT07463846; registry primary completion 2027-04-28, status active; topline typically ~3-6 mo later ; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ALN-4324",
  "indication": "obesity (Phase 1/2, overweight to obese volunteers)",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "MariTide (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06845202",
  "notes": "Phase 1 study NCT06845202; registry primary completion 2027-08-31, status active; topline typically ~3-6 mo later ; Phase 1/2 study per registry",
  "nct_id": "NCT06845202",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0600",
  "guidance_detail": "Phase 1 study NCT06845202; registry primary completion 2027-08-31, status active; topline typically ~3-6 mo later ; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0838"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ALN-6222",
  "indication": "obesity",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "competitors": [
   "Zepbound (Eli Lilly)",
   "Wegovy (Novo Nordisk)",
   "MariTide (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07624071",
  "notes": "Phase 1 study NCT07624071; registry primary completion 2027-12-14, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07624071",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0601",
  "guidance_detail": "Phase 1 study NCT07624071; registry primary completion 2027-12-14, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "event_type": "readout",
  "phase": "1",
  "date_quality": "inferred",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "drug": "ALN-BCAT",
  "indication": "hepatocellular carcinoma",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "competitors": [
   "Tecentriq + Avastin (Roche)",
   "Imfinzi + Imjudo (AstraZeneca)",
   "Nexavar (Bayer)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06600321",
  "notes": "Phase 1 study NCT06600321; registry primary completion 2027-09-30, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06600321",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0602",
  "guidance_detail": "Phase 1 study NCT06600321; registry primary completion 2027-09-30, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "MariTide/maridebart cafraglutide (Amgen)",
   "Retatrutide (Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AMG 127",
  "event_type": "readout",
  "indication": "Type 2 diabetes / cardiovascular disease (monoclonal antibody)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-10-02 (NCT07590193); SAD/MAD/proof-of-mechanism Phase 1; target undisclosed, comps are cardiometabolic.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07590193",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07590193",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0603",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-10-02 (NCT07590193); SAD/MAD/proof-of-mechanism Phase 1; target undisclosed, comps are cardiometabolic.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Tezepelumab/Tezspire (Amgen/AstraZeneca)",
   "Dupilumab/Dupixent (Regeneron/Sanofi)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AMG 691",
  "event_type": "readout",
  "indication": "Mild-to-moderate asthma (monoclonal antibody)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-04-10 (NCT06637371); active/not recruiting Phase 1 in healthy participants and asthma patients.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06637371",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06637371",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0604",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-04-10 (NCT06637371); active/not recruiting Phase 1 in healthy participants and asthma patients.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Ifinatamab deruxtecan (Daiichi Sankyo/Merck)",
   "BI 764532 (Boehringer Ingelheim)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "tarlatamab (subcutaneous)",
  "event_type": "readout",
  "indication": "Extensive-stage small cell lung cancer (DeLLphi-308)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-04-24 (NCT06598306); recruiting Phase 1 of SC tarlatamab.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06598306",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06598306",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0605",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-04-24 (NCT06598306); recruiting Phase 1 of SC tarlatamab.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v19-0003",
   "v16-0845"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Amgen Inc.",
  "competitors": [
   "JNJ-78278343 (Janssen, STEAP1xCD3)",
   "Pluvicto/lutetium Lu-177 vipivotide tetraxetan (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "xaluritamig (AMG 509)",
  "event_type": "readout",
  "indication": "High-risk biochemically recurrent non-metastatic castration-sensitive prostate cancer",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-03-13 (NCT06555796); STEAP1xCD3 T-cell engager Phase 1. Source note: fresher CT.gov record (crawled Sep 2026) confirms PCD 2027-03-13; older ichgcp/ozmosi mirror (Jan 2026 update) showed Oct 2026 PCD. Retained Q1 2027 on the fresher record; Timing is rechecked in the monthly refresh.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06555796",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06555796",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0606",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-03-13 (NCT06555796); STEAP1xCD3 T-cell engager Phase 1.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0607"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "JNJ-78278343 (Janssen, STEAP1xCD3)",
   "Pluvicto/lutetium Lu-177 vipivotide tetraxetan (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "xaluritamig (AMG 509)",
  "event_type": "readout",
  "indication": "Localized prostate cancer (neoadjuvant)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-02-17 (NCT06613100); recruiting neoadjuvant Phase 1.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06613100",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06613100",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0607",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-02-17 (NCT06613100); recruiting neoadjuvant Phase 1.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0606"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Aprea Therapeutics, Inc.",
  "competitors": [
   "Azenosertib (Zentalis)",
   "Adavosertib (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "APR-1051 (ACESOT-1051)",
  "event_type": "readout",
  "indication": "Advanced solid tumors (WEE1 inhibitor)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT06260514); recruiting Phase 1; company guided next interim update Q4 2026, registry supports 2027 primary-completion entry.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06260514",
  "ticker": "APRE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06260514",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0608",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT06260514); recruiting Phase 1; company guided next interim update Q4 2026, registry supports 2027 primary-completion entry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Arcutis Biotherapeutics, Inc.",
  "competitors": [
   "Crisaborole/Eucrisa (Pfizer)",
   "Tacrolimus ointment (generics)",
   "Pimecrolimus/Elidel (generics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-23",
  "date_quality": "hard",
  "drug": "ZORYVE (roflumilast) cream 0.05%",
  "event_type": "pdufa",
  "indication": "Mild-to-moderate atopic dermatitis in infants aged 3-24 months",
  "notes": "FDA accepted sNDA for infant AD indication; PDUFA date 2027-02-23 per company PR.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.arcutis.com/fda-accepts-supplemental-new-drug-application-for-arcutis-zoryve-roflumilast-cream-0-05-for-the-treatment-of-mild-to-moderate-atopic-dermatitis-in-infants-down-to-3-months/",
  "ticker": "ARQT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0609",
  "guidance_detail": "FDA accepted sNDA for infant AD indication; PDUFA date 2027-02-23 per company PR.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Artelo Biosciences, Inc.",
  "competitors": [
   "MM-120 (MindMed, generalized anxiety disorder)",
   "BNC210 (Bionomics, generalized anxiety disorder)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ART12.11",
  "event_type": "regulatory_other",
  "indication": "Anxiety and depression (proprietary CBD:TMP cocrystal)",
  "notes": "Company guides initiating human studies in H1 2027 pending 2026 toxicology; UK MHRA agreed FIH study design Aug 2025; initiation is a stock-moving event for preclinical-stage ARTL. Source quote (2026-09-20): \"Streamlined regulatory pathway for ART12.11: Received favorable UK MHRA regulatory guidance supporting Phase 1 study plans and potential accelerated pathways. Pending outcome of toxicology study results in 2026, the Com\u2026\"",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/02/24/3243466/0/en/Artelo-Biosciences-Provides-Business-Update-Highlighting-Clinical-Progress-and-Reports-Fiscal-2025-Year-End-Financial-Results.html",
  "ticker": "ARTL",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0610",
  "guidance_detail": "Company guides initiating human studies in H1 2027 pending 2026 toxicology; UK MHRA agreed FIH study design Aug 2025; initiation is a stock-moving event for preclinical-stage ARTL.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-10-01",
  "why_it_matters": "Artelo Biosciences guides starting its first human studies of ART12.11 for anxiety and depression in the first half of 2027, pending toxicology results."
 },
 {
  "as_of": "2026-09-24",
  "company": "Arvinas, Inc.",
  "competitors": [
   "Leuprolide (off-label, generics)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ARV-027",
  "event_type": "readout",
  "indication": "Spinal and bulbar muscular atrophy (oral PROTAC polyQ-AR degrader; Phase 1 in healthy volunteers)",
  "notes": "Company guided 2026-08-04 sharing Phase 1 data over the next 12 months; H1 2027 is the 2027 portion of that window; no approved disease-modifying therapy for SBMA. Source quote (2026-09-20): \"Continue enrollment in the multiple dose cohort of the Phase 1 clinical trial in healthy volunteers and share initial data evaluating androgen receptor (AR)-degradation in muscle (1H 2027).\"]. Source note: sponsor Q2 2026 PR: \"Continue enrollment in the multiple dose cohort of the Phase 1 clinical trial in healthy volunteers and share initial data evaluating androgen receptor (AR)-degradation in muscle (1H 2027).\" No calendar day printed, so guidance (not hard).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338149/0/en/Arvinas-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "ARVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-08-04",
  "record_id": "v16-0611",
  "guidance_detail": "Company guided 2026-08-04 sharing Phase 1 data over the next 12 months; H1 2027 is the 2027 portion of that window; no approved disease-modifying therapy for SBMA.",
  "audit_status": "v20_reverified",
  "audit_action": "inferred_to_guidance",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Arvinas, Inc.",
  "competitors": [
   "BIIB122/DNL151 (Biogen/Denali)",
   "BIIB094 (Biogen/Ionis)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ARV-102",
  "event_type": "readout",
  "indication": "Parkinson's disease / progressive supranuclear palsy (oral PROTAC LRRK2 degrader)",
  "notes": "Company guided 2026-08-04 sharing Phase 1 data over the next 12 months; H1 2027 is the 2027 portion of that 12-month window; no 2027 ARV-102 readout was specifically guided by the company. Source quote (2026-09-20): \"Continue discussions with global health authorities on plans to initiate clinical trials in patients with progressive supranuclear palsy (2027).\"\u2026\"",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338149/0/en/Arvinas-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "ARVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0612",
  "guidance_detail": "Company guided 2026-08-04 sharing Phase 1 data over the next 12 months; H1 2027 is the 2027 portion of that 12-month window; no 2027 ARV-102 readout was specifically guided by the company.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Arvinas, Inc.",
  "competitors": [
   "Glofitamab/Columvi (Roche)",
   "Epcoritamab/Epkinly (AbbVie/Genmab)",
   "Yescarta (Gilead Kite)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ARV-393",
  "event_type": "readout",
  "indication": "Relapsed/refractory non-Hodgkin lymphoma (oral PROTAC BCL6 degrader)",
  "notes": "Company guided 2026-08-04 sharing clinical data from three Phase 1 programs (ARV-393, ARV-102, ARV-027) over the next 12 months; H1 2027 is the 2027 portion of that window. Source quote (2026-09-20): \"Share additional monotherapy data from the ongoing Phase 1 dose escalation trial in B- and T-cell lymphomas (mid-2027).\"]. Source note: sponsor Q2 2026 PR: \"Share additional monotherapy data from the ongoing Phase 1 dose escalation trial in B- and T-cell lymphomas (mid-2027).\" No calendar day printed, so guidance (not hard).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338149/0/en/Arvinas-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "ARVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-08-04",
  "record_id": "v16-0613",
  "guidance_detail": "Company guided 2026-08-04 sharing clinical data from three Phase 1 programs (ARV-393, ARV-102, ARV-027) over the next 12 months; H1 2027 is the 2027 portion of that window.",
  "audit_status": "v20_reverified",
  "audit_action": "inferred_to_guidance",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Avalo Therapeutics, Inc.",
  "competitors": [
   "Cosentyx (Novartis)",
   "Bimzelx (UCB)",
   "Humira (AbbVie)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AVTX-010 (long-acting anti-IL-1\u03b2)",
  "event_type": "ind",
  "indication": "hidradenitis suppurativa",
  "notes": "Company guides IND submission in 1H 2027",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://ir.avalotx.com/news-events-presentations/press-releases/detail/225/avalo-therapeutics-expands-pipeline-with-avtx-010-a-long-acting-next-generation-anti-il-1-antibody",
  "ticker": "AVTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0614",
  "guidance_detail": "Company guides IND submission in 1H 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Carvykti (Johnson & Johnson/Legend Biotech)",
   "Abecma (Bristol Myers Squibb)",
   "linvoseltamab (Regeneron)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD0120 (DURGA-1)",
  "event_type": "readout",
  "indication": "relapsed/refractory multiple myeloma",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-10-01",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05850234",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0615",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-10-01.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Darzalex (Johnson & Johnson)",
   "Abecma (Bristol Myers Squibb)",
   "Lynozyfic (Regeneron)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD0305",
  "event_type": "readout",
  "indication": "multiple myeloma",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-08-16",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06106945",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0616",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-08-16.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "TN-501 (Tenaya Therapeutics)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD4063",
  "event_type": "readout",
  "indication": "PLN R14del dilated cardiomyopathy",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-11-22",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07241104",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0617",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-11-22.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Opdivo (Bristol Myers Squibb)",
   "Keytruda (Merck)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD4360",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-03-31",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06921928",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0618",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-03-31.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Tecentriq (Roche)",
   "Cabometyx (Exelixis)",
   "Lenvima (Eisai)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD5851 (GPC3)",
  "event_type": "readout",
  "indication": "GPC3+ advanced/recurrent hepatocellular carcinoma",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-12-13",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06084884",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0619",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-12-13.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Keytruda (Merck)",
   "Libtayo (Regeneron/Sanofi)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD5863",
  "event_type": "readout",
  "indication": "advanced/metastatic solid tumors",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-07-16",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06005493",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0620",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-07-16.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Keytruda (Merck)",
   "Tecentriq (Roche)",
   "Jemperli (GSK)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD8205",
  "event_type": "readout",
  "indication": "advanced/metastatic solid malignancies",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-09-29",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05123482",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0621",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-09-29.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "xaluritamig (Amgen)",
   "Erleada (Johnson & Johnson)",
   "GDC-2992 (Roche)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD8359 (STEAP2 TCE)",
  "event_type": "readout",
  "indication": "prostate cancer",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-11-17",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07529717",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0622",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-11-17.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Libtayo (Regeneron/Sanofi)",
   "Tecentriq (Roche)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD8421",
  "event_type": "readout",
  "indication": "advanced/metastatic solid tumors",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-08-04",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06188520",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0623",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-08-04.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Amtagvi (Iovance)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "KRAS TCR-T cell therapy",
  "event_type": "readout",
  "indication": "KRAS-mutant unresectable/advanced/metastatic solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-08-30",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06218914",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0624",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-08-30.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bayer AG",
  "competitors": [
   "Jemperli (GSK)",
   "Opdivo (Bristol Myers Squibb)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BAY3375968 (anti-CCR8)",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-04-30",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05537740",
  "ticker": "BAYRY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0625",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-04-30.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bayer AG",
  "competitors": [
   "Lumakras (Amgen)",
   "Krazati (Bristol Myers Squibb)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BAY3498264 + sotorasib",
  "event_type": "readout",
  "indication": "KRAS G12C-mutant advanced solid cancers",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-04-26",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06659341",
  "ticker": "BAYRY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0626",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-04-26.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bayer AG",
  "competitors": [
   "Pluvicto (Novartis)",
   "Verzenio (Eli Lilly)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BAY3546828 (Ac-225-macropa-pelgifatamab)",
  "event_type": "readout",
  "indication": "metastatic castration-resistant prostate cancer",
  "notes": "Phase 1 radiopharmaceutical readout inferred from CT.gov PCD 2027-06-08",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06052306",
  "ticker": "BAYRY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0627",
  "guidance_detail": "Phase 1 radiopharmaceutical readout inferred from CT.gov PCD 2027-06-08.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Beam Therapeutics Inc.",
  "competitors": [
   "mRNA-3745 (Moderna)",
   "Genglycos (Ultragenix)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BEAM-301",
  "event_type": "readout",
  "indication": "glycogen storage disease type Ia (GSDIa)",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-12-30",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06735755",
  "ticker": "BEAM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0628",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-12-30.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Biohaven Ltd.",
  "competitors": [
   "veligrotug (Viridian)",
   "batoclimab (Immunovant)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BHV-1300 (MoDE degrader)",
  "event_type": "readout",
  "indication": "Graves' disease",
  "notes": "Phase 1 readout inferred from CT.gov PCD Sep 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06980649",
  "ticker": "BHVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0629",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD Sep 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Biohaven Ltd.",
  "competitors": [
   "Fabhalta (Novartis)",
   "Trutakna (Vera Therapeutics)",
   "Tarpeyo (Calliditas)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BHV-1400 (TRAP degrader)",
  "event_type": "readout",
  "indication": "IgA nephropathy",
  "notes": "Phase 1 readout inferred from CT.gov PCD Jul 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07054684",
  "ticker": "BHVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0630",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD Jul 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "BlossomHill Therapeutics, Inc.",
  "competitors": [
   "Venclexta (AbbVie)",
   "Onureg (Bristol Myers Squibb)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BH-30236 (CLK inhibitor)",
  "event_type": "readout",
  "indication": "relapsed/refractory AML, higher-risk MDS",
  "notes": "Updated safety and anti-leukemic-effect data guided 1H 2027 The company\\'s GlobeNewswire release guides BH-30236 updated safety/anti-leukemic data guided 1H 2027 , source is a wire mirror, confidence flag retained.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.tradingview.com/news/globenewswire:bf870b616094b:0-blossomhill-therapeutics-reports-second-quarter-2026-financial-results/",
  "ticker": "BLSM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0631",
  "guidance_detail": "Updated safety and anti-leukemic-effect data guided 1H 2027 The company\\'s GlobeNewswire release guides BH-30236 updated safety/anti-leukemic data guided 1H 2027 , source is a wire mirror, confidence flag retained.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "BlossomHill Therapeutics, Inc.",
  "competitors": [
   "Tagrisso (AstraZeneca)",
   "Rybrevant (Johnson & Johnson)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BH-30643 (C797S durability update)",
  "event_type": "readout",
  "indication": "EGFR-mutant NSCLC",
  "notes": "Updated Phase 1 data incl. C797S durability guided 1H 2027 The company\\'s GlobeNewswire release guides BH-30643 updated C797S durability data guided 1H 2027 , source is a wire mirror, confidence flag retained.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.tradingview.com/news/globenewswire:bf870b616094b:0-blossomhill-therapeutics-reports-second-quarter-2026-financial-results/",
  "ticker": "BLSM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0632",
  "guidance_detail": "Updated Phase 1 data incl.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [
   "v16-0633"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "BlossomHill Therapeutics, Inc.",
  "competitors": [
   "Tagrisso (AstraZeneca)",
   "Rybrevant (Johnson & Johnson)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BH-30643 (TKI-naive + chemo-combo update)",
  "event_type": "readout",
  "indication": "EGFR-mutant NSCLC",
  "notes": "Updated TKI-naive durability + initial chemo-combination cohort data guided 2H 2027 The company\\'s GlobeNewswire release guides BH-30643 TKI-naive durability update and initial chemo-combination cohort data guided 2H 2027 , source is a wire mirror, confidence flag retained.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.tradingview.com/news/globenewswire:bf870b616094b:0-blossomhill-therapeutics-reports-second-quarter-2026-financial-results/",
  "ticker": "BLSM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0633",
  "guidance_detail": "Updated TKI-naive durability + initial chemo-combination cohort data guided 2H 2027 The company\\'s GlobeNewswire release guides BH-30643 TKI-naive durability update and initial chemo-combination cohort data guided 2H 2027 , source is a wire mirror, confidence flag retained.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [
   "v16-0632"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "BlossomHill Therapeutics, Inc.",
  "competitors": [
   "daraxonrasib (Revolution Medicines)",
   "Lumakras (Amgen)",
   "Krazati (Bristol Myers Squibb)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BH-501284 (pan-KRAS inhibitor)",
  "event_type": "ind",
  "indication": "KRAS-mutant tumors",
  "notes": "IND submission explicitly guided Q1 2027 The company\\'s GlobeNewswire release guides BH-501284 IND submission guided Q1 2027 , source is a wire mirror, confidence flag retained.",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.tradingview.com/news/globenewswire:bf870b616094b:0-blossomhill-therapeutics-reports-second-quarter-2026-financial-results/",
  "ticker": "BLSM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0634",
  "guidance_detail": "IND submission explicitly guided Q1 2027 The company\\'s GlobeNewswire release guides BH-501284 IND submission guided Q1 2027 , source is a wire mirror, confidence flag retained.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioMarin Pharmaceutical Inc.",
  "competitors": [
   "Elevidys (Sarepta/Roche)",
   "Emflaza (PTC Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMN 351",
  "event_type": "readout",
  "indication": "Duchenne muscular dystrophy",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-04-14",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06280209",
  "ticker": "BMRN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0635",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-04-14.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Rinvoq (AbbVie)",
   "Olumiant (Eli Lilly)",
   "Simponi (Johnson & Johnson)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986454",
  "event_type": "readout",
  "indication": "rheumatoid arthritis",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-06-28",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07171983",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0636",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-06-28.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Yescarta (Gilead)",
   "Kymriah (Novartis)",
   "Ordspono (Regeneron)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986458",
  "event_type": "readout",
  "indication": "relapsed/refractory non-Hodgkin lymphoma",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-10-28",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06090539",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0637",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-10-28.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Pyrukynd (Agios)",
   "Casgevy (Vertex/CRISPR Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986470",
  "event_type": "readout",
  "indication": "sickle cell disease",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-01-06",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06481306",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0638",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-01-06.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Keytruda (Merck)",
   "Imfinzi (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986484",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-10-14",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06544655",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0639",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-10-14.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Keytruda (Merck)",
   "Imfinzi (AstraZeneca)",
   "Jemperli (GSK)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986488",
  "event_type": "readout",
  "indication": "advanced malignant tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-10-15",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06764771",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0640",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-10-15.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Imfinzi (AstraZeneca)",
   "Tecentriq (Roche)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BMS-986489",
  "event_type": "readout",
  "indication": "relapsed/refractory small cell lung cancer (China)",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-05-26",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06799286",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0641",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-05-26.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "KYV-101 (Kyverna Therapeutics)",
   "rese-cel (Cabaletta Bio)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CC-97540 (BMS-986353)",
  "event_type": "readout",
  "indication": "relapsing/progressive MS or refractory myasthenia gravis",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-07-15; lead sponsor Juno Therapeutics (BMS)",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06220201",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0642",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-07-15; lead sponsor Juno Therapeutics (BMS).",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "AMG 193 (Amgen)",
   "TNG462 (Tango Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "MRTX1719",
  "event_type": "readout",
  "indication": "MTAP-deleted solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-12-10",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05245500",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0643",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-12-10.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-24",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Adcetris (Takeda)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "golcadomide (BMS-986369, GOLSEEK-3)",
  "event_type": "readout",
  "indication": "relapsed/refractory T-cell lymphoma (Japan)",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD 2027-01-30; distinct from the GOLSEEK-1 row (separate trial)",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06035497",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0644",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD 2027-01-30; distinct from the GOLSEEK-1 row (separate trial).",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0069"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bristol Myers Squibb",
  "competitors": [
   "Keytruda (Merck)",
   "Imfinzi (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "navlimetostat (BMS-986504)",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-01-19",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07077434",
  "ticker": "BMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0645",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-01-19.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioNTech SE",
  "competitors": [
   "Keytruda (Merck)",
   "Imfinzi (AstraZeneca)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BNT3212 +/- BNT327",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD Nov 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07147348",
  "ticker": "BNTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0646",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD Nov 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bolt Biotherapeutics, Inc.",
  "competitors": [
   "AZD0901 (AstraZeneca)",
   "Vyloy (Astellas)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BDC-4182",
  "event_type": "readout",
  "indication": "advanced gastric/gastroesophageal cancer",
  "notes": "Phase 1/2 readout inferred from CT.gov PCD May 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06921837",
  "ticker": "BOLT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0647",
  "guidance_detail": "Phase 1/2 readout inferred from CT.gov PCD May 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bio-Path Holdings, Inc.",
  "competitors": [
   "Keytruda (Merck)",
   "Imfinzi (AstraZeneca)",
   "Tecentriq (Roche)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BP1001-A",
  "event_type": "readout",
  "indication": "advanced/recurrent solid tumors",
  "notes": "Phase 1 readout inferred from CT.gov PCD Jul 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04196257",
  "ticker": "BPTH",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0648",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD Jul 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bio-Path Holdings, Inc.",
  "competitors": [
   "Venclexta (AbbVie)",
   "Idhifa (Bristol Myers Squibb)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BP1002",
  "event_type": "readout",
  "indication": "relapsed/refractory acute myeloid leukemia",
  "notes": "Phase 1 readout inferred from CT.gov PCD Mar 2027",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05190471",
  "ticker": "BPTH",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0649",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD Mar 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioXcel Therapeutics, Inc.",
  "competitors": [
   "Auvelity (Axsome Therapeutics)",
   "Abilify (Otsuka)",
   "Risperdal (Johnson & Johnson)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BXCL501 (sublingual dexmedetomidine)",
  "event_type": "readout",
  "indication": "agitation in pediatric schizophrenia/bipolar disorder",
  "notes": "Phase 1 readout inferred from CT.gov PCD 2027-07-31",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05025605",
  "ticker": "BTAI",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0650",
  "guidance_detail": "Phase 1 readout inferred from CT.gov PCD 2027-07-31.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Cullinan Therapeutics, Inc.",
  "competitors": [
   "AbbVie (Venclexta/venetoclax)",
   "Johnson & Johnson (vibecotamab CD123xCD3)",
   "Astellas (Xospata/gilteritinib)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CLN-049 (FLT3xCD3 T-cell engager) + azacitidine + venetoclax",
  "event_type": "readout",
  "indication": "Previously untreated acute myeloid leukemia (AML) \u2014 combination",
  "notes": "Inferred from CT.gov primary completion 2027-09-30 (status: not yet recruiting); company guided initiation of the frontline AML combination study in Q4 2026.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07722767",
  "ticker": "CGEM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0651",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-09-30 (status: not yet recruiting); company guided initiation of the frontline AML combination study in Q4 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Cullinan Therapeutics, Inc.",
  "competitors": [
   "Cabaletta Bio (rese-cel CD19 CAR-T)",
   "Kyverna Therapeutics (KYV-101 CD19 CAR-T)",
   "AbbVie (Rinvoq/upadacitinib)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CLN-978 (CD19-directed T-cell engager)",
  "event_type": "readout",
  "indication": "Treatment-refractory rheumatoid arthritis \u2014 OUTRACE Phase 1 study",
  "notes": "Inferred from CT.gov primary completion 2027-12-30 (recruiting); company guided 2026 readouts across autoimmune indications while the study continues into late 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06994143",
  "ticker": "CGEM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0652",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-12-30 (recruiting); company guided 2026 readouts across autoimmune indications while the study continues into late 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Compugen Ltd.",
  "competitors": [
   "Gilead Sciences (zimberelimab)",
   "Bristol-Myers Squibb (Opdivo/nivolumab)",
   "Simcha Therapeutics (ST-067 IL-18)"
  ],
  "country": "Israel",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "COM503 (anti-IL-18 binding protein antibody; licensed to Gilead)",
  "event_type": "readout",
  "indication": "Advanced solid tumors \u2014 monotherapy and + zimberelimab",
  "notes": "Inferred from CT.gov primary completion 2027-11-22 (recruiting); Gilead-partnered first-in-class IL-18BP blocker, Compugen conducts the Phase 1.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06759649",
  "ticker": "CGEN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0653",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-11-22 (recruiting); Gilead-partnered first-in-class IL-18BP blocker, Compugen conducts the Phase 1.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Celldex Therapeutics, Inc.",
  "competitors": [
   "Amgen/AstraZeneca (Tezspire/tezepelumab)",
   "Sanofi/Regeneron (Dupixent/dupilumab)",
   "GSK (Nucala/mepolizumab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CDX-622 (bispecific anti-SCF x anti-TSLP)",
  "event_type": "readout",
  "indication": "Mild to moderate asthma \u2014 Phase 1b proof-of-mechanism study",
  "notes": "Inferred from CT.gov primary completion 2027-03 (recruiting); healthy-volunteer Phase 1 data presented at EAACI June 2026, asthma study ongoing.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07330778",
  "ticker": "CLDX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0654",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-03 (recruiting); healthy-volunteer Phase 1 data presented at EAACI June 2026, asthma study ongoing.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Hemab Therapeutics Holdings, Inc.",
  "competitors": [
   "Pfizer (Myfembree)",
   "AbbVie (Oriahnn)",
   "Bayer (Mirena)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "HMB-003 (novel antifibrinolytic peptide)",
  "event_type": "readout",
  "indication": "Heavy menstrual bleeding \u2014 first-in-human study",
  "notes": "Inferred from CT.gov primary completion 2027-04-30 (recruiting); company said first-in-human begins H2 2026 with heavy-menstrual-bleeding development starting 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07798505",
  "ticker": "COAG",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0655",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-04-30 (recruiting); company said first-in-human begins H2 2026 with heavy-menstrual-bleeding development starting 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Women's Health",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-18",
  "company": "Cocrystal Pharma, Inc.",
  "competitors": [
   "Moderna (mRNA-1403 norovirus vaccine)",
   "Vaxart (oral norovirus vaccine candidate)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CDI-988 (norovirus protease inhibitor)",
  "event_type": "readout",
  "indication": "Norovirus \u2014 Phase 1b human challenge study",
  "notes": "Company guided preliminary efficacy results for 'late 2026 or early 2027' on 2026-09-09 after the last subject was dosed.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.cocrystalpharma.com/news/press-releases/detail/233/cocrystal-pharma-announces-last-subject-dosed-in-phase-1b",
  "ticker": "COCP",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0656",
  "guidance_detail": "Company guided preliminary efficacy results for 'late 2026 or early 2027' on 2026-09-09 after the last subject was dosed.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Cardiff Oncology, Inc.",
  "competitors": [
   "Avastin/bevacizumab (Roche)",
   "Krazati/adagrasib (Bristol Myers Squibb/Mirati)",
   "Vectibix/panitumumab (Amgen)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Onvansertib (PLK1 inhibitor) + FOLFIRI/bevacizumab",
  "event_type": "regulatory_other",
  "indication": "First-line RAS-mutated metastatic colorectal cancer \u2014 registrational Phase 3 initiation",
  "notes": "Registrational Phase 3 onvansertib 30 mg + FOLFIRI/bev vs SoC; initiation targeted Q1 2027 subject to securing additional financing; FDA EoP2 alignment complete.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/11/3343174/0/en/cardiff-oncology-reports-second-quarter-2026-results-and-provides-business-update.html",
  "ticker": "CRDF",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0658",
  "guidance_detail": "Registrational Phase 3 onvansertib 30 mg + FOLFIRI/bev vs SoC; initiation targeted Q1 2027 subject to securing additional financing; FDA EoP2 alignment complete.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Cardiff Oncology targets starting its registrational Phase 3 of onvansertib in first-line RAS-mutated metastatic colorectal cancer in Q1 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "CytomX Therapeutics, Inc.",
  "competitors": [
   "Enhertu/trastuzumab deruxtecan (Daiichi Sankyo/AstraZeneca)",
   "Lonsurf/trifluridine-tipiracil (Taiho Oncology)",
   "Stivarga/regorafenib (Bayer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Varsetatug masetecan / Varseta-M (CX-2051, masked EpCAM Topo-1 ADC) + bevacizumab",
  "event_type": "readout",
  "indication": "Advanced colorectal cancer \u2014 Phase 1 combination, initial data",
  "notes": "Phase 1 Varseta-M + bevacizumab combo study in advanced CRC starting Q1 2026; initial data expected by 1H 2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/01/08/3215318/37704/en/CytomX-Therapeutics-Announces-Business-Update-and-Company-Milestones-for-2026.html",
  "ticker": "CTMX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0659",
  "guidance_detail": "Phase 1 Varseta-M + bevacizumab combo study in advanced CRC starting Q1 2026; initial data expected by 1H 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "CytoSorbents Corporation",
  "competitors": [
   "Ondexxya/andexanet alfa (AstraZeneca/Alexion)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DrugSorb-ATR (antithrombotic removal device)",
  "event_type": "regulatory_other",
  "indication": "Ticagrelor removal in urgent cardiac surgery \u2014 new De Novo submission",
  "notes": "New De Novo submission planned early 2027 under Breakthrough Device designation; follows prior De Novo denial and FDA pre-submission feedback.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/cytosorbents-announces-new-real-world-data-demonstrating-significant-reduction-in-severe-bleeding-using-cytosorb-in-cabg-patients-on-ticagrelor-and-updates-recent-drugsorb-atr-fda-pre-submission-meetings-302867656.html",
  "ticker": "CTSO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0660",
  "guidance_detail": "New De Novo submission planned early 2027 under Breakthrough Device designation; follows prior De Novo denial and FDA pre-submission feedback.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "why_it_matters": "CytoSorbents plans a new De Novo submission for DrugSorb-ATR, its ticagrelor-removal device for urgent cardiac surgery, in early 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Denali Therapeutics Inc.",
  "competitors": [
   "UX111 (Ultragenyx)",
   "RGX-121 (REGENXBIO)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DNL126 (ETV:SGSH, Enzyme TransportVehicle-enabled enzyme replacement)",
  "event_type": "bla_filing",
  "indication": "Sanfilippo syndrome type A (MPS IIIA) \u2014 BLA submission",
  "notes": "Phase 1/2 ongoing with accelerated approval path via CSF heparan sulfate surrogate endpoint; company expects BLA submission and potential accelerated approval in 2027.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3290512/0/en/Denali-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Highlights.html",
  "ticker": "DNLI",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0661",
  "guidance_detail": "Phase 1/2 ongoing with accelerated approval path via CSF heparan sulfate surrogate endpoint; company expects BLA submission and potential accelerated approval in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Denali Therapeutics Inc.",
  "competitors": [
   "BIIB080/diranersen (Biogen)",
   "AL164 (Alector)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "DNL628 (OTV:MAPT, oligonucleotide targeting tau)",
  "event_type": "readout",
  "indication": "Early Alzheimer's disease \u2014 Phase 1b MAD data",
  "notes": "Phase 1b MAD study (NCT07328451) in early AD; registry primary completion 2027-02; company expects data 1H 2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3290512/0/en/Denali-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Business-Highlights.html",
  "ticker": "DNLI",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07328451",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0662",
  "guidance_detail": "Phase 1b MAD study (NCT07328451) in early AD; registry primary completion 2027-02; company expects data 1H 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Elutia Inc.",
  "competitors": [
   "AlloDerm (AbbVie)",
   "FlexHD (MTF Biologics)",
   "SimpliDerm (Cellution Biologics)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "NXT-41x (antibiotic-eluting biomatrix)",
  "event_type": "regulatory_other",
  "indication": "plastic and reconstructive surgery (post-operative infection prevention)",
  "notes": "FDA 510(k) clearance of full drug-eluting biologic guided H1 2027; NXT-41 base matrix 510(k) submitted Mar 2026 with clearance guided H2 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/18/3346759/0/en/elutia-completes-simpliderm-sale-on-schedule-adds-8-million-in-cash-to-fund-nxt-41x-through-full-commercial-launch.html",
  "ticker": "ELUT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0663",
  "guidance_detail": "FDA 510(k) clearance of full drug-eluting biologic guided H1 2027; NXT-41 base matrix 510(k) submitted Mar 2026 with clearance guided H2 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "Elicio guides FDA 510(k) clearance of its antibiotic-eluting biomatrix NXT-41x in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Enliven Therapeutics, Inc.",
  "competitors": [
   "asciminib (Scemblix, Novartis)",
   "olverembetamab (Ascentage Pharma)",
   "ponatinib (Iclusig, Takeda)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ELVN-001 (selective BCR-ABL inhibitor)",
  "event_type": "readout",
  "indication": "chronic myeloid leukemia (CML)",
  "notes": "ENABLE Phase 1a/1b trial NCT05304377 estimated primary completion Dec 2027; readout window inferred from registry PCD (History of Changes not inspected, CT.gov API unavailable).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05304377",
  "ticker": "ELVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05304377",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0664",
  "guidance_detail": "ENABLE Phase 1a/1b trial NCT05304377 estimated primary completion Dec 2027; readout window inferred from registry PCD (History of Changes not inspected, CT.gov API unavailable).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "evidence_note": "Link corrected 2026-09-24: was a clinicaltrials.gov API-endpoint URL (raw JSON), now the human-readable study page for the same NCT record."
 },
 {
  "as_of": "2026-10-01",
  "company": "Entera Bio Ltd.",
  "competitors": [
   "palopegteriparatide (Yorvipath, Ascendis Pharma)",
   "eneboparatide (AstraZeneca)",
   "teriparatide (generic)"
  ],
  "country": "Israel",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "EB612 (oral parathyroid hormone)",
  "event_type": "ind",
  "indication": "hypoparathyroidism",
  "notes": "IND filing intended H1 2027 per Q2 2026 business update.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/07/3341389/0/en/entera-announces-second-quarter-2026-financial-results-and-business-updates.html",
  "ticker": "ENTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0665",
  "guidance_detail": "IND filing intended H1 2027 per Q2 2026 business update.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Erasca, Inc.",
  "competitors": [
   "daraxonrasib (RMC-6236, Revolution Medicines)",
   "zoldonrasib (RMC-9805, Revolution Medicines)",
   "RMC-7977 (Revolution Medicines)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ERAS-0015 (pan-RAS molecular glue)",
  "event_type": "readout",
  "indication": "KRAS-mutant solid tumors",
  "notes": "Additional preliminary Phase 1 monotherapy and combination data expected H1 2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/13/3326444/0/en/Erasca-Announces-Updated-Preliminary-Phase-1-Data-and-Registration-Enabling-Plans-for-Potentially-Best-in-Class-Pan-RAS-Molecular-Glue-ERAS-0015-in-KRAS-Mutant-Solid-Tumors.html",
  "ticker": "ERAS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0666",
  "guidance_detail": "Additional preliminary Phase 1 monotherapy and combination data expected H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Eton Pharmaceuticals, Inc.",
  "competitors": [
   "propranolol oral solution (Hemangeol, Pierre Fabre)",
   "topical timolol (generic)",
   "atenolol (generic)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ASN-001",
  "event_type": "nda_filing",
  "indication": "infantile hemangioma",
  "notes": "NDA submission intended H2 2027 for late-stage product candidate acquired Aug 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339150/0/en/Eton-Pharmaceuticals-Expands-Infantile-Hemangioma-Franchise-with-Acquisition-of-U-S-Rights-to-Late-Stage-Product-Candidate-ASN-001.html",
  "ticker": "ETON",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0667",
  "guidance_detail": "NDA submission intended H2 2027 for late-stage product candidate acquired Aug 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Eton Pharmaceuticals, Inc. is expected to file its new drug application for ASN-001 in infantile hemangioma in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Eton Pharmaceuticals, Inc.",
  "competitors": [
   "ALKINDI SPRINKLE (hydrocortisone) oral granules",
   "compounded liquid hydrocortisone (non-FDA approved)",
   "Cortef (hydrocortisone tablets, Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "KHINDIVI (hydrocortisone) oral solution",
  "event_type": "regulatory_other",
  "indication": "adrenocortical insufficiency \u2014 label expansion to patients under 5 years",
  "notes": "Prior Approval Supplement submitted; label-expansion approval guided H1 2027 (not a PDUFA \u2014 no FDA acceptance letter found). Source quote (2026-09-20): \"The Company has submitted a Prior Approval Supplement (PAS) to the U.S. Food and Drug Administration (FDA) requesting an expansion of the product's label to include younger pediatric patients. Submission allows for a\u2026\"",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/29/3335064/0/en/Eton-Pharmaceuticals-Announces-Submission-of-Prior-Approval-Supplement-to-Expand-Indication-of-KHINDIVI-hydrocortisone-Oral-Solution.html",
  "ticker": "ETON",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0668",
  "guidance_detail": "Prior Approval Supplement submitted; label-expansion approval guided H1 2027 (not a PDUFA \u2014 no FDA acceptance letter found).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Eton's supplemental application expanding KHINDIVI (hydrocortisone oral solution) to younger children with adrenocortical insufficiency could be approved in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Edgewise Therapeutics, Inc.",
  "competitors": [
   "givinostat (Duvyzat, Italfarmaco)",
   "vamorolone (Agamree, Catalyst Pharmaceuticals)",
   "SGT-003 (Solid Biosciences)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "sevasemten",
  "event_type": "nda_filing",
  "indication": "Becker muscular dystrophy",
  "notes": "NDA submission planned H1 2027 following GRAND CANYON pivotal cohort readout guided Q4 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/edgewise-therapeutics-provides-corporate-updates-and-highlights-priorities-for-2026",
  "ticker": "EWTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0669",
  "guidance_detail": "NDA submission planned H1 2027 following GRAND CANYON pivotal cohort readout guided Q4 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Edgewise Therapeutics, Inc. is expected to file its new drug application for sevasemten in Becker muscular dystrophy in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-18",
  "company": "Genfit S.A.",
  "competitors": [
   "larsucosterol (DURECT, acute liver failure)",
   "HepaStem (Promethera Biosciences, ACLF cell therapy)"
  ],
  "country": "France",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CLM-022",
  "event_type": "regulatory_other",
  "indication": "Acute decompensation (AD) of cirrhosis / acute-on-chronic liver failure (ACLF)",
  "notes": "Company states that pending further positive developments (efficacy confirmation in AD/ACLF disease models, formulation development and first toxicology studies started in 2025), a first-in-human trial of CLM-022 could be initiated in H1 2027. No IND filing date separately guided.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/09/22/3154305/0/en/GENFIT-Reports-First-Half-2025-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "GNFT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0670",
  "guidance_detail": "Company states that pending further positive developments (efficacy confirmation in AD/ACLF disease models, formulation development and first toxicology studies started in 2025), a first-in-human trial of CLM-022 could be initiated in H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Genfit could start first-in-human studies of CLM-022 in acute decompensation of cirrhosis in the first half of 2027, pending further positive developments."
 },
 {
  "as_of": "2026-10-01",
  "company": "Genfit S.A.",
  "competitors": [
   "rifaximin (Bausch Health/Salix, hepatic encephalopathy)",
   "L-ornithine phenylacetate (Mallinckrodt, hepatic encephalopathy)"
  ],
  "country": "France",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VS-02-HE",
  "event_type": "regulatory_other",
  "indication": "Hepatic encephalopathy (HE) in acute decompensation / ACLF",
  "notes": "Oral gut-targeted formulation designed to act where ammonia is primarily produced, minimizing systemic absorption while reducing glutamine levels in the brain. IND-enabling nonclinical studies and formulation development expected complete by end of 2025; pending further confirmation, a first-in-human trial could be initiated in H2 2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/09/22/3154305/0/en/GENFIT-Reports-First-Half-2025-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "GNFT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0671",
  "guidance_detail": "Oral gut-targeted formulation designed to act where ammonia is primarily produced, minimizing systemic absorption while reducing glutamine levels in the brain.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Genfit could start first-in-human studies of VS-02-HE, a gut-targeted therapy for hepatic encephalopathy, in the second half of 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Structure Therapeutics Inc.",
  "competitors": [
   "amycretin (Novo Nordisk, oral amylin agonist)",
   "petrelintide (Zealand Pharma/Roche, long-acting amylin analog)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ACCG-2671 (oral small-molecule amylin receptor agonist / DACRA)",
  "event_type": "readout",
  "indication": "Chronic weight management (obesity)",
  "notes": "Topline data from the 12-week multiple-ascending-dose (MAD) portion of the Phase 1/2a trial in participants with obesity expected H1 2027; first participants dosed September 2026. Single-ascending-dose data showed an approximate 6-day half-life and up to 3.3% weight loss.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/de/news-release/2026/09/08/3357602/0/en/structure-therapeutics-reports-positive-clinical-data-across-oral-small-molecule-amylin-and-glp-1-programs-for-chronic-weight-management.html",
  "ticker": "GPCR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0672",
  "guidance_detail": "Topline data from the 12-week multiple-ascending-dose (MAD) portion of the Phase 1/2a trial in participants with obesity expected H1 2027; first participants dosed September 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "teclistamab (Janssen, BCMA-directed T-cell engager)",
   "talquetamab (Janssen, GPRC5D-directed T-cell engager)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Trispecific T-cell engager from Chimagen Biosciences (unnamed)",
  "event_type": "regulatory_other",
  "indication": "Multiple myeloma",
  "notes": "GSK announced September 15, 2026 that it will acquire a trispecific T-cell engager targeting T cells plus two tumor antigens from Chimagen Biosciences; the program is expected to enter Phase 1 trials in 2027. Distinct from the earlier CMG1A46 (CD19/CD20) program also acquired from Chimagen.",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.gsk.com/en-gb/media/press-releases/gsk-to-acquire-potential-best-in-class-t-cell-engager-tce-for-multiple-myeloma-from-chimagen-biosciences/",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0673",
  "guidance_detail": "GSK announced September 15, 2026 that it will acquire a trispecific T-cell engager targeting T cells plus two tumor antigens from Chimagen Biosciences; the program is expected to enter Phase 1 trials in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "HCW Biologics Inc.",
  "competitors": [
   "tisotumab vedotin (Genmab/Pfizer, tissue-factor ADC)",
   "BA3021 (BioAtla, tissue-factor ADC)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "HCW11-018b (tetravalent tissue-factor-targeting T-cell engager)",
  "event_type": "ind",
  "indication": "Pancreatic cancer (initial indication); solid tumors",
  "notes": "IND application projected for H1 2027 to seek FDA authorization for a clinical study in pancreatic cancer; trial initiation is contingent on FDA authorization. Company has requested a pre-IND (Type B) meeting with the FDA. Source quote (2026-09-20): \"IND application expected to be filed in first half of 2027 to seek authorization for clinical study in patients with pancreatic cancer\"; CEO Dr. Hing C. Wong stated, \"The IND application is projected to be filed in the\u2026\"",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/04/27/3281513/0/en/HCW-Biologics-Delivers-a-Major-Update-for-its-T-Cell-Engager-Program-Revealing-Mechanism-of-Action-and-Validating-Tissue-Factor-as-Target-for-Treatment-of-Solid-Tumors.html",
  "ticker": "HCWB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0674",
  "guidance_detail": "IND application projected for H1 2027 to seek FDA authorization for a clinical study in pancreatic cancer; trial initiation is contingent on FDA authorization.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Harmony Biosciences Holdings, Inc.",
  "competitors": [
   "oveporexton / Orzeyful (Takeda, OX2R agonist)",
   "alixorexton (Alkermes, OX2R agonist)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BP-205 (orexin-2 receptor agonist)",
  "event_type": "readout",
  "indication": "CNS disorders (orexin-2 receptor agonist; specific Phase 2 indications TBD)",
  "notes": "Phase 1b study in sleep-deprived healthy volunteers initiated Q3 2026 with data expected early 2027; single-ascending-dose data showed favorable PK and safety and multiple-ascending-dose data are expected Q4 2026; Phase 2 studies are planned for mid-2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/04/3338190/0/en/Harmony-Biosciences-Announces-Record-Q2-2026-Revenue-and-Shares-Initial-Clinical-Data-for-Its-Orexin-2-Agonist-BP-205-Reinforcing-Potential-Best-in-Class-Profile.html",
  "ticker": "HRMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0677",
  "guidance_detail": "Phase 1b study in sleep-deprived healthy volunteers initiated Q3 2026 with data expected early 2027; single-ascending-dose data showed favorable PK and safety and multiple-ascending-dose data are expected Q4 2026; Phase 2 studies are planned for mid-2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Harrow, Inc.",
  "competitors": [
   "Iluvien (Alimera Sciences, fluocinolone acetonide intravitreal implant)",
   "Yutiq (EyePoint Pharmaceuticals, fluocinolone acetonide intravitreal implant)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Next-generation TRIESENCE (triamcinolone acetonide injectable suspension)",
  "event_type": "nda_filing",
  "indication": "Visualization during vitrectomy; ocular inflammatory conditions",
  "notes": "Company plans to submit an NDA to the FDA before the end of 2027 for an enhanced version of TRIESENCE (triamcinolone acetonide injectable suspension), an approved corticosteroid. Phase is null: reformulation of an approved drug with no new clinical program disclosed. Distinct from the existing MELT-300 (G-MELT) NDA filing row. [2026-09-23 source check] businesswire.com timed out on both probe passes (not confirmed dead); event (Harrow next-gen TRIESENCE NDA filing guidance 2027) verified via company communications. Recommend re-source to the Harrow IR release via browser.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "http://www.businesswire.com/news/home/20250311672040/en/Harrow-Executes-Five-Year-Strategic-Supply-and-Development-Agreement-for-TRIESENCE",
  "ticker": "HROW",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0678",
  "guidance_detail": "Company plans to submit an NDA to the FDA before the end of 2027 for an enhanced version of TRIESENCE (triamcinolone acetonide injectable suspension), an approved corticosteroid.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Harrow, Inc. is expected to file its new drug application for next-generation TRIESENCE in visualization during vitrectomy and ocular inflammatory conditions sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Heron Therapeutics, Inc.",
  "competitors": [
   "Exparel (Pacira BioSciences, liposomal bupivacaine)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ZYNRELEF (bupivacaine/meloxicam) prefilled syringe",
  "event_type": "regulatory_other",
  "indication": "Postoperative pain (ready-to-use presentation)",
  "notes": "Supplemental NDA for a ready-to-use prefilled-syringe presentation of approved ZYNRELEF. Registration batches manufactured and on stability; company expects 12-month stability data in Q1 2027 and is continuing CMC and device-readiness activities to support the filing. Filing in 2027 is inferred (company has not stated an exact filing date); captured as regulatory_other consistent with sNDA precedent.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/11/3291812/0/en/Heron-Therapeutics-Announces-First-Quarter-2026-Financial-Results-and-Reaffirms-Guidance.html",
  "ticker": "HRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0679",
  "guidance_detail": "Supplemental NDA for a ready-to-use prefilled-syringe presentation of approved ZYNRELEF.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-10-01",
  "why_it_matters": "Heron expects to file a supplemental application for a ready-to-use prefilled-syringe version of ZYNRELEF for postoperative pain sometime in 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "SeaStar Medical Holding Corporation",
  "competitors": [
   "Prismaflex (Baxter, continuous renal replacement therapy system)",
   "NxStage System One (Fresenius Medical Care, CRRT system)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Selective Cytopheretic Device (SCD)",
  "event_type": "regulatory_other",
  "indication": "Adult acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT)",
  "notes": "PMA submission planned in 2027 contingent on a successful outcome of the NEUTRALIZE-AKI pivotal trial (NCT05758077; enrollment completion targeted for end of 2026; registry primary completion estimated December 2026). SCD holds Breakthrough Device designation for adult AKI. Phase is null (device). Source quote (2026-09-20): \"We also plan to accelerate enrollment in our NEUTRALIZE-AKI pivotal trial to complete enrollment near the end of 2026. Provided a successful outcome of the trial, we will submit our Premarket Approval application (PMA) ]. Source note: SeaStar's Q2 2026 earnings call refines prior 'PMA in 2027' guidance: NEUTRALIZE-AKI enrollment expected to finish around year-end 2026 or Q1 2027, with a late-2027 target for the final PMA module submission (modular PMA), contingent on a positive trial outcome. Bucket remains 2027; details updated to the newer timing and modular-submission contingency. Source: https://www.globenewswire.com/news-release/2026/01/07/3214506/0/en/SeaStar-Medical-Announces-2026-Milestones.html. Quote: \"late-2027\".",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/01/07/3214506/0/en/SeaStar-Medical-Announces-2026-Milestones.html",
  "ticker": "ICU",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05758077",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0680",
  "guidance_detail": "PMA submission planned in 2027 contingent on a successful outcome of the NEUTRALIZE-AKI pivotal trial (NCT05758077; enrollment completion targeted for end of 2026; registry primary completion estimated December 2026).",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-10-01",
  "why_it_matters": "SeaStar Medical plans a PMA submission for its Selective Cytopheretic Device in acute kidney injury in 2027, contingent on its pivotal trial succeeding."
 },
 {
  "as_of": "2026-09-18",
  "company": "IDEAYA Biosciences, Inc.",
  "competitors": [
   "ifinatamab deruxtecan (Daiichi Sankyo/Merck, B7-H3 ADC)",
   "vobramitamab duocarmazine (MacroGenics, B7-H3 ADC)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "IDE034 (B7H3/PTK7-targeting bispecific TOP1-inhibitor ADC)",
  "event_type": "readout",
  "indication": "Advanced solid tumors (Phase 1 dose escalation)",
  "notes": "Company guides initial clinical data (preliminary safety and efficacy) by the end of 2026 or early 2027; captured on the 2027-H1 side of the cross-year boundary window.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/ideaya-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-update-302841723.html",
  "ticker": "IDYA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0681",
  "guidance_detail": "Company guides initial clinical data (preliminary safety and efficacy) by the end of 2026 or early 2027; captured on the 2027-H1 side of the cross-year boundary window.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "InflaRx N.V.",
  "competitors": [
   "avacopan (Amgen, C5aR inhibitor)",
   "iptacopan (Novartis, factor B inhibitor for IgAN)"
  ],
  "country": "Germany",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "izicopan (oral C5a receptor inhibitor)",
  "event_type": "readout",
  "indication": "Complement-mediated renal diseases: atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), C3 glomerulopathy (C3G)",
  "notes": "May 2026 SEC 6-K: open-label proof-of-concept studies in aHUS, IgAN and C3G are expected to begin generating clinical data in 2027 ('next year'). Phase not stated (null); captured as a single program-level row because the studies were not individually detailed. Separate Phase 2 planning in ANCA-associated vasculitis (AAV) has no 2027 data guidance. Phase 2 in ANCA-associated vasculitis is in planning; 2027 data expected from open-label PoC studies in aHUS, IgAN, C3G. Watch item.",
  "phase": "2",
  "source_type": "SEC 6-K",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1708688/000114036126019215/ef20072565_6k.htm",
  "ticker": "IFRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0682",
  "guidance_detail": "May 2026 SEC 6-K: open-label proof-of-concept studies in aHUS, IgAN and C3G are expected to begin generating clinical data in 2027 ('next year').",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for izicopan (oral C5a receptor inhibitor) in complement-mediated renal diseases \u2014 atypical hemolytic uremic syndrome (aHUS), IgA nephropathy (IgAN), C3 glomerulopathy (C3G) \u2014 are expected sometime in 2027, the first real efficacy signal for InflaRx N.V.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Immunocore Holdings plc",
  "competitors": [
   "botensilimab + balstilimab (Agenus, MSS colorectal cancer)",
   "sotorasib (Amgen, KRAS G12C colorectal cancer)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "IMC-R117C (PIWIL1-targeting ImmTAC)",
  "event_type": "readout",
  "indication": "Advanced gastrointestinal cancers including colorectal cancer (HLA-A*02:01-positive)",
  "notes": "Company expects to present initial data in 2027 from the Phase 1/2 dose-escalation trial evaluating IMC-R117C as a single agent and in combination with standards of care; first patient dosed December 2024. Source quote (2026-09-20): \"The Company is enrolling patients in the Phase 1/2 dose escalation trial evaluating IMC-R117C in HLA-A*02:01 positive patients with advanced solid tumors, including colorectal cancer, as a single agent and in combinatio\u2026\"",
  "phase": "1",
  "source_type": "SEC filing",
  "source_url": "https://www.immunocore.com/investors/financials-filings/sec-filings/content/0001140361-26-019205/0001140361-26-019205.pdf",
  "ticker": "IMCR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0683",
  "guidance_detail": "Company expects to present initial data in 2027 from the Phase 1/2 dose-escalation trial evaluating IMC-R117C as a single agent and in combination with standards of care; first patient dosed December 2024.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Immatics N.V.",
  "competitors": [
   "brenetafusp (Immunocore, PRAME TCR bispecific)",
   "afamitresgene autoleucel (Adaptimmune, MAGE-A4 TCR-T cell therapy)"
  ],
  "country": "Germany",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "IMA401 (MAGEA4/8 TCER) + IMA402 (PRAME TCER) combination",
  "event_type": "readout",
  "indication": "Squamous cell non-small cell lung cancer (sqNSCLC)",
  "notes": "First data from the Phase 1 combination cohort of IMA401 plus IMA402 expected in 2027; enrollment initiated at multiple sites. Distinct from the existing IMA402 monotherapy readout row.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://ml-eu.globenewswire.com/Resource/Download/9afca9c8-16d0-49ac-8f05-0bd28ba17e4b",
  "ticker": "IMTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0684",
  "guidance_detail": "First data from the Phase 1 combination cohort of IMA401 plus IMA402 expected in 2027; enrollment initiated at multiple sites.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "IN8bio, Inc.",
  "competitors": [
   "ADIC (Adicet Bio - allogeneic gamma-delta T cell therapies)",
   "ImCheck Therapeutics (ICT01 - BTN3A gamma-delta T activator)",
   "Acepodia (ACE1831 - gamma-delta T cell conjugates)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "INB-100 (allogeneic gamma-delta T cells)",
  "event_type": "readout",
  "indication": "Hematologic malignancies (AML) post-haploidentical HSCT",
  "notes": "inferred from CT.gov primary completion Jan 2027 for INB-100, IN8bio's lead program; investigator-sponsored Phase 1 (NCT03533816) evaluating safety, durability and anti-leukemic activity post-transplant.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT03533816",
  "ticker": "INAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT03533816",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0685",
  "guidance_detail": "inferred from CT.gov primary completion Jan 2027 for INB-100, IN8bio's lead program; investigator-sponsored Phase 1 (NCT03533816) evaluating safety, durability and anti-leukemic activity post-transplant.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "InMed Pharmaceuticals Inc.",
  "competitors": [
   "LLY (donanemab)",
   "BIIB (lecanemab)",
   "AVXL (blarcamesine)"
  ],
  "country": "Canada",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "INM-901",
  "event_type": "ind",
  "indication": "Alzheimer's disease (neuroinflammation)",
  "notes": "company targets IND submission and Phase 1 initiation in 2027, subject to regulatory feedback and completion of IND-enabling work; pre-IND meeting planned Q3 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.inmedpharma.com/news_release/inmed-provides-update-on-pharmaceutical-development-programs-advancing-lead-drug-candidates-towards-ind-and-clinical-trial/",
  "ticker": "INM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0686",
  "guidance_detail": "company targets IND submission and Phase 1 initiation in 2027, subject to regulatory feedback and completion of IND-enabling work; pre-IND meeting planned Q3 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Century Therapeutics, Inc.",
  "competitors": [
   "VRTX (zimislecel/VX-880)",
   "SANA (SC451)",
   "CRSP (CTX211)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CNTY-813 (iPSC-derived islet replacement)",
  "event_type": "readout",
  "indication": "Type 1 diabetes",
  "notes": "company guides IND submission 4Q 2026 with initial clinical data anticipated in 2H 2027.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/13/3293915/0/en/Century-Therapeutics-Reports-First-Quarter-Financial-Results-and-Business-Updates.html",
  "ticker": "IPSC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0687",
  "guidance_detail": "company guides IND submission 4Q 2026 with initial clinical data anticipated in 2H 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Disc Medicine, Inc.",
  "competitors": [
   "Scenesse/afamelanotide (Clinuvel)",
   "dersimelagon (LEO Pharma/Tanabe Pharma)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Bitopertin (oral glycine transporter 1 / GlyT1 inhibitor)",
  "event_type": "regulatory_other",
  "indication": "Erythropoietic protoporphyria (EPP) \u2014 CRL response; FDA decision",
  "notes": "Type A meeting Jun 2026: APOLLO Phase 3, if successful, can support CRL response; response submission by end of 2026 with FDA decision expected by mid-2027 (Q2/Q3 boundary). [2026-09-23 re-source] Old IR URL truncated (403); replaced with Disc Medicine's official IR Type A meeting release (GlobeNewswire verbatim). Timing re-verified 2026-09-23: 'Data from APOLLO is expected in Q4 2026, after which a CRL response will be submitted with an FDA decision expected by mid-2027'.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://ir.discmedicine.com/news-releases/news-release-details/disc-medicine-provides-update-fda-type-meeting-bitopertin",
  "ticker": "IRON",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0688",
  "guidance_detail": "Type A meeting Jun 2026: APOLLO Phase 3, if successful, can support CRL response; response submission by end of 2026 with FDA decision expected by mid-2027 (Q2/Q3 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Disc Medicine plans to respond to the FDA's complete response letter for bitopertin in erythropoietic protoporphyria by end of 2026, with an FDA decision expected around mid-2027."
 },
 {
  "as_of": "2026-09-24",
  "company": "Jaguar Health, Inc.",
  "competitors": [
   "TAK (teduglutide/Gattex - short bowel syndrome)",
   "IRWD (apraglutide - SBS with intestinal failure)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Crofelemer powder for oral solution",
  "event_type": "nda_filing",
  "indication": "Microvillus inclusion disease (MVID) with intestinal failure (pediatric)",
  "notes": "NDA filing planned mid-2027 subject to pivotal trial completion and regulatory alignment; breakthrough therapy designation under FDA evaluation. The issuing wire's canonical page states: 'This trial is expected to support a New Drug Application (NDA) filing for the treatment of the MVID indication in mid-2027.' Forward-looking-statements section also states Jaguar's expectation of 'an NDA filing for MVID ... by mid-2027.' Note: this release was issued on ACCESS Newswire (dateline 'SAN FRANCISCO, CA / ACCESS Newswire', SOURCE: Jaguar Health, Inc.) \u2014 the issuing wire, not an aggregator mirror.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/all-randomized-pediatric-patients-to-continue-in-the-single-blind-ext-1218995",
  "ticker": "JAGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0689",
  "guidance_detail": "NDA filing planned mid-2027 subject to pivotal trial completion and regulatory alignment; breakthrough therapy designation under FDA evaluation.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Jaguar Health, Inc. is expected to file its new drug application for Crofelemer powder for oral solution in Microvillus inclusion disease (MVID) with intestinal failure (pediatric) in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-18",
  "company": "Janux Therapeutics, Inc.",
  "competitors": [
   "AMGN (xaluritamig - PSMA T cell engager)",
   "NVS (Pluvicto - PSMA radioligand)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "JANX007 (PSMA-TRACTr)",
  "event_type": "readout",
  "indication": "Metastatic castration-resistant prostate cancer (mCRPC)",
  "notes": "inferred from CT.gov primary completion Jul 2027 (estimated); ENGAGER-PSMA-01 Phase 1 dose escalation/expansion ongoing.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05519449",
  "ticker": "JANX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0690",
  "guidance_detail": "inferred from CT.gov primary completion Jul 2027 (estimated); ENGAGER-PSMA-01 Phase 1 dose escalation/expansion ongoing.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Kailera Therapeutics, Inc.",
  "competitors": [
   "LLY (retatrutide)",
   "NVO (CagriSema)",
   "AMGN (maridebart cafraglutide)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Ribupatide (KAI-9531) oral",
  "event_type": "regulatory_other",
  "indication": "Obesity",
  "notes": "Global Phase 3 initiation of ribupatide oral in obesity guided for H1 2027; IND already active with FDA. Kailera CMO Scott Wasserman in joint Kailera+Hengrui ADA 2026 release (GlobeNewswire 2026-06-05): 'we look forward to starting global Phase 3 trials for ribupatide oral as early as the first half of 2027.' Re-verified 2026-09-20.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/05/3307661/0/en/Hengrui-Pharma-and-Kailera-Therapeutics-Present-Ribupatide-Clinical-Data-at-ADA-2026.html",
  "ticker": "KLRA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0691",
  "guidance_detail": "Global Phase 3 initiation of ribupatide oral in obesity guided for H1 2027; IND already active with FDA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Kailera guides starting global Phase 3 trials of oral ribupatide in obesity in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Standard BioTools Inc. (expected to become Treeline Biosciences Holdings, Inc.; expected ticker TRLN post-merger)",
  "competitors": [
   "BMY (CC-99282 - BCL6 degrader)",
   "ADCT (Zynlonta - R/R DLBCL/FL)",
   "GILD (Yescarta - R/R LBCL)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TLN-121 (BCL6 degrader)",
  "event_type": "readout",
  "indication": "Relapsed/refractory lymphomas (DLBCL, FL, T-follicular PTCL)",
  "notes": "combined company (Treeline merger, closing expected H2 2026) guides 2027 data updates for TLN-121 Phase 1 in R/R lymphomas.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-announces-filing-registration-statement",
  "ticker": "LAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0692",
  "guidance_detail": "combined company (Treeline merger, closing expected H2 2026) guides 2027 data updates for TLN-121 Phase 1 in R/R lymphomas.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Standard BioTools Inc. (expected to become Treeline Biosciences Holdings, Inc.; expected ticker TRLN post-merger)",
  "competitors": [
   "RVMD (RMC-6236 - pan-RAS inhibitor)",
   "BBIO (pan-KRAS program)",
   "JAZZ (KRAS G12C-independent program)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TLN-372 (pan-KRAS inhibitor)",
  "event_type": "readout",
  "indication": "Solid tumors (KRAS-driven)",
  "notes": "planned 2027 data update for TLN-372 (pan-KRAS inhibitor) per combined-company guidance in Treeline merger S-4/PR.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://investors.standardbio.com/news-releases/news-release-details/standard-biotools-announces-filing-registration-statement",
  "ticker": "LAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0693",
  "guidance_detail": "planned 2027 data update for TLN-372 (pan-KRAS inhibitor) per combined-company guidance in Treeline merger S-4/PR.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Lyell Immunopharma, Inc.",
  "competitors": [
   "Yescarta (Gilead)",
   "Breyanzi (Bristol Myers Squibb)",
   "Kymriah (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "rondecabtagene autoleucel (ronde-cel)",
  "event_type": "readout",
  "indication": "Relapsed/refractory large B-cell lymphoma, 3L+ (PiNACLE single-arm pivotal Phase 1/2)",
  "notes": "Company guides pivotal PiNACLE data by mid-2027, ahead of BLA submission in 2027; existing calendar covers only the ronde-cel BLA filing, not this readout. 2L PiNACLE-H2H is Phase 3 and out of scope. Phase corrected 1 -> 2: PiNACLE is the single-arm pivotal (registrational) 3L+ trial. Opened and verified on globenewswire.com: official Lyell Q1 2026 business update states 'pivotal data are expected in mid-2027 with submission of a Biologics License Application (BLA) to the FDA expected to follow in 2027' for the PiNACLE pivotal single-arm ronde-cel trial. Same guidance as the June 4 EHA release (whose standalone globenewswire.com page is not indexed despite multiple exact-headline searches).",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/06/3289331/0/en/Lyell-Immunopharma-Reports-Business-Highlights-and-Financial-Results-for-the-First-Quarter-2026.html",
  "ticker": "LYEL",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0694",
  "guidance_detail": "Company guides pivotal PiNACLE data by mid-2027, ahead of BLA submission in 2027; existing calendar covers only the ronde-cel BLA filing, not this readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0121"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for rondecabtagene autoleucel (ronde-cel) in relapsed/refractory large B-cell lymphoma, 3L+ (PiNACLE single-arm pivotal Phase 1/2) are expected in the first half of 2027, the first real efficacy signal for Lyell Immunopharma, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Mirum Pharmaceuticals, Inc.",
  "competitors": [
   "Bulevirtide (Gilead)",
   "Peginterferon alfa-2a (generic)",
   "Elebsiran + tobevibart (Vir Biotechnology)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "brelovitug",
  "event_type": "bla_filing",
  "indication": "Chronic hepatitis D (HDV)",
  "notes": "Corporate deck guides brelovitug HDV BLA submission H1 2027; AZURE-1 and AZURE-4 toplines guided Q3 and Q4 2026. Timing not re-confirmed in the Aug 2026 Q2 update; re-verify at monthly refresh.",
  "phase": null,
  "source_type": "company deck",
  "source_url": "https://s21.q4cdn.com/142896768/files/doc_presentations/2026/Mirum-Updated-Corporate-Presentation_Feb-26-FINAL.pdf",
  "ticker": "MIRM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0695",
  "guidance_detail": "Corporate deck guides brelovitug HDV BLA submission H1 2027; AZURE-1 and AZURE-4 toplines guided Q3 and Q4 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Molecular Partners AG",
  "competitors": [
   "Tarlatamab (Amgen)",
   "Ifinatamab deruxtecan (Merck/Daiichi Sankyo)"
  ],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MP0712 (212Pb-DLL3 Radio-DARPin)",
  "event_type": "readout",
  "indication": "Small cell lung cancer and other neuroendocrine cancers",
  "notes": "Phase 1/2a (NCT07278479) with Orano Med; initial data expected 2026 with a more comprehensive safety/efficacy dataset guided for 2027 per company GNW release 2026-07-06. Registry check 2026-09-20: CT.gov shows PCD 2028-09 but record last updated 2026-05-22 (stale); company guidance stands \u2014 row kept. Company also guides two INDs across the portfolio in 2027 but the candidates are unnamed, so no IND entries recorded.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/06/3322137/0/en/Molecular-Partners-Updates-on-Clinical-Progress-Across-Expanding-Pipeline-of-DARPin-Radiotherapeutics.html",
  "ticker": "MOLN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07278479",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0696",
  "guidance_detail": "Phase 1/2a (NCT07278479) with Orano Med; initial data expected 2026 with a more comprehensive safety/efficacy dataset guided for 2027 per company GNW release 2026-07-06.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Nkarta, Inc.",
  "competitors": [
   "rese-cel (Cabaletta Bio \u2014 CD19 CAR-T in autoimmune)",
   "KYV-101 (Kyverna \u2014 CD19 CAR-T in lupus nephritis)",
   "Benlysta/belimumab (GSK \u2014 lupus nephritis SoC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "NKX019",
  "event_type": "readout",
  "indication": "lupus nephritis and primary membranous nephropathy",
  "notes": "Phase 1/2 study NCT06557265 (Ntrust-1); registry primary completion 2027-04, status recruiting; allogeneic CD19 CAR-NK; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06557265",
  "ticker": "NKTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06557265",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0697",
  "guidance_detail": "Phase 1/2 study NCT06557265 (Ntrust-1); registry primary completion 2027-04, status recruiting; allogeneic CD19 CAR-NK; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Nurix Therapeutics, Inc.",
  "competitors": [
   "Jaypirca/pirtobrutinib (Lilly \u2014 noncovalent BTK inhibitor)",
   "BGB-16673 (BeOne Medicines \u2014 BTK degrader)",
   "Imbruvica/ibrutinib (AbbVie/Johnson & Johnson \u2014 covalent BTK inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "bexobrutideg (NX-5948)",
  "event_type": "readout",
  "indication": "relapsed/refractory B-cell malignancies",
  "notes": "Phase 1 study NCT05131022; registry primary completion 2027-01, status recruiting; BTK degrader; bexobrutideg now in pivotal development per company \u2014 this first-in-human dose-escalation retains a 2027 PCD; topline typically ~3-6 mo later",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05131022",
  "ticker": "NRIX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05131022",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0698",
  "guidance_detail": "Phase 1 study NCT05131022; registry primary completion 2027-01, status recruiting; BTK degrader; bexobrutideg now in pivotal development per company \u2014 this first-in-human dose-escalation retains a 2027 PCD; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Nuvation Bio Inc.",
  "competitors": [
   "Enhertu/DS-8201 (AstraZeneca/Daiichi Sankyo \u2014 ADC)",
   "Trodelvy/sacituzumab govitecan (Gilead \u2014 ADC)",
   "Datroway/datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo \u2014 ADC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "NUV-1511",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1/2 study NCT06334432; registry primary completion 2027-03, status active/not recruiting; drug-drug conjugate platform candidate; first patient dosed Mar 2024 per company PR; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06334432",
  "ticker": "NUVB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06334432",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0699",
  "guidance_detail": "Phase 1/2 study NCT06334432; registry primary completion 2027-03, status active/not recruiting; drug-drug conjugate platform candidate; first patient dosed Mar 2024 per company PR; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Nuvectis Pharma, Inc.",
  "competitors": [
   "Sprycel/dasatinib (Bristol Myers Squibb \u2014 SRC inhibitor)",
   "Bosulif/bosutinib (Pfizer \u2014 SRC/ABL inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "NXP900",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Phase 1 study NCT05873686; registry primary completion 2027-03, status recruiting; SRC/YES1 kinase inhibitor; separate NXP900+lorlatinib Phase 1 in ALK+ NSCLC (NCT07784959, PCD 2027-08) suppressed per same-drug dedup; topline typically ~3-6 mo later",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05873686",
  "ticker": "NVCT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05873686",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0700",
  "guidance_detail": "Phase 1 study NCT05873686; registry primary completion 2027-03, status recruiting; SRC/YES1 kinase inhibitor; separate NXP900+lorlatinib Phase 1 in ALK+ NSCLC (NCT07784959, PCD 2027-08) suppressed per same-drug dedup; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "Inno8 (NNC0442-0344 A)",
  "indication": "hemophilia A",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Hemlibra/emicizumab (Roche \u2014 FVIII mimetic)",
   "Mim8/denecimig (Novo Nordisk \u2014 filed)",
   "Altuviiio/efanesoctocog alfa (Sanofi/Sobi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07220564",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07220564; registry primary completion 2027-02-05, status recruiting; oral factor VIII mimetic; topline typically ~3-6 mo later",
  "nct_id": "NCT07220564",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0701",
  "guidance_detail": "Phase 1 study NCT07220564; registry primary completion 2027-02-05, status recruiting; oral factor VIII mimetic; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "LX9851",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)",
   "orforglipron (Lilly \u2014 oral small molecule)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/03/23/3260282/0/en/Lexicon-Pharmaceuticals-and-Novo-Nordisk-Announce-initiation-of-Phase-1-study-with-oral-obesity-drug-candidate-LX9851.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Lexicon/Novo Nordisk joint Phase 1 of oral ACSL5 inhibitor LX9851; companies guide study completion Q1 2027; Source note: LX9851 (NVO/Lexicon): sponsor guides only a trial-completion date (not a public readout) in 2027. No company readout guidance found - downgraded guidance to inferred and bucket broadened to full-year 2027. Source: https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=200006.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0702",
  "guidance_detail": "Lexicon/Novo Nordisk joint Phase 1 of oral ACSL5 inhibitor LX9851; companies guide study completion Q1 2027;",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q1",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Sponsor guides only a trial-completion date (not a public readout); guidance->inferred; window broadened"
   }
  ],
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0113-5840",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07566390",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07566390; registry primary completion 2027-01-31, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07566390",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0703",
  "guidance_detail": "Phase 1 study NCT07566390; registry primary completion 2027-01-31, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0537-1482",
  "indication": "heart failure with preserved ejection fraction (HFpEF)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Farxiga/dapagliflozin (AstraZeneca \u2014 HFpEF)",
   "Jardiance/empagliflozin (Lilly/Boehringer \u2014 HFpEF)",
   "Wegovy/semaglutide (Novo Nordisk \u2014 HFpEF with obesity)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07218627",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07218627; registry primary completion 2027-01-15, status recruiting; CNP analogue in HFpEF; separate CKD PK study (NCT07808788, PCD 2027-07) suppressed per same-drug dedup; topline typically ~3-6 mo later",
  "nct_id": "NCT07218627",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0704",
  "guidance_detail": "Phase 1 study NCT07218627; registry primary completion 2027-01-15, status recruiting; CNP analogue in HFpEF; separate CKD PK study (NCT07808788, PCD 2027-07) suppressed per same-drug dedup; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0581-0001",
  "indication": "hepatic steatosis / liver disease",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Rezdiffra/resmetirom (Madrigal \u2014 approved MASH)",
   "Wegovy/semaglutide (Novo Nordisk \u2014 MASH)",
   "efruxifermin (Novo Nordisk/Akero \u2014 FGF21, MASH)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06891365",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT06891365; registry primary completion 2027-10-11, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT06891365",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0705",
  "guidance_detail": "Phase 1 study NCT06891365; registry primary completion 2027-10-11, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0638-0355",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06577766",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT06577766; registry primary completion 2027-10-11, status active/not recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT06577766",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0706",
  "guidance_detail": "Phase 1 study NCT06577766; registry primary completion 2027-10-11, status active/not recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0705-0002",
  "indication": "cardiometabolic disease (healthy volunteers)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07797855",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07797855; registry primary completion 2027-08-01, status not yet recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07797855",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0707",
  "guidance_detail": "Phase 1 study NCT07797855; registry primary completion 2027-08-01, status not yet recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0721-8060",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07767175",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 first-in-human study NCT07767175; registry primary completion 2027-09-23, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07767175",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0708",
  "guidance_detail": "Phase 1 first-in-human study NCT07767175; registry primary completion 2027-09-23, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC4005-0001",
  "indication": "fatty liver disease",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Rezdiffra/resmetirom (Madrigal \u2014 approved MASH)",
   "Wegovy/semaglutide (Novo Nordisk \u2014 MASH)",
   "efruxifermin (Novo Nordisk/Akero \u2014 FGF21, MASH)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07214870",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07214870; registry primary completion 2027-05-14, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07214870",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0709",
  "guidance_detail": "Phase 1 study NCT07214870; registry primary completion 2027-05-14, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC6022-0004",
  "indication": "obesity (elevated hsCRP)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)",
   "CagriSema (Novo Nordisk \u2014 filed)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07693868",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07693868; registry primary completion 2027-08-03, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07693868",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0710",
  "guidance_detail": "Phase 1 study NCT07693868; registry primary completion 2027-08-03, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC6989-0001",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)",
   "amycretin (Novo Nordisk \u2014 Phase 3)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07437079",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT07437079; registry primary completion 2027-01-21, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later",
  "nct_id": "NCT07437079",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0711",
  "guidance_detail": "Phase 1 study NCT07437079; registry primary completion 2027-01-21, status recruiting; mechanism undisclosed; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "177Lu-FAP-2286",
  "indication": "advanced solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Pluvicto (Novartis \u2014 radioligand therapy)",
   "Lutathera (Novartis \u2014 radioligand therapy)",
   "PNT2003 (Lantheus \u2014 Lu-177 radioligand)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04939610",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 study NCT04939610; registry primary completion 2027-12-31, status recruiting; FAP-targeted Lu-177 radioligand; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT04939610",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0712",
  "guidance_detail": "Phase 1/2 study NCT04939610; registry primary completion 2027-12-31, status recruiting; FAP-targeted Lu-177 radioligand; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "177Lu-NeoB",
  "indication": "GRPR-expressing solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Pluvicto (Novartis \u2014 radioligand therapy)",
   "Lutathera (Novartis \u2014 radioligand therapy)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06247995",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 study NCT06247995; registry primary completion 2027-04-14, status active/not recruiting; GRPR-targeted Lu-177 radioligand; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT06247995",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0713",
  "guidance_detail": "Phase 1/2 study NCT06247995; registry primary completion 2027-04-14, status active/not recruiting; GRPR-targeted Lu-177 radioligand; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "DFV890",
  "indication": "low-risk myelodysplastic syndrome (MDS)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Reblozyl/luspatercept (Bristol Myers Squibb \u2014 low-risk MDS)",
   "dapansutrile (Olatec \u2014 NLRP3 inhibitor, private)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05552469",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT05552469; registry primary completion 2027-02-01, status active/not recruiting; NLRP3 inhibitor in low-risk MDS; topline typically ~3-6 mo later",
  "nct_id": "NCT05552469",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0714",
  "guidance_detail": "Phase 1 study NCT05552469; registry primary completion 2027-02-01, status active/not recruiting; NLRP3 inhibitor in low-risk MDS; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "HRO761",
  "indication": "MSI-H/dMMR solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Keytruda/pembrolizumab (Merck \u2014 MSI-H)",
   "Opdivo/nivolumab (Bristol Myers Squibb \u2014 MSI-H)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05838768",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT05838768; registry primary completion 2027-08-31, status active/not recruiting; allosteric WRN helicase inhibitor; topline typically ~3-6 mo later",
  "nct_id": "NCT05838768",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0715",
  "guidance_detail": "Phase 1 study NCT05838768; registry primary completion 2027-08-31, status active/not recruiting; allosteric WRN helicase inhibitor; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "IAG933",
  "indication": "mesothelioma and solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "nivolumab+ipilimumab (Bristol Myers Squibb \u2014 mesothelioma SoC)",
   "pembrolizumab (Merck \u2014 solid tumors)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04857372",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT04857372; registry primary completion 2027-01-07, status active/not recruiting; TEAD inhibitor; topline typically ~3-6 mo later",
  "nct_id": "NCT04857372",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0716",
  "guidance_detail": "Phase 1 study NCT04857372; registry primary completion 2027-01-07, status active/not recruiting; TEAD inhibitor; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "KFA115",
  "indication": "advanced solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Keytruda/pembrolizumab (Merck \u2014 combo partner)",
   "Opdivo/nivolumab (Bristol Myers Squibb)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05544929",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Phase 1 study NCT05544929; registry primary completion 2027-10-05, status active/not recruiting; novel immunomodulatory oncology agent; topline typically ~3-6 mo later",
  "nct_id": "NCT05544929",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0717",
  "guidance_detail": "Phase 1 study NCT05544929; registry primary completion 2027-10-05, status active/not recruiting; novel immunomodulatory oncology agent; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "PIT565",
  "indication": "B-cell malignancies",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Blincyto/blinatumomab (Amgen \u2014 CD19 T-cell engager)",
   "Lunsumio/mosunetuzumab (Roche \u2014 CD20 T-cell engager)",
   "Columvi/glofitamab (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05397496",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1 study NCT05397496; registry primary completion 2027-01-04, status active/not recruiting; CD19/CD3/CD2 trispecific T-cell engager; separate SLE Phase 1 (NCT06335979, PCD 2027-11) suppressed per same-drug dedup; topline typically ~3-6 mo later",
  "nct_id": "NCT05397496",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0718",
  "guidance_detail": "Phase 1 study NCT05397496; registry primary completion 2027-01-04, status active/not recruiting; CD19/CD3/CD2 trispecific T-cell engager; separate SLE Phase 1 (NCT06335979, PCD 2027-11) suppressed per same-drug dedup; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "asciminib",
  "indication": "pediatric chronic myeloid leukemia (CML)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Sprycel/dasatinib (Bristol Myers Squibb \u2014 pediatric CML)",
   "Tasigna/nilotinib (Novartis \u2014 pediatric CML)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04925479",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 study NCT04925479; registry primary completion 2027-09-02, status recruiting; asciminib in pediatric CML (supplementary indication); topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT04925479",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0719",
  "guidance_detail": "Phase 1/2 study NCT04925479; registry primary completion 2027-09-02, status recruiting; asciminib in pediatric CML (supplementary indication); topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "opnurasib (JDQ443)",
  "indication": "KRAS G12C-mutant solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Lumakras/sotorasib (Amgen \u2014 KRAS G12C)",
   "Krazati/adagrasib (Bristol Myers Squibb \u2014 KRAS G12C)",
   "divarasib (Roche/Genentech \u2014 KRAS G12C)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04699188",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 study NCT04699188; registry primary completion 2027-01-25, status active/not recruiting; KRAS G12C inhibitor; topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT04699188",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0720",
  "guidance_detail": "Phase 1/2 study NCT04699188; registry primary completion 2027-01-25, status active/not recruiting; KRAS G12C inhibitor; topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "rapcabtagene autoleucel (YTB323)",
  "indication": "hematologic malignancies",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Yescarta (Gilead/Kite \u2014 CD19 CAR-T)",
   "Breyanzi (Bristol Myers Squibb \u2014 CD19 CAR-T)",
   "Kymriah (Novartis \u2014 CD19 CAR-T)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03960840",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 study NCT03960840; registry primary completion 2027-06-30, status active/not recruiting; CD19 CAR-T (T-Charge platform); topline typically ~3-6 mo later; Phase 1/2 study per registry",
  "nct_id": "NCT03960840",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0721",
  "guidance_detail": "Phase 1/2 study NCT03960840; registry primary completion 2027-06-30, status active/not recruiting; CD19 CAR-T (T-Charge platform); topline typically ~3-6 mo later; Phase 1/2 study per registry.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Ocugen, Inc.",
  "competitors": [
   "Alkeus Pharmaceuticals (gildeuretinol)",
   "Belite Bio (tinlarebant)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OCU410ST",
  "event_type": "bla_filing",
  "indication": "Stargardt disease \u2014 RORA modifier gene therapy",
  "notes": "Ocugen Q1 2026 business update (GlobeNewswire 2026-05-05): 'Plan to submit the BLA for OCU410ST by mid-2027'; GARDian3 dosing completed early, topline 2Q27. Re-verified 2026-09-20.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/05/3287702/0/en/Ocugen-Provides-Business-Update-with-First-Quarter-2026-Financial-Results.html",
  "ticker": "OCGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0722",
  "guidance_detail": "Ocugen Q1 2026 business update (GlobeNewswire 2026-05-05): 'Plan to submit the BLA for OCU410ST by mid-2027'; GARDian3 dosing completed early, topline 2Q27.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Ocugen, Inc. is expected to file its biologics license application for OCU410ST in Stargardt disease \u2014 RORA modifier gene therapy sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Odyssey Therapeutics, Inc.",
  "competitors": [
   "Bristol Myers Squibb (afimetoran \u2014 TLR7/8 inhibitor)",
   "Merck KGaA (enpatoran \u2014 TLR7/8 inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OD-002",
  "event_type": "regulatory_other",
  "indication": "autoimmune disease \u2014 oral SLC15A4 inhibitor (TLR7/8/9 pathway); healthy volunteers then cutaneous lupus erythematosus cohorts",
  "notes": "CTA filing guided H2 2026 enabling Phase 1/2a initiation H1 2027; blocks nucleic acid-driven TLR7/8/9 signaling for interferonopathies (SLE/CLE).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/17/3313811/0/en/Odyssey-Therapeutics-Reports-First-Quarter-2026-Financial-Results-and-Provides-Corporate-Update.html",
  "ticker": "ODTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0723",
  "guidance_detail": "CTA filing guided H2 2026 enabling Phase 1/2a initiation H1 2027; blocks nucleic acid-driven TLR7/8/9 signaling for interferonopathies (SLE/CLE).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Odyssey Therapeutics guides a regulatory filing in late 2026 enabling first-in-human studies of OD-002, an oral TLR7/8/9 pathway inhibitor for autoimmune disease, in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Olema Pharmaceuticals, Inc.",
  "competitors": [
   "Pfizer (PF-07248144 \u2014 KAT6A/B inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "OP-3136",
  "event_type": "readout",
  "indication": "advanced or metastatic solid tumors \u2014 KAT6A/B inhibitor",
  "notes": "Inferred from registry primary completion 2027-05-30 (NCT06784193, recruiting); company described program as Phase 1/2 (dose escalation + expansion).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06784193",
  "ticker": "OLMA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06784193",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0724",
  "guidance_detail": "Inferred from registry primary completion 2027-05-30 (NCT06784193, recruiting); company described program as Phase 1/2 (dose escalation + expansion).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Olema Pharmaceuticals, Inc.",
  "competitors": [
   "Menarini Group (elacestrant/Orserdu)",
   "AstraZeneca (camizestrant)",
   "Eli Lilly (imlunestrant)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "palazestrant",
  "event_type": "nda_filing",
  "indication": "ER+/HER2- metastatic breast cancer \u2014 oral CERAN/SERD",
  "notes": "8-K filed 2025-08-11 (Ex. 99.2): '2027: Anticipated submission of New Drug Application'; Phase 3 OPERA-01 topline moved to Q1 2027 (Phase 3 readout excluded). [2026-09-27 link audit] Replaced dead secdatabase.com mirror with the direct SEC EDGAR Exhibit 99.2 (investor presentation, CIK 1750284, accession 0000950170-25-106545), re-verified in-browser: slide 22 \"Upcoming Milestones\" states verbatim \"2027: Anticipated submission of New Drug Application for potential approval of palazestrant as a monotherapy in 2/3L ER+/HER2-MBC and prepare for commercial launch\".",
  "phase": null,
  "source_type": "SEC 8-K",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1750284/000095017025106545/olma-ex99_2.htm",
  "ticker": "OLMA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0725",
  "guidance_detail": "8-K filed 2025-08-11 (Ex.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Olema Pharmaceuticals, Inc. is expected to file its new drug application for palazestrant in ER+/HER2- metastatic breast cancer \u2014 oral CERAN/SERD sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-10-01",
  "company": "Omeros Corporation",
  "competitors": [
   "Pfizer (gemtuzumab ozogamicin/Mylotarg)",
   "AbbVie (pivekimab sunirine \u2014 CD123 ADC)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OMS805 (OncotoX-AML)",
  "event_type": "regulatory_other",
  "indication": "acute myeloid leukemia (AML)",
  "notes": "First-in-human Phase 1b AML trial targeted late 2027; engineered biologic (~half antibody size) delivering toxic payload to AML cells.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260812018593/en/Omeros-Corporation-Reports-Second-Quarter-2026-Financial-Results",
  "ticker": "OMER",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0726",
  "guidance_detail": "First-in-human Phase 1b AML trial targeted late 2027; engineered biologic (~half antibody size) delivering toxic payload to AML cells.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Omeros targets a first-in-human Phase 1b trial of OMS805 (OncotoX-AML) in acute myeloid leukemia in late 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "AstraZeneca (AZD9592 \u2014 EGFR\u00d7MET bispecific ADC)"
  ],
  "country": "China",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BG-C0902",
  "event_type": "readout",
  "indication": "advanced solid tumors \u2014 EGFR\u00d7MET\u00d7MET trispecific ADC",
  "notes": "Inferred from registry primary completion 2027-11-01 (NCT07181681, recruiting); company trial appendix confirms EGFR\u00d7MET\u00d7MET trispecific ADC.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07181681",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07181681",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0727",
  "guidance_detail": "Inferred from registry primary completion 2027-11-01 (NCT07181681, recruiting); company trial appendix confirms EGFR\u00d7MET\u00d7MET trispecific ADC.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "Merck KGaA (M9140 \u2014 CEACAM5 ADC)"
  ],
  "country": "China",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BG-C477",
  "event_type": "readout",
  "indication": "advanced solid tumors \u2014 CEA/CEACAM5 ADC",
  "notes": "Inferred from registry primary completion 2027-12-31 (NCT06596473, recruiting, sponsor BeOne Medicines).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06596473",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06596473",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0728",
  "guidance_detail": "Inferred from registry primary completion 2027-12-31 (NCT06596473, recruiting, sponsor BeOne Medicines).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "AstraZeneca (AZD8205 \u2014 B7-H4 TOP1 ADC)"
  ],
  "country": "China",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BG-C9074",
  "event_type": "readout",
  "indication": "advanced solid tumors \u2014 B7-H4-targeting topoisomerase-1 inhibitor ADC",
  "notes": "Inferred from registry primary completion 2027-09-28 (NCT06233942, recruiting); Phase 1a/1b first-in-human \u00b1 other therapeutics.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06233942",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06233942",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0729",
  "guidance_detail": "Inferred from registry primary completion 2027-09-28 (NCT06233942, recruiting); Phase 1a/1b first-in-human \u00b1 other therapeutics.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "AbbVie (venetoclax)",
   "Ascentage Pharma (lisaftoclax)"
  ],
  "country": "China",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BGB-21447 combinations",
  "event_type": "readout",
  "indication": "HR+/HER2- breast cancer \u2014 BCL2 inhibitor combinations",
  "notes": "Inferred from registry primary completion 2027-07-30 (NCT06756932, recruiting); company pipeline confirms BCL2 inhibitor in Phase 1.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06756932",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06756932",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0730",
  "guidance_detail": "Inferred from registry primary completion 2027-07-30 (NCT06756932, recruiting); company pipeline confirms BCL2 inhibitor in Phase 1.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "AstraZeneca/Daiichi Sankyo (trastuzumab deruxtecan/Enhertu)",
   "Roche (trastuzumab-based regimens)"
  ],
  "country": "China",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TEVIMBRA + ZIIHERA (tislelizumab + zanidatamab)",
  "event_type": "regulatory_other",
  "indication": "first-line HER2-positive gastroesophageal adenocarcinoma \u2014 China",
  "notes": "BeOne Q1 2026 update guides China regulatory action in H1 2027 for TEVIMBRA + ZIIHERA in 1L HER2+ GEA.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260506304875/en/BeOne-Medicines-Announces-First-Quarter-2026-Financial-Results-and-Business-Updates",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0732",
  "guidance_detail": "BeOne Q1 2026 update guides China regulatory action in H1 2027 for TEVIMBRA + ZIIHERA in 1L HER2+ GEA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "AbbVie (venetoclax)",
   "Ascentage Pharma (lisaftoclax)"
  ],
  "country": "China",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "sonrotoclax",
  "event_type": "readout",
  "indication": "mature B-cell malignancies \u2014 BCL2 inhibitor (Phase 1 study)",
  "notes": "Inferred from registry primary completion 2027-05-31 (NCT04277637, active not recruiting); sonrotoclax approved for MCL May 2026 \u2014 this Phase 1 covers broader mature B-cell malignancies.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04277637",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04277637",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0733",
  "guidance_detail": "Inferred from registry primary completion 2027-05-31 (NCT04277637, active not recruiting); sonrotoclax approved for MCL May 2026 \u2014 this Phase 1 covers broader mature B-cell malignancies.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "OPKO Health, Inc.",
  "competitors": [
   "Sanofi (CD28-costimulating T-cell engagers)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MDX2004",
  "event_type": "readout",
  "indication": "advanced tumors \u2014 CD3\u00d7CD28\u00d74-1BBL trispecific immune rejuvenator",
  "notes": "Company expects initial safety/tolerability/PK/immune data H1 2027; Phase 1/2 dose escalation+expansion NCT07110584 (registry PC 2031) \u2014 2027 data is the Phase 1 portion. Registry note (2026-09-23): CT.gov now lists primary completion 2031-06-30 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/27/3333870/0/en/opko-health-reports-second-quarter-2026-business-highlights-and-financial-results.html",
  "ticker": "OPK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07110584",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0734",
  "guidance_detail": "Company expects initial safety/tolerability/PK/immune data H1 2027; Phase 1/2 dose escalation+expansion NCT07110584 (registry PC 2031) \u2014 2027 data is the Phase 1 portion.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "OPKO Health, Inc.",
  "competitors": [
   "Invivyd (pemivibart/Pemgarda)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MDX2301",
  "event_type": "readout",
  "indication": "COVID-19 prevention \u2014 tetravalent multispecific antibody",
  "notes": "Company guides early Phase 1 data late 2026 or early 2027; registry primary completion 2027-09 (NCT07445971, ModeX/OPKO, BARDA-funded).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/27/3333870/0/en/opko-health-reports-second-quarter-2026-business-highlights-and-financial-results.html",
  "ticker": "OPK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07445971",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0735",
  "guidance_detail": "Company guides early Phase 1 data late 2026 or early 2027; registry primary completion 2027-09 (NCT07445971, ModeX/OPKO, BARDA-funded).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Oric Pharmaceuticals, Inc.",
  "competitors": [
   "Ipsen (tazemetostat \u2014 EZH2 inhibitor)",
   "Daiichi Sankyo (valemetostat \u2014 EZH1/2 inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ORIC-944",
  "event_type": "readout",
  "indication": "metastatic castration-resistant prostate cancer \u2014 allosteric PRC2/EED inhibitor",
  "notes": "Inferred from registry primary completion 2027-06 (NCT05413421, recruiting); mature Phase 1 study as program transitions to registrational development.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05413421",
  "ticker": "ORIC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05413421",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0736",
  "guidance_detail": "Inferred from registry primary completion 2027-06 (NCT05413421, recruiting); mature Phase 1 study as program transitions to registrational development.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ovid Therapeutics Inc.",
  "competitors": [
   "Acadia Pharmaceuticals (pimavanserin/Nuplazid)",
   "Bristol Myers Squibb (KarXT/Cobenfy)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OV4071",
  "event_type": "readout",
  "indication": "psychosis in Parkinson's disease / Lewy body dementia and schizophrenia \u2014 oral KCC2 activator",
  "notes": "OV4071 (first oral direct KCC2 activator) advancing through Phase 1 in healthy volunteers; per Aug 13, 2026 Q2 PR, Phase 1 data are expected to support initiation of a Phase 2 proof-of-concept study in acute schizophrenia in 2027. (Supersedes the Dec 2025 deck's Q1 2027 PoC timing.)",
  "phase": "1",
  "source_type": "company deck",
  "source_url": "https://s201.q4cdn.com/176459324/files/doc_presentations/2025/Dec/18/December-2025-Corporate-Presentation.pdf",
  "ticker": "OVID",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0737",
  "guidance_detail": "OV4071 (first oral direct KCC2 activator) advancing through Phase 1 in healthy volunteers; per Aug 13, 2026 Q2 PR, Phase 1 data are expected to support initiation of a Phase 2 proof-of-concept study in acute schizophrenia in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Pacira BioSciences, Inc.",
  "competitors": [
   "Heron Therapeutics (Zynrelef)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "EXPAREL (pediatric)",
  "event_type": "readout",
  "indication": "pediatric postoperative analgesia \u2014 PK/safety study",
  "notes": "Inferred from registry primary completion 2027-01 (NCT06271265, recruiting); PK/safety of liposomal bupivacaine in pediatric patients.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06271265",
  "ticker": "PCRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06271265",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0738",
  "guidance_detail": "Inferred from registry primary completion 2027-01 (NCT06271265, recruiting); PK/safety of liposomal bupivacaine in pediatric patients.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-01",
  "company": "Vaxcyte, Inc.",
  "competitors": [
   "Pfizer (GBS6 \u2014 group B strep vaccine, related streptococcal program)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VAX-A1",
  "event_type": "readout",
  "indication": "prevention of disease caused by Group A Streptococcus",
  "notes": "Company expects Phase 1 topline H2 2027; first participant dosed June 2026; no approved Group A Strep vaccine.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/02/3305592/0/en/Vaxcyte-Doses-First-Participant-in-Phase-1-Study-Evaluating-VAX-A1-for-the-Prevention-of-Disease-Caused-by-Group-A-Streptococcus-in-Healthy-Adults.html",
  "ticker": "PCVX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0739",
  "guidance_detail": "Company expects Phase 1 topline H2 2027; first participant dosed June 2026; no approved Group A Strep vaccine.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "Vaxneuvance (Merck)",
   "Capvaxive (Merck)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "20vPnC (pneumococcal 20-valent conjugate vaccine)",
  "event_type": "readout",
  "indication": "pneumococcal disease \u2014 safety study in healthy Chinese adults",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-05-14 for NCT07023081 (Phase 1, active not recruiting).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07023081",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07023081",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0740",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-05-14 for NCT07023081 (Phase 1, active not recruiting).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "dapagliflozin (AstraZeneca)",
   "empagliflozin (Boehringer Ingelheim/Eli Lilly)",
   "sacubitril/valsartan (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07328948 (oral candidate; hepatic impairment PK study)",
  "event_type": "readout",
  "indication": "heart failure \u2014 hepatic impairment PK study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-02-23 for NCT07269301 (Phase 1, recruiting); PF-07328948 is Pfizer's oral heart failure candidate (BRANCH-HF program).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07269301",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07269301",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0741",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-02-23 for NCT07269301 (Phase 1, recruiting); PF-07328948 is Pfizer's oral heart failure candidate (BRANCH-HF program).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0927",
   "v16-0742"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "dapagliflozin (AstraZeneca)",
   "empagliflozin (Boehringer Ingelheim/Eli Lilly)",
   "sacubitril/valsartan (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07328948 (oral candidate; renal impairment PK study)",
  "event_type": "readout",
  "indication": "heart failure \u2014 renal impairment PK study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-03-13 for NCT07315360 (Phase 1, recruiting); PF-07328948 is Pfizer's oral heart failure candidate (BRANCH-HF program).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07315360",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07315360",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0742",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-03-13 for NCT07315360 (Phase 1, recruiting); PF-07328948 is Pfizer's oral heart failure candidate (BRANCH-HF program).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0927",
   "v16-0741"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "daraxonrasib (Revolution Medicines)",
   "ERAS-0015 (Erasca)",
   "dabrafenib + trametinib (Novartis)",
   "encorafenib + binimetinib (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07799544 (polfurmetinib; oral brain-penetrant MEK inhibitor) + PF-07799933 (claturafenib; BRAF dimer inhibitor)",
  "event_type": "readout",
  "indication": "BRAF-mutant melanoma and advanced solid tumors",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-08-31 for NCT05538130 (Phase 1a/b master study; Phase 1b combo substudy reported initial data at ASCO 2026).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05538130",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05538130",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0743",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-08-31 for NCT05538130 (Phase 1a/b master study; Phase 1b combo substudy reported initial data at ASCO 2026).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "dabrafenib + trametinib (Novartis)",
   "encorafenib + binimetinib (Pfizer)",
   "vemurafenib + cobimetinib (Roche)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07799933 (claturafenib; BRAF dimer inhibitor)",
  "event_type": "readout",
  "indication": "BRAF-altered advanced solid tumors",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-08-31 for NCT05355701 (Phase 1 monotherapy, active not recruiting); combination with polfurmetinib (NCT05538130) already covered in phase3-watchitems.json.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05355701",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05355701",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0744",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-08-31 for NCT05355701 (Phase 1 monotherapy, active not recruiting); combination with polfurmetinib (NCT05538130) already covered in phase3-watchitems.json.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "dupilumab (Regeneron/Sanofi)",
   "lebrikizumab (Eli Lilly)",
   "abrocitinib (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07832837 (biologic; mechanism undisclosed)",
  "event_type": "readout",
  "indication": "atopic dermatitis \u2014 first-in-human SAD/MAD in healthy adults and AD patients",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-06-02 for NCT06564389 (Phase 1, recruiting); Pfizer pipeline lists PF-07832837 as Phase 1 atopic dermatitis biologic with undisclosed mechanism.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06564389",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06564389",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0745",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-06-02 for NCT06564389 (Phase 1, recruiting); Pfizer pipeline lists PF-07832837 as Phase 1 atopic dermatitis biologic with undisclosed mechanism.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "sparsentan (Travere)",
   "iptacopan (Novartis)",
   "atrasentan (Novartis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07985631 (biologic; mechanism undisclosed)",
  "event_type": "readout",
  "indication": "nephropathy (IgA nephropathy per trade press) \u2014 SAD/MAD in healthy adults",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-12-08 for NCT06994897 (Phase 1, recruiting); Pfizer pipeline lists PF-07985631 as Phase 1 nephropathy biologic with undisclosed mechanism.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06994897",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06994897",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0746",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-12-08 for NCT06994897 (Phase 1, recruiting); Pfizer pipeline lists PF-07985631 as Phase 1 nephropathy biologic with undisclosed mechanism.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "adalimumab (AbbVie)",
   "tofacitinib (Pfizer)",
   "upadacitinib (AbbVie)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08065010 (mechanism undisclosed)",
  "event_type": "readout",
  "indication": "rheumatoid arthritis \u2014 first-in-human SAD/MAD in healthy adults",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-09-01 for NCT07235163 (Phase 1, recruiting); Pfizer pipeline lists PF-08065010 as Phase 1 rheumatoid arthritis candidate with undisclosed mechanism.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07235163",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07235163",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0747",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-09-01 for NCT07235163 (Phase 1, recruiting); Pfizer pipeline lists PF-08065010 as Phase 1 rheumatoid arthritis candidate with undisclosed mechanism.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "mepolizumab (GSK)",
   "tezepelumab (AstraZeneca/Amgen)",
   "dupilumab (Regeneron/Sanofi)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08103402 (oral; mechanism undisclosed)",
  "event_type": "readout",
  "indication": "asthma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-03-30 for NCT07660731 (Phase 1 in healthy adults and adults with mild-to-moderate asthma; PK/food-effect/metabolism study).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07660731",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07660731",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0748",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-03-30 for NCT07660731 (Phase 1 in healthy adults and adults with mild-to-moderate asthma; PK/food-effect/metabolism study).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)",
   "retatrutide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08642534 (mechanism undisclosed)",
  "event_type": "readout",
  "indication": "obesity \u2014 SAD/MAD in adults",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-04-21 for NCT07731139 (Phase 1, not yet recruiting); obesity indication per registry, target undisclosed.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07731139",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07731139",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0749",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-04-21 for NCT07731139 (Phase 1, not yet recruiting); obesity indication per registry, target undisclosed.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08653945 (mechanism undisclosed)",
  "event_type": "readout",
  "indication": "overweight/obesity \u2014 single-dose PK study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-01-13 for NCT07725809 (Phase 1, recruiting); Metsera-origin obesity program candidate.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07725809",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07725809",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0750",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-01-13 for NCT07725809 (Phase 1, recruiting); Metsera-origin obesity program candidate.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "Capvaxive (Merck)",
   "Vaxneuvance (Merck)",
   "Prevnar 20 (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PG4 (multivalent pneumococcal conjugate vaccine)",
  "event_type": "readout",
  "indication": "Streptococcus pneumoniae \u2014 Phase 1 safety/tolerability in adults",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-10-21 for NCT07086677 (Phase 1, active not recruiting); adult study distinct from pediatric PG4 Phase 2 (NCT06524414, already covered).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07086677",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07086677",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0751",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-10-21 for NCT07086677 (Phase 1, active not recruiting); adult study distinct from pediatric PG4 Phase 2 (NCT06524414, already covered).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "gemtuzumab ozogamicin (Pfizer)",
   "magrolimab (Gilead)",
   "venetoclax (AbbVie)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SEA-CD70 (anti-CD70 antibody)",
  "event_type": "readout",
  "indication": "myeloid malignancies",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-07-04 for NCT04227847 (Phase 1).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04227847",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04227847",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0752",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-07-04 for NCT04227847 (Phase 1).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "abemaciclib (Eli Lilly)",
   "ribociclib (Novartis)",
   "palbociclib (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "atirmociclib (oral CDK4-selective inhibitor)",
  "event_type": "readout",
  "indication": "breast cancer \u2014 hepatic impairment PK study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-08-14 for NCT07677358 (Phase 1, recruiting); readout not company-guided.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07677358",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07677358",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0753",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-08-14 for NCT07677358 (Phase 1, recruiting); readout not company-guided.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)",
   "retatrutide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "berobenatide (PF-08653944; ultra-long-acting GLP-1 RA; gastric emptying study)",
  "event_type": "readout",
  "indication": "obesity \u2014 gastric emptying study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-01-27 for NCT07508241 (Phase 1, active not recruiting); monthly GLP-1 RA from Metsera acquisition; Phase 2b VESPER-3 positive Feb 2026.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07508241",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07508241",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0754",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-01-27 for NCT07508241 (Phase 1, active not recruiting); monthly GLP-1 RA from Metsera acquisition; Phase 2b VESPER-3 positive Feb 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0755"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)",
   "retatrutide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "berobenatide (PF-08653944; ultra-long-acting GLP-1 RA; hepatic impairment study)",
  "event_type": "readout",
  "indication": "obesity \u2014 hepatic impairment PK study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-07-09 for NCT07519135 (Phase 1, recruiting); monthly GLP-1 RA from Metsera acquisition.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07519135",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07519135",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0755",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-07-09 for NCT07519135 (Phase 1, recruiting); monthly GLP-1 RA from Metsera acquisition.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0754"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "iberdomide / mezigdomide (Bristol Myers Squibb)",
   "teclistamab (Johnson & Johnson)",
   "linvoseltamab (Regeneron)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "elranatamab (BCMA bispecific) + iberdomide (CELMoD)",
  "event_type": "readout",
  "indication": "multiple myeloma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-11-16 for NCT06215118 (Phase 1 combination).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06215118",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06215118",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0756",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-11-16 for NCT06215118 (Phase 1 combination).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "emicizumab (Roche)",
   "concizumab (Novo Nordisk)",
   "fitusiran (Sanofi)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "marstacimab (anti-TFPI antibody)",
  "event_type": "readout",
  "indication": "hemophilia \u2014 switch from emicizumab to marstacimab",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-05-05 for NCT06703606 (Phase 1, recruiting); safety/tolerability study after switching from emicizumab.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06703606",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06703606",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0757",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-05-05 for NCT06703606 (Phase 1, recruiting); safety/tolerability study after switching from emicizumab.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "crizanlizumab (Novartis)",
   "Casgevy (Vertex/CRISPR Therapeutics)",
   "Lyfgenia (bluebird bio)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "osivelotor (PF-07940367; sickle hemoglobin polymerization inhibitor)",
  "event_type": "readout",
  "indication": "sickle cell disease \u2014 pediatric formulation palatability study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-02-19 for NCT06507904 (Phase 1 palatability of pediatric formulations, not yet recruiting); next-gen HbS polymerization inhibitor from Global Blood Therapeutics acquisition.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06507904",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06507904",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0758",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-02-19 for NCT06507904 (Phase 1 palatability of pediatric formulations, not yet recruiting); next-gen HbS polymerization inhibitor from Global Blood Therapeutics acquisition.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca)",
   "sacituzumab tirumotecan (Merck)",
   "Rina-S (Genmab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "sigvotatug vedotin (anti-integrin beta-6 ADC)",
  "event_type": "readout",
  "indication": "advanced solid tumors",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-06-16 for NCT04389632 (Phase 1).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04389632",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04389632",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0759",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-06-16 for NCT04389632 (Phase 1).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-20",
  "company": "Pfizer Inc.",
  "competitors": [
   "dupilumab (Regeneron/Sanofi)",
   "lebrikizumab (Eli Lilly)",
   "upadacitinib (AbbVie)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "tilrekimig (anti-IL-4/IL-13/TSLP trispecific) + rHuPH20",
  "event_type": "readout",
  "indication": "atopic dermatitis \u2014 single-dose PK of subcutaneous formulation",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-02-20 for NCT07792941 (Phase 1, recruiting); rHuPH20 co-formulation supports subcutaneous delivery of the trispecific antibody.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07792941",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07792941",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0760",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-02-20 for NCT07792941 (Phase 1, recruiting); rHuPH20 co-formulation supports subcutaneous delivery of the trispecific antibody.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-20"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "rimegepant (Pfizer)",
   "atogepant (AbbVie)",
   "ubrogepant (AbbVie)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "zavegepant (intranasal CGRP receptor antagonist)",
  "event_type": "readout",
  "indication": "migraine \u2014 pediatric study",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-08-12 for NCT06995729 (Phase 1, recruiting); readout not company-guided.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06995729",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06995729",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0761",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-08-12 for NCT06995729 (Phase 1, recruiting); readout not company-guided.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "ProMIS Neurosciences Inc.",
  "competitors": [
   "donanemab (Eli Lilly)",
   "lecanemab (Eisai/Biogen)",
   "remternetug (Eli Lilly)"
  ],
  "country": "Canada",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PMN310 (anti-amyloid-beta oligomer antibody)",
  "event_type": "readout",
  "indication": "early Alzheimer's disease \u2014 PRECISE-AD Phase 1b",
  "notes": "Company guided unblinded 12-month topline including efficacy for Q1 2027 (PR Jul 28, 2026); NCT06750432 primary completion Dec 2026.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.promisneurosciences.com/news-media/press-releases/detail/271/promis-neurosciences-reports-positive-blinded-six-month",
  "ticker": "PMN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06750432",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0762",
  "guidance_detail": "Company guided unblinded 12-month topline including efficacy for Q1 2027 (PR Jul 28, 2026); NCT06750432 primary completion Dec 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Prime Medicine, Inc.",
  "competitors": [
   "UX701 (Ultragenix)",
   "penicillamine (generic)",
   "trientine (generic)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PM577 (prime editing therapy)",
  "event_type": "readout",
  "indication": "Wilson disease \u2014 initial clinical data",
  "notes": "Company guided initial Wilson disease clinical data in 2027 (Q1 2026 results, May 7, 2026); NCT07748403 Phase 1/2 primary completion Nov 2028. Registry note (2026-09-23): CT.gov now lists primary completion 2028-11 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3289924/0/en/Prime-Medicine-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html",
  "ticker": "PRME",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07748403",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0763",
  "guidance_detail": "Company guided initial Wilson disease clinical data in 2027 (Q1 2026 results, May 7, 2026); NCT07748403 Phase 1/2 primary completion Nov 2028.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Prime Medicine, Inc.",
  "competitors": [
   "fazirsiran (Arrowhead)",
   "Zemaira (CSL Behring)",
   "Prolastin-C (Grifols)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PM647 (prime editing therapy)",
  "event_type": "readout",
  "indication": "alpha-1 antitrypsin deficiency \u2014 initial clinical data",
  "notes": "Company guided initial AATD clinical data in 2027 (Q1 2026 results, May 7, 2026); no CT.gov trial posted yet.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3289924/0/en/Prime-Medicine-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Updates.html",
  "ticker": "PRME",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0764",
  "guidance_detail": "Company guided initial AATD clinical data in 2027 (Q1 2026 results, May 7, 2026); no CT.gov trial posted yet.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "ProQR Therapeutics N.V.",
  "competitors": [
   "SNY Aldurazyme (laronidase)",
   "OTL-203 (Orchard Therapeutics)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AX-0422 (Axiomer RNA editing oligonucleotide targeting IDUA)",
  "event_type": "readout",
  "indication": "Hurler syndrome (MPS I) \u2014 initial patient data",
  "notes": "CTA filing expected early 2027 with initial clinical data targeted H1 2027 (Q1 2026 results, May 12, 2026).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/12/3292670/33039/en/ProQR-Announces-First-Quarter-2026-Operating-and-Financial-Results.html",
  "ticker": "PRQR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0765",
  "guidance_detail": "CTA filing expected early 2027 with initial clinical data targeted H1 2027 (Q1 2026 results, May 12, 2026).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "ProQR Therapeutics N.V.",
  "competitors": [
   "Standard of care is surgical (Kasai portoenterostomy); no approved pharmacologic competitors"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AX-0810 (Axiomer RNA editing oligonucleotide targeting NTCP)",
  "event_type": "readout",
  "indication": "pediatric biliary atresia \u2014 investigator-initiated trial in China",
  "notes": "Company targets initial clinical data H1 2027 from pediatric biliary atresia IIT in China (Q1 2026 results, May 12, 2026).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/12/3292670/33039/en/ProQR-Announces-First-Quarter-2026-Operating-and-Financial-Results.html",
  "ticker": "PRQR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0766",
  "guidance_detail": "Company targets initial clinical data H1 2027 from pediatric biliary atresia IIT in China (Q1 2026 results, May 12, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "ProQR Therapeutics N.V.",
  "competitors": [
   "MDGL Rezdiffra (resmetirom)",
   "semaglutide (Novo Nordisk)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AX-2911 (Axiomer RNA editing oligonucleotide targeting PNPLA3)",
  "event_type": "regulatory_other",
  "indication": "MASH \u2014 first-in-human investigator-initiated trial in China",
  "notes": "FIH IIT initiation planned H1 2027 (Q1 2026 results, May 12, 2026); initiation included as stock-moving for micro-cap pipeline expansion.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/12/3292670/33039/en/ProQR-Announces-First-Quarter-2026-Operating-and-Financial-Results.html",
  "ticker": "PRQR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0767",
  "guidance_detail": "FIH IIT initiation planned H1 2027 (Q1 2026 results, May 12, 2026); initiation included as stock-moving for micro-cap pipeline expansion.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "ProQR plans to start a first-in-human investigator-initiated trial of AX-2911, its RNA-editing therapy for MASH, in the first half of 2027."
 },
 {
  "as_of": "2026-09-23",
  "company": "Protagonist Therapeutics, Inc.",
  "competitors": [
   "orforglipron (Eli Lilly)",
   "amycretin (Novo Nordisk)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PN-458o (oral dual GLP/GIP agonist peptide)",
  "event_type": "regulatory_other",
  "indication": "obesity \u2014 oral formulation",
  "notes": "Phase 1 initiation anticipated H2 2027; IND-enabling studies ongoing (Q2 2026 results, Aug 5, 2026). Initiation included as stock-moving wholly-owned pipeline expansion.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/protagonist-reports-second-quarter-2026-financial-results-and-provides-corporate-update",
  "ticker": "PTGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0768",
  "guidance_detail": "Phase 1 initiation anticipated H2 2027; IND-enabling studies ongoing (Q2 2026 results, Aug 5, 2026).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Protagonist anticipates starting Phase 1 studies of PN-458o, its oral dual GLP/GIP agonist peptide for obesity, in the second half of 2027."
 },
 {
  "as_of": "2026-09-23",
  "company": "Protagonist Therapeutics, Inc.",
  "competitors": [
   "retatrutide (Eli Lilly)",
   "amycretin (Novo Nordisk)",
   "orforglipron (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PN-477o (oral triple GLP1/GIP/GCG agonist peptide)",
  "event_type": "regulatory_other",
  "indication": "obesity \u2014 oral formulation",
  "notes": "Phase 1 initiation of oral formulation anticipated H1 2027; injectable (sc) Phase 1 already begun (Q2 2026 results, Aug 5, 2026). Initiation included as stock-moving wholly-owned pipeline expansion.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/protagonist-reports-second-quarter-2026-financial-results-and-provides-corporate-update",
  "ticker": "PTGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0769",
  "guidance_detail": "Phase 1 initiation of oral formulation anticipated H1 2027; injectable (sc) Phase 1 already begun (Q2 2026 results, Aug 5, 2026).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Protagonist anticipates starting Phase 1 studies of PN-477o, its oral triple GLP-1/GIP/glucagon agonist peptide for obesity, in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Protagonist Therapeutics, Inc.",
  "competitors": [
   "PTGX rusfertide (hepcidin mimetic, PV)",
   "No oral hepcidin-mimetic competitors disclosed"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PN-8047 (oral small molecule hepcidin functional mimetic)",
  "event_type": "regulatory_other",
  "indication": "hepcidin pathway (specific indication not disclosed)",
  "notes": "Phase 1 initiation anticipated Q1 2027; IND-enabling studies ongoing (Q2 2026 results, Aug 5, 2026). Initiation included as stock-moving wholly-owned pipeline expansion.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/protagonist-reports-second-quarter-2026-financial-results-and-provides-corporate-update",
  "ticker": "PTGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0770",
  "guidance_detail": "Phase 1 initiation anticipated Q1 2027; IND-enabling studies ongoing (Q2 2026 results, Aug 5, 2026).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24",
  "why_it_matters": "Protagonist anticipates starting Phase 1 studies of PN-8047, its oral hepcidin-mimetic peptide, in Q1 2027."
 },
 {
  "as_of": "2026-09-23",
  "company": "Palatin Technologies, Inc.",
  "competitors": [
   "setmelanotide (Rhythm Pharmaceuticals)",
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Next-generation oral MC4R agonist (unnamed)",
  "event_type": "ind",
  "indication": "obesity",
  "notes": "IND submission targeted H1 2027 (company guidance, May 2026); ticker moved from NYSE American to Nasdaq under PTN on May 29, 2026.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/palatin-to-begin-trading-on-nasdaq-stock-exchange-302774038.html",
  "ticker": "PTN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0771",
  "guidance_detail": "IND submission targeted H1 2027 (company guidance, May 2026); ticker moved from NYSE American to Nasdaq under PTN on May 29, 2026.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Pyxis Oncology, Inc.",
  "competitors": [
   "ABBV Elahere (mirvetuximab soravtansine)",
   "No other EDB-fibronectin-targeting ADC competitors identified"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PYX-201 (EDB-fibronectin-targeting ADC with auristatin-derived payload)",
  "event_type": "readout",
  "indication": "advanced solid tumors \u2014 Phase 1 monotherapy",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-04-25 for NCT05720117 (Phase 1, recruiting).",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05720117",
  "ticker": "PYXS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05720117",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0772",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-04-25 for NCT05720117 (Phase 1, recruiting).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Linvoseltamab + dupilumab",
  "indication": "Severe IgE-mediated food allergy",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "DBVT (Viaskin Peanut)",
   "RHHBY (Xolair/omalizumab)",
   "NVS (Xolair co-marketer)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06369467",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Short-term linvoseltamab (CD20xCD3) + dupilumab dose-escalation in food allergy. inferred from CT.gov primary completion 2027-08-31 (NCT06369467); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06369467",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0773",
  "guidance_detail": "Short-term linvoseltamab (CD20xCD3) + dupilumab dose-escalation in food allergy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "REGN20934",
  "indication": "Overweight/obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "LLY (Zepbound/tirzepatide)",
   "NVO (Wegovy/semaglutide)",
   "AMGN (maridebart)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07594093",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Single-ascending-dose study in adults with overweight/obesity; target not disclosed. inferred from CT.gov primary completion 2027-02-22 (NCT07594093); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07594093",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0774",
  "guidance_detail": "Single-ascending-dose study in adults with overweight/obesity; target not disclosed.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "REGN22044",
  "indication": "Healthy volunteers (first-in-human; undisclosed target)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [],
  "source_url": "https://clinicaltrials.gov/study/NCT07526116",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Single-ascending-dose FIH; target not disclosed. inferred from CT.gov primary completion 2027-02-08 (NCT07526116); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07526116",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0775",
  "guidance_detail": "Single-ascending-dose FIH; target not disclosed.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RGNX",
  "company": "REGENXBIO Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "RGX-202",
  "indication": "Duchenne muscular dystrophy",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "SRPT (Elevidys)",
   "Nippon Shinyaku/NS Pharma (viltolarsen)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/regenxbio-completes-dosing-in-confirmatory-study-of-rgx-202-marking-completion-of-registrational-development-program-and-supporting-planned-bla-submission-in-q3-2026-302808616.html",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Company-guided potential accelerated-approval decision 2H 2027; NOT a PDUFA (no FDA acceptance letter found); BLA initiation guided Q3 2026 per June 2026 PR, though a May 2026 community letter said filing in 2027 - filing timing ambiguous.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0776",
  "guidance_detail": "Company-guided potential accelerated-approval decision 2H 2027; NOT a PDUFA (no FDA acceptance letter found); BLA initiation guided Q3 2026 per June 2026 PR, though a May 2026 community letter said filing in 2027 - filing timing ambiguous.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "REGENXBONE guides a potential accelerated-approval decision for RGX-202 in Duchenne muscular dystrophy in the second half of 2027."
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Cevostamab + elranatamab",
  "indication": "Relapsed/refractory multiple myeloma",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "JNJ (Tecvayli/Talvey)",
   "PFE (Elrexfio/elranatamab)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05927571",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "FcRH5xCD3 + BCMAxCD3 bispecific combination. inferred from CT.gov primary completion 2027-07-31 (NCT05927571); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05927571",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0777",
  "guidance_detail": "FcRH5xCD3 + BCMAxCD3 bispecific combination.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Divarasib (GDC-6036)",
  "indication": "KRAS G12C-mutant NSCLC, colorectal and advanced solid tumors (combinations)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "AMGN (Lumakras)",
   "BMY (Krazati)",
   "RVMD (elironrasib/RMC-6291)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04449874",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Dose-escalation/expansion of divarasib alone and with atezolizumab, cetuximab, bevacizumab, erlotinib, GDC-1971, inavolisib. inferred from CT.gov primary completion 2027-12-31 (NCT04449874); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04449874",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0778",
  "guidance_detail": "Dose-escalation/expansion of divarasib alone and with atezolizumab, cetuximab, bevacizumab, erlotinib, GDC-1971, inavolisib.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Enicepatide",
  "indication": "Healthy Chinese adults (amylin analog; first clinical PK)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "NVO (CagriSema)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07626515",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Amylin analog in the Roche/Zealand obesity collaboration. inferred from CT.gov primary completion 2027-05-14 (NCT07626515); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07626515",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0779",
  "guidance_detail": "Amylin analog in the Roche/Zealand obesity collaboration.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Glofitamab + GemOx",
  "indication": "Relapsed/refractory DLBCL (US study)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Epkinco)",
   "GILD (Yescarta)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06624085",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Glofitamab (approved CD20xCD3) with gemcitabine + oxaliplatin. inferred from CT.gov primary completion 2027-03-22 (NCT06624085); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06624085",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0781",
  "guidance_detail": "Glofitamab (approved CD20xCD3) with gemcitabine + oxaliplatin.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Inavolisib",
  "indication": "PIK3CA-mutated cancers (single agent and + atezolizumab)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "NVS (alpelisib/Vijoice)",
   "AZN (capivasertib/Truqap)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06496568",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "inferred from CT.gov primary completion 2027-07-21 (NCT06496568); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06496568",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0782",
  "guidance_detail": "inferred from CT.gov primary completion 2027-07-21 (NCT06496568); registry completion does not guarantee data disclosure.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7121932",
  "indication": "Multiple sclerosis",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "NVS (Kesimpta)",
   "SNY (tolebrutinib)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05704361",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Adaptive SAD/MAD and long-term safety study (IV and SC) in MS patients. inferred from CT.gov primary completion 2027-07-08 (NCT05704361); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05704361",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0783",
  "guidance_detail": "Adaptive SAD/MAD and long-term safety study (IV and SC) in MS patients.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7566802",
  "indication": "Locally advanced/recurrent/metastatic solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "MRK (Keytruda)",
   "BMY (Opdivo)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06031441",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Undisclosed target; single agent and with atezolizumab; closest competitors are PD-1 standard of care. inferred from CT.gov primary completion 2027-03-03 (NCT06031441); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06031441",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0784",
  "guidance_detail": "Undisclosed target; single agent and with atezolizumab; closest competitors are PD-1 standard of care.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7567132",
  "indication": "Advanced solid tumors (neoplasms)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "MRK (Keytruda)",
   "BMY (Opdivo)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06537310",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Undisclosed target; with atezolizumab; closest competitors are PD-1 standard of care. inferred from CT.gov primary completion 2027-05-12 (NCT06537310); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06537310",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0785",
  "guidance_detail": "Undisclosed target; with atezolizumab; closest competitors are PD-1 standard of care.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7656594",
  "indication": "Advanced/metastatic prostate cancer",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "NVS (Pluvicto)",
   "JNJ (Erleada/Zytiga)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05800665",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Dose-escalation and expansion; undisclosed target. inferred from CT.gov primary completion 2027-06-30 (NCT05800665); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05800665",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0786",
  "guidance_detail": "Dose-escalation and expansion; undisclosed target.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7806881",
  "indication": "Healthy volunteers (first-in-human; undisclosed target)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [],
  "source_url": "https://clinicaltrials.gov/study/NCT07271693",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-24",
  "notes": "SAD/MAD first-in-human; target not disclosed. Inferred from CT.gov primary completion 2027-05-11 (NCT07271693; moved from 2027-03-01 per 2026-09-27 registry check); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07271693",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0787",
  "guidance_detail": "SAD/MAD first-in-human; target not disclosed.",
  "audit_status": "v20_reverified",
  "audit_action": "quarter_mismatch_flag",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7812653",
  "indication": "Early symptomatic Alzheimer's disease",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "LLY (Kisunla)",
   "BIIB (Leqembi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07234942",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Randomized, double-blind, placebo-controlled single-ascending-dose study. inferred from CT.gov primary completion 2027-03-31 (NCT07234942); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07234942",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0788",
  "guidance_detail": "Randomized, double-blind, placebo-controlled single-ascending-dose study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Runimotamab",
  "indication": "Advanced solid tumors (HER2 T-cell engager, single agent and combinations)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Enhertu)",
   "DSNKY (Daiichi Sankyo, Enhertu co-developer)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03448042",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-24",
  "notes": "inferred from CT.gov primary completion 2027-04-30 (NCT03448042); registry completion does not guarantee data disclosure. Source note: Timing note: inferred bucket 2027-Q4 conflicts with registry primary-completion quarter (PCD 2027-04-30); topline timing may differ from the bucket. Registry timing to be reconfirmed before the window.",
  "us_tradable": true,
  "nct_id": "NCT03448042",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0789",
  "guidance_detail": "inferred from CT.gov primary completion 2027-04-30 (NCT03448042); registry completion does not guarantee data disclosure.",
  "audit_status": "v20_reverified",
  "audit_action": "quarter_mismatch_flag",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RLAY",
  "company": "Relay Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "RLY-8161",
  "indication": "NRAS-mutant advanced melanoma and solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "RVMD (RMC-6236, pan-RAS)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07584226",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "First-in-human NRAS-selective molecule; closest competitors are pan-RAS programs. inferred from CT.gov primary completion 2027-12-30 (NCT07584226); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07584226",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0790",
  "guidance_detail": "First-in-human NRAS-selective molecule; closest competitors are pan-RAS programs.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RLAY",
  "company": "Relay Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Zovegalisib (RLY-2608)",
  "indication": "PIK3CA-mutant advanced solid tumors / HR+/HER2- breast cancer",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "NVS (alpelisib/Piqray)",
   "RHHBY (inavolisib/Itovebi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05216432",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "First-in-human mutant-selective PI3Kalpha inhibitor, single agent and combinations. inferred from CT.gov primary completion 2027-04-30 (NCT05216432); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05216432",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0791",
  "guidance_detail": "First-in-human mutant-selective PI3Kalpha inhibitor, single agent and combinations.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RLAY",
  "company": "Relay Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Zovegalisib + atirmociclib + AI",
  "indication": "Frontline PIK3CA-mutant HR+/HER2- metastatic breast cancer",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "RHHBY (inavolisib/Itovebi)",
   "NVS (alpelisib/Piqray)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/04/27/3281389/0/en/Relay-Therapeutics-Announces-Clinical-Data-for-Zovegalisib-plus-Atirmociclib-Triplet-Combination-Supportive-of-Further-Development-in-Frontline-Metastatic-Breast-Cancer.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Relay-guided Phase 3 frontline trial initiation early 2027 (zovegalisib + Pfizer's atirmociclib + aromatase inhibitor), subject to regulatory feedback; genuinely stock-moving trial start.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0792",
  "guidance_detail": "Relay-guided Phase 3 frontline trial initiation early 2027 (zovegalisib + Pfizer's atirmociclib + aromatase inhibitor), subject to regulatory feedback; genuinely stock-moving trial start.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Relay Therapeutics guides starting its frontline Phase 3 of zovegalisib plus atirmociclib in PIK3CA-mutant HR+/HER2- metastatic breast cancer in early 2027."
 },
 {
  "ticker": "RNAC",
  "company": "Cartesian Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "In-vivo BCMA CAR-T (Descartes-08 mRNA payload + WestGene LNP)",
  "indication": "Generalized myasthenia gravis",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "ABBV (Capstan in-vivo CAR-T)",
   "AZN (EsoBiotec in-vivo CAR-T)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/06/09/3308695/0/en/Cartesian-Therapeutics-Announces-Strategic-Licensing-Agreement-with-WestGene-Biopharma-to-Accelerate-the-Development-of-In-Vivo-CAR-T-Platform-in-Autoimmune-Diseases.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Company-guided: trial to initiate 2H 2026, clinical data expected 1H 2027; distinct in-vivo program from the dedup'd Descartes-08 autologous Phase 2 TRITON readout.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0793",
  "guidance_detail": "Company-guided: trial to initiate 2H 2026, clinical data expected 1H 2027; distinct in-vivo program from the dedup'd Descartes-08 autologous Phase 2 TRITON readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "RVMD",
  "company": "Revolution Medicines, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Elironrasib (RMC-6291)",
  "indication": "KRAS G12C-mutant advanced solid tumors",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "AMGN (Lumakras)",
   "BMY (Krazati)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05462717",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/1b dose-escalation and expansion monotherapy study. inferred from CT.gov primary completion 2027-03-31 (NCT05462717); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05462717",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0794",
  "guidance_detail": "Phase 1/1b dose-escalation and expansion monotherapy study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "SANA",
  "company": "Sana Biotechnology, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "SC451",
  "indication": "Type 1 diabetes (stem-cell-derived islet cells)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "VRTX (zimislecel)"
  ],
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-8-10-sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-updates",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Sana Q2 2026 PR (Aug 10, 2026): studies 'beginning soon'; expects 'valuable insight into the clinical profiles' of SC451 and SG293 over next 6-9 months (~Feb-May 2027); no formal data disclosure explicitly guided. No standalone globenewswire.com page is indexed for the Aug 10, 2026 Sana Q2 release despite multiple exact-headline and site-restricted searches; no Sana IR release page or SEC filing was locatable either. Mirror text (GLOBE NEWSWIRE dateline, consistent across independent wire-network mirrors) was corroborated: CEO quote \u2014 'we expect to gain valuable insight into the clinical profiles and potential of both SC451 and SG293 over the next 6-9 months' (~Feb-May 2027). This is an inferred insight window, not explicit formal data-disclosure guidance; flagged as date_quality inferred.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0795",
  "guidance_detail": "Sana Q2 2026 PR (Aug 10, 2026): studies 'beginning soon'; expects 'valuable insight into the clinical profiles' of SC451 and SG293 over next 6-9 months (~Feb-May 2027); no formal data disclosure explicitly guided.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SANA",
  "company": "Sana Biotechnology, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "SG293",
  "indication": "Non-Hodgkin lymphoma (in-vivo CAR-T)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Capstan in-vivo CAR-T)",
   "AZN (EsoBiotec in-vivo CAR-T)"
  ],
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-8-10-sana-biotechnology-reports-second-quarter-2026-financial-results-and-business-updates",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Sana Q2 2026 PR (Aug 10, 2026): studies 'beginning soon'; expects 'valuable insight into the clinical profiles' of SC451 and SG293 over next 6-9 months (~Feb-May 2027); no formal data disclosure explicitly guided. Same official event as index 811 (Sana Q2 2026 release, Aug 10, 2026): CEO quote on 'valuable insight into the clinical profiles and potential of both SC451 and SG293 over the next 6-9 months' (~Feb-May 2027). No standalone globenewswire.com page, Sana IR page, or SEC filing located despite multiple exact-headline searches; guidance is inferred from company commentary, not an explicit data-disclosure commitment.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0796",
  "guidance_detail": "Sana Q2 2026 PR (Aug 10, 2026): studies 'beginning soon'; expects 'valuable insight into the clinical profiles' of SC451 and SG293 over next 6-9 months (~Feb-May 2027); no formal data disclosure explicitly guided.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SDGR",
  "company": "Schr\u00f6dinger, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "SGR-1505",
  "indication": "Mature B-cell malignancies (NHL, DLBCL, Waldenstrom, follicular)",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Venclexta/Imbruvica)",
   "AZN (Calquence)",
   "BGB (Brukinsa)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05544019",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "MALT1 inhibitor dose-escalation; closest competitors are BTK/BCL2 agents in R/R B-cell malignancies. inferred from CT.gov primary completion 2027-11 (NCT05544019); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05544019",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0797",
  "guidance_detail": "MALT1 inhibitor dose-escalation; closest competitors are BTK/BCL2 agents in R/R B-cell malignancies.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SEPN",
  "company": "Septerna, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "SEP-479",
  "indication": "Hypoparathyroidism",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "ASND (Yorvipath)",
   "MBX (canvuparatide)"
  ],
  "source_url": "https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320258299&type=PDF&symbol=SEPN&cdn=a11ef631b7258b71e5695ce30873ac8c&companyName=Septerna+Inc.&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-08-10",
  "source_type": "SEC 8-K",
  "as_of": "2026-09-18",
  "notes": "Septerna 8-K (Aug 10, 2026): SAD/MAD data expected Q1 2027; registry SAD/MAD study PCD Feb 2027 (NCT07433179) aligns.",
  "us_tradable": true,
  "nct_id": "NCT07433179",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0798",
  "guidance_detail": "Septerna 8-K (Aug 10, 2026): SAD/MAD data expected Q1 2027; registry SAD/MAD study PCD Feb 2027 (NCT07433179) aligns.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SGP",
  "company": "SpyGlass Pharma, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "BIM-DRS (bimatoprost drug ring system)",
  "indication": "Glaucoma / ocular hypertension",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Durysta)",
   "GKOS (iDose TR)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07641296",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "First-in-human dose-response; study not yet recruiting though FIH start was guided H2 2026. inferred from CT.gov primary completion 2027-02-28 (NCT07641296); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07641296",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0799",
  "guidance_detail": "First-in-human dose-response; study not yet recruiting though FIH start was guided H2 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SIGA",
  "company": "SIGA Technologies, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "TPOXX (tecovirimat) - post-exposure prophylaxis",
  "indication": "Smallpox post-exposure prophylaxis (label expansion)",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "BVNRY (JYNNEOS/Imvanex)",
   "EBS (ACAM2000)"
  ],
  "source_url": "https://www.marketbeat.com/instant-alerts/siga-technologies-q2-earnings-call-highlights-2026-08-07/",
  "source_type": "trade press",
  "as_of": "2026-09-18",
  "notes": "Q2 2026 call (per transcript report): FDA submission for TPOXX PEP targeted H1 2027 (was 2026 per Nov 2025 deck); supplemental NDA for an already-approved drug, not a new-molecular-entity NDA. The H1 2027 target derives from the May 7, 2026 Q1 call, where management targeted a PEP FDA submission 'within the next 12 months' (implies by ~May 2027). No company press release or SEC filing (including the official Q1 and Q2 2026 releases, both opened and checked) states this timing. Uncontradicted but not officially published.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0800",
  "guidance_detail": "Q2 2026 call (per transcript report): FDA submission for TPOXX PEP targeted H1 2027 (was 2026 per Nov 2025 deck); supplemental NDA for an already-approved drug, not a new-molecular-entity NDA.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "SIGA Technologies, Inc. is expected to file its new drug application for TPOXX (tecovirimat) as a smallpox post-exposure prophylaxis label expansion in the first half of 2027, starting the FDA's formal review clock."
 },
 {
  "as_of": "2026-09-18",
  "company": "Solid Biosciences Inc.",
  "competitors": [
   "Nomlabofusp (Larimar Therapeutics)",
   "Vatiquinone (PTC Therapeutics)",
   "LX2006 (Lexeo Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SGT-212",
  "event_type": "readout",
  "indication": "Friedreich's ataxia",
  "notes": "Company guides initial data from Phase 1b FALCON trial in Q1 2027, subject to enrollment; dual-route AAV gene replacement delivering full-length frataxin via MRI-guided intradentate-nucleus + IV infusions.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-updates",
  "ticker": "SLDB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0801",
  "guidance_detail": "Company guides initial data from Phase 1b FALCON trial in Q1 2027, subject to enrollment; dual-route AAV gene replacement delivering full-length frataxin via MRI-guided intradentate-nucleus + IV infusions.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Solid Biosciences Inc.",
  "competitors": [
   "Nadolol (generic standard of care)",
   "Flecainide (generic standard of care)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SGT-501",
  "event_type": "readout",
  "indication": "catecholaminergic polymorphic ventricular tachycardia (CPVT)",
  "notes": "Company anticipates initial safety data H1 2027, subject to enrollment; AAV delivery of functional CASQ2 to cardiomyocytes stabilizing RYR2 to reduce diastolic calcium leak (NCT07148089, PCD Jun 2027).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/solid-biosciences-reports-second-quarter-2026-financial-results-and-provides-business-updates",
  "ticker": "SLDB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07148089",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0802",
  "guidance_detail": "Company anticipates initial safety data H1 2027, subject to enrollment; AAV delivery of functional CASQ2 to cardiomyocytes stabilizing RYR2 to reduce diastolic calcium leak (NCT07148089, PCD Jun 2027).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Silence Therapeutics plc",
  "competitors": [
   "Wegovy/semaglutide (Novo Nordisk)",
   "Zepbound/tirzepatide (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SLN098",
  "event_type": "ind",
  "indication": "obesity/body composition",
  "notes": "siRNA silencing INHBE, novel obesity target; diet-induced-obesity mouse data showed reduced visceral fat with preserved lean mass; company says 'well positioned for a potential IND filing in 2027' (soft guidance).",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260810075814/en/Silence-Therapeutics-Reports-Second-Quarter-2026-Financial-and-Business-Results",
  "ticker": "SLN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0803",
  "guidance_detail": "siRNA silencing INHBE, novel obesity target; diet-induced-obesity mouse data showed reduced visceral fat with preserved lean mass; company says 'well positioned for a potential IND filing in 2027' (soft guidance).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Silence Therapeutics plc",
  "competitors": [
   "Leqvio/inclisiran (Novartis)",
   "Repatha/evolocumab (Amgen)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SLN365",
  "event_type": "ind",
  "indication": "dyslipidemia",
  "notes": "siRNA silencing GPR146, a novel cholesterol-lowering mechanism independent of LDL-receptor function; company says 'well positioned for a potential IND filing in 2027' (soft guidance).",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260810075814/en/Silence-Therapeutics-Reports-Second-Quarter-2026-Financial-and-Business-Results",
  "ticker": "SLN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0804",
  "guidance_detail": "siRNA silencing GPR146, a novel cholesterol-lowering mechanism independent of LDL-receptor function; company says 'well positioned for a potential IND filing in 2027' (soft guidance).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Eylea HD/aflibercept (Regeneron)",
   "Vabysmo/faricimab (Roche)",
   "ixo-vec (Adverum Biotechnologies)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SAR402663",
  "event_type": "readout",
  "indication": "neovascular (wet) age-related macular degeneration",
  "notes": "Phase 1/2 safety/efficacy of one-time sFLT01 AAV gene therapy; active, not recruiting; PCD May 18 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06660667",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0805",
  "guidance_detail": "Phase 1/2 safety/efficacy of one-time sFLT01 AAV gene therapy; active, not recruiting; PCD May 18 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Anktiva/nogapendekin alfa (ImmunityBio)",
   "Keytruda/pembrolizumab (Merck)"
  ],
  "country": "France",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SAR445877",
  "event_type": "readout",
  "indication": "solid tumors",
  "notes": "First-in-human Phase 1/2 dose-escalation/expansion of PD-1xIL-15 fusion protein (+/- cetuximab, bevacizumab, nivolumab, ipilimumab); PCD Jan 19 2027, recruiting.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05584670",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0806",
  "guidance_detail": "First-in-human Phase 1/2 dose-escalation/expansion of PD-1xIL-15 fusion protein (+/- cetuximab, bevacizumab, nivolumab, ipilimumab); PCD Jan 19 2027, recruiting.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Syfovre/pegcetacoplan (Apellis)",
   "Izervay/avacincaptad pegol (Astellas)"
  ],
  "country": "France",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SAR446597",
  "event_type": "readout",
  "indication": "geographic atrophy",
  "notes": "Phase 1/2 of one-time intravitreal AAV encoding C1s and factor-Bb inhibitors vs sham; recruiting; PCD Oct 13 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07215234",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0807",
  "guidance_detail": "Phase 1/2 of one-time intravitreal AAV encoding C1s and factor-Bb inhibitors vs sham; recruiting; PCD Oct 13 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Arexvy (GSK)",
   "Abrysvo (Pfizer)",
   "mRESVIA (Moderna)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "investigational mRNA vaccine (RSV/H5)",
  "event_type": "readout",
  "indication": "respiratory syncytial virus and H5 influenza (vaccine formulations)",
  "notes": "Phase 1 dose-ranging of different RSV monovalent and H5 flu mRNA formulations; recruiting; PCD Apr 4 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07516418",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0808",
  "guidance_detail": "Phase 1 dose-ranging of different RSV monovalent and H5 flu mRNA formulations; recruiting; PCD Apr 4 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0809"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Arexvy (GSK)",
   "mRESVIA (Moderna)"
  ],
  "country": "France",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "investigational mRNA vaccine (hMPV/RSV)",
  "event_type": "readout",
  "indication": "human metapneumovirus and RSV (combination vaccine)",
  "notes": "Phase 1/2 safety/immunogenicity of mRNA hMPV, RSV and hMPV+RSV combos vs licensed RSV vaccine/placebo; active, not recruiting; PCD Jan 18 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06686654",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0809",
  "guidance_detail": "Phase 1/2 safety/immunogenicity of mRNA hMPV, RSV and hMPV+RSV combos vs licensed RSV vaccine/placebo; active, not recruiting; PCD Jan 18 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0808"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Penbraya (Pfizer)",
   "Bexsero (GSK)",
   "Menveo (GSK)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "pentavalent meningococcal ABCYW vaccine",
  "event_type": "readout",
  "indication": "meningococcal disease (MenABCWY vaccine)",
  "notes": "Phase 1/2 safety/immunogenicity vs MenACYW + MenB vaccines; active, not recruiting; PCD May 17 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06647407",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0810",
  "guidance_detail": "Phase 1/2 safety/immunogenicity vs MenACYW + MenB vaccines; active, not recruiting; PCD May 17 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sarepta Therapeutics, Inc.",
  "competitors": [
   "Tominersen (Roche)",
   "AMT-130 (uniQure)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SRP-1005",
  "event_type": "readout",
  "indication": "Huntington's disease",
  "notes": "First-in-human Phase 1 of subcutaneous HTT-targeting siRNA with monovalent TfR1-targeted Fab CNS delivery vs placebo; recruiting; PCD Nov 30 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07536061",
  "ticker": "SRPT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0811",
  "guidance_detail": "First-in-human Phase 1 of subcutaneous HTT-targeting siRNA with monovalent TfR1-targeted Fab CNS delivery vs placebo; recruiting; PCD Nov 30 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Stoke Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "STK-002",
  "event_type": "readout",
  "indication": "autosomal dominant optic atrophy (ADOA)",
  "notes": "Company anticipates safety/efficacy data from Phase 1 OSPREY study H1 2027; intravitreal TANGO antisense oligonucleotide increasing OPA1 expression from healthy allele to improve mitochondrial function. No approved or clinical-stage competitors identified.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260803082079/en/Stoke-Therapeutics-Announces-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates",
  "ticker": "STOK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0812",
  "guidance_detail": "Company anticipates safety/efficacy data from Phase 1 OSPREY study H1 2027; intravitreal TANGO antisense oligonucleotide increasing OPA1 expression from healthy allele to improve mitochondrial function.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Sutro Biopharma, Inc.",
  "competitors": [
   "Tivdak/tisotumab vedotin (Pfizer/Genmab)",
   "Dato-DXd/datopotamab deruxtecan (AstraZeneca/Daiichi Sankyo)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "STRO-004",
  "event_type": "readout",
  "indication": "tissue-factor-expressing metastatic solid tumors",
  "notes": "Company targets next Phase 1 STRIVE-01 update in H1 2027 with expansion cohorts planned H1 2027; tissue-factor-directed Fc-silent DAR8 ADC with beta-glucuronidase-cleavable exatecan payload (NCT07227168, PCD Dec 2027).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/12/3343515/0/en/sutro-biopharma-reports-second-quarter-2026-financial-results-and-provides-early-update-on-stro-004-phase-1-study.html",
  "ticker": "STRO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07227168",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0813",
  "guidance_detail": "Company targets next Phase 1 STRIVE-01 update in H1 2027 with expansion cohorts planned H1 2027; tissue-factor-directed Fc-silent DAR8 ADC with beta-glucuronidase-cleavable exatecan payload (NCT07227168, PCD Dec 2027).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Teva Pharmaceutical Industries Limited",
  "competitors": [
   "Lu AF82422 (Lundbeck)"
  ],
  "country": "Israel",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TEV-56286 (emrusolmin)",
  "event_type": "readout",
  "indication": "healthy volunteers (dose-ranging safety study)",
  "notes": "Phase 1 healthy-participant study of oral small molecule targeting early amyloidogenic/alpha-synuclein oligomers, intended to inhibit alpha-synuclein aggregation (MSA program); recruiting; PCD Jan 2027.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07674940",
  "ticker": "TEVA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0814",
  "guidance_detail": "Phase 1 healthy-participant study of oral small molecule targeting early amyloidogenic/alpha-synuclein oligomers, intended to inhibit alpha-synuclein aggregation (MSA program); recruiting; PCD Jan 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0989"
  ],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Tonix Pharmaceuticals Holding Corp.",
  "competitors": [
   "Ferring Pharmaceuticals (desmopressin/DDAVP, vasopressin-deficiency standard of care)",
   "Endo International (Vasostrict vasopressin)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TNX-1900 (intranasal oxytocin)",
  "event_type": "readout",
  "indication": "Arginine-vasopressin deficiency (cranial diabetes insipidus)",
  "notes": "Registry-inferred: Phase 1 trial (NCT04789148, investigator-sponsored, Tonix collaborator) has PCD 2027-06; date inferred, no company 2027 guidance located.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04789148",
  "ticker": "TNXP",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04789148",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0815",
  "guidance_detail": "Registry-inferred: Phase 1 trial (NCT04789148, investigator-sponsored, Tonix collaborator) has PCD 2027-06; date inferred, no company 2027 guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Vertex Pharmaceuticals Incorporated",
  "competitors": [
   "Sionna Therapeutics (SION-451/SION-719, CFTR NBD1 stabilizers)",
   "Arrowhead Pharmaceuticals (ARO-ENaC, inhaled ENaC silencer)",
   "PTC Therapeutics (PTC518 / CFTR programs)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VX-272",
  "event_type": "readout",
  "indication": "Cystic fibrosis (Phase 1 healthy-volunteer dose-escalation)",
  "notes": "Registry-inferred: Vertex-sponsored Phase 1 healthy-volunteer study (NCT07437105, recruiting) has PCD 2027-06-26 (moved from 2027-03-23 per 2026-09-27 registry check); no company 2027 readout guidance located.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07437105",
  "ticker": "VRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07437105",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0816",
  "guidance_detail": "Registry-inferred: Vertex-sponsored Phase 1 healthy-volunteer study (NCT07437105, recruiting) has PCD 2027-06-26; no company 2027 readout guidance located.",
  "audit_status": "v20_reverified",
  "audit_action": "quarter_mismatch_flag",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Vertex Pharmaceuticals Incorporated",
  "competitors": [
   "Alkermes (ALKS 2680, orexin 2 receptor agonist)",
   "Takeda (oveporexton/TAK-861, orexin 2R agonist)",
   "Jazz Pharmaceuticals (Xywav/Xyrem, narcolepsy standard of care)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VX-433",
  "event_type": "readout",
  "indication": "Narcolepsy type 1 (Phase 1 first-in-human, healthy volunteers)",
  "notes": "Registry-inferred: Vertex-sponsored Phase 1 first-in-human study (NCT07584434, recruiting) has PCD 2027-03-05; no company 2027 readout guidance located.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07584434",
  "ticker": "VRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07584434",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0817",
  "guidance_detail": "Registry-inferred: Vertex-sponsored Phase 1 first-in-human study (NCT07584434, recruiting) has PCD 2027-03-05; no company 2027 readout guidance located.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Voyager Therapeutics, Inc.",
  "competitors": [
   "Biogen (BIIB080)",
   "Eisai (E2814)",
   "UCB/Roche (bepranemab)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VY1706 (tau-silencing gene therapy)",
  "event_type": "readout",
  "indication": "Alzheimer's disease",
  "notes": "Company: 'Early 2027: Potential for initial acute safety data with VY1706, pending enrollment' (Q2 2026 PR).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340674/36461/en/Voyager-Reports-Second-Quarter-2026-Financial-and-Operating-Results.html",
  "ticker": "VYGR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0818",
  "guidance_detail": "Company: 'Early 2027: Potential for initial acute safety data with VY1706, pending enrollment' (Q2 2026 PR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [
   "v16-0819"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Voyager Therapeutics, Inc.",
  "competitors": [
   "Biogen (BIIB080)",
   "Eisai (E2814)",
   "UCB/Roche (bepranemab)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VY1706 (tau-silencing gene therapy)",
  "event_type": "readout",
  "indication": "Alzheimer's disease",
  "notes": "Company: 'H2 2027: Potential for initial biomarker-based data for VY1706, pending enrollment' (Q2 2026 PR).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340674/36461/en/Voyager-Reports-Second-Quarter-2026-Financial-and-Operating-Results.html",
  "ticker": "VYGR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0819",
  "guidance_detail": "Company: 'H2 2027: Potential for initial biomarker-based data for VY1706, pending enrollment' (Q2 2026 PR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [
   "v16-0818"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Voyager Therapeutics, Inc.",
  "competitors": [
   "Biogen (BIIB080)",
   "Eisai (E2814)",
   "UCB/Roche (bepranemab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VY7523 (anti-tau antibody)",
  "event_type": "readout",
  "indication": "Alzheimer's disease",
  "notes": "Registry Phase 1/2 MAD study (NCT06874621) active not recruiting; estimated primary completion May 2027. Company guided interim tau-PET data Q4 2026 only.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06874621",
  "ticker": "VYGR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06874621",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0820",
  "guidance_detail": "Registry Phase 1/2 MAD study (NCT06874621) active not recruiting; estimated primary completion May 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Beyond Air, Inc.",
  "competitors": [
   "Neuren Pharmaceuticals (NNZ-2591)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "BA-102 (nNOS inhibitor)",
  "event_type": "readout",
  "indication": "Phelan-McDermid syndrome",
  "notes": "Preclinical program with FDA orphan designation; company expects Phase 1 first-in-human by end-2026 'which could provide data in 2027' \u2014 soft timing. Aug 25, 2026: Beyond Air entered definitive agreement to sell NeuroNOS program; confirm at refresh whether closed and whether XAIR retains BA-102 economics.",
  "phase": "1",
  "source_type": "SEC 8-K",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1641631/000164117225024647/ex99-1.htm",
  "ticker": "XAIR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0821",
  "guidance_detail": "Preclinical program with FDA orphan designation; company expects Phase 1 first-in-human by end-2026 'which could provide data in 2027' \u2014 soft timing.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Yarrow Bioscience, Inc.",
  "competitors": [
   "Amgen (teprotumumab)",
   "Viridian (veligrotug)",
   "Immunovant (batoclimab)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "YB-101 (anti-TSHR antibody)",
  "event_type": "readout",
  "indication": "Thyroid eye disease",
  "notes": "GenSci-partnered Phase 1 MAD study in TED in China; data expected H2 2027. VYNE merged into Yarrow (now Nasdaq: YARW) July 2026.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260727317637/en/Yarrow-Bioscience-Announces-Closing-of-Merger-with-VYNE-Therapeutics-and-Initiation-of-Dosing-in-Phase-2a2b-Trial-of-YB-101-a-Potential-First-in-Class-Treatment-for-Graves-Disease-and-Thyroid-Eye-Disease",
  "ticker": "YARW",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0822",
  "guidance_detail": "GenSci-partnered Phase 1 MAD study in TED in China; data expected H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [
   "v16-1003"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Zai Lab Limited",
  "competitors": [
   "Sanofi/Regeneron (dupilumab)",
   "Galderma (nemolizumab)",
   "Eli Lilly (lebrikizumab)"
  ],
  "country": "China",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ZL-1503 (IL-13/IL-31R\u03b1 bispecific antibody)",
  "event_type": "readout",
  "indication": "Atopic dermatitis",
  "notes": "Phase 1/1b; SAD in healthy volunteers done, MAD in AD patients enrolling; initial MAD data expected H1 2027 (Q2 2026 PR).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260806560438/en/Zai-Lab-Announces-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Updates",
  "ticker": "ZLAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0823",
  "guidance_detail": "Phase 1/1b; SAD in healthy volunteers done, MAD in AD patients enrolling; initial MAD data expected H1 2027 (Q2 2026 PR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Zai Lab Limited",
  "competitors": [
   "SOTIO Biotech (SOT106)"
  ],
  "country": "China",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ZL-6201 (LRRC15-targeting ADC)",
  "event_type": "readout",
  "indication": "Sarcoma and LRRC15-positive solid tumors",
  "notes": "Global Phase 1 enrolling; initial dose-escalation data expected H1 2027 per Q2 2026 earnings call (trade-press transcript). Source quote (2026-09-20): Provide topline results from the dose-escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027.]",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260806560438/en/Zai-Lab-Announces-Second-Quarter-2026-Financial-Results-and-Recent-Corporate-Updates",
  "ticker": "ZLAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0824",
  "guidance_detail": "Global Phase 1 enrolling; initial dose-escalation data expected H1 2027 per Q2 2026 earnings call (trade-press transcript).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-18",
  "company": "Zai Lab Limited",
  "competitors": [
   "Amgen (tarlatamab)"
  ],
  "country": "China",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "zocilurtatug pelitecan (DLL3 ADC; formerly ZL-1310)",
  "event_type": "readout",
  "indication": "Small cell lung cancer",
  "notes": "Phase 1 SCLC study (NCT06179069) recruiting; estimated primary completion 2027-05-30; no company-guided 2027 readout. Distinct from captured zoci BLA filing.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06179069",
  "ticker": "ZLAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06179069",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0825",
  "guidance_detail": "Phase 1 SCLC study (NCT06179069) recruiting; estimated primary completion 2027-05-30; no company-guided 2027 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [
   "v16-0231",
   "v16-1005"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Zymeworks Inc.",
  "competitors": [
   "Chugai (codrituzumab)"
  ],
  "country": "Canada",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ZW251 (GPC3-targeting ADC)",
  "event_type": "readout",
  "indication": "GPC3-expressing solid tumors incl. hepatocellular carcinoma",
  "notes": "Phase 1 (NCT07164313) recruiting ~100 pts dose escalation/optimization; estimated primary completion Sep 2027; no company-guided 2027 data. Distinct from captured zanidatamab Phase 3 readout.",
  "phase": "1",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07164313",
  "ticker": "ZYME",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07164313",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0826",
  "guidance_detail": "Phase 1 (NCT07164313) recruiting ~100 pts dose escalation/optimization; estimated primary completion Sep 2027; no company-guided 2027 data.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "icalcaprant",
  "indication": "bipolar disorder",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Caplyta (Intra-Cellular)",
   "Cobenfy (Bristol Myers Squibb)",
   "Rexulti (Otsuka)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06696755",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06696755; registry primary completion 2027-11, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06696755",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0827",
  "guidance_detail": "Phase 2 study NCT06696755; registry primary completion 2027-11, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0828",
   "v17-0023"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "icalcaprant",
  "indication": "major depressive disorder",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Spravato (Johnson & Johnson)",
   "Auvelity (Axsome)",
   "Caplyta (Intra-Cellular)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07276997",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07276997; registry primary completion 2027-09, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07276997",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0828",
  "guidance_detail": "Phase 2 study NCT07276997; registry primary completion 2027-09, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0827"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "livmoniplimab combinations",
  "indication": "urothelial cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Padcev + Keytruda (Pfizer/Merck)",
   "Keytruda (Merck)",
   "Tecentriq (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06632951",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06632951; registry primary completion 2027-03, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06632951",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0829",
  "guidance_detail": "Phase 2 study NCT06632951; registry primary completion 2027-03, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "lutikizumab",
  "indication": "hidradenitis suppurativa",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Cosentyx (Novartis)",
   "Bimzelx (UCB)",
   "Humira (AbbVie)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05139602",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT05139602; registry primary completion 2027-12, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05139602",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0830",
  "guidance_detail": "Phase 2 study NCT05139602; registry primary completion 2027-12, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "lutikizumab / ravagalimab (master protocol)",
  "indication": "rheumatoid arthritis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Enbrel (Amgen)",
   "Simponi (Johnson & Johnson)",
   "Actemra (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06972446",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06972446; registry primary completion 2027-02, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06972446",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0831",
  "guidance_detail": "Phase 2 study NCT06972446; registry primary completion 2027-02, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "lutikizumab / risankizumab (master protocol)",
  "indication": "psoriatic arthritis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Cosentyx (Novartis)",
   "Bimzelx (UCB)",
   "Tremfya (Johnson & Johnson)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06865105",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06865105; registry primary completion 2027-12, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06865105",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0832",
  "guidance_detail": "Phase 2 study NCT06865105; registry primary completion 2027-12, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "lutikizumab \u00b1 other targeted therapies (master protocol)",
  "indication": "atopic dermatitis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Dupixent (Sanofi/Regeneron)",
   "Cibinqo (Pfizer)",
   "Ebglyss (Eli Lilly)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06718101",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06718101; registry primary completion 2027-05, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06718101",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0833",
  "guidance_detail": "Phase 2 study NCT06718101; registry primary completion 2027-05, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ABBV",
  "company": "AbbVie Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "venetoclax + carfilzomib + dexamethasone",
  "indication": "multiple myeloma",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Darzalex (Johnson & Johnson)",
   "Abecma (Bristol Myers Squibb)",
   "Sarclisa (Sanofi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT02899052",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT02899052; registry primary completion 2027-06, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT02899052",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0834",
  "guidance_detail": "Phase 2 study NCT02899052; registry primary completion 2027-06, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AGEN",
  "company": "Agenus Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "botensilimab + balstilimab",
  "indication": "metastatic colorectal cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Opdivo + Yervoy (Bristol Myers Squibb)",
   "Keytruda (Merck)",
   "Jemperli (GSK)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05608044",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT05608044; registry primary completion 2027-09, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT05608044",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0835",
  "guidance_detail": "Phase 2 study NCT05608044; registry primary completion 2027-09, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for botensilimab + balstilimab in metastatic colorectal cancer are expected in Q3 2027, the first real efficacy signal for Agenus Inc.'s program."
 },
 {
  "ticker": "ALKS",
  "company": "Alkermes plc",
  "country": "Ireland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ALKS 7290",
  "indication": "ADHD",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Vyvanse (Takeda)",
   "Jornay (Ironshore)",
   "Qelbree (Supernus)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07755410",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07755410; registry primary completion 2027-07, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07755410",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0836",
  "guidance_detail": "Phase 2 study NCT07755410; registry primary completion 2027-07, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALLR",
  "company": "Allarity Therapeutics, Inc.",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "2X-121",
  "indication": "recurrent ovarian cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Lynparza (AstraZeneca)",
   "Zejula (GSK)",
   "Elahere (AbbVie)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03878849",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT03878849; registry primary completion 2027-03, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT03878849",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0837",
  "guidance_detail": "Phase 2 study NCT03878849; registry primary completion 2027-03, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for 2X-121 in recurrent ovarian cancer are expected in Q1 2027, the first real efficacy signal for Allarity Therapeutics, Inc.'s program."
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ALN-4324",
  "indication": "type 2 diabetes (insulin sensitivity)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Mounjaro (Eli Lilly)",
   "Ozempic (Novo Nordisk)",
   "Wegovy (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07465224",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07465224; registry primary completion 2027-05-28, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07465224",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0838",
  "guidance_detail": "Phase 2 study NCT07465224; registry primary completion 2027-05-28, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0600"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ALN-6400",
  "indication": "von Willebrand disease / heavy menstrual bleeding",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Vonvendi (Takeda)",
   "Cablivi (Sanofi)",
   "wilate (Octapharma)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260730523296/en/Alnylam-Pharmaceuticals-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Recent-Period-Progress",
  "source_type": "company deck",
  "as_of": "2026-09-24",
  "notes": "Phase 2 study NCT07575308; registry primary completion 2027-06-30, status active; topline typically ~3-6 mo later. Source note: upgraded inferred->guidance; Alnylam Q2 2026 company release guides H2 2026 expected results from Phase 1 and Phase 2 ALN-6400 trials (healthy volunteers and HHT patients); specific quarter/month timing for the 2027 Phase 3 start remains registry-inferred working proxy. Source note: ALNY ALN-6400 Phase 1 MAD 2Q results reported Jul 30, 2026; company guides only \"2027\" for full study results (no half). Calendar's Q2 bucket was over-precise; broadened to 2027. Source: https://www.biospace.com/press-releases/alnylam-reports-positive-phase-1-results-for-aln-6400-a-novel-high-dose-low-volume-thrombin-receptor-agonist-peptide-trap-for-thrombosis. Quote: \"ALN-6400 Phase 1 MAD 2Q results\".",
  "nct_id": "NCT07575308",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0839",
  "guidance_detail": "Phase 2 study NCT07575308; registry primary completion 2027-06-30, status active; topline typically ~3-6 mo later. Source note: upgraded inferred->guidance; Alnylam Q2 2026 company release guides H2 2026 expected results from Phase 1 and Phase 2 ALN-6400 trials (healthy volunteers and HHT patients); specific quarter/month timing for the 2027 Phase 3 start remains registry-inferred working",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q2",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Company guides only 2027 for full study results; Q2 was over-precise"
   }
  ],
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "indication_group": "Hematology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "ALNY",
  "company": "Alnylam Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "ALN-APP (mivelsiran)",
  "indication": "cerebral amyloid angiopathy",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Leqembi (Eisai/Biogen)",
   "Kisunla (Eli Lilly)",
   "trontinemab (Roche)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06393712",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06393712; registry primary completion 2027-08-09, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT06393712",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0840",
  "guidance_detail": "Phase 2 study NCT06393712; registry primary completion 2027-08-09, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "ALT",
  "company": "Altimmune, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "pemvidutide (RESTORE trial)",
  "indication": "alcohol-associated liver disease",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Rezdiffra (Madrigal)",
   "pegozafermin (89bio)",
   "efruxifermin (Akero)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07009860",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07009860; registry primary completion 2027-09-30, status active; topline typically ~3-6 mo later",
  "nct_id": "NCT07009860",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0841",
  "guidance_detail": "Phase 2 study NCT07009860; registry primary completion 2027-09-30, status active; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for pemvidutide (RESTORE trial) in alcohol-associated liver disease are expected in Q3 2027, the first real efficacy signal for Altimmune, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Teprotumumab/Tepezza (Amgen)",
   "Veligrotug (Viridian Therapeutics)",
   "Batoclimab (Immunovant)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AMG 732",
  "event_type": "readout",
  "indication": "Thyroid eye disease",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-01-06 (NCT06401044); Phase 1/2 design with Phase 2 portion per registry (Phase 1 recruitment ended).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06401044",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06401044",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0842",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-01-06 (NCT06401044); Phase 1/2 design with Phase 2 portion per registry (Phase 1 recruitment ended).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Blincyto IV (Amgen)",
   "AUCATZYL/obe-cel (Autolus)",
   "Tecartus (Gilead Kite)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "blinatumomab (subcutaneous)",
  "event_type": "readout",
  "indication": "Relapsed/refractory and MRD-positive B-cell acute lymphoblastic leukemia",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-11-24 (NCT04521231); mixed Phase 1/2 classified Phase 2 per project precedent (catalyst concerns combined study).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04521231",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04521231",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0843",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-11-24 (NCT04521231); mixed Phase 1/2 classified Phase 2 per project precedent (catalyst concerns combined study).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Eculizumab/Soliris (AstraZeneca/Alexion)",
   "Satralizumab/Enspryng (Roche/Chugai)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "inebilizumab (Uplizna)",
  "event_type": "readout",
  "indication": "Pediatric neuromyelitis optica spectrum disorder",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-04-13 (NCT05549258); recruiting Phase 2 pediatric NMOSD study.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05549258",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05549258",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0844",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-04-13 (NCT05549258); recruiting Phase 2 pediatric NMOSD study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Amgen Inc.",
  "competitors": [
   "Ifinatamab deruxtecan (Daiichi Sankyo/Merck)",
   "BI 764532 (Boehringer Ingelheim)",
   "Topotecan (generics, standard of care)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "tarlatamab (DeLLphi-301)",
  "event_type": "readout",
  "indication": "Small cell lung cancer (long-term follow-up)",
  "notes": "Inferred from ClinicalTrials.gov PCD/completion 2027-12-30 (NCT05060016); Phase 2 long-term ORR/safety follow-up, mainly durability data.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05060016",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05060016",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0845",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD/completion 2027-12-30 (NCT05060016); Phase 2 long-term ORR/safety follow-up, mainly durability data.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v19-0003",
   "v16-0605",
   "v16-0885"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Arrowhead Pharmaceuticals, Inc.",
  "competitors": [
   "MariTide/maridebart cafraglutide (Amgen)",
   "Retatrutide (Lilly)",
   "Zepbound/tirzepatide (Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ARO-INHBE",
  "event_type": "readout",
  "indication": "Obesity with and without type 2 diabetes (first-in-class INHBE/activin E inhibitor)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-09-17 (NCT06700538); mixed Phase 1/2a classified Phase 2 per precedent; interim data released 2026, 2027 completion may reflect final readout.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06700538",
  "ticker": "ARWR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06700538",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0846",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-09-17 (NCT06700538); mixed Phase 1/2a classified Phase 2 per precedent; interim data released 2026, 2027 completion may reflect final readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Arrowhead Pharmaceuticals, Inc.",
  "competitors": [
   "BIIB080 (Biogen/Ionis, tau ASO)",
   "E2814 (Eisai, anti-tau mAb)",
   "Bepranemab (UCB, anti-tau mAb)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ARO-MAPT-SC",
  "event_type": "readout",
  "indication": "Early Alzheimer's disease (tau-targeted siRNA)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT07221344); mixed Phase 1/2a in healthy participants and early AD classified Phase 2 per precedent.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07221344",
  "ticker": "ARWR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07221344",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0847",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT07221344); mixed Phase 1/2a in healthy participants and early AD classified Phase 2 per precedent.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Arrowhead Pharmaceuticals, Inc.",
  "competitors": [
   "Tezepelumab/Tezspire (Amgen/AstraZeneca)",
   "Dupilumab/Dupixent (Regeneron/Sanofi)",
   "Depemokimab (GSK)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ARO-RAGE",
  "event_type": "readout",
  "indication": "Mild asthma (allergen challenge; inhaled RAGE inhibitor)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-12 (NCT07241546); recruiting Phase 2a allergen-challenge study.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07241546",
  "ticker": "ARWR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07241546",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0848",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-12 (NCT07241546); recruiting Phase 2a allergen-challenge study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Assembly Biosciences, Inc.",
  "competitors": [
   "Bulevirtide/Hepcludex (Gilead)",
   "Peginterferon alfa-2a (Roche, off-label)",
   "REP 2139 (Replicor)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ABI-6250",
  "event_type": "readout",
  "indication": "Chronic hepatitis D virus infection",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT07762027); record updated 2026-08-07 but trial was not yet recruiting with expected start 2026-10; re-verify on refresh. Source note: upgraded inferred->guidance; company Q2 2026 results (wire mirror of company release): Phase 2 in chronic HDV to start by year-end 2026 with interim data expected H2 2027. Bucket moved 2027-H1 -> 2027-H2.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://markets.financialcontent.com/dowtheoryletters/article/gnwcq-2026-8-13-assembly-biosciences-reports-second-quarter-2026-financial-results-and-recent-updates",
  "ticker": "ASMB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07762027",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0849",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-06 (NCT07762027); record updated 2026-08-07 but trial was not yet recruiting with expected start 2026-10; re-verify on refresh.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ABI-6250 in chronic hepatitis D virus infection are expected in the second half of 2027, the first real efficacy signal for Assembly Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Ascendis Pharma A/S",
  "competitors": [
   "Vosoritide/Voxzogo (BioMarin)",
   "Infigratinib (BridgeBio)",
   "Recifercept (Pfizer/Therachon)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "navepegritide (TransCon CNP)",
  "event_type": "readout",
  "indication": "Achondroplasia in adolescents 12-18 years (teACH Phase 2b)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-08 (NCT06732895); recruiting Phase 2b.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06732895",
  "ticker": "ASND",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06732895",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0850",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-08 (NCT06732895); recruiting Phase 2b.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0851",
   "v16-0866"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "Ascendis Pharma A/S",
  "competitors": [
   "Vosoritide/Voxzogo (BioMarin)",
   "Infigratinib (BridgeBio)",
   "Recifercept (Pfizer/Therachon)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "navepegritide (TransCon CNP)",
  "event_type": "readout",
  "indication": "Achondroplasia in infants 0-<2 years (reACHin)",
  "notes": "Inferred from ClinicalTrials.gov PCD 2027-12 (NCT06079398); sentinel-cohort data presented Sep 2026, blinded portion still to complete.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06079398",
  "ticker": "ASND",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06079398",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0851",
  "guidance_detail": "Inferred from ClinicalTrials.gov PCD 2027-12 (NCT06079398); sentinel-cohort data presented Sep 2026, blinded portion still to complete.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0850",
   "v16-0866"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-01",
  "company": "Avalyn Pharma Inc.",
  "competitors": [
   "Nintedanib/Ofev (Boehringer Ingelheim)",
   "Pirfenidone/Esbriet (Roche)",
   "Nerandomilast (Boehringer Ingelheim)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AP02 (inhaled nintedanib)",
  "event_type": "readout",
  "indication": "Idiopathic pulmonary fibrosis (AURA Phase 2)",
  "notes": "Company guided topline data anticipated by end of 2027 (PR 2026-06-03); registry PCD 2027-06 reflects 12-week core, company guidance governs.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/03/3305895/0/en/Avalyn-Reports-First-Quarter-2026-Financial-Results-and-Recent-Business-Highlights.html",
  "ticker": "AVLN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0852",
  "guidance_detail": "Company guided topline data anticipated by end of 2027 (PR 2026-06-03); registry PCD 2027-06 reflects 12-week core, company guidance governs.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for AP02 (inhaled nintedanib) in Idiopathic pulmonary fibrosis (AURA Phase 2) are expected in the second half of 2027, the first real efficacy signal for Avalyn Pharma Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "BHV-1420 (Biohaven)",
   "Gazyva (Roche)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ALXN1920",
  "event_type": "readout",
  "indication": "primary membranous nephropathy",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-07-02",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07157787",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0853",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-07-02.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Brinsupri (Insmed)",
   "GSK3862995 (GSK)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD0292",
  "event_type": "readout",
  "indication": "bronchiectasis with chronic Pseudomonas aeruginosa colonization",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-12-09",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07088926",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0854",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-12-09.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Rinvoq (AbbVie)",
   "Olumiant (Eli Lilly)",
   "Simponi (Johnson & Johnson)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD1163",
  "event_type": "readout",
  "indication": "rheumatoid arthritis",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-11-12",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07276581",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0855",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-11-12.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Rezdiffra (Madrigal)",
   "efruxifermin (Akero)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD2389",
  "event_type": "readout",
  "indication": "steatotic liver disease with advanced fibrosis",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-07-07",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07610837",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0856",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-07-07.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Zinplava (Merck)",
   "Vowst (Seres Therapeutics)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD5148 (monoclonal antibody)",
  "event_type": "readout",
  "indication": "prevention of recurrent C. difficile infection",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-04-20",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07285213",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0857",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-04-20.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [
   "Trelegy (GSK)",
   "Dupixent (Regeneron/Sanofi)",
   "Dupixent (Regeneron/Sanofi)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AZD6793",
  "event_type": "readout",
  "indication": "moderate to very severe COPD",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-11-05",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07082738",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0858",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-11-05.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bayer AG",
  "competitors": [
   "Vanrafia (Novartis)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BAY 3401016",
  "event_type": "readout",
  "indication": "Alport syndrome",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-11-29",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07211685",
  "ticker": "BAYRY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0859",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-11-29.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "BridgeBio Pharma, Inc.",
  "competitors": [
   "Vyndaqel (Pfizer)",
   "Amvuttra (Alnylam)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "acoramidis (AG10)",
  "event_type": "readout",
  "indication": "cardiomyopathy (ATTR)",
  "notes": "Phase 2 readout inferred from CT.gov PCD Jul 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT03536767",
  "ticker": "BBIO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0860",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Jul 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "BridgeBio Pharma, Inc.",
  "competitors": [
   "TYRA-300 (Tyra Biosciences)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "infigratinib",
  "event_type": "readout",
  "indication": "hypochondroplasia (children)",
  "notes": "Phase 2/3 readout inferred from CT.gov PCD Jan 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06873035",
  "ticker": "BBIO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0861",
  "guidance_detail": "Phase 2/3 readout inferred from CT.gov PCD Jan 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bausch Health Companies Inc.",
  "competitors": [
   "Linzess (AbbVie/Ironwood)",
   "Ibsrela (Ardelyx)"
  ],
  "country": "Canada",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "plecanatide",
  "event_type": "readout",
  "indication": "functional constipation (children/adolescents 6 to <18)",
  "notes": "Phase 2 readout inferred from CT.gov PCD 2027-10-18",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07723924",
  "ticker": "BHC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0862",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD 2027-10-18.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Bausch + Lomb Corporation",
  "competitors": [
   "Dextenza (Ocular Therapeutix)",
   "Iheezo (Harrow)"
  ],
  "country": "Canada",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BL1332 (topical ocular)",
  "event_type": "readout",
  "indication": "postoperative ocular pain after photorefractive keratectomy",
  "notes": "Phase 2 readout inferred from CT.gov PCD Feb 2027. Source note: Bausch + Lomb Aug 2026 guides Phase 2 post-PRK pain results 'later in the year' (2026), earlier than the Feb 2027 registry PCD (NCT07412496). Timing uncertain; retained Q1 2027 pending reconfirmation.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07412496",
  "ticker": "BLCO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07412496",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0863",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Feb 2027. Source note: Bausch + Lomb Aug 2026 guides Phase 2 post-PRK pain results 'later in the year' (2026), earlier than the Feb 2027 registry PCD (NCT07412496).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioMarin Pharmaceutical Inc.",
  "competitors": [
   "TransCon CNP (Ascendis Pharma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "vosoritide (BMN 111 long-term, achondroplasia)",
  "event_type": "readout",
  "indication": "achondroplasia (long-term safety/efficacy)",
  "notes": "Phase 2 readout inferred from CT.gov PCD Dec 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT02724228",
  "ticker": "BMRN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0864",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Dec 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0866",
   "v16-0865"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioMarin Pharmaceutical Inc.",
  "competitors": [
   "Skytrofa (Ascendis Pharma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "vosoritide (Noonan syndrome)",
  "event_type": "readout",
  "indication": "Noonan syndrome with inadequate growth on/after hGH",
  "notes": "Phase 2 readout inferred from CT.gov PCD Mar 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06668805",
  "ticker": "BMRN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0865",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Mar 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0866",
   "v16-0864"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioMarin Pharmaceutical Inc.",
  "competitors": [
   "navepegritide (Ascendis Pharma)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "vosoritide (at-risk infants, achondroplasia)",
  "event_type": "readout",
  "indication": "achondroplasia in at-risk infants",
  "notes": "Phase 2 readout inferred from CT.gov PCD Dec 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04554940",
  "ticker": "BMRN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0866",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Dec 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0865",
   "v16-0864",
   "v16-0851",
   "v16-0850"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioNTech SE",
  "competitors": [
   "Jynneos (Bavarian Nordic)",
   "ACAM2000 (Emergent BioSolutions)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BNT166a (mRNA mpox vaccine)",
  "event_type": "readout",
  "indication": "mpox (immunogenicity, Africa trial)",
  "notes": "Phase 2 readout inferred from CT.gov PCD Jun 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07379580",
  "ticker": "BNTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0867",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Jun 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "BioNTech SE",
  "competitors": [
   "Imfinzi (AstraZeneca)",
   "Tecentriq (Roche)"
  ],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BNT327 + chemotherapy",
  "event_type": "readout",
  "indication": "small-cell lung cancer",
  "notes": "Phase 2 readout inferred from CT.gov PCD Jun 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06449209",
  "ticker": "BNTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0868",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Jun 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Bio-Path Holdings, Inc.",
  "competitors": [
   "Venclexta (AbbVie)",
   "Onureg (Bristol Myers Squibb)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BP1001 + venetoclax/decitabine",
  "event_type": "readout",
  "indication": "acute myeloid leukemia",
  "notes": "Phase 2 readout inferred from CT.gov PCD Dec 2027",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT02781883",
  "ticker": "BPTH",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0870",
  "guidance_detail": "Phase 2 readout inferred from CT.gov PCD Dec 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for BP1001 + venetoclax/decitabine in acute myeloid leukemia are expected in Q4 2027, the first real efficacy signal for Bio-Path Holdings, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Can-Fite BioPharma Ltd.",
  "competitors": [
   "Novartis (alpelisib \u2014 investigational in OCRL-related Dent disease 2)"
  ],
  "country": "Israel",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Piclidenoson (A3 adenosine receptor agonist)",
  "event_type": "readout",
  "indication": "Lowe syndrome \u2014 open-label Phase 2 pilot in 5 patients",
  "notes": "Inferred from CT.gov primary completion 2027-08-31 (not yet recruiting); primary endpoint is improvement in 99mTc-DMSA renal uptake; no approved disease-modifying therapy exists.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07410455",
  "ticker": "CANF",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0871",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-08-31 (not yet recruiting); primary endpoint is improvement in 99mTc-DMSA renal uptake; no approved disease-modifying therapy exists.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Piclidenoson (A3 adenosine receptor agonist) in Lowe syndrome \u2014 open-label Phase 2 pilot in 5 patients are expected in Q3 2027, the first real efficacy signal for Can-Fite BioPharma Ltd.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Corcept Therapeutics Incorporated",
  "competitors": [
   "Revolution Medicines (daraxonrasib)",
   "Ipsen (Onivyde/irinotecan liposome)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Relacorilant + nab-paclitaxel + gemcitabine",
  "event_type": "readout",
  "indication": "Metastatic pancreatic adenocarcinoma, first-line \u2014 single-arm Phase 2",
  "notes": "Inferred from CT.gov primary completion 2027-09 (recruiting); Corcept-sponsored Phase 2 combining cortisol modulation with standard chemotherapy.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07259317",
  "ticker": "CORT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0872",
  "guidance_detail": "Inferred from CT.gov primary completion 2027-09 (recruiting); Corcept-sponsored Phase 2 combining cortisol modulation with standard chemotherapy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-18",
  "company": "Corbus Pharmaceuticals Holdings, Inc.",
  "competitors": [
   "monlunabant (Novo Nordisk)",
   "orforglipron (Eli Lilly)",
   "GSBR-1290 (Structure Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "CRB-913 (oral peripherally restricted CB1 inverse agonist)",
  "event_type": "regulatory_other",
  "indication": "Obesity \u2014 CANYON-2 Phase 2 monotherapy trial initiation",
  "notes": "CANYON-1 Phase 1b: 60 mg daily oral CRB-913 showed 5.0% placebo-adjusted weight loss at 12 wks (Sep 2026); Phase 2 monotherapy (CANYON-2) initiation expected H1 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://ir.corbuspharma.com/news-events/press-releases/detail/478/corbus-pharmaceuticals-announces-positive-topline-data-from-canyon-1-study-of-daily-oral-crb-913-for-the-treatment-of-obesity",
  "ticker": "CRBP",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0873",
  "guidance_detail": "CANYON-1 Phase 1b: 60 mg daily oral CRB-913 showed 5.0% placebo-adjusted weight loss at 12 wks (Sep 2026); Phase 2 monotherapy (CANYON-2) initiation expected H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Corbus plans to start CANYON-2, the Phase 2 monotherapy trial of oral CRB-913 in obesity, in the first half of 2027."
 },
 {
  "as_of": "2026-09-18",
  "company": "Curis, Inc.",
  "competitors": [
   "Brukinsa/zanubrutinib (BeiGene)",
   "Venclexta/venetoclax (AbbVie)",
   "Calquence/acalabrutinib (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Emavusertib + approved Bruton tyrosine kinase inhibitor (BTKi)",
  "event_type": "readout",
  "indication": "Chronic lymphocytic leukemia / B-cell malignancies (TakeAim CLL Phase 2)",
  "notes": "Phase 2 (NCT07271667) recruiting; registry primary completion 2027-11. IRAK4 inhibitor + BTKi combination.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07271667",
  "ticker": "CRIS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07271667",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0874",
  "guidance_detail": "Phase 2 (NCT07271667) recruiting; registry primary completion 2027-11.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Emavusertib + approved Bruton tyrosine kinase inhibitor (BTKi) in chronic lymphocytic leukemia / B-cell malignancies (TakeAim CLL Phase 2) are expected in Q4 2027, the first real efficacy signal for Curis, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Crinetics Pharmaceuticals, Inc.",
  "competitors": [
   "Lutathera/177Lu-dotatate (Novartis)",
   "ITM-11/177Lu-edotreotide (ITM Radiopharma)",
   "CAM2029/octreotide (Camurus)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CRN09682 (SST2 agonist)",
  "event_type": "readout",
  "indication": "SST2-positive neuroendocrine tumors \u2014 BRAVESST2 Phase 1/2",
  "notes": "BRAVESST2 Phase 1/2 (NCT07129252) recruiting since Dec 2025; registry primary completion 2027-08. Phase 1/2 filed as Phase 2 per calendar convention.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07129252",
  "ticker": "CRNX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07129252",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0875",
  "guidance_detail": "BRAVESST2 Phase 1/2 (NCT07129252) recruiting since Dec 2025; registry primary completion 2027-08.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for CRN09682 (SST2 agonist) in SST2-positive neuroendocrine tumors \u2014 BRAVESST2 Phase 1/2 are expected in Q3 2027, the first real efficacy signal for Crinetics Pharmaceuticals, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Denali Therapeutics Inc.",
  "competitors": [
   "Elaprase/idursulfase (Takeda)",
   "JR-141/pabinafusp alfa (JCR Pharmaceuticals)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Tividenofusp alfa / AVLAYAH (ETV:IDS)",
  "event_type": "readout",
  "indication": "Hunter syndrome (MPS II) \u2014 COMPASS confirmatory Phase 2/3",
  "notes": "COMPASS (NCT05371613) active, not recruiting; registry primary completion 2027-12. AVLAYAH received accelerated approval Mar 2026; COMPASS is the confirmatory study vs idursulfase.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05371613",
  "ticker": "DNLI",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05371613",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0876",
  "guidance_detail": "COMPASS (NCT05371613) active, not recruiting; registry primary completion 2027-12.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-01",
  "company": "Enlivex Therapeutics Ltd.",
  "competitors": [
   "Zilretta (Pacira BioSciences)",
   "Cingal (Anika Therapeutics)",
   "Orthovisc (Anika Therapeutics)"
  ],
  "country": "Israel",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Allocetra",
  "event_type": "readout",
  "indication": "age-related knee osteoarthritis",
  "notes": "Randomized Phase 2b topline expected by end of Q2 2027; RMAT-designated program.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/13/3326135/0/en/Enlivex-Receives-FDA-Regenerative-Medicine-Advanced-Therapy-RMAT-Designation-for-Allocetra-in-Age-Related-Knee-Osteoarthritis.html",
  "ticker": "ENLV",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0877",
  "guidance_detail": "Randomized Phase 2b topline expected by end of Q2 2027; RMAT-designated program.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Pain",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for Allocetra in age-related knee osteoarthritis are expected in Q2 2027, the first real efficacy signal for Enlivex Therapeutics Ltd.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Fortress Biotech, Inc.",
  "competitors": [
   "febuxostat (Uloric, Takeda)",
   "pegloticase (Krystexxa, Amgen)",
   "lesinurad (Zurampic, Grunenthal)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "dotinurad",
  "event_type": "readout",
  "indication": "difficult-to-treat gout",
  "notes": "Phase 2 AMETHYST trial NCT07535034 estimated primary completion Jul 2027; readout window inferred from registry PCD. Program run by Crystalys Therapeutics; Fortress subsidiary Urica retains equity/royalty exposure. Source quote (2026-09-20): Phase 2 trial of dotinurad (NCT07535034) is recruiting with primary completion expected in July 2027.]",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07535034",
  "ticker": "FBIO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07535034",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0878",
  "guidance_detail": "Phase 2 AMETHYST trial NCT07535034 estimated primary completion Jul 2027; readout window inferred from registry PCD.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0091",
   "v16-0090"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for dotinurad in difficult-to-treat gout are expected in Q3 2027, the first real efficacy signal for Fortress Biotech, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Fulgent Genetics, Inc.",
  "competitors": [
   "pembrolizumab (Keytruda, Merck)",
   "nivolumab (Opdivo, Bristol Myers Squibb)",
   "cetuximab (Erbitux, Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "FID-007 (nanoencapsulated paclitaxel) + cetuximab",
  "event_type": "readout",
  "indication": "recurrent/metastatic head and neck squamous cell carcinoma (post PD-L1 checkpoint inhibitor)",
  "notes": "Full data readout from Phase 2 trial NCT06332092 guided H2 2027 per CEO on Q4 2025 earnings call (transcript via MarketBeat); trial corroborated by company ASCO 2026 presentation PR (interim: ORR 61.9%, mPFS 6.7 mo). No contradiction: on the same call the CEO separately guided Phase 3 initiation as early as H1 2027 \u2014 both milestones were guided; the Phase 3 initiation is tracked as a separate row. Re-checked 2026-09-20. Full Phase 2 readout H2 2027 timing comes from the CEO on the Q4 2025 earnings call (MarketBeat transcript). Corroborated program status from Fulgent's SEC-filed Q2 2026 corporate deck (8-K Ex. 99.2): Phase 2 enrollment completed YE 2025, interim ORR 61.9%/mPFS 6.7 mo presented at ASCO 2026, EOP2 FDA meeting confirmed for 2H 2026, Phase 3 protocol in development, 125 mg/m2 dose proposed. The deck does NOT state H2 2027 readout timing. [2026-09-23 source check] MarketBeat transcript mirror returns 503 and is an aggregator (not citable per the evidence ladder); timing rests on the CEO's Q4 2025 earnings-call remarks. Needs browser re-source to the Quartr call transcript or Fulgent IR.",
  "phase": "2",
  "source_type": "trade press",
  "source_url": "https://www.MarketBeat.com/earnings/reports/2026-2-27-fulgent-genetics-inc-stock/",
  "ticker": "FLGT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06332092",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0879",
  "guidance_detail": "Full data readout from Phase 2 trial NCT06332092 guided H2 2027 per CEO on Q4 2025 earnings call (transcript via MarketBeat); trial corroborated by company ASCO 2026 presentation PR (interim: ORR 61.9%, mPFS 6.7 mo).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1024"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for FID-007 (nanoencapsulated paclitaxel) + cetuximab in recurrent/metastatic head and neck squamous cell carcinoma (post PD-L1 checkpoint inhibitor) are expected in the second half of 2027, the first real efficacy signal for Fulgent Genetics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Genmab A/S",
  "competitors": [
   "glofitamab (Roche, CD20xCD3 bispecific)",
   "mosunetuzumab (Roche, CD20xCD3 bispecific)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "epcoritamab (Epkinly) combinations \u2014 EPCORE NHL-2",
  "event_type": "readout",
  "indication": "B-cell non-Hodgkin lymphoma (diffuse large B-cell lymphoma, follicular lymphoma)",
  "notes": "Timing inferred from CT.gov NCT04663347: active (not recruiting) Genmab-sponsored Phase 1b/2 trial of epcoritamab combinations in B-cell NHL, estimated primary completion 2027-09-30. Distinct from the existing epcoritamab + R-CHOP Phase 3 row (NCT05578976).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04663347",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04663347",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0880",
  "guidance_detail": "Timing inferred from CT.gov NCT04663347: active (not recruiting) Genmab-sponsored Phase 1b/2 trial of epcoritamab combinations in B-cell NHL, estimated primary completion 2027-09-30.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0964",
   "v16-0961"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Genmab A/S",
  "competitors": [
   "pirtobrutinib (Eli Lilly, BTK inhibitor)",
   "venetoclax (AbbVie/Roche, BCL-2 inhibitor)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "epcoritamab (Epkinly) \u2014 EPCORE CLL-1",
  "event_type": "readout",
  "indication": "Relapsed/refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and Richter syndrome",
  "notes": "Timing inferred from CT.gov NCT04623541: active (not recruiting) Genmab-sponsored Phase 1b/2 trial, estimated primary completion 2027-12; monotherapy and combination arms (venetoclax, pirtobrutinib, lenalidomide, R-CHOP).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04623541",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04623541",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0881",
  "guidance_detail": "Timing inferred from CT.gov NCT04623541: active (not recruiting) Genmab-sponsored Phase 1b/2 trial, estimated primary completion 2027-12; monotherapy and combination arms (venetoclax, pirtobrutinib, lenalidomide, R-CHOP).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0882"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Genmab A/S",
  "competitors": [
   "zanubrutinib (BeiGene, BTK inhibitor)",
   "ibrutinib (AbbVie/Johnson & Johnson, BTK inhibitor)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "epcoritamab (Epkinly) \u2014 Waldenstrom macroglobulinemia (NCT06510491)",
  "event_type": "readout",
  "indication": "Previously treated Waldenstrom macroglobulinemia",
  "notes": "Timing inferred from CT.gov NCT06510491: recruiting investigator-led Phase 2 trial of epcoritamab in previously treated WM, estimated primary completion 2027-04-30.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06510491",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06510491",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0882",
  "guidance_detail": "Timing inferred from CT.gov NCT06510491: recruiting investigator-led Phase 2 trial of epcoritamab in previously treated WM, estimated primary completion 2027-04-30.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0881"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Genmab A/S",
  "competitors": [
   "datopotamab deruxtecan (Daiichi Sankyo/AstraZeneca, TROP2 ADC)",
   "sacituzumab govitecan (Gilead, TROP2 ADC)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "rinatabart sesutecan (Rina-S) \u2014 NSCLC (NCT07288177)",
  "event_type": "readout",
  "indication": "Non-small cell lung cancer",
  "notes": "Timing inferred from CT.gov NCT07288177: recruiting Genmab-sponsored Phase 2 open-label multi-cohort study of Rina-S in NSCLC, estimated primary completion 2027-11-22. Distinct indication from the existing Rina-S ovarian readout row.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07288177",
  "ticker": "GMAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07288177",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0883",
  "guidance_detail": "Timing inferred from CT.gov NCT07288177: recruiting Genmab-sponsored Phase 2 open-label multi-cohort study of Rina-S in NSCLC, estimated primary completion 2027-11-22.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Genfit S.A.",
  "competitors": [
   "zoldonrasib (Revolution Medicines, KRAS G12D inhibitor)",
   "RMC-6236 (Revolution Medicines, RAS(ON) multi-selective inhibitor)"
  ],
  "country": "France",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GNS561 (ezurpimtrostat) + trametinib",
  "event_type": "readout",
  "indication": "Advanced KRAS-mutated cholangiocarcinoma",
  "notes": "Timing inferred from CT.gov NCT05874414: recruiting Genfit-sponsored Phase 1b/2a trial (covers the Phase 1b and planned Phase 2 components), estimated primary completion 2027-12. Company reported positive Phase 1b data in June 2026, is expanding to higher-dose cohorts, and has Phase 2 initiation on track for H2 2026.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05874414",
  "ticker": "GNFT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05874414",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0884",
  "guidance_detail": "Timing inferred from CT.gov NCT05874414: recruiting Genfit-sponsored Phase 1b/2a trial (covers the Phase 1b and planned Phase 2 components), estimated primary completion 2027-12.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for GNS561 (ezurpimtrostat) + trametinib in advanced KRAS-mutated cholangiocarcinoma are expected in Q4 2027, the first real efficacy signal for Genfit S.A.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Genprex, Inc.",
  "competitors": [
   "tarlatamab (Amgen, DLL3 T-cell engager)",
   "lurbinectedin (Jazz Pharmaceuticals, ES-SCLC)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "quaratusugene ozeplasmid (Reqorsa) + atezolizumab",
  "event_type": "readout",
  "indication": "Extensive-stage small cell lung cancer (maintenance therapy)",
  "notes": "Timing inferred from CT.gov NCT05703971: recruiting Genprex-sponsored Phase 1/2 trial of Reqorsa plus atezolizumab maintenance in ES-SCLC, estimated primary completion 2027-12.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05703971",
  "ticker": "GNPX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05703971",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0885",
  "guidance_detail": "Timing inferred from CT.gov NCT05703971: recruiting Genprex-sponsored Phase 1/2 trial of Reqorsa plus atezolizumab maintenance in ES-SCLC, estimated primary completion 2027-12.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0845"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for quaratusugene ozeplasmid (Reqorsa) + atezolizumab in extensive-stage small cell lung cancer (maintenance therapy) are expected in Q3 2027, the first real efficacy signal for Genprex, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "RTS,S/AS01 (GSK, Mosquirix)",
   "R21/Matrix-M (Serum Institute of India/Oxford)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK next-generation malaria vaccine (pediatric)",
  "event_type": "readout",
  "indication": "Malaria (healthy children aged 5-60 months)",
  "notes": "Timing inferred from CT.gov NCT07036159: recruiting GSK-sponsored Phase 2a open-label randomized study of safety and immunogenicity of alternative malaria vaccine formulations in healthy children, estimated primary completion 2027-04-23.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07036159",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07036159",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0886",
  "guidance_detail": "Timing inferred from CT.gov NCT07036159: recruiting GSK-sponsored Phase 2a open-label randomized study of safety and immunogenicity of alternative malaria vaccine formulations in healthy children, estimated primary completion 2027-04-23.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "artemether/lumefantrine (Novartis, Coartem)",
   "atovaquone/proguanil (GSK, Malarone)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK novel antimalarial pyrrolidinamide",
  "event_type": "readout",
  "indication": "Uncomplicated Plasmodium falciparum malaria",
  "notes": "Timing inferred from CT.gov NCT07545681: not-yet-recruiting GSK-sponsored Phase 2a study of safety, tolerability and PK of a novel antimalarial pyrrolidinamide, estimated primary completion 2027-07-29.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07545681",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07545681",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0887",
  "guidance_detail": "Timing inferred from CT.gov NCT07545681: not-yet-recruiting GSK-sponsored Phase 2a study of safety, tolerability and PK of a novel antimalarial pyrrolidinamide, estimated primary completion 2027-07-29.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "antibiotic prophylaxis (standard of care; no approved UTI vaccine)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK urinary tract infection (UTI) vaccine",
  "event_type": "readout",
  "indication": "Urinary tract infections (adults 18-64)",
  "notes": "Timing inferred from CT.gov NCT06702449: recruiting GSK-sponsored seamless Phase 1/2 observer-blind, randomized, placebo-controlled study of safety and immune response of a UTI vaccine in adults 18-64, estimated primary completion 2027-05-31.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06702449",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06702449",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0888",
  "guidance_detail": "Timing inferred from CT.gov NCT06702449: recruiting GSK-sponsored seamless Phase 1/2 observer-blind, randomized, placebo-controlled study of safety and immune response of a UTI vaccine in adults 18-64, estimated primary completion 2027-05-31.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "GSK plc",
  "competitors": [
   "brensocatib (Insmed, DPP1 inhibitor)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK3862995B",
  "event_type": "readout",
  "indication": "Bronchiectasis",
  "notes": "Timing inferred from CT.gov NCT07201051: recruiting GSK-sponsored Phase 2 randomized, double-blind, placebo-controlled study, estimated primary completion 2027-05-04. Source note: Timing note: inferred bucket 2027-Q1 conflicts with registry primary-completion quarter (PCD 2027-05-04); topline timing may differ from the bucket. Registry timing to be reconfirmed before the window.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07201051",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07201051",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0889",
  "guidance_detail": "Timing inferred from CT.gov NCT07201051: recruiting GSK-sponsored Phase 2 randomized, double-blind, placebo-controlled study, estimated primary completion 2027-05-04.",
  "audit_status": "v20_reverified",
  "audit_action": "quarter_mismatch_flag",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "GSK plc",
  "competitors": [
   "larsucosterol (DURECT, alcohol-associated hepatitis)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK4532990",
  "event_type": "readout",
  "indication": "Steatohepatitis in alcohol-related liver disease",
  "notes": "Timing inferred from CT.gov NCT06613698: recruiting GSK-sponsored Phase 2 dose-finding, double-blind, placebo-controlled study in steatohepatitis in adults with alcohol-related liver disease, estimated primary completion 2027-11-26. Source note: two secondaries (academic review, DelveInsight) suggest 2028 completion, but GSK's own pipeline deck guides 'Data anticipated: 2026+' and the registry PCD 2027-11-26 is unrefuted; live CT.gov fetch blocked. Retained 2027-Q4 inferred; priority. Timing is rechecked in the monthly refresh.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06613698",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06613698",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0890",
  "guidance_detail": "Timing inferred from CT.gov NCT06613698: recruiting GSK-sponsored Phase 2 dose-finding, double-blind, placebo-controlled study in steatohepatitis in adults with alcohol-related liver disease, estimated primary completion 2027-11-26.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "xaluritamig (Amgen, STEAP1 T-cell engager)",
   "lutetium Lu-177 vipivotide tetraxetan (Novartis, Pluvicto)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "GSK5458514 (PSMA-targeting T-cell engager)",
  "event_type": "readout",
  "indication": "Metastatic castration-resistant prostate cancer",
  "notes": "Timing inferred from CT.gov NCT06990880: recruiting GSK-sponsored Phase 1/2 first-in-human dose-escalation and expansion study of GSK5458514 alone or with other anti-cancer agents in mCRPC, estimated primary completion 2027-10-26.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06990880",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06990880",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0891",
  "guidance_detail": "Timing inferred from CT.gov NCT06990880: recruiting GSK-sponsored Phase 1/2 first-in-human dose-escalation and expansion study of GSK5458514 alone or with other anti-cancer agents in mCRPC, estimated primary completion 2027-10-26.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "xalnesiran (Roche, HBV RNAi)",
   "tobevibart + elebsiran (Vir Biotechnology, HBV)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "bepirovirsen \u2014 HIV/HBV coinfection (NCT06497504)",
  "event_type": "readout",
  "indication": "Chronic hepatitis B in participants living with HIV",
  "notes": "Timing inferred from CT.gov NCT06497504: active (not recruiting) GSK-sponsored Phase 2 study of bepirovirsen in HIV/HBV coinfection, estimated primary completion 2027-04-22.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06497504",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06497504",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0892",
  "guidance_detail": "Timing inferred from CT.gov NCT06497504: active (not recruiting) GSK-sponsored Phase 2 study of bepirovirsen in HIV/HBV coinfection, estimated primary completion 2027-04-22.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v19-0011"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "linaclotide (AbbVie/Ironwood, IBS-C)",
   "tenapanor (Ardelyx, IBS-C)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "camlipixant \u2014 BALANCE (NCT07519395)",
  "event_type": "readout",
  "indication": "Irritable bowel syndrome (abdominal symptoms)",
  "notes": "Timing inferred from CT.gov NCT07519395 (BALANCE): recruiting GSK-sponsored Phase 2b 26-week randomized, double-blind, dose-ranging, placebo-controlled study of camlipixant for abdominal symptoms in IBS, estimated primary completion 2027-03-09.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07519395",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07519395",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0893",
  "guidance_detail": "Timing inferred from CT.gov NCT07519395 (BALANCE): recruiting GSK-sponsored Phase 2b 26-week randomized, double-blind, dose-ranging, placebo-controlled study of camlipixant for abdominal symptoms in IBS, estimated primary completion 2027-03-09.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "xalnesiran (Roche, HBV RNAi)",
   "tobevibart + elebsiran (Vir Biotechnology, HBV)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "daplusiran/tomligisiran followed by bepirovirsen",
  "event_type": "readout",
  "indication": "Chronic hepatitis B virus infection",
  "notes": "Timing inferred from CT.gov NCT06537414: active (not recruiting) GSK-sponsored Phase 2b study of sequential DAP/TOM followed by bepirovirsen in chronic HBV, estimated primary completion 2027-05-31.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06537414",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06537414",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0894",
  "guidance_detail": "Timing inferred from CT.gov NCT06537414: active (not recruiting) GSK-sponsored Phase 2b study of sequential DAP/TOM followed by bepirovirsen in chronic HBV, estimated primary completion 2027-05-31.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "pembrolizumab (Merck, neoadjuvant dMMR solid tumors)",
   "fluoropyrimidine-based chemoradiation (standard of care)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "dostarlimab (Jemperli) \u2014 locally advanced rectal cancer (NCT06640049)",
  "event_type": "readout",
  "indication": "Untreated locally advanced rectal cancer (China)",
  "notes": "Timing inferred from CT.gov NCT06640049: active (not recruiting) GSK-sponsored Phase 2 single-arm study of dostarlimab monotherapy in untreated stage II/III rectal cancer in China, estimated primary completion 2027-10-24.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06640049",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06640049",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0895",
  "guidance_detail": "Timing inferred from CT.gov NCT06640049: active (not recruiting) GSK-sponsored Phase 2 single-arm study of dostarlimab monotherapy in untreated stage II/III rectal cancer in China, estimated primary completion 2027-10-24.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-1013"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "mirvetuximab soravtansine (AbbVie, FRa ADC)",
   "tisotumab vedotin (Genmab/Pfizer, tissue-factor ADC)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "mocertatug rezetecan combinations \u2014 BEHOLD-2 (NCT06796907)",
  "event_type": "readout",
  "indication": "Advanced solid tumors (gynecological)",
  "notes": "Timing inferred from CT.gov NCT06796907 (BEHOLD-2): recruiting GSK-sponsored Phase 1/2 randomized multi-cohort study of mocertatug rezetecan with anti-cancer therapies, estimated primary completion 2027-06-21.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06796907",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06796907",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0896",
  "guidance_detail": "Timing inferred from CT.gov NCT06796907 (BEHOLD-2): recruiting GSK-sponsored Phase 1/2 randomized multi-cohort study of mocertatug rezetecan with anti-cancer therapies, estimated primary completion 2027-06-21.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "luspatercept (Bristol Myers Squibb, MDS anemia)",
   "imetelstat (Geron, lower-risk MDS)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "momelotinib (Ojjaara) \u2014 low-risk MDS (NCT06847867)",
  "event_type": "readout",
  "indication": "Anemia due to low-risk myelodysplastic syndrome",
  "notes": "Timing inferred from CT.gov NCT06847867: recruiting GSK-sponsored Phase 2 randomized open-label study of momelotinib in low-risk MDS, estimated primary completion 2027-07-14. New indication for the approved myelofibrosis drug.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06847867",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06847867",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0897",
  "guidance_detail": "Timing inferred from CT.gov NCT06847867: recruiting GSK-sponsored Phase 2 randomized open-label study of momelotinib in low-risk MDS, estimated primary completion 2027-07-14.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "ruxolitinib (Incyte/Novartis, JAK inhibitor)",
   "pelabresib (Novartis, BET inhibitor)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "momelotinib + luspatercept \u2014 myelofibrosis (NCT06517875)",
  "event_type": "readout",
  "indication": "Transfusion-dependent myelofibrosis",
  "notes": "Timing inferred from CT.gov NCT06517875: recruiting GSK-sponsored Phase 2 open-label study of momelotinib plus luspatercept in transfusion-dependent myelofibrosis, estimated primary completion 2027-03-19.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06517875",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06517875",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0898",
  "guidance_detail": "Timing inferred from CT.gov NCT06517875: recruiting GSK-sponsored Phase 2 open-label study of momelotinib plus luspatercept in transfusion-dependent myelofibrosis, estimated primary completion 2027-03-19.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-20",
  "company": "GSK plc",
  "competitors": [
   "trabectedin (PharmaMar/Johnson & Johnson, sarcoma)",
   "eribulin (Eisai, liposarcoma)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "risvutatug rezetecan \u2014 sarcoma (NCT07602777)",
  "event_type": "readout",
  "indication": "Advanced sarcomas (previously treated)",
  "notes": "Timing inferred from CT.gov NCT07602777: recruiting GSK-sponsored Phase 1b/2 study of risvutatug rezetecan in previously treated advanced sarcomas, estimated primary completion 2027-11-05. Distinct from the existing EMBOLD SCLC-301 Phase 3 row.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07602777",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07602777",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0899",
  "guidance_detail": "Timing inferred from CT.gov NCT07602777: recruiting GSK-sponsored Phase 1b/2 study of risvutatug rezetecan in previously treated advanced sarcomas, estimated primary completion 2027-11-05.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0099"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20"
 },
 {
  "as_of": "2026-09-18",
  "company": "GSK plc",
  "competitors": [
   "ripretinib (Deciphera, fourth-line GIST)",
   "avapritinib (Blueprint Medicines, PDGFRA-mutant GIST)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "velzatinib (GSK6042981)",
  "event_type": "readout",
  "indication": "Metastatic and/or unresectable GIST after imatinib, sunitinib and regorafenib",
  "notes": "Timing inferred from CT.gov NCT07689201: recruiting GSK-sponsored Phase 2 single-arm multicenter open-label study of velzatinib in metastatic/unresectable GIST after three prior TKIs, estimated primary completion 2027-11-29.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07689201",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07689201",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0900",
  "guidance_detail": "Timing inferred from CT.gov NCT07689201: recruiting GSK-sponsored Phase 2 single-arm multicenter open-label study of velzatinib in metastatic/unresectable GIST after three prior TKIs, estimated primary completion 2027-11-29.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "HUTCHMED (China) Limited",
  "competitors": [
   "trifluridine/tipiracil (Taiho, TAS-102)",
   "regorafenib (Bayer)"
  ],
  "country": "China",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "fruquintinib (Fruzaqla) + tegafur/gimeracil/oteracil (S-1)",
  "event_type": "readout",
  "indication": "Third-line metastatic colorectal cancer",
  "notes": "Timing inferred from CT.gov NCT06255379 (Hutchmed identifier HMPL-013-SC-CRC102): investigator-led (Guangzhou University of Traditional Chinese Medicine) Phase 2 study of fruquintinib plus S-1 in third-line mCRC, estimated primary completion 2027-03-21. Registry status is NOT_YET_RECRUITING with status last verified April 2024, so the primary-completion estimate may be stale.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06255379",
  "ticker": "HCM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06255379",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0901",
  "guidance_detail": "Timing inferred from CT.gov NCT06255379 (Hutchmed identifier HMPL-013-SC-CRC102): investigator-led (Guangzhou University of Traditional Chinese Medicine) Phase 2 study of fruquintinib plus S-1 in third-line mCRC, estimated primary completion 2027-03-21.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "IDEAYA Biosciences, Inc.",
  "competitors": [
   "tebentafusp (Immunocore, uveal melanoma)",
   "crizotinib (Pfizer, used in darovasertib combinations)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "darovasertib (IDE196) \u2014 GNAQ/11/PRKC-fusion basket (NCT03947385)",
  "event_type": "readout",
  "indication": "GNAQ/11-mutant or PRKC-fusion solid tumors (metastatic uveal melanoma, cutaneous melanoma, colorectal cancer)",
  "notes": "Timing inferred from CT.gov NCT03947385: recruiting IDEAYA-sponsored Phase 1/2 basket study (the original first-in-human study, ongoing since 2019), estimated primary completion 2027-01-29; registry status verified June 2026. Distinct from the existing darovasertib uveal-melanoma program rows (OptimUM-02, OptimUM-09 neoadjuvant, 1L metastatic).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT03947385",
  "ticker": "IDYA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT03947385",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0902",
  "guidance_detail": "Timing inferred from CT.gov NCT03947385: recruiting IDEAYA-sponsored Phase 1/2 basket study (the original first-in-human study, ongoing since 2019), estimated primary completion 2027-01-29; registry status verified June 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0468"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for darovasertib (IDE196) \u2014 GNAQ/11/PRKC-fusion basket (NCT03947385) \u2014 in GNAQ/11-mutant or PRKC-fusion solid tumors are expected in Q1 2027, the first real efficacy signal for IDEAYA Biosciences, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "SNX (revumenib/Revuforj - menin inhibitor)",
   "KURA (ziftomenib/KOMZIFTI - menin inhibitor)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Bleximenib",
  "event_type": "readout",
  "indication": "Relapsed/refractory acute leukemia (KMT2A-rearranged / NPM1-mutated)",
  "notes": "inferred from CT.gov primary completion Feb 2027 for Phase 1/2 cAMeLot-1 (NCT04811560); Phase 2 portion evaluates efficacy in R/R acute leukemia.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04811560",
  "ticker": "JNJ",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04811560",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0903",
  "guidance_detail": "inferred from CT.gov primary completion Feb 2027 for Phase 1/2 cAMeLot-1 (NCT04811560); Phase 2 portion evaluates efficacy in R/R acute leukemia.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "ARGX (Vyvgart - anti-FcRn, approved pediatric gMG)",
   "AZN (Ultomiris - C5, approved pediatric gMG)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Nipocalimab",
  "event_type": "readout",
  "indication": "Pediatric generalized myasthenia gravis (gMG), ages 2 to <18",
  "notes": "inferred from CT.gov primary completion Jun 2027; Phase 2/3 pediatric gMG trial.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05265273",
  "ticker": "JNJ",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0904",
  "guidance_detail": "inferred from CT.gov primary completion Jun 2027; Phase 2/3 pediatric gMG trial.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0905"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Johnson & Johnson",
  "competitors": [
   "ARGX (Vyvgart Hytrulo - approved CIDP)",
   "TAK (Gammagard - IVIg, CIDP standard of care)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Nipocalimab",
  "event_type": "readout",
  "indication": "Chronic inflammatory demyelinating polyneuropathy (CIDP)",
  "notes": "inferred from CT.gov primary completion May 2027; Phase 2/3 CIDP trial.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05327114",
  "ticker": "JNJ",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0905",
  "guidance_detail": "inferred from CT.gov primary completion May 2027; Phase 2/3 CIDP trial.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0904"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Kailera Therapeutics, Inc.",
  "competitors": [
   "LLY (orforglipron - oral GLP-1)",
   "NVO (oral semaglutide/amycretin)",
   "VKTX (VK2735 - oral GLP-1/GIP)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "KAI-7535 (oral small-molecule GLP-1 receptor agonist)",
  "event_type": "readout",
  "indication": "Obesity/overweight",
  "notes": "Genuine Kailera company release (2026-07-07, GLOBE NEWSWIRE dateline) via wire-network distribution \u2014 Kailera is private with no IR archive; no standalone globenewswire.com URL indexed. 'Kailera is concurrently advancing KAI-7535 in a global Phase 2 clinical trial in people living with obesity or overweight. The trial initiated in April 2026, with data expected in 2027.' Re-verified 2026-09-20. No standalone globenewswire.com page is indexed for the July 7, 2026 HRS-7535/KAI-7535 release after multiple exact-headline searches; Kailera's own press-release archive (kailera.com) does not carry it. Release text verified via independent wire mirrors with GLOBE NEWSWIRE dateline: 'Kailera is concurrently advancing KAI-7535 in a global Phase 2 clinical trial in people living with obesity or overweight. The trial initiated in April 2026, with data expected in 2027.' Note: prior note said Kailera was private \u2014 stale; Kailera is now Nasdaq-listed (KLRA) but still lacks the July 7 release in its site archive.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://markets.financialcontent.com/ibtimes/article/gnwcq-2026-7-7-kailera-therapeutics-announces-positive-topline-data-from-two-hengrui-pharma-phase-3-clinical-trials-of-oral-small-molecule-glp-1-receptor-agonist-hrs-7535kai-7535",
  "ticker": "KLRA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0906",
  "guidance_detail": "Genuine Kailera company release (2026-07-07, GLOBE NEWSWIRE dateline) via wire-network distribution \u2014 Kailera is private with no IR archive; no standalone globenewswire.com URL indexed.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for KAI-7535 (oral small-molecule GLP-1 receptor agonist) in Obesity/overweight are expected sometime in 2027, the first real efficacy signal for Kailera Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-24",
  "company": "Kailera Therapeutics, Inc.",
  "competitors": [
   "LLY (retatrutide)",
   "NVO (CagriSema)",
   "AMGN (maridebart cafraglutide)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Ribupatide (KAI-9531) injectable",
  "event_type": "readout",
  "indication": "Obesity (participants without type 2 diabetes)",
  "notes": "inferred from CT.gov primary completion May 2027; Phase 2b randomized double-blind placebo-controlled study of once-weekly ribupatide. Source note: upgraded inferred->guidance; Kailera Q2 2026 business update (press-release mirror of company release) guides US Phase 2b high-dose obesity data mid-2027; bucket 2027-H2 retained. Source note: KLRA ribupatide (KAI-9531): sponsor guides only 2027 for Phase 2 readout - no half printed. Calendar's H2 bucket was over-precise; broadened to full-year 2027. Source: https://www.globenewswire.com/news-release/2026/08/13/3346142/0/en/Kailera-Therapeutics-Reports-Second-Quarter-2026-Financial-Results.html.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.nasdaq.com/press-release/kailera-reports-second-quarter-2026-financial-results-and-provides-business-updates",
  "ticker": "KLRA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0907",
  "guidance_detail": "inferred from CT.gov primary completion May 2027; Phase 2b randomized double-blind placebo-controlled study of once-weekly ribupatide.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-H2",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Sponsor guides only 2027 for Phase 2 readout; broadened to full year"
   }
  ],
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Ribupatide (KAI-9531) injectable in Obesity (participants without type 2 diabetes) are expected sometime in 2027, the first real efficacy signal for Kailera Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Keros Therapeutics, Inc.",
  "competitors": [
   "DYN (DYNE-251)",
   "BHVN (taldefgrobep alfa)",
   "SRRK (apitegromab)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Rinvatercept (KER-065)",
  "event_type": "readout",
  "indication": "Duchenne muscular dystrophy (DMD)",
  "notes": "company explicitly guides initial Phase 2 DMD data in H1 2027; CT.gov primary completion is 2029, so data reflects an early cut per company guidance.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/03/3337854/0/en/Keros-Therapeutics-Reports-Second-Quarter-2026-Financial-Results.html",
  "ticker": "KROS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0908",
  "guidance_detail": "company explicitly guides initial Phase 2 DMD data in H1 2027; CT.gov primary completion is 2029, so data reflects an early cut per company guidance.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for Rinvatercept (KER-065) in Duchenne muscular dystrophy (DMD) are expected in the first half of 2027, the first real efficacy signal for Keros Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Liquidia Corporation",
  "competitors": [
   "Tyvaso DPI (United Therapeutics)",
   "Orenitram (United Therapeutics)",
   "Iloprost IV (generic)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "YUTREPIA (treprostinil) inhalation powder",
  "event_type": "readout",
  "indication": "Raynaud's phenomenon associated with systemic sclerosis (RE-WARM Phase 2a)",
  "notes": "Phase 2a RE-WARM (NCT07748000) not yet recruiting; registry primary completion 2027-02, study completion 2027-03. FDA Fast Track granted Sept 2026; company guides trial initiation Q4 2026. Readout inferred for Q1 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07748000",
  "ticker": "LQDA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07748000",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0909",
  "guidance_detail": "Phase 2a RE-WARM (NCT07748000) not yet recruiting; registry primary completion 2027-02, study completion 2027-03.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "MannKind Corporation",
  "competitors": [
   "Ofev (Boehringer Ingelheim)",
   "Esbriet (Roche/Genentech)",
   "Nerandomilast (Boehringer Ingelheim)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "MNKD-201 (nintedanib dry powder inhalation)",
  "event_type": "readout",
  "indication": "Idiopathic pulmonary fibrosis (INFLO-2 Phase 2)",
  "notes": "INFLO-2 Phase 2 (NCT07679893) recruiting since May 2026; registry primary completion 2027-12-30. Late-December PCD makes topline more likely early 2028; inferred 2027-Q4 per registry methodology. 2026 PDUFAs (Afrezza pediatric, FUROSCIX ReadyFlow) fall outside the 2027 window.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07679893",
  "ticker": "MNKD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07679893",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0911",
  "guidance_detail": "INFLO-2 Phase 2 (NCT07679893) recruiting since May 2026; registry primary completion 2027-12-30.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for MNKD-201 (nintedanib dry powder inhalation) in Idiopathic pulmonary fibrosis (INFLO-2 Phase 2) are expected in Q4 2027, the first real efficacy signal for MannKind Corporation's program."
 },
 {
  "ticker": "NBIX",
  "company": "Neurocrine Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NBI-1117570",
  "indication": "schizophrenia",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Cobenfy/KarXT (Bristol Myers Squibb \u2014 M1/M4)",
   "emraclidine (AbbVie \u2014 M4)",
   "GXV813 (Novartis \u2014 M4)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07288333",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07288333; registry primary completion 2027-08, status recruiting; oral dual M1/M4 agonist (partnered with Nxera); first patient dosed per partner PR; topline typically ~3-6 mo later",
  "nct_id": "NCT07288333",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0912",
  "guidance_detail": "Phase 2 study NCT07288333; registry primary completion 2027-08, status recruiting; oral dual M1/M4 agonist (partnered with Nxera); first patient dosed per partner PR; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0916"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "CDR132L",
  "indication": "heart failure",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Entresto (Novartis \u2014 HF)",
   "Farxiga/dapagliflozin (AstraZeneca \u2014 HF)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06979375",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06979375; registry primary completion 2027-05-16, status recruiting; anti-miR-132 antisense in HF; separate dose-ranging Phase 2 (NCT06979362, PCD 2027-11) suppressed per same-drug dedup; prior HF-REVERT Phase 2 failed May 2026; topline typically ~3-6 mo later",
  "nct_id": "NCT06979375",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0913",
  "guidance_detail": "Phase 2 study NCT06979375; registry primary completion 2027-05-16, status recruiting; anti-miR-132 antisense in HF; separate dose-ranging Phase 2 (NCT06979362, PCD 2027-11) suppressed per same-drug dedup; prior HF-REVERT Phase 2 failed May 2026; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NNC0662-0419",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Zepbound/tirzepatide (Lilly)",
   "Wegovy/semaglutide (Novo Nordisk)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07639021",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07639021; registry primary completion 2027-06-14, status active/not recruiting; mechanism undisclosed; separate T2D Phase 2 (NCT07415954, PCD 2027-09) suppressed per same-drug dedup; topline typically ~3-6 mo later",
  "nct_id": "NCT07639021",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0914",
  "guidance_detail": "Phase 2 study NCT07639021; registry primary completion 2027-06-14, status active/not recruiting; mechanism undisclosed; separate T2D Phase 2 (NCT07415954, PCD 2027-09) suppressed per same-drug dedup; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "EYU688",
  "indication": "dengue fever",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "mosnodenvir/JNJ-1802 (Johnson & Johnson \u2014 dengue antiviral)",
   "Qdenga (Takeda \u2014 dengue vaccine)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06006559",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06006559; registry primary completion 2027-07-22, status recruiting; NS4B inhibitor in dengue; topline typically ~3-6 mo later",
  "nct_id": "NCT06006559",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0915",
  "guidance_detail": "Phase 2 study NCT06006559; registry primary completion 2027-07-22, status recruiting; NS4B inhibitor in dengue; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "GXV813",
  "indication": "schizophrenia",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Cobenfy/KarXT (Bristol Myers Squibb \u2014 M1/M4)",
   "emraclidine (AbbVie \u2014 M4)",
   "NBI-1117570 (Neurocrine \u2014 M1/M4)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07467993",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07467993; registry primary completion 2027-07-29, status recruiting; M4 receptor agonist; topline typically ~3-6 mo later",
  "nct_id": "NCT07467993",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0916",
  "guidance_detail": "Phase 2 study NCT07467993; registry primary completion 2027-07-29, status recruiting; M4 receptor agonist; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0912"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "LXE408",
  "indication": "chronic Chagas disease",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Lampit/nifurtimox (Bayer \u2014 Chagas)",
   "benznidazole (generic \u2014 Chagas SoC)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06632600",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT06632600; registry primary completion 2027-07-22, status recruiting; proteasome inhibitor in chronic Chagas; topline typically ~3-6 mo later",
  "nct_id": "NCT06632600",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0917",
  "guidance_detail": "Phase 2 study NCT06632600; registry primary completion 2027-07-22, status recruiting; proteasome inhibitor in chronic Chagas; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "MAS825",
  "indication": "Still's disease",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "Ilaris/canakinumab (Novartis \u2014 IL-1\u03b2, Still's)",
   "Kineret/anakinra (Sobi \u2014 IL-1, Still's)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07203001",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07203001; registry primary completion 2027-04-22, status recruiting; IL-18/IL-1\u03b2 inhibition in Still's disease; topline typically ~3-6 mo later",
  "nct_id": "NCT07203001",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0918",
  "guidance_detail": "Phase 2 study NCT07203001; registry primary completion 2027-04-22, status recruiting; IL-18/IL-1\u03b2 inhibition in Still's disease; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "PKN605",
  "indication": "atrial fibrillation",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Eliquis/apixaban (Bristol Myers Squibb/Pfizer \u2014 AF)",
   "Xarelto/rivaroxaban (Johnson & Johnson/Bayer \u2014 AF)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07217067",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07217067; registry primary completion 2027-09-09, status recruiting; HDAC6 inhibitor in atrial fibrillation; separate Phase 1 PK study (NCT07797322, PCD 2027-02) suppressed per same-drug dedup; topline typically ~3-6 mo later",
  "nct_id": "NCT07217067",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0919",
  "guidance_detail": "Phase 2 study NCT07217067; registry primary completion 2027-09-09, status recruiting; HDAC6 inhibitor in atrial fibrillation; separate Phase 1 PK study (NCT07797322, PCD 2027-02) suppressed per same-drug dedup; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NVS",
  "company": "Novartis AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "cipargamin (KAE609) + KLU156",
  "indication": "uncomplicated malaria",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "Coartem (Novartis \u2014 malaria SoC)",
   "tafenoquine (GSK \u2014 antimalarial)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07811908",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2 study NCT07811908; registry primary completion 2027-02-04, status recruiting; cipargamin+KLU156 combination in uncomplicated malaria; topline typically ~3-6 mo later",
  "nct_id": "NCT07811908",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0920",
  "guidance_detail": "Phase 2 study NCT07811908; registry primary completion 2027-02-04, status recruiting; cipargamin+KLU156 combination in uncomplicated malaria; topline typically ~3-6 mo later.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "BeOne Medicines Ltd.",
  "competitors": [
   "Leads Biolabs (opamtistomig \u2014 PD-L1\u00d74-1BB bispecific, in HCC)",
   "Roche (atezolizumab + bevacizumab \u2014 HCC standard)"
  ],
  "country": "China",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "BGB-B2033",
  "event_type": "readout",
  "indication": "hepatocellular carcinoma and other GPC3-positive solid tumors \u2014 anti-GPC3\u00d74-1BB bispecific \u00b1 tislelizumab \u00b1 bevacizumab",
  "notes": "Registry Phase 1/2 classified once as Phase 2 per efficacy/dose-expansion convention (company: Phase 1 dose escalation); inferred from primary completion 2027-03-31 (NCT06427941, recruiting); FDA Fast Track granted Dec 2025 for post-systemic-therapy HCC.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06427941",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06427941",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0921",
  "guidance_detail": "Registry Phase 1/2 classified once as Phase 2 per efficacy/dose-expansion convention (company: Phase 1 dose escalation); inferred from primary completion 2027-03-31 (NCT06427941, recruiting); FDA Fast Track granted Dec 2025 for post-systemic-therapy HCC.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Oncolytics Biotech Inc.",
  "competitors": [
   "Replimune (RP1 \u2014 oncolytic immunotherapy)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "pelareorep",
  "event_type": "readout",
  "indication": "advanced or metastatic gastrointestinal cancers \u2014 pelareorep treatment combinations",
  "notes": "Registry Phase 1/2 classified once as Phase 2 per efficacy/dose-expansion convention; inferred from primary completion 2027-07-30 (NCT07280377, active not recruiting).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07280377",
  "ticker": "ONCY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07280377",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0922",
  "guidance_detail": "Registry Phase 1/2 classified once as Phase 2 per efficacy/dose-expansion convention; inferred from primary completion 2027-07-30 (NCT07280377, active not recruiting).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for pelareorep in advanced or metastatic gastrointestinal cancers \u2014 pelareorep treatment combinations are expected in Q3 2027, the first real efficacy signal for Oncolytics Biotech Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Oncolytics Biotech Inc.",
  "competitors": [
   "Roche (bevacizumab/Avastin)",
   "Bayer (regorafenib/Stivarga)",
   "Taiho Pharmaceutical (trifluridine/tipiracil/Lonsurf)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "pelareorep + FOLFIRI/bevacizumab",
  "event_type": "readout",
  "indication": "second-line metastatic colorectal cancer",
  "notes": "Inferred from registry primary completion 2027-08-30 (NCT07446322, recruiting); randomized Phase 2 FOLFIRI/bevacizumab \u00b1 pelareorep.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07446322",
  "ticker": "ONCY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07446322",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0923",
  "guidance_detail": "Inferred from registry primary completion 2027-08-30 (NCT07446322, recruiting); randomized Phase 2 FOLFIRI/bevacizumab \u00b1 pelareorep.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for pelareorep + FOLFIRI/bevacizumab in second-line metastatic colorectal cancer are expected in Q3 2027, the first real efficacy signal for Oncolytics Biotech Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "OPKO Health, Inc.",
  "competitors": [
   "Amgen (cinacalcet/Sensipar)",
   "Amgen (etelcalcetide/Parsabiv)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "CTAP101",
  "event_type": "readout",
  "indication": "secondary hyperparathyroidism in chronic kidney disease \u2014 extended-release calcifediol (PK/PD/safety)",
  "notes": "Inferred from registry primary completion 2027-10 (NCT07494045, recruiting); PK/PD/safety/tolerability evaluation of extended-release formulation.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07494045",
  "ticker": "OPK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07494045",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0924",
  "guidance_detail": "Inferred from registry primary completion 2027-10 (NCT07494045, recruiting); PK/PD/safety/tolerability evaluation of extended-release formulation.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for CTAP101 (extended-release calcifediol) in secondary hyperparathyroidism in chronic kidney disease are expected in Q4 2027, the first real efficacy signal for OPKO Health, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "OPKO Health, Inc.",
  "competitors": [
   "Boehringer Ingelheim/Zealand Pharma (survodutide)",
   "Altimmune (pemvidutide)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "OPK-88006",
  "event_type": "readout",
  "indication": "obesity and MASH \u2014 dual GLP-1/glucagon agonist",
  "notes": "Registry Phase 1/2a classified once as Phase 2 per efficacy/dose-expansion convention; inferred from primary completion 2027-12 (NCT07512427, recruiting); 16-week dosing in presumed MASH subjects.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07512427",
  "ticker": "OPK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07512427",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0925",
  "guidance_detail": "Registry Phase 1/2a classified once as Phase 2 per efficacy/dose-expansion convention; inferred from primary completion 2027-12 (NCT07512427, recruiting); 16-week dosing in presumed MASH subjects.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for OPK-88006 in obesity and MASH \u2014 dual GLP-1/glucagon agonist are expected in Q4 2027, the first real efficacy signal for OPKO Health, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Oruka Therapeutics, Inc.",
  "competitors": [
   "Johnson & Johnson (guselkumab/Tremfya)",
   "AbbVie (risankizumab/Skyrizi)",
   "Eli Lilly (mirikizumab/Omvoh)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "ORKA-001",
  "event_type": "readout",
  "indication": "moderate-to-severe plaque psoriasis \u2014 anti-IL-23p19",
  "notes": "Inferred from registry primary completion 2027-06 (NCT07290569, active not recruiting); dose-ranging Phase 2.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07290569",
  "ticker": "ORKA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07290569",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0926",
  "guidance_detail": "Inferred from registry primary completion 2027-06 (NCT07290569, active not recruiting); dose-ranging Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for ORKA-001 in moderate-to-severe plaque psoriasis \u2014 anti-IL-23p19 are expected in Q2 2027, the first real efficacy signal for Oruka Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "semaglutide (Novo Nordisk)",
   "tirzepatide (Eli Lilly)",
   "dapagliflozin (AstraZeneca)",
   "vericiguat (Merck/Bayer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-07328948 (oral BDK inhibitor/degrader)",
  "event_type": "readout",
  "indication": "heart failure (LVEF >40%; BRANCH-HF)",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-11-16 for NCT06991257 (BRANCH-HF, ~620 participants, 36-week dosing on top of SGLT2i). First-in-class mechanism for HF.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06991257",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06991257",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0927",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-11-16 for NCT06991257 (BRANCH-HF, ~620 participants, 36-week dosing on top of SGLT2i).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0742",
   "v16-0741"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "atezolizumab + bevacizumab (Roche)",
   "durvalumab + tremelimumab (AstraZeneca)",
   "ivonescimab (Summit Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08634404 (PD-1 x VEGF bispecific; 3SBio-licensed) (HCC)",
  "event_type": "readout",
  "indication": "hepatocellular carcinoma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-10-18 for NCT07227012 (Phase 1/2).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07227012",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07227012",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0928",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-10-18 for NCT07227012 (Phase 1/2).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0930",
   "v16-0929"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "ivonescimab (Summit Therapeutics)",
   "pembrolizumab + lenvatinib (Merck/Eisai)",
   "zanzalintinib (Exelixis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08634404 (PD-1 x VEGF bispecific; 3SBio-licensed) (RCC)",
  "event_type": "readout",
  "indication": "renal cell carcinoma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-11-02 for NCT07227415 (Phase 1/2). Pfizer in-licensed global rights from 3SBio in 2025.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07227415",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07227415",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0929",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-11-02 for NCT07227415 (Phase 1/2).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0930",
   "v16-0928"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-10-20",
  "company": "Pfizer Inc.",
  "competitors": [
   "pembrolizumab (Merck)",
   "enfortumab vedotin (Pfizer)",
   "ivonescimab (Summit Therapeutics)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PF-08634404 (PD-1 x VEGF bispecific; 3SBio-licensed) (urothelial)",
  "event_type": "readout",
  "indication": "urothelial carcinoma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-12-28 for NCT07421700 (Phase 1/2).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07421700",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07421700",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0930",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-12-28 for NCT07421700 (Phase 1/2).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0929",
   "v16-0928"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "eloralintide (Eli Lilly)",
   "cagrilintide (Novo Nordisk)",
   "petrelintide (Zealand Pharma)",
   "maridebart cafraglutide (Amgen)"
  ],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PF-08653945 (ultra-long-acting amylin analog) +/- berobenatide (PF-08653944, ultra-long-acting GLP-1 RA) \u2014 SOLIS-1 (Phase 2b)",
  "event_type": "readout",
  "indication": "obesity/overweight",
  "notes": "Company guided SOLIS-1 data expected in 2027 (Q2 2026 earnings transcript); CT.gov registry PCD 2027-08-04 for NCT07575932. berobenatide added via Metsera acquisition; amylin analog dosed as monotherapy and in combination.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07575932",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07575932",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0931",
  "guidance_detail": "Company guided SOLIS-1 data expected in 2027 (Q2 2026 earnings transcript); CT.gov registry PCD 2027-08-04 for NCT07575932.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "Vaxneuvance/Capvaxive (Merck)",
   "VAX-31 (Vaxcyte)",
   "Prevnar 20 (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PFE pneumococcal vaccine (new candidate)",
  "event_type": "readout",
  "indication": "pneumococcal disease prevention (infants)",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-05-01 for NCT06524414.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06524414",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06524414",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0932",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-05-01 for NCT06524414.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v17-0020"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "abemaciclib (Eli Lilly)",
   "ribociclib (Novartis)",
   "palbociclib (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "atirmociclib (PF-07220060; oral CDK4 inhibitor) + PF-07104091 + endocrine therapy",
  "event_type": "readout",
  "indication": "HR+/HER2- advanced breast cancer",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-02-26 for NCT05262400 (Phase 1b/2 dose escalation + expansion). Atirmociclib + fulvestrant reported positive mid-stage data Mar 2026.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05262400",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05262400",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0933",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-02-26 for NCT05262400 (Phase 1b/2 dose escalation + expansion).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "imipenem/relebactam (Merck)",
   "cefepime-taniborbactam (GSK)",
   "ceftazidime-avibactam (Bayer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "aztreonam-avibactam",
  "event_type": "readout",
  "indication": "serious Gram-negative infections",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-03-31 for NCT05639647.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05639647",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05639647",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0934",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-03-31 for NCT05639647.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0935"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "imipenem/relebactam (Merck)",
   "cefepime-taniborbactam (GSK)",
   "ceftazidime-avibactam (Bayer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "aztreonam-avibactam (pediatric)",
  "event_type": "readout",
  "indication": "serious Gram-negative infections (pediatric)",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-04-25 for NCT06462235.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06462235",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06462235",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0935",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-04-25 for NCT06462235.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0934"
  ],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "trastuzumab deruxtecan (Daiichi Sankyo/AstraZeneca)",
   "trastuzumab emtansine (Roche)",
   "petosemtamab (Genmab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "disitamab vedotin (HER2 ADC)",
  "event_type": "readout",
  "indication": "HER2-expressing breast cancer",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-10-25 for NCT06966453 (Phase 1/2).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06966453",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06966453",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0936",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-10-25 for NCT06966453 (Phase 1/2).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "mRNA-1010 (Moderna)",
   "GSK influenza vaccines",
   "Fluzone (Sanofi)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "mRNA influenza vaccines",
  "event_type": "readout",
  "indication": "influenza (prevention)",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-06-22 for NCT07431853.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07431853",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07431853",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0937",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-06-22 for NCT07431853.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "tezepelumab (AstraZeneca/Amgen)",
   "dupilumab (Regeneron/Sanofi)",
   "mepolizumab (GSK)",
   "benralizumab (AstraZeneca)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "tilrekimig (PF-07275315; once-monthly trispecific IL-4/IL-13/TSLP antibody)",
  "event_type": "readout",
  "indication": "moderate-to-severe asthma",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-03-08 for NCT06977581 (dose-ranging Phase 2, Week 12 pre-BD FEV1 primary). Pfizer reported positive Phase 2 atopic dermatitis topline Mar 2026 and plans Phase 3.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06977581",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06977581",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0938",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-03-08 for NCT06977581 (dose-ranging Phase 2, Week 12 pre-BD FEV1 primary).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [
   "vepdegestrant (Arvinas)",
   "camizestrant (AstraZeneca)",
   "palazestrant (Olema)",
   "imlunestrant (Eli Lilly)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "vepdegestrant (ER PROTAC degrader) + combination partners",
  "event_type": "readout",
  "indication": "ER+/HER2- advanced breast cancer",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-03-24 for NCT05548127 (Phase 1/2 vepdegestrant combination study).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05548127",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05548127",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0939",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-03-24 for NCT05548127 (Phase 1/2 vepdegestrant combination study).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0725"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "PTC Therapeutics, Inc.",
  "competitors": [
   "upadacitinib (AbbVie)",
   "baricitinib (Eli Lilly)",
   "tofacitinib (Pfizer)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PTC844 (dihydroorotate dehydrogenase inhibitor)",
  "event_type": "readout",
  "indication": "active rheumatoid arthritis \u2014 Phase 2a proof-of-concept",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-09-30 for NCT07779616 (Phase 2a, not yet recruiting).",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07779616",
  "ticker": "PTCT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07779616",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0940",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-09-30 for NCT07779616 (Phase 2a, not yet recruiting).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Protagonist Therapeutics, Inc.",
  "competitors": [
   "NVS Cosentyx (secukinumab)",
   "LLY Taltz (ixekizumab)",
   "UCB Bimzelx (bimekizumab)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PN-881 (oral IL-17 antagonist peptide)",
  "event_type": "regulatory_other",
  "indication": "moderate-to-severe plaque psoriasis \u2014 comprehensive Phase 2b program",
  "notes": "Phase 2b psoriasis program initiation expected early Q1 2027 based on supportive Phase 1 PK data (Q2 2026 results, Aug 5, 2026); not a Phase 1/preclinical readout, placed as Phase 2-tied regulatory initiation.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/protagonist-reports-second-quarter-2026-financial-results-and-provides-corporate-update",
  "ticker": "PTGX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0941",
  "guidance_detail": "Phase 2b psoriasis program initiation expected early Q1 2027 based on supportive Phase 1 PK data (Q2 2026 results, Aug 5, 2026); not a Phase 1/preclinical readout, placed as Phase 2-tied regulatory initiation.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24",
  "why_it_matters": "Protagonist expects to start its Phase 2b program of PN-881, an oral IL-17 antagonist peptide for plaque psoriasis, in early Q1 2027."
 },
 {
  "as_of": "2026-09-24",
  "company": "Palvella Therapeutics, Inc.",
  "competitors": [
   "No approved pharmacologic competitors for angiokeratomas; systemic sirolimus used off-label"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "PTX-022 (topical sirolimus gel 3.9%)",
  "event_type": "readout",
  "indication": "angiokeratomas \u2014 Phase 2 study",
  "notes": "Inferred from CT.gov primary completion (estimated) August 2027 for NCT07552077 (Phase 2, recruiting). Source note: upgraded inferred->guidance; Palvella May 2026 company release: CEO guides Phase 2 LOTU topline in H2 2027 (QTORIN rapamycin = topical sirolimus 3.9% gel); bucket 2027-Q3 sits inside H2 2027. Source note: PVLA LOTU: sponsor Q2 2026 PR guides Phase 2b LOTUS readout \"in the second half of 2027\". Calendar's Q3 bucket was over-precise; rebucketed to H2 2027. Source: https://www.globenewswire.com/news-release/2026/08/13/3346142/0/en/. Quote: \"second half of 2027\".",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/04/3286595/0/en/Palvella-Therapeutics-Announces-First-Patients-Dosed-in-Phase-2-LOTU-Trial-of-Fast-Track-Designated-QTORIN-Rapamycin-for-Clinically-Significant-Angiokeratomas.html",
  "ticker": "PVLA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07552077",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0942",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) August 2027 for NCT07552077 (Phase 2, recruiting).",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027-H2",
    "changed": "2026-09-23",
    "why": "Sponsor Q2 2026 PR guides Phase 2b LOTUS readout in H2 2027; Q3 was over-precise"
   }
  ],
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for PTX-022 (topical sirolimus gel 3.9%) in angiokeratomas are expected in the second half of 2027, the first real efficacy signal for Palvella Therapeutics, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Pyxis Oncology, Inc.",
  "competitors": [
   "MRK Keytruda (pembrolizumab)",
   "ABBV Elahere (mirvetuximab soravtansine)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "PYX-201 (EDB-fibronectin-targeting ADC) + pembrolizumab",
  "event_type": "readout",
  "indication": "advanced solid tumors \u2014 Phase 1/2 combination",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-12-06 for NCT06795412 (Phase 1/2, recruiting); placed in Workstream B per mixed Phase 1/2 convention.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06795412",
  "ticker": "PYXS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06795412",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0943",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-12-06 for NCT06795412 (Phase 1/2, recruiting); placed in Workstream B per mixed Phase 1/2 convention.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for PYX-201 (EDB-fibronectin-targeting ADC) + pembrolizumab in advanced solid tumors are expected in Q4 2027, the first real efficacy signal for Pyxis Oncology, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "uniQure N.V.",
  "competitors": [
   "SNY Fabrazyme (agalsidase beta)",
   "Amicus Galafold (migalastat)"
  ],
  "country": "Netherlands",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AMT-191 (AAV5 gene therapy)",
  "event_type": "readout",
  "indication": "classic Fabry disease \u2014 Phase 1/2",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-12-01 for NCT06270316 (Phase 1/2, recruiting); placed in Workstream B per mixed Phase 1/2 convention.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06270316",
  "ticker": "QURE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06270316",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0944",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-12-01 for NCT06270316 (Phase 1/2, recruiting); placed in Workstream B per mixed Phase 1/2 convention.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "ALN-CIDEB",
  "indication": "MASLD / metabolic dysfunction-associated steatohepatitis (MASH)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "ARWR (ARO-PNPLA3)",
   "MDGL (Rezdiffra)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06836609",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Alnylam-partnered siRNA; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-05-15 (NCT06836609); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06836609",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0945",
  "guidance_detail": "Alnylam-partnered siRNA; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "ALN-PNP",
  "indication": "Metabolic dysfunction-associated steatotic liver disease (MASLD)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "ARWR (ARO-PNPLA3)",
   "MDGL (Rezdiffra)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05648214",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Alnylam-partnered siRNA; Phase 1/2a recorded once as Phase 2. inferred from CT.gov primary completion 2027-08-10 (NCT05648214); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05648214",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0946",
  "guidance_detail": "Alnylam-partnered siRNA; Phase 1/2a recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Nezastomig (REGN5678)",
  "indication": "Metastatic castration-resistant prostate cancer; clear-cell renal cell carcinoma",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "NVS (Pluvicto)",
   "JNJ (pasritamig, PSMAxCD3)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03972657",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "PSMAxCD28 costimulatory bispecific with or without cemiplimab; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-11-15 (NCT03972657); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT03972657",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0948",
  "guidance_detail": "PSMAxCD28 costimulatory bispecific with or without cemiplimab; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "REGN5093",
  "indication": "MET-altered advanced non-small cell lung cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (telisotuzumab vedotin)",
   "NVS (Tabrecta/capmatinib)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04077099",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "METxMET bispecific; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-07-06 (NCT04077099); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04077099",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0949",
  "guidance_detail": "METxMET bispecific; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "REGN7075 + cemiplimab/chemotherapy",
  "indication": "Perioperative non-small cell lung cancer (platform study)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "MRK (Keytruda)",
   "BMY (Opdivo)",
   "AZN (Imfinzi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06465329",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Randomized Phase 2 perioperative platform study. inferred from CT.gov primary completion 2027-05-20 (NCT06465329); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06465329",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0951",
  "guidance_detail": "Randomized Phase 2 perioperative platform study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Ubamatamab (REGN4018)",
  "indication": "Recurrent ovarian, fallopian tube, peritoneal and endometrial cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Elahere/mirvetuximab)",
   "MRK (Keytruda)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT03564340",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "MUC16xCD3 bispecific alone or with cemiplimab; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-05-10 (NCT03564340); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT03564340",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0952",
  "guidance_detail": "MUC16xCD3 bispecific alone or with cemiplimab; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Vonsetamig",
  "indication": "Kidney transplant desensitization in chronic kidney disease patients",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "Hansa Biopharma (imlifidase)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05092347",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "BCMAxCD3 bispecific desensitization proof-of-concept; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-11-22 (NCT05092347); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05092347",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0953",
  "guidance_detail": "BCMAxCD3 bispecific desensitization proof-of-concept; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "REPL",
  "company": "Replimune Group, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "RP2",
  "indication": "Hepatocellular carcinoma and biliary tract cancer (2L combinations)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "EXEL (Cabometyx)",
   "BAYRY (Stivarga)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05733598",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Oncolytic immunotherapy with 2L systemic therapy or as monotherapy. inferred from CT.gov primary completion 2027-12-01 (NCT05733598); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05733598",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0954",
  "guidance_detail": "Oncolytic immunotherapy with 2L systemic therapy or as monotherapy.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for RP2 in Hepatocellular carcinoma and biliary tract cancer (2L combinations) are expected in Q4 2027, the first real efficacy signal for Replimune Group, Inc.'s program."
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Afimkibart (RO7790121)",
  "indication": "Moderate-to-severe rheumatoid arthritis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Rinvoq)",
   "LLY (Olumiant)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07137598",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Randomized, double-blind, placebo-controlled Phase 2. inferred from CT.gov primary completion 2027-04-17 (NCT07137598); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07137598",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0955",
  "guidance_detail": "Randomized, double-blind, placebo-controlled Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-1029"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Atezolizumab +/- bevacizumab",
  "indication": "Unresectable HCC with Child-Pugh B7/B8 cirrhosis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Imfinzi/Imjudo)",
   "MRK (Keytruda)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06096779",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Approved drugs tested in impaired-liver-function population. inferred from CT.gov primary completion 2027-07-30 (NCT06096779); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06096779",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0956",
  "guidance_detail": "Approved drugs tested in impaired-liver-function population.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Autogene cevumeran + nivolumab",
  "indication": "Adjuvant muscle-invasive urothelial (bladder) cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "MRNA (mRNA-4157/intismeran)",
   "BNTX (individualized neoantigen programs)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06534983",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Individualized neoantigen therapy + PD-1 vs nivolumab alone. inferred from CT.gov primary completion 2027-11-10 (NCT06534983); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06534983",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0957",
  "guidance_detail": "Individualized neoantigen therapy + PD-1 vs nivolumab alone.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Cevostamab",
  "indication": "Post-BCMA relapsed/refractory multiple myeloma",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "JNJ (Tecvayli)",
   "PFE (Elrexfio)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05535244",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "FcRH5xCD3 in prior BCMA-exposed patients; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-02-26 (NCT05535244); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05535244",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0958",
  "guidance_detail": "FcRH5xCD3 in prior BCMA-exposed patients; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Fenebrutinib (pediatric)",
  "indication": "Relapsing multiple sclerosis in children/adolescents (PK/PD)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "NVS (remibrutinib)",
   "SNY (tolebrutinib)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07161258",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Open-label pediatric PK/PD/safety study supporting potential pediatric filing. inferred from CT.gov primary completion 2027-06-08 (NCT07161258); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07161258",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0959",
  "guidance_detail": "Open-label pediatric PK/PD/safety study supporting potential pediatric filing.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "GDC-1261",
  "indication": "Advanced/metastatic prostate cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "NVS (Pluvicto)",
   "JNJ (Erleada/Zytiga)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07567846",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Dose-escalation and expansion; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-11-30 (NCT07567846); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07567846",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0960",
  "guidance_detail": "Dose-escalation and expansion; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Glofitamab (CRS optimization)",
  "indication": "Relapsed/refractory aggressive B-cell non-Hodgkin lymphoma",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Epkinco)",
   "GILD (Yescarta)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06806033",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Regimen/CRS-profile optimization study of approved CD20xCD3. inferred from CT.gov primary completion 2027-01-31 (NCT06806033); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06806033",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0961",
  "guidance_detail": "Regimen/CRS-profile optimization study of approved CD20xCD3.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0880"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Inavolisib combinations",
  "indication": "Early-stage breast cancer (neoadjuvant)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "NVS (alpelisib)",
   "AZN (capivasertib/Truqap)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07054190",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Neoadjuvant inavolisib with ribociclib, letrozole or giredestrant. inferred from CT.gov primary completion 2027-07-31 (NCT07054190); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07054190",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0962",
  "guidance_detail": "Neoadjuvant inavolisib with ribociclib, letrozole or giredestrant.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Morpheus-Liver (atezolizumab-based combinations)",
  "indication": "Advanced liver cancers (hepatocellular carcinoma)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Imfinzi + Imjudo)",
   "MRK (Keytruda)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04524871",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1b/2 umbrella study; combinations include tiragolumab, tovemstomig, TPST-1120; recorded once as Phase 2. inferred from CT.gov primary completion 2027-07-30 (NCT04524871); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04524871",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0963",
  "guidance_detail": "Phase 1b/2 umbrella study; combinations include tiragolumab, tovemstomig, TPST-1120; recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Mosunetuzumab (SC)",
  "indication": "Select B-cell non-Hodgkin lymphomas",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Epkinco)",
   "GILD (Yescarta)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05207670",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Subcutaneous CD20xCD3 in expansion cohorts of an approved drug. inferred from CT.gov primary completion 2027-07-31 (NCT05207670); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05207670",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0964",
  "guidance_detail": "Subcutaneous CD20xCD3 in expansion cohorts of an approved drug.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0880"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Petrelintide + enicepatide",
  "indication": "Obesity/overweight (dose-finding)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "NVO (CagriSema)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07589686",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Amylin-analog combination dose-finding; study not yet recruiting - timeline is aggressive. inferred from CT.gov primary completion 2027-11-12 (NCT07589686); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT07589686",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0965",
  "guidance_detail": "Amylin-analog combination dose-finding; study not yet recruiting - timeline is aggressive.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-1004"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7247669 (PD1-LAG3)",
  "indication": "Advanced solid tumors (melanoma, NSCLC, esophageal SCC)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "BMY (Opdualag)",
   "MRK (Keytruda)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04140500",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-06-30 (NCT04140500); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04140500",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0966",
  "guidance_detail": "Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "RO7837195",
  "indication": "Ulcerative colitis",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "ABBV (Skyrizi)",
   "JNJ (Tremfya)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06979336",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Phase 2b induction study with active treatment extension; undisclosed mechanism. inferred from CT.gov primary completion 2027-08-25 (NCT06979336); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06979336",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0967",
  "guidance_detail": "Phase 2b induction study with active treatment extension; undisclosed mechanism.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "Trontinemab (RO7126209)",
  "indication": "Alzheimer's disease",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "LLY (Kisunla)",
   "BIIB (Leqembi)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04639050",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Brain-shuttle anti-amyloid; Phase 1b/2a MAD study recorded once as Phase 2; external commentary flags potential 2027 readout. inferred from CT.gov primary completion 2027-07-31 (NCT04639050); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04639050",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0968",
  "guidance_detail": "Brain-shuttle anti-amyloid; Phase 1b/2a MAD study recorded once as Phase 2; external commentary flags potential 2027 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": false,
  "drug": "ZN-A-1041",
  "indication": "HER2-positive advanced solid tumors / breast cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "AZN (Enhertu)",
   "NVS (Tukysa)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05593094",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "HER2-targeted TKI alone and with T-DM1/T-DXd/PHESGO; Phase 1/1b recorded once as Phase 2. inferred from CT.gov primary completion 2027-08-31 (NCT05593094); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05593094",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0969",
  "guidance_detail": "HER2-targeted TKI alone and with T-DM1/T-DXd/PHESGO; Phase 1/1b recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RLMD",
  "company": "Relmada Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "NDV-01",
  "indication": "Non-muscle-invasive bladder cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "competitors": [
   "JNJ (TAR-200)",
   "CGON (cretostimogene)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06663137",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Intravesical controlled-release gemcitabine + docetaxel kit; single-center study. inferred from CT.gov primary completion 2027-11 (NCT06663137); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06663137",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0970",
  "guidance_detail": "Intravesical controlled-release gemcitabine + docetaxel kit; single-center study.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for NDV-01 in Non-muscle-invasive bladder cancer are expected in Q4 2027, the first real efficacy signal for Relmada Therapeutics, Inc.'s program."
 },
 {
  "ticker": "RNTX",
  "company": "Rein Therapeutics, Inc. (formerly Aileron Therapeutics)",
  "country": "United States",
  "us_listed": true,
  "drug": "LTI-03",
  "indication": "idiopathic pulmonary fibrosis (IPF) \u2014 RENEW Phase 2",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "inferred",
  "competitors": [
   "Boehringer Ingelheim (nintedanib/Ofev, approved)",
   "Roche (pirfenidone/Esbriet, approved)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06968845",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-24",
  "notes": "inferred from CT.gov NCT06968845 (RENEW, sponsor Rein Therapeutics) PCD 2027-09-30; (ticker remapped ALRN\u2192RNTX on rename); Source quote (2026-09-20): Phase 2 study of LTI-03 in patients with idiopathic pulmonary fibrosis (NCT06968845) is recruiting with primary completion expected September 30, 2027.]",
  "us_tradable": true,
  "nct_id": "NCT06968845",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0971",
  "guidance_detail": "inferred from CT.gov NCT06968845 (RENEW, sponsor Rein Therapeutics) PCD 2027-09-30; (ticker remapped ALRN\u2192RNTX on rename); Source quote (2026-09-20): Phase 2 study of LTI-03 in patients with idiopathic pulmonary fibrosis (NCT06968845) is recruiting with primary completion expected September 30, 2027.].",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for LTI-03 in idiopathic pulmonary fibrosis (IPF) \u2014 RENEW Phase 2 are expected in Q3 2027, the first real efficacy signal for Rein Therapeutics, Inc. (formerly Aileron Therapeutics)'s program."
 },
 {
  "ticker": "RVMD",
  "company": "Revolution Medicines, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "Daraxonrasib (RMC-6236)",
  "indication": "RAS-mutant advanced solid tumors (NSCLC, CRC, PDAC)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "AMGN (Lumakras)",
   "BMY (Krazati)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT05379985",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Pan-RAS(ON) inhibitor; Phase 1/2 recorded once as Phase 2; closest approved competitors are KRAS G12C agents. inferred from CT.gov primary completion 2027-05-31 (NCT05379985); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT05379985",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0972",
  "guidance_detail": "Pan-RAS(ON) inhibitor; Phase 1/2 recorded once as Phase 2; closest approved competitors are KRAS G12C agents.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "RVMD",
  "company": "Revolution Medicines, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "RAS(ON) inhibitor combinations (NSCLC)",
  "indication": "RAS-mutant non-small cell lung cancer",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "MRK (Keytruda)",
   "AMGN (Lumakras)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06162221",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Platform study of RMC-6291/RMC-6236/RMC-9805 with pembrolizumab or chemo; Phase 1/2 recorded once as Phase 2. inferred from CT.gov primary completion 2027-06 (NCT06162221); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06162221",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0974",
  "guidance_detail": "Platform study of RMC-6291/RMC-6236/RMC-9805 with pembrolizumab or chemo; Phase 1/2 recorded once as Phase 2.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "ticker": "RYTM",
  "company": "Rhythm Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "RM-718 (bivamelagon)",
  "indication": "Hypothalamic obesity; Prader-Willi syndrome",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "inferred",
  "competitors": [
   "LLY (retatrutide)",
   "NVO (CagriSema)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT06239116",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-10-20",
  "notes": "Weekly MC4R agonist; Phase 1/2 recorded once as Phase 2; preliminary Phase 2 data were already released Aug 2026 - this PCD may reflect later portions. inferred from CT.gov primary completion 2027-05-07 (NCT06239116); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT06239116",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0975",
  "guidance_detail": "Weekly MC4R agonist; Phase 1/2 recorded once as Phase 2; preliminary Phase 2 data were already released Aug 2026 - this PCD may reflect later portions.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-20"
 },
 {
  "ticker": "SIGA",
  "company": "SIGA Technologies, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "TPOXX + JYNNEOS",
  "indication": "Smallpox (drug-vaccine interaction study)",
  "event_type": "readout",
  "phase": "2",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "competitors": [
   "BVNRY (JYNNEOS/Imvanex)",
   "EBS (ACAM2000)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT04957485",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-18",
  "notes": "Registry lists Phase 2 (title describes Phase 1-design drug-vaccine interaction study); supports TPOXX PEP label expansion. inferred from CT.gov primary completion 2027-01-01 (NCT04957485); registry completion does not guarantee data disclosure.",
  "us_tradable": true,
  "nct_id": "NCT04957485",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0976",
  "guidance_detail": "Registry lists Phase 2 (title describes Phase 1-design drug-vaccine interaction study); supports TPOXX PEP label expansion.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for TPOXX + JYNNEOS in smallpox (drug-vaccine interaction study) are expected in Q1 2027, the first real efficacy signal for SIGA Technologies, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Tzield/teplizumab (Sanofi/Provention Bio)",
   "Diamyd (Diamyd Medical)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Frexalimab",
  "event_type": "readout",
  "indication": "type 1 diabetes",
  "notes": "Phase 2 anti-CD40L monoclonal antibody to preserve endogenous insulin secretion vs placebo + insulin; active, not recruiting; PCD Apr 28 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06111586",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0977",
  "guidance_detail": "Phase 2 anti-CD40L monoclonal antibody to preserve endogenous insulin secretion vs placebo + insulin; active, not recruiting; PCD Apr 28 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-1010"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Darzalex Faspro/daratumumab SC (Johnson & Johnson)",
   "Empliciti/elotuzumab (Bristol Myers Squibb)"
  ],
  "country": "France",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Isatuximab SC (on-body delivery system)",
  "event_type": "readout",
  "indication": "multiple myeloma",
  "notes": "Phase 2 of subcutaneous isatuximab in combination with weekly carfilzomib backbone; recruiting; PCD Jan 8 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06356571",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0978",
  "guidance_detail": "Phase 2 of subcutaneous isatuximab in combination with weekly carfilzomib backbone; recruiting; PCD Jan 8 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Dupixent/dupilumab (Sanofi/Regeneron)",
   "Tezspire/tezepelumab (AstraZeneca/Amgen)",
   "Fasenra/benralizumab (AstraZeneca)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Lunsekimig (SAR443765)",
  "event_type": "readout",
  "indication": "high-risk asthma",
  "notes": "Phase 2 IL-13xTSLP Nanobody (VHH) vs placebo in adults with high-risk asthma; active, not recruiting; PCD Jun 21 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06676319",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0979",
  "guidance_detail": "Phase 2 IL-13xTSLP Nanobody (VHH) vs placebo in adults with high-risk asthma; active, not recruiting; PCD Jun 21 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Budesonide/Entocort (generic standard of care)",
   "Rezpegaldesleukin (Nektar)"
  ],
  "country": "France",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SAR444336",
  "event_type": "readout",
  "indication": "microscopic colitis",
  "notes": "Phase 2 of non-beta IL-2 Synthorin (pegylated IL-2) vs placebo; recruiting; PCD Apr 8 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07156175",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0980",
  "guidance_detail": "Phase 2 of non-beta IL-2 Synthorin (pegylated IL-2) vs placebo; recruiting; PCD Apr 8 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Sanofi",
  "competitors": [
   "Humira/adalimumab (AbbVie)",
   "Cosentyx/secukinumab (Novartis)",
   "Bimzelx/bimekizumab (UCB)"
  ],
  "country": "France",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SAR445399",
  "event_type": "readout",
  "indication": "hidradenitis suppurativa",
  "notes": "Sanofi SAR445399 (IL-1R3 mAb) Phase 2 in moderate-to-severe hidradenitis suppurativa vs placebo; RECRUITING, PCD 2027-09-22 (est), updated 2026-09-22. Related NCT07547436 (non-CF bronchiectasis) SUSPENDED for strategic/portfolio reasons (explicitly not safety) since 2026-07-29; not an HS trial.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07225569",
  "ticker": "SNY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07225569",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0981",
  "guidance_detail": "Sanofi SAR445399 (IL-1R3 mAb) Phase 2 in moderate-to-severe hidradenitis suppurativa vs placebo; RECRUITING, PCD 2027-09-22 (est), updated 2026-09-22.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Supernus Pharmaceuticals, Inc.",
  "competitors": [
   "Xcopri/cenobamate (SK Biopharmaceuticals)",
   "Briviact/brivaracetam (UCB)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SPN-817",
  "event_type": "readout",
  "indication": "focal-onset seizures (RENAISSANCE 2)",
  "notes": "Phase 2 double-blind placebo-controlled RENAISSANCE 2; synthetic extended-release huperzine A, a potent acetylcholinesterase inhibitor raising cortical acetylcholine; recruiting; PCD Aug 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06798896",
  "ticker": "SUPN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0982",
  "guidance_detail": "Phase 2 double-blind placebo-controlled RENAISSANCE 2; synthetic extended-release huperzine A, a potent acetylcholinesterase inhibitor raising cortical acetylcholine; recruiting; PCD Aug 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0983"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Supernus Pharmaceuticals, Inc.",
  "competitors": [
   "Fintepla/fenfluramine (UCB)",
   "Epidiolex/cannabidiol (Jazz Pharmaceuticals)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "SPN-817",
  "event_type": "readout",
  "indication": "treatment-resistant epilepsy",
  "notes": "Open-label Phase 2 safety/tolerability study in adults with treatment-resistant epilepsy; recruiting; PCD Dec 31 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05518578",
  "ticker": "SUPN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0983",
  "guidance_detail": "Open-label Phase 2 safety/tolerability study in adults with treatment-resistant epilepsy; recruiting; PCD Dec 31 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0982"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Spyre Therapeutics Inc.",
  "competitors": [
   "Humira/adalimumab (AbbVie)",
   "Cosentyx/secukinumab (Novartis)",
   "Bimzelx/bimekizumab (UCB)",
   "Duvakitug (Sanofi, anti-TL1A class peer)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "SPY072",
  "event_type": "readout",
  "indication": "hidradenitis suppurativa",
  "notes": "Phase 2 anti-TL1A monoclonal antibody vs placebo vs bimekizumab in moderate-to-severe HS; not yet recruiting; PCD Oct 2027; company also advancing SPY072 in RA (readout expected 2026) \u2014 verify indication linkage on refresh. Source note: upgraded inferred->guidance; company release guides SPY072 topline late 2027 or early 2028, within the row Q4 window.\n[2026-09-23 primary-source upgrade] Direct GlobeNewswire company PR: 'site activation has begun with topline Week 16 HiSCR75 data planned for late 2027 or early 2028'. TIMING FLAG: row currently uses 2027-Q4 but source guidance is a cross-year 'late 2027 or early 2028' window; consider widening to 2027-H2 or a 2027/2028 split.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/10/3341779/0/en/spyre-therapeutics-announces-launch-of-spy772-program-and-initiation-of-phase-2-skylight-trial-in-hidradenitis-suppurativa.html",
  "ticker": "SYRE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0984",
  "guidance_detail": "Phase 2 anti-TL1A monoclonal antibody vs placebo vs bimekizumab in moderate-to-severe HS; not yet recruiting; PCD Oct 2027; company also advancing SPY072 in RA (readout expected 2026) \u2014 verify indication linkage on refresh.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "date_history": [
   {
    "from": "2027-Q4",
    "to": "2027-H2",
    "changed": "2026-09-23",
    "why": "Company PR: topline data planned for late 2027 or early 2028; bucket widened"
   }
  ],
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for SPY072 in hidradenitis suppurativa are expected in the second half of 2027, the first real efficacy signal for Spyre Therapeutics Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "Oveporexton/TAK-861 (Takeda)",
   "Wakix/pitolisant (Harmony Biosciences)",
   "Xywav/calcium-magnesium-potassium-sodium oxybates (Jazz Pharmaceuticals)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TAK-360",
  "event_type": "readout",
  "indication": "narcolepsy type 1 (with cataplexy)",
  "notes": "Phase 2 oral orexin-2 receptor agonist vs placebo; recruiting; PCD Nov 28 2027; company timeline also cites NT2/IH Phase 2b readouts across FY26/FY27 \u2014 verify indication linkage on refresh.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07633301",
  "ticker": "TAK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0985",
  "guidance_detail": "Phase 2 oral orexin-2 receptor agonist vs placebo; recruiting; PCD Nov 28 2027; company timeline also cites NT2/IH Phase 2b readouts across FY26/FY27 \u2014 verify indication linkage on refresh.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "Vyvgart Hytrulo/efgartigimod (argenx)",
   "Hizentra (CSL Behring)",
   "Gammagard (Takeda)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TAK-411",
  "event_type": "readout",
  "indication": "chronic inflammatory demyelinating polyneuropathy (CIDP)",
  "notes": "Open-label Phase 2 of hypersialylated immune globulin G with week-24 functional-improvement endpoint; 36-participant study; recruiting; PCD Dec 2 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06798012",
  "ticker": "TAK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0986",
  "guidance_detail": "Open-label Phase 2 of hypersialylated immune globulin G with week-24 functional-improvement endpoint; 36-participant study; recruiting; PCD Dec 2 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Takeda Pharmaceutical Company Limited",
  "competitors": [
   "Activase/alteplase (Genentech)",
   "Tenecteplase (Genentech)"
  ],
  "country": "Japan",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TAK-755",
  "event_type": "readout",
  "indication": "acute ischemic stroke",
  "notes": "Phase 2 recombinant ADAMTS13 vs placebo; recruiting; PCD Dec 6 2027; Takeda discontinued TAK-755 in immune TTP for strategic reasons but stroke trial continues per pipeline.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07392450",
  "ticker": "TAK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0987",
  "guidance_detail": "Phase 2 recombinant ADAMTS13 vs placebo; recruiting; PCD Dec 6 2027; Takeda discontinued TAK-755 in immune TTP for strategic reasons but stroke trial continues per pipeline.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Tectonic Therapeutic, Inc.",
  "competitors": [
   "Yutrepia (Liquidia)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TX45 (APEX)",
  "event_type": "readout",
  "indication": "pulmonary hypertension with HFpEF (PH-HFpEF)",
  "notes": "Phase 2 topline guided early Q1 2027; v1.1 tracked TX45 under legacy ticker AVRO, re-keyed to TECX post-merger",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/tectonic-therapeutic-completes-enrollment-in-tx45-apex-phase-2-clinical-trial-in-ph-hfpef-patients",
  "ticker": "TECX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0988",
  "guidance_detail": "Phase 2 topline guided early Q1 2027; v1.1 tracked TX45 under legacy ticker AVRO, re-keyed to TECX post-merger.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for TX45 (APEX) in pulmonary hypertension with HFpEF (PH-HFpEF) are expected in Q1 2027, the first real efficacy signal for Tectonic Therapeutic, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Teva Pharmaceutical Industries Limited",
  "competitors": [
   "Lu AF82422 (Lundbeck)",
   "Northera/droxidopa (Lundbeck, symptomatic)"
  ],
  "country": "Israel",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TEV-56286 (emrusolmin)",
  "event_type": "readout",
  "indication": "multiple system atrophy",
  "notes": "Phase 2 of oral small molecule targeting early amyloidogenic/alpha-synuclein oligomers to inhibit alpha-synuclein aggregation; FDA Fast Track designation for MSA (Jan 2025); recruiting; PCD Sep 15 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06568237",
  "ticker": "TEVA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0989",
  "guidance_detail": "Phase 2 of oral small molecule targeting early amyloidogenic/alpha-synuclein oligomers to inhibit alpha-synuclein aggregation; FDA Fast Track designation for MSA (Jan 2025); recruiting; PCD Sep 15 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0814"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Tharimmune, Inc.",
  "competitors": [
   "Livdelzi/seladelpar (Gilead)",
   "Bylvay/odevixibat (Ipsen)",
   "Livmarli/maralixibat (Mirum)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TH104 (nalmefene buccal film)",
  "event_type": "readout",
  "indication": "pruritus in primary biliary cholangitis",
  "notes": "Phase 2 transmucosal buccal film with nalmefene (dual mu/kappa opioid receptor mechanism), designed to avoid first-pass metabolism; not yet recruiting; PCD Mar 1 2027.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06733519",
  "ticker": "THAR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0990",
  "guidance_detail": "Phase 2 transmucosal buccal film with nalmefene (dual mu/kappa opioid receptor mechanism), designed to avoid first-pass metabolism; not yet recruiting; PCD Mar 1 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for TH104 (nalmefene buccal film) in pruritus in primary biliary cholangitis are expected in Q1 2027, the first real efficacy signal for Tharimmune, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Tiziana Life Sciences LTD",
  "competitors": [
   "Alterity Therapeutics (ATH434, MSA)",
   "Ionis Pharmaceuticals / AstraZeneca (ION717, MSA antisense)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Foralumab (intranasal anti-CD3)",
  "event_type": "readout",
  "indication": "Multiple system atrophy (Phase 2a)",
  "notes": "Registry-inferred: Tiziana-sponsored Phase 2a study (NCT06868628, recruiting) has PCD 2027-04-01; no company 2027 readout guidance located.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06868628",
  "ticker": "TLSA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06868628",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0991",
  "guidance_detail": "Registry-inferred: Tiziana-sponsored Phase 2a study (NCT06868628, recruiting) has PCD 2027-04-01; no company 2027 readout guidance located.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0992"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Foralumab (intranasal anti-CD3) in Multiple system atrophy (Phase 2a) are expected in Q2 2027, the first real efficacy signal for Tiziana Life Sciences LTD's program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Tiziana Life Sciences LTD",
  "competitors": [
   "Ionis / Biogen (tofersen, SOD1-ALS)",
   "Amylyx Pharmaceuticals (AMX0035)",
   "Denali Therapeutics (DNL343, ALS)"
  ],
  "country": "United Kingdom",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Foralumab (intranasal anti-CD3)",
  "event_type": "readout",
  "indication": "Amyotrophic lateral sclerosis (BANYAN ALS MyMatch trial)",
  "notes": "Registry-inferred: Tiziana-sponsored Phase 2 BANYAN trial (NCT07688239, not yet recruiting) has PCD 2027-07; no company 2027 readout guidance located.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07688239",
  "ticker": "TLSA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07688239",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0992",
  "guidance_detail": "Registry-inferred: Tiziana-sponsored Phase 2 BANYAN trial (NCT07688239, not yet recruiting) has PCD 2027-07; no company 2027 readout guidance located.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0991"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for Foralumab (intranasal anti-CD3) in Amyotrophic lateral sclerosis (BANYAN ALS MyMatch trial) are expected in Q3 2027, the first real efficacy signal for Tiziana Life Sciences LTD's program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Taysha Gene Therapies, Inc.",
  "competitors": [
   "Passage Bio (PBGM01, GM2 gangliosidosis gene therapy)",
   "IntraBio (IB1001, GM2 gangliosidosis)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "TSHA-101",
  "event_type": "readout",
  "indication": "Infantile GM2 gangliosidosis (Phase 1/2 gene therapy)",
  "notes": "Registry-inferred: first-in-human Phase 1/2 study (NCT04798235, investigator-sponsored, Taysha collaborator, active not recruiting) has PCD 2027-03-12; Taysha's company guidance focuses on TSHA-102 Rett program instead.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04798235",
  "ticker": "TSHA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT04798235",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0993",
  "guidance_detail": "Registry-inferred: first-in-human Phase 1/2 study (NCT04798235, investigator-sponsored, Taysha collaborator, active not recruiting) has PCD 2027-03-12; Taysha's company guidance focuses on TSHA-102 Rett program instead.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for TSHA-101 in Infantile GM2 gangliosidosis (Phase 1/2 gene therapy) are expected in Q1 2027, the first real efficacy signal for Taysha Gene Therapies, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Travere Therapeutics, Inc.",
  "competitors": [
   "Novartis (atrasentan/Vanrafia, endothelin receptor antagonist)",
   "Calliditas Therapeutics (Tarpeyo, IgAN)",
   "Otsuka Pharmaceutical (sibeprenlimab, IgAN)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Sparsentan",
  "event_type": "readout",
  "indication": "Pediatric proteinuric glomerular diseases (FSGS, minimal change disease)",
  "notes": "Registry-inferred: Travere-sponsored Phase 2 pediatric study (NCT05003986, recruiting) has PCD 2027-03-12; no company 2027 readout guidance located.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05003986",
  "ticker": "TVTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05003986",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0994",
  "guidance_detail": "Registry-inferred: Travere-sponsored Phase 2 pediatric study (NCT05003986, recruiting) has PCD 2027-03-12; no company 2027 readout guidance located.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "United Therapeutics Corporation",
  "competitors": [
   "Liquidia (Yutrepia, inhaled treprostinil)",
   "Gossamer Bio (seralutinib, pulmonary hypertension)",
   "Merck (Winrevair, PAH)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "Inhaled treprostinil (Tyvaso nebulizer)",
  "event_type": "readout",
  "indication": "COPD with hypoxemia (investigator-initiated Phase 2)",
  "notes": "Registry-inferred: investigator-sponsored Phase 2 (NCT07037836, recruiting, United Therapeutics collaborator) has PCD 2027-07-01; no company 2027 readout guidance located.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07037836",
  "ticker": "UTHR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07037836",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0995",
  "guidance_detail": "Registry-inferred: investigator-sponsored Phase 2 (NCT07037836, recruiting, United Therapeutics collaborator) has PCD 2027-07-01; no company 2027 readout guidance located.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Vertex Pharmaceuticals Incorporated",
  "competitors": [
   "Otsuka Pharmaceutical (tolvaptan/Jynarque, ADPKD standard of care)",
   "Regulus Therapeutics (RGLS8429, ADPKD)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VX-407",
  "event_type": "readout",
  "indication": "Autosomal dominant polycystic kidney disease (AGLOW Phase 2a)",
  "notes": "Registry-inferred: Vertex-sponsored Phase 2 AGLOW study (NCT07161037, active not recruiting) has PCD 2027-07-22; company guides enrollment/dosing ongoing, no 2027 data window stated. Source note: date moved Jul->Dec 2027 per registry-derived listing; live CT.gov fetch blocked,. Timing is rechecked in the monthly refresh. Source note: Timing note: inferred bucket 2027-Q4 conflicts with registry primary-completion quarter (PCD 2027-07-22); topline timing may differ from the bucket. Registry timing to be reconfirmed before the window.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07161037",
  "ticker": "VRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07161037",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0996",
  "guidance_detail": "Registry-inferred: Vertex-sponsored Phase 2 AGLOW study (NCT07161037, active not recruiting) has PCD 2027-07-22; company guides enrollment/dosing ongoing, no 2027 data window stated.",
  "audit_status": "v20_reverified",
  "audit_action": "quarter_mismatch_flag",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Renal/Urology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Vertex Pharmaceuticals Incorporated",
  "competitors": [
   "Vertex (suzetrigine/Journavx, NaV1.8 inhibitor, internal)",
   "Latigo Biotherapeutics (LTG-001, NaV1.8)",
   "Algiax Pharmaceuticals (GAT100)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VX-993",
  "event_type": "readout",
  "indication": "Diabetic peripheral neuropathic pain (NaV1.8 inhibitor)",
  "notes": "Registry-inferred: Vertex-sponsored Phase 2 study (NCT06619860, recruiting) has PCD 2027-03-25; Jan 2026 company update confirmed trial ongoing, no 2027 readout window stated.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06619860",
  "ticker": "VRTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06619860",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0997",
  "guidance_detail": "Registry-inferred: Vertex-sponsored Phase 2 study (NCT06619860, recruiting) has PCD 2027-03-25; Jan 2026 company update confirmed trial ongoing, no 2027 readout window stated.",
  "audit_status": "v18_reverified",
  "audit_action": "nct-cleanup",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-18",
  "company": "Verastem, Inc.",
  "competitors": [
   "Revolution Medicines (RMC-9805/RMC-6236, RAS inhibitors)",
   "Astellas Pharma (ASP3082, KRAS G12D degrader)",
   "Boehringer Ingelheim (BI 1823911, pan-KRAS)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VS-7375 (oral KRAS G12D ON/OFF inhibitor)",
  "event_type": "readout",
  "indication": "KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (TARGET-D 201)",
  "notes": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 201 (NCT07644559, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07644559",
  "ticker": "VSTM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07644559",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0998",
  "guidance_detail": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 201 (NCT07644559, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1000",
   "v16-0999"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for VS-7375 (oral KRAS G12D ON/OFF inhibitor) in KRAS G12D-mutated metastatic pancreatic ductal adenocarcinoma (TARGET-D 201) are expected in Q2 2027, the first real efficacy signal for Verastem, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Verastem, Inc.",
  "competitors": [
   "Revolution Medicines (RMC-9805/RMC-6236, RAS inhibitors)",
   "Astellas Pharma (ASP3082, KRAS G12D degrader)",
   "Boehringer Ingelheim (BI 1823911, pan-KRAS)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VS-7375 (oral KRAS G12D ON/OFF inhibitor)",
  "event_type": "readout",
  "indication": "KRAS G12D-mutated advanced non-small cell lung cancer (TARGET-D 202)",
  "notes": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 202 (NCT07659782, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07659782",
  "ticker": "VSTM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07659782",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-0999",
  "guidance_detail": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 202 (NCT07659782, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1000",
   "v16-0998"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for VS-7375 (oral KRAS G12D ON/OFF inhibitor) in KRAS G12D-mutated advanced non-small cell lung cancer (TARGET-D 202) are expected in Q2 2027, the first real efficacy signal for Verastem, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Verastem, Inc.",
  "competitors": [
   "Revolution Medicines (RMC-9805/RMC-6236, RAS inhibitors)",
   "Astellas Pharma (ASP3082, KRAS G12D degrader)",
   "Boehringer Ingelheim (BI 1823911, pan-KRAS)"
  ],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "VS-7375 (oral KRAS G12D ON/OFF inhibitor)",
  "event_type": "readout",
  "indication": "KRAS G12D-mutated metastatic colorectal cancer (TARGET-D 203)",
  "notes": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 203 (NCT07659795, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07659795",
  "ticker": "VSTM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07659795",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1000",
  "guidance_detail": "Registry-inferred: Verastem-sponsored Phase 2 TARGET-D 203 (NCT07659795, recruiting) has PCD 2027-06; company data updates guided for Oct 2026 only.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-0999",
   "v16-0998"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for VS-7375 (oral KRAS G12D ON/OFF inhibitor) in KRAS G12D-mutated metastatic colorectal cancer (TARGET-D 203) are expected in Q2 2027, the first real efficacy signal for Verastem, Inc.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Vaxart, Inc.",
  "competitors": [
   "Pfizer/BioNTech (Comirnaty)",
   "Moderna (Spikevax)",
   "Novavax (Nuvaxovid)"
  ],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "VXA-CoV2-3.3 (oral tablet COVID-19 vaccine)",
  "event_type": "readout",
  "indication": "COVID-19",
  "notes": "Topline efficacy/safety from ~5,000-person cohort guided H1 2027 (Q2 2026 PR); registry NCT06672055 primary completion May 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/06/3340721/0/en/vaxart-provides-business-update-and-reports-second-quarter-2026-financial-results.html",
  "ticker": "VXRT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06672055",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1001",
  "guidance_detail": "Topline efficacy/safety from ~5,000-person cohort guided H1 2027 (Q2 2026 PR); registry NCT06672055 primary completion May 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for VXA-CoV2-3.3 (oral tablet COVID-19 vaccine) in COVID-19 are expected in the first half of 2027, the first real efficacy signal for Vaxart, Inc.'s program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Wave Life Sciences Ltd.",
  "competitors": [
   "Eli Lilly (retatrutide)",
   "Amgen (maridebart cafraglutide)",
   "Roche/Zealand (petrelintide)"
  ],
  "country": "Singapore",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "WVE-007 (INHBE-targeting siRNA)",
  "event_type": "readout",
  "indication": "Obesity",
  "notes": "INLIGHT Phase 1/2a (NCT06842186) recruiting; estimated primary completion Dec 2027; Phase 2a includes 12-month assessments. Phase 1 data were guided for H2 2026 \u2014 not duplicated.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06842186",
  "ticker": "WVE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06842186",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1002",
  "guidance_detail": "INLIGHT Phase 1/2a (NCT06842186) recruiting; estimated primary completion Dec 2027; Phase 2a includes 12-month assessments.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for WVE-007 (INHBE-targeting siRNA) in Obesity are expected in the second half of 2027, the first real efficacy signal for Wave Life Sciences Ltd.'s program."
 },
 {
  "as_of": "2026-10-01",
  "company": "Yarrow Bioscience, Inc.",
  "competitors": [
   "Immunovant (batoclimab/IMVT-1402)",
   "Amgen (teprotumumab)",
   "Viridian (veligrotug)"
  ],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "YB-101 (anti-TSHR antibody)",
  "event_type": "readout",
  "indication": "Graves' disease",
  "notes": "Phase 2a/2b trial in GD with/without TED; dosing underway; Phase 2a topline expected H2 2027. VYNE merged into Yarrow (now Nasdaq: YARW) July 2026.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260727317637/en/Yarrow-Bioscience-Announces-Closing-of-Merger-with-VYNE-Therapeutics-and-Initiation-of-Dosing-in-Phase-2a2b-Trial-of-YB-101-a-Potential-First-in-Class-Treatment-for-Graves-Disease-and-Thyroid-Eye-Disease",
  "ticker": "YARW",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1003",
  "guidance_detail": "Phase 2a/2b trial in GD with/without TED; dosing underway; Phase 2a topline expected H2 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-0822"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for YB-101 (anti-TSHR antibody) in Graves' disease are expected in the second half of 2027, the first real efficacy signal for Yarrow Bioscience, Inc.'s program."
 },
 {
  "as_of": "2026-09-23",
  "company": "Zealand Pharma A/S",
  "competitors": [
   "retatrutide (Eli Lilly)",
   "CagriSema (Novo Nordisk)",
   "eloralintide (Eli Lilly)"
  ],
  "country": "Denmark",
  "date_bucket": "2027-Q4",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "petrelintide + enicepatide (CT-388/RO7795068)",
  "event_type": "readout",
  "indication": "obesity/overweight",
  "notes": "Inferred from CT.gov primary completion (estimated) 2027-11-12 for NCT07589686 (Phase 2 dose-finding study of petrelintide co-administered with enicepatide, ~486 participants). Roche-run combination trial of Zealand-partnered petrelintide; no company 2027 readout guidance found.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07589686",
  "ticker": "ZLDPF",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT07589686",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1004",
  "guidance_detail": "Inferred from CT.gov primary completion (estimated) 2027-11-12 for NCT07589686 (Phase 2 dose-finding study of petrelintide co-administered with enicepatide, ~486 participants).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-0965"
  ],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 2 results for petrelintide + enicepatide (CT-388/RO7795068) in obesity/overweight are expected in Q4 2027, the first real efficacy signal for Zealand Pharma A/S's program."
 },
 {
  "as_of": "2026-09-18",
  "company": "Zai Lab Limited",
  "competitors": [
   "Amgen (tarlatamab)"
  ],
  "country": "China",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "zocilurtatug pelitecan (DLL3 ADC; formerly ZL-1310)",
  "event_type": "readout",
  "indication": "Selected solid tumors (incl. extrapulmonary neuroendocrine carcinomas)",
  "notes": "Phase 1b/2 in selected solid tumors (NCT06885281) recruiting; estimated primary completion Aug 2027; no company-guided 2027 readout. Distinct from captured zoci BLA filing.",
  "phase": "2",
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT06885281",
  "ticker": "ZLAB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06885281",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1005",
  "guidance_detail": "Phase 1b/2 in selected solid tumors (NCT06885281) recruiting; estimated primary completion Aug 2027; no company-guided 2027 readout.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [
   "v16-0231",
   "v16-0825"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "DMRA",
  "company": "Damora Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "DMR-001",
  "indication": "mutant calreticulin-driven essential thrombocythemia and myelofibrosis",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "INCA033989 (Incyte)",
   "ruxolitinib (Jakafi, Incyte)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/03/19/3259440/0/en/Damora-Therapeutics-Reports-Full-Year-2025-Financial-Results-and-Recent-Corporate-Highlights.html",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Phase 1/1b CLARITY-101 of anti-mutCALR mAb DMR-001; initial data guided 'beginning mid-2027' (Aug 2026 PRs); company is Galecto renamed Damora after Nov 2025 acquisition. Opened and fully verified: the Aug 5, 2026 Damora release carries a GLOBE NEWSWIRE dateline (Waltham, Mass.) and states 'Damora continues to expect to report initial data from the trial beginning mid-2027' for CLARITY-101 (DMR-001, Phase 1/1b). No standalone globenewswire.com page is indexed for the Aug 5 or Aug 10 releases despite multiple exact-headline searches; Damora IR page could not be located. Event itself fully corroborated.\n[2026-09-23 primary-source upgrade] Direct GlobeNewswire company PR (FY2025 results, 2026-03-19): '-- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 --'. Same guidance as the Aug 5, 2026 CLARITY-101 initiation PR (whose exact globenewswire.com article URL could not be recovered; only Intrado mirrors found).",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1006",
  "guidance_detail": "Phase 1/1b CLARITY-101 of anti-mutCALR mAb DMR-001; initial data guided 'beginning mid-2027' (Aug 2026 PRs); company is Galecto renamed Damora after Nov 2025 acquisition.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "MTVA",
  "company": "MetaVia Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "DA-1726",
  "indication": "obesity",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "survodutide (Boehringer Ingelheim/Zealand Pharma)",
   "pemvidutide (Altimmune)",
   "retatrutide (Eli Lilly)"
  ],
  "source_url": "https://www.prnewswire.com/news-releases/metavia-announces-preclinical-findings-supporting-biological-rationale-for-da-1726s-waist-circumference-reduction-302873244.html",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "24-week topline from Phase 1 Part 3 dose-titration study of dual oxyntomodulin analog DA-1726 in obese adults, guided Q1 2027 (Sept 2026 PR); company formerly NeuroBo Pharmaceuticals. Source quote (2026-09-20): We anticipate reporting 16-week topline data in the fourth quarter of this year, followed by 24-week topline results in the first quarter of 2027.]",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1007",
  "guidance_detail": "24-week topline from Phase 1 Part 3 dose-titration study of dual oxyntomodulin analog DA-1726 in obese adults, guided Q1 2027 (Sept 2026 PR); company formerly NeuroBo Pharmaceuticals.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "CLLS",
  "company": "Cellectis",
  "country": "France",
  "us_listed": true,
  "us_tradable": true,
  "drug": ".HEAL-101",
  "indication": "severe hypertriglyceridemia",
  "event_type": "readout",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "olezarsen (Tryngolza, Ionis Pharmaceuticals)",
   "plozasiran (Arrowhead Pharmaceuticals)",
   "volanesorsen (Waylivra, Ionis Pharmaceuticals)"
  ],
  "source_url": "https://www.cellectis.com/en/press/cellectis-announces-strategic-transformation-to-in-vivo-gene-editing-company/",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "Preliminary Phase 1 data for in vivo APOC3 base-editing candidate .HEAL-101, planned H2 2027 (Sept 14, 2026 strategic-pivot PR).",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1008",
  "guidance_detail": "Preliminary Phase 1 data for in vivo APOC3 base-editing candidate .HEAL-101, planned H2 2027 (Sept 14, 2026 strategic-pivot PR).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "NGNE",
  "company": "Neurogene Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "NGN-401",
  "indication": "Rett syndrome",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [
   "TSHA-102 (Taysha Gene Therapies)"
  ],
  "source_url": "https://www.businesswire.com/news/home/20260811540370/en/Neurogene-Reports-Second-Quarter-2026-Financial-Results-and-Highlights-Recent-Updates",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "Registrational trial (company does not formally call it Phase 3). Embolden registrational trial of NGN-401 gene therapy; company guides topline H2 2027 toward planned BLA (June 2026 PR); company calls it 'registrational', not formally Phase 3; competitor mapping to be confirmed at refresh. Source quote (2026-09-20): Report topline data from Embolden registrational trial in the second half of 2027.]. Registry note (2026-09-23): CT.gov now lists primary completion 2029-12 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "nct_id": "NCT05898620",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1009",
  "guidance_detail": "Registrational trial (company does not formally call it Phase 3).",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1033"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for NGN-401 in Rett syndrome is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Neurogene Inc. can file for approval."
 },
 {
  "ticker": "SNY",
  "company": "Sanofi",
  "country": "France",
  "us_listed": true,
  "us_tradable": true,
  "drug": "frexalimab",
  "indication": "relapsing multiple sclerosis",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "ocrelizumab (Ocrevus, RHHBY)",
   "ofatumumab (Kesimpta, NVS)",
   "ublituximab (Briumvi, TG Therapeutics)"
  ],
  "source_url": "https://files.quartr.com/reports/54057-2026-04-23-05-31-32.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=",
  "source_type": "company PR",
  "as_of": "2026-09-18",
  "notes": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Sanofi Q1 2026 pipeline moved frexalimab relapsing-MS regulatory submission to H2 2026 (from 2027); a standard ~12-month review would imply an H2 2027 FDA decision window; inferred from submission timing only \u2014 re-verify at monthly refresh. Per Caleb's 2026-09-20 directive, Quartr-hosted reports are legitimate for this row; no URL change.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1010",
  "guidance_detail": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (per evidence rules, a PDUFA date requires an FDA acceptance letter): Sanofi Q1 2026 pipeline moved frexalimab relapsing-MS regulatory submission to H2 2026 (from 2027); a standard ~12-month review would imply an H2 2027 FDA decision window; inferred from submission timing only \u2014 re-verify at monthly refresh.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "VERA",
  "company": "Vera Therapeutics",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "TRUTAKNA (atacicept-vymj)",
  "indication": "IgA nephropathy \u2014 full approval",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "sparsentan (Filspari, TVTX)",
   "iptacopan (Fabhalta, NVS)",
   "budesonide (Tarpeyo, Calliditas)"
  ],
  "source_url": "https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-announces-trutaknatm-atacicept-vymj-stabilized",
  "source_type": "company IR",
  "as_of": "2026-10-01",
  "notes": "Accelerated approval July 7, 2026; Q4 2026 sBLA guided for full approval; FDA decision expected 2027; timing inferred from standard review, re-verify at monthly refresh. Source note: sponsor CEO (Sep 15 2026 release): \"We plan to submit the supplemental BLA in the fourth quarter of this year. We look forward to the potential full approval of TRUTAKNA in 2027.\" Half-year precision not sponsor-stated; window broadened from inferred 2027-H2 to guidance 2027.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-09-15",
  "record_id": "v16-1011",
  "guidance_detail": "Accelerated approval July 7, 2026; Q4 2026 sBLA guided for full approval; FDA decision expected 2027; timing inferred from standard review, re-verify at monthly refresh.",
  "audit_status": "v20_reverified",
  "audit_action": "inferred_to_guidance",
  "date_history": [
   {
    "from": "2027-H2",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Upgrade inferred->guidance: sponsor CEO guides potential full approval in 2027; window broadened"
   }
  ],
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Vera Therapeutics plans to file its supplemental application for full approval of TRUTAKNA (atacicept) in IgA nephropathy in Q4 2026, with an FDA decision expected in 2027."
 },
 {
  "ticker": "BLTE",
  "company": "Belite Bio, Inc",
  "drug": "Tinlarebant",
  "indication": "Stargardt disease type 1",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-12",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/11/3343136/0/en/belite-bio-announces-u-s-food-and-drug-administration-acceptance-and-priority-review-of-new-drug-application-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1.html",
  "notes": "FDA accepted NDA and granted Priority Review for tinlarebant in Stargardt disease type 1; PDUFA date 2027-02-12 per Aug 11, 2026 company PR. Potential first approved therapy for STGD1; no approved therapies exist. [Source verified 2026-09-20: U.S. Food and Drug Administration accepted the New Drug Application with Priority Review for tinlarebant for the treatment of Stargardt disease type 1; Prescription Drug User Fee Act target action date of February 12, 20] [2026-09-24] Source upgraded to the Aug 11, 2026 GlobeNewswire company release: FDA acceptance plus Priority Review confirmed; no Advisory Committee meeting planned. PDUFA 2027-02-12 re-confirmed.",
  "competitors": [],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-24",
  "nct_id": "",
  "application_type": "",
  "review_class": "priority",
  "adcom_planned": "no",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1012",
  "guidance_detail": "FDA accepted NDA and granted Priority Review for tinlarebant in Stargardt disease type 1; PDUFA date 2027-02-12 per Aug 11, 2026 company PR.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on tinlarebant for Stargardt disease type 1 falls on 2027-02-12 \u2014 the agency's yes-or-no moment for Belite Bio, Inc.'s application."
 },
 {
  "ticker": "GSK",
  "company": "GSK plc",
  "drug": "dostarlimab (Jemperli)",
  "indication": "dMMR/MSI-H locally advanced rectal cancer (AZUR-1)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "source_type": "company PR",
  "source_url": "https://us.gsk.com/en-us/media/press-releases/jemperli-dostarlimab-gxly-accepted-for-priority-review-by-the-us-fda/",
  "notes": "FDA accepted sBLA for Priority Review for dostarlimab in dMMR/MSI-H locally advanced rectal cancer supported by the AZUR-1 trial; PDUFA expected February 2027 (no exact day given) per GSK Aug 24, 2026 PR.",
  "competitors": [
   "Keytruda (Merck)"
  ],
  "country": "United Kingdom",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-24",
  "nct_id": "",
  "application_type": "",
  "review_class": "priority",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1013",
  "guidance_detail": "FDA accepted sBLA for Priority Review for dostarlimab in dMMR/MSI-H locally advanced rectal cancer supported by the AZUR-1 trial; PDUFA expected February 2027 (no exact day given) per GSK Aug 24, 2026 PR.",
  "audit_status": "v16_verified",
  "audit_action": "source-repair",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v16-0895"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "RNAC",
  "company": "Cartesian Therapeutics, Inc.",
  "drug": "Descartes-08 (AURORA)",
  "indication": "generalized myasthenia gravis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/26/3300928/0/en/Cartesian-Therapeutics-Secures-up-to-150-Million-of-Non-Dilutive-Financing-from-K2-HealthVentures-and-Expects-Topline-Data-from-the-Phase-3-AURORA-Trial-in-First-Quarter-2027.html",
  "notes": "Topline data from the randomized, double-blind, placebo-controlled Phase 3 AURORA trial of Descartes-08 (autologous mRNA CAR-T, six weekly infusions) in myasthenia gravis expected 1Q27 per May 26, 2026 company PR.",
  "competitors": [
   "Vyvgart (argenx)",
   "Ultomiris (AstraZeneca)",
   "Rystiggo (UCB)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-23",
  "nct_id": "NCT06799247",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1014",
  "guidance_detail": "Topline data from the randomized, double-blind, placebo-controlled Phase 3 AURORA trial of Descartes-08 (autologous mRNA CAR-T, six weekly infusions) in myasthenia gravis expected 1Q27 per May 26, 2026 company PR.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-1015",
   "v16-0557",
   "v16-0221",
   "v16-0209",
   "v16-0154"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for Descartes-08 (AURORA) in generalized myasthenia gravis is expected in Q1 2027 \u2014 the pivotal readout that determines whether Cartesian Therapeutics, Inc. can file for approval."
 },
 {
  "ticker": "RNAC",
  "company": "Cartesian Therapeutics, Inc.",
  "drug": "Descartes-08",
  "indication": "generalized myasthenia gravis",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/26/3300928/0/en/Cartesian-Therapeutics-Secures-up-to-150-Million-of-Non-Dilutive-Financing-from-K2-HealthVentures-and-Expects-Topline-Data-from-the-Phase-3-AURORA-Trial-in-First-Quarter-2027.html",
  "notes": "REGULATORY WATCH \u2014 Cartesian guides BLA filing for Descartes-08 in gMG for mid-2027 (per May 26, 2026 PR); bucketed at the H1/H2 boundary. Filing contingent on positive AURORA topline.",
  "competitors": [
   "Vyvgart (argenx)",
   "Ultomiris (AstraZeneca)",
   "Rystiggo (UCB)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-10-01",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1015",
  "guidance_detail": "REGULATORY WATCH \u2014 Cartesian guides BLA filing for Descartes-08 in gMG for mid-2027 (per May 26, 2026 PR); bucketed at the H1/H2 boundary.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Cartesian Therapeutics, Inc. is expected to file its biologics license application for Descartes-08 in generalized myasthenia gravis in the second half of 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "VRTX",
  "company": "Vertex Pharmaceuticals Incorporated",
  "drug": "suzetrigine",
  "indication": "diabetic peripheral neuropathy (DPN)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "source_type": "trade press",
  "source_url": "https://transcriptdaily.com/2026/09/13/vertex-pharmaceuticals-maps-growth-beyond-cf-at-cantor-conference.html",
  "notes": "Vertex guides Phase 3 suzetrigine DPN readouts mid-2027 (SVP IR Susie Lisa, Sept 2026 Cantor Global Healthcare Conference, via transcriptdaily); Q2 2026 release stated enrollment in both Phase 3 DPN studies completes by end-2026. Bucketed at H1/H2 boundary. Oral NaV1.8 inhibitor. Re-bucketed 2027-H2 to 2027-H1 on 2026-09-20: Vertex SVP IR Susie Lisa at the Sept 2026 Cantor conference guided both Phase 3 DPN studies (12-week, enrollment completing end-2026) with data potentially available by mid-2027, per multiple trade outlets carrying the same company remarks. Vertex official Q2 2026 release confirms enrollment completion by end-2026 only and states no readout timing. Official Vertex Q2 2026 Business Wire release (opened and verified): both Phase 3 suzetrigine DPN studies on track to complete enrollment by end-2026 \u2014 no readout timing stated. The mid-2027 readout window comes from SVP IR Susie Lisa's remarks at the Sept 2026 Cantor conference via trade coverage. TIMING DISCREPANCY: current row is bucketed 2027-H2; company-derived coverage points to data by mid-2027 (H1), so the row appears to be one half too late \u2014 recommend re-bucketing to H1 2027. [2026-09-23: row covers one of two parallel Phase 3 DPN efficacy studies (NCT07231419); per-trial timing not separately guided; split from combined row.]",
  "competitors": [
   "Lyrica / gabapentin (generics, symptomatic care)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-23",
  "nct_id": "NCT07231419",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1016",
  "guidance_detail": "Vertex guides Phase 3 suzetrigine DPN readouts mid-2027 (SVP IR Susie Lisa, Sept 2026 Cantor Global Healthcare Conference, via transcriptdaily); Q2 2026 release stated enrollment in both Phase 3 DPN studies completes by end-2026.",
  "audit_status": "v17_reverified",
  "audit_action": "split",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0024"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "SGIOY",
  "company": "Shionogi & Co., Ltd.",
  "drug": "Fetroja (cefiderocol) \u2014 pediatric",
  "indication": "hospital-acquired / ventilator-associated bacterial pneumonia and complicated urinary tract infection (pediatric)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-23",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "source_type": "company PR",
  "source_url": "https://www.shionogi.com/content/dam/shionogi/global/news/pdf/2026/7%E6%9C%88/E_20260717_2.pdf",
  "notes": "FDA accepted sNDA for Fetroja (cefiderocol) in pediatric patients (at least 26 weeks gestational age) with HABP/VABP and cUTI; PDUFA date 2027-02-23 per Shionogi July 17, 2026 PR. SGIOY is the US ADR.",
  "competitors": [],
  "country": "Japan",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-24",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1017",
  "guidance_detail": "FDA accepted sNDA for Fetroja (cefiderocol) in pediatric patients (at least 26 weeks gestational age) with HABP/VABP and cUTI; PDUFA date 2027-02-23 per Shionogi July 17, 2026 PR.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Respiratory",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": null,
  "company": "LEO Pharma A/S",
  "drug": "dersimelagon",
  "indication": "erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "source_type": "company PR",
  "source_url": "https://leo-pharma.com/media-center/news/leo-pharma-announces-fda-acceptance-of-dersimelagon-nda-with-priority-review-and-closes-acquisition-from-tanabe-pharma/",
  "notes": "FDA accepted NDA for filing and granted Priority Review for dersimelagon, a potential first-in-class oral therapy for EPP/XLP; PDUFA action date by end of February 2027 (no exact day) per LEO Pharma Sept 18, 2026 PR. LEO is private (acquired worldwide rights from Tanabe Pharma, closed 2026-09-18); included per universe rules alongside other private-company PDUFAs.",
  "competitors": [
   "Scenesse (Clinuvel)"
  ],
  "country": "Denmark",
  "us_listed": false,
  "us_tradable": false,
  "as_of": "2026-09-24",
  "nct_id": "",
  "application_type": "",
  "review_class": "priority",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1018",
  "guidance_detail": "FDA accepted NDA for filing and granted Priority Review for dersimelagon, a potential first-in-class oral therapy for EPP/XLP; PDUFA action date by end of February 2027 (no exact day) per LEO Pharma Sept 18, 2026 PR.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "high",
  "related_events": [
   "v16-0688"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on dersimelagon for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) falls in Q1 2027 \u2014 the agency's yes-or-no moment for LEO Pharma A/S's application."
 },
 {
  "ticker": "RCUS",
  "company": "Arcus Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "quemliclustat (PRISM-1)",
  "indication": "first-line metastatic pancreatic ductal adenocarcinoma",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://investors.arcusbio.com/investors-and-media/press-releases/press-release-details/2026/Arcus-Biosciences-Reports-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Provides-a-Pipeline-Update/default.aspx",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "Phase 3 PRISM-1 (quemliclustat + gemcitabine/nab-paclitaxel vs placebo + gemcitabine/nab-paclitaxel) completed enrollment Sep 2025; company guided topline results H1 2027 per Q4/FY2025 results release. Added 2026-09-20 via PDF cross-check. Registry note (2026-09-23): CT.gov now lists primary completion 2030-11-30 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "us_tradable": true,
  "nct_id": "NCT06608927",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1019",
  "guidance_detail": "Phase 3 PRISM-1 (quemliclustat + gemcitabine/nab-paclitaxel vs placebo + gemcitabine/nab-paclitaxel) completed enrollment Sep 2025; company guided topline results H1 2027 per Q4/FY2025 results release.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for quemliclustat (PRISM-1) in first-line metastatic pancreatic ductal adenocarcinoma is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Arcus Biosciences, Inc. can file for approval."
 },
 {
  "ticker": "RCUS",
  "company": "Arcus Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "oral TNF/TNFR1 inhibitor",
  "indication": "undisclosed (first-in-human)",
  "event_type": "ind",
  "phase": "1",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.businesswire.com/news/home/20260805395862/en/Arcus-Biosciences-Reports-Second-Quarter-2026-Financial-Results-and-Provides-a-Pipeline-Update",
  "source_type": "company PR",
  "as_of": "2026-09-24",
  "notes": "Arcus guided entry into clinic in late 2026 or early 2027; an early-2027 IND clearance/Phase 1 initiation is inferred (guided window straddles 2026/2027 boundary). Added 2026-09-20 via PDF cross-check. Source note: upgraded inferred->guidance; company Q2 2026 PR guides oral TNFR1 clinic entry in early 2027.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1020",
  "guidance_detail": "Arcus guided entry into clinic in late 2026 or early 2027; an early-2027 IND clearance/Phase 1 initiation is inferred (guided window straddles 2026/2027 boundary).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "ticker": "IKT",
  "company": "Inhibikase Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "IKT-001 (IMPROVE-PAH Part A)",
  "indication": "pulmonary arterial hypertension",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.inhibikase.com/investors/sec-filings/all-sec-filings/content/0001193125-25-289768/0001193125-25-289768.pdf",
  "source_type": "SEC 8-K",
  "as_of": "2026-09-24",
  "notes": "Phase 3 IMPROVE-PAH (imatinib prodrug, two-part: Part A n=140 PVR, Part B n=346 6MWD); company projects an interim safety readout for Part A (n=50) in 1H 2027 per the May 2026 corporate deck (also filed as Exhibit 99.1 to an SEC 8-K). Part A PVR efficacy data projected mid-2028; Part B topline mid-2029 (out of scope). Registry note: CT.gov now lists primary completion 2029-06 (RECRUITING); calendar timing rests on company guidance, not the registry. [2026-09-27 link audit] Replaced access-denied CloudFront deck URL with the identical corporate presentation as Exhibit 99.1 to the Nov 20, 2025 8-K, hosted on inhibikase.com; states verbatim \"1H 2027 Interim Safety Readout for Part A of IMPROVE-PAH (n=50)\".",
  "us_tradable": true,
  "nct_id": "NCT07365332",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1021",
  "guidance_detail": "Phase 3 IMPROVE-PAH (prodrug of imatinib, two-part: Part A n=140 PVR, Part B n=346 6MWD); company projects interim safety readout for Part A (n=50) in 1H 2027 per May 2026 corporate deck.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-27",
  "why_it_matters": "Phase 3 data for IKT-001 (IMPROVE-PAH Part A) in pulmonary arterial hypertension is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Inhibikase Therapeutics, Inc. can file for approval."
 },
 {
  "ticker": "ZBIO",
  "company": "Zenas BioPharma",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "obexelimab",
  "indication": "IgG4-related disease (IgG4-RD)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-05-27",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "competitors": [
   "Uplizna (Amgen)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/09/08/3357503/0/en/zenas-biopharma-to-host-obexelimab-igg4-rd-investor-event.html",
  "source_type": "company PR",
  "as_of": "2026-10-01",
  "notes": "FDA accepted the BLA for obexelimab in IgG4-RD in Aug 2026 and assigned PDUFA target action date May 27, 2027 (standard review; no priority review announced). Backed by Phase 3 INDIGO (HR 0.44, p=0.0005). Competing: Amgen Uplizna (approved Apr 2025). Added 2026-09-20 via missing-PDUFA sweep.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1022",
  "guidance_detail": "FDA accepted the BLA for obexelimab in IgG4-RD in Aug 2026 and assigned PDUFA target action date May 27, 2027 (standard review; no priority review announced).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on obexelimab for IgG4-related disease (IgG4-RD) falls on 2027-05-27 \u2014 the agency's yes-or-no moment for Zenas BioPharma's application."
 },
 {
  "ticker": "BMRN",
  "company": "BioMarin Pharmaceutical Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "VOXZOGO (vosoritide)",
  "indication": "full (traditional) approval in children with achondroplasia",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-28",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "TransCon CNP (Ascendis Pharma)"
  ],
  "source_url": "https://www.biomarin.com/news/press-releases/u-s-food-and-drug-administration-accepts-biomarins-supplemental-new-drug-application-for-full-approval-of-voxzogo-vosoritide-for-children-with-achondroplasia/",
  "source_type": "company IR",
  "as_of": "2026-09-24",
  "notes": "FDA accepted the sNDA for full (traditional) approval of VOXZOGO in children with achondroplasia; PDUFA target action date Feb 28, 2027 (announced 2026-07-13). Would be the first accelerated-to-full conversion in achondroplasia. Added 2026-09-20 via missing-PDUFA sweep.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1023",
  "guidance_detail": "FDA accepted the sNDA for full (traditional) approval of VOXZOGO in children with achondroplasia; PDUFA target action date Feb 28, 2027 (announced 2026-07-13).",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "FLGT",
  "company": "Fulgent Genetics, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "FID-007 (nanoencapsulated paclitaxel) + cetuximab",
  "indication": "recurrent/metastatic head and neck squamous cell carcinoma (2L)",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.MarketBeat.com/earnings/reports/2026-2-27-fulgent-genetics-inc-stock/",
  "source_type": "earnings transcript",
  "as_of": "2026-09-20",
  "notes": "CEO guided Phase 3 initiation as early as H1 2027 on Q4 2025 earnings call (transcript via MarketBeat), reaffirmed on Q1 2026 call; EOP2 FDA meeting targeted H2 2026. Added 2026-09-20 from source-flag re-check. Phase 3 initiation 'as early as H1 2027' guided by the CEO on the Q4 2025 call and reaffirmed on Q1/Q2 2026 calls (MarketBeat transcripts). Corroborated by Fulgent's SEC-filed Q2 2026 deck: EOP2 FDA meeting confirmed 2H 2026, Phase 3 protocol development ongoing. No official document states the H1 2027 initiation timing. [2026-09-23 source check] MarketBeat transcript mirror returns 503 and is an aggregator (not citable per the evidence ladder); timing rests on the CEO's Q4 2025 earnings-call remarks. Needs browser re-source to the Quartr call transcript or Fulgent IR.",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1024",
  "guidance_detail": "CEO guided Phase 3 initiation as early as H1 2027 on Q4 2025 earnings call (transcript via MarketBeat), reaffirmed on Q1 2026 call; EOP2 FDA meeting targeted H2 2026.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Fulgent's CEO guides starting a Phase 3 trial of FID-007 plus cetuximab in recurrent/metastatic head and neck cancer as early as the first half of 2027."
 },
 {
  "as_of": "2026-09-24",
  "company": "Novo Nordisk A/S (efruxifermin via Akero Therapeutics acquisition, closed 2025-12-09)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "efruxifermin",
  "event_type": "readout",
  "indication": "MASH (SYNCHRONY Histology Phase 3)",
  "notes": "Novo Nordisk completed its acquisition of Akero Therapeutics on 2025-12-09 ($4.7B + $0.5B CVR; AKRO delisted); row remapped to the acquirer ticker NVO. SYNCHRONY Histology Phase 3 topline of efruxifermin in MASH still expected H1 2027. Source: company completion PR (akerotx.com, 2025-12-09). Akero corporate update (GlobeNewswire company release) states SYNCHRONY Histology Phase 3 topline expected H1 2027. Major MASH binary previously absent from the calendar. Registry note (2026-09-23): CT.gov now lists primary completion 2033-02 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2024/11/08/2977557/0/en/akero-therapeutics-reports-third-quarter-2024-financial-results-and-provides-business-update.html",
  "ticker": "NVO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06215716",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1025",
  "guidance_detail": "Akero corporate update (GlobeNewswire company release) states SYNCHRONY Histology Phase 3 topline expected H1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for efruxifermin in MASH (SYNCHRONY Histology Phase 3) is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Akero Therapeutics, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Roche Holding AG",
  "competitors": [],
  "country": "Switzerland",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "pegozafermin",
  "event_type": "readout",
  "indication": "MASH with fibrosis stage F2/F3 (ENLIGHTEN-Fibrosis Phase 3)",
  "notes": "89bio Q1 2025 company release guides ENLIGHTEN-Fibrosis histology data in H1 2027; Roche acquired 89bio (~$3.5B, ~Sep 2025) and its Apr 2026 pipeline deck still lists pegozafermin Phase 3 for MASH. Ticker RHHBY post-acquisition. Pairs with efruxifermin to complete the 2027 MASH histology catalyst set. Registry note (2026-09-23): CT.gov now lists primary completion 2029-02 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/05/01/3072831/0/en/89bio-Reports-First-Quarter-2025-Financial-Results-and-Corporate-Updates.html",
  "ticker": "RHHBY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06318169",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1026",
  "guidance_detail": "89bio Q1 2025 company release guides ENLIGHTEN-Fibrosis histology data in H1 2027; Roche acquired 89bio (~$3.5B, ~Sep 2025) and its Apr 2026 pipeline deck still lists pegozafermin Phase 3 for MASH.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "NewAmsterdam Pharma Company N.V.",
  "competitors": [],
  "country": "Netherlands",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "obicetrapib",
  "event_type": "readout",
  "indication": "atherosclerotic cardiovascular disease (PREVAIL CVOT interim)",
  "notes": "NewAmsterdam Q1 2026 corporate update (company release, also 8-K): interim analysis of the ~10,000-patient PREVAIL CVOT in Q4 2026 with results expected Q1 2027. A positive interim could stop the trial early - the defining CETP-inhibitor binary of 2027.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3289808/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-First-Quarter-Financial-Results.html",
  "ticker": "NAMS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05202509",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1027",
  "guidance_detail": "NewAmsterdam Q1 2026 corporate update (company release, also 8-K): interim analysis of the ~10,000-patient PREVAIL CVOT in Q4 2026 with results expected Q1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-1028"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for obicetrapib in atherosclerotic cardiovascular disease (PREVAIL CVOT interim) is expected in Q1 2027 \u2014 the pivotal readout that determines whether NewAmsterdam Pharma Company N.V. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "NewAmsterdam Pharma Company N.V.",
  "competitors": [],
  "country": "Netherlands",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "obicetrapib",
  "event_type": "readout",
  "indication": "atherosclerotic cardiovascular disease (PREVAIL CVOT final)",
  "notes": "Same company release: if PREVAIL does not stop early at the Q1 2027 interim, the company anticipates trial completion by end-2027. Conditional companion row to the interim readout.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/07/3289808/0/en/NewAmsterdam-Pharma-Provides-Corporate-Update-and-Reports-First-Quarter-Financial-Results.html",
  "ticker": "NAMS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05202509",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1028",
  "guidance_detail": "Same company release: if PREVAIL does not stop early at the Q1 2027 interim, the company anticipates trial completion by end-2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [
   "v16-1027"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for obicetrapib in atherosclerotic cardiovascular disease (PREVAIL CVOT final) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether NewAmsterdam Pharma Company N.V. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Roche Holding AG",
  "competitors": [],
  "country": "Switzerland",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "afimkibart",
  "event_type": "bla_filing",
  "indication": "ulcerative colitis",
  "notes": "Roche Group development pipeline deck (Apr 2026) lists RG6631 afimkibart (anti-TL1A) Phase 3 for ulcerative colitis; BioSpace reporting of Roche Q2 2025 earnings states Roche anticipates a UC regulatory filing in 2027. Confidence note: filing timing reaches us via trade press citing earnings - year-only bucket. Calendar previously carried afimkibart only for rheumatoid arthritis.",
  "phase": null,
  "source_type": "trade press",
  "source_url": "https://assets.roche.com/f/176343/x/b992aea799/irp260423-a.pdf",
  "ticker": "RHHBY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1029",
  "guidance_detail": "Roche Group development pipeline deck (Apr 2026) lists RG6631 afimkibart (anti-TL1A) Phase 3 for ulcerative colitis; BioSpace reporting of Roche Q2 2025 earnings states Roche anticipates a UC regulatory filing in 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-24",
  "company": "Arrowhead Pharmaceuticals, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "plozasiran",
  "event_type": "regulatory_other",
  "indication": "severe hypertriglyceridemia",
  "notes": "Company Dec 2026 release: FDA Breakthrough Therapy designation for plozasiran in sHTG; company anticipates sNDA submission before end-2026 and holds a priority review voucher (6-month review), implying an FDA decision ~mid-2027. Derived, not company-guided: NOT a PDUFA (no FDA acceptance letter) - kept as regulatory_other watch item per the PDUFA acceptance gate.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20251202987041/en/Arrowhead-Pharmaceuticals-Receives-FDA-Breakthrough-Therapy-Designation-for-Plozasiran-in-Severe-Hypertriglyceridemia",
  "ticker": "ARWR",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1030",
  "guidance_detail": "Company Dec 2026 release: FDA Breakthrough Therapy designation for plozasiran in sHTG; company anticipates sNDA submission before end-2026 and holds a priority review voucher (6-month review), implying an FDA decision ~mid-2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "NCCN 2027 Annual Congress: Hematologic Malignancies",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-17",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "NCCN's own event page: Friday Sep 17 - Saturday Sep 18, 2027, Sheraton Boston Hotel, Boston, MA. Organizer-confirmed. Distinct conference from ESMO Congress 2027 (separate event, separate organizer); shares only the start date 2027-09-17 \u2014 not a duplicate.",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://nccn.org/education-research/educational-events-and-programs/annual-congress-hematologic-malignancies",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1031",
  "guidance_detail": "NCCN's own event page: Friday Sep 17 - Saturday Sep 18, 2027, Sheraton Boston Hotel, Boston, MA.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "International Congress on Myelodysplastic Syndromes 2027 (MDS 2027)",
  "competitors": [],
  "country": "Germany",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-14",
  "date_quality": "hard",
  "drug": null,
  "event_type": "conference",
  "indication": null,
  "notes": "Official congress site (Kenes, the organizer/PCO): MDS 2027, 19th International Congress on Myelodysplastic Syndromes, Leipzig, Germany, opening Apr 14, 2027. Note: organizer page lists Apr 14-16 while congress flyer PDFs list Apr 14-17 - start date Apr 14 consistent; Close date to be reconfirmed with the organizer. Distinct conference from ISHLT Annual Meeting & Scientific Sessions 2027 (47th, International Society for Heart and Lung Transplantation) (separate event, separate organizer); shares only the start date 2027-04-14 \u2014 not a duplicate.\n[2026-09-23 conference re-source] URL unchanged: dedicated event page prints the 2027 dates; date confirmed hard. (Flyer variant prints end date 17 Apr; start 14 Apr agreed.)\n[2026-09-23 source review] organizer_dates_printed=True: dedicated organizer event site verified live 2026-09-23 to print the 2027 dates (not a bare homepage with no dates).",
  "phase": null,
  "source_type": "conference organizer",
  "source_url": "https://mds.kenes.com/",
  "ticker": null,
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1032",
  "guidance_detail": "Official congress site (Kenes, the organizer/PCO): MDS 2027, 19th International Congress on Myelodysplastic Syndromes, Leipzig, Germany, opening Apr 14, 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "organizer_dates_printed": true,
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Taysha Gene Therapies, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TSHA-102",
  "event_type": "readout",
  "indication": "Rett syndrome",
  "notes": "SEC-filed 8-K (Taysha Gene Therapies): REVEAL program of TSHA-102 in Rett syndrome - 6-month interim topline and FDA feedback expected 1H 2027.\n[2026-09-23 primary-source upgrade] 8-K Exhibit 99.1 (Taysha Q2 2026 PR): 'expect to report topline data from 6-month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027' for TSHA-102 REVEAL pivotal trial. Registry note (2026-09-23): CT.gov now lists primary completion 2031-06 (status ACTIVE_NOT_RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1806310/000119312526344594/d161230dex991.htm",
  "ticker": "TSHA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05606614",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1033",
  "guidance_detail": "SEC-filed 8-K (Taysha Gene Therapies): REVEAL program of TSHA-102 in Rett syndrome - 6-month interim topline and FDA feedback expected 1H 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [
   "v16-1009"
  ],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for TSHA-102 in Rett syndrome is expected in the first half of 2027 \u2014 the pivotal readout that determines whether Taysha Gene Therapies, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "uniQure N.V.",
  "competitors": [],
  "country": "Netherlands",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "AMT-130",
  "event_type": "regulatory_other",
  "indication": "Huntington's disease",
  "notes": "SEC-filed 8-K material event on AMT-130; regulatory milestone watch item inferred for H1 2027. Kept as regulatory_other, not a PDUFA, per the FDA-acceptance gate.\n[2026-09-23 primary-source upgrade] 8-K Exhibit 99.1 (uniQure Q2 2026 PR): 'U.S. and U.K. regulatory submissions for AMT-130 for Huntington\\u2019s disease on track as planned for the third quarter of 2026' / 'remain on track to submit our BLA for AMT-130 in the third quarter'. Direct SEC-filed exhibit supports the AMT-130 regulatory-milestone watch item; timing link to 2027-H1 is the BLA-review runway.",
  "phase": "2",
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1590560/000110465926087808/qure-20260729xex99d1.htm",
  "ticker": "QURE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1034",
  "guidance_detail": "SEC-filed 8-K material event on AMT-130; regulatory milestone watch item inferred for H1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "Novartis AG",
  "competitors": [],
  "country": "Switzerland",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "delpacibart zotadirsen (del-zota)",
  "event_type": "regulatory_other",
  "indication": "Duchenne muscular dystrophy (exon 44)",
  "notes": "Novartis Sep 2026 company update on del-zota Phase 3 HARBOR study; regulatory milestone watch item inferred for H1 2027. Not a PDUFA (no acceptance) - regulatory_other per the acceptance gate.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.novartis.com/news/media-releases/novartis-provides-update-delpacibart-etedesiran-del-desiran-phase-iii-harbor-study-treatment-myotonic-dystrophy-type-1-dm1",
  "ticker": "NVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1035",
  "guidance_detail": "Novartis Sep 2026 company update on del-zota Phase 3 HARBOR study; regulatory milestone watch item inferred for H1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Beam Therapeutics Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "risto-cel (BEAM-101)",
  "event_type": "regulatory_other",
  "indication": "sickle cell disease",
  "notes": "Company update on risto-cel (BEAM-101); regulatory milestone watch item inferred for H1 2027. Not a PDUFA (no acceptance) - regulatory_other per the acceptance gate.\n[2026-09-23 primary-source upgrade] Direct GlobeNewswire company PR (same release the stocktitan mirror copied): Beam announces NEJM publication of BEACON Phase 1/2 risto-cel data (31 patients, durable profile) and states 'U.S. Biologics License Application (BLA) Submission for risto-cel Expected as Early as Year-End 2026' - supports the risto-cel regulatory-milestone watch item.",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/04/01/3267053/0/en/Beam-Therapeutics-Announces-Publication-of-BEACON-Phase-1-2-Data-for-risto-cel-in-Patients-with-Sickle-Cell-Disease-SCD-in-The-New-England-Journal-of-Medicine.html",
  "ticker": "BEAM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1036",
  "guidance_detail": "Company update on risto-cel (BEAM-101); regulatory milestone watch item inferred for H1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Beam Therapeutics has a regulatory milestone watch for risto-cel (BEAM-101) in sickle cell disease in the first half of 2027."
 },
 {
  "as_of": "2026-09-24",
  "company": "GRAIL Inc",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Galleri (multi-cancer early detection blood test)",
  "event_type": "device_regulatory_decision",
  "indication": "multi-cancer early detection (screening, 50+ cancers)",
  "notes": "Company filed PMA in early 2026; FDA panel met Sep 23, 2026; management's stated expectation is a potential approval in the first part of 2027 (H1 2027). First-ever FDA approval of an MCED screening test would be a major binary regulatory event. Confidence note: timing via third-party transcript mirror (fool.com), not Quartr - flagged honestly.",
  "phase": null,
  "source_type": "earnings transcript",
  "source_url": "https://www.fool.com/earnings/call-transcripts/2026/08/13/grail-gral-q2-2026-earnings-call-transcript/",
  "ticker": "GRAL",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1037",
  "guidance_detail": "Company filed PMA in early 2026; FDA panel met Sep 23, 2026; management's stated expectation is a potential approval in the first part of 2027 (H1 2027).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "FDA decision expected in the first half of 2027 on GRAIL Inc.'s Galleri (multi-cancer early detection blood test) \u2014 the clearance the company needs to market the test."
 },
 {
  "as_of": "2026-09-24",
  "company": "Aquestive Therapeutics Inc",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Anaphylm (dibutepinephrine) sublingual film",
  "event_type": "maa_filing",
  "indication": "type I allergic reactions, including anaphylaxis",
  "notes": "Company's first ex-US regulatory submission for its lead asset; MAA submission to EMA is company-guided for Q1 2027. Separately, the US NDA resubmission was filed Aug 2026 (CRL remediation complete) - no PDUFA goal date confirmed, so no PDUFA row per the acceptance gate.\n[2026-09-23 primary-source upgrade] Direct GlobeNewswire company PR (Q2 2026 results, 2026-08-11): 'remains on track to submit regulatory applications in Canada by the end of 2026 and in the European Union in the first quarter of 2027' for Anaphylm.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/11/3343140/0/en/aquestive-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html",
  "ticker": "AQST",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1039",
  "guidance_detail": "Company's first ex-US regulatory submission for its lead asset; MAA submission to EMA is company-guided for Q1 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Aquestive Therapeutics Inc plans its European filing for Anaphylm (dibutepinephrine) sublingual film in type I allergic reactions, including anaphylaxis in Q1 2027, opening the EU review path."
 },
 {
  "as_of": "2026-09-24",
  "company": "Aquestive Therapeutics Inc",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Anaphylm (dibutepinephrine) sublingual film",
  "event_type": "maa_filing",
  "indication": "type I allergic reactions, including anaphylaxis (UK)",
  "notes": "Distinct from the Q1 2027 EU filing row: a UK MHRA submission is company-guided for 2027 with no stated quarter. Broad annual bucket, guidance quality.\n[2026-09-23 primary-source upgrade] Same GlobeNewswire PR: 'The Company expects its existing clinical data to support regulatory submissions in additional markets in 2027, including the United Kingdom.' Supports the UK MHRA year-only 2027 guidance row.",
  "phase": null,
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/11/3343140/0/en/aquestive-therapeutics-reports-second-quarter-2026-financial-results-and-provides-business-update.html",
  "ticker": "AQST",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1042",
  "guidance_detail": "Distinct from the Q1 2027 EU filing row: a UK MHRA submission is company-guided for 2027 with no stated quarter.",
  "audit_status": "v17_reverified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Aquestive Therapeutics Inc plans its European filing for Anaphylm (dibutepinephrine) sublingual film in type I allergic reactions, including anaphylaxis (UK) sometime in 2027, opening the EU review path."
 },
 {
  "as_of": "2026-09-24",
  "company": "IDEAYA Biosciences, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "darovasertib + crizotinib",
  "event_type": "regulatory_other",
  "indication": "first-line HLA-A*02:01-negative metastatic uveal melanoma",
  "notes": "IDEAYA Q1 2026 business update: OptimUM-02 Phase 2/3 met primary PFS endpoint (HR 0.42, median PFS 6.9 vs 3.1 months); NDA submission planned H2 2026 for potential US accelerated approval under FDA Real-Time Oncology Review. The dataset already carries the PFS readout and the mid-2027 OS interim; this is the regulatory-decision watch row. Flagged inferred: no company guidance pins the approval decision to 2027, and it must NOT be recorded as a PDUFA per the acceptance gate.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://ir.ideayabio.com/2026-05-05-IDEAYA-Biosciences-Reports-First-Quarter-2026-Financial-Results-and-Provides-Business-Update",
  "ticker": "IDYA",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1044",
  "guidance_detail": "IDEAYA Q1 2026 business update: OptimUM-02 Phase 2/3 met primary PFS endpoint (HR 0.42, median PFS 6.9 vs 3.1 months); NDA submission planned H2 2026 for potential US accelerated approval under FDA Real-Time Oncology Review.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24",
  "why_it_matters": "IDEAYA's NDA submission for darovasertib plus crizotinib in metastatic uveal melanoma is planned for late 2026, with a regulatory decision watch in the second half of 2027."
 },
 {
  "as_of": "2026-09-24",
  "company": "Adverum Biotechnologies, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ixoberogene soroparvovec (ixo-vec)",
  "event_type": "readout",
  "indication": "wet age-related macular degeneration",
  "notes": "Issuer press release (GlobeNewswire, 2025-09-22): ARTEMIS pivotal Phase 3 of single-administration ixo-vec (6E10 vg/eye) vs aflibercept q8w completed screening ahead of expectations; topline readout accelerated to Q1 2027 (trial NCT06856577).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/adverum-biotechnologies-announces-completion-of-screening-for-pivotal-phase-3-artemis-trial-of-ixo-vec-for-wet-age-related-macular-degeneration",
  "ticker": "ADVM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT06856577",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1045",
  "guidance_detail": "Issuer press release (GlobeNewswire, 2025-09-22): ARTEMIS pivotal Phase 3 of single-administration ixo-vec (6E10 vg/eye) vs aflibercept q8w completed screening ahead of expectations; topline readout accelerated to Q1 2027 (trial NCT06856577).",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [
   "v16-1046",
   "v16-0092"
  ],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "Phase 3 data for ixoberogene soroparvovec (ixo-vec) in wet age-related macular degeneration is expected in Q1 2027 \u2014 the pivotal readout that determines whether Adverum Biotechnologies, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Opus Genetics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OPGx-LCA5",
  "event_type": "readout",
  "indication": "Leber congenital amaurosis (LCA5)",
  "notes": "Issuer press release (2026-08-03): enrollment complete in registrational Phase 1/2/3 trial of one-time subretinal AAV8 gene therapy OPGx-LCA5; dosing to begin Q4 2026; topline expected by end of 2027. Program holds FDA Rare Pediatric Disease, Orphan Drug, and RMAT designations. NCT + STALENESS CAVEAT (2026-09-23): trial identified as CT.gov NCT05616793 (Opus Genetics, AAV8.hLCA5, LCA5-IRD); registry record last updated 2026-02-19 (stale) vs Opus Aug 2026 PR: registrational Phase 1/2/3 enrollment complete, topline end 2027. Registry note (2026-09-23): CT.gov now lists primary completion 2028-06-15 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "phase": "3",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/03/3337367/0/en/Opus-Genetics-Completes-Patient-Enrollment-in-Registrational-Phase-3-Trial-of-OPGx-LCA5-for-LCA5-Associated-Inherited-Retinal-Disease.html",
  "ticker": "IRD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "NCT05616793",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1047",
  "guidance_detail": "Issuer press release (2026-08-03): enrollment complete in registrational Phase 1/2/3 trial of one-time subretinal AAV8 gene therapy OPGx-LCA5; dosing to begin Q4 2026; topline expected by end of 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "nct_backfill",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 3 data for OPGx-LCA5 in Leber congenital amaurosis (LCA5) is expected in the second half of 2027 \u2014 the pivotal readout that determines whether Opus Genetics, Inc. can file for approval."
 },
 {
  "as_of": "2026-09-24",
  "company": "Novavax, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "C. difficile vaccine candidate (undisclosed)",
  "event_type": "ind",
  "indication": "Clostridioides difficile infection (prevention)",
  "notes": "Company Q2 2026 quarterly materials: GMP manufacturing initiated for C. difficile vaccine candidate, supporting potential clinical entry as early as 2027.",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/novavax-reports-second-quarter-2026-financial-results-and-operational-highlights-302844473.html",
  "ticker": "NVAX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1048",
  "guidance_detail": "Company Q2 2026 quarterly materials: GMP manufacturing initiated for C.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "PTC Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "inferred",
  "drug": "isaralgagene civaparvovec (ST-920)",
  "event_type": "regulatory_other",
  "indication": "Fabry disease",
  "notes": "Sangamo Therapeutics was acquired by PTC Therapeutics (closed 2026-09-21); row remapped to the acquirer's ticker PTCT, with the company field retaining legacy-sponsor attribution. Program (ST-920 rolling BLA, Fabry disease) continues under PTC. Issuer press release (2025-12-18): rolling BLA submission initiated under accelerated approval for one-time gene therapy ST-920; BLA completion guided Q2 2026. No PDUFA or FDA acceptance date located \u2014 FDA decision timing in 2027 inferred from review timelines; regulatory_other watch item, not a PDUFA, per the acceptance gate. BLA timing to be reconfirmed under the new owner.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2025/12/18/3207689/33816/en/Sangamo-Therapeutics-Initiates-Rolling-Submission-of-BLA-to-U-S-FDA-for-ST-920-in-Fabry-Disease.html",
  "ticker": "PTCT",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1049",
  "guidance_detail": "Rolling BLA submission initiated under accelerated approval for one-time gene therapy ST-920 in Fabry disease (issuer press release, 2025-12-18); BLA completion guided Q2 2026.",
  "audit_status": "v20_reverified",
  "audit_action": "metadata_update",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "TScan Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "in vivo-engineered TCR-T (PRAME and MAGE-A4)",
  "event_type": "ind",
  "indication": "solid tumors",
  "notes": "Issuer press release (2026-09-02, strategic reorganization): first two in vivo TCR-T candidates (PRAME, MAGE-A4) advanced to IND-enabling studies; first IND filing expected Q3 2027, with Phase 1 initiation planned Q4 2027.",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors",
  "ticker": "TCRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1050",
  "guidance_detail": "Issuer press release (2026-09-02, strategic reorganization): first two in vivo TCR-T candidates (PRAME, MAGE-A4) advanced to IND-enabling studies; first IND filing expected Q3 2027, with Phase 1 initiation planned Q4 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "TScan Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "in vivo-engineered TCR-T (PRAME and MAGE-A4)",
  "event_type": "readout",
  "indication": "solid tumors (preclinical data disclosure)",
  "notes": "Same issuer press release (2026-09-02): preclinical data for the two in vivo TCR-T solid-tumor candidates expected in Q1 2027. Preclinical data disclosure, not a clinical readout.",
  "phase": "preclinical",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors",
  "ticker": "TCRX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v16-1051",
  "guidance_detail": "Same issuer press release (2026-09-02): preclinical data for the two in vivo TCR-T solid-tumor candidates expected in Q1 2027.",
  "audit_status": "v16_verified",
  "audit_action": "none",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [
   "v16-1050"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "AZD0780",
  "indication": "hypercholesterolaemia / LDL-C in ASCVD",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "Praluent (Regeneron/Sanofi)",
   "Repatha (Amgen)"
  ],
  "source_url": "https://www.tradingview.com/news/gurufocus:9db2a0668094b:0-astrazeneca-shares-rise-as-j-p-morgan-stays-overweight/",
  "source_type": "trade press",
  "as_of": "2026-09-23",
  "notes": "Phase 3 study NCT07000136; registry primary completion Jan 2027. Split from a combined two-study row in v1.7.",
  "us_tradable": true,
  "nct_id": "NCT07000136",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0001",
  "guidance_detail": "Phase 3 study NCT07000136; registry primary completion Jan 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0030"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "country": "United Kingdom",
  "us_listed": true,
  "drug": "laroprovstat/rosuvastatin FDC",
  "indication": "hypercholesterolaemia",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "inferred",
  "competitors": [
   "Praluent (Regeneron/Sanofi)",
   "Repatha (Amgen)"
  ],
  "source_url": "https://clinicaltrials.gov/study/NCT07619131",
  "source_type": "clinicaltrials.gov",
  "as_of": "2026-09-23",
  "notes": "Phase 3 study NCT07619131; registry primary completion 2027-07-30. Split from a combined two-study row in v1.7.",
  "us_tradable": true,
  "nct_id": "NCT07619131",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0002",
  "guidance_detail": "Phase 3 factorial-design study NCT07619131 (distinct from parallel-group NCT07619118); recruiting since 2026-08-12; registry primary completion 2027-07-30.",
  "audit_status": "v17_reverified",
  "audit_action": "competitor_normalize",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0031"
  ],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0003",
  "ticker": "",
  "company": "Nanoscope Therapeutics",
  "us_listed": false,
  "us_tradable": false,
  "country": "United States",
  "drug": "MOGENRY (sonpiretigene isteparvovec; MCO-010)",
  "indication": "retinitis pigmentosa with severe vision loss",
  "phase": "",
  "event_type": "pdufa",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "BLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://nanostherapeutics.com/2026/09/09/nanoscope-therapeutics-announces-u-s-food-and-drug-administration-acceptance-of-biologics-license-application-for-mogenry-for-the-treatment-of-retinitis-pigmentosa-with-severe-vision-loss/",
  "source_date": "2026-09-09",
  "as_of": "2026-09-24",
  "notes": "FDA accepted and filed the BLA (company release 2026-09-09). PDUFA expected H1 2027 (company via Eyewire News). Private sponsor admitted under the private-PDUFA gate (accepted 2027 action disclosed).",
  "guidance_detail": "FDA accepted and filed the BLA (company release 2026-09-09).",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Ophthalmology",
  "last_verified": "2026-09-24",
  "why_it_matters": "The FDA's decision date on MOGENRY (sonpiretigene isteparvovec; MCO-010) for retinitis pigmentosa with severe vision loss falls in the first half of 2027 \u2014 the agency's yes-or-no moment for Nanoscope Therapeutics's application."
 },
 {
  "record_id": "v17-0004",
  "ticker": "",
  "company": "SK Life Science, Inc.",
  "us_listed": false,
  "us_tradable": false,
  "country": "United States",
  "drug": "cenobamate oral suspension",
  "indication": "focal seizures in adults (formulation extension for patients who have difficulty swallowing tablets)",
  "phase": "",
  "event_type": "pdufa",
  "date_exact": "2027-01-31",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "nct_id": "",
  "application_type": "NDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.prnewswire.com/news-releases/sk-life-science-inc-announces-fda-acceptance-for-review-of-new-drug-application-for-cenobamate-oral-suspension-302800433.html",
  "source_date": "2026-06-15",
  "as_of": "2026-09-24",
  "notes": "FDA accepted the NDA for review and assigned a PDUFA target action date of January 31, 2027 (company PR). Formulation extension of XCOPRI; US subsidiary of SK Biopharmaceuticals. Private PDUFA gate: accepted 2027 action disclosed.",
  "guidance_detail": "FDA accepted the NDA for review and assigned a PDUFA target action date of January 31, 2027 (company PR).",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0005",
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Enspryng (satralizumab)",
  "indication": "myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) (EU)",
  "phase": null,
  "event_type": "regulatory_other",
  "date_exact": null,
  "date_bucket": "2027-Q3",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.roche.com/investors/updates/inv-update-2026-09-10",
  "source_date": "2026-09-10",
  "as_of": "2026-10-20",
  "notes": "Roche 10 Sep 2026: 'the European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe. The decision by the European Commission is expected in the third quarter of 2027.' Type II extension-of-indication to the existing EU MA (NMOSD, authorised 24 Jun 2021); filing rests on Phase 3 METEOROID (68% relapse-risk reduction vs placebo, p=0.0025). Distinct from the US PDUFA row (book date 2027-01-10 per Roche Business Wire; CheckRare lists 20 Jan 2027). Source note: RECLASSIFIED chmp_opinion -> regulatory_other: Roche (10 Sep 2026) describes the EUROPEAN COMMISSION decision expected in Q3 2027 (Type II extension-of-indication to the existing EU MA for NMOSD), not a CHMP opinion date. No duplicate row created.",
  "guidance_detail": "Roche 10 Sep 2026: 'the European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe.",
  "audit_status": "v20_reverified",
  "audit_action": "reclassify",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-20"
 },
 {
  "record_id": "v17-0006",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "remibrutinib",
  "indication": "relapsing-remitting MS",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. REMODEL-1/-2 met primary endpoints; Novartis 1 Sep 2026 PR: 'plans to submit to health authorities globally'. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0007",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Rhapsido (remibrutinib)",
  "indication": "chronic spontaneous urticaria, pediatrics",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0008",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Rhapsido (remibrutinib)",
  "indication": "hidradenitis suppurativa",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0009",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Scemblix (asciminib)",
  "indication": "chronic myeloid leukemia, pediatrics",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0010",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Mayzent (siponimod)",
  "indication": "multiple sclerosis, pediatrics",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0011",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "zigakibart",
  "indication": "IgA nephropathy",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. BEYOND Phase 3 ongoing; filing is pipeline guidance, readout not yet reported. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0012",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Leqvio (inclisiran)",
  "indication": "cardiovascular risk reduction, secondary prevention",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. VICTORION-2P readout pending; filing is pipeline guidance. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0013",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Fabhalta (iptacopan)",
  "indication": "generalized myasthenia gravis",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0014",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Kesimpta (ofatumumab)",
  "indication": "multiple sclerosis, new dosing regimen",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0015",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "Rydapt (midostaurin)",
  "indication": "acute myeloid leukemia, pediatrics",
  "phase": null,
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0016",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "ianalumab",
  "indication": "systemic lupus erythematosus",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0017",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "ianalumab",
  "indication": "immune thrombocytopenia, first-line",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0018",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "ianalumab",
  "indication": "immune thrombocytopenia, second-line",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0019",
  "ticker": "NVS",
  "company": "Novartis AG",
  "us_listed": true,
  "us_tradable": true,
  "country": "Switzerland",
  "drug": "ianalumab",
  "indication": "warm autoimmune hemolytic anemia",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://www.novartis.com/research-development/novartis-pipeline",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing. Novartis pipeline 'Filing Date: 2027' is a global planning date, jurisdiction-unspecified; US vs EU sequencing unconfirmed. No quarter stated by the sponsor; not a PDUFA (acceptance not disclosed).",
  "guidance_detail": "Novartis official pipeline lists \"Filing Date: 2027\" for this supplementary-indication filing.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0020",
  "ticker": "PCVX",
  "company": "Vaxcyte, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "VAX-31",
  "indication": "invasive pneumococcal disease and pneumonia, adults",
  "phase": null,
  "event_type": "bla_filing",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/05/3339693/0/en/Vaxcyte-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Update.html",
  "source_date": "2026-08-05",
  "as_of": "2026-10-01",
  "notes": "CEO Grant Pickering (5 Aug 2026 company PR): 'we expect to announce the results of the OPUS-2 and OPUS-3 trials in the first half of 2027, which along with a manufacturing consistency study, would enable our planned Biologics License Application (BLA) submission and potential U.S. commercial launch.' The year 2027 is derived from the 1H27-enabling sequence, not printed next to the filing itself.",
  "guidance_detail": "CEO Grant Pickering (5 Aug 2026 company PR): 'we expect to announce the results of the OPUS-2 and OPUS-3 trials in the first half of 2027, which along with a manufacturing consistency study, would enable our planned Biologics License Application (BLA) submission and potential U.S.",
  "audit_status": "v17_reverified",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01",
  "why_it_matters": "Vaxcyte, Inc. is expected to file its biologics license application for VAX-31 in invasive pneumococcal disease and pneumonia, adults sometime in 2027, starting the FDA's formal review clock."
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "Cobenfy (KarXT) \u2014 ADEPT-2",
  "indication": "Alzheimer's disease psychosis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Nuplazid (Acadia)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "ADEPT-2 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT06126224). BMS guides ADEPT-1/-2/-4 readouts to begin early 2027 and continue through 2027; per-trial windows not separately guided. Row split from combined ADEPT-1/-2/-4 row (v16-0065) on 2026-09-23.",
  "us_tradable": true,
  "nct_id": "NCT06126224",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0021",
  "guidance_detail": "ADEPT-2 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT06126224).",
  "audit_status": "v17_reverified",
  "audit_action": "corrected",
  "date_history": [
   {
    "from": "2027-H1",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "BMS Q2 2026 deck guides ADEPT program at year-level 2027; per-trial H1 was invented precision"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0023",
   "v17-0022",
   "v16-0066",
   "v16-0065"
  ],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "Cobenfy (KarXT) \u2014 ADEPT-4",
  "indication": "Alzheimer's disease psychosis",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Nuplazid (Acadia)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "ADEPT-4 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT06585787). BMS guides ADEPT-1/-2/-4 readouts to begin early 2027 and continue through 2027; per-trial windows not separately guided. Row split from combined ADEPT-1/-2/-4 row (v16-0065) on 2026-09-23.",
  "us_tradable": true,
  "nct_id": "NCT06585787",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0022",
  "guidance_detail": "ADEPT-4 Phase 3 readout in psychosis associated with Alzheimer's disease (NCT06585787).",
  "audit_status": "v17_reverified",
  "audit_action": "corrected",
  "date_history": [
   {
    "from": "2027-H1",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "BMS Q2 2026 deck guides ADEPT program at year-level 2027; per-trial H1 was invented precision"
   }
  ],
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0023",
   "v17-0021",
   "v16-0066",
   "v16-0065"
  ],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "country": "United States",
  "us_listed": true,
  "drug": "Cobenfy (KarXT) \u2014 BALSAM-2",
  "indication": "bipolar I disorder",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Vraylar (AbbVie)"
  ],
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_type": "company deck",
  "as_of": "2026-09-23",
  "notes": "BALSAM-2 Phase 3 readout in manic episodes in bipolar-I disorder (NCT06951711). BMS guides BALSAM-1/-2 readouts in 2027; individual study windows unresolved. Row split from combined BALSAM-1/-2 row (v16-0066) on 2026-09-23.",
  "us_tradable": true,
  "nct_id": "NCT06951711",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0023",
  "guidance_detail": "BALSAM-2 Phase 3 readout in manic episodes in bipolar-I disorder (NCT06951711).",
  "audit_status": "v17_reverified",
  "audit_action": "split",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v17-0022",
   "v17-0021",
   "v16-0066",
   "v16-0065",
   "v16-0827"
  ],
  "date_history": [],
  "indication_group": "Psychiatry",
  "last_verified": "2026-09-27"
 },
 {
  "ticker": "VRTX",
  "company": "Vertex Pharmaceuticals Incorporated",
  "drug": "suzetrigine",
  "indication": "diabetic peripheral neuropathy (DPN)",
  "event_type": "readout",
  "phase": "3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "source_type": "trade press",
  "source_url": "https://transcriptdaily.com/2026/09/13/vertex-pharmaceuticals-maps-growth-beyond-cf-at-cantor-conference.html",
  "notes": "Vertex guides Phase 3 suzetrigine DPN readouts mid-2027 (SVP IR Susie Lisa, Sept 2026 Cantor Global Healthcare Conference, via transcriptdaily); Q2 2026 release stated enrollment in both Phase 3 DPN studies completes by end-2026. Bucketed at H1/H2 boundary. Oral NaV1.8 inhibitor. Re-bucketed 2027-H2 to 2027-H1 on 2026-09-20: Vertex SVP IR Susie Lisa at the Sept 2026 Cantor conference guided both Phase 3 DPN studies (12-week, enrollment completing end-2026) with data potentially available by mid-2027, per multiple trade outlets carrying the same company remarks. Vertex official Q2 2026 release confirms enrollment completion by end-2026 only and states no readout timing. Official Vertex Q2 2026 Business Wire release (opened and verified): both Phase 3 suzetrigine DPN studies on track to complete enrollment by end-2026 \u2014 no readout timing stated. The mid-2027 readout window comes from SVP IR Susie Lisa's remarks at the Sept 2026 Cantor conference via trade coverage. TIMING DISCREPANCY: current row is bucketed 2027-H2; company-derived coverage points to data by mid-2027 (H1), so the row appears to be one half too late \u2014 recommend re-bucketing to H1 2027. [2026-09-23: row covers one of two parallel Phase 3 DPN efficacy studies (NCT06628908); per-trial timing not separately guided; split from combined row.]",
  "competitors": [
   "Lyrica / gabapentin (generics, symptomatic care)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "as_of": "2026-09-23",
  "nct_id": "NCT06628908",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v17-0024",
  "guidance_detail": "Vertex guides Phase 3 suzetrigine DPN readouts mid-2027 (SVP IR Susie Lisa, Sept 2026 Cantor Global Healthcare Conference, via transcriptdaily); Q2 2026 release stated enrollment in both Phase 3 DPN studies completes by end-2026.",
  "audit_status": "v17_reverified",
  "audit_action": "split",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-1016"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-24"
 },
 {
  "record_id": "v17-0025",
  "ticker": "GILD",
  "company": "Gilead Sciences, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "sacituzumab govitecan + pembrolizumab (Trodelvy)",
  "indication": "high-risk early triple-negative breast cancer, residual invasive disease post-neoadjuvant therapy (ASCENT-05 / AFT-65 / OptimICE-RD)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "inferred",
  "nct_id": "NCT05633654",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05633654",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Inferred from CT.gov: pivotal Phase 3 ASCENT-05 (NCT05633654), sponsor Gilead Sciences, status RECRUITING, primary completion ESTIMATED 2027-06 (registry estimate; trial is event-driven iDFS readout). Readout expected 2027 per registry timing. No tighter bucket claimed (month-precision estimated PCD). No company-guided 2027 window located \u2014 this row rests on registry timing for a registrational in-universe trial.",
  "guidance_detail": "CT.gov registry (NCT05633654): OverallStatus RECRUITING; PrimaryCompletionDate 2027-06 (ESTIMATED). Official title: 'Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)'.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "record_id": "v17-0026",
  "ticker": "BNTX",
  "company": "BioNTech SE",
  "us_listed": true,
  "us_tradable": true,
  "country": "Germany",
  "drug": "BNT116 (FixVac)",
  "indication": "1L NSCLC, PD-L1 >=50% (EMPOWERVAX Lung 1)",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05557591",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ACTIVE_NOT_RECRUITING",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/41f7c457-5c4d-3b1f-89c7-139410a7bb2e/presentation.pdf",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Company-guided 2027: BioNTech FY2025 results deck (10 Mar 2026) guides 'Phase 2 final analysis expected in 2027' for BNT116 in 1L NSCLC, with recruitment completed (EMPOWERVAX Lung 1, NCT05557591, BNT116 + cemiplimab vs cemiplimab). GAP: CT.gov shows estimated PCD 2028-01-26 and status ACTIVE_NOT_RECRUITING (lead sponsor Regeneron Pharmaceuticals, BioNTech SE collaborator) \u2014 registry PCD postdates the company-guided final analysis; company guidance outranks per source ladder.",
  "guidance_detail": "BioNTech FY2025 results deck (10 Mar 2026), 'Development Focus of mRNA Cancer Immunotherapy iNeST and FixVac Portfolios' slide, BNT116 column: 'Recruitment completed in Phase 2 in 1L NSCLC' and 'Phase 2 final analysis expected in 2027' ('In collaboration with Regeneron'). Corroborating 6-K text: 'A Phase 2 clinical trial (NCT05557591) is being conducted in collaboration with Regeneron to evaluate ",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "record_id": "v17-0027",
  "ticker": "PFE",
  "company": "Pfizer Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "disitamab vedotin + pembrolizumab",
  "indication": "1L HER2-expressing locally advanced/metastatic urothelial cancer (DV-001)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "nct_id": "NCT05911295",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ACTIVE_NOT_RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05911295",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Inferred from CT.gov: pivotal Phase 3 DV-001 (NCT05911295), sponsor Seagen (wholly owned subsidiary of Pfizer), fully enrolled, primary completion ESTIMATED 2027-01-29 -> inferred 2027-Q1 (PCD month -> quarter bucket; derivation shown). Corroborated: Pfizer Q2 2026 earnings deck lists Disitamab vedotin (PF-08046051) HER2+ 1L metastatic urothelial cancer among anticipated data readouts over the next 12 months (Aug 2026 deck). Distinct from in-book v16-0936 (disitamab vedotin, HER2-expressing breast cancer, NCT06966453) \u2014 different trial, indication, and NCT; not a duplicate.",
  "guidance_detail": "CT.gov registry (NCT05911295): OverallStatus ACTIVE_NOT_RECRUITING; PrimaryCompletionDate 2027-01-29 (ESTIMATED); 'Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2'. Pfizer Q2 2026 earnings deck (4 Aug 2026), 'A Look Ahead: Select Catalysts Anticipated Over Next 12 Months' \u2014 Data Readouts column: 'Disitamab vedotin (PF-08046051) / HER2+",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "record_id": "v17-0028",
  "ticker": "PFE",
  "company": "Pfizer Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "tucatinib + trastuzumab + mFOLFOX6",
  "indication": "1L HER2+ metastatic colorectal cancer (MOUNTAINEER-03)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-Q4",
  "date_quality": "inferred",
  "nct_id": "NCT05253651",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05253651",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Inferred from CT.gov: pivotal Phase 3 MOUNTAINEER-03 (NCT05253651), sponsor Seagen (wholly owned subsidiary of Pfizer), status RECRUITING, primary completion ESTIMATED 2027-12-31 -> inferred 2027-Q4 (PCD month -> quarter bucket; derivation shown). Corroborated: Pfizer Q2 2026 earnings deck lists TUKYSA (tucatinib) 1L HER2+ metastatic colorectal cancer among anticipated data readouts over the next 12 months (Aug 2026 deck). GAP/caveat: 2027-12-31 is a year-end placeholder PCD and the trial is still RECRUITING \u2014 the Q4 inference rests entirely on the registry estimate; the company deck's rolling 12-month window implies ~Aug 2027, i.e. earlier than registry PCD. Disagreement kept conservative per brief rule 8.",
  "guidance_detail": "CT.gov registry (NCT05253651): OverallStatus RECRUITING; PrimaryCompletionDate 2027-12-31 (ESTIMATED); 'A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer'. Pfizer Q2 2026 earnings deck (4 Aug 2026), 'A Look Ahead: Select Catalysts Anticipated Over Next 12 Months' \u2014 Data Readouts column: 'TUKYSA (tucatinib) / 1L HER",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "record_id": "v17-0029",
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "us_listed": true,
  "us_tradable": true,
  "country": "United Kingdom",
  "drug": "puxitatug samrotecan (AZD8205)",
  "indication": "2-3L B7-H4+ endometrial cancer (Bluestar-Endometrial01)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT07044336",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT07044336",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Company-guided 2027 (year-level only): AZ Development Pipeline 2025 (as at 10 Feb 2026) lists Bluestar-Endometrial01 (puxitatug samrotecan, 2-3L B7-H4+ endometrial cancer, Phase 3) with 'Data readout/submission status: 2027'. No tighter window given. CT.gov context only: NCT07044336, RECRUITING, estimated PCD 2027-10-15 \u2014 not used to tighten the bucket. [2026-09-23 source check] Adobe CQ author-preview URL returns 403 to crawlers (access-blocked, not confirmed dead); document substance verified via search-index crawl 2026-09-23. Needs browser re-source to the public astrazeneca.com pipeline page.",
  "guidance_detail": "AstraZeneca Development Pipeline 2025 (as at 10 Feb 2026), Phase III table, Data readout/submission status column: 'puxitatug samrotecan | B7-H4 TOP1i ADC | 2-3L B7-H4+ endometrial cancer | Bluestar-Endometrial01 | 2027'.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record Bluestar-Endometrial01, AZD8205 (puxitatug samrotecan) Phase 3 in B7-H4-selected endometrial cancer; primary completion est. 2027-10-15."
 },
 {
  "record_id": "v17-0031",
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "us_listed": true,
  "us_tradable": true,
  "country": "United Kingdom",
  "drug": "acalabrutinib + R-CHOP (Calquence)",
  "indication": "1L DLBCL (ESCALADE / ACE-LY-312)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT04529772",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ACTIVE_NOT_RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT04529772",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Company-guided 2027 (year-level only): AZ Development Pipeline 2025 (as at 10 Feb 2026) lists Calquence + R-CHOP (ESCALADE, 1L DLBCL, Phase 3) with 'Data readout/submission status: 2027'. No tighter window given. CT.gov context only: NCT04529772 (ACE-LY-312; sponsor Acerta Pharma BV), ACTIVE_NOT_RECRUITING, estimated PCD 2027-02-22 \u2014 not used to tighten the bucket. Note: CT.gov specifies non-GCB DLBCL; pipeline says 1L DLBCL \u2014 same trial per ESCALADE identity. [2026-09-23 source check] Adobe CQ author-preview URL returns 403 to crawlers (access-blocked, not confirmed dead); document substance verified via search-index crawl 2026-09-23. Needs browser re-source to the public astrazeneca.com pipeline page.",
  "guidance_detail": "AstraZeneca Development Pipeline 2025 (as at 10 Feb 2026), Phase III table, Data readout/submission status column: 'Calquence + R-CHOP | BTK inhibitor + R-CHOP | 1L DLBCL | ESCALADE | 2027'.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record ESCALADE, acalabrutinib + R-CHOP Phase 3 in untreated non-GCB DLBCL; primary completion est. 2027-02-22."
 },
 {
  "record_id": "v17-0032",
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "us_listed": true,
  "us_tradable": true,
  "country": "United Kingdom",
  "drug": "osimertinib (Tagrisso)",
  "indication": "EGFRm stage IA2-IA3 NSCLC following complete tumour resection (ADAURA2)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05120349",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ACTIVE_NOT_RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05120349",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Company-guided 2027 (year-level only): AZ Development Pipeline 2025 (as at 10 Feb 2026) lists Tagrisso (ADAURA2, EGFRm stage IA2-IA3 NSCLC post complete resection, Phase 3) with 'Data readout/submission status: 2027'. No tighter window given. CT.gov context only: NCT05120349, ACTIVE_NOT_RECRUITING, estimated PCD 2027-08-02 \u2014 not used to tighten the bucket. [2026-09-23 source check] Adobe CQ author-preview URL returns 403 to crawlers (access-blocked, not confirmed dead); document substance verified via search-index crawl 2026-09-23. Needs browser re-source to the public astrazeneca.com pipeline page.",
  "guidance_detail": "AstraZeneca Development Pipeline 2025 (as at 10 Feb 2026), Significant Lifecycle Management table, Data readout/submission status column: 'Tagrisso | EGFR TKI | EGFRm NSCLC stage Ia2-Ia3 following complete tumour resection | ADAURA2 | 2027'.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record ADAURA2, adjuvant osimertinib Phase 3 in EGFRm stage IA2-IA3 NSCLC; primary completion est. 2027-08-02."
 },
 {
  "record_id": "v17-0033",
  "ticker": "AZN",
  "company": "AstraZeneca PLC",
  "us_listed": true,
  "us_tradable": true,
  "country": "United Kingdom",
  "drug": "anifrolumab (Saphnelo)",
  "indication": "systemic sclerosis (DAISY)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05925803",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ACTIVE_NOT_RECRUITING",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.gov/study/NCT05925803",
  "source_date": "",
  "as_of": "2026-09-23",
  "notes": "Company-guided 2027 (year-level only): AZ Development Pipeline 2025 (as at 10 Feb 2026) lists Saphnelo (anifrolumab, DAISY, systemic sclerosis, Phase 3) with 'Data readout/submission status: 2027'. No tighter window given. CT.gov context only: NCT05925803, ACTIVE_NOT_RECRUITING, estimated PCD 2027-01-06 \u2014 not used to tighten the bucket.",
  "guidance_detail": "AstraZeneca Development Pipeline 2025 (as at 10 Feb 2026), Significant Lifecycle Management table, Data readout/submission status column: 'Saphnelo | type I IFN receptor mAb | PP | systemic sclerosis | DAISY | 2027'.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0032"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27",
  "evidence_note": "Re-sourced 2026-09-24: official CT.gov record DAISY, anifrolumab Phase 3 in systemic sclerosis; primary completion est. 2027-01-06."
 },
 {
  "record_id": "v17-0034",
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "nivolumab SC (Opdivo Qvantig) + ipilimumab + chemotherapy",
  "indication": "first-line metastatic or recurrent non-small cell lung cancer",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06946797",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_date": "2026-07-30",
  "as_of": "2026-09-23",
  "notes": "BMS Q2 2026 investor presentation (2026-07-30) lists CheckMate-1533 as Phase II with projected data readout 2027. CT.gov NCT06946797 official title matches subcutaneous nivolumab + IV ipilimumab + chemotherapy in previously untreated metastatic/recurrent NSCLC, Phase 2, acronym CheckMate-1533. Registry estimated PCD 2027-02-05 exists but company guidance is 2027 only; not tightened.",
  "guidance_detail": "Phase II - CheckMate-1533; Opdivo Qvantig + Yervoy + chemotherapy; Projected data readout 2027; NCT06946797",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0035",
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "BMS-986368 (irafamdastat)",
  "indication": "multiple-sclerosis spasticity",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06782490",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_date": "2026-07-30",
  "as_of": "2026-09-23",
  "notes": "BMS Q2 2026 investor presentation (2026-07-30) lists BALANCE-MSS-1 as Phase II with projected data readout 2027. CT.gov NCT06782490 confirms BMS-986368/irafamdastat (FAAH/MAGL inhibitor) in multiple-sclerosis spasticity, Phase 2. Registry estimated PCD 2027-05-26; company guidance retained as 2027.",
  "guidance_detail": "Phase II - BALANCE-MSS-1; Projected data readout 2027; NCT06782490",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v17-0036"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0036",
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "BMS-986368 (irafamdastat)",
  "indication": "agitation associated with Alzheimer's disease",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06808984",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_date": "2026-07-30",
  "as_of": "2026-09-23",
  "notes": "BMS Q2 2026 investor presentation (2026-07-30) lists BALANCE-AAD-1 as Phase II with projected data readout 2027. CT.gov NCT06808984 confirms BMS-986368/irafamdastat in agitation associated with Alzheimer's disease, Phase 2. Registry estimated PCD 2027-11-26; company guidance retained as 2027.",
  "guidance_detail": "Phase II - BALANCE-AAD-1; Projected data readout 2027; NCT06808984",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v17-0035"
  ],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0037",
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "mezigdomide + elranatamab + dexamethasone",
  "indication": "relapsed/refractory multiple myeloma",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06988488",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://bms.com/assets/bms/us/en-us/pdf/investor-info/doc_presentations/2026/BMY-2026-Q2-Results-Investor-Presentation-with-Appendix.pdf",
  "source_date": "2026-07-30",
  "as_of": "2026-10-01",
  "notes": "BMS Q2 2026 investor presentation (2026-07-30) lists CA057-1040 as Phase I/II with projected data readout 2027. CT.gov NCT06988488 official title matches mezigdomide + elranatamab in R/R multiple myeloma; registry lists both Phase 1 and Phase 2 (official wording Phase 1b/2a) - dominant/expansion phase recorded as 2 per Phase 1/2 convention. Phase 1 eligibility: 2-4 prior lines; Phase 2: 1-3 prior lines. Registry estimated PCD 2027-05-31; company guidance retained as 2027. Dexamethasone retained in drug field as both deck and registry list it.",
  "guidance_detail": "Phase I/II - CA057-1040; Mezigdomide + elranatamab + dexamethasone; Projected data readout 2027; NCT06988488",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0038",
  "ticker": "GILD",
  "company": "Gilead Sciences, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "anitocabtagene autoleucel (anito-cel)",
  "indication": "2nd- to 4th-line relapsed/refractory multiple myeloma",
  "phase": "3",
  "event_type": "regulatory_other",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06413498",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf",
  "source_date": "2026-08-04",
  "as_of": "2026-09-23",
  "notes": "Q2 2026 earnings presentation deck (mirror) states: 'Completed Enrollment of P3 iMMagine-3; Filing in 2-4L R/R MM as Early as 2027'. No verified company source explicitly identifies the filing as a BLA, so event typed regulatory_other (not bla_filing); application_type left empty. CT.gov NCT06413498: Phase 3 iMMagine-3, anitocabtagene autoleucel vs standard of care in R/R MM after 1-3 prior lines, ACTIVE_NOT_RECRUITING, actual enrollment 452. Registry PCD 2028-07 does not conflict with an as-early-as-2027 filing on interim data.",
  "guidance_detail": "We completed enrollment of iMMagine-3 in secondline multiple myeloma this quarter and look forward to potentially filing in this indication as early as 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0039",
  "ticker": "GILD",
  "company": "Gilead Sciences, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "islatravir + lenacapavir (oral, once weekly)",
  "indication": "HIV-1 treatment in virologically suppressed people (switch regimen)",
  "phase": "3",
  "event_type": "regulatory_other",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT06630286",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Prepared-Remarks-4-August-2026.pdf",
  "source_date": "2026-08-04",
  "as_of": "2026-09-23",
  "notes": "CEO Daniel O'Day, Q2 2026 prepared remarks. Official Gilead IR resource book (s29.q4cdn.com, Aug 2026): 'ISL/LEN Phase 3 ISLEND-1 and -2 Full Readout at AIDS 2026 2027' under 'Up to 8 Potential Launches Through 2033' timeline. CT.gov: NCT06630286 = ISLEND-1 (vs Biktarvy), NCT06630299 = ISLEND-2 (vs standard of care); both Phase 3, Gilead sponsor (Merck collaborator), ACTIVE_NOT_RECRUITING, primary endpoints met June 2026. Single program-level launch row supported by both pivotal trials. Typed regulatory_other (launch), per instructions.",
  "guidance_detail": "These data are expected to support the filing and potential launch of the first once-weekly oral HIV treatment regimen, islatravir plus lenacapavir, in 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0040",
  "ticker": "GILD",
  "company": "Gilead Sciences, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "bictegravir + lenacapavir (oral, once daily)",
  "indication": "HIV-1 treatment switch in virologically suppressed people (ARTISTRY-1: on a complicated regimen; ARTISTRY-2: on Biktarvy)",
  "phase": "3",
  "event_type": "regulatory_other",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05502341",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://cdn.prod.nntech.io/company-events/reports/cc4e67fc-15a0-3e1b-9231-ea858a18722b/presentation.pdf",
  "source_date": "2026-08-04",
  "as_of": "2026-09-24",
  "notes": "HIV pipeline timeline: U.S. launch August 2026, EC decision 2027. Official Gilead IR resource book (s29.q4cdn.com, Aug 2026) corroborates the program: 'Daily Oral BIC/LEN Phase 3 ARTISTRY-1 and -2 Full Readouts at CROI25 FDA Decision Exp. August 2026 2H26' but does not state the EC decision date. Source note: the 'EC Decision 2027' wording is confirmed IN THE Q2 2026 EARNINGS PRESENTATION ITSELF (GILD-Q226-Earnings-Presentation-4-August-2026, slide 'Lenacapavir Unlocks Broad HIV Pipeline': 'Daily Oral Bictegravir + Lenacapavir | U.S. Launch August 2026 | EC Decision 2027'; the Q1 2026 deck carries the identical slide). However, no official gilead.com/s29.q4cdn.com URL for the Q2 2026 presentation could be located via search; the only indexed copy remains the vendor-mirrored deck. Official prepared remarks (s29.q4cdn.com) corroborate the program but not the EC wording. Caveat: the EC wording is confirmed in the company deck, but the only indexed copy is a vendor-mirrored deck. CT.gov: NCT05502341 = ARTISTRY-1 (Phase 2/3 seamless design; dominant/expansion phase recorded as 3), NCT06333808 = ARTISTRY-2 (Phase 3); both ACTIVE_NOT_RECRUITING. Typed regulatory_other (EC decision in 2027).",
  "guidance_detail": "Daily Oral Bictegravir + Lenacapavir - U.S. Launch August 2026 - EC Decision 2027",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-27"
 },
 {
  "record_id": "v17-0041",
  "ticker": "GILD",
  "company": "Gilead Sciences, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "lenacapavir (intramuscular, once yearly)",
  "indication": "HIV pre-exposure prophylaxis (PrEP)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT07047716",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://s29.q4cdn.com/585078350/files/doc_financials/2026/q2/GILD-Q226-Resource-Book-4-August-2026.pdf",
  "source_date": "2026-08-04",
  "as_of": "2026-10-01",
  "notes": "Official Gilead IR resource book (s29.q4cdn.com, Aug 2026), 'HIV Launch Timelines': company guides a Phase 3 PURPOSE 365 update in 2027 with launch in 2028. CT.gov NCT07047716: Phase 3, Gilead, once-yearly IM lenacapavir for HIV PrEP, ACTIVE_NOT_RECRUITING, actual enrollment 339, registry estimated PCD 2028-09. The 2027 event is a company-guided update (may be interim - Gilead notes non-registrational readouts may be interim) preceding the registry primary completion; company guidance retained as 2027.",
  "guidance_detail": "Once-Yearly Injectable LEN for PrEP Phase 3 PURPOSE 365 Enrollment Complete Ph3 Update Exp. 2027 2028",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0042",
  "ticker": "ARGX",
  "company": "argenx SE",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "efgartigimod (VYVGART)",
  "indication": "Primary immune thrombocytopenia (ADVANCE-NEXT)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "nct_id": "NCT06544499",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/07/23/3331862/0/en/argenx-Reports-Half-Year-2026-Financial-Results-and-Provides-Second-Quarter-Business-Update.html",
  "source_date": "2026-07-23",
  "as_of": "2026-10-01",
  "notes": "Registrational Phase 3 ADVANCE-NEXT (NCT06544499, efgartigimod IV vs placebo, primary ITP) verified on ClinicalTrials.gov; argenx's own clinical-trials page (clinicaltrials.argenx.com/advancenext) lists the study. No identical same-trial/same-event row in book. Discovery report's claim that no NCT was disclosed is corrected by this NCT. GAP: No exact readout day within H1 2027; registry PCD for NCT06544499 is long (2028-06), so company guidance governs. Registry recruiting status not re-verified in this pass. [V17: NCT06544499 verified on CT.gov; slip INTO 2027 from prior Q4 2026 guidance per argenx HY 2026 PR.]",
  "guidance_detail": "Topline results from registrational ADVANCE-NEXT study (primary ITP) expected in first half of 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0446",
   "v16-0015"
  ],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0043",
  "ticker": "INCY",
  "company": "Incyte Corporation",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "tafasitamab (Monjuvi/Minjuvi)",
  "indication": "Newly diagnosed diffuse large B-cell lymphoma (frontMIND)",
  "phase": "3",
  "event_type": "regulatory_other",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "nct_id": "NCT04824092",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260728733422/en/Incyte-Reports-Second-Quarter-2026-Financial-Results-and-Provides-Business-Updates",
  "source_date": "2026-07-28",
  "as_of": "2026-10-01",
  "notes": "Phase 3 frontMIND (NCT04824092, tafasitamab + lenalidomide + R-CHOP, newly diagnosed DLBCL) verified on ClinicalTrials.gov. Global submissions submitted and accepted Q2 2026 per company. Distinct from in-book autoimmune tafasitamab row v16-0480. No PDUFA date was disclosed, so PDUFA event type is not justified. GAP: Exact approval/launch day not disclosed; no PDUFA date stated, so this is an approval-watch item, not a PDUFA row. FDA review class unknown.",
  "guidance_detail": "Global regulatory submissions for Monjuvi/Minjuvi as a treatment for patients with newly diagnosed DLBCL were submitted and accepted in the second quarter of 2026. The Company anticipates a potential approval and launch in the U.S. in the first quarter of 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0044",
  "ticker": "MDGL",
  "company": "Madrigal Pharmaceuticals, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "resmetirom (Rezdiffra)",
  "indication": "Compensated MASH cirrhosis (MAESTRO-NASH OUTCOMES)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05500222",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "SEC 10-Q",
  "source_url": "https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm",
  "source_date": "",
  "as_of": "2026-10-01",
  "notes": "Phase 3 MAESTRO-NASH-OUTCOMES (NCT05500222, resmetirom, well-compensated MASH/NASH cirrhosis) verified on ClinicalTrials.gov. Timing is company guidance in the Q2 2026 10-Q (filed 2026-07-30, period ended 2026-06-30); no sub-year window. Source note: verbatim filing language confirmed from Madrigal's own SEC filings (2025 10-K and Q2 2026 10-Q filing copies): 'We expect results from the OUTCOMES trial in 2027.' Direct EDGAR page re-open was not possible in this verification pass, but the filing itself (Nasdaq SEC filings table: 10-Q filed 07/30/2026, period 06/30/2026) and the verbatim quote are confirmed from independent filing copies; canonical EDGAR URL retained as derived from SEC submissions data. Never cite StockTitan for this filing. GAP: No window within 2027 disclosed (year only).",
  "guidance_detail": "We expect results from the MAESTRO-NASH OUTCOMES trial in 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0045",
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "CagriSema (cagrilintide + semaglutide)",
  "indication": "Type 2 diabetes",
  "phase": "3",
  "event_type": "nda_filing",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://www.novonordisk.com/content/dam/nncorp/global/en/investors/pdfs/financial-results/2026/Q2-2026-Full%20presentation.pdf",
  "source_date": "",
  "as_of": "2026-10-01",
  "notes": "Distinct from in-book REDEFINE 3 readout row v16-0139. Filing event spans the multi-trial REIMAGINE T2D pivotal program, so nct_id is intentionally left blank. Deck states the T2D regulatory pathway is pending REDEFINE 3 (CV outcomes, NCT05669755, est. completion Oct 13, 2027 per registry). Deck heading: 'Most CagriSema pivotal trials successfully completed in type 2 diabetes with submission expected late 2027.' GAP: Exact REIMAGINE T2D pivotal trial IDs and exact filing timing not confirmed in this pass. REDEFINE 3 est. primary completion Sept 1, 2027 (registry) is consistent with late-2027 submission. Deck source date not independently confirmed (Q2 2026 results period, early Aug 2026).",
  "guidance_detail": "Most CagriSema pivotal trials successfully completed in type 2 diabetes with submission expected late 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0046",
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "linvoseltamab (Lynozyfic)",
  "indication": "3L+ relapsed/refractory multiple myeloma (LINKER-MM3)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "NCT05730036",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company deck",
  "source_url": "https://files.quartr.com/conference-calls/91889-2026-04-29-12-51-27.pdf?ref=TWFya2V0QmVhdCBNZWRpYSBMTEM=",
  "source_date": "2026-04-29",
  "as_of": "2026-10-01",
  "notes": "Phase 3 LINKER-MM3 (NCT05730036, linvoseltamab vs elotuzumab + pomalidomide + dexamethasone/EPd, R/R multiple myeloma) verified on ClinicalTrials.gov; fully enrolled per deck. Registry's long formal PCD is not the event date; company deck guidance governs. GAP: No sub-year window disclosed; company deck explicitly notes 'Timing of results are estimated.' Discovery mis-dated the deck as January 2026 (it is April 2026). Registry note (2026-09-23): CT.gov now lists primary completion 2033-04-19 (status RECRUITING); calendar timing rests on company guidance, not the registry \u2014; company guidance to be reconfirmed. Row retained per policy (registry moves alone do not remove rows).",
  "guidance_detail": "3L+ RRMM LINKER-MM3 Phase 3 410 Fully enrolled Monotherapy EPd TTP Ongoing 2027.",
  "audit_status": "v17_reverified",
  "audit_action": "added",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0006"
  ],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0047",
  "ticker": "REGN",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "fianlimab + cemiplimab (fixed-dose combination)",
  "indication": "Unresectable/metastatic melanoma (Harmony Head-to-Head)",
  "phase": "3",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "inferred",
  "nct_id": "NCT06246916",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "clinicaltrials.gov",
  "source_url": "https://clinicaltrials.regeneron.com/clinical-trials/a0MPr0000009ckPMAQ/nct06246916",
  "source_date": "",
  "as_of": "2026-10-01",
  "notes": "Phase 3 fixed-dose fianlimab + cemiplimab vs relatlimab + nivolumab (Opdualag) in unresectable/metastatic melanoma verified on ClinicalTrials.gov and on Regeneron's own trial registry page (status Enrolling, 560 participants). Q1 2027 bucket inferred from registry PCD; derivation: CT.gov estimated primary completion 2027-03-22 as observed 2026-09-23; Regeneron registry page states trial date September 9, 2024 - March 22, 2027. GAP: Inferred, not company-guided. Exact readout day not stated anywhere; quarter bucket only. No company readout guidance located. CONTEXT (2026-09-23): separate Phase 3 of fianlimab+cemiplimab vs pembrolizumab in 1L melanoma missed PFS (HR 0.845, p=0.0627) per Regeneron GlobeNewswire 2026-05-15; Harmony Head-to-Head vs Opdualag (this row) remains ongoing.",
  "guidance_detail": "Trial date: September 9, 2024 - March 22, 2027 . What is the trial testing? cemiplimab, fianlimab, relatlimab+nivolumab",
  "audit_status": "v18_reverified",
  "audit_action": "improved",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v17-0048",
  "ticker": "BMY",
  "company": "Bristol Myers Squibb",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "Reblozyl (luspatercept)",
  "indication": "Myelofibrosis-associated anemia (INDEPENDENCE, with concomitant JAK inhibitor)",
  "phase": "3",
  "event_type": "pdufa",
  "date_exact": "2027-03-11",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "nct_id": "NCT04717414",
  "application_type": "sBLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://investors.bms.com/iframes/press-releases/press-release-details/2026/Bristol-Myers-Squibb-Reports-Second-Quarter-Financial-Results-for-2026/default.aspx",
  "source_date": "2026-07-30",
  "as_of": "2026-10-01",
  "notes": "Phase 3 INDEPENDENCE (NCT04717414, luspatercept vs placebo in transfusion-dependent myelofibrosis-associated anemia on concomitant JAK inhibitor) is listed on ClinicalTrials.gov. INDEPENDENCE missed its primary endpoint (p=0.0674); the filing relies on secondary outcomes. FDA acceptance was disclosed verbatim in the BMS Q2 2026 earnings press release (Exhibit 99.1 to 8-K, 2026-07-30): 'The U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions. The acceptance was supported by results from the Phase 3 INDEPENDENCE study. The FDA granted a Prescription Drug User Fee Act (PDUFA) date of March 11, 2027.' date_exact=2027-03-11; date_bucket=2027-Q1. Acceptance quoted from the company PR; the FDA acceptance letter text itself was not viewed. Canonical SEC EDGAR accession for the 8-K was not locatable via search; investors.bms.com PR URL retained.",
  "guidance_detail": "The U.S. Food and Drug Administration (FDA) accepted the supplemental Biologics License Application for Reblozyl with concomitant janus kinase inhibitor therapy in adult patients with myelofibrosis-associated anemia receiving red blood cell transfusions. The acceptance was supported by results from the Phase 3 INDEPENDENCE study. The FDA granted a Prescription Drug User Fee Act (PDUFA) date of Mar",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_to_hard",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v18-0001",
  "ticker": "KARD",
  "company": "Kardigan, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "danicamtiv",
  "indication": "genetic dilated cardiomyopathy (KINSHIP-DCM Phase 2b/3, Cohort 1)",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260811514909/en/Kardigan-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Updates",
  "source_date": "2026-08-11",
  "as_of": "2026-09-23",
  "notes": "Company-guided (Kardigan Q2 2026 PR, 2026-08-11): 'The Company expects to share Phase 2b topline data in the first half of 2027.' KINSHIP-DCM is an adaptive Phase 2b/3 trial; Cohort 1 (MYH7/TTN) enrollment completed July 2026, Phase 3 portion now underway. Kardigan (Nasdaq: KARD) IPO June 2026; South San Francisco + Princeton.",
  "guidance_detail": "The Company expects to share Phase 2b topline data in the first half of 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "added",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for danicamtiv in genetic dilated cardiomyopathy (KINSHIP-DCM Phase 2b/3, Cohort 1) are expected in the first half of 2027, the first real efficacy signal for Kardigan, Inc.'s program."
 },
 {
  "record_id": "v18-0002",
  "ticker": "KARD",
  "company": "Kardigan, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "ataciguat",
  "indication": "moderate calcific aortic valve stenosis (KATALYST-AV Phase 2b interim 24-week analysis)",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260811514909/en/Kardigan-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Updates",
  "source_date": "2026-08-11",
  "as_of": "2026-09-23",
  "notes": "Company-guided (Kardigan Q2 2026 PR, 2026-08-11): 'The Company expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.' sGC activator in CAVS patients with moderate disease (KATALYST-AV).",
  "guidance_detail": "The Company expects to share Phase 2b topline data from the interim 24-week analysis in the first half of 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "added",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23",
  "why_it_matters": "Phase 2 results for ataciguat in moderate calcific aortic valve stenosis (KATALYST-AV Phase 2b interim 24-week analysis) are expected in the first half of 2027, the first real efficacy signal for Kardigan, Inc.'s program."
 },
 {
  "record_id": "v18-0003",
  "ticker": "KARD",
  "company": "Kardigan, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "tonlamarsen",
  "indication": "post-hospitalization acute severe hypertension (KARDINAL-ASH Phase 2)",
  "phase": "2",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260811514909/en/Kardigan-Reports-Second-Quarter-2026-Financial-Results-and-Recent-Business-Updates",
  "source_date": "2026-08-11",
  "as_of": "2026-10-01",
  "notes": "Company-guided (Kardigan Q2 2026 PR, 2026-08-11): 'expects to share Phase 2 topline data in the first half of 2027.' Angiotensinogen-targeted ASO (KARDINAL-ASH); first patient randomized Q2 2026.",
  "guidance_detail": "expects to share Phase 2 topline data in the first half of 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "added",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01",
  "why_it_matters": "Phase 2 results for tonlamarsen in post-hospitalization acute severe hypertension (KARDINAL-ASH Phase 2) are expected in the first half of 2027, the first real efficacy signal for Kardigan, Inc.'s program."
 },
 {
  "record_id": "v18-0004",
  "ticker": "AKTS",
  "company": "Aktis Oncology, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "AKY-1189 (Nectin-4 miniprotein radioconjugate)",
  "indication": "locally advanced/metastatic urothelial cancer and other Nectin-4 expressing solid tumors (Phase 1b Part 1 preliminary)",
  "phase": "1",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "nct_id": "NCT07020117",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/02/24/3243465/0/en/Aktis-Oncology-Receives-U-S-FDA-Fast-Track-Designation-for-AKY-1189-a-Nectin-4-Miniprotein-Radioconjugate.html",
  "source_date": "2026-02-24",
  "as_of": "2026-10-01",
  "notes": "Company-guided (Aktis PR, 2026-02-24; reaffirmed Q1 2026 PR 2026-05-11): 'Aktis expects to present preliminary results from Part 1 of the trial in the first quarter of 2027.' Multi-site Phase 1b (NCT07020117) in mUC, breast, NSCLC, colorectal, cervical, head and neck. FDA Fast Track designated for mUC. Aktis (Nasdaq: AKTS) IPO Jan 2026; Boston, MA. Phase 1b preliminary-data readout - admitted with honest phase=1 tagging.",
  "guidance_detail": "Aktis expects to present preliminary results from Part 1 of the trial in the first quarter of 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "added",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v18-0005",
  "ticker": "AKTS",
  "company": "Aktis Oncology, Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "AKY-2519 (B7-H3 miniprotein radioconjugate)",
  "indication": "mCRPC and B7-H3-expressing solid tumors (Phase 1b preliminary)",
  "phase": "1",
  "event_type": "readout",
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/05/11/3292282/0/en/Aktis-Oncology-Reports-Financial-Results-and-Business-Highlights-for-First-Quarter-2026.html",
  "source_date": "2026-05-11",
  "as_of": "2026-10-01",
  "notes": "Company-guided (Aktis Q1 2026 PR, 2026-05-11): 'Expect preliminary data from the Phase 1b mCRPC clinical trial in 2027.' Second Phase 1b basket trial in lung/colorectal/other B7-H3 solid tumors to initiate H2 2026. Phase 1b preliminary-data readout - admitted with honest phase=1 tagging.",
  "guidance_detail": "Expect preliminary data from the Phase 1b mCRPC clinical trial in 2027.",
  "audit_status": "v18_reverified",
  "audit_action": "added",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-23",
  "company": "Rhythm Pharmaceuticals, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-10",
  "date_quality": "hard",
  "drug": "setmelanotide",
  "event_type": "hta_decision",
  "indication": "Acquired hypothalamic obesity",
  "notes": "NICE technology appraisal guidance ID6542: \"Setmelanotide for treating acquired hypothalamic obesity in people 4 years and over [ID6542] | Technology appraisal guidance | 10 February 2027\". NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "RYTM",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0001",
  "guidance_detail": "NICE appraisal guidance ID6542, expected 10 Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Metabolic/Obesity/Diabetes",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-14",
  "date_quality": "hard",
  "drug": "baxdrostat",
  "event_type": "hta_decision",
  "indication": "Uncontrolled or resistant hypertension",
  "notes": "NICE technology appraisal guidance ID6623: \"Baxdrostat for treating uncontrolled or resistant hypertension [ID6623] | Technology appraisal guidance | 14 April 2027\". NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0002",
  "guidance_detail": "NICE appraisal guidance ID6623, expected 14 Apr 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Amgen Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-13",
  "date_quality": "hard",
  "drug": "tarlatamab",
  "event_type": "hta_decision",
  "indication": "Extended-stage small cell lung cancer",
  "notes": "NICE technology appraisal: tarlatamab for ES-SCLC, expected 13 Jan 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "AMGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0003",
  "guidance_detail": "NICE appraisal, expected 13 Jan 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Biogen Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-17",
  "date_quality": "hard",
  "drug": "tofersen",
  "event_type": "hta_decision",
  "indication": "SOD1-ALS",
  "notes": "NICE Highly Specialised Technologies appraisal: tofersen for SOD1-ALS, expected 17 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "BIIB",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0004",
  "guidance_detail": "NICE HST appraisal, expected 17 Mar 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Gilead Sciences, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-20",
  "date_quality": "hard",
  "drug": "anitocabtagene autoleucel (anito-cel)",
  "event_type": "hta_decision",
  "indication": "Relapsed/refractory multiple myeloma",
  "notes": "NICE technology appraisal: anito-cel for R/R multiple myeloma, expected 20 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "GILD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0005",
  "guidance_detail": "NICE appraisal, expected 20 May 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-17",
  "date_quality": "hard",
  "drug": "linvoseltamab",
  "event_type": "hta_decision",
  "indication": "Relapsed/refractory multiple myeloma",
  "notes": "NICE technology appraisal: linvoseltamab, expected 17 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "REGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0006",
  "guidance_detail": "NICE appraisal, expected 17 Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Regeneron Pharmaceuticals, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-24",
  "date_quality": "hard",
  "drug": "cemiplimab",
  "event_type": "hta_decision",
  "indication": "Adjuvant cutaneous squamous cell carcinoma",
  "notes": "NICE technology appraisal: cemiplimab in adjuvant cSCC, expected 24 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "REGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0007",
  "guidance_detail": "NICE appraisal, expected 24 Mar 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-28",
  "date_quality": "hard",
  "drug": "elranatamab",
  "event_type": "hta_decision",
  "indication": "Relapsed/refractory multiple myeloma (managed-access review)",
  "notes": "NICE managed-access review: elranatamab, expected 28 Jan 2027 per the NICE in-development guidance table. Managed-access review of an existing recommendation, not a first appraisal. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0008",
  "guidance_detail": "NICE managed-access review, expected 28 Jan 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-06",
  "date_quality": "hard",
  "drug": "brentuximab vedotin (Adcetris) combination",
  "event_type": "hta_decision",
  "indication": "Combination therapy in lymphoma (per NICE appraisal schedule)",
  "notes": "NICE technology appraisal: brentuximab vedotin combination, expected 6 May 2027 per the NICE in-development guidance table. Indication per the NICE appraisal record; confirm detail at monthly refresh. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0009",
  "guidance_detail": "NICE appraisal, expected 6 May 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-10",
  "date_quality": "hard",
  "drug": "enfortumab vedotin + pembrolizumab",
  "event_type": "hta_decision",
  "indication": "Perioperative bladder cancer",
  "notes": "NICE technology appraisal: enfortumab vedotin (Padcev, Astellas/Pfizer) with pembrolizumab (Keytruda, Merck) in perioperative bladder cancer, expected 10 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0010",
  "guidance_detail": "NICE appraisal, expected 10 Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "GSK plc",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-10",
  "date_quality": "hard",
  "drug": "bepirovirsen",
  "event_type": "hta_decision",
  "indication": "Chronic hepatitis B",
  "notes": "NICE technology appraisal: bepirovirsen for HBV, expected 10 Mar 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "GSK",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0011",
  "guidance_detail": "NICE appraisal, expected 10 Mar 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-04",
  "company": "Novo Nordisk A/S",
  "competitors": [],
  "country": "Denmark",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-24",
  "date_quality": "hard",
  "drug": "denecimig (Mim8)",
  "event_type": "hta_decision",
  "indication": "Haemophilia A",
  "notes": "NICE technology appraisal: denecimig (Mim8) for haemophilia A, expected 24 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "NVO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0012",
  "guidance_detail": "NICE appraisal, expected 24 Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [
   "v41-0001"
  ],
  "date_history": [],
  "indication_group": "Hematology",
  "last_verified": "2026-10-04"
 },
 {
  "as_of": "2026-09-23",
  "company": "BeOne Medicines Ltd.",
  "competitors": [],
  "country": "China",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-10",
  "date_quality": "hard",
  "drug": "tislelizumab",
  "event_type": "hta_decision",
  "indication": "Oesophageal cancer",
  "notes": "NICE technology appraisal: tislelizumab for oesophageal cancer, expected 10 Feb 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0013",
  "guidance_detail": "NICE appraisal, expected 10 Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "BeOne Medicines Ltd.",
  "competitors": [],
  "country": "China",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-13",
  "date_quality": "hard",
  "drug": "tislelizumab",
  "event_type": "hta_decision",
  "indication": "Nasopharyngeal cancer",
  "notes": "NICE technology appraisal: tislelizumab for nasopharyngeal cancer, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "ONC",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0014",
  "guidance_detail": "NICE appraisal, expected 13 May 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Roche Holding AG",
  "competitors": [],
  "country": "Switzerland",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-13",
  "date_quality": "hard",
  "drug": "obinutuzumab",
  "event_type": "hta_decision",
  "indication": "Lupus",
  "notes": "NICE technology appraisal: obinutuzumab for lupus, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "RHHBY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0015",
  "guidance_detail": "NICE appraisal, expected 13 May 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-27"
 },
 {
  "as_of": "2026-09-23",
  "company": "Incyte Corporation",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-05-13",
  "date_quality": "hard",
  "drug": "povorcitinib",
  "event_type": "hta_decision",
  "indication": "Hidradenitis suppurativa",
  "notes": "NICE technology appraisal: povorcitinib for hidradenitis suppurativa, expected 13 May 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "INCY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0016",
  "guidance_detail": "NICE appraisal, expected 13 May 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Incyte Corporation",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-10",
  "date_quality": "hard",
  "drug": "tafasitamab + R-CHOP",
  "event_type": "hta_decision",
  "indication": "Diffuse large B-cell lymphoma",
  "notes": "NICE technology appraisal: tafasitamab with R-CHOP for DLBCL, expected 10 Jun 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "INCY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0017",
  "guidance_detail": "NICE appraisal, expected 10 Jun 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Incyte Corporation",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-06-03",
  "date_quality": "hard",
  "drug": "ruxolitinib cream",
  "event_type": "hta_decision",
  "indication": "Atopic dermatitis",
  "notes": "NICE technology appraisal: ruxolitinib cream for atopic dermatitis, expected 3 Jun 2027 per the NICE in-development guidance table. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "INCY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0018",
  "guidance_detail": "NICE appraisal, expected 3 Jun 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "AstraZeneca PLC",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-01-13",
  "date_quality": "hard",
  "drug": "trastuzumab deruxtecan (Enhertu)",
  "event_type": "hta_decision",
  "indication": "Gastric cancer (guidance review)",
  "notes": "NICE review of guidance: Enhertu (trastuzumab deruxtecan, AstraZeneca/Daiichi Sankyo) for gastric cancer, expected 13 Jan 2027 per the NICE in-development guidance table. Guidance review, not a first appraisal. NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0019",
  "guidance_detail": "NICE guidance review, expected 13 Jan 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-01",
  "company": "Minoryx Therapeutics",
  "competitors": [],
  "country": "Spain",
  "date_bucket": "2027-Q2",
  "date_exact": "2027-04-11",
  "date_quality": "hard",
  "drug": "leriglitazone",
  "event_type": "hta_decision",
  "indication": "Highly Specialised Technologies appraisal",
  "notes": "NICE Highly Specialised Technologies appraisal: leriglitazone, expected 11 Apr 2027 per the NICE in-development guidance table. Sponsor is private (Minoryx Therapeutics). NICE expected publication dates slip routinely; the date here is the agency-published expected date from the NICE in-development guidance table.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.nice.org.uk/guidance/indevelopment",
  "ticker": "",
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0020",
  "guidance_detail": "NICE HST appraisal, expected 11 Apr 2027; private sponsor.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-09-24",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "encorafenib (Braftovi)",
  "event_type": "hta_decision",
  "indication": "Colorectal cancer, first line",
  "notes": "G-BA benefit assessment decision for encorafenib (Braftovi) in first-line CRC expected early Jan 2027. G-BA decision windows are guidance, not fixed days. Source note: G-BA Verfahren page (2026-07-07): encorafenib (Braftovi) in combination with cetuximab + FOLFOX6 as first-line therapy for metastatic colorectal cancer - benefit assessment procedure active; decision timing inferred from procedure start, bucket kept 2027-Q1. Note: EC approved Braftovi+Erbitux+mFOLFOX6 for 1L mCRC on June 22, 2026. Source: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1233/. Quote: \"Encorafenib in Kombination mit Cetuximab und Fluorouracil, Folinsaure und Oxaliplatin, Behandlung des metastasierten kolorektalen Karzinoms bei erwachsenen Patienten. zur Erstlinientherapie\".",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.g-ba.de",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0022",
  "guidance_detail": "G-BA benefit assessment expected early Jan 2027.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-24",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "enfortumab vedotin + pembrolizumab",
  "event_type": "hta_decision",
  "indication": "Muscle-invasive bladder cancer",
  "notes": "G-BA benefit assessment decision for enfortumab vedotin with pembrolizumab in MIBC expected mid-Jan 2027. G-BA decision windows are guidance, not fixed days. Distinct from the NICE appraisal of the perioperative-bladder combination (separate agency decision). Source note: G-BA Verfahren for enfortumab vedotin + pembrolizumab in MIBC: press release (2026-08-11) confirms the G-BA opened the benefit assessment on August 6, 2026; decision timing inferred from procedure start, bucket kept 2027-Q1. Distinct from the NICE appraisal of the perioperative-bladder indication. Source: https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/1281/. Quote: \"Der Gemeinsame Bundesausschuss (G-BA) hat am 6. August 2026 das Verfahren zur Nutzenbewertung von Enfortumab-Vedotin in Kombination mit Pembrolizumab in der Erstlinienbehandlung des metastasierten Urothelkarzinoms eingeleitet\".",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.g-ba.de",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0023",
  "guidance_detail": "G-BA benefit assessment expected mid-Jan 2027.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-24"
 },
 {
  "as_of": "2026-09-23",
  "company": "Gilead Sciences, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "sacituzumab govitecan (Trodelvy)",
  "event_type": "hta_decision",
  "indication": "Triple-negative breast cancer, first line",
  "notes": "G-BA benefit assessment decision for sacituzumab govitecan in first-line TNBC expected late Jan 2027. G-BA decision windows are guidance, not fixed days.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.g-ba.de",
  "ticker": "GILD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0024",
  "guidance_detail": "G-BA benefit assessment expected late Jan 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-09-23",
  "company": "Novartis AG",
  "competitors": [],
  "country": "Switzerland",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "inclisiran",
  "event_type": "hta_decision",
  "indication": "Paediatric heterozygous familial hypercholesterolaemia",
  "notes": "G-BA benefit assessment decision for inclisiran in paediatric HeFH expected mid-Feb 2027. G-BA decision windows are guidance, not fixed days.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.g-ba.de",
  "ticker": "NVS",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0026",
  "guidance_detail": "G-BA benefit assessment expected mid-Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-09-23"
 },
 {
  "as_of": "2026-10-01",
  "company": "AstraZeneca PLC",
  "competitors": [],
  "country": "United Kingdom",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "datopotamab deruxtecan",
  "event_type": "hta_decision",
  "indication": "Triple-negative breast cancer, first line",
  "notes": "G-BA benefit assessment decision for datopotamab deruxtecan in first-line TNBC expected mid-Feb 2027. G-BA decision windows are guidance, not fixed days.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.g-ba.de",
  "ticker": "AZN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0027",
  "guidance_detail": "G-BA benefit assessment expected mid-Feb 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "EBR Systems, Inc.",
  "competitors": [],
  "country": "Australia",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-03",
  "date_quality": "guidance",
  "drug": "WiSE leadless pacing system",
  "event_type": "hta_decision",
  "indication": "Leadless cardiac pacing",
  "notes": "CMS National Coverage Determination for EBR Systems' WiSE leadless pacing system (ASX:EBR). EBR's June 4, 2026 ASX announcement quotes the CMS NCD tracking sheet: 'Final NCD expected: March 3, 2027' (formal request accepted June 3, 2026; proposed decision memo due Dec 3, 2026). CMS-projected date, contingent on the Dec 3, 2026 proposed memo staying on schedule \u2014 guidance, not a confirmed final NCD. High binary for the small cap. Source note: EBR Systems ASX announcement (September 2026) quotes the CMS NCD tracking sheet again: \"Final NCD expected: March 3, 2027\" (formal request accepted June 3, 2026; proposed memo expected Dec 3, 2026). Same schedule as EBR's June 4, 2026 ASX announcement. CMS-expected dates can shift; final NCD contingent on the December 2026 proposed memo. Row kept at guidance with exact date 2027-03-03. Source: https://announcements.asx.com.au/asxpdf/2026/06/04/pdf/06lx8z7w2jq5l3.pdf. Quote: \"Final NCD expected: March 3, 2027\".",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.businesswire.com/news/home/20260609744651/en/EBR-Systems-Secures-National-Coverage-Analysis-Under-TCET-Pathway-from-CMS-for-the-WiSE-System",
  "ticker": "",
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0028",
  "guidance_detail": "CMS NCD expected per CMS coverage documents.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "mktcap_tier": "unknown",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Organon & Co.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Organon acquisition by Sun Pharma",
  "event_type": "ma_close",
  "indication": "$14.00/share cash (~$11.75B EV) close",
  "notes": "Sun Pharma acquires Organon: $14.00/share cash, ~$11.75B EV, expected close early 2027. Organon shareholders approved the merger at a virtual special meeting on/around July 23, 2026; remaining conditions per the DEFM14A proxy include HSR waiting-period expiry and non-US antitrust / foreign-direct-investment / EU FSR clearances. No regulatory clearance announcements as of Sep 23, 2026. Living row \u2014 update or remove on close/termination.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.businesswire.com/news/home/20260426881370/en/Sun-Pharma-signs-Definitive-Agreement-to-Acquire-Organon",
  "ticker": "OGN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0029",
  "guidance_detail": "Company-guided close early 2027; Organon shareholders approved Jul 23, 2026.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "Sun Pharma's $14.00/share cash acquisition of Organon (~$11.75B EV) is expected to close in the first half of 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Bio-Techne Corporation",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Bio-Techne acquisition by Merck KGaA",
  "event_type": "ma_close",
  "indication": "$73.00/share cash (~$11.3B EV) close",
  "notes": "Merck KGaA acquires Bio-Techne: $73.00/share cash, ~$11.3B EV. Shareholders approved the merger agreement at the Sep 23, 2026 special meeting; HSR waiting period expired Sep 18, 2026. Company continues to expect close late 2026 or early 2027, subject to remaining regulatory approvals.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/bio-techne-shareholders-approve-acquisition-by-merck-kgaa-darmstadt-germany-302887726.html",
  "ticker": "TECH",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0030",
  "guidance_detail": "Shareholders approved Sep 23, 2026; HSR waiting period expired Sep 18, 2026; company-guided close late 2026 or early 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Lantheus Holdings, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Lantheus acquisition by Curium",
  "event_type": "ma_close",
  "indication": "$102.50/share cash + CVR up to $12/share (~$8B) close; Lantheus goes private",
  "notes": "Curium acquires Lantheus: $102.50/share cash + non-transferable CVRs up to $12.00 (through 2030 milestones), ~$8.0B; Lantheus goes private. Definitive agreement signed Aug 3, 2026; DEFM14A proxy filed Sep 8, 2026; virtual special meeting of Lantheus stockholders scheduled Oct 14, 2026, 10:00 a.m. ET (record date Sep 1, 2026). Close guidance unchanged: H1 2027. No regulatory clearances announced. Living row \u2014 update or remove on close/termination.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://investor.lantheus.com/node/17091/pdf",
  "ticker": "LNTH",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0031",
  "guidance_detail": "Company-guided close H1 2027 (definitive agreement Aug 3, 2026).",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "Curium's acquisition of Lantheus ($102.50/share cash plus CVRs worth up to $12/share, ~$8B total) is expected to close in the first half of 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Aethlon Medical, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "Aethlon / North Immunology merger",
  "event_type": "ma_close",
  "indication": "All-stock merger + ~$180M PIPE close; combined company Nasdaq: NRTX",
  "notes": "Aethlon Medical / North Immunology all-stock merger + ~$180M PIPE, guided close Q1 2027 (announcement Sep 17, 2026). Combined company named North Immunology, Inc., Nasdaq ticker NRTX; AEMD holders also get a CVR on legacy Hemopurifier monetization. Conditions: stockholder approvals of both companies, S-4 effectiveness, Nasdaq initial-listing approval. No proxy filed yet; watch for S-4 as next signal. Living row \u2014 update or remove on close/termination.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/aethlon-medical--north-immunology-announce-merger-to-advance-novel-il-13-x-il-18-bispecific-antibody-for-atopic-dermatitis-302881438.html",
  "ticker": "AEMD",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0032",
  "guidance_detail": "Company-guided close Q1 2027 (merger announcement Sep 17, 2026).",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "micro",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "The all-stock merger of Aethlon Medical and North Immunology, plus a ~$180M PIPE, is expected to close in Q1 2027."
 },
 {
  "as_of": "2026-10-01",
  "company": "Centers for Medicare & Medicaid Services (Medicare Drug Price Negotiation Program)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-02-01",
  "date_quality": "hard",
  "drug": "IPAY 2029 selected-drug list",
  "event_type": "pricing_decision",
  "indication": "Medicare drug price negotiation",
  "notes": "CMS publishes the Medicare Drug Price Negotiation selected-drug list for IPAY 2029 (up to 20 Part B/D drugs; first cycle at the 20-drug scale) \u2014 statutory deadline 2027-02-01. Per the proposed-rule summary: \"for IPAY 2029, this information would be published no later than February 1, 2027.\" Statutory date, hard. Ticker-agnostic sector event.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.hfma.org/wp-content/uploads/2026/06/510136_Medicare_Drug_Price_Negotiation_Program_Proposed_Rule_Summary.pdf",
  "ticker": "",
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0033",
  "guidance_detail": "Statutory deadline: CMS publishes IPAY 2029 selected-drug list by 2027-02-01.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Centers for Medicare & Medicaid Services (Medicare Drug Price Negotiation Program)",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-30",
  "date_quality": "guidance",
  "drug": "IPAY 2029 maximum fair prices",
  "event_type": "pricing_decision",
  "indication": "Medicare drug price negotiation",
  "notes": "CMS publishes maximum fair prices (MFPs) for IPAY 2029 selected drugs. IRA statutory deadline: November 30, 2027 (Nov 30 of the year preceding the initial price applicability year) \u2014 publication may come earlier; carried at guidance, quarter bucket, with the statutory day shown as the deadline (not a confirmed publication date). Second-round IRA negotiation wave (up to 20 Part B/D drugs selected by Feb 1, 2027); high binary for any selected-drug sponsor with no prior experience of MFP negotiation.",
  "phase": "",
  "source_type": "agency",
  "source_url": "https://www.hklaw.com/en/insights/publications/2026/06/cms-issues-first-proposed-rule-for-ira-medicare-drug-price-negotiation",
  "ticker": "",
  "us_listed": false,
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0034",
  "guidance_detail": "IRA statutory deadline: publish MFPs by November 30, 2027; may publish earlier.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "BioNTech SE",
  "competitors": [],
  "country": "Germany",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "mRNA-vaccine patent dispute (GSK v. Pfizer/BioNTech)",
  "event_type": "litigation_milestone",
  "indication": "Patent infringement, mRNA vaccines",
  "notes": "GSK v. Pfizer/BioNTech mRNA-vaccine patent infringement \u2014 five-day jury trial, summer 2027 (D. Del. 1:24-cv-00512-GBW; Judge Gregory B. Williams entered a scheduling order on April 4, 2025). \"Summer 2027\" is season precision from a court scheduling order \u2014 kept at guidance with bucket 2027-Q3 per the no-invented-precision rule; no day exists in the order. Source note: Goodwin's write-up of the court scheduling order confirms a five-day jury trial in \"summer 2027\" for GSK v. Pfizer/BioNTech mRNA-vaccine patent infringement (D. Del. 1:24-cv-00512-GBW). Summer spans late Q2 and Q3, so the row's 2027-Q3 bucket was over-precise; rebucketed to 2027. Source: http://www.goodwinlaw.com/en/insights/blogs/2025/04/gsk-and-pfizer-stipulate-to-dismissal-of-rsv-vaccines-lawsuit. Quote: \"summer 2027\".",
  "phase": "",
  "source_type": "trade press",
  "source_url": "http://www.goodwinlaw.com/en/insights/blogs/2025/04/gsk-and-pfizer-stipulate-to-dismissal-of-rsv-vaccines-lawsuit",
  "ticker": "BNTX",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0035",
  "guidance_detail": "Court scheduling order sets five-day jury trial for summer 2027.",
  "audit_status": "v20_reverified",
  "audit_action": "guidance_revision",
  "date_history": [
   {
    "from": "2027-Q3",
    "to": "2027",
    "changed": "2026-09-23",
    "why": "Court scheduling order confirms five-day jury trial in summer 2027; Q3 was over-precise"
   }
  ],
  "mktcap_tier": "large",
  "impact": "low",
  "related_events": [],
  "indication_group": "Infectious Disease",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Pfizer Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-05",
  "date_quality": "hard",
  "drug": "palbociclib (Ibrance)",
  "event_type": "key_patent_expiry",
  "indication": "US composition-of-matter patent expiry",
  "notes": "Ibrance (palbociclib) US composition-of-matter patent RE47,739 effective expiry September 5, 2027 \u2014 first-wave LOE (~$4.2B annualized, ~7% of Pfizer). Pfizer's PTE certificate extended the term to March 5, 2027 (PR, 2021) but noted it 'does not include potential pediatric exclusivity'; that exclusivity has since been granted \u2014 FDA Orange Book (NDA 207103, openFDA last_updated 2026-09-22) lists RE47739*PED expiring 20270905, making September 5, 2027 the effective US LOE. Later-listed solid-forms patent 10723730 (expires 2034) could independently delay full generic entry \u2014 beyond this row's composition-of-matter claim. Fixed expiry date only; generic-entry timing stays out of scope.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-confirms-us-patent-term-extension-ibrancer",
  "ticker": "PFE",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0037",
  "guidance_detail": "US patent RE47,739 effective expiry September 5, 2027 (Pfizer PR + FDA Orange Book PED).",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Astellas Pharma Inc.",
  "competitors": [],
  "country": "Japan",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-08-13",
  "date_quality": "hard",
  "drug": "enzalutamide (Xtandi)",
  "event_type": "key_patent_expiry",
  "indication": "US patent protection expiry",
  "notes": "Xtandi (enzalutamide) US patent protection expiry August 13, 2027 \u2014 first-wave LOE (~$5B global, >40% of Astellas; Pfizer ~$1.4B/yr alliance revenue). FDA Orange Book (NDA 203415, openFDA last_updated 2026-09-22): US 7,709,517 (drug substance + drug product flags, Regents of UC) expires 20270813; no *PED row. Astellas shareholder Q&A (17th annual meeting): 'XTANDI's substance patents will expire in August 2027 in the United States'. Later narrow use/formulation patents (e.g., 12,161,628 rifampin-combination use, Feb 2037) are beyond this row's substance-patent claim. Fixed expiry date only; generic-entry timing stays out of scope. [2026-09-23 source check] URL contained an unencoded space (probe InvalidURL); percent-encoded. Needs browser verification that the Astellas shareholder-meeting PDF resolves.",
  "phase": "",
  "source_type": "regulatory (FDA)",
  "source_url": "https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2021/209614Orig1s000ltr.pdf",
  "ticker": "ALPMY",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0038",
  "guidance_detail": "US 7,709,517 expires August 13, 2027 (FDA Orange Book; Astellas shareholder Q&A).",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": "US patent protection on enzalutamide (Xtandi) expires on 2027-08-13, opening the door to generic competition.",
  "evidence_note": "Re-sourced 2026-09-24: FDA ANDA approval letter (ANDA 209614) cites Orange Book RLD Xtandi Capsules: US Patent 7,709,517 expires August 13 2027; supports exact 2027-08-13 date."
 },
 {
  "as_of": "2026-10-01",
  "company": "Biohaven Ltd.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "opakalim / Kv7 ion-channel platform licensing (SK Biopharmaceuticals)",
  "event_type": "milestone_payment",
  "indication": "Standalone licensing payment",
  "notes": "Biohaven to receive $50M second tranche of cash consideration from SK Biopharmaceuticals (Kv7/opakalim licensing), payable in 2027: \"Biohaven will receive $400 million in cash consideration, consisting of $350 million payable at closing and an additional $50 million payable in 2027\". Standalone, fixed calendar-2027 payment, independent of any readout \u2014 not a derivative of a listed event.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/biohaven-and-sk-biopharmaceuticals-enter-into-strategic-global-licensing-agreement-for-novel-kv7-ion-channel-platform-and-opakalim-lead-candidate-for-epilepsy-302860299.html",
  "ticker": "BHVN",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0039",
  "guidance_detail": "Company PR: $50M second tranche payable in 2027.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Harrow, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "OPUVIZ (aflibercept-yszy, EYLEA biosimilar)",
  "event_type": "biosimilar_launch",
  "indication": "US biosimilar launch",
  "notes": "Harrow OPUVIZ (aflibercept-yszy), an EYLEA-referenced biosimilar \u2014 NOT a Lucentis biosimilar (the Lucentis biosimilar is BYOOVIZ/ranibizumab-nuna). Current company guidance (Q2 2026 earnings, Aug 10, 2026 8-K letter/PR): launch expected 'in 2027' / 'early 2027' (earnings-call summary); the month-specific 'January 2027' guidance from the March 2026 deck is no longer stated. IP path settled: Samsung Bioepis\u2013Regeneron settlement (Feb 2026) permits US launch beginning January 2027. Kept at guidance, H1 bucket \u2014 no invented month.",
  "phase": "",
  "source_type": "SEC filing",
  "source_url": "https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=320258586&type=PDF&symbol=HROW&cdn=d09aff73612616bec86a1b1c3e3eabe2&companyName=Harrow+Inc+Com&formType=8-K&formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&dateFiled=2026-08-10",
  "ticker": "HROW",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0040",
  "guidance_detail": "Company guidance: US launch expected in 2027 / early 2027 (Q2 2026 earnings).",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01"
 },
 {
  "as_of": "2026-10-01",
  "company": "Alvotech",
  "competitors": [],
  "country": "Luxembourg",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "AVT16 (proposed interchangeable biosimilar to Entyvio/vedolizumab)",
  "event_type": "biosimilar_decision",
  "indication": "Ulcerative colitis / Crohn's disease",
  "notes": "Alvotech (development/manufacturing; Teva to commercialize in the US) announced FDA acceptance for review of the aBLA for AVT16, a proposed interchangeable biosimilar to Entyvio (vedolizumab), on June 8, 2026; company expects a potential FDA decision in Q1 2027. Pipeline de-risking catalyst, NOT a commercial one: Entyvio's US patent protection runs to May 2032, so approval does not enable near-term launch.",
  "phase": "",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/06/08/3307832/0/en/Alvotech-announces-FDA-acceptance-of-Biologics-License-Application-for-AVT16-a-proposed-interchangeable-biosimilar-to-Entyvio.html",
  "ticker": "ALVO",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v19-0041",
  "guidance_detail": "FDA accepted the AVT16 aBLA (Jun 8, 2026); company expects Q1 2027 decision.",
  "audit_status": "v19_admitted",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v19-0042",
  "ticker": "QURE",
  "company": "uniQure N.V.",
  "us_listed": true,
  "us_tradable": true,
  "country": "Netherlands",
  "drug": "ifezuntirgene inilparvovec (AMT-130)",
  "indication": "Huntington's disease",
  "nct_id": "",
  "phase": "",
  "event_type": "hta_decision",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "source_type": "agency",
  "source_url": "https://icer.org/news-insights/press-releases/institute-for-clinical-and-economic-review-to-assess-gene-therapy-for-huntingtons-disease/",
  "source_date": "2026-08-20",
  "notes": "ICER assessment of ifezuntirgene inilparvovec (AMT-130) for Huntington's disease \u2014 the ICER value-assessment report will be the subject of a Midwest CEPAC meeting in March 2027 (ICER press release, Aug 20, 2026; draft scoping document comments due Sep 11, 2026). Payer-value narrative into a potential mid-2027 BLA decision: QURE submitted the BLA for accelerated approval on Sep 2, 2026 (Breakthrough/RMAT/Fast Track). Low-medium binary, informational \u2014 an ICER report shapes payer coverage posture, not approval. Kept at guidance, quarter bucket; no day published.",
  "guidance_detail": "ICER press release (Aug 20, 2026): report subject of Midwest CEPAC meeting in March 2027.",
  "audit_status": "verified",
  "audit_action": "none",
  "as_of": "2026-10-01",
  "competitors": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "",
  "trial_status": "",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01"
 },
 {
  "record_id": "v20-0001",
  "ticker": "NUVB",
  "company": "Nuvation Bio Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "IBTROZI (taletrectinib)",
  "indication": "Updated efficacy information in TKI-naive and TKI-pretreated advanced ROS1-positive non-small cell lung cancer (NSCLC); submission fulfills an FDA post-marketing commitment.",
  "phase": null,
  "event_type": "pdufa",
  "date_exact": "2027-01-04",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.prnewswire.com/news-releases/nuvation-bio-announces-fda-acceptance-of-supplemental-new-drug-application-for-ibtrozi-taletrectinib-with-updated-duration-of-response-in-advanced-ros1-positive-non-small-cell-lung-cancer-302763329.html",
  "source_date": "2026-05",
  "as_of": "2026-10-20",
  "notes": "FDA accepted the sNDA for IBTROZI (taletrectinib) with updated duration-of-response data in TKI-naive and TKI-pretreated advanced ROS1+ NSCLC; target action date January 4, 2027. Quote: \"announced today that the U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) with updated data for IBTROZI (taletrectinib) in both TKI-naive and TKI-pretreated advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) with a target action date of January 4, 2027.\" Nuvation Bio is NYSE: NUVB. Review class not disclosed in the acceptance release; do not assume Priority vs Standard. Per sponsor-issued PRNewswire release 2026-09-23.",
  "guidance_detail": "Sponsor-issued acceptance release; review class undisclosed.",
  "audit_status": "v20_reverified",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "why_it_matters": "The FDA's decision date on IBTROZI (taletrectinib) for ROS1-positive non-small cell lung cancer falls on 2027-01-04 \u2014 the agency's yes-or-no moment for Nuvation Bio Inc.'s application."
 },
 {
  "record_id": "v20-0002",
  "ticker": "SVRA",
  "company": "Savara Inc.",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "drug": "MOLBREEVI (molgramostim)",
  "indication": "autoimmune pulmonary alveolar proteinosis (aPAP) (EU)",
  "phase": null,
  "event_type": "chmp_opinion",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company IR",
  "source_url": "https://investors.savarapharma.com/news/news-details/2026/Savara-Announces-European-Medicines-Agency-EMA-Validation-of-Marketing-Authorization-Application-MAA-for-MOLBREEVI-in-Autoimmune-Pulmonary-Alveolar-Proteinosis-Autoimmune-PAP/default.aspx",
  "source_date": "",
  "as_of": "2026-10-01",
  "notes": "Savara (Nasdaq: SVRA) announced EMA validation of the Marketing Authorization Application for MOLBREEVI in autoimmune pulmonary alveolar proteinosis; review proceeds through CHMP; company expects a decision in Q1 2027. New ticker entry. Per Savara IR announcement 2026-09-23.",
  "guidance_detail": "Company expects CHMP decision in Q1 2027.",
  "audit_status": "v20_reverified",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Europe's medicines committee is expected to give its opinion on MOLBREEVI (molgramostim) in autoimmune pulmonary alveolar proteinosis (aPAP) (EU) in Q1 2027, the step just before a formal EU decision."
 },
 {
  "record_id": "v20-0003",
  "ticker": "PHVS",
  "company": "Pharvaris N.V.",
  "us_listed": true,
  "us_tradable": true,
  "country": "Netherlands",
  "drug": "deucrictibant immediate-release (IR)",
  "indication": "on-demand treatment of hereditary angioedema (HAE) attacks (EU)",
  "phase": null,
  "event_type": "chmp_opinion",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "inferred",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "competitors": [],
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/08/12/3343484/0/en/pharvaris-reports-second-quarter-2026-financial-results-and-provides-business-update.html",
  "source_date": "2026-08-12",
  "as_of": "2026-10-01",
  "notes": "Deucrictibant IR CHMP opinion in H1 2027 inferred from centralized-procedure clock derivation, not sponsor/agency guidance - quality stays inferred. No EU/EMA rows previously in book for deucrictibant IR. Distinct from the US deucrictibant IR PDUFA row (2027-04-23, hard), the deucrictibant XR nda_filing (2027-Q2), and the readout (2027-Q1).",
  "guidance_detail": "Centralized-procedure clock derivation; no sponsor/agency timing guidance.",
  "audit_status": "v20_reverified",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "Europe's medicines committee is expected to give its opinion on deucrictibant immediate-release (IR) in on-demand treatment of hereditary angioedema (HAE) attacks (EU) in the first half of 2027, the step just before a formal EU decision."
 },
 {
  "record_id": "v40-0001",
  "as_of": "2026-10-01",
  "company": "Cardiol Therapeutics Inc.",
  "ticker": "CRDL",
  "drug": "CardiolRx (cannabidiol oral solution)",
  "indication": "recurrent pericarditis",
  "phase": "Phase 3",
  "event_type": "readout",
  "date_quality": "guidance",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "guidance_detail": "Company guidance (Sept 23, 2026): MAVERIC enrollment target achieved ahead of schedule; trial expanded to strengthen efficacy assessment; topline data now expected mid-2027 (previously Q1 2027).",
  "notes": "Phase 3 MAVERIC evaluating CardiolRx (cannabidiol oral solution) in recurrent pericarditis. September 23, 2026 company release: enrollment target achieved ahead of schedule; trial expanded to strengthen the efficacy assessment; topline data now expected mid-2027 (moved from Q1 2027). Company PR reproduced verbatim by PR Newswire feed.",
  "source_type": "company PR",
  "source_url": "https://www.morningstar.com/news/pr-newswire/20260923to54697/cardiol-therapeutics-achieves-phase-iii-maveric-enrollment-target-ahead-of-schedule-and-expands-pivotal-trial-to-strengthen-assessment-of-cardiolrxs-efficacy",
  "source_date": "2026-09-23",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "RECRUITING",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "mktcap_tier": "micro",
  "impact": "high",
  "competitors": [],
  "related_events": [],
  "date_history": [
   {
    "as_of": "2026-09-24",
    "change": "added; timing moved from Q1 2027 to mid-2027 per company release"
   }
  ],
  "audit_status": "v40_admitted",
  "audit_action": "add",
  "last_verified": "2026-10-01",
  "indication_group": "Cardiology",
  "why_it_matters": "Phase 3 MAVERIC readout of CardiolRx in recurrent pericarditis, with topline now guided to mid-2027 after the trial was expanded."
 },
 {
  "record_id": "v40-0002",
  "as_of": "2026-10-01",
  "company": "Werewolf Therapeutics, Inc.",
  "ticker": "HOWL",
  "drug": "Werewolf\u2013Ambros Therapeutics merger",
  "indication": "all-stock; combined company expected to trade as AMBX; close Q1 2027",
  "phase": "",
  "event_type": "ma_close",
  "date_quality": "guidance",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "guidance_detail": "Definitive merger agreement (Aug 21, 2026): all-stock transaction; combined company to operate as Ambros Therapeutics, expected to trade under Nasdaq ticker AMBX; transaction expected to close Q1 2027.",
  "notes": "Werewolf Therapeutics (Nasdaq: HOWL) and Ambros Therapeutics announced a definitive merger agreement (Aug 21, 2026): all-stock combination; combined company to operate as Ambros Therapeutics, headquartered in San Diego, expected to trade under Nasdaq ticker AMBX. Merger expected to close Q1 2027. Concurrent oversubscribed $150M private placement funds operations through CRPS-RISE Phase 3 topline and planned NDA submission (cash runway into 1H 2029). Context: Werewolf sold its preclinical INDUCER platform to EMD Serono (Sept 2026); the two INDUCER IND rows (v16-0675, v16-0676) are parked on the watchlist pending confirmation of the IND programs under the combined company. Living row \u2014 update or remove on close/termination.",
  "source_type": "company IR",
  "source_url": "https://ambrostherapeutics.com/news/werewolf-therapeutics-and-ambros-therapeutics-announce-merger-agreement-and-concurrent-oversubscribed-150-million-private-placement/",
  "source_date": "2026-08-21",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "us_listed": true,
  "us_tradable": true,
  "country": "United States",
  "mktcap_tier": "micro",
  "impact": "high",
  "competitors": [],
  "related_events": [],
  "date_history": [],
  "audit_status": "v40_admitted",
  "audit_action": "add",
  "last_verified": "2026-10-01",
  "indication_group": "Other",
  "why_it_matters": "Definitive merger agreement expected to close in Q1 2027, with the combined company trading as AMBX."
 },
 {
  "as_of": "2026-10-01",
  "company": "Belite Bio, Inc",
  "country": "Japan",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "tinlarebant",
  "event_type": "regulatory_other",
  "impact": "high",
  "indication": "Stargardt disease type 1",
  "mktcap_tier": "mid",
  "nct_id": null,
  "notes": "Belite Bio submitted a New Drug Application to Japan's health ministry (MHLW) for tinlarebant in Stargardt disease type 1 on September 8, 2026. The drug carries Sakigake designation \u2014 Japan's fast-track review pathway for breakthrough medicines. Belite says the Japan filing was made 'side-by-side with the United States NDA to enable simultaneous early access for patients in both regions'. The US decision date is February 12, 2027 (book row v16-1012), so a Japan decision is expected in the same window, first half of 2027. No exact Japan decision date has been printed by the company or PMDA/MHLW, so this stays a guided window, not a hard date. No clock-math was used \u2014 the window comes from the company's own 'simultaneous early access' wording.",
  "phase": "",
  "record_id": "v40-0500",
  "source_date": "2026-09-08",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/belite-bio-announces-submission-of-new-drug-application-to-the-ministry-of-health-labour-and-welfare-in-japan-under-the-sakigake-designation-system-for-tinlarebant-for-the-treatment-of-stargardt-disease-type-1",
  "ticker": "BLTE",
  "adcom_planned": "unknown",
  "application_type": "",
  "audit_action": "none",
  "audit_status": "v40_new",
  "competitors": [],
  "date_history": [],
  "guidance_detail": "",
  "related_events": [],
  "review_class": "",
  "trial_status": "",
  "us_listed": true,
  "us_tradable": true,
  "last_verified": "2026-10-01",
  "indication_group": "Ophthalmology",
  "why_it_matters": "Japan NDA decision on tinlarebant for Stargardt disease type 1, filed side-by-side with the US application under the Sakigake fast-track pathway."
 },
 {
  "ticker": "PHAR",
  "company": "Pharming Group N.V.",
  "country": "Netherlands",
  "us_listed": true,
  "us_tradable": true,
  "drug": "leniolisib (Joenja)",
  "indication": "activated PI3K-delta syndrome (APDS), lower-dose pediatric (4+ yrs, 13 to <27 kg)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-01-30",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [],
  "source_url": "https://www.globenewswire.com/news-release/2026/09/25/3369191/0/en/pharming-announces-u-s-fda-acceptance-and-priority-review-of-snda-for-lower-doses-of-joenja-to-treat-children-with-apds.html",
  "source_type": "company PR",
  "source_date": "2026-09-25",
  "as_of": "2026-10-01",
  "notes": "FDA accepted sNDA and granted Priority Review for lower doses of Joenja (leniolisib), oral PI3K-delta inhibitor, for children aged 4+ weighing 13 to <27 kg with APDS (activated phosphoinositide 3-kinase delta syndrome); PDUFA target action date January 30, 2027 per Sep 25, 2026 company PR. Supported by positive open-label Phase 3 data in children 4-11 yrs (reduced lymphadenopathy, increased naive B cells). Would extend Joenja to eligible patients 4+ weighing 13+ kg.",
  "guidance_detail": "FDA accepted sNDA with Priority Review; PDUFA target action date January 30, 2027 (Sep 25, 2026 company PR).",
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "priority",
  "adcom_planned": "unknown",
  "trial_status": "",
  "record_id": "v40-0501",
  "audit_status": "v40_new",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision date on lower pediatric doses of Joenja for APDS falls on 2027-01-30 \u2014 a Priority Review label expansion for Pharming Group N.V.'s rare-disease franchise."
 },
 {
  "ticker": "RHHBY",
  "company": "Roche Holding AG",
  "country": "Switzerland",
  "us_listed": true,
  "us_tradable": true,
  "drug": "fenebrutinib",
  "indication": "relapsing multiple sclerosis (RMS) and primary progressive MS (PPMS)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "competitors": [
   "Ocrevus (Roche)",
   "Kesimpta (Novartis)"
  ],
  "source_url": "https://www.roche.com/investors/updates/inv-update-2026-09-30",
  "source_type": "company IR",
  "source_date": "2026-09-30",
  "as_of": "2026-10-01",
  "notes": "FDA accepted NDA under Priority Review for fenebrutinib, oral non-covalent BTK inhibitor, in relapsing MS and primary progressive MS (first BTK inhibitor accepted in both populations) per Sep 30, 2026 Roche investor update. Supported by three positive Phase 3s: FENhance 1 & 2 (ARR -51.1%, -58.5% vs teriflunomide) and FENtrepid (non-inferior to Ocrevus on cCDP12, HR 0.88). Roche disclosed no PDUFA date; Q1 2027 window inferred from the priority-review clock \u2014 do not treat as a hard date.",
  "guidance_detail": "NDA accepted under Priority Review (Sep 30, 2026 Roche update); no PDUFA date disclosed \u2014 Q1 2027 window inferred from the 6-month priority-review clock.",
  "nct_id": "",
  "application_type": "NDA",
  "review_class": "priority",
  "adcom_planned": "unknown",
  "trial_status": "",
  "record_id": "v40-0502",
  "audit_status": "v40_new",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "why_it_matters": "The FDA's decision on fenebrutinib \u2014 the first BTK inhibitor submitted for both relapsing and primary progressive MS \u2014 is expected in Q1 2027 under Priority Review; the exact PDUFA date has not been disclosed."
 },
 {
  "ticker": "COYA",
  "company": "Coya Therapeutics, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "COYA 302",
  "indication": "amyotrophic lateral sclerosis (ALS)",
  "event_type": "readout",
  "phase": "Phase 2/3",
  "date_exact": null,
  "date_bucket": "2027-Q2",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.businesswire.com/news/home/20260915845910/en/Coya-Therapeutics-Announces-Enrollment-of-100th-Participant-in-Phase-23-ALSTARS-Trial-of-COYA-302-for-the-Treatment-of-ALS",
  "source_type": "company PR",
  "source_date": "2026-09-15",
  "as_of": "2026-10-01",
  "notes": "Company enrolled the 100th participant in the Phase 2/3 ALSTARS trial of COYA 302 (proprietary low-dose IL-2 + CTLA-4 Ig) in ALS; full enrollment of 120 participants expected within weeks, with topline data anticipated early Q2 2027 per Sep 15, 2026 company PR. FDA Fast Track designation for COYA 302 in ALS. Found via Oct 2026 CT.gov coverage-gap sweep.",
  "guidance_detail": "Topline data from the Phase 2/3 ALSTARS trial anticipated early Q2 2027 (Sep 15, 2026 company PR).",
  "nct_id": "NCT07161999",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ongoing",
  "record_id": "v40-0503",
  "audit_status": "v40_new",
  "audit_action": "added",
  "date_history": [],
  "impact": "high",
  "indication_group": "Neurology",
  "last_verified": "2026-10-01",
  "mktcap_tier": "micro",
  "related_events": [],
  "why_it_matters": "COYA 302 is Coya's lead program in ALS with Fast Track designation, and the ALSTARS readout is the first efficacy test of its Treg-enhancing approach in patients."
 },
 {
  "ticker": "MESO",
  "company": "Mesoblast Limited",
  "country": "Australia",
  "us_listed": true,
  "us_tradable": true,
  "drug": "rexlemestrocel-L",
  "indication": "chronic low back pain (degenerative disc disease)",
  "event_type": "readout",
  "phase": "Phase 3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://s2.listcorp.com/asx/msb/mesoblast-limited/news/patient-recruitment-target-achieved-in-clbp-pivotal-trial-3345681.pdf",
  "source_type": "company PR",
  "source_date": "2026-04-29",
  "as_of": "2026-10-01",
  "notes": "Pivotal Phase 3 MSB-DR004 trial of rexlemestrocel-L (single intradiscal injection vs sham) in chronic low back pain due to degenerative disc disease achieved recruitment target (300+ patients; expanded to 350); topline results expected mid-CY2027 after the last patient completes 12-month follow-up per Apr 2026 company announcement. Positive readout to support BLA filing expected Q3 CY2027. FDA RMAT designation. Nasdaq-listed (MESO) + ASX. Found via Oct 2026 CT.gov coverage-gap sweep.",
  "guidance_detail": "Topline results expected mid-CY2027 after last patient completes 12-month follow-up (Apr 2026 company announcement); treatment completion announced Aug 2026.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ongoing",
  "record_id": "v40-0504",
  "audit_status": "v40_new",
  "audit_action": "added",
  "date_history": [],
  "impact": "high",
  "indication_group": "Pain",
  "last_verified": "2026-10-01",
  "mktcap_tier": "mid",
  "related_events": [],
  "why_it_matters": "A positive MSB-DR004 readout would support Mesoblast's planned Q3 2027 BLA filing for rexlemestrocel-L in chronic low back pain, a large market with no approved disease-modifying therapy."
 },
 {
  "ticker": "OKYO",
  "company": "OKYO Pharma Limited",
  "country": "United Kingdom",
  "us_listed": true,
  "us_tradable": true,
  "drug": "urcosimod (OK-101)",
  "indication": "neuropathic corneal pain",
  "event_type": "readout",
  "phase": "Phase 2/3",
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://inovation.escrs.org/wp-content/uploads/2026/08/ESCRS26-ECS-2338Support-documents_10002148.pdf",
  "source_type": "company PR",
  "source_date": "2026-08-01",
  "as_of": "2026-10-01",
  "notes": "Company corporate summary (ESCRS 2026): Phase 2b/3 trial of urcosimod 0.05% eyedrops in neuropathic corneal pain (~150 subjects, design confirmed with FDA, Fast Track designation) fully enrolled expected 4Q26, topline data expected 1H2027. Sep 29, 2026 company PR adds a global Phase 3 pivotal trial (111 patients, single-dose regimen) to initiate H2 2026. Nasdaq-listed (OKYO). Found via Oct 2026 CT.gov coverage-gap sweep.",
  "guidance_detail": "Topline data from Phase 2b/3 NCP trial expected 1H2027 (company corporate summary, ESCRS 2026 submission).",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ongoing",
  "record_id": "v40-0505",
  "audit_status": "v40_new",
  "audit_action": "added",
  "date_history": [],
  "impact": "high",
  "indication_group": "Ophthalmology",
  "last_verified": "2026-10-01",
  "mktcap_tier": "micro",
  "related_events": [],
  "why_it_matters": "Urcosimod would be the first FDA-approved therapy for neuropathic corneal pain, a condition with no approved treatment options."
 },
 {
  "ticker": "HURA",
  "company": "TuHURA Biosciences, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "IFx-2.0",
  "indication": "advanced/metastatic Merkel cell carcinoma (1L, + Keytruda)",
  "event_type": "readout",
  "phase": "Phase 3",
  "date_exact": null,
  "date_bucket": "2027-H2",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://www.prnewswire.com/news-releases/tuhura-biosciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-a-corporate-update-302730804.html",
  "source_type": "company PR",
  "source_date": "2026-04-01",
  "as_of": "2026-10-01",
  "notes": "Randomized placebo-controlled Phase 3 accelerated-approval trial of IFx-2.0 (innate immune agonist) as adjunctive therapy to Keytruda in first-line advanced/metastatic Merkel cell carcinoma, conducted under FDA SPA; company anticipates topline results 2H 2027 and enrollment completion mid-2027 per Apr 1, 2026 company PR. Primary endpoint ORR (accelerated approval); PFS key secondary. Nasdaq-listed (HURA). Found via Oct 2026 CT.gov coverage-gap sweep.",
  "guidance_detail": "2H 2027: anticipate topline results from the Phase 3 accelerated approval trial (Apr 1, 2026 company PR).",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "ongoing",
  "record_id": "v40-0506",
  "audit_status": "v40_new",
  "audit_action": "added",
  "date_history": [],
  "impact": "high",
  "indication_group": "Oncology",
  "last_verified": "2026-10-01",
  "mktcap_tier": "micro",
  "related_events": [],
  "why_it_matters": "The Phase 3 readout is the registration decision point for IFx-2.0, TuHURA's lead asset, in first-line advanced Merkel cell carcinoma under an FDA SPA."
 },
 {
  "company": "EADV Congress 2027 (European Academy of Dermatology and Venereology, 36th Congress)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-22",
  "date_quality": "hard",
  "notes": "Amsterdam, Netherlands; September 22-25, 2027; dermatology/venereology",
  "country": "Netherlands",
  "source_url": "https://eadv.org/events/calendar/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-01",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v40-0507",
  "guidance_detail": "Amsterdam, Netherlands; September 22-25, 2027; dermatology/venereology",
  "audit_status": "v40_new",
  "audit_action": "added",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-01",
  "why_it_matters": ""
 },
 {
  "company": "CTOS Annual Meeting 2027 (Connective Tissue Oncology Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-10-27",
  "date_quality": "hard",
  "notes": "Austria Center Vienna, Vienna, Austria; October 27-30, 2027; sarcoma/connective tissue oncology",
  "country": "Austria",
  "source_url": "https://www.ctos.org/Meeting/FutureMeetings.aspx",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v40-0508",
  "guidance_detail": "Austria Center Vienna, Vienna, Austria; October 27-30, 2027; sarcoma/connective tissue oncology",
  "audit_status": "v40_new",
  "audit_action": "added",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20",
  "why_it_matters": ""
 },
 {
  "ticker": "MBRX",
  "company": "Moleculin Biotech, Inc.",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "Annamycin + cytarabine (AnnAraC)",
  "indication": "Relapsed/refractory acute myeloid leukemia (R/R AML)",
  "event_type": "readout",
  "phase": "Phase 2/3",
  "date_exact": null,
  "date_bucket": "2027-Q1",
  "date_quality": "guidance",
  "source_url": "https://moleculin.com/moleculin-biotech-completes-enrollment-in-part-a-of-phase-2-3-r-r-aml-miracle-trial-keeping-program-on-track-for-q1-2027-data-readout/",
  "source_type": "company PR",
  "source_date": "2026-09-29",
  "as_of": "2026-10-20",
  "notes": "Part A of pivotal Phase 2/3 MIRACLE trial: enrollment closed with 89 subjects (plus one in screening); comprehensive Part A data readout planned Q1 2027. Final Part A population expected ~50/50 between prior intensive 7+3 chemotherapy ('fit') and prior venetoclax-based regimens ('unfit'); company notes the venetoclax-relapsed population is a more challenging environment for responses. Blinded data continue to show no cardiotoxicity. Readout will be deeper than the earlier 45-patient interim readout and guide dose selection for Part B.",
  "guidance_detail": "Comprehensive Part A data readout in the first quarter of 2027, per company PR September 29, 2026.",
  "nct_id": "",
  "record_id": "v40-0509",
  "audit_status": "v40_new",
  "audit_action": "added",
  "date_history": [],
  "impact": "high",
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "mktcap_tier": "micro",
  "related_events": [],
  "why_it_matters": "MIRACLE Part A is the key binary data event for Annamycin, Moleculin's lead program, with a full 89-patient randomized dataset due in Q1 2027 after enrollment closed.",
  "trial_status": "",
  "competitors": [],
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown"
 },
 {
  "ticker": "NVO",
  "company": "Novo Nordisk A/S",
  "country": "Denmark",
  "us_listed": true,
  "us_tradable": true,
  "drug": "denecimig (Mim8)",
  "indication": "Haemophilia A, with or without inhibitors (adults and children)",
  "event_type": "regulatory_other",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [
   "Hemlibra/emicizumab (Roche \u2014 FVIII mimetic)",
   "Altuviiio/efanesoctocog alfa (Sanofi/Sobi)"
  ],
  "source_url": "https://www.globenewswire.com/news-release/2026/10/02/3374048/0/en/novo-provides-update-on-the-denecimig-biologics-license-application-bla-in-the-us.html",
  "source_type": "company PR",
  "as_of": "2026-11-01",
  "notes": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA (a PDUFA date requires an FDA acceptance letter / communicated action date): Novo submitted the denecimig BLA in September 2025 (decision had been anticipated Q3 2026). On 02 Oct 2026 Novo announced FDA extended the review with no new timeline, solely due to manufacturing-facility remediation after a pre-license inspection; FDA identified no deficiencies in FRONTIER efficacy/safety data. Novo guides US launch H1 2027 pending approval, no impact to 2026 outlook. CHMP positive opinion 17 Sep 2026 (EMA pending). Re-verify at monthly refresh. Re-checked 2026-11-01: no new FDA timeline disclosed since the 02 Oct 2026 extension announcement; H1 2027 US launch guidance stands.",
  "guidance_detail": "REGULATORY WATCH \u2014 not an FDA-confirmed PDUFA: FDA review extended 02 Oct 2026, no new action date; company guides H1 2027 US launch.",
  "nct_id": "",
  "application_type": "BLA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-02",
  "record_id": "v41-0001",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v19-0012"
  ],
  "date_history": [
   {
    "as_of": "2026-10-04",
    "change": "added; FDA review extended 02 Oct 2026 with no new action date, company-guided H1 2027 US launch"
   }
  ],
  "indication_group": "Hematology",
  "last_verified": "2026-11-01",
  "why_it_matters": "Denecimig is Novo's FVIIIa-mimetic for haemophilia A; its US approval slipped past Q3 2026 on a manufacturing-facility issue (not clinical data), with a company-guided H1 2027 launch \u2014 a dated US regulatory watch where no PDUFA date currently exists."
 },
 {
  "as_of": "2026-10-09",
  "ticker": "BBIO",
  "company": "BridgeBio Pharma, Inc.",
  "competitors": [
   "Vosoritide/Voxzogo (BioMarin)",
   "TransCon CNP (Ascendis Pharma)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "infigratinib",
  "indication": "achondroplasia (children)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-04",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "notes": "FDA accepted the NDA for oral infigratinib for filing and granted Priority Review (announced Oct 6, 2026); PDUFA target action date February 4, 2027. PROPEL 3 met its primary endpoint and key secondaries: largest AHV treatment effect of any Phase 3 study in achondroplasia (+2.10 cm/yr, p<0.0001), and the first and only statistically significant improvement in both body proportionality and arm span in an achondroplasia Phase 3. If approved, oral infigratinib would be the first and only approved oral therapy for children with achondroplasia.",
  "guidance_detail": "FDA accepted the NDA for oral infigratinib (achondroplasia, children) for filing with Priority Review; PDUFA target action date February 4, 2027.",
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-06",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/10/06/3375352/0/en/bridgebio-announces-fda-acceptance-and-priority-review-of-nda-for-oral-infigratinib-for-children-with-achondroplasia.html",
  "record_id": "v41-0002",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "large",
  "impact": "medium",
  "related_events": [
   "v16-0861"
  ],
  "date_history": [
   {
    "as_of": "2026-10-09",
    "change": "added; NDA accepted for filing with Priority Review 06 Oct 2026, PDUFA target action date 2027-02-04"
   }
  ],
  "indication_group": "Rare Disease/Genetic",
  "last_verified": "2026-10-09",
  "why_it_matters": "The FDA's decision date on oral infigratinib for achondroplasia falls on 2027-02-04 \u2014 the agency's yes-or-no moment for BridgeBio's application, and if approved it would be the first and only approved oral therapy for children with achondroplasia."
 },
 {
  "as_of": "2026-10-20",
  "ticker": "AQST",
  "company": "Aquestive Therapeutics Inc",
  "competitors": [
   "EpiPen (epinephrine auto-injector)",
   "neffy (epinephrine nasal spray)"
  ],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "Anaphylm (dibutepinephrine) sublingual film",
  "indication": "type I allergic reactions, including anaphylaxis",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-03-16",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "notes": "FDA accepted Aquestive's resubmission of the Anaphylm (dibutepinephrine) sublingual film NDA as complete, classified as a Class 2 response (resubmitted September 16, 2026, following the January 30, 2026 Complete Response Letter); PDUFA goal date March 16, 2027.",
  "guidance_detail": "FDA accepted Aquestive's resubmission of the Anaphylm (dibutepinephrine) sublingual film NDA as complete, classified as a Class 2 response (resubmitted September 16, 2026, following the January 30, 2026 Complete Response Letter); PDUFA goal date March 16, 2027.",
  "nct_id": "",
  "application_type": "NDA",
  "review_class": "Class 2 resubmission",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-15",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/10/15/3381477/0/en/aquestive-therapeutics-announces-fda-acceptance-of-anaphylm-nda-resubmission-and-pdufa-goal-date-of-march-16-2027.html",
  "record_id": "v41-0003",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-20",
  "why_it_matters": "The FDA's decision date on Anaphylm (dibutepinephrine) sublingual film for type I allergic reactions, including anaphylaxis falls on 2027-03-16 \u2014 the agency's yes-or-no moment for Aquestive Therapeutics Inc's application."
 },
 {
  "as_of": "2026-10-20",
  "ticker": "URGN",
  "company": "UroGen Pharma Ltd.",
  "competitors": [],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "UGN-103 (mitomycin) for intravesical solution",
  "indication": "recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-06-14",
  "date_bucket": "2027-Q2",
  "date_quality": "hard",
  "notes": "FDA accepted the NDA for UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk NMIBC (supported by the Phase 3 UTOPIA trial, NCT06331299); PDUFA target action date June 14, 2027.",
  "guidance_detail": "FDA accepted the NDA for UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk NMIBC (supported by the Phase 3 UTOPIA trial, NCT06331299); PDUFA target action date June 14, 2027.",
  "nct_id": "NCT06331299",
  "application_type": "NDA",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-19",
  "source_type": "company PR",
  "source_url": "https://www.morningstar.com/news/globe-newswire/9847629/urogen-announces-fda-acceptance-of-the-new-drug-application-for-ugn-103-an-investigational-treatment-for-adults-with-recurrent-lg-ir-nmibc",
  "record_id": "v41-0004",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "why_it_matters": "The FDA's decision date on UGN-103 (mitomycin) for intravesical solution for recurrent low-grade intermediate-risk NMIBC falls on 2027-06-14 \u2014 the agency's yes-or-no moment for UroGen Pharma Ltd.'s application."
 },
 {
  "as_of": "2026-10-20",
  "ticker": "ATRA",
  "company": "Atara Biotherapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "drug": "tabelecleucel (Tab-cel)",
  "indication": "Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-03-31",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "notes": "FDA accepted the resubmitted BLA for tabelecleucel (Tab-cel), held by Pierre Fabre Pharmaceuticals, Inc., as monotherapy for adult and pediatric patients two years of age and older with EBV+ PTLD who have received at least one prior therapy; Class 2 resubmission PDUFA target action date March 31, 2027. Atara is Pierre Fabre's U.S. partner.",
  "guidance_detail": "FDA accepted the resubmitted BLA for tabelecleucel (Tab-cel), held by Pierre Fabre Pharmaceuticals, Inc., as monotherapy for adult and pediatric patients two years of age and older with EBV+ PTLD who have received at least one prior therapy; Class 2 resubmission PDUFA target action date March 31, 2027. Atara is Pierre Fabre's U.S. partner.",
  "nct_id": "",
  "application_type": "BLA",
  "review_class": "Class 2 resubmission",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-14",
  "source_type": "company PR",
  "source_url": "https://www.biospace.com/press-releases/atara-biotherapeutics-reports-that-the-resubmitted-tabelecleucel-tab-cel-biologics-license-application-has-been-accepted-by-the-u-s-food-and-drug-administration",
  "record_id": "v41-0005",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "high",
  "related_events": [],
  "date_history": [],
  "indication_group": "Oncology",
  "last_verified": "2026-10-20",
  "why_it_matters": "The FDA's decision date on tabelecleucel (Tab-cel) for EBV+ PTLD falls on 2027-03-31 \u2014 the agency's yes-or-no moment for the Pierre Fabre/Atara application; if approved, Tab-cel would be the first therapy available in the U.S. for EBV+ PTLD."
 },
 {
  "as_of": "2026-10-20",
  "company": "Monte Rosa Therapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "MRT-8102 (GEMINI-1)",
  "event_type": "readout",
  "indication": "gout",
  "notes": "Initial data from GEMINI-1, the Phase 2 study of MRT-8102 (NEK7-directed molecular glue degrader) in gout, expected H2 2027 (Monte Rosa Therapeutics, Oct 1, 2026). GEMINI-1 initiation guided Q4 2026/Q1 2027.",
  "phase": "2",
  "source_type": "company PR",
  "source_url": "https://www.globenewswire.com/news-release/2026/10/01/3372740/0/en/monte-rosa-therapeutics-announces-positive-results-for-mrt-8102-in-gforce-1-phase-1-study-showing-normalization-of-key-pathogenic-drivers-of-ascvd-in-subjects-with-elevated-cvd-ris.html",
  "ticker": "GLUE",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-01",
  "record_id": "v41-0006",
  "guidance_detail": "Initial data from GEMINI-1, the Phase 2 study of MRT-8102 (NEK7-directed molecular glue degrader) in gout, expected H2 2027 (Monte Rosa Therapeutics, Oct 1, 2026). GEMINI-1 initiation guided Q4 2026/Q1 2027.",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Immunology/Inflammation",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "as_of": "2026-10-20",
  "company": "Editas Medicine, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "EDIT-401 (Strive)",
  "event_type": "readout",
  "indication": "heterozygous familial hypercholesterolemia (HeFH)",
  "notes": "Initial safety and tolerability data from Strive, the Phase 1/2 first-in-human trial of EDIT-401 in heterozygous familial hypercholesterolemia, expected in the first quarter of 2027 (Editas Medicine, Oct 8, 2026).",
  "phase": "1/2",
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-10-8-editas-medicine-receives-approval-to-initiate-first-in-human-clinical-trial-of-edit-401-in-patients-with-hyperlipidemia",
  "ticker": "EDIT",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-08",
  "record_id": "v41-0007",
  "guidance_detail": "Initial safety and tolerability data from Strive, the Phase 1/2 first-in-human trial of EDIT-401 in heterozygous familial hypercholesterolemia, expected in the first quarter of 2027 (Editas Medicine, Oct 8, 2026).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "as_of": "2026-10-20",
  "company": "First Tracks Biotherapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ANB033",
  "event_type": "readout",
  "indication": "celiac disease",
  "notes": "Topline data from Cohort 2 of the Phase 1b trial of ANB033 (CD122 antagonist) in celiac disease anticipated in Q1 2027 (First Tracks Biotherapeutics, Oct 12, 2026). Cohort 1 (gluten challenge) met its histologic and symptom endpoints.",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-10-12-first-tracks-biotherapeutics-announces-positive-top-line-results-for-anb033-in-gluten-challenge-study-in-celiac-disease",
  "ticker": "TRAX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-12",
  "record_id": "v41-0008",
  "guidance_detail": "Topline data from Cohort 2 of the Phase 1b trial of ANB033 (CD122 antagonist) in celiac disease anticipated in Q1 2027 (First Tracks Biotherapeutics, Oct 12, 2026). Cohort 1 (gluten challenge) met its histologic and symptom endpoints.",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "as_of": "2026-10-20",
  "company": "First Tracks Biotherapeutics, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-Q3",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "ANB033",
  "event_type": "readout",
  "indication": "eosinophilic esophagitis (EoE)",
  "notes": "Topline data from the 50-patient Phase 1b cohort of ANB033 (CD122 antagonist) in eosinophilic esophagitis anticipated in Q3 2027 (First Tracks Biotherapeutics, Oct 12, 2026).",
  "phase": "1",
  "source_type": "company PR",
  "source_url": "https://www.financialcontent.com/article/gnwcq-2026-10-12-first-tracks-biotherapeutics-announces-positive-top-line-results-for-anb033-in-gluten-challenge-study-in-celiac-disease",
  "ticker": "TRAX",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-12",
  "record_id": "v41-0009",
  "guidance_detail": "Topline data from the 50-patient Phase 1b cohort of ANB033 (CD122 antagonist) in eosinophilic esophagitis anticipated in Q3 2027 (First Tracks Biotherapeutics, Oct 12, 2026).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "small",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "as_of": "2026-10-20",
  "company": "TRex Bio, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H2",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "TRB-061",
  "event_type": "readout",
  "indication": "atopic dermatitis (moderate-to-severe)",
  "notes": "Topline data from the Phase 1b portion of the TRB-061 (selective TNFR2 agonist) trial in moderate-to-severe atopic dermatitis expected in mid-2027 (TRex Bio 424B4 prospectus, Oct 9, 2026). Bucketed H2 2027: \"mid-2027\" spans the Q2/Q3 boundary and is not tightened to a quarter.",
  "phase": "1",
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/Archives/edgar/data/2139097/000119312526419203/project_dino_-_424b4.htm",
  "ticker": "TRXB",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-09",
  "record_id": "v41-0010",
  "guidance_detail": "Topline data from the Phase 1b portion of the TRB-061 (selective TNFR2 agonist) trial in moderate-to-severe atopic dermatitis expected in mid-2027 (TRex Bio 424B4 prospectus, Oct 9, 2026). Bucketed H2 2027: \"mid-2027\" spans the Q2/Q3 boundary and is not tightened to a quarter.",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Dermatology",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "as_of": "2026-10-20",
  "company": "Retension Pharmaceuticals, Inc.",
  "competitors": [],
  "country": "United States",
  "date_bucket": "2027-H1",
  "date_exact": null,
  "date_quality": "guidance",
  "drug": "RTN-001",
  "event_type": "readout",
  "indication": "uncontrolled hypertension",
  "notes": "Initial data from the Phase 2b trial of RTN-001 (once-daily oral PDE-5 inhibitor; modified-release formulation, ~280 adults with uncontrolled hypertension on 2-5 concomitant antihypertensives) expected in the first half of 2027 (Retension Pharmaceuticals 424B4 prospectus, Oct 9, 2026).",
  "phase": "2",
  "source_type": "SEC filing",
  "source_url": "https://www.sec.gov/Archives/edgar/data/2002988/000121390026108587/ea0276911-10.htm",
  "ticker": "RTSN",
  "us_listed": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-09",
  "record_id": "v41-0011",
  "guidance_detail": "Initial data from the Phase 2b trial of RTN-001 (once-daily oral PDE-5 inhibitor; modified-release formulation, ~280 adults with uncontrolled hypertension on 2-5 concomitant antihypertensives) expected in the first half of 2027 (Retension Pharmaceuticals 424B4 prospectus, Oct 9, 2026).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "micro",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "Cardiology",
  "last_verified": "2026-10-20",
  "us_tradable": true
 },
 {
  "ticker": "MIRM",
  "company": "Mirum Pharmaceuticals, Inc.",
  "country": "United States",
  "us_listed": true,
  "drug": "LIVMARLI (maralixibat)",
  "indication": "cholestatic pruritus in ultra-rare cholestatic liver diseases (additional settings)",
  "event_type": "nda_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027-H1",
  "date_quality": "guidance",
  "competitors": [],
  "source_url": "https://s21.q4cdn.com/142896768/files/doc_presentations/2026/Oct/Mirum-Corporate-Presentation-October-Final.pdf",
  "source_type": "company deck",
  "as_of": "2026-10-20",
  "notes": "sNDA submission for LIVMARLI (maralixibat) for cholestatic pruritus in additional ultra-rare cholestatic liver disease settings (including biliary atresia) targeted H1 2027, following the Phase 3 EXPAND study, which met its primary endpoint (topline reported Oct 12, 2026) (Mirum corporate presentation, Oct 2026).",
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10",
  "record_id": "v41-0015",
  "guidance_detail": "sNDA submission for LIVMARLI (maralixibat) for cholestatic pruritus in additional ultra-rare cholestatic liver disease settings (including biliary atresia) targeted H1 2027, following the Phase 3 EXPAND study, which met its primary endpoint (topline reported Oct 12, 2026) (Mirum corporate presentation, Oct 2026).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "mid",
  "impact": "medium",
  "related_events": [],
  "date_history": [],
  "indication_group": "GI/Hepatology",
  "last_verified": "2026-10-20"
 },
 {
  "company": "AHA Scientific Sessions 2027 (American Heart Association)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q4",
  "date_exact": "2027-11-05",
  "date_quality": "hard",
  "notes": "American Heart Association Scientific Sessions, November 5\u20138, 2027, Boston, MA (Thomas M. Menino Convention & Exhibition Center).",
  "country": "United States",
  "source_url": "https://exhibitatsessions.org/scientific-sessions/future-meetings/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v41-0012",
  "guidance_detail": "American Heart Association Scientific Sessions, November 5\u20138, 2027, Boston, MA (Thomas M. Menino Convention & Exhibition Center).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20",
  "why_it_matters": ""
 },
 {
  "company": "ERS Congress 2027 (European Respiratory Society)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q3",
  "date_exact": "2027-09-11",
  "date_quality": "hard",
  "notes": "European Respiratory Society (ERS) Congress, September 11\u201314, 2027, Milan, Italy. Distinct conference from the IASLC World Conference on Lung Cancer 2027, which shares the September 11 start date (Denver).",
  "country": "Italy",
  "source_url": "https://www.ersnet.org/congress-and-events/congress/priority-topics-congress-2027/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v41-0013",
  "guidance_detail": "European Respiratory Society (ERS) Congress, September 11\u201314, 2027, Milan, Italy. Distinct conference from the IASLC World Conference on Lung Cancer 2027, which shares the September 11 start date (Denver).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20",
  "why_it_matters": ""
 },
 {
  "company": "ACTRIMS Forum 2027 (Americas Committee for Treatment and Research in Multiple Sclerosis)",
  "ticker": null,
  "us_listed": false,
  "drug": null,
  "indication": null,
  "phase": null,
  "event_type": "conference",
  "date_bucket": "2027-Q1",
  "date_exact": "2027-03-11",
  "date_quality": "hard",
  "notes": "ACTRIMS Forum 2027, March 11\u201313, 2027, Phoenix, AZ. Distinct conference from the EAACI Skin Allergy Meeting 2027, which shares the March 11 start date (Paris).",
  "country": "United States",
  "source_url": "https://www.forum.actrims.org/",
  "source_type": "conference organizer",
  "competitors": [],
  "as_of": "2026-10-20",
  "us_tradable": false,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "",
  "record_id": "v41-0014",
  "guidance_detail": "ACTRIMS Forum 2027, March 11\u201313, 2027, Phoenix, AZ. Distinct conference from the EAACI Skin Allergy Meeting 2027, which shares the March 11 start date (Paris).",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "mktcap_tier": "unknown",
  "impact": "low",
  "related_events": [],
  "date_history": [],
  "indication_group": "Other",
  "last_verified": "2026-10-20",
  "why_it_matters": "",
  "organizer_dates_printed": true
 },
 {
  "as_of": "2026-11-01",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "NDA",
  "review_class": "Class II resubmission",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-21",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "related_events": [],
  "date_history": [],
  "last_verified": "2026-11-01",
  "ticker": "UNCY",
  "company": "Unicycive Therapeutics, Inc.",
  "drug": "oxylanthanum carbonate (OLC)",
  "indication": "hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-03-25",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "Auryxia/ferric citrate (Akebia)",
   "Velphoro/sucroferric oxyhydroxide (Fresenius)",
   "Phoslyra/calcium acetate"
  ],
  "source_url": "https://www.morningstar.com/news/globe-newswire/9850066/unicycive-therapeutics-announces-fda-acceptance-of-oxylanthanum-carbonate-new-drug-application-resubmission-and-pdufa-date-of-march-25-2027",
  "source_type": "company PR",
  "notes": "FDA accepted Unicycive's resubmission of the OLC NDA, deemed a Class II resubmission with a six-month review period, and set a PDUFA target action date of March 25, 2027. Resubmission (Sep 30, 2026) followed a June 2026 Complete Response Letter citing manufacturing deficiencies at the original drug-product vendor; it includes CMC data from a new vendor whose facility last received 'No Action Indicated' status (Mar 2024). FDA raised no concerns about OLC's clinical/safety data; approval sought via the 505(b)(2) pathway.",
  "guidance_detail": "FDA accepted the OLC NDA resubmission (Class II, six-month review); PDUFA target action date March 25, 2027.",
  "mktcap_tier": "small",
  "impact": "high",
  "indication_group": "Renal/Urology",
  "why_it_matters": "The FDA's decision date on oxylanthanum carbonate (OLC) for hyperphosphatemia in patients with chronic kidney disease on dialysis falls on 2027-03-25 \u2014 the agency's yes-or-no moment for Unicycive Therapeutics, Inc.'s application, after two prior Complete Response Letters on manufacturing grounds.",
  "record_id": "v41-0016"
 },
 {
  "as_of": "2026-11-01",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "NDA",
  "review_class": "Priority Review",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-28",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "related_events": [
   "v16-0125"
  ],
  "date_history": [],
  "last_verified": "2026-11-01",
  "ticker": "PVLA",
  "company": "Palvella Therapeutics, Inc.",
  "drug": "QTORIN rapamycin (3.9% rapamycin anhydrous gel)",
  "indication": "microcystic lymphatic malformations",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-28",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "PFE (Rapamune/sirolimus \u2014 used off-label; no FDA-approved therapy for microcystic LMs)"
  ],
  "source_url": "https://www.morningstar.com/news/globe-newswire/9854829/palvella-announces-fda-acceptance-and-priority-review-of-qtorin-rapamycin-nda-february-28-2027-pdufa-target-action-date-set",
  "source_type": "company PR",
  "notes": "FDA accepted Palvella's NDA for filing and granted Priority Review for QTORIN 3.9% rapamycin anhydrous gel in microcystic lymphatic malformations; PDUFA target action date February 28, 2027. Rolling NDA completed Aug 31, 2026; supported by the Phase 3 SELVA study (all six prespecified efficacy endpoints p<0.001) plus Breakthrough Therapy, Fast Track and Orphan Drug designations. If approved, QTORIN would be the first FDA-approved therapy for microcystic LMs; Palvella targets a US launch in H1 2027.",
  "guidance_detail": "FDA accepted the QTORIN rapamycin NDA for filing and granted Priority Review; PDUFA target action date February 28, 2027.",
  "mktcap_tier": "mid",
  "impact": "high",
  "indication_group": "Rare Disease/Genetic",
  "why_it_matters": "The FDA's decision date on QTORIN rapamycin for microcystic lymphatic malformations falls on 2027-02-28 \u2014 the agency's yes-or-no moment for Palvella Therapeutics, Inc.'s application, which would be the first FDA-approved therapy for this rare disease if approved.",
  "record_id": "v41-0017"
 },
 {
  "as_of": "2026-11-01",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "sNDA",
  "review_class": "Priority Review",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-30",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "related_events": [],
  "date_history": [],
  "last_verified": "2026-11-01",
  "ticker": "AGIO",
  "company": "Agios Pharmaceuticals, Inc.",
  "drug": "mitapivat",
  "indication": "sickle cell disease (patients aged 16 years and older)",
  "event_type": "pdufa",
  "phase": null,
  "date_exact": "2027-02-01",
  "date_bucket": "2027-Q1",
  "date_quality": "hard",
  "competitors": [
   "voxelotor (Pfizer \u2014 withdrawn worldwide 2024)",
   "crizanlizumab (Novartis)"
  ],
  "source_url": "https://www.morningstar.com/news/globe-newswire/9856739/agios-announces-new-pdufa-goal-date-of-february-1-2027-for-mitapivat-sickle-cell-disease-snda-company-is-launch-ready-and-in-labeling-discussions-with-fda",
  "source_type": "company PR",
  "notes": "FDA extended the PDUFA goal date for the mitapivat sickle cell disease sNDA from November 1, 2026 to February 1, 2027, after classifying Agios's response to an FDA information request as a major amendment (three-month extension). The sNDA was submitted under the accelerated approval pathway and granted Priority Review. FDA's Oct 9, 2026 request concerned whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary; Agios's Oct 19 response added ~9 months of updated safety data from the RISE UP Phase 2/3 open-label extensions, with no hepatocellular-injury cases in SCD patients matching the thalassemia pattern; benefit-risk profile unchanged, labeling discussions ongoing.",
  "guidance_detail": "FDA extended the mitapivat SCD sNDA PDUFA goal date from Nov 1, 2026 to February 1, 2027 (major amendment; REMS information request).",
  "mktcap_tier": "mid",
  "impact": "high",
  "indication_group": "Hematology",
  "why_it_matters": "The FDA's decision date on mitapivat for sickle cell disease falls on 2027-02-01 \u2014 the agency's yes-or-no moment for Agios Pharmaceuticals, Inc.'s supplemental application, extended three months while FDA weighs whether a REMS is necessary.",
  "record_id": "v41-0018"
 },
 {
  "as_of": "2026-11-01",
  "country": "United States",
  "us_listed": true,
  "us_tradable": true,
  "nct_id": "",
  "application_type": "",
  "review_class": "",
  "adcom_planned": "unknown",
  "trial_status": "",
  "source_date": "2026-10-28",
  "audit_status": "v41_hotfix",
  "audit_action": "add",
  "related_events": [],
  "date_history": [],
  "last_verified": "2026-11-01",
  "ticker": "DBVT",
  "company": "DBV Technologies S.A.",
  "drug": "VIASKIN Peanut Patch",
  "indication": "peanut allergy in toddlers aged 1 through 3 years",
  "event_type": "bla_filing",
  "phase": null,
  "date_exact": null,
  "date_bucket": "2027",
  "date_quality": "guidance",
  "competitors": [
   "Palforzia (Stallergenes Greer \u2014 peanut oral immunotherapy, ages 4-17)"
  ],
  "source_url": "https://www.morningstar.com/news/globe-newswire/1001280507/dbv-technologies-reports-third-quarter-2026-financial-results-and-business-update",
  "source_type": "company PR",
  "notes": "DBV expects to submit a BLA for the VIASKIN Peanut Patch in toddlers aged 1 through 3 years in 2027, following its Sep 29, 2026 BLA submission for children aged 4 through 7 years (acceptance/Priority Review determination still pending, expected Q4 2026). Same FDA review team would review both BLAs; DBV has discussed a potential rolling submission for the toddler BLA.",
  "guidance_detail": "DBV expects to submit the toddler (ages 1-3) VIASKIN Peanut BLA in 2027.",
  "mktcap_tier": "small",
  "impact": "medium",
  "indication_group": "Immunology/Inflammation",
  "why_it_matters": "DBV Technologies S.A. is expected to file its biologics license application for the VIASKIN Peanut Patch in toddlers aged 1 through 3 years sometime in 2027, expanding the peanut-allergy program beyond the pending 4-through-7 BLA.",
  "record_id": "v41-0019"
 }
]